<SEC-DOCUMENT>0001171843-21-006231.txt : 20210830
<SEC-HEADER>0001171843-21-006231.hdr.sgml : 20210830
<ACCEPTANCE-DATETIME>20210830172125
ACCESSION NUMBER:		0001171843-21-006231
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210830
DATE AS OF CHANGE:		20210830

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PORTAGE BIOTECH INC.
		CENTRAL INDEX KEY:			0001095435
		STANDARD INDUSTRIAL CLASSIFICATION:	CRUDE PETROLEUM & NATURAL GAS [1311]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40086
		FILM NUMBER:		211224559

	BUSINESS ADDRESS:	
		STREET 1:		6 ADELAIDE ST. EAST
		STREET 2:		SUITE 300
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5C 1H6
		BUSINESS PHONE:		416-737-7600

	MAIL ADDRESS:	
		STREET 1:		6 ADELAIDE ST. EAST
		STREET 2:		SUITE 300
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5C 1H6

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BONTAN CORP INC
		DATE OF NAME CHANGE:	20030421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DEALCHECK COM INC
		DATE OF NAME CHANGE:	19990921
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_082621p.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" xmlns:ptgef="http://portagebiotech.com/20210630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_023_IFRS%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_ptgef_portagebiotech.com_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20210401_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001095435 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DCurrentFiscalYearEndDate_03/31 -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_exh__991.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityCentralIndexKey">0001095435</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2021-06-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2021-06-30" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate">03/31</ix:nonNumeric>
  <ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0135" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0147" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:GainsOnDisposalsOfInvestmentProperties" contextRef="From2021-04-01to2021-06-30" id="xdx2ixbrl0155" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:IssuedUnderPrivatePlacement" contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember" id="xdx2ixbrl0208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:IssuedUnderPrivatePlacement" contextRef="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:IssuedUnderPrivatePlacement" contextRef="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:IssuedUnderPrivatePlacement" contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0228" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UnrealizedLossOnInvestmentInInvestments" contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UnrealizedLossOnInvestmentInInvestments" contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UnrealizedLossOnInvestmentInInvestments" contextRef="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UnrealizedLossOnInvestmentInInvestments" contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossIncomeOnFairValueOfWarrantLiability" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ValueOfSharesIssuedForServices" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForAmortisationExpense" contextRef="From2021-04-01to2021-06-30" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:IncreasingDecreasingAccountsReceivable" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:OtherAsset" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PurchaseOfInvestmentProperty" contextRef="From2021-04-01to2021-06-30" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2021-04-01to2021-06-30" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CashPaidForInterest" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:IncreaseInAccountsPayableForStockIssuanceCosts" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FairValueOfWarrantLiabilityForPortageWarrantsIssued" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UnrealizedLossOnInvestmentInInvestment" contextRef="From2021-04-01to2021-06-30" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:InvestmentAssetAvailableForSale" contextRef="AsOf2021-03-31" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UnrealizedLossGainOnInvestment" contextRef="From2021-04-01to2021-06-30" id="xdx2ixbrl0540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:InvestmentAssetAvailableForSale" contextRef="AsOf2021-06-30" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AdditionalInvestments" contextRef="From2021-04-01to2021-06-30" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RepaymentOfNotesPayable" contextRef="From2020-04-012021-03-31_custom_PplMember" id="xdx2ixbrl0704" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RepaymentOfNotesPayable" contextRef="From2020-04-012021-03-31_custom_IoxMember" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AmortizationOfDebtDiscount" contextRef="From2020-04-012021-03-31_custom_PplMember" id="xdx2ixbrl0712" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AmortizationOfDebtDiscount" contextRef="From2020-04-012021-03-31_custom_IoxMember" id="xdx2ixbrl0714" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ValueOfNotesExchangedInWarrantExercise" contextRef="From2020-04-012021-03-31_custom_PplMember" id="xdx2ixbrl0720" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ValueOfNotesExchangedInWarrantExercise" contextRef="From2020-04-012021-03-31_custom_IoxMember" id="xdx2ixbrl0722" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SettlementInConnectionWithDispositionOfPpl" contextRef="From2020-04-012021-03-31_custom_IoxMember" id="xdx2ixbrl0730" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SettlementInConnectionWithDispositionOfPpl" contextRef="From2020-04-012021-03-31_custom_SalvaRxMember" id="xdx2ixbrl0732" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnExtinguishmentOfDebt" contextRef="From2020-04-012021-03-31_custom_PplMember" id="xdx2ixbrl0736" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossOnExtinguishmentOfDebt" contextRef="From2020-04-012021-03-31_custom_IoxMember" id="xdx2ixbrl0738" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromLoanPayable" contextRef="From2020-04-012021-03-31_custom_PplMember" id="xdx2ixbrl0744" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromLoanPayable" contextRef="From2020-04-012021-03-31_custom_SalvaRxMember" id="xdx2ixbrl0748" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2021-03-31_custom_PplMember" id="xdx2ixbrl0752" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2021-03-31_custom_SalvaRxMember" id="xdx2ixbrl0756" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromLoanPayable" contextRef="From2021-04-012021-06-30_custom_PplMember" id="xdx2ixbrl0760" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromLoanPayable" contextRef="From2021-04-012021-06-30_custom_IoxMember" id="xdx2ixbrl0762" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromLoanPayable" contextRef="From2021-04-012021-06-30_custom_SalvaRxMember" id="xdx2ixbrl0764" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromLoanPayable" contextRef="From2021-04-01to2021-06-30" id="xdx2ixbrl0766" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2021-06-30_custom_PplMember" id="xdx2ixbrl0768" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2021-06-30_custom_SalvaRxMember" id="xdx2ixbrl0772" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FairValueAdjustmentExercisePriceAtEnd" contextRef="From2021-04-012021-06-30_custom_SalvaRxGroupPlcMember" id="xdx2ixbrl0816" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FairValueAdjustmentShares" contextRef="From2021-04-012021-06-30_custom_SalvaRxGroupPlcMember" id="xdx2ixbrl0818" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedForServicesShares" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0860" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedForService" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0862" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember" id="xdx2ixbrl0912" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2020-03-31_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl0945" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2021-03-31_custom_PBI2013OptionPlanMember" id="xdx2ixbrl0947" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl0955" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2020-04-012020-06-30_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl0957" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl0959" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2020-04-012020-06-30_custom_PBI2013OptionPlanMember" id="xdx2ixbrl0961" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2021-04-012021-06-30_custom_IOxOptionPlanMember" id="xdx2ixbrl0963" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2020-04-012020-06-30_custom_IOxOptionPlanMember" id="xdx2ixbrl0965" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl0967" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2020-04-012020-06-30_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl0969" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2021-04-012021-06-30_custom_PBI2013OptionPlanMember" id="xdx2ixbrl0971" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2020-04-012020-06-30_custom_PBI2013OptionPlanMember" id="xdx2ixbrl0973" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2021-04-012021-06-30_custom_IOxOptionPlanMember" id="xdx2ixbrl0975" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2020-04-012020-06-30_custom_IOxOptionPlanMember" id="xdx2ixbrl0977" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2020-06-30_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl0981" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2021-06-30_custom_PBI2013OptionPlanMember" id="xdx2ixbrl0983" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="AsOf2020-06-30_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl0993" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="AsOf2021-06-30_custom_PBI2013OptionPlanMember" id="xdx2ixbrl0995" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2020-04-012020-06-30_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl1007" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2021-04-012021-06-30_custom_PBI2013OptionPlanMember" id="xdx2ixbrl1009" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShar" contextRef="From2020-04-012020-06-30_custom_RestrictedStockUnitsMember" id="xdx2ixbrl1058" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShar" contextRef="From2020-04-012020-06-30_custom_WarrantsMember" id="xdx2ixbrl1062" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1098" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivables" contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivables" contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1106" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentInvestments" contextRef="AsOf2021-06-30_custom_AmortizedCostMember" id="xdx2ixbrl1108" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentInvestments" contextRef="AsOf2021-03-31_custom_AmortizedCostMember" id="xdx2ixbrl1112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentPayables" contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1126" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentPayables" contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1130" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:WarrantLiability" contextRef="AsOf2021-06-30_custom_AmortizedCostMember" id="xdx2ixbrl1132" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:WarrantLiability" contextRef="AsOf2021-03-31_custom_AmortizedCostMember" id="xdx2ixbrl1134" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-03-31_custom_PglMember" id="xdx2ixbrl1174" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-03-31_custom_SalvaRxMember" id="xdx2ixbrl1176" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2021-04-012021-06-30_custom_PglMember" id="xdx2ixbrl1184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2021-04-012021-06-30_custom_SalvaRxMember" id="xdx2ixbrl1186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2021-04-012021-06-30_custom_SaugatuckMember" id="xdx2ixbrl1190" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2021-04-012021-06-30_custom_PglMember" id="xdx2ixbrl1194" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2021-04-012021-06-30_custom_SalvaRxMember" id="xdx2ixbrl1196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-06-30_custom_PglMember" id="xdx2ixbrl1204" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-06-30_custom_SalvaRxMember" id="xdx2ixbrl1206" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2020-04-012020-06-30_custom_PglMember" id="xdx2ixbrl1219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2020-04-012020-06-30_custom_SalvaRxMember" id="xdx2ixbrl1221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2020-04-012020-06-30_custom_SaugatuckMember" id="xdx2ixbrl1225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2020-04-012020-06-30_custom_PglMember" id="xdx2ixbrl1229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2020-04-012020-06-30_custom_SalvaRxMember" id="xdx2ixbrl1231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ptgef-20210630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-04-01to2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-13_custom_SalvaRxGroupPlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxGroupPlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-012015-02-10_custom_SubsidiariesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-01</xbrli:startDate>
        <xbrli:endDate>2015-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SubsidiariesTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-032018-01-31_custom_PortageGlasgowLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PortageGlasgowLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-03</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SubsidiariesThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_ifrs-full_SubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-10-31_custom_PPLSettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PPLSettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_PPLSettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PPLSettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-012020-08-30_custom_BiohavenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypeOfMeasurementOfExpectedCreditLossesAxis">ptgef:BiohavenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-01</xbrli:startDate>
        <xbrli:endDate>2020-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-302020-06-01_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-30</xbrli:startDate>
        <xbrli:endDate>2020-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-012021-03-03_custom_PortageGlasgowLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:PortageGlasgowLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-03_custom_PortageGlasgowLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:PortageGlasgowLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-08-31_custom_SeriesAPreferredStockInSentienBiotechnologiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:SeriesAPreferredStockInSentienBiotechnologiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SeriesAPreferredStockInSentienBiotechnologiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:SeriesAPreferredStockInSentienBiotechnologiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_IntensityMember_custom_AcquisitionOfSalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IntensityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfSalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_IntensityMember_custom_AcquisitionOfSalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IntensityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfSalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-11_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IntensityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfIntensityHoldingLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_IntensityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IntensityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IntensityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfIntensityHoldingLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_IMM60IOXMelanomaLungCancersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM60IOXMelanomaLungCancersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_IMM60IOXMelanomaLungCancersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM60IOXMelanomaLungCancersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_IMM65IOXOvarianProstateCancersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM65IOXOvarianProstateCancersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_IMM65IOXOvarianProstateCancersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM65IOXOvarianProstateCancersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_OncomerSaugatuckDNAAptamersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:OncomerSaugatuckDNAAptamersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_OncomerSaugatuckDNAAptamersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:OncomerSaugatuckDNAAptamersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_PplMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PplMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_IoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_PplMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PplMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_IoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_PplMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PplMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_IoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_PplMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PplMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_IoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_PplMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PplMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_IoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-31_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-012020-09-30_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-31_custom_PortageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:PortageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-032019-01-31_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-03</xbrli:startDate>
        <xbrli:endDate>2019-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-032019-01-31_custom_IoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-03</xbrli:startDate>
        <xbrli:endDate>2019-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SalvaRxGroupPlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxGroupPlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SalvaRxGroupPlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxGroupPlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SalvaRxGroupPlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxGroupPlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-022020-06-16_custom_AccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:AccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-02</xbrli:startDate>
        <xbrli:endDate>2020-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-022020-06-16_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-02</xbrli:startDate>
        <xbrli:endDate>2020-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:N2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_PBI2013OptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_PBI2013OptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_IOxOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_IOxOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_PBI2013OptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_IOxOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_IOxOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_PBI2013OptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_PBI2013OptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_PBI2013OptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_IOxOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_IOxOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_Equity2021IncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:Equity2021IncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember444649546">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_AmortizedCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_AmortizedCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_PglMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_PglMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_PglMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_PglMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_PglMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_IoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_PglMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_IoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-07-31_custom_EventsAfterTheBalanceSheetDateMember_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ptgef:EventsAfterTheBalanceSheetDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt 0; font-size: 10pt; text-align: right"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<div style="text-align: center"><p style="font-size: 14pt; text-align: center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase; text-align: center"><strong>Form <span id="xdx_90B_edei--DocumentType_c20210401__20210630_zuPLVGIjKUGb"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:DocumentType">6-K</ix:nonNumeric></span></strong></p><p style="text-align: center"><strong></strong></p><p style="text-align: center"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p>

<p style="text-align: center"><strong><span id="xdx_906_edei--DocumentPeriodEndDate_c20210401__20210630_zOUfDlMUs9eh" style="display: none"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, 2021</ix:nonNumeric></span></strong></p><p style="text-align: center"><strong></strong><strong>For the month of  August 2021</strong></p><p style="text-align: center">Commission File Number: <strong><span id="xdx_90F_edei--EntityFileNumber_c20210401__20210630_zu3W6FKftYbf"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityFileNumber">0-30314</ix:nonNumeric></span></strong></p><p style="text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityRegistrantName_c20210401__20210630_zTRtvgwZ7SRd"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityRegistrantName">Portage
                                            Biotech Inc.</ix:nonNumeric></span></span></b></span><br />(Translation of registrant's name into English)</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; orphans: 2; text-transform: none; widows: 2; letter-spacing: normal; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="margin-left: auto; font-size: 10pt; text-align: center; margin-right: auto"><span style="font-size: 10pt"><b><span style="text-decoration: underline">N/A</span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="margin-left: auto; font-size: 10pt; text-align: center; margin-right: auto"><span style="font-size: 10pt">(Translation of Registrant's name into English)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="margin-left: auto; font-size: 10pt; margin-right: auto">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="margin-left: auto; font-size: 10pt; text-align: center; margin-right: auto"><span style="font-size: 10pt"><b><span style="text-decoration: underline">British Virgin Islands</span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="margin-left: auto; font-size: 10pt; text-align: center; margin-right: auto"><span style="font-size: 10pt">(Jurisdiction of incorporation or organization)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="margin-left: auto; font-size: 10pt; margin-right: auto">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="margin-left: auto; font-size: 10pt; text-align: center; margin-right: auto"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20210401__20210630_zYjmm30NBxOb"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityAddressAddressLine1">Craigmuir Chambers</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20210401__20210630_zFYyYp9e1lol"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityAddressAddressLine2">Road Town</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine3_c20210401__20210630_zIumiNlk0wu6"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityAddressAddressLine3">Tortola</ix:nonNumeric></span>, British Virgin Islands,</b></span><b><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20210401__20210630_zNvNYHzj8myk"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityAddressPostalZipCode">VG1110</ix:nonNumeric></span>.</b></td></tr>
  <tr style="vertical-align: top">
    <td style="margin-left: auto; font-size: 10pt; text-align: center; margin-right: auto"><span style="font-size: 10pt">(Address of principal executive offices)</span></td></tr>
  </table>
<p style="font: 400 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: rgb(0, 0, 0); text-align: center; text-indent: 0px">&#160;</p></div><p style="font: 400 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: rgb(0, 0, 0); text-align: center; text-indent: 0px"><b>c/o Portage Biotech, Inc., Ian Walters, 203.221.7376</b></p>

<p style="font: 400 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: rgb(0, 0, 0); text-align: center; text-indent: 0px"><b><span style="text-decoration: underline">6
Adelaide Street East, Suite 300, Toronto, Ontario, Canada M5C 1H6<br />
</span></b>(Name, telephone, e-mail and/or facsimile number and Address of Company Contact Person)</p>

<p style="font: 400 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: rgb(0, 0, 0); text-align: center; text-indent: 0px">&#160;</p>

<p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<br />Form 20-F &#9746; &#160;&#160;&#160;&#160;&#160;Form 40-F &#9744;</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <span style="text-decoration: underline">&#160;&#160;&#160;&#160;&#160;&#160;</span></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <span style="text-decoration: underline">&#160;&#160;&#160;&#160;&#160;&#160;</span></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>
<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>EXHIBITS</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 10%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="padding-bottom: 1pt; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 89%; font-size: 10pt"><span style="font-size: 10pt"><b>Exhibit</b></span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="text-decoration: underline"><a href="#a_fs"><span style="font-size: 10pt">99.1</span></a></span></td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="text-decoration: underline"><a href="#a_fs"><span style="font-size: 10pt">Unaudited Condensed
    Consolidated Interim Financial Statements for the three months ended June 30, 2021. Unaudited - Prepared by Management as of August
    30, 2021.</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="text-decoration: underline; font-size: 10pt; color: #0000EE">99.2</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><a href="exh_992.htm"><span style="text-decoration: underline; font-size: 10pt; color: #0000EE">Management&#8217;s
    Discussion and Analysis for the three months ended June 30, 2021.</span></a></td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; background-color: white"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; text-align: right; font-size: 10pt"></p>

<p style="margin: 0pt 0; text-align: right; font-size: 10pt"><b><span id="a_fs">Exhibit 99.1</span></b></p>

<p style="margin: 0pt 0; text-align: right; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; text-align: right; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt"><b>Condensed Consolidated Interim Financial Statements</b></p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt"><b>For the Three Months Ended June 30, 2021</b></p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt"><b>(Unaudited &#8211; Prepared by Management)</b></p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt"><b>(U.S. Dollars)</b></p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Financial Statements</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 88%; text-align: center"><span style="font-size: 10pt"><b>Index</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Notice to Reader</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Condensed Consolidated Interim Statements of Financial Position</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">As of June 30, 2021 (Unaudited) and March 31, 2021</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Unaudited)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Three months ended June 30, 2021 and 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Condensed Consolidated Interim Statements of Changes in Shareholders&#8217; Equity (Unaudited)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">Three months ended June 30, 2021 and 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Three months ended June 30, 2021 and 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Notes to Condensed Consolidated Interim Financial Statements</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-6 to F-27</span></td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>NOTICE TO READER OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS </b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">The condensed consolidated interim financial statements for Portage Biotech Inc. are comprised
of the condensed consolidated statements of financial position as of June 30, 2021 and March 31, 2021, and the condensed consolidated
interim statements of operations and comprehensive loss for the three months ended June 30, 2021 and 2020 and the statements of equity
and cash flows for each of the three months then ended and are the responsibility of the Company&#8217;s management.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">The condensed consolidated interim financial statements have been prepared by management and
include the selection of appropriate accounting principles, judgments and estimates necessary to prepare these condensed consolidated
interim financial statements in accordance with International Financial Reporting Standards.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: center"><span style="font-size: 10pt">&#8220;signed&#8221;</span></td>
    <td style="width: 50%; text-align: center"><span style="font-size: 10pt">&#8220;signed&#8221; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Allan Shaw, CFO</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Ian Walters MD, Director </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">DATE:&#160;&#160;August <span style="background-color: white">30</span>, 2021</span></td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Statements of Financial Position</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars in thousands)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; see Notice to Reader dated August <span style="background-color: white">30</span>,
2021)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_111_pn3n3_zZPxuqxIyTV9" summary="xdx: Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_497_20210630" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_495_20210331" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">As of,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Notes</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30,<br /> 2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,<br /> 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">(Audited)</td></tr>
  <tr id="xdx_408_eifrs-full--AssetsAbstract_iB_zWnmvHp57Fh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CurrentAssetsAbstract_i01B_zJMLOBFnFAF" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CashAndCashEquivalents_i02I_maCzgE0_z7LFSBtLZrUh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 55%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 14%; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,617</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,770</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--TradeAndOtherCurrentReceivables_i02I_maCzgE0_zM5prFuADS47" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">5</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,995</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,176</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--CurrentAssets_i02I_maCzhDM_zVfjSSBVpCkl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); font-size: 10pt">Total current asset</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,612</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,946</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--NoncurrentAssetsAbstract_i01B_zTDwbr4RP76c" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Long-term assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--OtherReceivables_i02I_maCzhDM_zCcUM4Lvu5Vl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Long-term portion of other receivables</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">5</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherReceivables" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:OtherReceivables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_i02I_maCzhDM_zTdpZaTPkd8d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Investment in associate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">7</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,691</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,735</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--InvestmentProperty_i02I_maCzhDM_zEFpK55oPXOa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Investments in private companies</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">9</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentProperty" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,409</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentProperty" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,409</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--Goodwill_i02I_maCzhDM_zvMB7LafoG91" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">Goodwill</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">10</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,324</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,324</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--InprocessResearchAndDevelopment_i02I_maCzhDM_zUmuTEt532qe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">In-process research and development</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">11</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,388</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,388</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--OtherAssets_i02I_maCzhDM_zA0hjBHOwida" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherAssets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:OtherAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--Assets_i01TI_mtCzhDM_zigvQykGGWF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200,482</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">174,860</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--EquityAndLiabilitiesAbstract_iB_zze9NYIGgOgb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Equity</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentLiabilitiesAbstract_i01B_zTMfHqyrXQA7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--TradeAndOtherCurrentPayables_i02I_maCz3YT_maCLzO9B_zbyp93zDIec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accounts payable and accrued liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,605</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,938</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--WarrantLiabilityCurrent_i02I_maCz3YT_maCLzO9B_zVJa8et8iK6g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">13</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WarrantLiabilityCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">751</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantLiabilityCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,120</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--UnsecuredNotesPayable_i02I_maCz3YT_maCLzO9B_zOCRpTUNMWK3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Unsecured notes payable</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">12</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:UnsecuredNotesPayable" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:UnsecuredNotesPayable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CurrentLiabilities_i02TI_mtCLzO9B_maLzM2C_zQYR5pegZA53" style="vertical-align: bottom; background-color: White">
    <td style="color: White; font-size: 10pt; padding-bottom: 1pt">Total current liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,506</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,208</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--NoncurrentLiabilitiesAbstract_i01B_zoMWVQlIYsy6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-current liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--DeferredTaxLiabilities_i02I_maCzl46_maNLzBkv_zELfInXpUe3e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred tax liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">11</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,171</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,050</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--NoncurrentLiabilities_i02TI_mtNLzBkv_maLzM2C_zzb9WkIpZqhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Total non-current liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,171</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,050</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--Liabilities_i02TI_maCzFbJ_mtLzM2C_zMxrImOoRjre" style="vertical-align: bottom; background-color: White">
    <td style="color: White; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,677</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,258</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--EquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Shareholders&#8217; Equity</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--IssuedCapital_i02I_maCzPWP_zDeSx17d1Dw9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Capital stock</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">14</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">157,895</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130,649</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--OtherReserves_i02I_maCzPWP_zsWMUg71NoXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Stock option reserve</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">15</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,059</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,977</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--AccumulatedOtherComprehensiveIncome_i02I_maCzPWP_zeUEUC171di9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Accumulated other comprehensive income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">958</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">958</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--RetainedEarnings_i02I_maCzPWP_zjQKZem5wYl4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated deficit</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">41,201</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,135</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--EquityAttributableToOwnersOfParent_i02TI_mtCzPWP_maCzxJm_z71kWV8aGkzj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total equity attributable to owners of the Company</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127,711</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101,449</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--NoncontrollingInterests_i02I_maCzxJm_zFJSVSiEzvnb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">21</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,094</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,153</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Equity_i02TI_mtCzxJm_maCzFbJ_zEQVIRm5hgWk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total equity</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">173,805</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147,602</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--EquityAndLiabilities_i01TI_mtCzFbJ_zYGBvGob2ZIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200,482</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">174,860</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--CommitmentAndContingencies_i01I_zlPQYUWlSZE5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Commitments and Contingent Liabilities (Note 17)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 22%"><span style="font-size: 10pt"><b>On behalf of the Board</b></span></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 20%; text-align: center"><span style="font-size: 10pt">&#8220;Allan Shaw&#8221;</span></td>
    <td style="white-space: nowrap; width: 20%; padding-left: 1.45pt"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 20%; text-align: center"><span style="font-size: 10pt">&#8220;Ian Walters&#8221;</span></td>
    <td style="width: 18%; padding-left: 1.45pt"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">(signed)</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">(signed)</span></td>
    <td style="text-align: center">&#160;</td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Statements of Operations and Other Comprehensive
(Loss)</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(U.S. Dollars in thousands, except per share amounts)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; see Notice to Reader dated August <span style="background-color: white">30</span>,
2021)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_302_113_pn3n3_zgPtheVDmSC4" summary="xdx: Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive (Loss) (Unaudited)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_495_20210401_20210630" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_493_20200401_20200630" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Note</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30, 2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30, 2020</td></tr>
  <tr id="xdx_409_eifrs-full--ProfitLossAbstract_iB_zeIKearHNWf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--ResearchAndDevelopmentExpense_i01_msCzv8R_zYvwGHmPCbV" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 55%; font-size: 10pt; text-align: left">Research and development</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 14%; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,546</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">452</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--GeneralAndAdministrativeExpense_i01_msCzv8R_zGnedvkkJMN2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,047</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">521</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--ProfitLossFromOperatingActivities_i01T_mtCzv8R_maCzmY2_z39zZlkTY83k" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,593</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">973</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--GainsLossesOnChangeInFairValueOfWarrants_i01_maCzmY2_zu7o2svCTWof" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">13</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">369</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0135">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_i01_maCzmY2_zIP9tg861cZg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Share of (loss) income in associates accounted for using equity method</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">7</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">440</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--InterestExpense_i01N_di_msCzmY2_zQuNDV7orzya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Interest (expense)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">122</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--ProfitLossBeforeTax_i01T_mtCzmY2_maCzni6_zTSJ5Bv20w9i" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss before provision for income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,302</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">655</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--IncomeTaxExpenseContinuingOperations_i01N_di_msCzni6_ztQGG2qJ83H4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9.35pt">Income tax benefit</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">79</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0147">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--ProfitLoss_i01T_mtCzni6_maCzy7Z_zWIWgx5hfErj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,223</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">655</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eifrs-full--OtherComprehensiveIncomeAbstract_iB_ztCCY7AvDAR5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other comprehensive income (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--GainsOnDisposalsOfInvestmentProperties_i01_maCzy7Z_zBMyO96agkn" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 8.9pt">Unrealized gain on investments</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">6, 9</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0155">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GainsOnDisposalsOfInvestmentProperties" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--ComprehensiveIncome_i01T_mtCzy7Z_zS2u0UDZnxfd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive (loss) for period</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,223</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">577</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--ProfitLossAttributableToAbstract_iB_zSIbZLpYwqO" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net (loss) income attributable to:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_maNLIzdDY_maNLIzpYm_zN0sqcdNteN8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Owners of the Company</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,066</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">696</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--ProfitLossAttributableToNoncontrollingInterests_i01_maNLIzdDY_maNLIzpYm_zFWJ8Ws5hbm8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">21</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">157</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--NetLossIncome_i01T_mtNLIzdDY_mtNLIzpYm_zip2qshAZFfj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><b style="color: White">Net (loss) income</b></td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetLossIncome" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,223</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetLossIncome" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">655</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eifrs-full--ComprehensiveIncomeAttributableToAbstract_iB_z3Vbu1v0wmF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Comprehensive (loss) income attributable to:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--ComprehensiveIncomeAttributableToOwnersOfParent_i01_maTCLIFzhns_zFqC3LkW34Md" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Owners of the Company</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,066</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">618</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eifrs-full--ComprehensiveIncomeAttributableToNoncontrollingInterests_i01_maTCLIFzhns_zv0YciRxZjWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">21</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">157</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--TotalComprehensiveLossIncomeForYear_i01T_mtTCLIFzhns_z125zdIftnj5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><b style="color: White">Total comprehensive (loss) income for year</b></td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:TotalComprehensiveLossIncomeForYear" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,223</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:TotalComprehensiveLossIncomeForYear" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">577</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--EarningsPerShareAbstract_iB_zW36izj5Rmn" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">(Loss) per share</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">16</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--BasicAndDilutedLossPerShare_i01_pip0_zFpWqe2XKqLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:BasicAndDilutedLossPerShare" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.25</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:BasicAndDilutedLossPerShare" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.06</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_iB_zDHGfv3iluXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Weighted average shares outstanding</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">16</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WeightedAveragesSharesoutstandingBasicAndDiluted_i01_zJNcS1MF7wi6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 8.9pt">Basic and diluted</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">12,213</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">11,104</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Statements of Changes in Shareholders&#8217;
Equity</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>For the Three Months Ended June 30, 2021 and 2020</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; see Notice to Reader dated August <span style="background-color: white">30</span>,
2021)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_114_pn3n3_zM2UTsdia1zb" summary="xdx: Statement - Condensed Consolidated Interim Statements of Changes in Shareholders&apos; Equity (Unaudited)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_4B5_ifrs-full--ComponentsOfEquityAxis_ifrs-full--IssuedCapitalMember_z5GGg0VokMI7" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_4B7_ifrs-full--ComponentsOfEquityAxis_custom--StockOptionReserveMember_zooyJfiYrHPe" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_4BF_ifrs-full--ComponentsOfEquityAxis_ifrs-full--AccumulatedOtherComprehensiveIncomeMember_zLRlDQAr1OR4" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_4B4_ifrs-full--ComponentsOfEquityAxis_ifrs-full--RetainedEarningsMember_zFePQpEmBmM1" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_4B2_ifrs-full--ComponentsOfEquityAxis_ifrs-full--EquityAttributableToOwnersOfParentMember_zCGBTMSdsNR3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_4B0_ifrs-full--ComponentsOfEquityAxis_ifrs-full--NoncontrollingInterestsMember_zBcIfi3nKloj" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_4B3_z9eiHqkEv7tb" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Capital Stock</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Accumulated <br />Other Comprehensive Income</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Retained Earnings<br /> (Accumulated Deficit)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Equity Attributable to Owners of Company</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-controlling Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total Equity</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt; white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td></tr>
  <tr id="xdx_43B_c20200401__20200630_eifrs-full--Equity_iS_zp6xnV3Z8Tfi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; width: 44%; font-size: 10pt">Balance, April 1, 2020</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfSharesOutstanding_iS_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z54SCkClJPT4" title="Balance, shares" style="width: 4%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">10,988</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,817</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">958</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,302</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96,531</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49,110</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145,641</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IssuedUnderPrivatePlacement_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">Issued under private placement</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--IssuedUnderPrivatePlacementShares_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zE5klEaMCNM2" title="Issued under private placement, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:IssuedUnderPrivatePlacementShares" contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">698</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:IssuedUnderPrivatePlacement" contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,980</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0208">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0209">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:IssuedUnderPrivatePlacement" contextRef="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,980</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0212">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:IssuedUnderPrivatePlacement" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,980</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--PaymentsForShareIssueCosts_iN_di_zzGZN67dWNVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt">Share issuance costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">248</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0219">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0220">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">248</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0222">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">248</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">Share-based compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0227">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0228">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0229">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--UnrealizedLossOnInvestmentInInvestments_zg5Hnn26Yx9c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">Unrealized gain  on investments</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0234">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:UnrealizedLossOnInvestmentInInvestments" contextRef="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">79</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:UnrealizedLossOnInvestmentInInvestments" contextRef="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">79</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:UnrealizedLossOnInvestmentInInvestments" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">79</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--ProfitLoss_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss for period</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8211;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0241">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0242">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">696</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">696</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">655</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_433_c20200401__20200630_eifrs-full--Equity_iE_zyj6TQkWP0Sd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; padding-bottom: 2.5pt">Balance, June 30, 2020</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfSharesOutstanding_iE_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z4onTO46evTj" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2020-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">11,686</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">124,549</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-06-30_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,037</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,998</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102,646</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-06-30_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49,446</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">152,092</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20210401__20210630_eifrs-full--Equity_iS_z8lDBPJmvva8" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold">Balance, April 1, 2021</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NumberOfSharesOutstanding_iS_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zAW3PxrDvTOf" title="Balance, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">12,084</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130,649</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,977</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">958</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,135</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101,449</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,153</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147,602</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_zFFz5HQO85c1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,082</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,082</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,180</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--SharesIssuedUnderAtm_iP3ifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_zusxifa1jrhf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Shares issued under ATM</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharesIssuedUnderAtmShares_iP3custom--SharesIssuedUnderAtm_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zczT48LsYk1" title="Shares issued under ATM, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtmShares" contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">91</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,643</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,643</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,643</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--SharesIssuedUnderOffering_iP3custom--SharesIssuedUnderAtmShares_zATCIJXBqO94" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Shares issued under offering</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--SharesIssuedUnderOfferingShares_iP3custom--SharesIssuedUnderOffering_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zuwDVSvyUx2e" title="Shares issued under offering, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderOfferingShares" contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,150</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,450</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,450</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,450</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--PaymentsForShareIssueCosts_iN_di_zNdlsDSm8MAj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold">Share issuance costs</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,877</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,877</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,877</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--SharesIssuedOrAccruedForServices_iP3ifrs-full--PaymentsForShareIssueCosts_zSWD82TsVBl1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Shares issued or accrued for services</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharesIssuedOrAccruedForServicesShares_iP3custom--SharesIssuedOrAccruedForServices_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zzGNtOnXRtL5" title="Shares issued or accrued for services, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServicesShares" contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--ProfitLoss_zMmzO3MrY9Fb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss for period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,066</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,066</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">157</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,223</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20210401__20210630_eifrs-full--Equity_iE_zITVIDUKOOE5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, June 30, 2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NumberOfSharesOutstanding_iE_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zQNBVDWojrD8" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13,326</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">157,895</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,059</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">958</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">41,201</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127,711</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,094</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">173,805</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Statements of Cash Flows</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>For the Three Months Ended June 30, 2021 and 2020</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars in thousands)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; see Notice to Reader dated August <span style="background-color: white">30</span>,
2021)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_112_pn3n3_zeS3dDkYEOde" summary="xdx: Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_499_20210401__20210630_zpUTK3ILDRl9" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_49F_20200401__20200630_z7efInQ5wvl1" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td></tr>
  <tr id="xdx_403_eifrs-full--CashFlowsFromUsedInOperatingActivitiesAbstract_iB_z3rfp8vOTkic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Cash flows provided by (used in) operating activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--ProfitLoss_i01_maCzosB_zAjA7Q06swOd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 70%; font-size: 10pt; text-align: left">Net loss for the period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,223</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">655</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--AdjustmentsForReconcileProfitLossAbstract_i01B_zLifDMRn5q2j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Adjustments for non-cash items:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--IncreaseDecreaseInDeferredTaxLiabilityAsset_i02_maCzosB_zeJS97oaTiv9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Increase in deferred tax liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--LossIncomeOnFairValueOfWarrantLiability_i02_maCzosB_zT293I2y6xS" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Income on fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossIncomeOnFairValueOfWarrantLiability" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">369</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ValueOfSharesIssuedForServices_i02_maCzosB_zfegJZK3Jhb2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">Value of shares issued for services</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ValueOfSharesIssuedForServices" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--AdjustmentsForAmortisationExpense_i02_maCzosB_zSeQsXnJBroe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Amortization of debt discount</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForAmortisationExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--GainLossOnHedgeIneffectiveness_i02_maCzosB_zwed9267bYo" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Share of loss (gain) in associates</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectiveness" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectiveness" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">440</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--AdjustmentsForSharebasedPayments_i02_maCzosB_zqKyrlyCBwj4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Stock-based compensation expense</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,180</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">296</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--NetChangeInWorkingCapitalComponentsAbstract_i01B_zAPq2xQawNU" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Changes in operating working capital:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IncreasingDecreasingAccountsReceivable_i02_maCzosB_zft1P0LBQwo5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accounts receivable</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:IncreasingDecreasingAccountsReceivable" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">215</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--AdjustmentsForDecreaseIncreaseInOtherAssets_i02_maCzosB_zkcISq8WUn8h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">394</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAccountPayable_i02_maCzosB_zWYhltQUHtq6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accounts payable and accrued liabilities</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">544</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OtherAsset_i02_maCzosB_zggLMt8Or3Y9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:OtherAsset" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CashFlowsFromUsedInOperatingActivities_i01T_mtCzosB_maCzPQx_zBAxgACGEtTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20.15pt">Net cash used in operating activities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,580</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">688</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--CashFlowsFromUsedInInvestingActivitiesAbstract_iB_zeWOdZOeKjb4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Cash flows provided by (used in) investing activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--PurchaseOfInvestmentProperty_i01N_di_msCzPRS_zciv5cVLwXZ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9.35pt">Investment in associates</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfInvestmentProperty" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--CashFlowsFromUsedInInvestingActivities_i01T_mtCzPRS_maCzPQx_zbIVm7NMQZA6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20.15pt">Net cash used in investing activities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,000</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--CashFlowsFromUsedInFinancingActivitiesAbstract_iB_znYvfBYUiQ9l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Cash flows provided by (used in) financing activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ProceedsFromSharesIssuedUnderRegisteredOffering_i01_maCzrit_zXmYeMvVDai1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Proceeds from shares issued under registered offering</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderRegisteredOffering" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,093</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderRegisteredOffering" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,980</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ShareIssuanceCosts_i01N_di_msCzrit_zcWz8OKWP49k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; padding-bottom: 1pt">Share issuance costs</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,666</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">248</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eifrs-full--CashFlowsFromUsedInFinancingActivities_i01T_mtCzrit_maCzPQx_zsLAHl37wBa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20.15pt">Net cash provided by financing activities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,427</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,732</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--IncreaseDecreaseInCashAndCashEquivalents_iT_mtCzPQx_zFLwXpHJhxaf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Increase in cash and cash equivalents during period</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,847</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,044</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CashAndCashEquivalents_iS_zwSjUDN8tHo3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,770</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,152</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CashAndCashEquivalents_iE_z3fbNYjDqxY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,617</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,196</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--SupplementalDisclosureOfCashFlowInformation_iB_zweaijCHrQ6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--CashPaidForInterest_i01_zFSaXJiMlPgb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CashPaidForInterest" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IncreaseInAccountsPayableForStockIssuanceCosts_i01_zHoisNOK7Ggk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -9.35pt; padding-left: 10pt">Increase in accounts payable for stock issuance costs</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:IncreaseInAccountsPayableForStockIssuanceCosts" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">210</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract_iB_ziarFqXmJx6f" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FairValueOfWarrantLiabilityForPortageWarrantsIssued_i01_zPViZUqA4K3d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Fair value of warrant liability for Portage warrants issued</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantLiabilityForPortageWarrantsIssued" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">751</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--UnrealizedLossOnInvestmentInInvestment_i01_zPWCpPNEqC04" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Unrealized (loss) on investment in investments</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:UnrealizedLossOnInvestmentInInvestment" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>












<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated August <span style="background-color: white">30</span>,
2021)</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:NatureOfOperationsTextBlock"><p id="xdx_801_ecustom--NatureOfOperationsTextBlock_zGbLtoA3Nq6k" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
1. <span id="xdx_82F_z2lcUwxfNAW6">NATURE OF OPERATIONS</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Portage
Biotech Inc. (the &#34;Company&#34; or &#8220;Portage&#8221;) is incorporated in the British Virgin Islands (&#34;BVI&#34;) with its
registered office located at FH Chambers, P.O. Box 4649, Road Town, Tortola, BVI. Its Toronto agent, Portage Services Ltd., is located
at 6 Adelaide Street East, Suite 300, Toronto, Ontario, M5C 1H6, Canada.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is a reporting issuer with the securities commissions of the provinces of Ontario and British Columbia. Its ordinary shares were
listed on the Canadian Stock Exchange (&#8220;CSE&#8221;) under the symbol &#8220;PBT.U&#8221;. On February 25, 2021, the ordinary shares
of the Company began trading on the NASDAQ Capital Market (&#8220;NASDAQ&#8221;) under the symbol &#8220;PRTG&#8221;. The Company voluntarily
delisted its common shares from the CSE at the market close on April 23, 2021, since the Company&#8217;s shares began trading on NASDAQ.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Portage
is a clinical stage immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets
at various development stages. We source, nurture and develop the creation of early- to mid-stage, first- and best-in-class therapies
for a variety of cancers, by funding, implementing viable, cost effective product development strategies, clinical counsel/trial design,
shared services, financial and project management to enable efficient, turnkey execution of commercially informed development plans.
Our drug development pipeline portfolio encompasses products or technologies based on biology addressing known resistance pathways/mechanisms
of current check point inhibitors with established scientific rationales, including intratumoral delivery, nanoparticles, liposomes,
aptamers, and virus-like particles.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
August 13, 2018, the Company reached a definitive agreement to acquire <span id="xdx_902_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pdp0_dp_c20180813__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zcxKJl7CVWq8"><ix:nonFraction name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" contextRef="AsOf2018-08-13_custom_SalvaRxGroupPlcMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of SalvaRx Limited (&#8220;SalvaRx&#8221;) in exchange for <span id="xdx_906_eifrs-full--NumberOfInstrumentsOrInterestsIssuedOrIssuable_iI_pid_uShares_c20180813__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zYRBfyjXUu2j"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" contextRef="AsOf2018-08-13_custom_SalvaRxGroupPlcMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,050,701</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">ordinary shares of the Company (the &#34;SalvaRx
Acquisition&#34;). The SalvaRx Acquisition was completed on January 8, 2019 (the &#8220;Acquisition Date&#8221;) upon receiving shareholder
and regulatory approval. In connection with the SalvaRx Acquisition, the Company acquired interests in SalvaRx&#8217;s five research
and development invested entities and subsidiaries: iOx Therapeutics Ltd. (&#8220;iOx&#8221;), Nekonal Oncology Limited (&#8220;Nekonal&#8221;),
Intensity Therapeutics, Inc. (&#8220;Intensity&#8221;), Saugatuck Therapeutics Ltd. (&#8220;Saugatuck&#8221;) and Rift Biotherapeutics
Inc. (&#8220;Rift&#8221;).&#160; In connection with the SalvaRx Acquisition, the Company also acquired an option in Nekonal SARL, a Luxembourg-based
company holding intellectual property rights for therapeutics and diagnostics in the field of autoimmune disorders and oncology, to participate
in the funding of its autoimmune programs. During fiscal 2021, the Company abandoned its interests in Nekonal.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">On
June 5, 2020, the Company effected a 100:1 reverse stock split. All share and per share information included in the consolidated financial
statements have been retroactively adjusted to reflect the impact of the reverse stock split. The shares of ordinary shares authorized
remained at an unlimited number of ordinary shares without par value.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Portage
filed a registration statement and prospectus with the Securities and Exchange Commission (&#8220;SEC&#8221;) pursuant to Rule 424(b)(2)
under which it may sell shares, debt securities, warrants and units that Portage may sell in one or more offerings from time to time,
which became effective on March 8, 2021 (&#8220;Registration Statement&#8221; or &#8220;Prospectus&#8221;). The Registration Statement
includes:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">a
                                            base prospectus, which covers the offering, issuance and sales by us of up to $<span id="xdx_90A_ecustom--IssuanceAndSales_pn3p0_c20210401__20210630_zTGX4glTyxdd" title="Issuance and sales"><ix:nonFraction name="ptgef:IssuanceAndSales" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">200,000,000</ix:nonFraction>
                                            </span></span><span style="font: 10pt Times New Roman, Times, Serif">in
                                            the aggregate of the securities identified above from time to time in one or more offerings;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">a
                                            sales agreement supplemental prospectus covering the offer, issuance and sale by us of up
                                            to a maximum aggregate offering price of up to $<span id="xdx_901_ecustom--MaximumAggregateOfferingPrice_pn3p0_c20210401__20210630_zukpUnWZB5u2" title="Maximum aggregate offering price"><ix:nonFraction name="ptgef:MaximumAggregateOfferingPrice" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">50,000,000</ix:nonFraction>
                                            </span></span><span style="font: 10pt Times New Roman, Times, Serif">of
                                            our ordinary shares that may be issued and sold from time to time at-the-market, under sales
                                            agreement, or sales agreement, with Cantor Fitzgerald &amp; Co., or Cantor Fitzgerald, the
                                            sales agent; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">a
                                            prospectus supplement dated June 24, 2021, for the offer, issuance and sale by us of 1,150,000
                                            ordinary shares for gross proceeds of approximately $26.5 million in a firm commitment underwriting
                                            with Cantor Fitzgerald.</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_232_zzaRRUGNkWI1" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div id="xdx_238_z2kVhbIRMjRl" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td id="xdx_237_z6vSAg1zq12i" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zVr2WVRwxxla" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_231_zl0oiiVMGuU5" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zJqnBRuSFA5i" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zBYme0XVMYhg" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_z1nVO2ulofv4" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zcTHgyPHeDGc" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated August <span style="background-color: white">30</span>,
2021)</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zkAQI9nFt7Jh" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zNRyN1kWh5w1" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zPtEcAbOLzO5" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 1. NATURE OF OPERATIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zIl8wDdXOZhc" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span id="xdx_90F_ecustom--CashFundDescription_c20210401__20210630" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="ptgef:CashFundDescription">The
specific terms of any securities to be offered through the sales agreement with Cantor Fitzgerald, in the at the market offering, are
specified in the sales agreement prospectus. The $50,000,000 of ordinary shares that may be offered, issued and sold under the sales
agreement prospectus is included in the $200,000,000 of securities that may be offered, issued and sold by us under the base prospectus.
The sales under the prospectus will be deemed to be made pursuant to an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4)
promulgated under the Securities Act of 1933 (the Securities Act). Upon termination of the sales agreement, any portion of the $50,000,000
included in the sales agreement prospectus that is not sold pursuant to the sales agreement will be available for sale in other offerings
pursuant to the base prospectus, and if no shares are sold under the sales agreement, the full $50,000,000 of securities may be sold
in other offerings pursuant to the base prospectus. See Note 2, &#8220;Liquidity&#8221; and Note 14, &#8220;Capital Stock&#8221; for
a further discussion.</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:LiquidityTextBlock"><p id="xdx_800_ecustom--LiquidityTextBlock_z6ArZJZLYESf" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
2. <span id="xdx_823_zLyl4Ou6YAE9">LIQUIDITY</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, the Company had cash and cash equivalents of $<span id="xdx_904_eifrs-full--Cash_iI_pn3n3_dm_c20210630_zI0LcaPotXu2"><ix:nonFraction name="ifrs-full:Cash" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">28.6</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million and total current liabilities of $2.5
million <span id="xdx_900_eifrs-full--CurrentLiabilities_iI_pn3n3_c20210630_zOdx01OTFGhf" style="display: none"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,506</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">(inclusive
of $0.7 million warrant liability settleable on a non-cash basis). For the three months ended June 30, 2021, the Company is reporting
a net loss of ($3.2) million <span id="xdx_904_eifrs-full--ProfitLoss_iN_pn3n3_di_c20210401__20210630_zokCQreGsQQh" style="display: none"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,223</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">and
cash used in operating activities of $1.6 million<span id="xdx_903_eifrs-full--CashFlowsFromUsedInOperatingActivities_pn3n3_c20210401__20210630_zfekiL6TnMF1" style="display: none">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,580</ix:nonFraction>)</span></span><span style="font: 10pt Times New Roman, Times, Serif">.
As of July 31, 2021, we had approximately $<span id="xdx_903_eifrs-full--CashOnHand_iI_pn3n3_dm_c20210630_zupEaMVPfY2d"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">28.0</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
of cash on hand.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span id="xdx_900_ecustom--OfferingAndThroughThatProcessDescription_c20210401__20210630_zzJfa1HSREWe" title="Offering and through that process description" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="ptgef:OfferingAndThroughThatProcessDescription">During the quarter ended June 30, 2021, the Company commenced an &#8220;at the market&#8221; offering, under which
it sold 90,888 shares generating gross proceeds of approximately $2.6 million ($2.5 million, net of commissions). Further,
the Company initiated an offering pursuant to the Prospectus. On June 24, 2021, the Company completed a firm commitment underwritten
public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $26.5
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $1.8
million, including approximately $1.6 million of management, underwriting and selling expenses. The Company will use the net proceeds
raised to fund its research and development activities and support operations. The amount raised is sufficient to fund operations through
September 2022. Funds may be used to accelerate development activities to advance the Company&#8217;s product portfolio, working capital
and general corporate purposes</ix:nonNumeric></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the
foreseeable future and may never become profitable. The losses result primarily from its conduct of research and development activities.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company historically has funded its operations principally from proceeds from issuances of equity and debt securities and would expect
to enter the capital markets if additional funding is required.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_238_ze7tNEzfrD61" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div id="xdx_23F_zR5NPhDZPK8g" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zAi7zym4eMNe" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td id="xdx_238_ze0faGbOTuIg" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zVnE6LWtpt29" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zYAmyakDbif6" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_z1eJN1Muk7i3" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zPdcpDDqHUjf" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zULA2XC6Wk2c" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated August <span style="background-color: white">30</span>,
2021)</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zZcDEq1zeK9f" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zbLzss5DvUnd" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>&#160;</i></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zj7qmkgj7mKl" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 2. LIQUIDITY <span style="background-color: white"><i>(Cont&#8217;d)</i></span></b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zoDJUY3QmLej" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>COVID-19 Effect</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">B<span style="font: 10pt Times New Roman, Times, Serif">eginning
in early March 2020, the COVID-19 pandemic and the measures imposed to contain this pandemic have disrupted and are expected to continue
to impact the Company's business operations. The magnitude of the impact of the COVID-19 pandemic on the Company's productivity, results
of operations and financial position, and its disruption to the Company's business and clinical programs and timelines, will depend,
in part, on the length and severity of these restrictions and on the Company's ability to conduct business in the ordinary course.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfBasisOfConsolidationExplanatory"><p id="xdx_80B_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_zFnmQM81bXg4" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
3. <span id="xdx_822_zZne0Bfe82Vg">BASIS OF PRESENTATION</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Statement
of Compliance and Basis of Presentation</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">These
condensed consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards
(&#8220;IFRS&#8221;) issued by the International Accounting Standards Board (&#8220;IASB&#8221;), IAS 34 <i>Interim Financial Reporting
</i>and interpretations of the International Financial Reporting Interpretations Committee. These condensed consolidated interim financial
statements do not include all of the information required for full annual financial statements and should be read in conjunction with
the audited consolidated financial statements of the Company for the year ended March 31, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">These
condensed consolidated interim financial statements have been prepared on an historical cost basis except for items disclosed herein
at fair value (see Note ----19, Financial Instruments and Risk Management&#8221;). In addition, these condensed consolidated interim
financial statements have been prepared using the accrual basis of accounting, except for cash flow information.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has only one reportable operating segment.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">These
condensed consolidated interim financial statements were approved and authorized for issuance by the Audit Committee and Board of Directors
on August <span style="background-color: white">26</span>, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Consolidation</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
condensed consolidated interim financial statements include the accounts of the Company and,</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">(a)
SalvaRx Limited (&#8220;SalvaRx&#8221;), a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">(b)
iOx Therapeutics Ltd. (&#8220;iOx&#8221;), a United Kingdom based immune-oncology company, a <span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20150201__20150210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesOneMember_ztp9stDcFj0f"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2015-02-012015-02-10_custom_SubsidiariesOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.49</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
subsidiary, incorporated in the United Kingdom on February 10, 2015.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">(c)
Saugatuck Therapeutics, Ltd. (&#8220;Saugatuck&#8221;), a <span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_zyDYIPfh9ZY7"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-04-012021-06-30_custom_SubsidiariesTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
owned subsidiary incorporated in the British Virgin Islands.</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">(d)
Portage Developmental Services, a 100% owned subsidiary incorporated in Delaware, which provides human resources, and other services
to each operating subsidiary via a shared services agreement.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_234_zH2FzWlP2lO6" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div id="xdx_232_zbBhDIEGgF67" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td id="xdx_238_zVCcTPSwvIq3" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zxQKavkkiSW3" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zUnTyDAZM9Lg" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_z2l0loIyN3Hl" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zS8MY2vCsxP6" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_z0e9FqnT8EX2" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zVz93gjErnnf" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zkPxRUdWAbCk" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
3. BASIS OF PRESENTATION <i>(Cont'd)</i></b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zaRQsEAHw0Sg" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zE2KmFMgi405" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Consolidation
(Cont&#8217;d)</i></b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z5WArlr5jaMa" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following companies were disposed of on March 3, 2021 (see Note 8, &#8220;Disposition of PPL&#8221;):</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 12.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Portage
                                            Pharmaceuticals Ltd. (&#8220;PPL&#8221;), a wholly-owned subsidiary acquired in a merger
                                            on July 23, 2013, incorporated in the British Virgin Islands.</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 12.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">EyGen
                                            Limited, (&#8220;EyGen&#8221;), a wholly-owned subsidiary of PPL, incorporated on September
                                            20, 2016, in the British Virgin Islands.</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 12.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Portage
                                            Glasgow Ltd. (&#8220;PGL&#8221;), a <span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pdp0_dp_c20180103__20180131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PortageGlasgowLtdMember_zPapxxO7Q17d"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2018-01-032018-01-31_custom_PortageGlasgowLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">65</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
                                            subsidiary of PPL, incorporated in Glasgow, Scotland.</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">All
inter-company balances and transactions have been eliminated in consolidation.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">Non-controlling
interest in the equity of a subsidiary is accounted for and reported as a component of stockholders&#8217; equity. Non-controlling interests
represent the <span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesThreeMember_zZM5gvi1rFQk"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-04-012021-06-30_custom_SubsidiariesThreeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39.51</ix:nonFraction></span></span><span style="font: normal 10pt Times New Roman, Times, Serif">%
shareholder ownership interest in iOx and the <span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_zM3ZcHUgUOPj"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" contextRef="From2021-04-012021-06-30_custom_SubsidiariesTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></span></span><span style="font: normal 10pt Times New Roman, Times, Serif">%
shareholder ownership interest in Saugatuck, which are consolidated by the Company. In years prior to March 31, 2021, non-controlling
interest also included <span id="xdx_908_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--SubsidiariesMember_zclBkFNGkO7g"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" contextRef="From2021-04-012021-06-30_ifrs-full_SubsidiariesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span></span><span style="font: normal 10pt Times New Roman, Times, Serif">%
in PGL.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Functional
and Presentation Currency</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s functional and presentation currency is the U.S. Dollar.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Use of Estimates
and Judgments</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of the condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments,
estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income
and expenses. Actual results may differ from these estimates.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which
the estimates are revised and in any future periods affected.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Significant
areas where estimates are made include valuation of financial instruments, research and development costs, fair value used for acquisition
and measurement of share-based compensation. Significant areas where critical judgments are applied include assessment of impairment
of investments and goodwill and the determination of the accounting acquirer and acquiree in the business combination accounting.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Reclassifications</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Certain
prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on
the reported results of operations.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_231_zf9spB2v3kh6" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div id="xdx_238_zoWb71VFgX71" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td id="xdx_237_zLiUmXPSBCX1" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zljtmrQXhJNh" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_z3DDKI1Khti4" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zAXGi7xM47Uh" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zVR4t1BXNk6g" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zGszi5eCW0Y2" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zZs3W3gCLcJc" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"><p id="xdx_80C_eifrs-full--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_z4WsQ66SBqCh" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
4. <span id="xdx_823_zGRLTd8XwCPj">SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
accounting policies are set out in Note 4 to the fiscal 2021 audited consolidated financial statements. These policies have been applied
consistently to all periods presented in these condensed consolidated interim financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory"><p id="xdx_844_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_z4mLy5fbVNWa" style="margin: 0pt 0; font-size: 10pt"><span id="xdx_868_zhHGqONeO9Ik" style="font: 10pt Times New Roman, Times, Serif"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Impact of Adoption
of Significant New IFRS Standards in 2020</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(a)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            1: Presentation of Financial Statements, and IAS 8: Accounting Policies, Changes in Accounting
                                            Estimates and Errors (Amendment)</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendments to IAS 1 and IAS 8 clarify the definition of material and seek to align the definition used in the Conceptual Framework with
that in the standards themselves, as well as ensuring the definition of material is consistent across all IFRS. The Company adopted these
amendments effective January 1, 2020. The adoption of these amendments did not have a significant impact on the Company&#8217;s annual
consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(b)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Conceptual
                                            Framework for Financial Reporting</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b>Together
with the revised Conceptual Framework published in March 2018, the IASB also issued Amendments to References to the Conceptual Framework
in IFRS Standards. The Company adopted the Revised Conceptual Framework effective January 1, 2020. The adoption of these amendments did
not have a significant impact on the Company&#8217;s annual consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>IFRS Pronouncements
Issued But Not Yet Effective</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>New Accounting
Standards, Interpretations and Amendments</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Standards
issued but not yet effective up to the date of issuance of the Company's condensed consolidated interim financial statements are listed
below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date.
The Company intends to adopt those standards when they become effective.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(c)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Annual
                                            Improvements to IFRS Standards 2018-2020</b></span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.35in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
annual improvements process addresses issues in the 2018-2020 reporting cycles including changes to IFRS 9, &#8220;Financial Instruments,&#8221;
IFRS 1, &#8220;First Time Adoption of IFRS,&#8221; IFRS 16, &#8220;Leases,&#8221; and IAS 41, &#8220;Biological Assets&#8221;.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">i)
The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition of financial liabilities.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">ii)
The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent to also measure cumulative translation differences
using the amounts reported by the parent based on the parent&#8217;s date of transition to IFRS.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">iii)
The amendment to IFRS 16&#8217;s illustrative example 13 removes the illustration of payments from the lessor related to leasehold improvements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">These
amendments will be effective for annual periods beginning on or after January 1, 2022. The Company is currently evaluating the new guidance
and impacts on its consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_234_zuIKDlh6Bbxe" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div id="xdx_23D_zCTRY1Cs6ki4" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td id="xdx_23C_zTHC9vtUvYa3" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zFUBCGHo41H9" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zXTFrkH4aDKd" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zg6kdm5a1Nt7" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zJFr49G0er66" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zFuXtKgHUHSd" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zzYWaS5U1zh1" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zlyB5h6wQEP6" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
4. SIGNIFICANT ACCOUNTING POLICIES <i>(Cont'd)</i></b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zchl6t5abtPk" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(d)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            37: Onerous Contracts - Cost of Fulfilling a Contract</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment to IAS 37 clarifies the meaning of costs to fulfil a contract and that before a separate provision for an onerous contract
is established, an entity recognizes any impairment loss that has occurred on assets used in fulfilling the contract, rather than on
assets dedicated to the contract. This amendment will be effective for annual periods beginning on or after January 1, 2022. The Company
is currently evaluating the new guidance and impacts on its consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(e)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            16: Proceeds Before Intended Use</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment to IAS 16 prohibits an entity from deducting from the cost of an item of Property, plant and equipment any proceeds received
from selling items produced while the entity is preparing the assets for its intended use (for example, the proceeds from selling samples
produced when testing a machine to see if it is functioning properly). It also clarifies that an entity is testing whether the asset
is functioning properly when it assesses the technical and physical performance of the asset. The amendment also requires certain related
disclosures. This amendment will be effective for annual periods beginning on or after January 1, 2022. The Company is currently evaluating
the new guidance and impacts on its consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(f)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            1: Presentation of Financial Statements</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment to IAS 1 clarifies how to classify debt and other liabilities as either current or non-current. The amendment will be effective
for annual periods beginning on or after January 1, 2023. The Company is currently evaluating the new guidance and impacts on its consolidated
financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(g)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Amendments
                                            to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate
                                            or Joint Venture</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment addresses the conflict between IFRS 10 and IAS 28 in dealing with the loss of control of a subsidiary that is sold or contributed
to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that
constitute a business, as defined in IFRS 3, between an investor and its associate or joint venture, is recognized in full. Any gain
or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognized only to the extent
of unrelated investors' interests in the associate or joint venture. The IASB has deferred the effective date of these amendments indefinitely,
but an entity that early adopts the amendments must apply them prospectively. The Company is evaluating whether the adoption of the above
amendment will have a material impact on its financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23C_zhnkfB2IeA8" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div id="xdx_235_z9I7ifBmtpbk" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td id="xdx_239_zzkBdAEYR4Ej" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zeB1WdI3QJy3" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_23B_zNjTrBvWrnMl" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zxpl0mmNVgll" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_z9wIIWGs2zP" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zD0ZUO9IYS31" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zeLpu3e5q9Fh" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zAEsWTC5hID8" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfOtherAssetsExplanatory"><p id="xdx_809_eifrs-full--DisclosureOfOtherAssetsExplanatory_zT8NhJfCrF9a" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
5. <span id="xdx_822_zL3MH4R5mVM9">PREPAID EXPENSES AND OTHER RECEIVABLES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_zzPU8Y1MX4l" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span id="xdx_8B1_zATsIatsLBW3" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of prepaid expenses and other receivables</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_496_20210630_zLITEimfRkmb" style="white-space: nowrap; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_492_20210331_zc7OQMsU7nra" style="white-space: nowrap; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br /> June 30, 2021</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br /> March 31, 2021</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
    insurance</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:CurrentAdvancesToSuppliers" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,032</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:CurrentAdvancesToSuppliers" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,445</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Research
    &amp; development tax credits</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:ResearchAndDevelopmentCredit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">849</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:ResearchAndDevelopmentCredit" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">649</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Other
    prepaid expenses</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
    receivables</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--CurrentPrepayments_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    prepaid expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:CurrentPrepayments" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,995</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:CurrentPrepayments" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,176</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2016, the Company's wholly-owned subsidiary, PPL, agreed to a settlement, from a claim made against a supplier, to receive $<span id="xdx_90A_eifrs-full--Accruals_c20161031__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0"><ix:nonFraction name="ifrs-full:Accruals" contextRef="AsOf2016-10-31_custom_PPLSettlementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in annual instalments of $<span id="xdx_907_eifrs-full--LoansPayableInDefault_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0"><ix:nonFraction name="ifrs-full:LoansPayableInDefault" contextRef="AsOf2021-06-30_custom_PPLSettlementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,250</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">.&#160;
Through June 30, 2021, the Company has collected $<span id="xdx_909_eifrs-full--TradeAndOtherReceivables_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="AsOf2021-06-30_custom_PPLSettlementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">86,250</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">.
The balance of $<span id="xdx_900_eifrs-full--CurrentPortionOfLongtermBorrowings_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0"><ix:nonFraction name="ifrs-full:CurrentPortionOfLongtermBorrowings" contextRef="AsOf2021-06-30_custom_PPLSettlementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,750</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">was classified $11,250 as a current asset in
prepaid expenses and other receivables and $<span id="xdx_903_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivables" contextRef="AsOf2021-06-30_custom_PPLSettlementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,500</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">as a long-term receivable as of each of June
30, 2021 and March 31, 2021. The installment receivable was assigned to Portage by PPL prior to the disposition of PPL (see Note 8, &#8220;Disposition
of PPL&#8221;). The installment note was repaid in full in July 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfAvailableforsaleAssetsExplanatory"><p id="xdx_80D_eifrs-full--DisclosureOfAvailableforsaleAssetsExplanatory_zQ4StmvrigO7" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
6. <span id="xdx_825_ztpAoZiaBXYk">INVESTMENT IN MARKETABLE EQUITY SECURITIES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, the Company&#8217;s investment in marketable equity securities was comprised of <span id="xdx_906_ecustom--InvestmentInMarketableEquitySecurities_pp0p0_c20200401__20200630_zXT1LewwsJi7" title="Investment in marketable equity securities"><ix:nonFraction name="ptgef:InvestmentInMarketableEquitySecurities" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares in Biohaven Pharmaceutical Holding Company
Limited (&#8220;Biohaven&#8221;), a public company listed on the New York Stock Exchange. The Company accounted for its investment in
Biohaven as a financial asset classified as fair value through the statement of other comprehensive income (&#8220;FVTOCI&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2020, the Company sold the shares of Biohaven for proceeds of $<span id="xdx_90D_eifrs-full--ProceedsFromIssuingShares_c20200801__20200830__ifrs-full--TypeOfMeasurementOfExpectedCreditLossesAxis__custom--BiohavenMember_pp0p0"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="From2020-08-012020-08-30_custom_BiohavenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">resulting in a gain of $<span id="xdx_903_ecustom--UnrealizedGains_c20200801__20200830__ifrs-full--TypeOfMeasurementOfExpectedCreditLossesAxis__custom--BiohavenMember_pp0p0"><ix:nonFraction name="ptgef:UnrealizedGains" contextRef="From2020-08-012020-08-30_custom_BiohavenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table is a roll-forward of the investment in Biohaven as of June 30, 2021 and 2020:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfInvestmentPropertyExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_88D_eifrs-full--DisclosureOfInvestmentPropertyExplanatory_pn3n3_zEAii1U9Fq69" summary="xdx: Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8B8_zSrRpKxvKXVh" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of investment in marketable equity securities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--InvestmentAssetAvailableForSale_iS_pn3n3_c20210401__20210630_zCA5Qnlbfw9e" title="Balance, beginning of year" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--InvestmentAssetAvailableForSale_iS_pn3n3_c20200401__20200630_zlwkqBfF1wz1" title="Balance, beginning of year" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:InvestmentAssetAvailableForSale" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">68</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Unrealized
    gain on investment</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--UnrealizedLossGainOnInvestment_c20210401__20210630_pn3n3" title="Unrealized (loss) gain on investment" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--UnrealizedLossGainOnInvestment_c20200401__20200630_pn3n3" title="Unrealized (loss) gain on investment" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:UnrealizedLossGainOnInvestment" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--InvestmentAssetAvailableForSale_iE_pn3n3_c20210401__20210630_zP6Npos3TaPe" title="Balance, end of year" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--InvestmentAssetAvailableForSale_iE_pn3n3_c20200401__20200630_zsb26HMHNDYf" title="Balance, end of year" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:InvestmentAssetAvailableForSale" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">146</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:InvestmentInAssociateDisclosureTextBlock"><p id="xdx_807_ecustom--InvestmentInAssociateDisclosureTextBlock_zNgueblrnsHf" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
7. <span id="xdx_828_zIAPcWTwcxFf">INVESTMENT IN ASSOCIATE</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Details
of the Company&#8217;s associate as of June 30, 2021 and March 31, 2021 are as follows:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:DisclosureOfInvestmentAssociatetableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_z67DQh5jFEVl" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE  (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_8BA_zMrtrCHDZEqc" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of investment associate</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Principal
    Activity</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Place
    of Incorporation and <br />Principal Place of Business</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Voting
    Rights Held as <br />of June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Voting
    Rights Held as <br />of March&#160;31, 2021</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-size: 10pt; text-align: justify"><span id="xdx_906_eifrs-full--NameOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-04-012021-06-30_custom_StimunitySAMember" name="ifrs-full:NameOfAssociate">Associate:
    Stimunity S.A.</ix:nonNumeric></span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_907_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-04-012021-06-30_custom_StimunitySAMember" name="ifrs-full:PrincipalPlaceOfBusinessOfAssociate">Biotechnology</ix:nonNumeric></span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90E_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-04-012021-06-30_custom_StimunitySAMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfAssociate">Paris,
    France</ix:nonNumeric></span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90D_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z8kB5OGIJDr9" style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" contextRef="From2021-04-012021-06-30_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">44</ix:nonFraction></span><span style="font: 10pt Times New Roman, Times, Serif">.0%</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90B_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210101__20210331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zrKCG6wMVcLi" style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" contextRef="From2021-01-012021-03-31_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">44.0</ix:nonFraction></span><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><p id="xdx_8A2_zMp0Lez7Lbig" style="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
abovementioned associate is accounted for using the equity method in these condensed consolidated interim financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23B_zAFIigOt41C" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div id="xdx_23E_zgdRT6huVck6" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td id="xdx_23F_z4j2S1Jal7j7" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zlb66c1I43Ib" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zMncneFLQnsc" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zwYBkscKrxsf" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zgyisNwZbPIe" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zsbLwrN4feH1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zrVuRNRr5MKg" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zPifWudYNPB5" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
7. INVESTMENT IN ASSOCIATE (<i>Cont&#8217;d</i>)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zvFFWrp9LAE6" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table is a roll-forward of the Company&#8217;s investment in Stimunity S.A. as of June 30, 2021 and 2020:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:ScheduleOfInvestmentInStimunitySaTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_z2mnB0ETQFp1" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE  (Details 1)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B3_zZOiRpE3Z168" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of investment in Stimunity S.A.</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20210401__20210630_z9Y2sFe9cxhc" title="Balance" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,735</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20200401__20200630_ztP8YlyKyPad" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,225</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Additional
    investment</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--AdditionalInvestments_c20210401__20210630_pn3n3" title="Additional investment" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--AdditionalInvestments_c20200401__20200630_pn3n3" title="Additional investment" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:AdditionalInvestments" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Share
    of (loss) income</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--UnrecognisedShareOfGainLossesOfAssociates_pn3n3_c20210401__20210630_zyj2KG9btyu5" title="Share of (loss) income" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:UnrecognisedShareOfGainLossesOfAssociates" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--UnrecognisedShareOfGainLossesOfAssociates_pn3n3_c20200401__20200630_zlhnYiClQRm8" title="Share of (loss) income" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:UnrecognisedShareOfGainLossesOfAssociates" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">440</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20210401__20210630_z8ORzsOCDjP5" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,691</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20200401__20200630_zZNFddVsYCwi" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,665</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zgBSoYA7TdLb" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
June 1, 2020, the Company made an additional $<span id="xdx_90D_ecustom--AdditionalInvestments_pn3n3_dm_c20200530__20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zMcJ4aw24Umf"><ix:nonFraction name="ptgef:AdditionalInvestments" contextRef="From2020-05-302020-06-01_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.0</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million investment in Stimunity upon Stimunity's
achievement of certain agreed milestones, increasing its equity share in Stimunity to <span id="xdx_902_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zkmJHsDGjHP7"><ix:nonFraction name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" contextRef="From2021-04-012021-06-30_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">44</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
(see Note 17, &#8220;Commitments and Contingent Liabilities&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for its investment in Stimunity under the equity method and accordingly, records its share of Stimunity&#8217;s earnings
or loss based on its ownership percentage. The Company recorded equity in (loss) income in Stimunity of ($<span id="xdx_900_ecustom--EquityInLossIncome_pn3p0_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z1hYvKNiFmk6" title="Equity in loss income"><ix:nonFraction name="ptgef:EquityInLossIncome" contextRef="From2021-04-012021-06-30_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">44,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">)
and $<span id="xdx_90B_ecustom--EquityInLossIncome_pn3p0_c20200401__20200630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zJJo5SMvZXE9"><ix:nonFraction name="ptgef:EquityInLossIncome" contextRef="From2020-04-012020-06-30_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">440,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the three months ended June 30, 2021 and
2020, respectively.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Under
the shareholders agreement, Portage has (i) a preferential subscription right to maintain its equity interest in Stimunity in the event
of a capital increase from the issuance of new securities by Stimunity, except for issuances of new securities for stock options under
a merger plan or for an acquisition, or (ii) the right to vote against any (a) issuances of additional securities that would call for
the Company to waive its preferential subscription right, or (b) any dilutive issuance.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23A_zhtFRjTRKkKd" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zTJGp7ZWnFW5" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zithj4wFlBHk" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zxYrwrD9ZGB4" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zO6VeF8e4AGe" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zek84ylf2c6d" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zFVrAsJnQtn2" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zgm0pp9MfUY7" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zHKjy4TN6jU4" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zrQ4xPWT9R21" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zg3fOsR6KiYj" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_znC45FMJjc43" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div id="xdx_23B_zqmsmD5gXBNd" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td id="xdx_23D_zR4cNdfkBXH7" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_z9HnYs07sbUe" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_z691BhilP7r8" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zseSbnZwTkc5" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_znpDwByXUt8k" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zKZ8UgW2Riz4" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zvP44go4Tgo8" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:DispositionOfPplTextBlock"><p id="xdx_807_ecustom--DispositionOfPplTextBlock_zFwwE7s7p7La" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
8. <span id="xdx_829_zDtrM7TLPvs1">DISPOSITION OF PPL</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
March 3, 2021, the Company disposed of <span id="xdx_908_ecustom--DispositionPercentage_dp_c20210301__20210303__dei--LegalEntityAxis__custom--PortageGlasgowLtdMember_zojUfQwrx9Ui" title="Disposition Percentage"><ix:nonFraction name="ptgef:DispositionPercentage" contextRef="From2021-03-012021-03-03_custom_PortageGlasgowLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of its interest in PPL, which includes PPL&#8217;s interest in PGL and EyGen for $<span id="xdx_90A_ecustom--DispositionValue_pp0p0_c20210301__20210303__dei--LegalEntityAxis__custom--PortageGlasgowLtdMember_z6e1bqDWqmNd" title="Disposition value"><ix:nonFraction name="ptgef:DispositionValue" contextRef="From2021-03-012021-03-03_custom_PortageGlasgowLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">to an entity controlled by one of the Company&#8217;s
current directors and one of the Company&#8217;s former directors (the &#8220;Purchaser&#8217;s Executives&#8221;). Under the terms of
the arrangement, all outstanding payable obligations were assumed by the purchaser. Simultaneously, the Company and the Purchaser&#8217;s
Executives entered into a Revenue Share Deed with PPL under which they will be entitled to certain revenue shares based on the achievement
of milestones defined in the Revenue Share Deed. The Company may also be entitled to recover an intercompany receivable from the purchaser
in the amount of $<span id="xdx_908_ecustom--IntercompanyReceivable_iI_pp0p0_c20210303__dei--LegalEntityAxis__custom--PortageGlasgowLtdMember_zYWRAmXayFtg" title="Intercompany receivable"><ix:nonFraction name="ptgef:IntercompanyReceivable" contextRef="AsOf2021-03-03_custom_PortageGlasgowLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">229,848</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">on the fourth anniversary of the Revenue Share
Deed. The Company valued its interest in the Revenue Share Deed and the recovery of the $229,848 at zero for financials statement purposes.
All other intercompany balances were cancelled. The Company no longer has any interest or obligations associated with PPL, PGL and EyGen,
other than the interests provided for in the Revenue Share Deed.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock"><p id="xdx_80B_ecustom--DisclosureOfPrivateCompaniesExplanatoryTextBlock_zIxMHPCnZrwe" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
9. <span id="xdx_823_z5UEKgMCo2p3">INVESTMENTS IN PRIVATE COMPANIES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following is a discussion of our investments in private companies as of June 30, 2021 and March 31, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Sentien</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2015, the Company acquired <span id="xdx_90E_ecustom--InvestmentOwnedShares_iI_c20150831__ifrs-full--CounterpartiesAxis__custom--SeriesAPreferredStockInSentienBiotechnologiesMember_zQjWjYloYLBj"><ix:nonFraction name="ptgef:InvestmentOwnedShares" contextRef="AsOf2015-08-31_custom_SeriesAPreferredStockInSentienBiotechnologiesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,210</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Series A preferred stock in Sentien
(&#8220;Preferred Stock&#8221;), a Medford, MA based private company for $700,000 of cash. The Preferred Stock is fully convertible into
an equal number of common shares. The Company&#8217;s holdings represent <span id="xdx_906_ecustom--InvestmentOwnershipPercentage_iI_dp_c20210331__ifrs-full--CounterpartiesAxis__custom--SeriesAPreferredStockInSentienBiotechnologiesMember_zCPDoNwOxsbj"><ix:nonFraction name="ptgef:InvestmentOwnershipPercentage" contextRef="AsOf2021-03-31_custom_SeriesAPreferredStockInSentienBiotechnologiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.06</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity of Sentien on a fully diluted basis as of June 30, 2021 and March 31, 2021, respectively. The investment in Sentien has
been irrevocably designated as a financial asset recorded at fair value with changes in fair value recorded through other comprehensive
income. As of March 31, 2020, the Company recorded an unrealized loss of $<span id="xdx_909_ecustom--UnrealizedGainLossOnInvestment_pn3n3_dm_c20210401__20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_z2ZHsIjzFTFk"><ix:nonFraction name="ptgef:UnrealizedGainLossOnInvestment" contextRef="From2021-04-012021-06-30_custom_IntensityMember_custom_AcquisitionOfSalvaRxMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.7</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million after determining that cost no longer
was the best estimate of fair value due to a significant change in the strategy of Sentien and determined that the investment in Sentien
no longer had any fair value as Sentien was no longer pursing the proposed indication from the time of the Company's initial investment.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Intensity</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the SalvaRx Acquisition in fiscal 2019, the Company acquired a $4.5 million interest in Intensity, a clinical stage biotechnology
company, of <span id="xdx_90B_ecustom--InvestmentOwnedShares_iI_pp0n3_dm_c20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_zbmw6dwLk7j5"><ix:nonFraction name="ptgef:InvestmentOwnedShares" contextRef="AsOf2021-06-30_custom_IntensityMember_custom_AcquisitionOfSalvaRxMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="Shares">1.0</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million shares, which represented a <span id="xdx_90A_ecustom--InvestmentOwnershipPercentage_iI_dp_c20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_zbksqj4IWeg3"><ix:nonFraction name="ptgef:InvestmentOwnershipPercentage" contextRef="AsOf2021-06-30_custom_IntensityMember_custom_AcquisitionOfSalvaRxMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
equity interest in Intensity. The investment was recorded at fair value (which approximates cost) at the acquisition date. The investment
in Intensity has been irrevocably designated as a financial asset recorded at fair value with gains and losses recorded through other
comprehensive income. The fair value of the asset is determined by considering other comparable equity funding transactions by Intensity
with unrelated investors.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
July 11, 2019, the Company entered into an agreement with Fast Forward Innovations Limited (&#34;Fast Forward&#34;) to purchase Intensity
Holdings Limited (&#34;IHL&#34;), a wholly-owned subsidiary of Fast Forward. The Company paid $<span id="xdx_909_eifrs-full--EquityInterestsOfAcquirer_iI_pn3n3_dm_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zmpUmR68PASd"><ix:nonFraction name="ifrs-full:EquityInterestsOfAcquirer" contextRef="AsOf2019-07-11_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.3</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million for IHL through the issuance of <span id="xdx_90D_eifrs-full--NumberOfInstrumentsOrInterestsIssuedOrIssuable_iI_uShares_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_znzpDI4xcVl6"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" contextRef="AsOf2019-07-11_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">129,806</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">ordinary shares. The sole asset of IHL consists
of <span id="xdx_902_ecustom--NumberOfPrivateCompanyShareConsistsInSoleAsset_iI_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zIUbGEVr0V4h"><ix:nonFraction name="ptgef:NumberOfPrivateCompanyShareConsistsInSoleAsset" contextRef="AsOf2019-07-11_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">288,458</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the private company, Intensity. This
transaction increased the Company's ownership to <span id="xdx_909_eifrs-full--NumberOfSharesOutstanding_iI_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zspeD25odiX8"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2019-07-11_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,288,458</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Intensity.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended March 31, 2020, the Company recorded an unrealized gain of $<span id="xdx_907_ecustom--UnrealizedGainLossOnInvestment_pn3n3_dm_c20200401__20200630__ifrs-full--CounterpartiesAxis__custom--IntensityMember_ziHX5cqInkz5"><ix:nonFraction name="ptgef:UnrealizedGainLossOnInvestment" contextRef="From2020-04-012020-06-30_custom_IntensityMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.6</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million with respect to its investment in Intensity
based upon Intensity&#8217;s then most recent valuation. There were no unrealized gains or losses recognized in the three-month periods
ended June 30, 2021 and 2020.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of each of June 30, 2021 and March 31, 2021, the Company owned approximately <span id="xdx_908_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_dp_c20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zb1vK55IFOQb"><ix:nonFraction name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" contextRef="AsOf2021-06-30_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the outstanding shares of Intensity, on a fully diluted basis.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:exclude><p id="xdx_239_zC6Ge3rUcgz" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 1 -->
    <div id="xdx_232_zSppdQzPYijb" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zHrTIx4zCFU3" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td id="xdx_23A_zeo7UmukWWcg" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_z5dpflnXz0O7" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zYq2JVkHD4Ri" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zZTr7SRfWaVa" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zQp86B1eIlse" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zqf3MsVyNhVd" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zZzfCxQoG6o7" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory"><p id="xdx_80D_eifrs-full--DisclosureOfResearchAndDevelopmentExpenseExplanatory_zoQbroQX59w7" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
10. <span id="xdx_822_zdx7OPza6mSl">GOODWILL</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_zmHSAVyZd0R6" summary="xdx: Disclosure - GOODWILL (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span id="xdx_8B3_zwqsJO77v4r5" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of IPR&amp;D projects</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br /> June 30, 2021</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br /> March 31, 2021</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eifrs-full--Goodwill_iI_pn3n3_c20210331_znUtYuntDBEk" title="Goodwill" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,324</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--Goodwill_iI_pn3n3_c20200331_zSHCIr1yeFxf" title="Goodwill" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,324</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--Goodwill_iI_pn3n3_c20210630_zeVA6ToRAL12" title="Goodwill" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,324</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">43,324</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s goodwill arose from the acquisition of SalvaRx and its portfolio of several projects and investments.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, the Company determined that it has only one cash-generating unit (&#8220;CGU&#8221;), the consolidated Portage Biotech,
Inc.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Impairment
Review</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">On
an annual basis, pursuant to IAS 36, &#8220;Impairment of Assets,&#8221; the Company assesses its long-lived assets with definite lives,
which are not yet available for use, for potential indicators of impairment.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">If
any such indication exists, the Company estimates the recoverable amount of the asset or CGU and compares it to the carrying value.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company performed its annual impairment test in each of fiscal 2021 and fiscal 2020 and estimated the recoverable amount of the above-noted
CGU based on its value in use, which was determined using a capitalized cash flow methodology and categorized within level 3 of the fair
market value hierarchy.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_230_zS50kZFuBnuh" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z0Qz8i3pauCj" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zSYBSYP8ziD8" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zR6pkJRQKK29" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zw20JF53rHKc" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 1 -->
    <div id="xdx_23A_zGvBLxZsV8Nc" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td id="xdx_23B_zGTAJo8BXTRg" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zOdIu28YWfb9" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zOPUblD7LUP" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zcBKuKMc8ZF5" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zkKHSIAhYbm8" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zrt6KVdy0Slb" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zh1BZ8K7Cl3b" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zNRO1Lqkd5Cg" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
10. GOODWILL <i>(Cont&#8217;d)</i></b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zpeH2XjOLIVd" style="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
recoverable amount of the CGU has been determined based on its value in use. The recoverable amount considered assumptions based on probabilities
of technical, regulatory and clinical acceptances and financial support. Further, Management uses risk-adjusted cash flow projections
based on financial budgets. Management believes that any reasonably possible change in the key assumptions on which the recoverable amount
is based would not cause the carrying amount to exceed its recoverable amount. The discount rate has been determined based on the Company&#8217;s
best estimate of a risk adjusted discount rate.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
key assumptions used in the calculation of the recoverable amount include forecasts of the following:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">revenues;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">normalized
                                            operating expenses;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(c)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">income
                                            taxes; and</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(d)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">capital
                                            expenditures.</span></td>
</tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">Discounted
cash flows are determined with reference to undiscounted risk adjusted cash flows, and the discount rate approximated <span id="xdx_90D_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_dp_c20210630_zvsSfxI3eRV4"><ix:nonFraction name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20.0</ix:nonFraction></span></span><span style="font: normal 10pt Times New Roman, Times, Serif">%
and <span id="xdx_90F_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_dp_c20210331_z7BKk5fH5mih"><ix:nonFraction name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20.5</ix:nonFraction></span></span><span style="font: normal 10pt Times New Roman, Times, Serif">%
as of March 31, 2021 and 2020, respectively, based on the individual characteristics of the Company&#8217;s CGU, the risk-free rate of
return and other economic and operating factors.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 28.1pt; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">Additionally,
at the end of each reporting period, the Company is required to assess whether there is any indication that an asset may be impaired.
Pursuant to IAS 36, the Company reviewed its assets for any indicators of impairment and considered underlying fundamentals, execution,
de-risking/advancement of assets and the value creation activities during the three months ended June 30, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">As
of June 30, 2021, management assessed whether any indications of impairment existed for the Company&#8217;s CGU and concluded no indicators
were present. Therefore, a test for impairment was not required and no impairment was recorded for the three months ended June 30, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability"><p id="xdx_80A_ecustom--InProcessResearchAndDevelopmentAndDeferredTaxLiability_zFU0nASzyqN4" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
11. <span id="xdx_827_zLFz3OUZaRC5">IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In-process
research and development (&#8220;IPR&amp;D&#8221;) consists of the following projects (in 000&#8217;$):</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_zy1DxOYFfoY3" summary="xdx: Disclosure - IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold"><span id="xdx_8BF_zTlal8IvyLKh" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of In process research and development</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Project
    #</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Description</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value
    as of <br />June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value
    as of <br />March 31, 2021</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">iOx:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 25%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">IMM 60</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Melanoma
    &amp; Lung Cancers</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_z3i3mZ6d6ZE5" title="In-process research and development" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2021-06-30_custom_IMM60IOXMelanomaLungCancersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84,213</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_zPtYiObznPV" title="In-process research and development" style="width: 22%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2021-03-31_custom_IMM60IOXMelanomaLungCancersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84,213</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">IMM 65</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Ovarian/Prostate
    Cancers</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_zG31u7vWUGz3" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2021-06-30_custom_IMM65IOXOvarianProstateCancersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,997</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_zax1oFtyREpb" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2021-03-31_custom_IMM65IOXOvarianProstateCancersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,997</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">117,210</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">117,210</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Oncomer/Saugatuck</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">DNA
    Aptamers</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zU6geDRVgr47" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2021-06-30_custom_OncomerSaugatuckDNAAptamersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zhv7HNT8Gt7g" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2021-03-31_custom_OncomerSaugatuckDNAAptamersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--InprocessResearchAndDevelopment_c20210630_pn3n3" title="In-process research and development" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,388</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--InprocessResearchAndDevelopment_c20210331_pn3n3" title="In-process research and development" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,388</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
    tax liability</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eifrs-full--DeferredTaxLiabilities_c20210630_pn3n3" title="Deferred tax liability" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,171</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--DeferredTaxLiabilities_c20210331_pn3n3" title="Deferred tax liability" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,050</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:exclude><p id="xdx_234_zGIymqRNdRN6" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zN7UrJeSRqD1" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zLFkToRRN056" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zrwHVBqC5Cue" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 18; Value: 1 -->
    <div id="xdx_234_zqtYlmYM79Qi" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td id="xdx_23B_zBdk49eGe5Fj" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zqaxqvovt3rd" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zTRJNVW6zkfk" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zz1NkQeatQKi" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zNsjsU5bkKL1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zCw7oDnq0pnb" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zwCpucSPiiZ4" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zaUHKlHlanwf" style="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">NOTE
11. IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY <i>(Cont&#8217;d)</i></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zHgvWaiPUFS6" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, management assessed whether any indications of impairment existed for the Company&#8217;s IPR&amp;D and concluded no
indicators were present. Therefore, a test for impairment was not required and no impairment was recorded for the three months ended
June 30, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
tax liability (DTL) represents iOx&#8217;s estimated tax on the difference between book and tax basis of the IPR&amp;D which is taxable
in the United Kingdom. As of June 30, 2021, the Company recorded deferred tax expense of $<span id="xdx_900_eifrs-full--DeferredTaxExpenseIncome_pn3n3_dm_c20210401__20210630_zcvnznLgvfCb"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncome" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.1</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million to reflect the effect of the change in
currency translation rate during the three months ended June 30, 2021 for this obligation settleable in Great British Pounds.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:UnsecuredNotesPayableAndWarrantsTextBlock"><p id="xdx_807_ecustom--UnsecuredNotesPayableAndWarrantsTextBlock_zK8Oxtgar8F3" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
12. <span id="xdx_829_zWk638dEkwXe">UNSECURED NOTES PAYABLE</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Following
is a roll-forward of notes payable:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:ScheduleOfNotesPayableTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfNotesPayableTableTextBlock_pn3n3_ztEgvgtOF8Zd" summary="xdx: Disclosure - UNSECURED NOTES PAYABLE (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BD_zi5BnKUOfUDh" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of notes payable</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CURRENT</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CURRENT</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">NON-CURRENT</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PPL</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">iOx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">SalvaRx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance, April
    1, 2020</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zlYDbqWAGgE3" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2020-03-31_custom_PplMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zExGdy5tgmS" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2020-03-31_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zBTF3CFoBMc5" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2020-03-31_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,361</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--NotePayable_iS_pn3n3_c20200401__20210331_zt0fJP5fmmij" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,661</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Repayment</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" title="Repayment" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0704">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" title="Repayment" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" title="Repayment" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:RepaymentOfNotesPayable" contextRef="From2020-04-012021-03-31_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,020</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--RepaymentOfNotesPayable_c20200401__20210331_pn3n3" title="Repayment" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:RepaymentOfNotesPayable" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,020</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
    of debt discount</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" title="Amortization of debt discount" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" title="Amortization of debt discount" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0714">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" title="Amortization of debt discount" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:AmortizationOfDebtDiscount" contextRef="From2020-04-012021-03-31_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--AmortizationOfDebtDiscount_c20200401__20210331_pn3n3" title="Amortization of debt discount" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:AmortizationOfDebtDiscount" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Value of notes exchanged in
    warrant exercise</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" title="Value of notes exchanged in warrant exercise" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0720">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" title="Value of notes exchanged in warrant exercise" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0722">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" title="Value of notes exchanged in warrant exercise" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:ValueOfNotesExchangedInWarrantExercise" contextRef="From2020-04-012021-03-31_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,640</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331_pn3n3" title="Value of notes exchanged in warrant exercise" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:ValueOfNotesExchangedInWarrantExercise" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,640</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Settlement
    in connection with disposition of PPL</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" title="Settlement in connection with disposition of PPL" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:SettlementInConnectionWithDispositionOfPpl" contextRef="From2020-04-012021-03-31_custom_PplMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">200</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" title="Settlement in connection with disposition of PPL" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0730">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" title="Settlement in connection with disposition of PPL" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0732">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331_pn3n3" title="Settlement in connection with disposition of PPL" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:SettlementInConnectionWithDispositionOfPpl" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">200</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Loss on extinguishment
    of debt</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" title="Loss on extinguishment of debt" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0736">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" title="Loss on extinguishment of debt" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0738">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" title="Loss on extinguishment of debt" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:LossOnExtinguishmentOfDebt" contextRef="From2020-04-012021-03-31_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331_pn3n3" title="Loss on extinguishment of debt" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:LossOnExtinguishmentOfDebt" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from loan payable</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" title="Proceeds from loan payable" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0744">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" title="Proceeds from loan payable" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:ProceedsFromLoanPayable" contextRef="From2020-04-012021-03-31_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" title="Proceeds from loan payable" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ProceedsFromLoanPayable_c20200401__20210331_pn3n3" title="Proceeds from loan payable" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:ProceedsFromLoanPayable" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    March 31, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zzSP6nG3oOTj" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0752">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zlP79saAfey7" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2021-03-31_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zn77sbxo7mMg" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0756">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--NotePayable_iS_pn3n3_c20210401__20210630_zJl31BJTq3ol" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from loan payable</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td title="Proceeds from loan payable" id="xdx_980_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0760">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td title="Proceeds from loan payable" id="xdx_984_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0762">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td title="Proceeds from loan payable" id="xdx_98C_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0764">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td title="Proceeds from loan payable" id="xdx_983_ecustom--ProceedsFromLoanPayable_c20210401__20210630_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zItD8ZbzNFMc" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zFT0XLbrU3Qi" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2021-06-30_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zezgC9M9RB79" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--NotePayable_iE_pn3n3_c20210401__20210630_zQD9myfIu3o7" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>PPL
and EyGen Unsecured Notes Payable</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended March 31, 2017, the Company's subsidiaries, PPL and EyGen, completed a private placement of unsecured notes (the &#34;PPL
Unsecured Notes&#34;). The balance outstanding as of March 31, 2020 was $<span id="xdx_908_ecustom--AggregatePrincipalAmountOfUnsecuredNotes_iI_pn3n3_dm_c20200630_zmJbTMSfezDj"><ix:nonFraction name="ptgef:AggregatePrincipalAmountOfUnsecuredNotes" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
PPL Unsecured Notes were settled as part of the disposition of PPL in March 2021 (see Note 8, &#8220;Disposition of PPL&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>SalvaRx Unsecured
Notes Payable and Warrants</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the SalvaRx Acquisition in January 2019, the Company assumed $<span id="xdx_903_ecustom--AggregatePrincipalAmountOfUnsecuredNotes_iI_pn3n3_dm_c20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zx9XK5gC54T4"><ix:nonFraction name="ptgef:AggregatePrincipalAmountOfUnsecuredNotes" contextRef="AsOf2019-01-31_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">3.96</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million of principal in unsecured notes due on
March 2, 2021 (or earlier upon a qualifying event), that bear interest at <span id="xdx_900_ecustom--UnsecuredNotesInterest_iI_dp_c20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_z81XE7Yw0t66"><ix:nonFraction name="ptgef:UnsecuredNotesInterest" contextRef="AsOf2019-01-31_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
per annum (the &#34;SalvaRx Notes&#34;). The fair value of the SalvaRx Notes was determined to be $3.4 million at January 2019. As the
SalvaRx Acquisition was a qualifying event, the SalvaRx Notes became due upon the acquisition. In December 2019, the maturity date of
the SalvaRx Notes was extended to June 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--IssuanceOfUnsecuredNotesDescription_c20210401__20210630"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="ptgef:IssuanceOfUnsecuredNotesDescription">The
holders of the SalvaRx Notes received $7,500 of warrants in respect of each $10 thousand of principal issued. The warrants vest in the
event of a qualifying transaction and are exercisable at a 30% discount to the implied valuation of SalvaRx.</ix:nonNumeric> </span>On the Acquisition Date,
the fair value of the warrants, which are included in non-controlling interest, was determined to be $</span><span id="xdx_903_eifrs-full--FinancialLiabilitiesAtFairValue_iI_pn3n3_dm_c20210630_zAB7i6dt8Icj" style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.5</ix:nonFraction>
</span><span style="font: 10pt Times New Roman, Times, Serif">million
using the Black Scholes Model.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_237_zWHIt5tUa86" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 1 -->
    <div id="xdx_236_zVDjq1FqgOFj" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td id="xdx_230_zNjsD8jtSNyb" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zJPLUUevyKi7" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_23A_zFnmJ8P4zItb" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zNSxVFSyT4d7" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zQmBeWBF6cob" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zFWdVyHkUxVc" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zTcEr5XGq1O6" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zZRFGUAfm6j5" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z4OKVrLj7Kdh" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
12. UNSECURED NOTES PAYABLE <i>(Cont&#8217;d)</i></b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_z03EISkmK751" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">During
September 2020, the Company settled the SalvaRx Notes obligations originally due in June 2021 in an aggregate principal amount of approximately
$3.7 million, plus accrued interest of $0.75 million in exchange for cash payments totaling $<span id="xdx_902_ecustom--PaymentForSettlement_pn3n3_dm_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zM4CrL3LFm0e" title="Payment for settlement"><ix:nonFraction name="ptgef:PaymentForSettlement" contextRef="From2020-09-012020-09-30_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.77</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million and <span id="xdx_90D_ecustom--WarrantsExercised_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zEMVYcvnYzz" title="Warrants exercised"><ix:nonFraction name="ptgef:WarrantsExercised" contextRef="From2020-09-012020-09-30_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">397,604</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">of the associated SalvaRx warrants with an exercise
price of $<span id="xdx_90F_ecustom--ExercisePrice_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zdoM3WGX9Cm" title="Exercise Price"><ix:nonFraction name="ptgef:ExercisePrice" contextRef="From2020-09-012020-09-30_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.64</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">The noteholders who
accepted the offer exchanged their SalvaRx warrants for an equal number of Portage shares at the same price per share. <span id="xdx_905_ecustom--ContractualValueOfWarrantsExercisedDescription_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zU6auhgVe2ai" title="Contractual value of warrants exercised description"><ix:nonNumeric contextRef="From2020-09-012020-09-30_custom_SalvaRxMember" name="ptgef:ContractualValueOfWarrantsExercisedDescription">The
Company accounted for the contractual value of the exercised and outstanding warrants of $2.64 million (397,604 shares at $6.64 per share)
as accrued equity issuable at September 30, 2020. The Company also recorded a loss of $1.26 million during the year ended March 31, 2021,
to recognize the discount between the fair value of the underlying shares on October 13, 2020, the settlement date, ($9.80 per share)
and the warrant exercise (contract) price of $6.64 per share.</ix:nonNumeric></span></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Four
of the Company's directors, Gregory Bailey, James Mellon (former director), Steven Mintz (in trust) and Kam Shah, received, in total,
<span id="xdx_908_ecustom--SharesReceived_c20210401__20210630_zO9EQYOTMV2g" title="Shares received"><ix:nonFraction name="ptgef:SharesReceived" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">363,718</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">of
the warrants pursuant to this transaction. Subsequent to the exercise of the warrants in October 2020, Portage had <span id="xdx_907_ecustom--NumberOfExerciseOfWarrantsIssued_iI_c20201031__ifrs-full--CounterpartiesAxis__custom--PortageMember_z2S2GcYLfb39" title="Number of exercise of warrants issued"><ix:nonFraction name="ptgef:NumberOfExerciseOfWarrantsIssued" contextRef="AsOf2020-10-31_custom_PortageMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,083,395</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_90B_ecustom--NumberOfExerciseOfWarrantsOutstanding_iI_c20201031__ifrs-full--CounterpartiesAxis__custom--PortageMember_zrNHnvXtt3o" title="Number of exercise of warrants outstanding"><ix:nonFraction name="ptgef:NumberOfExerciseOfWarrantsOutstanding" contextRef="AsOf2020-10-31_custom_PortageMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,701</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">issued and outstanding shares and warrants, respectively.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company also recorded a loss on early extinguishment of debt of $<span id="xdx_904_ecustom--LossOnExtinguishmentOfDebt_pn3n3_dm_c20210401__20210630_zxld0Tc5zLC9"><ix:nonFraction name="ptgef:LossOnExtinguishmentOfDebt" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.22</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million in the year ended March 31, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>iOx Unsecured
Notes Payable</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the SalvaRx Acquisition in January 2019, the <span id="xdx_90B_ecustom--DescriptionOfBusinessCombination_c20190103__20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember"><ix:nonNumeric contextRef="From2019-01-032019-01-31_custom_SalvaRxMember" name="ptgef:DescriptionOfBusinessCombination">Company
assumed $2.0 million of 7% convertible notes issued by iOx, a wholly owned subsidiary of SalvaRx (the &#8220;Convertible Notes&#8221;),
of which the Company holds $1.9 million.</ix:nonNumeric> </span></span><span style="font: 10pt Times New Roman, Times, Serif">As a
result of the SalvaRx Acquisition, iOx became a subsidiary of the Company during the year ended March 31, 2019. In accordance with IFRS
3, the fair value, including interest receivable, of the Convertible Notes were effectively settled against the note receivable upon
the business combination. $0.15 million Convertible Notes were outstanding at each of June 30, 2021 and March 31, 2021. The holder of
the Convertible Notes can convert the notes and accrued interest into ordinary shares of iOx at any time before maturity at &#163;120
per share. There is an automatic conversion in the event iOx raises $<span id="xdx_90C_eifrs-full--IssueOfConvertibleInstruments_pn3n3_dm_c20190103__20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zUK8feurVK12"><ix:nonFraction name="ifrs-full:IssueOfConvertibleInstruments" contextRef="From2019-01-032019-01-31_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.0</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, and the conversion price will be determined
based on the timing of the capital raised and the price at which the money was raised. iOx has the right to repay the Convertible Notes
together with accrued interest at any time. </span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:WarrantLiabilitytextblock"><p id="xdx_801_ecustom--WarrantLiabilitytextblock_zVtRf63FGr3k" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
13. <span id="xdx_822_zCgSE3x6Mvug">WARRANT LIABILITY</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Below
is the roll-forward of warrants issued by entity (see Note 12, &#8220;Unsecured Notes Payable&#8221;):</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:ScheduleOfWarrantLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_pn3n3_zLpnmYFaPf87" summary="xdx: Disclosure - WARRANT LIABILITY (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8BD_zuItXHtnvEu8" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of warrant liability</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PBI</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Warrants</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amount</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;$</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Warrants
    outstanding, April 1, 2021</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--WarrantsOutstandingExercisePrice_iS_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zTPyaeEkSLpb" title="Warrants outstanding exercise price at beginning" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:WarrantsOutstandingExercisePrice" contextRef="AsOf2021-03-31_custom_SalvaRxGroupPlcMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.64</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--WarrantsOutstandingShares_iS_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zsqnFSGA76og" title="Warrants outstanding, shares at beginning" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:WarrantsOutstandingShares" contextRef="AsOf2021-03-31_custom_SalvaRxGroupPlcMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">49,701</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--WarrantsOutstandingAmount_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zxFVDjkYPCCc" title="Warrants outstanding, amount at beginning" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:WarrantsOutstandingAmount" contextRef="AsOf2021-03-31_custom_SalvaRxGroupPlcMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,120</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Fair
    value adjustment as of June 30, 2021 (1) (2)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--FairValueAdjustmentExercisePriceAtEnd_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zIQqk64MIAA" title="Fair value adjustment , exercise price at end" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--FairValueAdjustmentShares_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_ziKIvKEhzQC2" title="Fair value adjustment, shares at end" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0818">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--FairValueAdjustment_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_pn3n3" title="Fair value adjustment, amount at end" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:FairValueAdjustment" contextRef="From2021-04-012021-06-30_custom_SalvaRxGroupPlcMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">369</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Warrants
    outstanding, June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--WarrantsOutstandingExercisePrice_iE_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zCvelJGfAYTe" title="Warrants outstanding, exercise price, at end" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:WarrantsOutstandingExercisePrice" contextRef="AsOf2021-06-30_custom_SalvaRxGroupPlcMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.64</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--WarrantsOutstandingShares_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zMH5rwvsDHRa" title="Warrants outstanding, amount at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:WarrantsOutstandingShares" contextRef="AsOf2021-06-30_custom_SalvaRxGroupPlcMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">49,701</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--WarrantsOutstandingAmount_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zX3jMALENqka" title="Warrants outstanding, amount, at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:WarrantsOutstandingAmount" contextRef="AsOf2021-06-30_custom_SalvaRxGroupPlcMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">751</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td id="xdx_F01_z1ewmPsvx5Ze" style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="width: 0.25in"></td><td id="xdx_F1C_zAFv9abyuCT9"><ix:footnote id="Footnote000827" xml:lang="en-US"><span style="font: 10pt Times New Roman, Times, Serif">Portage
                                            warrant liability valued at contract price, adjusted for fair value using the Black Scholes
                                            model.</span></ix:footnote></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">The Black
Scholes assumptions used in the fair value calculation of the warrants as of June 30, 2021 were:</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Risk free
rate: 0.11%</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expected
Dividend: $0</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expected
Life: 1.28 years</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Volatility:
92.6%</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td id="xdx_F08_zsJ7wNBixOVh" style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="width: 0.25in"></td><td id="xdx_F18_zgzS229mfuje"><ix:footnote id="Footnote000828" xml:lang="en-US"><span style="font: 10pt Times New Roman, Times, Serif">The
                                            Company recognized a gain of $0.4 million in the three months ended June 30, 2021 to reflect
                                            the change in fair value of the underlying warrants. The warrants were not outstanding during
                                            the three months ended June 30, 2020.</span></ix:footnote></td></tr></table>

</ix:nonNumeric><p id="xdx_8A4_zazPGgavwiS4" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23F_z5rh3RJVBId3" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 20; Value: 1 -->
    <div id="xdx_238_zQtFSD8VYP5c" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td id="xdx_231_ziaaSU6g4y0h" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zSOnaNOLH789" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zn6VT7YWJsM5" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zCfNeFXr8Ove" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_239_z4tRDZXKzKSj" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zdc22kSXLNeg" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zBs0KOQsEpp3" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:CapitalStockTextBlock"><p id="xdx_800_ecustom--CapitalStockTextBlock_zwRvIEEfyWnh" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
14. <span id="xdx_82A_zNUlRCPdb2W">CAPITAL STOCK</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Authorized
                                            ordinary shares<b>: </b>Unlimited number of common shares without par value.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Following
                                            is a roll-forward of ordinary shares as of June 30, 2021, and 2020:</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_zRkyUBL1D6gg" summary="xdx: Disclosure - CAPITAL STOCK (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BE_zhn5R5cV7JL9" style="font: 10pt Times New Roman, Times, Serif; display: none">Common
    shares: Unlimited number of common shares without par value</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Ordinary<br />
    Shares</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amount</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Ordinary
    <br /> Shares</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amount</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;$</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;$</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--CommonStockShares_iS_c20210401__20210630_zlzUa9RsTd1e" title="Balance, Shares" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:CommonStockShares" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">12,084</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--CommonStockValues_iS_pn3n3_c20210401__20210630_z11lCw4pUSD5" title="Balance" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:CommonStockValues" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130,649</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--CommonStockShares_iS_c20200401__20200630_zOu78bXbLPEc" title="Balance, Shares" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:CommonStockShares" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">10,988</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--CommonStockValues_iS_pn3n3_c20200401__20200630_zXtX2fGTQpz2" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:CommonStockValues" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,817</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued in a private placement, net of share issue costs</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20210401__20210630_zPkcaW29phk2" title="Shares issued in a private placement, net of issue costs, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,241</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_c20210401__20210630_pn3n3" title="Shares issued in a private placement, net of issue costs" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,216</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200401__20200630_zzCcZWr2avR1" title="Shares issued in a private placement, net of issue costs, shares" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">698</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_c20200401__20200630_pn3n3" title="Shares issued in a private placement, net of issue costs" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,732</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued for services</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--SharesIssuedForServicesShares_c20210401__20210630_z0VSIXjjYzka" title="Shares issued for services, shares" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:SharesIssuedForServicesShares" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--SharesIssuedForService_c20210401__20210630_pn3n3" title="Shares issued for services" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:SharesIssuedForService" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--SharesIssuedForServicesShares_c20200401__20200630_zi6tOKZv1YL7" title="Shares issued for services, shares" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0860">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--SharesIssuedForService_c20200401__20200630_pn3n3" title="Shares issued for services" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0862">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--CommonStockShares_iE_c20210401__20210630_zT7P8a1BZyj3" title="Balance, Shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:CommonStockShares" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13,326</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--CommonStockValues_iE_pn3n3_c20210401__20210630_zHt1zAznjl7a" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:CommonStockValues" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">157,895</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--CommonStockShares_iE_c20200401__20200630_zn1ldTTL3RJe" title="Balance, Shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:CommonStockShares" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">11,686</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--CommonStockValues_iE_pn3n3_c20200401__20200630_z6urXE1KhlGh" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:CommonStockValues" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">124,549</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Number
                                            of ordinary shares have been retroactively adjusted to reflect the impact of 100:1 reverse
                                            stock split on June 5, 2020.</span></td></tr></table>

</ix:nonNumeric><p id="xdx_8A1_zfUuQoNrH3ba" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
June 16, 2020, the Company completed a private placement of <span id="xdx_903_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zjx3yytMieNb" title="Shares issued in a private placement, net of issue costs, shares"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares" contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">698,145</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">restricted ordinary shares at a price of $<span id="xdx_908_ecustom--PricePerShare_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zQ6NIvQm8x04" title="Shares price"><ix:nonFraction name="ptgef:PricePerShare" contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share for gross proceeds of $<span id="xdx_90E_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zxIHEVwg11v9" title="Shares issued in a private placement, net of issue costs"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts" contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">6.98</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million to accredited investors. Directors of
the Company subscribed for <span id="xdx_900_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_pdd"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares" contextRef="From2020-06-022020-06-16_custom_DirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">215,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares, or approximately 30.8% of the private
placement, for proceeds of $<span id="xdx_905_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_zX6L3YwwCq5a"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts" contextRef="From2020-06-022020-06-16_custom_DirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.15</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million. The Company incurred costs of approximately
$0.25 million in connection with the offering, which was treated as contra-equity on the Company&#8217;s balance sheet.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the quarter ended June 30, 2021, the Company commenced an &#8220;at the market&#8221; offering, under which it sold <span id="xdx_909_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostShares_c20210401__20210630_z5ins8HYbrdl" title="Shares issued in private placement net of issue cost, shares"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostShares" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,888</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares generating gross proceeds of approximately
$<span id="xdx_907_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCost_pn3n3_dm_c20210401__20210630_zDuczjqXzZD6" title="Shares issued in private placement net of issue cost"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCost" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.6</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
($<span id="xdx_909_ecustom--OfferingExpenses_pn3n3_dm_c20210401__20210630_zfALxTQkixQk" title="Offering expenses"><ix:nonFraction name="ptgef:OfferingExpenses" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.5</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">million,
net of commissions). Further, the Company initiated an offering pursuant to the Prospectus. On June 24, 2021, the <span id="xdx_90B_ecustom--PublicofferingDescription_c20210601__20210624_zR1ipCS3eRT9" title="Public offering description"><ix:nonNumeric contextRef="From2021-06-012021-06-24" name="ptgef:PublicofferingDescription">Company
completed a firm commitment underwritten public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share
for gross proceeds of approximately $26.5 million and was settled June 28, 2021. The Company incurred aggregate offering expenses for
the public offering of approximately $1.8 million, including approximately $1.6 million of management, underwriting and selling expenses.
The Company will use the net proceeds raised to fund its research and development activities and support operations. The amount raised
is sufficient to fund operations through at least September 2022. Funds may be used to accelerate development activities to advance the
Company&#8217;s product portfolio, working capital and general corporate purposes.</ix:nonNumeric></span></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_237_zCX0mUN0wAF3" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 21; Value: 1 -->
    <div id="xdx_236_zxZuqxSYOlBc" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td id="xdx_237_zzYJ0MHZAgSk" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zYFpTi1aZiJ6" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zhGpjnDruSAf" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zfDmFnf9wQl7" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zacrUIIIE0S" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zFeyjXFuWLq1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zPgkfc7ueHzl" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory"><p id="xdx_80D_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zkWVFaiUwAz9" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
15. <span id="xdx_82E_zID4ZEqor7dj">STOCK OPTION RESERVE</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">The
                                            following table provides the activity for the Company&#8217;s stock option reserve for the
                                            three months ended June 30, 2021 and 2020:</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:DisclosureOfTermsStockOptionReserveExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_z7NxeJz9tr0d" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span id="xdx_8B8_zpTnk8nOdM8j" style="font: 10pt Times New Roman, Times, Serif; display: none">Disclosure
    Of Terms Stock Option Reserve Explanatory</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Non-Controlling
    Interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    Option Reserve</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Non-Controlling
    Interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    Option Reserve</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zVgCUGYXjmfe" title="Balance" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,468</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z7fDbdd6HIWa" title="Balance" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2021-03-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,977</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zw1XEjSd9zNl" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2020-03-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,618</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--StockOptionReserve_iS_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zWo1XYbIESG8" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2020-03-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Share-based
    compensation expense</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" title="Stock based compensation expense" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" title="Stock based compensation expense" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,082</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eifrs-full--AdjustmentsForSharebasedPayments_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" title="Stock based compensation expense" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eifrs-full--AdjustmentsForSharebasedPayments_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" title="Stock based compensation expense" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0912">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_znP2zHBj2vll" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2021-06-30_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,566</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zOQ78WEhryZa" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2021-06-30_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,059</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--StockOptionReserve_iE_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zp7t4u5MtwMi" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2020-06-30_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,913</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--StockOptionReserve_iE_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zqdYdRcFI4kf" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2020-06-30_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A0_z2YZMzXmfhl3" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock Options</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Board of Directors of the Company (the &#34;Board&#34;) established a stock option plan (the &#34;2013 Option Plan&#34;) under which
options to acquire ordinary shares of the Company are granted to directors, employees and consultants of the Company. The maximum number
of ordinary shares issuable under the 2013 Option Plan shall not exceed 10% of the total number of issued and outstanding ordinary shares,
inclusive of all shares presently reserved for issuance pursuant to previously granted stock options. If a stock option was surrendered,
terminated or expired without being exercised, the ordinary shares reserved for issuance pursuant to such stock option were available
for new stock options granted under the 2013 Option Plan. The options vest on a schedule determined by the Board of Directors, generally
over two to four years, and expire after five years.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2019, the Board decided to discontinue the 2013 Option Plan and during the year ended March 31, 2021, <span id="xdx_90A_ecustom--StockOptionsIssued_iI_c20210331_zU93VLwXJ2x"><ix:nonFraction name="ptgef:StockOptionsIssued" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,980</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">outstanding options issued under the plan expired
unexercised and no options remained outstanding under the 2013 Option Plan.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
June 25, 2020, at the annual meeting of shareholders, the Company&#8217;s new incentive stock option plan (the &#8220;2020 Stock Option
Plan&#8221;) was approved, which authorized the directors to fix the option exercise price and to issue stock options under the plan
as they see fit. The Company's 2020 Stock Option Plan is a 10% rolling stock option plan under which the directors are authorized to
grant up to a maximum of 10% of the issued and outstanding ordinary shares on the date of grant.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Effective
January 13, 2021, the Company amended and restated its 2020 Stock Option Plan to permit the grant of additional types of equity compensation
securities, including restricted stock units and dividend equivalent rights (the &#34;2021 Equity Incentive Plan&#34;). The aggregate
number of equity securities, which may be issued under the 2021 Equity Incentive Plan has not been changed.&#160; Pursuant to the 2021
Equity Incentive Plan, on January 13, 2021, the Company granted an aggregate of <span id="xdx_903_eifrs-full--NumberOfSharesIssued_iI_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_zgLVKAilDJo7"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">868,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">stock options exercisable
at a price of US$<span id="xdx_909_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_zlTdZAQ2czc4"><ix:nonFraction name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" contextRef="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.75</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">per share, representing
the closing price of the shares on the day immediately preceding the grant date, which expire on January 13, 2031 to various directors,
officers and consultants of the Company. <span id="xdx_900_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember_pdd"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2021-01-13_custom_BoardOfDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">options granted to members
of the board of directors vest 1/3 on grant date, 1/3 on the first anniversary of the grant and 1/3 on the second anniversary of the
grant. <span id="xdx_907_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--ConsultantsMember_pdd"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2021-01-13_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">518,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">options granted to consultants
(one of whom is also a director) vest 1/3 on each of the first three anniversaries of the date of grant.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23C_zIZqj4Nx0X35" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zE4iqGtfQGh3" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 22; Value: 1 -->
    <div id="xdx_23D_zvJDwVM1Jgs9" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td id="xdx_231_zC76Y14Z7oL8" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zXLzTzvc6aA5" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_23D_zg7D6mtZaQqi" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zfgKDXx9Kui5" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zul3VfqVLLil" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_z15X0jE5JK38" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zVQu78AwUiVe" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zNYTtr31Vhe4" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z6DSYtAQn8Nf" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
15. STOCK OPTION RESERVE <i>(Cont&#8217;d)</i></b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zzPZoqZindDa" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Additionally,
the Company granted <span id="xdx_90C_ecustom--StockGranted_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zyqhCmCPkRQ5" title="Stock granted"><ix:nonFraction name="ptgef:StockGranted" contextRef="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">243,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">restricted stock units
on January 13, 2021, with a fair value of $<span id="xdx_903_ecustom--FairValuePerShare_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zwTvxiYV6oF2" title="Fair value per share"><ix:nonFraction name="ptgef:FairValuePerShare" contextRef="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">17.75</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">per share, which was
the closing price on the day immediately preceding the grant date. The restricted stock units vested on the date of grant but underlying
shares cannot be sold until one of four conditions are met.&#160; In accordance with IFRS 2, &#8220;Share-based Payment,&#8221; the Company
recognized compensation expense of $<span id="xdx_908_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zLFHweFdJzJ7"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">4.3</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">million in the year
ended March 31, 2021, in connection with the RSU grants.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">The
                                            movements in the number of options issued were:</span></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_pn3n3_zMAggIIvjj86" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8BF_zE2XtvBR4Cmd" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of outstanding stock options</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">PBI 2021 Equity Incentive</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Plan&#160;</span></p></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PBI
    2013 Option Plan</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; text-align: center">iOx Option Plan <br />
(Subsidiary Plan)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5cUWyWsYI36" title="Balance" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2021-03-31_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">868,000</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zjBndRClykJ9" title="Balance" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0945">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zL1SKWkjEdyj" title="Balance" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0947">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_z7Pne5dtHer9" title="Balance" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2020-03-31_custom_PBI2013OptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,980</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z66b0QW0sXDi" title="Balance" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2021-03-31_custom_IOxOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,924</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z8qkZVzpDI4b" title="Balance" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2020-03-31_custom_IOxOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,599</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zVyjffxYdIp7" title="Granted" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0955">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zrvrPFAScIZj" title="Granted" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0957">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zi4WmCdd6TQ1" title="Granted" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0959">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zfYnHSB62ff9" title="Granted" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0961">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zE1QXRt1TJv3" title="Granted" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0963">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z7LPACdAytPa" title="Granted" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0965">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired
    or forfeited</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5GJnboORkdk" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0967">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zKFXqOmCz04f" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0969">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zmQ49OvXqBzc" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0971">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zREWgvErtZfl" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zttlqUIjGvyl" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z4N4xeM7afHa" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--NumberOfOutstandingShareOption_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zE2zzv1YlAvi" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2021-06-30_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">868,000</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zOhWqISGDhFk" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zpA8nuZSaTVg" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0983">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zgterYG3Uxki" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2020-06-30_custom_PBI2013OptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,980</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--NumberOfOutstandingShareOption_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zNexzDUBma89" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2021-06-30_custom_IOxOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,924</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--NumberOfOutstandingShareOption_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zDRGHHyGAnH9" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2020-06-30_custom_IOxOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,599</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_ztIOzBJSZGNi" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="AsOf2021-06-30_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">116,666</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_ziMDLPhqXPX3" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0993">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zdRUTPdfivP" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0995">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_ztnNGqmKAxI9" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="AsOf2020-06-30_custom_PBI2013OptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,980</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zieZS7Gy9Mxg" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="AsOf2021-06-30_custom_IOxOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,764</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z1dX11pVDoRc" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="AsOf2020-06-30_custom_IOxOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,723</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z2XevsW82nH" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Board discontinued the 2013 Option Plan in fiscal 2019.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Following
                                            are the weighted average exercise price and the remaining contractual life for outstanding
                                            options by plan:</span></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zering4CO0M8" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8BC_z6PsFLfELT93" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of weighted average exercise price and the remaining contractual life</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">PBI 2021 Equity Incentive</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Plan&#160;</span></p></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PBI 2013 Option Plan</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="padding-bottom: 1pt; font-size: 10pt; text-align: center">iOx Option Plan
(Subsidiary Plan)<span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
    of June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
    of June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
    of June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zE1mY1GDkDd3" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">17.75</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z1POhsB5IPEg" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1007">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zss2jKWoqvy5" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1009">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zohgv9HVRNWk" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2020-04-012020-06-30_custom_PBI2013OptionPlanMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">15.00</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z4KSKT6wkWLe" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2021-04-012021-06-30_custom_IOxOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">165.20</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z13AHMaYUHoe" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2020-04-012020-06-30_custom_IOxOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">152.74</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average remaining contractual life (in years)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zBrxBbA4j4Ui" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">9.54</ix:nonNumeric></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zw4zAr4h3jFf" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-04-012020-06-30_custom_PBI2013OptionPlanMember" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">1.47</ix:nonNumeric></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zC1ewvJmO1w" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-04-012021-06-30_custom_IOxOptionPlanMember" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">0.70</ix:nonNumeric></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zVtzm8V1AT3f" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-04-012020-06-30_custom_IOxOptionPlanMember" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">1.24</ix:nonNumeric></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zZo41SzkVBZf" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
vested options can be exercised at any time in accordance with the applicable option agreement. The exercise price was greater than the
market price on the date of the grants for all options outstanding as of June 30, 2021 and March 31, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded approximately $<span id="xdx_904_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--Equity2021IncentivePlanMember_zuIUFRNx9Gr3"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2021-04-012021-06-30_custom_Equity2021IncentivePlanMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.1</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million of stock-based compensation expense with
respect to the 2021 Equity Incentive Plan in the three months ended June 30, 2021. There were no stock options outstanding in the prior
year period under this plan. The Company expects to record additional stock-based compensation expense of $8.9 million through January
2024 with respect to the 2021 Equity Incentive Plan. Additionally, the intrinsic value of the stock options granted under the 2021 Equity
Incentive Plan was approximately $2.8 million at June 30, 2021, of which $0.4 million is associated with vested</span> exercisable options.</p>
<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded $<span id="xdx_908_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20210630_zArnk8aTBm6"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.1</ix:nonFraction></span></span> <span style="font: 10pt Times New Roman, Times, Serif">million
and $<span id="xdx_904_eifrs-full--CommunicationExpense_pn3n3_dm_c20200401__20200630_zYIJKquvZGIb"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.3</ix:nonFraction></span></span> <span style="font: 10pt Times New Roman, Times, Serif">million
of stock-based compensation expense related to the iOx stock option plan for the three months ended June 30, 2021 and 2020, respectively.
The Company expects to record $0.1 million of aggregate stock-based compensation expense through the remaining vesting period of outstanding
iOx options. Additionally, the intrinsic value of the iOx stock options was approximately $0.1 million at June 30, 2021, substantially
all of which is associated with vested exercisable options.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_236_zKEsSxvhy2G8" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zkiOLMMwF7Q1" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 23; Value: 1 -->
    <div id="xdx_236_zG52nP4pzzF5" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td id="xdx_234_zmEbMhMtYwt7" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zYv2Xi5WhOo7" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zfIGTCulTbDa" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zN6bldFOPUqj" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zyvXSiSlho5g" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zEcDoACW4Ckl" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zzJOTbfT4oQ5" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:EarningsPerShareExplanatory"><p id="xdx_807_eifrs-full--EarningsPerShareExplanatory_zaKLvMEzsKw" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
16. <span id="xdx_82A_zAI8S5FIHX84">(LOSS) PER SHARE</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Basic
earnings per share (&#34;EPS&#34;) is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company
by the weighted average number of ordinary shares outstanding during the year.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Diluted
EPS is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number
of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion
of all the dilutive potential ordinary shares into ordinary shares.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table reflects the loss and share data used in the basic and diluted EPS calculations (dollars in thousands, except per share
amounts):</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:EarningsPerShareTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--EarningsPerShareTableTextBlock_pn3n3_zJY953plXK6i" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B2_zVjRZhdMMRh1" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of basic and diluted EPS calculations</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_496_20210401__20210630_zmfwE9kNqg6l" style="text-align: right; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_499_20200401__20200630_zPOOnXkZb191" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Numerator
    (in 000&#8217;$)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss attributable to owners of the Company</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,066</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">696</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Denominator
    (in 000&#8217;)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eifrs-full--WeightedAverageShares_i01_pdd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average number of shares &#8211; Basic and Diluted</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,213</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,104</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--BasicAndDilutedLossPerShare_i01_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Basic
    and diluted (loss) per share (Actual)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:BasicAndDilutedLossPerShare" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.25</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:BasicAndDilutedLossPerShare" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.06</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zliuc5yfZvT5" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
inclusion of the Company's stock options, restricted stock units and share purchase warrants in the computation of diluted loss per share
would have an anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference
between basic loss per share and diluted loss per share for the three months ended June 30, 2021, and 2020. The following table reflects
the outstanding securities by year that would have an anti-dilutive effect on loss per share, and accordingly, were excluded from the
calculation.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock_zQ4g5JGfAVhi" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B8_ztjYhz3FiGl7" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of Anti-Dilutive effect on Loss Per Share</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>As
    of June 30,</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    options</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" title="Anti-dilutive effect on loss per shar" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShar" contextRef="From2021-04-012021-06-30_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">868,000</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" title="Anti-dilutive effect on loss per shar" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShar" contextRef="From2020-04-012020-06-30_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,980</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Restricted
    stock units</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" title="Anti-dilutive effect on loss per shar" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShar" contextRef="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember444649546" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">243,000</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" title="Anti-dilutive effect on loss per shar" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Warrants</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" title="Anti-dilutive effect on loss per shar" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShar" contextRef="From2021-04-012021-06-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,701</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" title="Anti-dilutive effect on loss per shar" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1062">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zvs5VAoxOgpc" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Inclusion
of outstanding options or other common stock equivalents in the computation of diluted loss per share would have an anti-dilutive effect
on the loss per share and are therefore excluded from the computation. Consequently, there is no difference between loss per share and
diluted loss per share.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"><p id="xdx_805_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_z494Ywm4Tcpd" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
17. <span id="xdx_821_zKtvJZzd3z1h">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is committed to invest approximately &#8364;1.5 million ($<span id="xdx_906_ecustom--CommitmentToInvestment_iI_pn3n3_dm_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StimunitySAMember_ziXI1jq90ycj"><ix:nonFraction name="ptgef:CommitmentToInvestment" contextRef="AsOf2021-06-30_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.9</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million) in Stimunity upon Stimunity&#8217;s
achievement of certain agreed milestones. During the year ended March 31, 2019, the Company made a discretionary investment of &#8364;600,129
($<span id="xdx_90A_ecustom--DiscretionaryInvestment_iI_pp0p0_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StimunitySAMember_zjNOfGa8xkPj" title="Discretionary Investment"><ix:nonFraction name="ptgef:DiscretionaryInvestment" contextRef="AsOf2021-06-30_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">688,359</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">)
and on June 1, 2020, the Company made an additional discretionary investment of &#8364;800,000 ($<span id="xdx_906_ecustom--AdditionalDiscretionaryInvestment_iI_pp0n3_dm_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StimunitySAMember_zmMm1gKONWpb"><ix:nonFraction name="ptgef:AdditionalDiscretionaryInvestment" contextRef="AsOf2021-06-30_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">1.0</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million) investment towards the commitment. The
remaining commitment was &#8364;100,000 as of March 31, 2021 (see Note 7, &#8220;Investment in Associate&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23F_zbL5ieVV2AT2" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 24; Value: 1 -->
    <div id="xdx_236_zLlDbPI6PVi2" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td id="xdx_23F_zLqlTMfWjdye" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zowdoYWBlA2h" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zRC0hAQmHUI5" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zaH9rp2nQ95c" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_ziwedTFsRK38" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zc9vNGPU4pke" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zDKZvH7jTvL8" style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfRelatedPartyExplanatory"><p id="xdx_80A_eifrs-full--DisclosureOfRelatedPartyExplanatory_zrFzE5tclF64" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
18. <span id="xdx_82D_zePOtrKEiKy">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Investments</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has entered into related party transactions and certain services agreements with its investees.&#160; Key management of the Company
has also entered into related party transactions with investees. Key management personnel are those persons having the authority and
responsibility for planning, directing and controlling the activities of the Company. The Board of Directors, Chairman, Chief Executive
Officer and Chief Financial Officer are key management personnel.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following subsidiaries and associates are considered related parties:</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Stimunity</b>.
                                            One of the three directors on the Board of Directors of Stimunity is controlled by Portage
                                            (see Note 7, &#8220;Investment in Associate&#8221;).</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>iOx</b>.
                                            Two of the five directorships on the Board of Directors of iOx is controlled by Portage.
                                            Additionally, Portage has an observer on the Board of iOx. The CEO of the Company is also
                                            the CEO of iOx, and the management team of the Company comprise the management team of iOx.</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Saugatuck</b>.
                                            One of the three directorships on the Board of Directors of Saugatuck is controlled by Portage.
                                            Additionally, the CEO of the Company is also the CEO of Saugatuck and the management team
                                            of the Company comprise the management team of Saugatuck.</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(d)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Intensity</b>.
                                            One of the four directorships on the Board of Directors of Intensity is represented by Portage.
                                            Additionally, the CEO of the Company is an officer and employee of Intensity (see Note 9,
                                            &#8220;Investments in Private Companies&#8221;).</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(e)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>PGL</b>.
                                            PPL holds 65% equity in PGL, committed to provide financing and also handles financial and
                                            administrative matters of PGL. The Company disposed of 100% of its interests in PPL and PGL
                                            on March 3, 2021 (see Note 8, &#8220;Disposition of PPL&#8221;).</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(f)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
                                            Development Services</b>. A 100% owned subsidiary incorporated in Delaware, which provides
                                            human resources, and other services to each operating subsidiary via a shared services agreement.</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following are significant related party balances and transactions other than those disclosed elsewhere in the condensed consolidated
interim financial statements:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Interest
expense includes $<span id="xdx_907_eifrs-full--InterestCostsIncurred_pn3n3_dm_c20200401__20200630_zl3jDwBfmcoc"><ix:nonFraction name="ifrs-full:InterestCostsIncurred" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.06</ix:nonFraction></span></span> <span style="font: 10pt Times New Roman, Times, Serif">million
interest incurred on notes issued to directors during the three months ended June 30, 2020.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2020, a board member of the Company advanced the Company $<span id="xdx_900_ecustom--RepaymentsOfAdvanceToBoardMemberOfCompany_pn3n3_dm_c20200701__20200731_zXSivIGa33lj"><ix:nonFraction name="ptgef:RepaymentsOfAdvanceToBoardMemberOfCompany" contextRef="From2020-07-012020-07-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.0</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, which was repaid in July 2020. There
was no interest or fees associated with this advance.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_234_zzEeicM6Jst4" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 25; Value: 1 -->
    <div id="xdx_23A_zd42HCzeh1tl" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td id="xdx_231_zpNc7Z1ZCAj1" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zzOxo9H2nl42" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zYqTUqCatvfc" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zpt9dVFdCRC1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zjuDUzftEI67" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zV4B1X3qklob" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zRRwa3jLGYd9" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zv4VhQcf3LWc" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
18. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zUnaqBFSGkO4" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Transactions
between the parent company and its subsidiaries, which are related parties, have been eliminated in consolidation and are not disclosed
in this note.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory"><p id="xdx_801_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zoIeLwv6Z8G5" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
19. <span id="xdx_82B_zpkgRBNRAka7">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s financial instruments recognized in the Company&#8217;s condensed consolidated interim statements of financial position
consist of the following:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Fair
value estimates are made at a specific point in time, based on relevant market information and information about financial instruments.
These estimates are subject to and involve uncertainties and matters of significant judgment, therefore cannot be determined with precision.
Changes in assumptions could significantly affect the estimates.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the Company&#8217;s financial instruments as of June 30, 2021 and March 31, 2021:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilities"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilities_pn3n3_z0Nqakhay848" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BF_zZRv6Wy5BGWi" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of financial instruments</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>As
    of June 30, 2021</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>As
    of March 31, 2021</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amortized
    Cost</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fair
    Value through Other Comprehensive <br />Income (FVTOCI)</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amortized
    Cost</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>FVTOCI</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Financial
    assets</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--CashAndCashEquivalents_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" title="Cash and cash equivalents" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-06-30_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,617</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eifrs-full--CashAndCashEquivalents_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" title="Cash and cash equivalents" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1094">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--CashAndCashEquivalents_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" title="Cash and cash equivalents" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-03-31_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,770</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eifrs-full--CashAndCashEquivalents_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" title="Cash and cash equivalents" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1098">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
    expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" title="Prepaid expenses and Other Receivables" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivables" contextRef="AsOf2021-06-30_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,995</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" title="Prepaid expenses and Other Receivables" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--PrepaidExpensesAndOtherReceivables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" title="Prepaid expenses and Other Receivables" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivables" contextRef="AsOf2021-03-31_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,176</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--PrepaidExpensesAndOtherReceivables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" title="Prepaid expenses and Other Receivables" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1106">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Investments</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eifrs-full--CurrentInvestments_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" title="Investment" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1108">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--CurrentInvestments_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" title="Investment" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:CurrentInvestments" contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,100</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eifrs-full--CurrentInvestments_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" title="Investment" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--CurrentInvestments_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" title="Investment" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:CurrentInvestments" contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,144</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Fair
    Value through Profit or Loss (FVTPL)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">FVTPL</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Financial
    liabilities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--AccountsPayableAndAccruedLiabilities_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" title="Accounts payable and accrued liabilities" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2021-06-30_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,605</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--AccountsPayableAndAccruedLiabilities_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" title="Accounts payable and accrued liabilities" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--AccountsPayableAndAccruedLiabilities_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" title="Accounts payable and accrued liabilities" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2021-03-31_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,938</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--AccountsPayableAndAccruedLiabilities_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" title="Accounts payable and accrued liabilities" style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Unsecured
    notes payable</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eifrs-full--NoncurrentPayables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" title="Unsecured notes payable" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncurrentPayables" contextRef="AsOf2021-06-30_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--NoncurrentPayables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" title="Unsecured notes payable" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1126">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncurrentPayables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" title="Unsecured notes payable" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncurrentPayables" contextRef="AsOf2021-03-31_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eifrs-full--NoncurrentPayables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" title="Unsecured notes payable" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1130">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Warrant
    liability</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--WarrantLiability_iI_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_z64vCpi2M7Dh" title="Warrant liability" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1132">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--WarrantLiability_iI_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z9mvXqtUPtGl" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:WarrantLiability" contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">751</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--WarrantLiability_iI_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zyOG7DWITl7f" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--WarrantLiability_iI_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zMoBBnRcpHni" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:WarrantLiability" contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,120</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zdkAELRgL3K4" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s risk exposures as it relates to financial instruments are reflected below.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Fair value
of financial instruments</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s financial assets and liabilities are comprised of cash, receivables and investments in equities and private entities,
accounts payable, warrant liability and unsecured notes payable.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company classifies the fair value of these transactions according to the following fair value hierarchy based on the amount of observable
inputs used to value the instrument:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 41.05pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Level
                                            1 &#8211; Values are based on unadjusted quoted prices available in active markets for identical
                                            assets or liabilities as of the reporting date.</span></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 41.05pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Level
                                            2 &#8211; Values are based on inputs, including quoted forward prices for commodities, time
                                            value and volatility factors, which can be substantially observed or corroborated in the
                                            marketplace. Prices in Level 2 are either directly or indirectly observable as of the reporting
                                            date.</span></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 41.05pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Level
                                            3 &#8211; Values are based on prices or valuation techniques that are not based on observable
                                            market data. Investments are classified as Level 3 financial instrument.</span></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_238_zU0DRSvVzzKc" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zmhTqaPjzWih" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 26; Value: 1 -->
    <div id="xdx_230_zy02tAlqgAyd" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td id="xdx_238_zjXxNkUiWLhk" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zMPXhOytYGff" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_ztL9zKCOUL98" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zm4mDHrpFq1e" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zDDwmRU5DAz2" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_z0qC6zqtJMYk" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zWYV08CYEECb" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zwLmDset5xIj" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
19. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT <i>(Cont&#8217;d)</i></b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zL1ewcEnCbs5" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Assessment
of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair
value hierarchy.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Management
has assessed that the fair values of cash and cash equivalents, other receivables and accounts payable approximate their carrying amounts
largely due to the short-term maturities of these instruments.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following methods and assumptions were used to estimate their fair values:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Biohaven</b>: Fair value was based on a quoted market price of $<span id="xdx_903_ecustom--FairValueMarketPricePerShare_c20210401__20210630_pdd"><ix:nonFraction name="ptgef:FairValueMarketPricePerShare" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">34.03</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share as of March 31, 2020 (Level 1). The
investment was sold in August 2020.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Sentien</b>: Fair value of the asset is determined by considering strategy changes by Sentien (Level 3).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Intensity</b>: Fair value of the asset is determined by considering other comparable equity funding transactions by Intensity with
unrelated investors (Level 3).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Accrued
equity issuable: </b>The fair value is estimated based on the average of the quoted market prices for the period in which the shares
were earned (Level 1).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Unsecured
notes payable</b>: The fair value is estimated using a Black Scholes model (Level 3) (see Note 12, Unsecured Notes Payable&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrant
Liability</b>: The fair value is estimated using a Black Scholes model (Level 3) (see Note 13, &#8220;Warrant Liability&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">There
have been no transfers between levels of the fair value hierarchy for the three months ended June 30, 2021 and the year ended March 31,
2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s financial instruments are exposed to certain financial risks: credit risk and liquidity risk.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Credit Risk</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Credit
risk is the risk of loss associated with a counterparty&#8217;s inability to fulfil its payment obligations. The credit risk is attributable
to various financial instruments, as noted below. The credit risk is limited to the carrying value as reflected in the Company&#8217;s
condensed consolidated interim statements of financial position.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Cash</i>.
</b>Cash is held with major international financial institutions and therefore the risk of loss is minimal.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Other
receivables.</i></b> The Company was exposed to credit risk attributable to its debtor since a significant portion of this amount represents
the amount agreed on a settlement of a claim by PPL (see Note 5, &#8220;Prepaid Expenses and Other Receivables&#8221;), originally payable
over the next four years. The installment note was repaid in full in July 2021 (see Note 22, &#8220;Events After the Balance Sheet Date
&#8211; Installment Note Receivable&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23C_zilXqlOj51N4" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zxlUxTPL6Gh2" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 27; Value: 1 -->
    <div id="xdx_237_zBfQl9fIvdB9" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td id="xdx_235_zEDNPuiBTkN9" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zifbNMXasxWc" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_z3Vo1bSQVxf9" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z3ETryfhAJP" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zWZYXOppTE4d" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zUET1qaEOUTh" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zlr703wv2N54" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_z8XGRpehyYWh" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
19. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT <i>(Cont&#8217;d)</i></b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zdw4K4chAGrc" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Liquidity Risk</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Liquidity
risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities
when due, under both normal and stressed conditions without incurring unacceptable losses or risking harm to the Company&#8217;s reputation.
The Company holds sufficient cash to satisfy obligations under accounts payable and accruals.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company monitors its liquidity position regularly to assess whether it has the funds necessary to meet its operating needs and needs
for investing in new projects. The Company believes that it has sufficient funding to finance the committed drug development work, apart
from meeting its operational needs for the foreseeable future.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">However,
as a biotech company at an early stage of development and without significant internally generated cash flows, there are inherent liquidity
risks, including the possibility that additional financing may not be available to the Company, or that actual drug development expenditures
may exceed those planned. The current uncertainty in global markets could have an impact on the Company&#8217;s future ability to access
capital on terms that are acceptable to the Company. There can be no assurance that required financing will be available to the Company.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock"><p id="xdx_808_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zeJpidIDOKSh" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
20. <span id="xdx_82D_z8e7foYhSSBb">CAPITAL DISCLOSURES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers the items included in shareholders&#8217; equity as capital. The Company had accounts payable and accrued expenses
of approximately $<span id="xdx_90D_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20210630_zNpSjU4YOAk"><ix:nonFraction name="ptgef:PayablesAndAccruedExpense" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.6</ix:nonFraction></span></span> <span style="font: 10pt Times New Roman, Times, Serif">million
as of June 30, 2021 (approximately $<span id="xdx_901_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20210331_zLupsvr6eSf1"><ix:nonFraction name="ptgef:PayablesAndAccruedExpense" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.9</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
as of March 31, 2021) and current assets of approximately $30.6 million <span id="xdx_90B_eifrs-full--CurrentAssets_iI_pn3n3_c20210630_z3Gzo6gsTzsl" style="display: none"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,612</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">as of June 30, 2021 (approximately $4.9 million
as <span id="xdx_903_eifrs-full--CurrentAssets_iI_pn3n3_c20210331_zb8I0J07bUrh" style="display: none"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,946</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">of
March 31, 2021). The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as a going
concern in order to pursue new business opportunities and to maintain a flexible capital structure, which optimizes the costs of capital
at an acceptable risk.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics
of the underlying assets.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, shareholders&#8217; equity attributable to the owners of the company was approximately $127.7 million <span id="xdx_905_eifrs-full--EquityAttributableToOwnersOfParent_iI_pn3n3_c20210630_zs033cEJaeq9" style="display: none"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127,711</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">(approximately $101.4 million <span id="xdx_90B_eifrs-full--EquityAttributableToOwnersOfParent_iI_pn3n3_c20210331_zzAFv2fQ4ja2" style="display: none"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101,449</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">as of March 31, 2021).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is not subject to any externally imposed capital requirements and does not presently utilize any quantitative measures to monitor
its capital. There have been no changes to the Company&#8217;s approach to capital management during the three months ended June 30,
2021 and 2020.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_233_zkP77D2NHrPc" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 28; Value: 1 -->
    <div id="xdx_239_znBqtl3npG0c" style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td id="xdx_233_zicEolfagKZ4" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zfy7kMJPNdIi" style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zIw9cXsGtT7g" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
Biotech Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zqlenoVgReD6" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes
to Condensed Consolidated Interim Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zXLnNANQyaR4" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_ze1pmqepsMi2" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited
&#8211; See Notice to Reader dated August <span style="background-color: white">30</span>, 2021)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zesO865gByX7" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory"><p id="xdx_809_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zeuic0PQH5yl" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
21. <span id="xdx_823_zmmLhXdLHzd2">NON-CONTROLLING INTEREST</span></b></span></p>

<p style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:ScheduleOfNoncontrollingInterestTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zjsCpKSB6cw9" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span id="xdx_8B6_zq0dsri5ZC34" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of non-controlling interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PGL</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">SalvaRx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">iOx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Saugatuck</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of April 1, 2021</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zYWBmeuA7dhh" title="Balance" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1174">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zuA7TgGQ6LP5" title="Balance" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_z3OImeKTvcQi" title="Balance" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-03-31_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,173</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zhjVPEJPPNVf" title="Balance" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-03-31_custom_SaugatuckMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630_zyc8qumhnDX2" title="Balance" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,153</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
    compensation expense</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1184">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2021-04-012021-06-30_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1190">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--StockBasedCompensationExpense_c20210401__20210630_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    (loss) attributable to non-controlling interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2021-04-012021-06-30_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">140</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2021-04-012021-06-30_custom_SaugatuckMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">157</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zXxATiNflqT7" title="Non-controlling interest" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zXby7ThrGE84" title="Non-controlling interest" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1206">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zfCUJoiK2Yld" title="Non-controlling interest" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-06-30_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,131</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zAFFANIZmoij" title="Non-controlling interest" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-06-30_custom_SaugatuckMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">37</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630_zSDG3aEFH5Gi" title="Non-controlling interest" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,094</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PGL</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">SalvaRx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">iOx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Saugatuck</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of April 1, 2020</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zolCUCYq2U0f" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2020-03-31_custom_PglMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">81</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zxvOxzbumpn2" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2020-03-31_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,451</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zFGjxaOJuHcb" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2020-03-31_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,712</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zIEImgneAMri" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2020-03-31_custom_SaugatuckMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630_zRmGV96fe2F3" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49,110</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
    compensation expense</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1219">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1221">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2020-04-012020-06-30_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1225">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--StockBasedCompensationExpense_c20200401__20200630_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    income attributable to non-controlling interest</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1229">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1231">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2020-04-012020-06-30_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of June 30, 2020</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zmQnHefF1W72" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2020-06-30_custom_PglMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">81</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zyqyFfq0D8Wf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2020-06-30_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,451</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_z7wy3kYV4Evd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2020-06-30_custom_IoxMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47,048</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zVDevKtSFpxf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2020-06-30_custom_SaugatuckMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630_zCCxi9NwywZf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49,446</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zIVT69K3drjc" style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock"><p id="xdx_800_ecustom--DisclosureOfEventAfterBalanceSheetDateTextBlock_zRbn0bX8A67b" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
22. <span id="xdx_828_zyvsqUR0YKBe">EVENTS AFTER THE BALANCE SHEET DATE</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Installment
Note Receivable</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
installment note receivable of approximately $<span id="xdx_90D_ecustom--RepaymentOfInstallmentNoteReceivable_pn3n3_dm_c20210701__20210731__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--EventsAfterTheBalanceSheetDateMember__dei--LegalEntityAxis__custom--SalvaRxMember_zmV99IQkh0b6"><ix:nonFraction name="ptgef:RepaymentOfInstallmentNoteReceivable" contextRef="From2021-07-012021-07-31_custom_EventsAfterTheBalanceSheetDateMember_custom_SalvaRxMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.034</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million described in Note 5, &#8220;Prepaid Expenses
and Other Receivables,&#8221; was repaid in full in July 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

</ix:nonNumeric><p id="xdx_81A_zPnATXxqMFm7" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">F-27</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 100%; font-size: 10pt"><span style="font-size: 10pt">Dated:&#160;&#160;August 30, 2021</span></td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white"><b>PORTAGE BIOTECH INC.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%; font-size: 10pt"><span style="font-size: 10pt">By:</span>&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 35%; font-size: 10pt"><span style="font-size: 10pt">/s/ Allan Shaw</span></td>
    <td style="width: 62%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Allan Shaw</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>


<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>
<p style="margin: 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--  
     6Q9Xd1HJ04pIhBzEXg2WeVCdEXChFi0FnJxVVIw+Hvdky0tfNsB78Nqdq5c/f9UCgU2EPKGxO/uDdfU5atU0cy6MpI6t1I7POYllHQ1lqE1eysKUL0aLw/QIpXL/2TRWF+D8a51jDTS+uckYXLqUzWN94+TRUV/aGrkqb1avU80F0xqOoRXeHNQ9BHKHLw51Qfvmom1EZM7Rx3iyGjVzv15drtNivqMGx++R4b1JSuOjL4Ll8w59D2UTeFc/9BM6S0KyGQsZ6vqc9Rj+sdLwrvnppKWmQK+Z01XMw+xFWVVZ4y5lYWYfyo1APbtG9TorIPBLOvnD4sGNs65O3P+nv9dHyidq7CPKIMF7PexKD3qHaW9MJleuET6sGTsL3s5hC977WPB/cPt5vw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>2
<FILENAME>exh_992.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="text-align: right; margin: 0"><b>Exhibit 99.2</b></p>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>PORTAGE BIOTECH INC.</b></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>THREE MONTHS ENDED JUNE 30, 2021</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS</b></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0">Prepared as of August 30, 2021</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 18pt; text-align: center">Index</p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%;  font-size: 10pt">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 90%"><font style="font-size: 10pt">Forward-Looking Statements</font></td>
    <td style="width: 10%; text-align: center"><font style="font-size: 10pt">3</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><font style="font-size: 10pt">Nature of Operations and Overview</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">4</font></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Summary of Results</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">8</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><font style="font-size: 10pt">Number of Ordinary Shares and Options</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">8</font></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Business Environment - Risk Factors</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">8</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><font style="font-size: 10pt">Our Programs and Technology - Recent Developments</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">9</font></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Results of Operations</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">12</font></td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Liquidity and Capital Resources</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">14</font></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Key Contractual Obligations</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">16</font></td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Off-balance Sheet Arrangements</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">16</font></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Transactions with Related Parties</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">16</font></td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Financial and Derivative Instruments</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">17</font></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Use of Estimates and Judgments</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">19</font></td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-size: 10pt">New Accounting Standards, Interpretations and Amendments</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">19</font></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Internal Controls over Financial Reporting</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">19</font></td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Public Securities Filings</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">20</font></td></tr>
  </table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Management Discussion and Analysis</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following discussion and analysis by management of the financial condition
and financial results for Portage Biotech Inc. for the three months ended June 30, 2021, should be read in conjunction with the unaudited
condensed consolidated interim financial statements for the three months ended June 30, 2020, together with the related Management&rsquo;s
Discussion and Analysis and audited consolidated financial statements for the year ended March 31, 2021, and Annual Report on Form 20-F
for the same period.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0">Forward-Looking Statements</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">This document includes &quot;forward looking statements.&rdquo; All statements,
other than statements of historical facts, included herein or incorporated by reference herein, including without limitation, statements
regarding our business strategy, plans and objectives of management for future operations and those statements preceded by, followed by
or that otherwise include the words &quot;believe,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;estimates&quot;
or similar expressions or variations on such expressions are forward-looking statements. We can give no assurances that such forward-looking
statements will prove to be correct.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Each forward-looking statement reflects our current view of future events
and is subject to risks, uncertainties and other factors that could cause actual results to differ materially from any results expressed
or implied by our forward-looking statements.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Risks and uncertainties include, but are not limited to:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%;  font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 2%"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">our plans and ability to develop and commercialize product candidates and the timing of these development programs;</font></td></tr>
  </table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%;  font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 2%"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">clinical development of our product candidates, including the results of current and future clinical trials;</font></td></tr>
  </table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%;  font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 2%"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">the benefits and risks of our product candidates as compared to others;</font></td></tr>
  </table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%;  font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 2%"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">our maintenance and establishment of intellectual property rights in our product candidates;</font></td></tr>
  </table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%;  font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 2%"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">our need for additional financing and our estimates regarding our capital requirements and future revenues and profitability;</font></td></tr>
  </table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%;  font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 2%"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">our estimates of the size of the potential markets for our product candidates; and</font></td></tr>
  </table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%;  font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 2%"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">our selection and licensing of product candidates.</font></td></tr>
  </table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">These statements are based on assumptions and analyses made by us in light
of our experience and our perception of historical trends, current conditions and expected future developments based on the focus of our
business activities on biotechnology, as well as other factors we believe are appropriate in particular circumstances. However, whether
actual results and developments will meet our expectations and predictions depends on a number of risks and uncertainties, which could
cause actual results to differ materially from our expectations, including the risks set forth in &quot;Item 3 - Key Information-Risk
Factors&rdquo; in the Company&rsquo;s Annual Report on Form 20-F for the year ended March 31, 2021.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Our business focus is that of being primarily a pharmaceutical development
business subject to all of the risks of a pharmaceutical development business. We do not anticipate directly engaging in the post pharmaceutical
development endeavors of manufacturing, marketing and distribution of our development products.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Consequently, all of the forward-looking statements made in this document
are qualified by these cautionary statements. We cannot assure you that the actual results or developments anticipated by us will be realized
or, even if substantially realized, that they will have the expected effect on us or our business or operations.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Unless the context indicates otherwise the terms &ldquo;Portage Biotech
Inc.,&rdquo; &ldquo;the Company,&rdquo; &ldquo;Portage,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; or &ldquo;our&rdquo; are used interchangeably
in this document and refer to Portage Biotech Inc. and its subsidiaries.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Nature of Operations and Overview</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Portage is a clinical stage immune-oncology company focused on overcoming
immune resistance. It currently manages 10 immuno-oncology assets at various development stages. We source, nurture and develop the creation
of early- to mid-stage, first- and best-in-class therapies for a variety of cancers, by funding, implementing viable, cost-effective product
development strategies, clinical counsel/trial design, shared services, financial and project management to enable efficient, turnkey
execution of commercially informed development plans. Our drug development pipeline portfolio encompasses products or technologies based
on biology addressing known resistance pathways/mechanisms of current check point inhibitors with established scientific rationales, including
intratumoral delivery, nanoparticles, liposomes, aptamers, and virus-like particles.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><b>The Portage Approach</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">Our mission is to advance and grow a portfolio
of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance. Given
these foundations, we manage capital allocation and risk as much as we oversee drug development. By focusing our efforts on translational
medicine and pipeline diversification, we seek to mitigate overall exposure to many of the inherent risks of drug development. Our approach
is guided by the following core elements:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%;  font-size: 10pt">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 2%; text-align: center"><font style="font-size: 10pt">&bull;</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">Portfolio diversification to mitigate risk and maximize optionality;</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">&bull;</font></td>
    <td><font style="font-size: 10pt">Capital allocation based on risk-adjusted potential, including staged funding to pre-specified scientific and clinical results;</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">&bull;</font></td>
    <td><font style="font-size: 10pt">Virtual infrastructure and key external relationships to maintain a lean operating base;</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">&bull;</font></td>
    <td><font style="font-size: 10pt">Internal development capabilities complemented by external business development;</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">&bull;</font></td>
    <td><font style="font-size: 10pt">Rigorous asset selection with disciplined ongoing evaluation; and&nbsp;</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">&bull;</font></td>
    <td><font style="font-size: 10pt">Focus on translational medicine and therapeutic candidates with in vivo single agent activity.</font></td></tr>
  </table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><font style="background-color: white">We believe that our corporate structure
results in enhanced operational efficiency and maintains an optimal cost structure by centralizing strategic/tactical support, shared
services, including all research and development operations, capital allocation/ contribution, human resources,</font>&nbsp;<font style="background-color: white">administrative
services, and business development, as well as other services to each of our immuno-oncology platforms and assets currently in various
development stages.&nbsp; Our execution is achieved, in part, through our internal core team and utilizing our large network of experts,
contract labs, and academic partners.</font></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; background-color: white"><b>Our Science Strategy</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">Our goal is to develop immuno-oncology therapeutics
that will dramatically improve the standard-of-care for patients with cancer. The key elements of our scientific strategy are to:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%;  font-size: 10pt">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 2%; text-align: center"><font style="font-size: 10pt">&bull;</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">Build a pipeline of differentiated oncology therapeutic candidates that are diversified by mechanism, therapeutic approach, modality, stage of development, leading to a variety of deal types that can be executed with partners;</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">&bull;</font></td>
    <td><font style="font-size: 10pt">Expand our pipeline through research collaborations, business development, and internally designed programs;</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">&bull;</font></td>
    <td><font style="font-size: 10pt">Continue to advance and evolve our pipeline with a goal of advancing one therapeutic candidate into the clinic and one program into IND-enabling studies each year; and</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">&bull;</font></td>
    <td><font style="font-size: 10pt">Evaluate strategic opportunities to accelerate development timelines and maximize the value of our portfolio.</font></td></tr>
  </table>
<p style="font-size: 10pt; margin: 0pt 0; background-color: white"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; background-color: white"><b>Our Pipeline</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">We have built a pipeline of targeted oncology
and immuno-oncology therapeutic candidates and programs that are diversified by mechanism, therapeutic approach, modality, and stage of
development. On an ongoing basis, we rigorously assess each of our programs using internally defined success criteria to justify continued
investment and determine proper capital allocation. When certain programs do not meet our de-risking criteria for advancement, we look
to monetize or terminate those programs and preserve our capital and resources to invest in programs with greater potential. As a result,
our pipeline will continue to be dynamic.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">The chart below sets forth only as of August
1, 2021, the current state of our immuno-oncology therapeutic candidates and programs.&nbsp; The chart contains forward looking information
and projections based on management's current estimates. The chart information is based on and subject to many assumptions, as determined
by management and not verified by any independent third party, which may change or may not occur as modeled. We undertake no obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.&nbsp; Before you
make an investment decision regarding the Company, you should make your own analysis of forward-looking statements and our projections
about candidate and program development and results.</p>

<p style="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; background-color: white; color: Red"><img src="pipe.jpg" alt=""></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0; background-color: white"><b>Our Business Model</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">We employ a shared service business model to
execute our strategy of building a diversified oncology company in a capital efficient manner and to provide us with the flexibility to
either advance therapeutic candidates ourselves or through transactions with third parties. Our flat organization consists of a holding
company, Portage Biotech Inc. and an operating company, Portage Development Services (&quot;PDS&quot;), which provide human resources,
and other services to each operating entity via a shared services agreement. We believe that by centralizing these shared services, including
all research and development operations, administrative services, and business development, and allocating employees and resources to
each operating entity, we can enhance operational efficiency and maintain an optimal cost structure.</p>

<p style="font-size: 10pt; margin: 0pt 0; background-color: white"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white">Our business model also enables us to access
both internal and external expertise to build and develop our pipeline. We incubate internal programs in our hub, leveraging PDS's internal
resources and network of service providers as needed to support our discovery, lead optimization, and IND-enabling efforts. When we decide
to license from or collaborate with external parties, we establish distinct operating entities, to hold and advance those programs. This
structure enables us to keep licensors economically incentivized at the program level through our ability to offer equity and access to
potential cash milestones and royalty payments.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">In the figure below, each operating entity reflects
its respective technology platform, therapeutic candidates as well as approximate economic ownership, as of June 30, 2021, as a percentage
of shares outstanding (excluding stock options) is listed below each circle.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; background-color: white"><b>Our Organization</b></p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; background-color: white; color: Red"><img src="org.jpg" alt=""></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">The structure of our financing arrangements with
each subsidiary enables us to increase our economic ownership when we provide additional capital.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">PDS is our wholly-owned operating subsidiary
that contracts all of our team members and incubates discovery programs until we establish an operating subsidiary in which to further
advance them. We centralize shared services, including all research and development operations, administrative services, and business
development at PDS Management, and allocate employees and resources to each spoke based on the needs and development stage of each therapeutic
candidate.</p>

<p style="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white">Our business model is designed to (i) enhance
operational efficiency, (ii) maintain an optimal cost structure, (iii) attract leading collaborators, and (iv) promote asset flexibility,
as further described below.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%;  font-size: 10pt">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 2%"><font style="font-size: 10pt">&bull;</font></td>
    <td style="width: 96%"><font style="font-size: 10pt"><i>Enhance operational efficiency</i>: We centralize all employees and services at our hub and allocate resources to spokes as needed.&nbsp;&nbsp;We empower managers to access these resources and make program-level decisions in order to increase productivity and speed.&nbsp;&nbsp;We believe this model enables a flexible organizational structure that can achieve scale through the addition of programs without increasing burdensome bureaucracy or redundant infrastructure.</font></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">&bull;</font></td>
    <td><font style="font-size: 10pt"><i>Maintain an optimal cost structure</i>: We have a relatively small number of employees and have built a network of trusted external service providers, choosing to leverage their infrastructure and expertise as needed instead of embarking on capital-intensive lab, manufacturing, and equipment expenditures.&nbsp;&nbsp;By reducing overhead costs, we believe we can increase the likelihood that we can generate a return on invested capital.</font></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white">&nbsp;</td>
    <td><font style="font-size: 10pt">&bull;</font></td>
    <td><font style="font-size: 10pt"><i>Attract leading collaborators and licensors</i>: Each of our subsidiaries has its own capitalization and governance, enabling us to keep licensors economically incentivized at the program level.&nbsp;&nbsp;We believe that the experienced leadership team and shared services at our hub differentiate us from other potential licensees.</font></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white">&nbsp;</td>
    <td><font style="font-size: 10pt">&bull;</font></td>
    <td><font style="font-size: 10pt"><i>Promote asset flexibility</i>: Each operating subsidiary is a separate legal entity that holds the relevant intellectual property of its therapeutic candidates or programs and has none of its&nbsp;own employees, fixed assets, or overhead costs.&nbsp;&nbsp;This allows us to efficiently pursue various subsidiary-level transactions, such as stock or asset sales, licensing transactions, strategic partnerships, co-development arrangements, or spin-outs.&nbsp;&nbsp;It also provides us with the flexibility to terminate programs with minimal costs if results do not meet our de-risking criteria for advancement.</font></td></tr>
  </table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company is a BVI incorporated company with its registered office located
at FH Chambers, P.O. Box 4649, Road Town, Tortola, BVI. Its USA agent, Portage Development Services, is located at 61 Wilton Road, Westport,
CT 06880.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company is a reporting issuer with the United States Securities and
Exchange Commission. From October 28, 2013 until April 23, 2021, the Company's ordinary shares were also listed for trading in United
States currency on the Canadian Securities Exchange (&ldquo;CSE&rdquo;) (formerly, Canadian National Stock Exchange) under the symbol
&quot;PBT.U&quot;. On February 25, 2021, the ordinary shares of the Company began trading on the Nasdaq Capital Market (&ldquo;NASDAQ&rdquo;)
under the symbol &ldquo;PRTG&rdquo;. The Company voluntarily delisted its common shares from the CSE at the market close on April 23,
2021, since the Company&rsquo;s shares began trading on NASDAQ.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; font-weight: bold">Summary of Results</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following table summarizes financial information for the quarter ended
June 30, 2021, and the preceding eight quarters (all amounts in 000&rsquo;US$ except net loss per share, which are actual amounts). All
share and per share amounts reflect the 1:100 reverse stock split effected June 5, 2020.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style=" width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">June 30,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">Mar. 31,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">Dec. 31,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">Sept. 30</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">June 30,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">Mar. 31,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">Dec. 31,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">Sept. 30,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Quarter ended</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2021</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2021</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2020</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2020</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2020</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2020</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2019</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2019</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2019</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">(Revised)</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-size: 10pt; text-align: left">Net (loss) - attributable to the owners of the Company</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 3%; font-size: 10pt; text-align: right">(3,066</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 3%; font-size: 10pt; text-align: right">(11,498</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 3%; font-size: 10pt; text-align: right">(1,184</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 3%; font-size: 10pt; text-align: right">(2,455</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 3%; font-size: 10pt; text-align: right">(696</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 3%; font-size: 10pt; text-align: right">(1,302</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 3%; font-size: 10pt; text-align: right">(1,316</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 3%; font-size: 10pt; text-align: right">(1,273</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 3%; font-size: 10pt; text-align: right">(1,442</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Working capital (1) (2) (3) (4)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">28,106</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,738</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,875</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">25</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,293</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,226</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,977</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,500</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,604</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Shareholders&rsquo; equity</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">127,711</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">101,449</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">104,945</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">102,233</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">102,646</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">96,531</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">98,574</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">98,248</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">98,222</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Net (loss) per share - Basic</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.25</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1.35</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.10</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.21</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.06</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.12</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.12</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.12</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.13</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Net (loss) per share - Diluted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.25</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1.35</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.10</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.21</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.06</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.12</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.12</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.12</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.13</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>





<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.05pt"></td><td style="width: 18pt">(1)</td><td>June 30, 2021 working capital is net of warrant liability of $751 settleable on a non-cash basis.</td></tr></table>

<p style="font-size: 10pt; margin: 0pt 0 0pt 23.05pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.05pt"></td><td style="width: 18pt">(2)</td><td>March 31, 2021 working capital is net of warrant liability of $1,120 settleable on a non-cash basis.</td></tr></table>

<p style="font-size: 10pt; margin: 0pt 0 0pt 23.05pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.05pt"></td><td style="width: 18pt">(3)</td><td>December 31, 2020 working capital is net of warrant liability of $771 settleable on a non-cash basis.</td></tr></table>

<p style="font-size: 10pt; margin: 0pt 0 0pt 23.05pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.05pt"></td><td style="width: 18pt">(4)</td><td>September 30, 2020 working capital is net of accrued equity issuable of $3,972 and warrant liability of $271 settled or settleable
on a non-cash basis.</td></tr></table>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Number of Ordinary Shares and Warrants</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">These are as follows:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style=" width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">As of,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">June 30, 2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">August
    25, 2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Shares issued and outstanding (a) (b)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">13,326,213</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">13,326,213</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Warrants (c)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">49,701</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">49,701</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  </table>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(a)</td><td>This amount excludes an aggregate 243,000 restricted stock units granted to a director and a consultant on January 13, 2021, which
vested immediately on the date of grant.</td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(b)</td><td>August 25, 2021 amount excludes 548 shares earned for services rendered in July and accrued as of July 31, 2021 not yet issued.</td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(c)</td><td>Warrants are exercisable into equal number of ordinary shares at an average exercise prise of $6.64 and have a remaining contractual
life of approximately 1.25 years as of June 30, 2021.</td></tr></table>

<p style="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0">Business Environment - Risk Factors</p>

<p style="font-size: 10pt; font-weight: bold; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Please refer to the Annual Report on Form 20-F for the year ended March
31, 2021 for detailed information as the economic and industry factors that are substantially unchanged as of the date hereof.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Our Programs and Technology - Recent Developments</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Invariant Natural Killer T-cells (iNKT cells) Platform</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">iNKT cells play an important role in anti-tumour immune responses and
are a distinct class of T lymphocyte displaying a limited diversity of T-cell receptors. They recognize lipid antigens on the surface
of tumour cells and produce large amounts of cytokines within hours of stimulation without the need for clonal expansion. Furthermore,
iNKT cells activate multiple immune system components, including dendritic cells, T-cells and B-cells and stimulate an antigen-specific
expansion of these cells. An operating subsidiary holds an exclusive license (with the right to sub-license) from the Ludwig Institute
to use, research, develop and commercialize iNKT cell agonists, for the treatment of various forms of human disease, including cancer,
under the Ludwig Institute's intellectual property and know-how.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>PORT 2 (IMM60)</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">PORT-2 is an iNKT cell activator/agonist formulated in a liposome with
a 6-member carbon head structure that has been shown to activate both human and murine iNKT cells, resulting in dendritic cell (DC) maturation
and the priming of Ag-specific T and B cells. We recently dosed the first patient in the IMP-MEL PORT-2 clinical trial, a Phase 1/2 dose
escalation and randomized expansion trial. The PORT-2 study has 6 arms and is expected to enroll up to 100 patients with melanoma or non-small
cell lung carcinoma (NSCLC) in order to evaluate the safety and efficacy after receiving regulatory approval from the Medicines and Healthcare
products Regulatory Agency in the United Kingdom and Research Ethics Board at Oxford University.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In animal models, PORT-2 enhanced the frequency of tumour specific immune
responses (Jukes 2016). iNKT cells are unique lymphocytes defined by their co-expression of surface markers associated with NK cells along
with a T-cell antigen receptor (Schmieg 2005). They recognise amphipathic ligands such as glycolipids or phospholipids presented in the
context of the non-polymorphic, MHC class I-like molecule CD1d. Activated iNKT cells rapidly produce IFN-gamma and IL-4 and induce dendritic
cell (DC) maturation and IL-12 production (Cerundolo 2009, Salio 2009, Speak 2008, Fujii 2013).</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>PORT 3 (IMM65)</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">PORT-3 is a PLGA-nanoparticle formulation of IMM60 combined with a NY-ESO-1
peptide vaccine and the first patient was dosed in an open-label, dose-escalation and expansion study of its iNKT agonist. The Phase 1
portion of the trial is expected to enroll 15 patients while the randomized Phase 2 portion is expected to enroll an additional 42 patients.
This platform is designed to demonstrate proof of concept with NY-ESO-1 as our enrichment factor for patient accrual. The combination
product has the ability to prime and boost an anti-tumor immune response. Our patent position extends to other known tumor antigens, and
we are prepared to rapidly launch other assets into the clinic if we see strong activity of this formulation. Notably, Portage received
additional grant support from the Horizon 2020 program to explore next generation targeted nanoparticles.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Biodegradable PLGA-nanoparticles function as a delivery platform for immunomodulators
and tumor antigens to induce a specific anti-tumor immune response. PLGA has minimal (systemic) toxicity and is used in various drug-carrying
platforms as an encapsulating agent. Furthermore, co-formulating an iNKT inhibitor with a peptide vaccine in a particle has shown to be
approximately 5 times more potent in killing cancer cells and generating an antigen specific CD8 T-cell response than giving the 2 agents
individually (ref Dolen et al Oncoimmunology paper).</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">NY-ESO-1 is a cancer-testis antigen expressed during embryogenesis and
in the testis, an immune privileged site. Furthermore, NY-ESO-1 expression is observed in several advanced cancers: lung (2-32%), melanoma
(40%), bladder (32-35%), prostate (38%), ovarian (30%), esophageal (24-33%), and gastric cancers (8-12%). Clinical trials have shown the
safety and tolerability of Good Manufacturing Practices (GMP)-grade NY-ESO-1 peptides in patients with cancer.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">There is substantial opportunity for potential expansion in the PD-1 market
with PORT-2 and PORT-3. 70-80% of patients do not respond or have a limited response to existing therapies, such as PD-1 checkpoint inhibitors.
The market is saturated with 14 approved PD-1 antibodies, and every major pharma company competing in this space. With iNKT agonists upregulating
expression of PD-L1, patient populations who are typically not good candidates for PD-1 antibodies due to their lack of or low expression
of PD-L1 may be able to utilize PORT 2 or PORT-3 to sensitize tumors to PD-1 agents. Extending the use of PD-1 antibodies represents a
significant upside for one of these companies competing for market share, should they choose to partner with Portage.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Amphiphilic platform</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">DfuseRx SM, identifies combinations of anti cancer agents with amphiphilic
diffuse enhancers that can passively enter into cancer cells.&nbsp; These novel formulations with unique IP can be directly injected into
any solid tumours, and the payloads will diffuse across the membrane and disperse throughout the tumor, while sparing healthy cells. Once
inside the cells, the technology is diluted away and the payloads are stuck inside the cell. The payloads are able to disperse to areas
of the tumor that do not have blood supply and hence oral or IV drugs will not reach.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>PORT 1 (INT230-6)</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">PORT-1 is a fixed dose formulation of cisplatin, vinblastine and a penetration
enhancer being developed by our affiliate, Intensity Therapeutics, Inc.&nbsp; In animal models, the drug is able to cure the majority
of the animals, by a combination of direct killing of the cancer, and also a CD4 and CD8 T-cell response (Bloom et al).&nbsp; Newly released
interim safety and survival data from the Phase 1/2 IT-01 study presented at ASCO 2021 demonstrated that both INT230-6 (PORT-1) monotherapy
and combination therapy with immune checkpoint drugs are well-tolerated. The proven mechanism of action includes direct tumor-killing
effects, as well as responses generated in non-injected tumors (abscopal responses) resulting from antigen presentation and immune activation.
PORT-1 is the first of Portage&rsquo;s assets that entered the clinic and has demonstrated proof-of-concept in humans. The specific rapid
local killing in the normal 3-dimensional environment inside the body we believe is critical for robust antigen presentation and immune
activation.&nbsp; Animal studies also showed synergy when combined with checkpoint inhibition (Bender et al, Bloom et al). The product
has been dosed into 80 subjects in a Phase 1/2 trial. This has shown proof of concept that the vast majority of the drug stays in the
tumor, and a dose equivalent to 3x the approved dose of the cytotoxic agent was very well tolerated without the typical chemo side effects.&nbsp;
The most common adverse event related to the treatment was pain at the injection site.&nbsp; As a result, PORT-1 has launched 9 phase
2 studies including 7 clinical collaborations with the two largest immuno-oncology drug manufacturers, BMS and Merck in combination with
their respective checkpoints in high unmet need medical types (pancreatic, gall bladder, sarcoma, non-microsatellite unstable colorectal,
etc.).&nbsp; Intensity has also launched a randomized Phase 2 study of INT230-6 vs no treatment in early stage breast cancer (the INVINCIBLE
Trial) and has expanded its collaboration efforts with the INVINCIBLE study, conducted by the Ottawa Hospital and the Ontario Institute
for Cancer Research. The company plans on presenting updates from the INVINCIBLE and IT-01 studies at upcoming industry meetings.&nbsp;
As a result of exciting preliminary data (ref ASCO 2020, SITC 2020), we have secured fast track regulatory status from the FDA for triple
negative breast cancer.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>PORT 4, Nanolipogel (NLG) co-formulation Platform</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Scientists are interested in novel ways to deliver multiple signals to
the immune system in order to better activate an anti-tumor response.&nbsp; We have been impressed with a platform from Yale University
that allows different types of agents to be packaged together and will concentrate them in tumors.&nbsp; We have licensed the platform
for delivery of DNA aptamers and certain aptamer-small molecule-based combination products. In order to have multiple proprietary agents
with known mechanisms of action, we have licensed rights to create DNA aptamers for immune-oncology targets and the first one developed
is a proprietary PD1 aptamer, which has been placed in the NLG formulation.&nbsp; Early testing has shown the formulation properly modulates
PD1 signaling in vitro similar to a PD1 antibody I.&nbsp; In non-clinical, in vivo experiments, the NLG-PD1 performed favorably compared
to a mouse PD1 antibody.&nbsp; The current level of funding is expected to support exploration of multiple PD1 based co-formulations with
small molecules and other DNA aptamers. We are looking to accelerate preclinical development of our PORT-4 platform, which may potentially
increase the potency and improve the safety of numerous anti-cancer drugs through co-delivery of combination treatments to the tumor.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b><i>PORT-5, STING Agonist Platform</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Proprietary immune priming and boosting technology (using a STING agonist
delivered in a virus-like particle) have shown proof of concept in animal models and are beginning to progress the lead asset towards
the clinic.&nbsp; This platform offers multiple ways to target immune stimulation towards the cancer, as well as to co-deliver multiple
signals in a single product.&nbsp; Our researchers have developed a way to administer the product systemically and does not require direct
tumor injections.&nbsp; PORT-5 STING platform provides distinct advantages over chemical intratumoral approaches by offering a potent
immune priming and boosting pathway within a virus-like particle (VLP) to enable convenient systemic administration and traffic to the
correct targets. This technology preferentially targets dendritic cells, which is differentiated from other chemical STING approaches.&nbsp;
The Company is progressing this project towards clinical trials as well as developing next generation compounds.&nbsp; Given that this
is a simple way to boost the immune response to any target, we are also pursuing a project to boost immune response to COVID and other
pathogens.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Other Early-Stage R&amp;D</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">We continue to evaluate and test new antibody targets.&nbsp; Our interest
here lies in the suppressive tumor micro-environment, and how we can down regulate or remove MDSC, TAMs, Tregs and other signals that
impede the immune response from clearing cancer cells.&nbsp; One new effort that we have initiated is collaborations with two leading
artificial intelligence/machine learning companies in order to screen for agents with specific attributes in this area.&nbsp; This may
allow us a fast track an asset to the clinic with a re-purposed product.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Three Months Ended June 30, 2021 Compared to the Three Months Ended
June 30, 2020</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>(All Amounts in 000&rsquo;$)</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0">Results of Operations</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following details major expenses for the three months ended June 30,
2021, compared to the three months ended June 30, 2020.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style=" width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Three months ended June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Operating expenses</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(3,593</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(973</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">369</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&ndash;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Share of (loss) income in associates accounted for using equity method</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(44</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">440</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Interest (expense)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(34</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(122</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"> Loss before provision for income taxes</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(3,302</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(655</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax benefit</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">79</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&ndash;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net (loss)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(3,223</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(655</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Unrealized gain on investments</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&ndash;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">78</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive (loss) for period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(3,223</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(577</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Comprehensive (loss) income attributable to:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Owners of the Company</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(3,066</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(618</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(157</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">41</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive (loss) for period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(3,223</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(577</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0"><i>Results of Operations for the Three Months Ended June 30, 2021 Compared
to the Three Months Ended June 30, 2020</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company generated a net loss and comprehensive loss of approximately
$3.2 million in the three months ended June 30, 2021 (&ldquo;Fiscal 2022 Quarter&rdquo;), compared to a net loss of approximately $0.7
million and comprehensive loss of approximately $0.6 million in the three months ended June 30, 2020 (&ldquo;Fiscal 2021 Quarter&rdquo;),
an increase in loss of $2.5 million and $2.6 million, respectively, year over year. Operating expenses, which include research and development
and general and administrative expenses, were $3.6 million in the Fiscal 2022 Quarter, compared to $1.0 million in the Fiscal 2021 Quarter,
an increase of $2.6 million, which is discussed more fully below. Operating expenses included $2.2 million of non-cash stock-based compensation
expense in the Fiscal 2022 Quarter, compared to $0.3 million in the Fiscal 2021 Quarter.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company&rsquo;s other items of income and expense were substantially
non-cash in nature, and were approximately $0.3 million net income in each of the Fiscal 2022 Quarter and the Fiscal 2021 Quarter. Other
items of income and expense in the Fiscal 2022 Quarter were:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&middot;</font></td><td>a gain of $0.4 million representing the change in the fair value of the warrants issued with respect to the SalvaRx settlement;</td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&middot;</font></td><td>a small loss generated by Stimunity accounted for under the equity method in the Fiscal 2022 Quarter, compared to $0.4 million gain
in the Fiscal 2021 Quarter; and</td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&middot;</font></td><td>interest expense of $0.03 million in the Fiscal 2022 Quarter, compared to $0.1 million in the Fiscal 2021 Quarter. The prior year
period reflects interest expense on the SalvaRx Notes, which were repaid in Fiscal 2021. The current year period reflects interest on
the iOx Notes and the financing of the insurance premium obligation.</td></tr></table>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Additionally, the Company reflected a net income tax benefit of approximately
$0.1 million in the Fiscal 2022 Quarter, attributable to recoverable research and development tax credits generated in the U.K., partially
offset by the foreign currency exchange rate effect on deferred tax liability.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Operating Expenses</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The overall analysis of the operating expenses is as follows:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style=" width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Three months ended June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Research and development</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">1,546</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">452</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,047</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">521</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating expenses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">3,593</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">973</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  </table>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Research and Development Costs</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">These costs comprised the following:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style=" width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Three months ended June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&rsquo;$</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Consultants - scientists and researchers</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">1,329</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">452</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Legal regarding Patents&rsquo; registration</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">42</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">83</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other outside services - lab testing, peptide handling, etc.</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">6</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">414</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development services and storage</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">169</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">73</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,546</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,022</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from a legal settlement with a vendor</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&ndash;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(570</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total research and development costs</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,546</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">452</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  </table>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Research &amp; development (&quot;R&amp;D&quot;) costs increased by approximately
$1.0 million, from approximately $0.5 million during the three months ended June 30, 2020, to approximately $1.5 million during the three
months ended June 30, 2021. The increase was primarily attributable to non-cash stock-based compensation expense (included in consultants
- scientists and researchers) associated with grants made under the 2021 Equity Incentive Plan of $1.0 million, partially offset by a
decrease in iOx related stock-based compensation expense of $0.2 million and a decrease of $0.4 in other R&amp;D costs relating to outside
services. Additionally, the three months ended June 30, 2020 was impacted by the receipt of a $0.6 million cash settlement for a legal
dispute the Company had with a vendor while developing one of its products, which reduced R&amp;D costs, as well as a general slow down
in expenditures resulting from the pandemic.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b><i>General and Administrative Expenses</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 23.05pt"><font style="font-weight: normal">Key components of general and administrative
expenses are:</font></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style=" width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Three months ended June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&rsquo;$</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Consulting fees</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">506</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">139</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Directors&rsquo; fees</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">729</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">222</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">D&amp;O insurance</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">413</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Professional fees</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">351</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">75</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Office and general expenses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">48</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">81</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,047</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">521</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  </table>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">General and administrative (&quot;G&amp;A&quot;) expenses increased by
approximately $1.5 million, from approximately $0.5 million during the three months ended June 30, 2020, to approximately $2.0 million
during the three months ended June 30, 2021. The principal reason for the increase in the Fiscal 2022 Quarter was the $1.1 million of
non-cash stock-based compensation expense associated with the Company&rsquo;s 2021 Equity Incentive Plan, of which $0.7 million is associated
with Directors&rsquo; compensation, and $0.4 million is associated with management compensation, partially offset by a decrease in iOx
related stock-based compensation expense of $0.2 million. No stock-based compensation expense under the 2021 Equity Incentive Plan was
incurred during the three months ended June 30, 2020. Additionally, the Company incurred an increase of $0.3 million in professional fees
relating to initiatives associated with a corporate restructuring and public relations / business development. Finally, D&amp;O insurance
premiums increased $0.4 million in the current year period due to market rate increases in the cost of coverage.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0">Liquidity and Capital Resources</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On June 16, 2020, the Company closed a private placement of ordinary shares
(the &ldquo;Offering&rdquo;) for gross proceeds of approximately $6.98 million through the issuance of 698,145 ordinary shares (the &ldquo;Ordinary
Shares&rdquo;) at a price of $10.00 per Ordinary Share. The Company incurred costs of $248,000 in connection with the Offering, which
was offset against the gross proceeds. The net proceeds from the Offering are being used to finance operating expenses and accelerate
pipeline development/execution and will enable management to pursue new opportunistic value creation. A portion of the proceeds was used
to settle the SalvaRx notes.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Portage filed a registration statement and prospectus with the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) under which it may sell ordinary shares, debt securities, warrants and units in one or more
offerings from time to time, which became effective on March 8, 2021 (&ldquo;Registration Statement&rdquo; or &ldquo;Prospectus&rdquo;).
The Registration Statement includes:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&middot;</font></td><td>a base prospectus, which covers the offering, issuance and sales by us of up to $200,000,000 in the aggregate of the securities identified
above from time to time in one or more offerings; and</td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&middot;</font></td><td>a sales agreement prospectus covering the offer, issuance and sale by us in an &ldquo;at the market&rdquo; offering of up to a maximum
aggregate offering price of $50,000,000 of our ordinary shares that may be issued and sold from time to time under sales agreement, or
sales agreement, with Cantor Fitzgerald &amp; Co., or Cantor Fitzgerald, the sales agent.</td></tr></table>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The specific terms of any securities to be offered pursuant to the base
prospectus are specified in the sales agreement prospectus. The $50,000,000 of ordinary shares that may be offered, issued and sold under
the sales agreement prospectus is included in the $200,000,000 of securities that may be offered, issued and sold by us under the base
prospectus. The sales under the prospectus will be deemed to be made pursuant to an &ldquo;at the market offering&rdquo; as defined in
Rule 415(a)(4) promulgated under the Securities Act of 1933 (the Securities Act). Upon termination of the sales agreement, any portion
of the $50,000,000 included in the sales agreement prospectus that is not sold pursuant to the sales agreement will be available for
sale in other offerings pursuant to the base prospectus, and if no shares are sold under the sales agreement, the full $50,000,000 of
securities may be sold in other offerings pursuant to the base prospectus. The offering was declared effective by the SEC on March 8,
2021.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">During the quarter ended June 30, 2021, the Company commenced an &ldquo;at
the market&rdquo; offering, under which it sold 90,888 shares generating gross proceeds of approximately $2.6 million ($2.5 million, net
of commissions).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&nbsp;</p>
<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 24, 2021, the Company completed the sale of 1,150,000 ordinary
shares, including the underwriters&rsquo; overallotment, at a price of $23.00 per share, which generated gross proceeds of approximately
$26.5 million and net proceeds of approximately $25.0 million, and was settled June 28, 2021. Management believes the funds generated,
along with existing cash, will be sufficient to fund the Company&rsquo;s research and development activities, as well as the expansion
of its operating infrastructure and achievement of numerous developmental milestones. The Company was added to the Russell 2000 Index
effective after the U.S. market opened on June 28, 2021.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0"><i>Liquidity</i></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The accompanying condensed consolidated interim financial statements have
been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations,
the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying
condensed consolidated interim financial statements do not include any adjustments relating to the recoverability and classification of
recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of June 30, 2021, the Company had cash and cash equivalents of approximately
$28.6 million and total current liabilities of approximately $2.5 million (inclusive of approximately $0.7 million warrant liability settleable
on a non-cash basis). For the three months ended June 30, 2021, the Company is reporting a net loss of approximately ($3.2) million and
cash used in operating activities of approximately $1.6 million. As of July 31, 2021, we had approximately $28.0 million of cash on hand.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">During the quarter ended June 30, 2021, the Company commenced an &ldquo;at
the market&rdquo; offering, under which it sold 90,888 shares generating gross proceeds of approximately $2.6 million ($2.5 million,
net of commissions). Further, the Company initiated an offering pursuant to the Prospectus. On June 24, 2021, the Company completed a
firm commitment underwritten public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share for gross proceeds
of approximately $26.5 million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering
of approximately $1.8 million, including approximately $1.6 million of management, underwriting and selling expenses. The Company will
use the net proceeds raised to fund its research and development activities and support operations. The amount raised is sufficient to
fund operations through September 2022. Funds may be used to accelerate development activities to advance the Company&rsquo;s product
portfolio, working capital and general corporate purposes.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company has incurred substantial operating losses since inception
and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result
primarily from its conduct of research and development activities.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company historically has funded its operations principally from proceeds
from issuances of equity and debt securities and would expect to enter the capital markets if additional funding is required.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0"><i>Cash Flows Used In Operating Activities</i></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">During the three months ended June 30, 2021, the Company used cash of
approximately $1.6 million to fund operating activities, compared to $0.7 million used during the three months ended June 30, 2020. Operations
in the three months ended June 30, 2021 were funded by existing cash. Operations during the three months ended June 30, 2020 were funded
by existing cash plus a portion of the net proceeds from the private placement of approximately $6.7 million, net of offering costs, which
closed in June 2020.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company does not currently have any contractual commitments to fund
further research and development at its subsidiaries.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company's continuing operations are dependent upon any one of:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp; the development and identification of economically
recoverable medical solutions;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp; the ability of the Company to obtain the necessary
financing to complete the research; or</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp; future profitable production from or proceeds from
the disposition of intellectual property.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company's cash at June 30, 2021 of approximately $28.6 million will
be sufficient to fund the Company&rsquo;s current research and development activities, as well as expansion of its operating infrastructure.
The Company will need additional funds in the future to fund its operations and development plans, which if not obtained when needed may
require the Company to adjust its plans and curtail or delay parts of its overall business plans.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0"><i>Cash Flows Used In Investing Activities</i></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-align: left; text-indent: 23.05pt"><font style="font-weight: normal">During the three months
ended June 30, 2021, the Company did not use any cash for investing activities. During the three months ended June 30, 2020, the Company
used cash of $1.0 million to fund investing activities.</font></p>

<p style="font-size: 10pt; margin: 0pt 0; text-align: left; text-indent: 23.05pt"><font style="font-weight: normal">&nbsp;</font></p>

<p style="font-size: 10pt; margin: 0pt 0; text-align: left; text-indent: 23.05pt"><font style="font-weight: normal">On June 1, 2020, the
Company made an additional $1.0 million investment in Stimunity upon Stimunity's achievement of certain agreed milestones, increasing
its equity share in Stimunity to 44%.</font></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Cash Flows Provided By Financing Activities</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 23.05pt"><font style="font-weight: normal">During the three months ended June
30, 2021, the Company generated cash from financing activities of $27.4 million, compared to $6.7 million during the three months ended
June 30, 2020.</font></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><font style="font-weight: normal">&nbsp;</font></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><font style="font-weight: normal">During the quarter ended June 30, 2021, the Company commenced an &ldquo;at the market&rdquo; offering, under which it sold
90,888 shares generating gross proceeds of approximately $2.6 million ($2.5 million, net of commissions). Further, the Company initiated
an offering pursuant to the Prospectus. On June 24, 2021, the Company completed a firm commitment underwritten public offering of 1,150,000
ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $26.5 million and was settled June
28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $1.8 million, including approximately
$1.6 million of management, underwriting and selling expenses.</font></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 23.05pt"><font style="font-weight: normal">On June 16, 2020, the Company completed
a private placement offering of 698,145 restricted ordinary shares at a price of $10 per share for gross proceeds of $6.98 million to
accredited investors. Directors of the Company subscribed for 215,000 shares for $2,150,000. The Company incurred offering costs of $248,000
in connection with the private placement.</font></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0">Key Contractual Obligations</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Details of contractual obligations, commitments and contingent liabilities
are provided in Note 17, &ldquo;Commitments and Contingent Liabilities,&rdquo; to the unaudited condensed consolidated interim financial
statements for the three months ended June 30, 2021.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0">Off-balance Sheet Arrangements</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of June 30, 2021 and 2020, the Company did not have any off-balance
sheet arrangements, including any relationships with unconsolidated entities or financial partnership to enhance perceived liquidity.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0"><font style="font-size: 10pt">Transactions with Related Parties</font>&#9;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Significant related party transactions are detailed in Note 18, &ldquo;Related
Party Transactions,&rdquo; to the unaudited condensed consolidated interim financial statements for the three months ended June 30, 2021.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; font-weight: bold">Financial and Derivative Instruments</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company&rsquo;s financial instruments recognized in the Company&rsquo;s
condensed consolidated interim statements of financial position consist of the following:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Fair value estimates are made at a specific point in time, based on relevant
market information and information about financial instruments. These estimates are subject to and involve uncertainties and matters of
significant judgment, therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimates.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following table summarizes the Company&rsquo;s financial instruments
as of June 30, 2021 and March 31, 2021:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style=" width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of June 30, 2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of March 31, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value through Other Comprehensive <BR>Income (FVTOCI)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: left">Financial assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">28,617</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">&ndash;</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">2,770</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">&ndash;</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,995</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&ndash;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,176</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">&ndash;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Investments</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&ndash;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">9,100</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">&ndash;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9,144</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  </table>


<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style=" width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value through Profit or Loss (FVTPL)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: left">Financial liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">1,605</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">&ndash;</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">1,938</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">&ndash;</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Unsecured notes payable</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">150</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&ndash;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">150</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">&ndash;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&ndash;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">751</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">&ndash;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1,120</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  </table>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">A summary of the Company&rsquo;s risk exposures as it relates to financial
instruments are reflected below.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Fair value of financial instruments</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company&rsquo;s financial assets and liabilities are comprised of
cash, receivables and investments in equities and private entities, accounts payable, warrant liability and unsecured notes payable.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company classifies the fair value of these transactions according
to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&middot;</font></td><td>Level 1 &ndash; Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of
the reporting date.</td></tr></table>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&middot;</font></td><td>Level 2 &ndash; Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which
can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of
the reporting date.</td></tr></table>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&middot;</font></td><td>Level 3 &ndash; Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified
as Level 3 financial instrument.</td></tr></table>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Assessment of the significance of a particular input to the fair value
measurement requires judgment and may affect the placement within the fair value hierarchy.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Management has assessed that the fair values of cash and cash equivalents,
other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following methods and assumptions were used to estimate their fair
values:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>Investment in Biohaven</b>: Fair value was based on a quoted market
price of $34.03 per share as of March 31, 2020 (Level 1). The investment was sold in August 2020.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>Investment in Sentien</b>: Fair value of the asset is determined by
considering strategy changes by Sentien (Level 3).</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>Investment in Intensity</b>: Fair value of the asset is determined
by considering other comparable equity funding transactions by Intensity with unrelated investors (Level 3).</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>Accrued equity issuable</b>: The fair value is estimated based on the
average of the quoted market prices for the period in which the shares were earned (Level 1).</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>Unsecured notes payable</b>: The fair value is estimated using a Black
Scholes model (Level 3).</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>Warrant Liability</b>: The fair value is estimated using a Black Scholes
model (Level 3).</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">There have been no transfers between levels of the fair value hierarchy
for the three months ended June 30, 2021 and the year ended March 31, 2021.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company&rsquo;s financial instruments are exposed to certain financial
risks: credit risk and liquidity risk.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Credit risk</i></b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Credit risk is the risk of loss associated with a counterparty&rsquo;s
inability to fulfil its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&rsquo;s condensed consolidated interim statements of financial position.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b><i>Cash</i>.</b> Cash is held with major international financial institutions
and therefore the risk of loss is minimal.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b><i>Other receivables.</i></b> The Company was exposed to credit risk
attributable to its debtor since a significant portion of this amount represents the amount agreed on a settlement of a claim by PPL,
originally payable over the next four years. The installment note was repaid in full in July 2021.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Liquidity Risk</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Liquidity risk is the risk that the Company will encounter difficulty
in satisfying financial obligations as they become due.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company&rsquo;s approach to managing liquidity is to ensure, as far
as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without
incurring unacceptable losses or risking harm to the Company&rsquo;s reputation. The Company holds sufficient cash to satisfy obligations
under accounts payable and accruals.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company monitors its liquidity position regularly to assess whether
it has the funds necessary to meet its operating needs and needs for investing in new projects. The Company believes that it has sufficient
funding to finance the committed drug development work, apart from meeting its operational needs for the foreseeable future.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">However, as a biotech company at an early stage of development and without
significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may
not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty in global
markets could have an impact on the Company&rsquo;s future ability to access capital on terms that are acceptable to the Company. There
can be no assurance that required financing will be available to the Company. See Note 22, &ldquo;Events After the Balance Sheet Date,&rdquo;
for a discussion of the Company&rsquo;s share offering.</p>

<p style="font-size: 10pt; text-indent: 15.85pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Use of Estimates and Judgments</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The preparation of the condensed consolidated interim financial statements
in conformity with <font style="color: #222222; background-color: white">International Financial Reporting Standards (&ldquo;</font>IFRS&rdquo;)
requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts
of assets, liabilities, income and expenses. Actual results may differ from these estimates.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Estimates and underlying assumptions are reviewed on an ongoing basis.
Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Significant areas where estimates are made include valuation of financial
instruments, research and development costs, fair value used for acquisition and measurement of share-based compensation. Significant
areas where critical judgments are applied include assessment of impairment of investments and goodwill and the determination of the accounting
acquirer and acquiree in the business combination accounting.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>New Accounting Standards, Interpretations and Amendments</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company is also unaware of any applicable but not-yet-adopted standards
that are expected to materially affect the financial statements of future periods.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0">Internal Controls Over Financial Reporting</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The management of the Company, including the CEO and CFO, is responsible
for establishing and maintaining adequate internal controls over financial reporting (as defined in Rule 13a-15(f) under the Exchange
Act). The Company's internal control system was designed to provide reasonable assurance to the Company's management and the board of
directors regarding the reliability of financial reporting and preparation and fair presentation of published financial statements for
external purposes in accordance with IFRS. Internal control over financial reporting includes those policies and procedures that:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">1.</td><td>pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of
the assets of the Company;</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">2.</td><td>provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors
of the Company; and</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 25.9pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">3.</td><td>provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's
assets that could have a material effect on the financial statements.</td></tr></table>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">All internal control systems, no matter how well designed, have inherent
limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial
statement preparation and presentation. Because of its inherent limitations, internal control over financial reporting may not prevent
or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style=" width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Management assessed the effectiveness of the Company's internal control
over financial reporting as of June 30, 2021. In making this assessment, it used the criteria established in Internal Control - Integrated
Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on the evaluation under
these criteria, management identified material weaknesses in the Company's internal controls over financial reporting, and as a result,
management concluded that the Company's internal control over financial reporting was not effective as of June 30, 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Management identified the following material weaknesses set forth below
in our internal control over financial reporting.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><font style="font-family: Symbol">&middot;</font></td><td style="width: 5pt"></td><td style="text-align: justify">Management was unable to perform an effective risk assessment or monitor internal controls
over financial reporting;</td>
</tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><font style="font-family: Symbol">&middot;</font></td><td style="width: 5pt"></td><td style="text-align: justify">The management of the Company lacks the number of skilled persons it requires given the complexity
of the reporting requirements it has to make, which more specifically include the staff and expertise (i) to properly segregate duties
and perform oversight of work performed and to perform compensating controls over the finance and accounting functions, (ii) to establish
and perform fair value estimates or subsequently monitor fluctuations in fair value estimates, and (iii) to apply complex accounting
principles, including those relating to business combination accounting, income taxes and fair value estimates; and</td>
</tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><font style="font-family: Symbol">&middot;</font></td><td style="width: 5pt"></td><td style="text-align: justify">There are insufficient written policies and procedures in place to ensure the correct application
of accounting and financial reporting with respect to the current requirements of IFRS and SEC disclosure requirements, some of which
specifically relate to investment accounting and fair value measures, assessment of in-process research and development assets, share
based payments, carrying amounts of goodwill and intangible assets and business combination accounting.</td>
</tr></table>

<p style="font-size: 10pt; text-indent: 25.9pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; font-weight: bold; margin: 0pt 0">Public Securities Filings</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Additional information, including the Company&rsquo;s annual information
in the Annual Report on Form 20-F, is filed with the Canadian Securities Administrators at www.sedar.com and with the United States Securities
and Exchange Commission at www.edgar.com.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">20</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ptgef-20210630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSa2NecPtxJFz2Zkhv2p+felK/y4sasdaGC4nUwZWgTkB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ptgef="http://portagebiotech.com/20210630" elementFormDefault="qualified" targetNamespace="http://portagebiotech.com/20210630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://portagebiotech.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" id="InterimStatementsOfFinancialPosition">
	  <link:definition>00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss" id="InterimStatementsOfOperationsAndOtherComprehensiveLoss">
	  <link:definition>00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive (Loss) (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" id="InterimStatementsOfChangesInShareholdersEquity">
	  <link:definition>00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" id="InterimStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/NatureOfOperations" id="NatureOfOperations">
	  <link:definition>00000006 - Disclosure - NATURE OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000007 - Disclosure - LIQUIDITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/BasisOfPresentation" id="BasisOfPresentation">
	  <link:definition>00000008 - Disclosure - BASIS OF PRESENTATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" id="PrepaidExpensesAndOtherReceivables">
	  <link:definition>00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecurities" id="InvestmentInMarketableEquitySecurities">
	  <link:definition>00000011 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInAssociate" id="InvestmentInAssociate">
	  <link:definition>00000012 - Disclosure - INVESTMENT IN ASSOCIATE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/DispositionOfPpl" id="DispositionOfPpl">
	  <link:definition>00000013 - Disclosure - DISPOSITION OF PPL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentsInPrivateCompanies" id="InvestmentsInPrivateCompanies">
	  <link:definition>00000014 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/Goodwill" id="Goodwill">
	  <link:definition>00000015 - Disclosure - GOODWILL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" id="In-processResearchAndDevelopmentAndDeferredTaxLiability">
	  <link:definition>00000016 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/UnsecuredNotesPayable" id="UnsecuredNotesPayable">
	  <link:definition>00000017 - Disclosure - UNSECURED NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/WarrantLiability" id="WarrantLiability">
	  <link:definition>00000018 - Disclosure - WARRANT LIABILITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalStock" id="CapitalStock">
	  <link:definition>00000019 - Disclosure - CAPITAL STOCK</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserve" id="StockOptionReserve">
	  <link:definition>00000020 - Disclosure - STOCK OPTION RESERVE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/LossPerShare" id="LossPerShare">
	  <link:definition>00000021 - Disclosure - (LOSS) PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
	  <link:definition>00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000023 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" id="FinancialInstrumentsAndRiskManagement">
	  <link:definition>00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalDisclosures" id="CapitalDisclosures">
	  <link:definition>00000025 - Disclosure - CAPITAL DISCLOSURES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterest" id="Non-controllingInterest">
	  <link:definition>00000026 - Disclosure - NON-CONTROLLING INTEREST</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/EventsAfterBalanceSheetDate" id="EventsAfterBalanceSheetDate">
	  <link:definition>00000027 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" id="PrepaidExpensesAndOtherReceivablesTables">
	  <link:definition>00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables" id="InvestmentInMarketableEquitySecuritiesTables">
	  <link:definition>00000030 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInAssociateTables" id="InvestmentInAssociateTables">
	  <link:definition>00000031 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/GoodwillTables" id="GoodwillTables">
	  <link:definition>00000032 - Disclosure - GOODWILL (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" id="In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables">
	  <link:definition>00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableTables" id="UnsecuredNotesPayableTables">
	  <link:definition>00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" id="WarrantLiabilityTables">
	  <link:definition>00000035 - Disclosure - WARRANT LIABILITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalStockTables" id="CapitalStockTables">
	  <link:definition>00000036 - Disclosure - CAPITAL STOCK (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveTables" id="StockOptionReserveTables">
	  <link:definition>00000037 - Disclosure - STOCK OPTION RESERVE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/LossPerShareTables" id="LossPerShareTables">
	  <link:definition>00000038 - Disclosure - (LOSS) PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" id="FinancialInstrumentsAndRiskManagementTables">
	  <link:definition>00000039 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" id="Non-controllingInterestTables">
	  <link:definition>00000040 - Disclosure - NON-CONTROLLING INTEREST (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" id="NatureOfOperationsDetailsNarrative">
	  <link:definition>00000041 - Disclosure - NATURE OF OPERATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
	  <link:definition>00000042 - Disclosure - LIQUIDITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
	  <link:definition>00000043 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" id="PrepaidExpensesAndOtherReceivablesDetails">
	  <link:definition>00000044 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" id="PrepaidExpensesAndOtherReceivablesDetailsNarrative">
	  <link:definition>00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetails" id="InvestmentInMarketableEquitySecuritiesDetails">
	  <link:definition>00000046 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative" id="InvestmentInMarketableEquitySecuritiesDetailsNarrative">
	  <link:definition>00000047 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails" id="InvestmentInAssociateDetails">
	  <link:definition>00000048 - Disclosure - INVESTMENT IN ASSOCIATE  (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails1" id="InvestmentInAssociateDetails1">
	  <link:definition>00000049 - Disclosure - INVESTMENT IN ASSOCIATE  (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" id="InvestmentInAssociateDetailsNarrative">
	  <link:definition>00000050 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/DispositionOfPplDetailsNarrative" id="DispositionOfPplDetailsNarrative">
	  <link:definition>00000051 - Disclosure - DISPOSITION OF PPL (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative" id="InvestmentsInPrivateCompaniesDetailsNarrative">
	  <link:definition>00000052 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/GoodwillDetails" id="GoodwillDetails">
	  <link:definition>00000053 - Disclosure - GOODWILL (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/GoodwillDetailsNarrative" id="GoodwillDetailsNarrative">
	  <link:definition>00000054 - Disclosure - GOODWILL (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails" id="InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails">
	  <link:definition>00000055 - Disclosure - IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" id="In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative">
	  <link:definition>00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" id="UnsecuredNotesPayableDetails">
	  <link:definition>00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" id="UnsecuredNotesPayableDetailsNarrative">
	  <link:definition>00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" id="WarrantLiabilityDetails">
	  <link:definition>00000059 - Disclosure - WARRANT LIABILITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalStockDetails" id="CapitalStockDetails">
	  <link:definition>00000060 - Disclosure - CAPITAL STOCK (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalStockDetailsNarrative" id="CapitalStockDetailsNarrative">
	  <link:definition>00000061 - Disclosure - CAPITAL STOCK (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" id="StockOptionReserveDetails">
	  <link:definition>00000062 - Disclosure - STOCK OPTION RESERVE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" id="StockOptionReserveDetails1">
	  <link:definition>00000063 - Disclosure - STOCK OPTION RESERVE (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" id="StockOptionReserveDetails2">
	  <link:definition>00000064 - Disclosure - STOCK OPTION RESERVE (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" id="StockOptionReserveDetailsNarrative">
	  <link:definition>00000065 - Disclosure - STOCK OPTION RESERVE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/LossPerShareDetails" id="LossPerShareDetails">
	  <link:definition>00000066 - Disclosure - (LOSS) PER SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/LossPerShareDetails1" id="LossPerShareDetails1">
	  <link:definition>00000067 - Disclosure - (LOSS) PER SHARE (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" id="CommitmentsAndContingentLiabilitiesDetailsNarrative">
	  <link:definition>00000068 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" id="FinancialInstrumentsAndRiskManagementDetails">
	  <link:definition>00000070 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" id="FinancialInstrumentsAndRiskManagementDetailsNarrative">
	  <link:definition>00000071 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" id="CapitalDisclosuresDetailsNarrative">
	  <link:definition>00000072 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" id="Non-controllingInterestDetails">
	  <link:definition>00000073 - Disclosure - NON-CONTROLLING INTEREST (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" id="EventsAfterBalanceSheetDateDetailsNarrative">
	  <link:definition>00000074 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="ptgef_StockOptionReserveMember" name="StockOptionReserveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SalvaRxGroupPlcMember" name="SalvaRxGroupPlcMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SubsidiariesOneMember" name="SubsidiariesOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SubsidiariesTwoMember" name="SubsidiariesTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PortageGlasgowLtdMember" name="PortageGlasgowLtdMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SubsidiariesThreeMember" name="SubsidiariesThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PPLSettlementMember" name="PPLSettlementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BiohavenMember" name="BiohavenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StimunitySAMember" name="StimunitySAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember" name="SeriesAPreferredStockInSentienBiotechnologiesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IntensityMember" name="IntensityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AcquisitionOfSalvaRxMember" name="AcquisitionOfSalvaRxMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AcquisitionOfIntensityHoldingLimitedMember" name="AcquisitionOfIntensityHoldingLimitedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IMM60IOXMelanomaLungCancersMember" name="IMM60IOXMelanomaLungCancersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IMM65IOXOvarianProstateCancersMember" name="IMM65IOXOvarianProstateCancersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OncomerSaugatuckDNAAptamersMember" name="OncomerSaugatuckDNAAptamersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PplMember" name="PplMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IoxMember" name="IoxMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SalvaRxMember" name="SalvaRxMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PortageMember" name="PortageMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccreditedInvestorsMember" name="AccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DirectorsMember" name="DirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_N2021EquityIncentivePlanMember" name="N2021EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ConsultantsMember" name="ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RestrictedStockUnitsMember" name="RestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PBI2021EquityIncentivePlanMember" name="PBI2021EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PBI2013OptionPlanMember" name="PBI2013OptionPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IOxOptionPlanMember" name="IOxOptionPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Equity2021IncentivePlanMember" name="Equity2021IncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AmortizedCostMember" name="AmortizedCostMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueToOtherComprehensiveIncomeMember" name="FairValueToOtherComprehensiveIncomeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PglMember" name="PglMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SaugatuckMember" name="SaugatuckMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EventsAfterTheBalanceSheetDateMember" name="EventsAfterTheBalanceSheetDateMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InprocessResearchAndDevelopment" name="InprocessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantLiabilityCurrent" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnsecuredNotesPayable" name="UnsecuredNotesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommitmentAndContingencies" name="CommitmentAndContingencies" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GainsLossesOnChangeInFairValueOfWarrants" name="GainsLossesOnChangeInFairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetLossIncome" name="NetLossIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TotalComprehensiveLossIncomeForYear" name="TotalComprehensiveLossIncomeForYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BasicAndDilutedLossPerShare" name="BasicAndDilutedLossPerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" name="WeightedAveragesSharesoutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IfrsStatementLineItems" name="IfrsStatementLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IssuedUnderPrivatePlacement" name="IssuedUnderPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IssuedUnderPrivatePlacementShares" name="IssuedUnderPrivatePlacementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedOrAccruedForServices" name="SharesIssuedOrAccruedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedOrAccruedForServicesShares" name="SharesIssuedOrAccruedForServicesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderAtm" name="SharesIssuedUnderAtm" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderAtmShares" name="SharesIssuedUnderAtmShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderOffering" name="SharesIssuedUnderOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderOfferingShares" name="SharesIssuedUnderOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnrealizedLossOnInvestmentInInvestments" name="UnrealizedLossOnInvestmentInInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossIncomeOnFairValueOfWarrantLiability" name="LossIncomeOnFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ValueOfSharesIssuedForServices" name="ValueOfSharesIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetChangeInWorkingCapitalComponentsAbstract" name="NetChangeInWorkingCapitalComponentsAbstract" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncreasingDecreasingAccountsReceivable" name="IncreasingDecreasingAccountsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OtherAsset" name="OtherAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" name="ProceedsFromSharesIssuedUnderRegisteredOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareIssuanceCosts" name="ShareIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SupplementalDisclosureOfCashFlowInformation" name="SupplementalDisclosureOfCashFlowInformation" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashPaidForInterest" name="CashPaidForInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncreaseInAccountsPayableForStockIssuanceCosts" name="IncreaseInAccountsPayableForStockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract" name="SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfWarrantLiabilityForPortageWarrantsIssued" name="FairValueOfWarrantLiabilityForPortageWarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnrealizedLossOnInvestmentInInvestment" name="UnrealizedLossOnInvestmentInInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NatureOfOperationsAbstract" name="NatureOfOperationsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NatureOfOperationsTextBlock" name="NatureOfOperationsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureLiquidityAbstract" name="DisclosureLiquidityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LiquidityTextBlock" name="LiquidityTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SignificantAccountingPoliciesAbstract" name="SignificantAccountingPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidExpensesAndOtherReceivableAbstract" name="PrepaidExpensesAndOtherReceivableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InvestmentInBiohavenAbstract" name="InvestmentInBiohavenAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureInvestmentInAssociateAbstract" name="DisclosureInvestmentInAssociateAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InvestmentInAssociateDisclosureTextBlock" name="InvestmentInAssociateDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureDispositionOfPplAbstract" name="DisclosureDispositionOfPplAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DispositionOfPplTextBlock" name="DispositionOfPplTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract" name="DisclosureInvestmentsInPrivateCompaniesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock" name="DisclosureOfPrivateCompaniesExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GoodwilAbstract" name="GoodwilAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" name="DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability" name="InProcessResearchAndDevelopmentAndDeferredTaxLiability" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureUnsecuredNotesPayableAbstract" name="DisclosureUnsecuredNotesPayableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnsecuredNotesPayableAndWarrantsTextBlock" name="UnsecuredNotesPayableAndWarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureWarrantLiabilityAbstract" name="DisclosureWarrantLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantLiabilitytextblock" name="WarrantLiabilitytextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureCapitalStockAbstract" name="DisclosureCapitalStockAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalStockTextBlock" name="CapitalStockTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareBasedPaymentAbstract" name="ShareBasedPaymentAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FinancialInstrumentsAndRiskManagementAbstract" name="FinancialInstrumentsAndRiskManagementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureCapitalDisclosuresAbstract" name="DisclosureCapitalDisclosuresAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" name="DisclosureOfCapitalManagementExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NonControllingInterestAbstract" name="NonControllingInterestAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureEventsAfterBalanceSheetDateAbstract" name="DisclosureEventsAfterBalanceSheetDateAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock" name="DisclosureOfEventAfterBalanceSheetDateTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" name="DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" name="DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfInvestmentAssociatetableTextBlock" name="DisclosureOfInvestmentAssociatetableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock" name="ScheduleOfInvestmentInStimunitySaTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" name="DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" name="ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfNotesPayableTableTextBlock" name="ScheduleOfNotesPayableTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" name="ScheduleOfWarrantLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" name="CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfTermsStockOptionReserveExplanatory" name="DisclosureOfTermsStockOptionReserveExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" name="DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EarningsPerShareTableTextBlock" name="EarningsPerShareTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock" name="ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilities" name="DisclosureOfFinancialAssetsAndFinancialLiabilities" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" name="ScheduleOfNoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IssuanceAndSales" name="IssuanceAndSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashFundDescription" name="CashFundDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OfferingAndThroughThatProcessDescription" name="OfferingAndThroughThatProcessDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ResearchAndDevelopmentCredit" name="ResearchAndDevelopmentCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidExpensesAndOtherReceivables" name="PrepaidExpensesAndOtherReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InvestmentAssetAvailableForSale" name="InvestmentAssetAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnrealizedLossGainOnInvestment" name="UnrealizedLossGainOnInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InvestmentInMarketableEquitySecurities" name="InvestmentInMarketableEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnrealizedGains" name="UnrealizedGains" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AdditionalInvestments" name="AdditionalInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnrecognisedShareOfGainLossesOfAssociates" name="UnrecognisedShareOfGainLossesOfAssociates" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EquityInLossIncome" name="EquityInLossIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DispositionPercentage" name="DispositionPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DispositionValue" name="DispositionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IntercompanyReceivable" name="IntercompanyReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InvestmentOwnedShares" name="InvestmentOwnedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InvestmentOwnershipPercentage" name="InvestmentOwnershipPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnrealizedGainLossOnInvestment" name="UnrealizedGainLossOnInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" name="NumberOfPrivateCompanyShareConsistsInSoleAsset" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NotePayable" name="NotePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RepaymentOfNotesPayable" name="RepaymentOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AmortizationOfDebtDiscount" name="AmortizationOfDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ValueOfNotesExchangedInWarrantExercise" name="ValueOfNotesExchangedInWarrantExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SettlementInConnectionWithDispositionOfPpl" name="SettlementInConnectionWithDispositionOfPpl" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnExtinguishmentOfDebt" name="LossOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromLoanPayable" name="ProceedsFromLoanPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AggregatePrincipalAmountOfUnsecuredNotes" name="AggregatePrincipalAmountOfUnsecuredNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnsecuredNotesInterest" name="UnsecuredNotesInterest" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IssuanceOfUnsecuredNotesDescription" name="IssuanceOfUnsecuredNotesDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PaymentForSettlement" name="PaymentForSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsExercised" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ContractualValueOfWarrantsExercisedDescription" name="ContractualValueOfWarrantsExercisedDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesReceived" name="SharesReceived" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfExerciseOfWarrantsIssued" name="NumberOfExerciseOfWarrantsIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfExerciseOfWarrantsOutstanding" name="NumberOfExerciseOfWarrantsOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfBusinessCombination" name="DescriptionOfBusinessCombination" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsOutstandingExercisePrice" name="WarrantsOutstandingExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsOutstandingShares" name="WarrantsOutstandingShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsOutstandingAmount" name="WarrantsOutstandingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueAdjustmentExercisePriceAtEnd" name="FairValueAdjustmentExercisePriceAtEnd" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueAdjustmentShares" name="FairValueAdjustmentShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueAdjustment" name="FairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommonStockShares" name="CommonStockShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommonStockValues" name="CommonStockValues" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" name="SharesIssuedInPrivatePlacementNetOfIssueCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" name="SharesIssuedInPrivatePlacementNetOfIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedForServicesShares" name="SharesIssuedForServicesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedForService" name="SharesIssuedForService" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PricePerShare" name="PricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares" name="SharesIssuedInPrivatePlacementNetOfIssueCostShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost" name="SharesIssuedInPrivatePlacementNetOfIssueCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OfferingExpenses" name="OfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PublicofferingDescription" name="PublicofferingDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionReserve" name="StockOptionReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfOutstandingShareOption" name="NumberOfOutstandingShareOption" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" name="NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" name="NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" name="NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionsIssued" name="StockOptionsIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockGranted" name="StockGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValuePerShare" name="FairValuePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumeratorAbstract" name="NumeratorAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DenominatorAbstract" name="DenominatorAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AntidilutiveEffectOnLossPerShar" name="AntidilutiveEffectOnLossPerShar" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommitmentToInvestment" name="CommitmentToInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DiscretionaryInvestment" name="DiscretionaryInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AdditionalDiscretionaryInvestment" name="AdditionalDiscretionaryInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany" name="RepaymentsOfAdvanceToBoardMemberOfCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAccruedLiabilities" name="AccountsPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantLiability" name="WarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueMarketPricePerShare" name="FairValueMarketPricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PayablesAndAccruedExpense" name="PayablesAndAccruedExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockBasedCompensationExpense" name="StockBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetLossAttributableToNoncontrollingInterest" name="NetLossAttributableToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RepaymentOfInstallmentNoteReceivable" name="RepaymentOfInstallmentNoteReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>ptgef-20210630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://portagebiotech.com/role/Cover" xlink:href="ptgef-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:href="ptgef-20210630.xsd#InterimStatementsOfFinancialPosition" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss" xlink:href="ptgef-20210630.xsd#InterimStatementsOfOperationsAndOtherComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:href="ptgef-20210630.xsd#InterimStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:href="ptgef-20210630.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperations" xlink:href="ptgef-20210630.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Liquidity" xlink:href="ptgef-20210630.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentation" xlink:href="ptgef-20210630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:href="ptgef-20210630.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecurities" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociate" xlink:href="ptgef-20210630.xsd#InvestmentInAssociate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/DispositionOfPpl" xlink:href="ptgef-20210630.xsd#DispositionOfPpl" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentsInPrivateCompanies" xlink:href="ptgef-20210630.xsd#InvestmentsInPrivateCompanies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Goodwill" xlink:href="ptgef-20210630.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:href="ptgef-20210630.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiability" xlink:href="ptgef-20210630.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStock" xlink:href="ptgef-20210630.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserve" xlink:href="ptgef-20210630.xsd#StockOptionReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShare" xlink:href="ptgef-20210630.xsd#LossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:href="ptgef-20210630.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:href="ptgef-20210630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosures" xlink:href="ptgef-20210630.xsd#CapitalDisclosures" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterest" xlink:href="ptgef-20210630.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventsAfterBalanceSheetDate" xlink:href="ptgef-20210630.xsd#EventsAfterBalanceSheetDate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:href="ptgef-20210630.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillTables" xlink:href="ptgef-20210630.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:href="ptgef-20210630.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:href="ptgef-20210630.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockTables" xlink:href="ptgef-20210630.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveTables" xlink:href="ptgef-20210630.xsd#StockOptionReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareTables" xlink:href="ptgef-20210630.xsd#LossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:href="ptgef-20210630.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:href="ptgef-20210630.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:href="ptgef-20210630.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ptgef-20210630.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetails" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/DispositionOfPplDetailsNarrative" xlink:href="ptgef-20210630.xsd#DispositionOfPplDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative" xlink:href="ptgef-20210630.xsd#InvestmentsInPrivateCompaniesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetails" xlink:href="ptgef-20210630.xsd#GoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:href="ptgef-20210630.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:href="ptgef-20210630.xsd#InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:href="ptgef-20210630.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:href="ptgef-20210630.xsd#WarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetails" xlink:href="ptgef-20210630.xsd#CapitalStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:href="ptgef-20210630.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails" xlink:href="ptgef-20210630.xsd#LossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails1" xlink:href="ptgef-20210630.xsd#LossPerShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="ptgef-20210630.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ptgef-20210630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:href="ptgef-20210630.xsd#CapitalDisclosuresDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:href="ptgef-20210630.xsd#Non-controllingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" xlink:href="ptgef-20210630.xsd#EventsAfterBalanceSheetDateDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:title="00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-fullOtherReceivables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullOtherReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentProperty" xlink:label="loc_ifrs-fullInvestmentProperty" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullInvestmentProperty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-fullGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InprocessResearchAndDevelopment" xlink:label="loc_ptgefInprocessResearchAndDevelopment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ptgefInprocessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-fullOtherAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantLiabilityCurrent" xlink:label="loc_ptgefWarrantLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ptgefWarrantLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnsecuredNotesPayable" xlink:label="loc_ptgefUnsecuredNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ptgefUnsecuredNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-fullNoncurrentLiabilities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-fullDeferredTaxLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentLiabilities" xlink:to="loc_ifrs-fullDeferredTaxLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullNoncurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-fullIssuedCapital" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullIssuedCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-fullOtherReserves" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullOtherReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-fullAccumulatedOtherComprehensiveIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullAccumulatedOtherComprehensiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-fullEquityAndLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAndLiabilities" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAndLiabilities" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss" xlink:title="00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive (Loss) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-fullProfitLossFromOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-fullGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:to="loc_ifrs-fullGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:label="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-fullInterestExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLoss" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLoss" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullComprehensiveIncome" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsOnDisposalsOfInvestmentProperties" xlink:label="loc_ifrs-fullGainsOnDisposalsOfInvestmentProperties" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullComprehensiveIncome" xlink:to="loc_ifrs-fullGainsOnDisposalsOfInvestmentProperties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NetLossIncome" xlink:label="loc_ptgefNetLossIncome" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefNetLossIncome" xlink:to="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefNetLossIncome" xlink:to="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_TotalComprehensiveLossIncomeForYear" xlink:label="loc_ptgefTotalComprehensiveLossIncomeForYear" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToOwnersOfParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefTotalComprehensiveLossIncomeForYear" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToNoncontrollingInterests" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefTotalComprehensiveLossIncomeForYear" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_LossIncomeOnFairValueOfWarrantLiability" xlink:label="loc_ptgefLossIncomeOnFairValueOfWarrantLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefLossIncomeOnFairValueOfWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ValueOfSharesIssuedForServices" xlink:label="loc_ptgefValueOfSharesIssuedForServices" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefValueOfSharesIssuedForServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="loc_ifrs-fullAdjustmentsForAmortisationExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForAmortisationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainLossOnHedgeIneffectiveness" xlink:label="loc_ifrs-fullGainLossOnHedgeIneffectiveness" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullGainLossOnHedgeIneffectiveness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IncreasingDecreasingAccountsReceivable" xlink:label="loc_ptgefIncreasingDecreasingAccountsReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefIncreasingDecreasingAccountsReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_OtherAsset" xlink:label="loc_ptgefOtherAsset" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefOtherAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfInvestmentProperty" xlink:label="loc_ifrs-fullPurchaseOfInvestmentProperty" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-fullPurchaseOfInvestmentProperty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderRegisteredOffering" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderRegisteredOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ShareIssuanceCosts" xlink:label="loc_ptgefShareIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefShareIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="00000006 - Disclosure - NATURE OF OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Liquidity" xlink:title="00000007 - Disclosure - LIQUIDITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecurities" xlink:title="00000011 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociate" xlink:title="00000012 - Disclosure - INVESTMENT IN ASSOCIATE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DispositionOfPpl" xlink:title="00000013 - Disclosure - DISPOSITION OF PPL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentsInPrivateCompanies" xlink:title="00000014 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Goodwill" xlink:title="00000015 - Disclosure - GOODWILL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:title="00000016 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:title="00000017 - Disclosure - UNSECURED NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="00000018 - Disclosure - WARRANT LIABILITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStock" xlink:title="00000019 - Disclosure - CAPITAL STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="00000020 - Disclosure - STOCK OPTION RESERVE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="00000021 - Disclosure - (LOSS) PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="00000023 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosures" xlink:title="00000025 - Disclosure - CAPITAL DISCLOSURES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="00000026 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventsAfterBalanceSheetDate" xlink:title="00000027 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables" xlink:title="00000030 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:title="00000031 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillTables" xlink:title="00000032 - Disclosure - GOODWILL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:title="00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:title="00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="00000035 - Disclosure - WARRANT LIABILITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockTables" xlink:title="00000036 - Disclosure - CAPITAL STOCK (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="00000037 - Disclosure - STOCK OPTION RESERVE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="00000038 - Disclosure - (LOSS) PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="00000039 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="00000040 - Disclosure - NON-CONTROLLING INTEREST (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:title="00000041 - Disclosure - NATURE OF OPERATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:title="00000042 - Disclosure - LIQUIDITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000043 - Disclosure - BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="00000044 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:title="00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetails" xlink:title="00000046 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative" xlink:title="00000047 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:title="00000048 - Disclosure - INVESTMENT IN ASSOCIATE  (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:title="00000049 - Disclosure - INVESTMENT IN ASSOCIATE  (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:title="00000050 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DispositionOfPplDetailsNarrative" xlink:title="00000051 - Disclosure - DISPOSITION OF PPL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative" xlink:title="00000052 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetails" xlink:title="00000053 - Disclosure - GOODWILL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:title="00000054 - Disclosure - GOODWILL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:title="00000055 - Disclosure - IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:title="00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:title="00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:title="00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="00000059 - Disclosure - WARRANT LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetails" xlink:title="00000060 - Disclosure - CAPITAL STOCK (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:title="00000061 - Disclosure - CAPITAL STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="00000062 - Disclosure - STOCK OPTION RESERVE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="00000063 - Disclosure - STOCK OPTION RESERVE (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="00000064 - Disclosure - STOCK OPTION RESERVE (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="00000065 - Disclosure - STOCK OPTION RESERVE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="00000066 - Disclosure - (LOSS) PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="00000067 - Disclosure - (LOSS) PER SHARE (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000068 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="00000070 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:title="00000071 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:title="00000072 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="00000073 - Disclosure - NON-CONTROLLING INTEREST (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" xlink:title="00000074 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>ptgef-20210630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://portagebiotech.com/role/Cover" xlink:href="ptgef-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:href="ptgef-20210630.xsd#InterimStatementsOfFinancialPosition" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss" xlink:href="ptgef-20210630.xsd#InterimStatementsOfOperationsAndOtherComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:href="ptgef-20210630.xsd#InterimStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:href="ptgef-20210630.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperations" xlink:href="ptgef-20210630.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Liquidity" xlink:href="ptgef-20210630.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentation" xlink:href="ptgef-20210630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:href="ptgef-20210630.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecurities" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociate" xlink:href="ptgef-20210630.xsd#InvestmentInAssociate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/DispositionOfPpl" xlink:href="ptgef-20210630.xsd#DispositionOfPpl" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentsInPrivateCompanies" xlink:href="ptgef-20210630.xsd#InvestmentsInPrivateCompanies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Goodwill" xlink:href="ptgef-20210630.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:href="ptgef-20210630.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiability" xlink:href="ptgef-20210630.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStock" xlink:href="ptgef-20210630.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserve" xlink:href="ptgef-20210630.xsd#StockOptionReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShare" xlink:href="ptgef-20210630.xsd#LossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:href="ptgef-20210630.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:href="ptgef-20210630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosures" xlink:href="ptgef-20210630.xsd#CapitalDisclosures" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterest" xlink:href="ptgef-20210630.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventsAfterBalanceSheetDate" xlink:href="ptgef-20210630.xsd#EventsAfterBalanceSheetDate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:href="ptgef-20210630.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillTables" xlink:href="ptgef-20210630.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:href="ptgef-20210630.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:href="ptgef-20210630.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockTables" xlink:href="ptgef-20210630.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveTables" xlink:href="ptgef-20210630.xsd#StockOptionReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareTables" xlink:href="ptgef-20210630.xsd#LossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:href="ptgef-20210630.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:href="ptgef-20210630.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:href="ptgef-20210630.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ptgef-20210630.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetails" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/DispositionOfPplDetailsNarrative" xlink:href="ptgef-20210630.xsd#DispositionOfPplDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative" xlink:href="ptgef-20210630.xsd#InvestmentsInPrivateCompaniesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetails" xlink:href="ptgef-20210630.xsd#GoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:href="ptgef-20210630.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:href="ptgef-20210630.xsd#InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:href="ptgef-20210630.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:href="ptgef-20210630.xsd#WarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetails" xlink:href="ptgef-20210630.xsd#CapitalStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:href="ptgef-20210630.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails" xlink:href="ptgef-20210630.xsd#LossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails1" xlink:href="ptgef-20210630.xsd#LossPerShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="ptgef-20210630.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ptgef-20210630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:href="ptgef-20210630.xsd#CapitalDisclosuresDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:href="ptgef-20210630.xsd#Non-controllingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" xlink:href="ptgef-20210630.xsd#EventsAfterBalanceSheetDateDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:title="00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss" xlink:title="00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive (Loss) (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullIssuedCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ptgefStockOptionReserveMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuedUnderPrivatePlacement" xlink:label="loc_ptgefIssuedUnderPrivatePlacement_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuedUnderPrivatePlacement_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuedUnderPrivatePlacementShares" xlink:label="loc_ptgefIssuedUnderPrivatePlacementShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuedUnderPrivatePlacementShares_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-fullPaymentsForShareIssueCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPaymentsForShareIssueCosts_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="loc_ptgefSharesIssuedOrAccruedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServices_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="loc_ptgefSharesIssuedOrAccruedForServicesShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServicesShares_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderAtm" xlink:label="loc_ptgefSharesIssuedUnderAtm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtm_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderAtmShares" xlink:label="loc_ptgefSharesIssuedUnderAtmShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtmShares_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderOffering" xlink:label="loc_ptgefSharesIssuedUnderOffering_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderOffering_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderOfferingShares" xlink:label="loc_ptgefSharesIssuedUnderOfferingShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderOfferingShares_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedLossOnInvestmentInInvestments" xlink:label="loc_ptgefUnrealizedLossOnInvestmentInInvestments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnrealizedLossOnInvestmentInInvestments_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss_80" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="00000006 - Disclosure - NATURE OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Liquidity" xlink:title="00000007 - Disclosure - LIQUIDITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecurities" xlink:title="00000011 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociate" xlink:title="00000012 - Disclosure - INVESTMENT IN ASSOCIATE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DispositionOfPpl" xlink:title="00000013 - Disclosure - DISPOSITION OF PPL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentsInPrivateCompanies" xlink:title="00000014 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Goodwill" xlink:title="00000015 - Disclosure - GOODWILL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:title="00000016 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:title="00000017 - Disclosure - UNSECURED NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="00000018 - Disclosure - WARRANT LIABILITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStock" xlink:title="00000019 - Disclosure - CAPITAL STOCK" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="00000020 - Disclosure - STOCK OPTION RESERVE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="00000021 - Disclosure - (LOSS) PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="00000023 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosures" xlink:title="00000025 - Disclosure - CAPITAL DISCLOSURES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="00000026 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventsAfterBalanceSheetDate" xlink:title="00000027 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables" xlink:title="00000030 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:title="00000031 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillTables" xlink:title="00000032 - Disclosure - GOODWILL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:title="00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:title="00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="00000035 - Disclosure - WARRANT LIABILITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockTables" xlink:title="00000036 - Disclosure - CAPITAL STOCK (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="00000037 - Disclosure - STOCK OPTION RESERVE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="00000038 - Disclosure - (LOSS) PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="00000039 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="00000040 - Disclosure - NON-CONTROLLING INTEREST (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:title="00000041 - Disclosure - NATURE OF OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxGroupPlcMember" xlink:label="loc_ptgefSalvaRxGroupPlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxGroupPlcMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuanceAndSales" xlink:label="loc_ptgefIssuanceAndSales_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuanceAndSales_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_MaximumAggregateOfferingPrice" xlink:label="loc_ptgefMaximumAggregateOfferingPrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefMaximumAggregateOfferingPrice_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CashFundDescription" xlink:label="loc_ptgefCashFundDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCashFundDescription_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:title="00000042 - Disclosure - LIQUIDITY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000043 - Disclosure - BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SubsidiariesOneMember" xlink:label="loc_ptgefSubsidiariesOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSubsidiariesOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SubsidiariesTwoMember" xlink:label="loc_ptgefSubsidiariesTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSubsidiariesTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PortageGlasgowLtdMember" xlink:label="loc_ptgefPortageGlasgowLtdMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefPortageGlasgowLtdMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SubsidiariesThreeMember" xlink:label="loc_ptgefSubsidiariesThreeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSubsidiariesThreeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SubsidiariesMember" xlink:label="loc_ifrs-fullSubsidiariesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ifrs-fullSubsidiariesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="00000044 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:title="00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PPLSettlementMember" xlink:label="loc_ptgefPPLSettlementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefPPLSettlementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Accruals" xlink:label="loc_ifrs-fullAccruals_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAccruals_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LoansPayableInDefault" xlink:label="loc_ifrs-fullLoansPayableInDefault_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullLoansPayableInDefault_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-fullTradeAndOtherReceivables_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherReceivables_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="loc_ifrs-fullCurrentPortionOfLongtermBorrowings_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentPortionOfLongtermBorrowings_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PrepaidExpensesAndOtherReceivables" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivables_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivables_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetails" xlink:title="00000046 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative" xlink:title="00000047 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" xlink:label="loc_ifrs-fullDisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypeOfMeasurementOfExpectedCreditLossesAxis" xlink:label="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" xlink:to="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypeOfMeasurementOfExpectedCreditLossesMember" xlink:label="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesAxis" xlink:to="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypeOfMeasurementOfExpectedCreditLossesMember" xlink:label="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesAxis" xlink:to="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BiohavenMember" xlink:label="loc_ptgefBiohavenMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesMember" xlink:to="loc_ptgefBiohavenMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentInMarketableEquitySecurities" xlink:label="loc_ptgefInvestmentInMarketableEquitySecurities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInvestmentInMarketableEquitySecurities_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-fullProceedsFromIssuingShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromIssuingShares_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedGains" xlink:label="loc_ptgefUnrealizedGains_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnrealizedGains_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:title="00000048 - Disclosure - INVESTMENT IN ASSOCIATE  (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StimunitySAMember" xlink:label="loc_ptgefStimunitySAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:to="loc_ptgefStimunitySAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NameOfAssociate" xlink:label="loc_ifrs-fullNameOfAssociate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNameOfAssociate_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:label="loc_ifrs-fullPrincipalPlaceOfBusinessOfAssociate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPrincipalPlaceOfBusinessOfAssociate_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:label="loc_ifrs-fullCountryOfIncorporationOrResidenceOfAssociate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCountryOfIncorporationOrResidenceOfAssociate_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:title="00000049 - Disclosure - INVESTMENT IN ASSOCIATE  (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:title="00000050 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StimunitySAMember" xlink:label="loc_ptgefStimunitySAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:to="loc_ptgefStimunitySAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AdditionalInvestments" xlink:label="loc_ptgefAdditionalInvestments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalInvestments_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_EquityInLossIncome" xlink:label="loc_ptgefEquityInLossIncome_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefEquityInLossIncome_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DispositionOfPplDetailsNarrative" xlink:title="00000051 - Disclosure - DISPOSITION OF PPL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable" xlink:label="loc_deiEntitiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_deiEntitiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntitiesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PortageGlasgowLtdMember" xlink:label="loc_ptgefPortageGlasgowLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ptgefPortageGlasgowLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DispositionPercentage" xlink:label="loc_ptgefDispositionPercentage_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ptgefDispositionPercentage_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DispositionValue" xlink:label="loc_ptgefDispositionValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ptgefDispositionValue_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IntercompanyReceivable" xlink:label="loc_ptgefIntercompanyReceivable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ptgefIntercompanyReceivable_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative" xlink:title="00000052 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember" xlink:label="loc_ptgefSeriesAPreferredStockInSentienBiotechnologiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefSeriesAPreferredStockInSentienBiotechnologiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IntensityMember" xlink:label="loc_ptgefIntensityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIntensityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-fullBusinessCombinationsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullBusinessCombinationsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullBusinessCombinationsAxis" xlink:to="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullBusinessCombinationsAxis" xlink:to="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AcquisitionOfSalvaRxMember" xlink:label="loc_ptgefAcquisitionOfSalvaRxMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" xlink:to="loc_ptgefAcquisitionOfSalvaRxMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AcquisitionOfIntensityHoldingLimitedMember" xlink:label="loc_ptgefAcquisitionOfIntensityHoldingLimitedMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" xlink:to="loc_ptgefAcquisitionOfIntensityHoldingLimitedMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentOwnedShares" xlink:label="loc_ptgefInvestmentOwnedShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInvestmentOwnedShares_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentOwnershipPercentage" xlink:label="loc_ptgefInvestmentOwnershipPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInvestmentOwnershipPercentage_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedGainLossOnInvestment" xlink:label="loc_ptgefUnrealizedGainLossOnInvestment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnrealizedGainLossOnInvestment_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-fullEquityInterestsOfAcquirer_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquityInterestsOfAcquirer_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" xlink:label="loc_ptgefNumberOfPrivateCompanyShareConsistsInSoleAsset_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfPrivateCompanyShareConsistsInSoleAsset_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetails" xlink:title="00000053 - Disclosure - GOODWILL (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:title="00000054 - Disclosure - GOODWILL (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:title="00000055 - Disclosure - IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IMM60IOXMelanomaLungCancersMember" xlink:label="loc_ptgefIMM60IOXMelanomaLungCancersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIMM60IOXMelanomaLungCancersMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IMM65IOXOvarianProstateCancersMember" xlink:label="loc_ptgefIMM65IOXOvarianProstateCancersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIMM65IOXOvarianProstateCancersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_OncomerSaugatuckDNAAptamersMember" xlink:label="loc_ptgefOncomerSaugatuckDNAAptamersMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefOncomerSaugatuckDNAAptamersMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InprocessResearchAndDevelopment" xlink:label="loc_ptgefInprocessResearchAndDevelopment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInprocessResearchAndDevelopment_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-fullDeferredTaxLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeferredTaxLiabilities_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:title="00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:title="00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PplMember" xlink:label="loc_ptgefPplMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefPplMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IoxMember" xlink:label="loc_ptgefIoxMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIoxMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NotePayable" xlink:label="loc_ptgefNotePayable_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNotePayable_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RepaymentOfNotesPayable" xlink:label="loc_ptgefRepaymentOfNotesPayable_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRepaymentOfNotesPayable_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AmortizationOfDebtDiscount" xlink:label="loc_ptgefAmortizationOfDebtDiscount_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAmortizationOfDebtDiscount_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ValueOfNotesExchangedInWarrantExercise" xlink:label="loc_ptgefValueOfNotesExchangedInWarrantExercise_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefValueOfNotesExchangedInWarrantExercise_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SettlementInConnectionWithDispositionOfPpl" xlink:label="loc_ptgefSettlementInConnectionWithDispositionOfPpl_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSettlementInConnectionWithDispositionOfPpl_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_LossOnExtinguishmentOfDebt" xlink:label="loc_ptgefLossOnExtinguishmentOfDebt_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnExtinguishmentOfDebt_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ProceedsFromLoanPayable" xlink:label="loc_ptgefProceedsFromLoanPayable_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefProceedsFromLoanPayable_210" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:title="00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IoxMember" xlink:label="loc_ptgefIoxMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIoxMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PortageMember" xlink:label="loc_ptgefPortageMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefPortageMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AggregatePrincipalAmountOfUnsecuredNotes" xlink:label="loc_ptgefAggregatePrincipalAmountOfUnsecuredNotes_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregatePrincipalAmountOfUnsecuredNotes_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnsecuredNotesInterest" xlink:label="loc_ptgefUnsecuredNotesInterest_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnsecuredNotesInterest_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuanceOfUnsecuredNotesDescription" xlink:label="loc_ptgefIssuanceOfUnsecuredNotesDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuanceOfUnsecuredNotesDescription_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-fullFinancialLiabilitiesAtFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullFinancialLiabilitiesAtFairValue_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PaymentForSettlement" xlink:label="loc_ptgefPaymentForSettlement_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPaymentForSettlement_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsExercised" xlink:label="loc_ptgefWarrantsExercised_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsExercised_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ExercisePrice" xlink:label="loc_ptgefExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePrice_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ContractualValueOfWarrantsExercisedDescription" xlink:label="loc_ptgefContractualValueOfWarrantsExercisedDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefContractualValueOfWarrantsExercisedDescription_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesReceived" xlink:label="loc_ptgefSharesReceived_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesReceived_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfExerciseOfWarrantsIssued" xlink:label="loc_ptgefNumberOfExerciseOfWarrantsIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfExerciseOfWarrantsIssued_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfExerciseOfWarrantsOutstanding" xlink:label="loc_ptgefNumberOfExerciseOfWarrantsOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfExerciseOfWarrantsOutstanding_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_LossOnExtinguishmentOfDebt" xlink:label="loc_ptgefLossOnExtinguishmentOfDebt_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnExtinguishmentOfDebt_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DescriptionOfBusinessCombination" xlink:label="loc_ptgefDescriptionOfBusinessCombination_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDescriptionOfBusinessCombination_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="loc_ifrs-fullIssueOfConvertibleInstruments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIssueOfConvertibleInstruments_90" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="00000059 - Disclosure - WARRANT LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxGroupPlcMember" xlink:label="loc_ptgefSalvaRxGroupPlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxGroupPlcMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingExercisePrice" xlink:label="loc_ptgefWarrantsOutstandingExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsOutstandingExercisePrice_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingShares" xlink:label="loc_ptgefWarrantsOutstandingShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsOutstandingShares_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingAmount" xlink:label="loc_ptgefWarrantsOutstandingAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsOutstandingAmount_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueAdjustmentExercisePriceAtEnd" xlink:label="loc_ptgefFairValueAdjustmentExercisePriceAtEnd_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueAdjustmentExercisePriceAtEnd_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueAdjustmentShares" xlink:label="loc_ptgefFairValueAdjustmentShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueAdjustmentShares_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueAdjustment" xlink:label="loc_ptgefFairValueAdjustment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueAdjustment_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetails" xlink:title="00000060 - Disclosure - CAPITAL STOCK (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:title="00000061 - Disclosure - CAPITAL STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AccreditedInvestorsMember" xlink:label="loc_ptgefAccreditedInvestorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefAccreditedInvestorsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DirectorsMember" xlink:label="loc_ptgefDirectorsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefDirectorsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostsShares_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PricePerShare" xlink:label="loc_ptgefPricePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPricePerShare_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCosts_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostShares_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCost_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_OfferingExpenses" xlink:label="loc_ptgefOfferingExpenses_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingExpenses_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PublicofferingDescription" xlink:label="loc_ptgefPublicofferingDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPublicofferingDescription_50" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="00000062 - Disclosure - STOCK OPTION RESERVE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ptgefStockOptionReserveMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionReserve" xlink:label="loc_ptgefStockOptionReserve_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockOptionReserve_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments_130" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="00000063 - Disclosure - STOCK OPTION RESERVE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PBI2013OptionPlanMember" xlink:label="loc_ptgefPBI2013OptionPlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2013OptionPlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IOxOptionPlanMember" xlink:label="loc_ptgefIOxOptionPlanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefIOxOptionPlanMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_190" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="00000064 - Disclosure - STOCK OPTION RESERVE (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PBI2013OptionPlanMember" xlink:label="loc_ptgefPBI2013OptionPlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2013OptionPlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IOxOptionPlanMember" xlink:label="loc_ptgefIOxOptionPlanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefIOxOptionPlanMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="00000065 - Disclosure - STOCK OPTION RESERVE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_N2021EquityIncentivePlanMember" xlink:label="loc_ptgefN2021EquityIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefN2021EquityIncentivePlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefRestrictedStockUnitsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_Equity2021IncentivePlanMember" xlink:label="loc_ptgefEquity2021IncentivePlanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefEquity2021IncentivePlanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BoardOfDirectorsMember" xlink:label="loc_ptgefBoardOfDirectorsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefBoardOfDirectorsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ConsultantsMember" xlink:label="loc_ptgefConsultantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefConsultantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionsIssued" xlink:label="loc_ptgefStockOptionsIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockOptionsIssued_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockGranted" xlink:label="loc_ptgefStockGranted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockGranted_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValuePerShare" xlink:label="loc_ptgefFairValuePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValuePerShare_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CommunicationExpense" xlink:label="loc_ifrs-fullCommunicationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCommunicationExpense_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="00000066 - Disclosure - (LOSS) PER SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="00000067 - Disclosure - (LOSS) PER SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionsMember" xlink:label="loc_ptgefStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefRestrictedStockUnitsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsMember" xlink:label="loc_ptgefWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AntidilutiveEffectOnLossPerShar" xlink:label="loc_ptgefAntidilutiveEffectOnLossPerShar_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAntidilutiveEffectOnLossPerShar_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000068 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StimunitySAMember" xlink:label="loc_ptgefStimunitySAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefStimunitySAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommitmentToInvestment" xlink:label="loc_ptgefCommitmentToInvestment_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCommitmentToInvestment_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DiscretionaryInvestment" xlink:label="loc_ptgefDiscretionaryInvestment_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDiscretionaryInvestment_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AdditionalDiscretionaryInvestment" xlink:label="loc_ptgefAdditionalDiscretionaryInvestment_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalDiscretionaryInvestment_20" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="00000070 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AmortizedCostMember" xlink:label="loc_ptgefAmortizedCostMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefAmortizedCostMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="loc_ptgefFairValueToOtherComprehensiveIncomeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefFairValueToOtherComprehensiveIncomeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashAndCashEquivalents_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PrepaidExpensesAndOtherReceivables" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivables_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentInvestments" xlink:label="loc_ifrs-fullCurrentInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentInvestments_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilities_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentPayables" xlink:label="loc_ifrs-fullNoncurrentPayables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncurrentPayables_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantLiability" xlink:label="loc_ptgefWarrantLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantLiability_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:title="00000071 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:title="00000072 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="00000073 - Disclosure - NON-CONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PglMember" xlink:label="loc_ptgefPglMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefPglMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IoxMember" xlink:label="loc_ptgefIoxMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIoxMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSaugatuckMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockBasedCompensationExpense" xlink:label="loc_ptgefStockBasedCompensationExpense_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockBasedCompensationExpense_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="loc_ptgefNetLossAttributableToNoncontrollingInterest_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetLossAttributableToNoncontrollingInterest_310" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" xlink:title="00000074 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-fullNonadjustingEventsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-fullNonadjustingEventsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_EventsAfterTheBalanceSheetDateMember" xlink:label="loc_ptgefEventsAfterTheBalanceSheetDateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullNonadjustingEventsMember" xlink:to="loc_ptgefEventsAfterTheBalanceSheetDateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ptgefSalvaRxMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RepaymentOfInstallmentNoteReceivable" xlink:label="loc_ptgefRepaymentOfInstallmentNoteReceivable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRepaymentOfInstallmentNoteReceivable_20" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ptgef-20210630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Issued capital [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionReserveMember" xlink:label="ptgef_StockOptionReserveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserveMember" xlink:to="ptgef_StockOptionReserveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionReserveMember_lbl" xml:lang="en-US">Stock Option Reserve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Retained earnings [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="ifrs-full_NoncontrollingInterestsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xml:lang="en-US">Non-controlling interests [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxGroupPlcMember" xlink:label="ptgef_SalvaRxGroupPlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SalvaRxGroupPlcMember" xlink:to="ptgef_SalvaRxGroupPlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SalvaRxGroupPlcMember_lbl" xml:lang="en-US">SalvaRx Group plc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SubsidiariesOneMember" xlink:label="ptgef_SubsidiariesOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SubsidiariesOneMember" xlink:to="ptgef_SubsidiariesOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SubsidiariesOneMember_lbl" xml:lang="en-US">United Kingdom based immune-oncology [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SubsidiariesTwoMember" xlink:label="ptgef_SubsidiariesTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SubsidiariesTwoMember" xlink:to="ptgef_SubsidiariesTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SubsidiariesTwoMember_lbl" xml:lang="en-US">Saugatuck [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PortageGlasgowLtdMember" xlink:label="ptgef_PortageGlasgowLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PortageGlasgowLtdMember" xlink:to="ptgef_PortageGlasgowLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PortageGlasgowLtdMember_lbl" xml:lang="en-US">Portage Glasgow Ltd. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SubsidiariesThreeMember" xlink:label="ptgef_SubsidiariesThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SubsidiariesThreeMember" xlink:to="ptgef_SubsidiariesThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SubsidiariesThreeMember_lbl" xml:lang="en-US">IOX [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SubsidiariesMember" xlink:label="ifrs-full_SubsidiariesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SubsidiariesMember" xlink:to="ifrs-full_SubsidiariesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SubsidiariesMember_lbl" xml:lang="en-US">Subsidiaries [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PPLSettlementMember" xlink:label="ptgef_PPLSettlementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PPLSettlementMember" xlink:to="ptgef_PPLSettlementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PPLSettlementMember_lbl" xml:lang="en-US">PPL Settlement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypeOfMeasurementOfExpectedCreditLossesAxis" xlink:label="ifrs-full_TypeOfMeasurementOfExpectedCreditLossesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypeOfMeasurementOfExpectedCreditLossesAxis" xlink:to="ifrs-full_TypeOfMeasurementOfExpectedCreditLossesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypeOfMeasurementOfExpectedCreditLossesAxis_lbl" xml:lang="en-US">Type of measurement of expected credit losses [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BiohavenMember" xlink:label="ptgef_BiohavenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BiohavenMember" xlink:to="ptgef_BiohavenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BiohavenMember_lbl" xml:lang="en-US">Biohaven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xml:lang="en-US">Associates [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StimunitySAMember" xlink:label="ptgef_StimunitySAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StimunitySAMember" xlink:to="ptgef_StimunitySAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StimunitySAMember_lbl" xml:lang="en-US">Stimunity S.A. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US">Counterparties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember" xlink:label="ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember" xlink:to="ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember_lbl" xml:lang="en-US">Series A preferred stock in Sentien Biotechnologies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IntensityMember" xlink:label="ptgef_IntensityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IntensityMember" xlink:to="ptgef_IntensityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IntensityMember_lbl" xml:lang="en-US">Intensity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xml:lang="en-US">Business combinations [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AcquisitionOfSalvaRxMember" xlink:label="ptgef_AcquisitionOfSalvaRxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AcquisitionOfSalvaRxMember" xlink:to="ptgef_AcquisitionOfSalvaRxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AcquisitionOfSalvaRxMember_lbl" xml:lang="en-US">Acquisition Of SalvaRx [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AcquisitionOfIntensityHoldingLimitedMember" xlink:label="ptgef_AcquisitionOfIntensityHoldingLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AcquisitionOfIntensityHoldingLimitedMember" xlink:to="ptgef_AcquisitionOfIntensityHoldingLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AcquisitionOfIntensityHoldingLimitedMember_lbl" xml:lang="en-US">Acquisition Of Intensity Holding Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IMM60IOXMelanomaLungCancersMember" xlink:label="ptgef_IMM60IOXMelanomaLungCancersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IMM60IOXMelanomaLungCancersMember" xlink:to="ptgef_IMM60IOXMelanomaLungCancersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IMM60IOXMelanomaLungCancersMember_lbl" xml:lang="en-US">IMM 60 IOX Melanoma &amp;amp;amp;amp; Lung Cancers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IMM65IOXOvarianProstateCancersMember" xlink:label="ptgef_IMM65IOXOvarianProstateCancersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IMM65IOXOvarianProstateCancersMember" xlink:to="ptgef_IMM65IOXOvarianProstateCancersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IMM65IOXOvarianProstateCancersMember_lbl" xml:lang="en-US">IMM 65 IOX Ovarian/Prostate Cancers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_OncomerSaugatuckDNAAptamersMember" xlink:label="ptgef_OncomerSaugatuckDNAAptamersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OncomerSaugatuckDNAAptamersMember" xlink:to="ptgef_OncomerSaugatuckDNAAptamersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OncomerSaugatuckDNAAptamersMember_lbl" xml:lang="en-US">Oncomer Saugatuck DNA Aptamers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PplMember" xlink:label="ptgef_PplMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PplMember" xlink:to="ptgef_PplMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PplMember_lbl" xml:lang="en-US">Ppl [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IoxMember" xlink:label="ptgef_IoxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IoxMember" xlink:to="ptgef_IoxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IoxMember_lbl" xml:lang="en-US">Iox [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxMember" xlink:label="ptgef_SalvaRxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SalvaRxMember" xlink:to="ptgef_SalvaRxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SalvaRxMember_lbl" xml:lang="en-US">SalvaRx [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PortageMember" xlink:label="ptgef_PortageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PortageMember" xlink:to="ptgef_PortageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PortageMember_lbl" xml:lang="en-US">Portage [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AccreditedInvestorsMember" xlink:label="ptgef_AccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccreditedInvestorsMember" xlink:to="ptgef_AccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccreditedInvestorsMember_lbl" xml:lang="en-US">Accredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DirectorsMember" xlink:label="ptgef_DirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DirectorsMember" xlink:to="ptgef_DirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DirectorsMember_lbl" xml:lang="en-US">Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="ifrs-full_DefinedBenefitPlansAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefinedBenefitPlansAxis_lbl" xml:lang="en-US">Defined benefit plans [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_N2021EquityIncentivePlanMember" xlink:label="ptgef_N2021EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_N2021EquityIncentivePlanMember" xlink:to="ptgef_N2021EquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_N2021EquityIncentivePlanMember_lbl" xml:lang="en-US">N 2021 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BoardOfDirectorsMember" xlink:label="ptgef_BoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BoardOfDirectorsMember" xlink:to="ptgef_BoardOfDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board Of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ConsultantsMember" xlink:label="ptgef_ConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ConsultantsMember" xlink:to="ptgef_ConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="ptgef_RestrictedStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RestrictedStockUnitsMember" xlink:to="ptgef_RestrictedStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RestrictedStockUnitsMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="ptgef_PBI2021EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PBI2021EquityIncentivePlanMember" xlink:to="ptgef_PBI2021EquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PBI2021EquityIncentivePlanMember_lbl" xml:lang="en-US">P B I 2021 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PBI2013OptionPlanMember" xlink:label="ptgef_PBI2013OptionPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PBI2013OptionPlanMember" xlink:to="ptgef_PBI2013OptionPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PBI2013OptionPlanMember_lbl" xml:lang="en-US">P B I 2013 Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IOxOptionPlanMember" xlink:label="ptgef_IOxOptionPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IOxOptionPlanMember" xlink:to="ptgef_IOxOptionPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IOxOptionPlanMember_lbl" xml:lang="en-US">I Ox Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_Equity2021IncentivePlanMember" xlink:label="ptgef_Equity2021IncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Equity2021IncentivePlanMember" xlink:to="ptgef_Equity2021IncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Equity2021IncentivePlanMember_lbl" xml:lang="en-US">Equity 2021 Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionsMember" xlink:label="ptgef_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionsMember" xlink:to="ptgef_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionsMember_lbl" xml:lang="en-US">PBI 2013 Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsMember" xlink:label="ptgef_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsMember" xlink:to="ptgef_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AmortizedCostMember" xlink:label="ptgef_AmortizedCostMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AmortizedCostMember" xlink:to="ptgef_AmortizedCostMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AmortizedCostMember_lbl" xml:lang="en-US">Amortized cost [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="ptgef_FairValueToOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:to="ptgef_FairValueToOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueToOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Fair Value to Other Comprehensive Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PglMember" xlink:label="ptgef_PglMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PglMember" xlink:to="ptgef_PglMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PglMember_lbl" xml:lang="en-US">Pgl [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SaugatuckMember" xlink:label="ptgef_SaugatuckMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SaugatuckMember" xlink:to="ptgef_SaugatuckMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SaugatuckMember_lbl" xml:lang="en-US">SaugatuckMember</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_EventsAfterTheBalanceSheetDateMember" xlink:label="ptgef_EventsAfterTheBalanceSheetDateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EventsAfterTheBalanceSheetDateMember" xlink:to="ptgef_EventsAfterTheBalanceSheetDateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EventsAfterTheBalanceSheetDateMember_lbl" xml:lang="en-US">Events After The Balance Sheet Date [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">Long-term assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US">Long-term portion of other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_lbl" xml:lang="en-US">Investment in associate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentProperty" xlink:label="ifrs-full_InvestmentProperty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentProperty" xlink:to="ifrs-full_InvestmentProperty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentProperty_lbl" xml:lang="en-US">Investments in private companies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Goodwill" xlink:label="ifrs-full_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Goodwill" xlink:to="ifrs-full_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InprocessResearchAndDevelopment" xlink:label="ptgef_InprocessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InprocessResearchAndDevelopment" xlink:to="ptgef_InprocessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InprocessResearchAndDevelopment_lbl" xml:lang="en-US">In-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantLiabilityCurrent" xlink:label="ptgef_WarrantLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantLiabilityCurrent" xlink:to="ptgef_WarrantLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantLiabilityCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnsecuredNotesPayable" xlink:label="ptgef_UnsecuredNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnsecuredNotesPayable" xlink:to="ptgef_UnsecuredNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnsecuredNotesPayable_lbl" xml:lang="en-US">Unsecured notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Capital stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Stock option reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Total equity attributable to owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterests" xlink:label="ifrs-full_NoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and equity</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommitmentAndContingencies" xlink:label="ptgef_CommitmentAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommitmentAndContingencies" xlink:to="ptgef_CommitmentAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommitmentAndContingencies_lbl" xml:lang="en-US">Commitments and Contingent Liabilities (Note 17)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAbstract" xlink:label="ifrs-full_ProfitLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="ifrs-full_ProfitLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAbstract_lbl" xml:lang="en-US">Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:label="ptgef_GainsLossesOnChangeInFairValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:to="ptgef_GainsLossesOnChangeInFairValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GainsLossesOnChangeInFairValueOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Share of (loss) income in associates accounted for using equity method</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpense" xlink:label="ifrs-full_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestExpense_lbl" xml:lang="en-US">Interest (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Net (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsOnDisposalsOfInvestmentProperties" xlink:label="ifrs-full_GainsOnDisposalsOfInvestmentProperties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsOnDisposalsOfInvestmentProperties" xlink:to="ifrs-full_GainsOnDisposalsOfInvestmentProperties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsOnDisposalsOfInvestmentProperties_lbl" xml:lang="en-US">Unrealized gain on investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Total comprehensive (loss) for period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US">Net (loss) income attributable to:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NetLossIncome" xlink:label="ptgef_NetLossIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLossIncome" xlink:to="ptgef_NetLossIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgef_NetLossIncome_lbl" xml:lang="en-US">Net (loss) income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xml:lang="en-US">Comprehensive (loss) income attributable to:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xml:lang="en-US">Owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_TotalComprehensiveLossIncomeForYear" xlink:label="ptgef_TotalComprehensiveLossIncomeForYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TotalComprehensiveLossIncomeForYear" xlink:to="ptgef_TotalComprehensiveLossIncomeForYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgef_TotalComprehensiveLossIncomeForYear_lbl" xml:lang="en-US">Total comprehensive (loss) income for year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US">(Loss) per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BasicAndDilutedLossPerShare" xlink:label="ptgef_BasicAndDilutedLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BasicAndDilutedLossPerShare" xlink:to="ptgef_BasicAndDilutedLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BasicAndDilutedLossPerShare_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xml:lang="en-US">Weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" xlink:label="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" xlink:to="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="ptgef_IfrsStatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IfrsStatementLineItems" xlink:to="ptgef_IfrsStatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IfrsStatementLineItems_lbl" xml:lang="en-US">IfrsStatementLineItems [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuedUnderPrivatePlacement" xlink:label="ptgef_IssuedUnderPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IssuedUnderPrivatePlacement" xlink:to="ptgef_IssuedUnderPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IssuedUnderPrivatePlacement_lbl" xml:lang="en-US">Issued under private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuedUnderPrivatePlacementShares" xlink:label="ptgef_IssuedUnderPrivatePlacementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IssuedUnderPrivatePlacementShares" xlink:to="ptgef_IssuedUnderPrivatePlacementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IssuedUnderPrivatePlacementShares_lbl" xml:lang="en-US">Issued under private placement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US">Share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="ptgef_SharesIssuedOrAccruedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedOrAccruedForServices" xlink:to="ptgef_SharesIssuedOrAccruedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedOrAccruedForServices_lbl" xml:lang="en-US">Shares issued or accrued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="ptgef_SharesIssuedOrAccruedForServicesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedOrAccruedForServicesShares" xlink:to="ptgef_SharesIssuedOrAccruedForServicesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedOrAccruedForServicesShares_lbl" xml:lang="en-US">Shares issued or accrued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderAtm" xlink:label="ptgef_SharesIssuedUnderAtm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderAtm" xlink:to="ptgef_SharesIssuedUnderAtm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderAtm_lbl" xml:lang="en-US">Shares issued under ATM</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderAtmShares" xlink:label="ptgef_SharesIssuedUnderAtmShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderAtmShares" xlink:to="ptgef_SharesIssuedUnderAtmShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderAtmShares_lbl" xml:lang="en-US">Shares issued under ATM, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderOffering" xlink:label="ptgef_SharesIssuedUnderOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderOffering" xlink:to="ptgef_SharesIssuedUnderOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderOffering_lbl" xml:lang="en-US">Shares issued under offering</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderOfferingShares" xlink:label="ptgef_SharesIssuedUnderOfferingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderOfferingShares" xlink:to="ptgef_SharesIssuedUnderOfferingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderOfferingShares_lbl" xml:lang="en-US">Shares issued under offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedLossOnInvestmentInInvestments" xlink:label="ptgef_UnrealizedLossOnInvestmentInInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedLossOnInvestmentInInvestments" xlink:to="ptgef_UnrealizedLossOnInvestmentInInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_UnrealizedLossOnInvestmentInInvestments_lbl" xml:lang="en-US">Unrealized gain on investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_2_lbl" xml:lang="en-US">Net loss for period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows provided by (used in) operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_3_lbl" xml:lang="en-US">Net loss for the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments for non-cash items:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xml:lang="en-US">Increase in deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_LossIncomeOnFairValueOfWarrantLiability" xlink:label="ptgef_LossIncomeOnFairValueOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossIncomeOnFairValueOfWarrantLiability" xlink:to="ptgef_LossIncomeOnFairValueOfWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossIncomeOnFairValueOfWarrantLiability_lbl" xml:lang="en-US">Income on fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ValueOfSharesIssuedForServices" xlink:label="ptgef_ValueOfSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ValueOfSharesIssuedForServices" xlink:to="ptgef_ValueOfSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ValueOfSharesIssuedForServices_lbl" xml:lang="en-US">Value of shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainLossOnHedgeIneffectiveness" xlink:label="ifrs-full_GainLossOnHedgeIneffectiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainLossOnHedgeIneffectiveness" xlink:to="ifrs-full_GainLossOnHedgeIneffectiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainLossOnHedgeIneffectiveness_lbl" xml:lang="en-US">Share of loss (gain) in associates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NetChangeInWorkingCapitalComponentsAbstract" xlink:label="ptgef_NetChangeInWorkingCapitalComponentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetChangeInWorkingCapitalComponentsAbstract" xlink:to="ptgef_NetChangeInWorkingCapitalComponentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetChangeInWorkingCapitalComponentsAbstract_lbl" xml:lang="en-US">Changes in operating working capital:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IncreasingDecreasingAccountsReceivable" xlink:label="ptgef_IncreasingDecreasingAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncreasingDecreasingAccountsReceivable" xlink:to="ptgef_IncreasingDecreasingAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncreasingDecreasingAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_OtherAsset" xlink:label="ptgef_OtherAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OtherAsset" xlink:to="ptgef_OtherAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OtherAsset_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows provided by (used in) investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfInvestmentProperty" xlink:label="ifrs-full_PurchaseOfInvestmentProperty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentProperty" xlink:to="ifrs-full_PurchaseOfInvestmentProperty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInvestmentProperty_lbl" xml:lang="en-US">Investment in associates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows provided by (used in) financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" xlink:label="ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" xlink:to="ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering_lbl" xml:lang="en-US">Proceeds from shares issued under registered offering</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ShareIssuanceCosts" xlink:label="ptgef_ShareIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareIssuanceCosts" xlink:to="ptgef_ShareIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_ShareIssuanceCosts_lbl" xml:lang="en-US">Share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Increase in cash and cash equivalents during period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_3_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SupplementalDisclosureOfCashFlowInformation" xlink:label="ptgef_SupplementalDisclosureOfCashFlowInformation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SupplementalDisclosureOfCashFlowInformation" xlink:to="ptgef_SupplementalDisclosureOfCashFlowInformation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SupplementalDisclosureOfCashFlowInformation_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CashPaidForInterest" xlink:label="ptgef_CashPaidForInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashPaidForInterest" xlink:to="ptgef_CashPaidForInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashPaidForInterest_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IncreaseInAccountsPayableForStockIssuanceCosts" xlink:label="ptgef_IncreaseInAccountsPayableForStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncreaseInAccountsPayableForStockIssuanceCosts" xlink:to="ptgef_IncreaseInAccountsPayableForStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncreaseInAccountsPayableForStockIssuanceCosts_lbl" xml:lang="en-US">Increase in accounts payable for stock issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:label="ptgef_SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:to="ptgef_SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueOfWarrantLiabilityForPortageWarrantsIssued" xlink:label="ptgef_FairValueOfWarrantLiabilityForPortageWarrantsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfWarrantLiabilityForPortageWarrantsIssued" xlink:to="ptgef_FairValueOfWarrantLiabilityForPortageWarrantsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfWarrantLiabilityForPortageWarrantsIssued_lbl" xml:lang="en-US">Fair value of warrant liability for Portage warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedLossOnInvestmentInInvestment" xlink:label="ptgef_UnrealizedLossOnInvestmentInInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedLossOnInvestmentInInvestment" xlink:to="ptgef_UnrealizedLossOnInvestmentInInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnrealizedLossOnInvestmentInInvestment_lbl" xml:lang="en-US">Unrealized (loss) on investment in investments</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NatureOfOperationsAbstract" xlink:label="ptgef_NatureOfOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NatureOfOperationsAbstract" xlink:to="ptgef_NatureOfOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NatureOfOperationsAbstract_lbl" xml:lang="en-US">Nature Of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NatureOfOperationsTextBlock" xlink:label="ptgef_NatureOfOperationsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NatureOfOperationsTextBlock" xlink:to="ptgef_NatureOfOperationsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NatureOfOperationsTextBlock_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureLiquidityAbstract" xlink:label="ptgef_DisclosureLiquidityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureLiquidityAbstract" xlink:to="ptgef_DisclosureLiquidityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureLiquidityAbstract_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_LiquidityTextBlock" xlink:label="ptgef_LiquidityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LiquidityTextBlock" xlink:to="ptgef_LiquidityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LiquidityTextBlock_lbl" xml:lang="en-US">LIQUIDITY</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BasisOfPresentationAbstract" xlink:label="ptgef_BasisOfPresentationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BasisOfPresentationAbstract" xlink:to="ptgef_BasisOfPresentationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BasisOfPresentationAbstract_lbl" xml:lang="en-US">Basis Of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SignificantAccountingPoliciesAbstract" xlink:label="ptgef_SignificantAccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SignificantAccountingPoliciesAbstract" xlink:to="ptgef_SignificantAccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PrepaidExpensesAndOtherReceivableAbstract" xlink:label="ptgef_PrepaidExpensesAndOtherReceivableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivableAbstract" xlink:to="ptgef_PrepaidExpensesAndOtherReceivableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidExpensesAndOtherReceivableAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER RECEIVABLES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentInBiohavenAbstract" xlink:label="ptgef_InvestmentInBiohavenAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentInBiohavenAbstract" xlink:to="ptgef_InvestmentInBiohavenAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InvestmentInBiohavenAbstract_lbl" xml:lang="en-US">Investment In Marketable Equity Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAvailableforsaleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfAvailableforsaleAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAvailableforsaleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfAvailableforsaleAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAvailableforsaleAssetsExplanatory_lbl" xml:lang="en-US">INVESTMENT IN MARKETABLE EQUITY SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInvestmentInAssociateAbstract" xlink:label="ptgef_DisclosureInvestmentInAssociateAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureInvestmentInAssociateAbstract" xlink:to="ptgef_DisclosureInvestmentInAssociateAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureInvestmentInAssociateAbstract_lbl" xml:lang="en-US">Investment In Associate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentInAssociateDisclosureTextBlock" xlink:label="ptgef_InvestmentInAssociateDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentInAssociateDisclosureTextBlock" xlink:to="ptgef_InvestmentInAssociateDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InvestmentInAssociateDisclosureTextBlock_lbl" xml:lang="en-US">INVESTMENT IN ASSOCIATE</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureDispositionOfPplAbstract" xlink:label="ptgef_DisclosureDispositionOfPplAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureDispositionOfPplAbstract" xlink:to="ptgef_DisclosureDispositionOfPplAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureDispositionOfPplAbstract_lbl" xml:lang="en-US">Disposition Of Ppl</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DispositionOfPplTextBlock" xlink:label="ptgef_DispositionOfPplTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DispositionOfPplTextBlock" xlink:to="ptgef_DispositionOfPplTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DispositionOfPplTextBlock_lbl" xml:lang="en-US">DISPOSITION OF PPL</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract" xlink:label="ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract" xlink:to="ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract_lbl" xml:lang="en-US">Investments In Private Companies</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock" xlink:label="ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock" xlink:to="ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock_lbl" xml:lang="en-US">INVESTMENTS IN PRIVATE COMPANIES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_GoodwilAbstract" xlink:label="ptgef_GoodwilAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GoodwilAbstract" xlink:to="ptgef_GoodwilAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_GoodwilAbstract_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:label="ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract_lbl" xml:lang="en-US">In-process Research And Development And Deferred Tax Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability" xlink:label="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability" xlink:to="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability_lbl" xml:lang="en-US">IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureUnsecuredNotesPayableAbstract" xlink:label="ptgef_DisclosureUnsecuredNotesPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureUnsecuredNotesPayableAbstract" xlink:to="ptgef_DisclosureUnsecuredNotesPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureUnsecuredNotesPayableAbstract_lbl" xml:lang="en-US">Unsecured Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnsecuredNotesPayableAndWarrantsTextBlock" xlink:label="ptgef_UnsecuredNotesPayableAndWarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnsecuredNotesPayableAndWarrantsTextBlock" xlink:to="ptgef_UnsecuredNotesPayableAndWarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnsecuredNotesPayableAndWarrantsTextBlock_lbl" xml:lang="en-US">UNSECURED NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="ptgef_DisclosureWarrantLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureWarrantLiabilityAbstract" xlink:to="ptgef_DisclosureWarrantLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureWarrantLiabilityAbstract_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantLiabilitytextblock" xlink:label="ptgef_WarrantLiabilitytextblock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantLiabilitytextblock" xlink:to="ptgef_WarrantLiabilitytextblock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantLiabilitytextblock_lbl" xml:lang="en-US">WARRANT LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureCapitalStockAbstract" xlink:label="ptgef_DisclosureCapitalStockAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureCapitalStockAbstract" xlink:to="ptgef_DisclosureCapitalStockAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureCapitalStockAbstract_lbl" xml:lang="en-US">Capital Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CapitalStockTextBlock" xlink:label="ptgef_CapitalStockTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalStockTextBlock" xlink:to="ptgef_CapitalStockTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalStockTextBlock_lbl" xml:lang="en-US">CAPITAL STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ShareBasedPaymentAbstract" xlink:label="ptgef_ShareBasedPaymentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareBasedPaymentAbstract" xlink:to="ptgef_ShareBasedPaymentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareBasedPaymentAbstract_lbl" xml:lang="en-US">Stock Option Reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">STOCK OPTION RESERVE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US">(LOSS) PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommitmentsAndContingenciesAbstract" xlink:label="ptgef_CommitmentsAndContingenciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommitmentsAndContingenciesAbstract" xlink:to="ptgef_CommitmentsAndContingenciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommitmentsAndContingenciesAbstract_lbl" xml:lang="en-US">Commitments And Contingent Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related party transactions [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="ptgef_FinancialInstrumentsAndRiskManagementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ptgef_FinancialInstrumentsAndRiskManagementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US">Financial Instruments And Risk Management</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureCapitalDisclosuresAbstract" xlink:label="ptgef_DisclosureCapitalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureCapitalDisclosuresAbstract" xlink:to="ptgef_DisclosureCapitalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureCapitalDisclosuresAbstract_lbl" xml:lang="en-US">Capital Disclosures</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:label="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:to="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock_lbl" xml:lang="en-US">CAPITAL DISCLOSURES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NonControllingInterestAbstract" xlink:label="ptgef_NonControllingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NonControllingInterestAbstract" xlink:to="ptgef_NonControllingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NonControllingInterestAbstract_lbl" xml:lang="en-US">Non-controlling Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory_lbl" xml:lang="en-US">NON-CONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureEventsAfterBalanceSheetDateAbstract" xlink:label="ptgef_DisclosureEventsAfterBalanceSheetDateAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureEventsAfterBalanceSheetDateAbstract" xlink:to="ptgef_DisclosureEventsAfterBalanceSheetDateAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureEventsAfterBalanceSheetDateAbstract_lbl" xml:lang="en-US">Events After Balance Sheet Date</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock" xlink:label="ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock" xlink:to="ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock_lbl" xml:lang="en-US">EVENTS AFTER THE BALANCE SHEET DATE</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:label="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:to="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:label="ifrs-full_DisclosureOfInvestmentPropertyExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentPropertyExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInvestmentPropertyExplanatory_lbl" xml:lang="en-US">Schedule of investment in marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfInvestmentAssociatetableTextBlock" xlink:label="ptgef_DisclosureOfInvestmentAssociatetableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfInvestmentAssociatetableTextBlock" xlink:to="ptgef_DisclosureOfInvestmentAssociatetableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfInvestmentAssociatetableTextBlock_lbl" xml:lang="en-US">Schedule of investment associate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock" xlink:label="ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock" xlink:to="ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock_lbl" xml:lang="en-US">Schedule of investment in Stimunity S.A.</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" xlink:label="ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" xlink:to="ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Schedule of IPR&amp;D projects</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" xlink:label="ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" xlink:to="ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_lbl" xml:lang="en-US">Schedule of In process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfNotesPayableTableTextBlock" xlink:label="ptgef_ScheduleOfNotesPayableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfNotesPayableTableTextBlock" xlink:to="ptgef_ScheduleOfNotesPayableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfNotesPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:label="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:to="ptgef_ScheduleOfWarrantLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" xlink:label="ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" xlink:to="ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_lbl" xml:lang="en-US">Common shares: Unlimited number of common shares without par value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfTermsStockOptionReserveExplanatory" xlink:label="ptgef_DisclosureOfTermsStockOptionReserveExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfTermsStockOptionReserveExplanatory" xlink:to="ptgef_DisclosureOfTermsStockOptionReserveExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfTermsStockOptionReserveExplanatory_lbl" xml:lang="en-US">Disclosure Of Terms Stock Option Reserve Explanatory</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" xlink:label="ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" xlink:to="ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_lbl" xml:lang="en-US">Schedule of outstanding stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of weighted average exercise price and the remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_EarningsPerShareTableTextBlock" xlink:label="ptgef_EarningsPerShareTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EarningsPerShareTableTextBlock" xlink:to="ptgef_EarningsPerShareTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EarningsPerShareTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted EPS calculations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock" xlink:label="ptgef_ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock" xlink:to="ptgef_ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock_lbl" xml:lang="en-US">Schedule of Anti-Dilutive effect on Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:label="ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:to="ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl" xml:lang="en-US">Schedule of financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:label="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:to="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock_lbl" xml:lang="en-US">Schedule of non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xml:lang="en-US">Number of instruments or interests issued or issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuanceAndSales" xlink:label="ptgef_IssuanceAndSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IssuanceAndSales" xlink:to="ptgef_IssuanceAndSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IssuanceAndSales_lbl" xml:lang="en-US">Issuance and sales</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_MaximumAggregateOfferingPrice" xlink:label="ptgef_MaximumAggregateOfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_MaximumAggregateOfferingPrice" xlink:to="ptgef_MaximumAggregateOfferingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US">Maximum aggregate offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CashFundDescription" xlink:label="ptgef_CashFundDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashFundDescription" xlink:to="ptgef_CashFundDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashFundDescription_lbl" xml:lang="en-US">Cash fund, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentLiabilities_2_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLoss_4_lbl" xml:lang="en-US">Profit (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOnHand" xlink:label="ifrs-full_CashOnHand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOnHand_lbl" xml:lang="en-US">Cash on hand</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_OfferingAndThroughThatProcessDescription" xlink:label="ptgef_OfferingAndThroughThatProcessDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OfferingAndThroughThatProcessDescription" xlink:to="ptgef_OfferingAndThroughThatProcessDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OfferingAndThroughThatProcessDescription_lbl" xml:lang="en-US">Offering and through that process description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:to="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_lbl" xml:lang="en-US">Proportion of ownership interests held by non-controlling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAdvancesToSuppliers" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ResearchAndDevelopmentCredit" xlink:label="ptgef_ResearchAndDevelopmentCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ResearchAndDevelopmentCredit" xlink:to="ptgef_ResearchAndDevelopmentCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ResearchAndDevelopmentCredit_lbl" xml:lang="en-US">Research &amp; development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepayments_lbl" xml:lang="en-US">Total prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Accruals" xlink:label="ifrs-full_Accruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Accruals_lbl" xml:lang="en-US">Accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LoansPayableInDefault" xlink:label="ifrs-full_LoansPayableInDefault" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansPayableInDefault" xlink:to="ifrs-full_LoansPayableInDefault_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LoansPayableInDefault_lbl" xml:lang="en-US">Loans payable in default</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="ifrs-full_TradeAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivables" xlink:to="ifrs-full_TradeAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivables_lbl" xml:lang="en-US">Trade and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="ifrs-full_CurrentPortionOfLongtermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:to="ifrs-full_CurrentPortionOfLongtermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPortionOfLongtermBorrowings_lbl" xml:lang="en-US">Current portion of non-current borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PrepaidExpensesAndOtherReceivables" xlink:label="ptgef_PrepaidExpensesAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivables" xlink:to="ptgef_PrepaidExpensesAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidExpensesAndOtherReceivables_lbl" xml:lang="en-US">Prepaid expenses and Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentAssetAvailableForSale" xlink:label="ptgef_InvestmentAssetAvailableForSale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentAssetAvailableForSale" xlink:to="ptgef_InvestmentAssetAvailableForSale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_InvestmentAssetAvailableForSale_lbl" xml:lang="en-US">Balance, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedLossGainOnInvestment" xlink:label="ptgef_UnrealizedLossGainOnInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedLossGainOnInvestment" xlink:to="ptgef_UnrealizedLossGainOnInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnrealizedLossGainOnInvestment_lbl" xml:lang="en-US">Unrealized (loss) gain on investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentAssetAvailableForSale" xlink:to="ptgef_InvestmentAssetAvailableForSale_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_InvestmentAssetAvailableForSale_2_lbl" xml:lang="en-US">Balance, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable_lbl" xml:lang="en-US">Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentInMarketableEquitySecurities" xlink:label="ptgef_InvestmentInMarketableEquitySecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentInMarketableEquitySecurities" xlink:to="ptgef_InvestmentInMarketableEquitySecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InvestmentInMarketableEquitySecurities_lbl" xml:lang="en-US">Investment in marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US">Proceeds from issuing shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedGains" xlink:label="ptgef_UnrealizedGains" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedGains" xlink:to="ptgef_UnrealizedGains_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnrealizedGains_lbl" xml:lang="en-US">Unrealized gains</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_lbl" xml:lang="en-US">Disclosure of associates [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NameOfAssociate" xlink:label="ifrs-full_NameOfAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NameOfAssociate" xlink:to="ifrs-full_NameOfAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NameOfAssociate_lbl" xml:lang="en-US">Name of associate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfAssociate_lbl" xml:lang="en-US">Principal place of business of associate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate_lbl" xml:lang="en-US">Country of incorporation of associate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="ifrs-full_ProportionOfVotingPowerHeldInAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:to="ifrs-full_ProportionOfVotingPowerHeldInAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfVotingPowerHeldInAssociate_lbl" xml:lang="en-US">Proportion of voting rights held in associate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AdditionalInvestments" xlink:label="ptgef_AdditionalInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdditionalInvestments" xlink:to="ptgef_AdditionalInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AdditionalInvestments_lbl" xml:lang="en-US">Additional investment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrecognisedShareOfGainLossesOfAssociates" xlink:label="ptgef_UnrecognisedShareOfGainLossesOfAssociates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrecognisedShareOfGainLossesOfAssociates" xlink:to="ptgef_UnrecognisedShareOfGainLossesOfAssociates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnrecognisedShareOfGainLossesOfAssociates_lbl" xml:lang="en-US">Share of (loss) income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_EquityInLossIncome" xlink:label="ptgef_EquityInLossIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EquityInLossIncome" xlink:to="ptgef_EquityInLossIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EquityInLossIncome_lbl" xml:lang="en-US">Equity in loss income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US">Entities [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="dei_EntityListingsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingsLineItems_lbl" xml:lang="en-US">Entity Listings [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DispositionPercentage" xlink:label="ptgef_DispositionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DispositionPercentage" xlink:to="ptgef_DispositionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DispositionPercentage_lbl" xml:lang="en-US">Disposition Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DispositionValue" xlink:label="ptgef_DispositionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DispositionValue" xlink:to="ptgef_DispositionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DispositionValue_lbl" xml:lang="en-US">Disposition value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IntercompanyReceivable" xlink:label="ptgef_IntercompanyReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IntercompanyReceivable" xlink:to="ptgef_IntercompanyReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IntercompanyReceivable_lbl" xml:lang="en-US">Intercompany receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable_lbl" xml:lang="en-US">Disclosure of offsetting of financial assets [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentOwnedShares" xlink:label="ptgef_InvestmentOwnedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentOwnedShares" xlink:to="ptgef_InvestmentOwnedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InvestmentOwnedShares_lbl" xml:lang="en-US">Number of shares purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentOwnershipPercentage" xlink:label="ptgef_InvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentOwnershipPercentage" xlink:to="ptgef_InvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InvestmentOwnershipPercentage_lbl" xml:lang="en-US">InvestmentOwnershipPercentage</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedGainLossOnInvestment" xlink:label="ptgef_UnrealizedGainLossOnInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedGainLossOnInvestment" xlink:to="ptgef_UnrealizedGainLossOnInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnrealizedGainLossOnInvestment_lbl" xml:lang="en-US">Unrealized Gain (Loss) On Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="ifrs-full_EquityInterestsOfAcquirer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityInterestsOfAcquirer" xlink:to="ifrs-full_EquityInterestsOfAcquirer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityInterestsOfAcquirer_lbl" xml:lang="en-US">Equity interests of acquirer</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" xlink:label="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" xlink:to="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset_lbl" xml:lang="en-US">Number Of Private Company Share Consists In Sole Asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_3_lbl" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:to="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_lbl" xml:lang="en-US">Discount rate applied to cash flow projections</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncome" xlink:to="ifrs-full_DeferredTaxExpenseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xml:lang="en-US">Deferred tax expense (income)</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NotePayable" xlink:label="ptgef_NotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NotePayable" xlink:to="ptgef_NotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_NotePayable_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RepaymentOfNotesPayable" xlink:label="ptgef_RepaymentOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RepaymentOfNotesPayable" xlink:to="ptgef_RepaymentOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RepaymentOfNotesPayable_lbl" xml:lang="en-US">Repayment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AmortizationOfDebtDiscount" xlink:label="ptgef_AmortizationOfDebtDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AmortizationOfDebtDiscount" xlink:to="ptgef_AmortizationOfDebtDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_AmortizationOfDebtDiscount_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ValueOfNotesExchangedInWarrantExercise" xlink:label="ptgef_ValueOfNotesExchangedInWarrantExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ValueOfNotesExchangedInWarrantExercise" xlink:to="ptgef_ValueOfNotesExchangedInWarrantExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ValueOfNotesExchangedInWarrantExercise_lbl" xml:lang="en-US">Value of notes exchanged in warrant exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SettlementInConnectionWithDispositionOfPpl" xlink:label="ptgef_SettlementInConnectionWithDispositionOfPpl" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SettlementInConnectionWithDispositionOfPpl" xlink:to="ptgef_SettlementInConnectionWithDispositionOfPpl_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SettlementInConnectionWithDispositionOfPpl_lbl" xml:lang="en-US">Settlement in connection with disposition of PPL</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_LossOnExtinguishmentOfDebt" xlink:label="ptgef_LossOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnExtinguishmentOfDebt" xlink:to="ptgef_LossOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ProceedsFromLoanPayable" xlink:label="ptgef_ProceedsFromLoanPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromLoanPayable" xlink:to="ptgef_ProceedsFromLoanPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromLoanPayable_lbl" xml:lang="en-US">Proceeds from loan payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NotePayable" xlink:to="ptgef_NotePayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_NotePayable_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AggregatePrincipalAmountOfUnsecuredNotes" xlink:label="ptgef_AggregatePrincipalAmountOfUnsecuredNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AggregatePrincipalAmountOfUnsecuredNotes" xlink:to="ptgef_AggregatePrincipalAmountOfUnsecuredNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AggregatePrincipalAmountOfUnsecuredNotes_lbl" xml:lang="en-US">Aggregate principal amount of Unsecured Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnsecuredNotesInterest" xlink:label="ptgef_UnsecuredNotesInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnsecuredNotesInterest" xlink:to="ptgef_UnsecuredNotesInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnsecuredNotesInterest_lbl" xml:lang="en-US">Unsecured Notes interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuanceOfUnsecuredNotesDescription" xlink:label="ptgef_IssuanceOfUnsecuredNotesDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IssuanceOfUnsecuredNotesDescription" xlink:to="ptgef_IssuanceOfUnsecuredNotesDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IssuanceOfUnsecuredNotesDescription_lbl" xml:lang="en-US">Issuance of unsecured notes, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValue" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xml:lang="en-US">Financial liabilities, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PaymentForSettlement" xlink:label="ptgef_PaymentForSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PaymentForSettlement" xlink:to="ptgef_PaymentForSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PaymentForSettlement_lbl" xml:lang="en-US">Payment for settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsExercised" xlink:label="ptgef_WarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsExercised" xlink:to="ptgef_WarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ExercisePrice" xlink:label="ptgef_ExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExercisePrice" xlink:to="ptgef_ExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ContractualValueOfWarrantsExercisedDescription" xlink:label="ptgef_ContractualValueOfWarrantsExercisedDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ContractualValueOfWarrantsExercisedDescription" xlink:to="ptgef_ContractualValueOfWarrantsExercisedDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ContractualValueOfWarrantsExercisedDescription_lbl" xml:lang="en-US">Contractual value of warrants exercised description</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesReceived" xlink:label="ptgef_SharesReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesReceived" xlink:to="ptgef_SharesReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesReceived_lbl" xml:lang="en-US">Shares received</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfExerciseOfWarrantsIssued" xlink:label="ptgef_NumberOfExerciseOfWarrantsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfExerciseOfWarrantsIssued" xlink:to="ptgef_NumberOfExerciseOfWarrantsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfExerciseOfWarrantsIssued_lbl" xml:lang="en-US">Number of exercise of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfExerciseOfWarrantsOutstanding" xlink:label="ptgef_NumberOfExerciseOfWarrantsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfExerciseOfWarrantsOutstanding" xlink:to="ptgef_NumberOfExerciseOfWarrantsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfExerciseOfWarrantsOutstanding_lbl" xml:lang="en-US">Number of exercise of warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnExtinguishmentOfDebt" xlink:to="ptgef_LossOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_LossOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss On Extinguishment Of Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DescriptionOfBusinessCombination" xlink:label="ptgef_DescriptionOfBusinessCombination" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfBusinessCombination" xlink:to="ptgef_DescriptionOfBusinessCombination_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfBusinessCombination_lbl" xml:lang="en-US">Acquistion, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="ifrs-full_IssueOfConvertibleInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ifrs-full_IssueOfConvertibleInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfConvertibleInstruments_lbl" xml:lang="en-US">Issue of convertible instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingExercisePrice" xlink:label="ptgef_WarrantsOutstandingExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingExercisePrice" xlink:to="ptgef_WarrantsOutstandingExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_WarrantsOutstandingExercisePrice_lbl" xml:lang="en-US">Warrants outstanding exercise price at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingShares" xlink:label="ptgef_WarrantsOutstandingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingShares" xlink:to="ptgef_WarrantsOutstandingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_WarrantsOutstandingShares_lbl" xml:lang="en-US">Warrants outstanding, shares at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingAmount" xlink:label="ptgef_WarrantsOutstandingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingAmount" xlink:to="ptgef_WarrantsOutstandingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_WarrantsOutstandingAmount_lbl" xml:lang="en-US">Warrants outstanding, amount at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueAdjustmentExercisePriceAtEnd" xlink:label="ptgef_FairValueAdjustmentExercisePriceAtEnd" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueAdjustmentExercisePriceAtEnd" xlink:to="ptgef_FairValueAdjustmentExercisePriceAtEnd_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueAdjustmentExercisePriceAtEnd_lbl" xml:lang="en-US">Fair value adjustment , exercise price at end</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueAdjustmentShares" xlink:label="ptgef_FairValueAdjustmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueAdjustmentShares" xlink:to="ptgef_FairValueAdjustmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueAdjustmentShares_lbl" xml:lang="en-US">Fair value adjustment, shares at end</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueAdjustment" xlink:label="ptgef_FairValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueAdjustment" xlink:to="ptgef_FairValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueAdjustment_lbl" xml:lang="en-US">Fair value adjustment, amount at end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingExercisePrice" xlink:to="ptgef_WarrantsOutstandingExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_WarrantsOutstandingExercisePrice_2_lbl" xml:lang="en-US">Warrants outstanding, exercise price, at end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingShares" xlink:to="ptgef_WarrantsOutstandingShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_WarrantsOutstandingShares_2_lbl" xml:lang="en-US">Warrants outstanding, amount at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingAmount" xlink:to="ptgef_WarrantsOutstandingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_WarrantsOutstandingAmount_2_lbl" xml:lang="en-US">Warrants outstanding, amount, at end</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommonStockShares" xlink:label="ptgef_CommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockShares" xlink:to="ptgef_CommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_CommonStockShares_lbl" xml:lang="en-US">Balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommonStockValues" xlink:label="ptgef_CommonStockValues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockValues" xlink:to="ptgef_CommonStockValues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_CommonStockValues_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:to="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares_lbl" xml:lang="en-US">Shares issued in a private placement, net of issue costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:to="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts_lbl" xml:lang="en-US">Shares issued in a private placement, net of issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedForServicesShares" xlink:label="ptgef_SharesIssuedForServicesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedForServicesShares" xlink:to="ptgef_SharesIssuedForServicesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedForServicesShares_lbl" xml:lang="en-US">Shares issued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedForService" xlink:label="ptgef_SharesIssuedForService" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedForService" xlink:to="ptgef_SharesIssuedForService_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedForService_lbl" xml:lang="en-US">Shares issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockShares" xlink:to="ptgef_CommonStockShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_CommonStockShares_2_lbl" xml:lang="en-US">Balance, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockValues" xlink:to="ptgef_CommonStockValues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_CommonStockValues_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PricePerShare" xlink:label="ptgef_PricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PricePerShare" xlink:to="ptgef_PricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PricePerShare_lbl" xml:lang="en-US">Shares price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares" xlink:to="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares_lbl" xml:lang="en-US">Shares issued in private placement net of issue cost, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost" xlink:to="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost_lbl" xml:lang="en-US">Shares issued in private placement net of issue cost</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_OfferingExpenses" xlink:label="ptgef_OfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OfferingExpenses" xlink:to="ptgef_OfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OfferingExpenses_lbl" xml:lang="en-US">Offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PublicofferingDescription" xlink:label="ptgef_PublicofferingDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PublicofferingDescription" xlink:to="ptgef_PublicofferingDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PublicofferingDescription_lbl" xml:lang="en-US">Public offering description</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionReserve" xlink:label="ptgef_StockOptionReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_StockOptionReserve_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_2_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_StockOptionReserve_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="ptgef_NumberOfOutstandingShareOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_NumberOfOutstandingShareOption_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:label="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:to="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:to="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_lbl" xml:lang="en-US">Expired or forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_NumberOfOutstandingShareOption_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfOutstandingShareOption_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:to="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_lbl" xml:lang="en-US">Exercisable as at end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:to="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_2_lbl" xml:lang="en-US">Exercisable as at end</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionsIssued" xlink:label="ptgef_StockOptionsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionsIssued" xlink:to="ptgef_StockOptionsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionsIssued_lbl" xml:lang="en-US">Stock options issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Exercise price of outstanding share options</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockGranted" xlink:label="ptgef_StockGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockGranted" xlink:to="ptgef_StockGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockGranted_lbl" xml:lang="en-US">Stock granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValuePerShare" xlink:label="ptgef_FairValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValuePerShare" xlink:to="ptgef_FairValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValuePerShare_lbl" xml:lang="en-US">Fair value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CommunicationExpense" xlink:label="ifrs-full_CommunicationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationExpense" xlink:to="ifrs-full_CommunicationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommunicationExpense_lbl" xml:lang="en-US">Communication expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumeratorAbstract" xlink:label="ptgef_NumeratorAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumeratorAbstract" xlink:to="ptgef_NumeratorAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumeratorAbstract_lbl" xml:lang="en-US">Numerator (in 000&#8217;$)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Net loss attributable to owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DenominatorAbstract" xlink:label="ptgef_DenominatorAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DenominatorAbstract" xlink:to="ptgef_DenominatorAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DenominatorAbstract_lbl" xml:lang="en-US">Denominator (in 000&#8217;)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average number of shares &#8211; Basic and Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BasicAndDilutedLossPerShare" xlink:to="ptgef_BasicAndDilutedLossPerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_BasicAndDilutedLossPerShare_2_lbl" xml:lang="en-US">Basic and diluted (loss) per share (Actual)</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AntidilutiveEffectOnLossPerShar" xlink:label="ptgef_AntidilutiveEffectOnLossPerShar" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AntidilutiveEffectOnLossPerShar" xlink:to="ptgef_AntidilutiveEffectOnLossPerShar_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AntidilutiveEffectOnLossPerShar_lbl" xml:lang="en-US">Anti-dilutive effect on loss per shar</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommitmentToInvestment" xlink:label="ptgef_CommitmentToInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommitmentToInvestment" xlink:to="ptgef_CommitmentToInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommitmentToInvestment_lbl" xml:lang="en-US">Commitment To Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DiscretionaryInvestment" xlink:label="ptgef_DiscretionaryInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DiscretionaryInvestment" xlink:to="ptgef_DiscretionaryInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DiscretionaryInvestment_lbl" xml:lang="en-US">Discretionary Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AdditionalDiscretionaryInvestment" xlink:label="ptgef_AdditionalDiscretionaryInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdditionalDiscretionaryInvestment" xlink:to="ptgef_AdditionalDiscretionaryInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AdditionalDiscretionaryInvestment_lbl" xml:lang="en-US">Additional Discretionary Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestCostsIncurred" xlink:label="ifrs-full_InterestCostsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestCostsIncurred" xlink:to="ifrs-full_InterestCostsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestCostsIncurred_lbl" xml:lang="en-US">Interest costs incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany" xlink:label="ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany" xlink:to="ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany_lbl" xml:lang="en-US">Repayments Of Advance To Board Member Of Company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentInvestments" xlink:label="ifrs-full_CurrentInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInvestments_lbl" xml:lang="en-US">Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilities" xlink:to="ptgef_AccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentPayables" xlink:label="ifrs-full_NoncurrentPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPayables" xlink:to="ifrs-full_NoncurrentPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentPayables_lbl" xml:lang="en-US">Unsecured notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantLiability" xlink:label="ptgef_WarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantLiability" xlink:to="ptgef_WarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_WarrantLiability_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueMarketPricePerShare" xlink:label="ptgef_FairValueMarketPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueMarketPricePerShare" xlink:to="ptgef_FairValueMarketPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueMarketPricePerShare_lbl" xml:lang="en-US">Fair value market price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PayablesAndAccruedExpense" xlink:label="ptgef_PayablesAndAccruedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PayablesAndAccruedExpense" xlink:to="ptgef_PayablesAndAccruedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PayablesAndAccruedExpense_lbl" xml:lang="en-US">Payables and accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentAssets_2_lbl" xml:lang="en-US">Current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Equity attributable to owners of parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NoncontrollingInterests_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockBasedCompensationExpense" xlink:label="ptgef_StockBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockBasedCompensationExpense" xlink:to="ptgef_StockBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="ptgef_NetLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLossAttributableToNoncontrollingInterest" xlink:to="ptgef_NetLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net income (loss) attributable to non-controlling interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NoncontrollingInterests_3_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RepaymentOfInstallmentNoteReceivable" xlink:label="ptgef_RepaymentOfInstallmentNoteReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RepaymentOfInstallmentNoteReceivable" xlink:to="ptgef_RepaymentOfInstallmentNoteReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RepaymentOfInstallmentNoteReceivable_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashFundDescription" xlink:to="ptgef_CashFundDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_CashFundDescription_doc" xml:lang="en-US">Cash fund, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ResearchAndDevelopmentCredit" xlink:to="ptgef_ResearchAndDevelopmentCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_ResearchAndDevelopmentCredit_doc" xml:lang="en-US">The amount of expenditure directly attributable to research or development activities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivables" xlink:to="ptgef_PrepaidExpensesAndOtherReceivables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_PrepaidExpensesAndOtherReceivables_doc" xml:lang="en-US">Amount of prepaid expenses and other receivables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockBasedCompensationExpense" xlink:to="ptgef_StockBasedCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_StockBasedCompensationExpense_doc" xml:lang="en-US">Stock based compensation expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLossAttributableToNoncontrollingInterest" xlink:to="ptgef_NetLossAttributableToNoncontrollingInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_NetLossAttributableToNoncontrollingInterest_doc" xml:lang="en-US">Net loss attributable to non-controlling interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueMarketPricePerShare" xlink:to="ptgef_FairValueMarketPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_FairValueMarketPricePerShare_doc" xml:lang="en-US">Fair value market price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilities" xlink:to="ptgef_AccountsPayableAndAccruedLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities_doc" xml:lang="en-US">Amount of accounts payable and accrued liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany" xlink:to="ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany_doc" xml:lang="en-US">Represents amount of Repayments Of Advance To Board member of company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommitmentToInvestment" xlink:to="ptgef_CommitmentToInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_CommitmentToInvestment_doc" xml:lang="en-US">Represents the amount related to commitment to investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdditionalDiscretionaryInvestment" xlink:to="ptgef_AdditionalDiscretionaryInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_AdditionalDiscretionaryInvestment_doc" xml:lang="en-US">Represents the amount of additional discretionary investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_StockOptionReserve_doc" xml:lang="en-US">Stock option reserve for option under share-based payment arrangement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_NumberOfOutstandingShareOption_doc" xml:lang="en-US">The number of share options outstanding in a share-based payment arrangement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:to="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_doc" xml:lang="en-US">The number of share options granted in a share-based payment arrangement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:to="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_doc" xml:lang="en-US">The number of share options exercisable in a share-based payment arrangement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionsIssued" xlink:to="ptgef_StockOptionsIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_StockOptionsIssued_doc" xml:lang="en-US">Stock options issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedGains" xlink:to="ptgef_UnrealizedGains_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_UnrealizedGains_doc" xml:lang="en-US">Unrealized gains.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdditionalInvestments" xlink:to="ptgef_AdditionalInvestments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_AdditionalInvestments_doc" xml:lang="en-US">Amount of additional investments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentOwnedShares" xlink:to="ptgef_InvestmentOwnedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_InvestmentOwnedShares_doc" xml:lang="en-US">Number of shares purchased.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedGainLossOnInvestment" xlink:to="ptgef_UnrealizedGainLossOnInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_UnrealizedGainLossOnInvestment_doc" xml:lang="en-US">Amount of unrealized gain (loss) on investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AcquisitionOfSalvaRxMember" xlink:to="ptgef_AcquisitionOfSalvaRxMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_AcquisitionOfSalvaRxMember_doc" xml:lang="en-US">This member stands for the acquisition of SalvaRx.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentOwnershipPercentage" xlink:to="ptgef_InvestmentOwnershipPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_InvestmentOwnershipPercentage_doc" xml:lang="en-US">The percentage of equity ownership percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AcquisitionOfIntensityHoldingLimitedMember" xlink:to="ptgef_AcquisitionOfIntensityHoldingLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_AcquisitionOfIntensityHoldingLimitedMember_doc" xml:lang="en-US">This member stands for the acquisition of Intensity Holding Limited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" xlink:to="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset_doc" xml:lang="en-US">Represent the number of private company share consists in sole asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IMM60IOXMelanomaLungCancersMember" xlink:to="ptgef_IMM60IOXMelanomaLungCancersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_IMM60IOXMelanomaLungCancersMember_doc" xml:lang="en-US">This member stands for IMM 60 IOX Melanoma &amp;amp;amp;amp; Lung Cancers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IMM65IOXOvarianProstateCancersMember" xlink:to="ptgef_IMM65IOXOvarianProstateCancersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_IMM65IOXOvarianProstateCancersMember_doc" xml:lang="en-US">This member stands for IMM 65 IOX Ovarian/Prostate Cancers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OncomerSaugatuckDNAAptamersMember" xlink:to="ptgef_OncomerSaugatuckDNAAptamersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_OncomerSaugatuckDNAAptamersMember_doc" xml:lang="en-US">This member stands for Oncomer Saugatuck DNA Aptamers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NotePayable" xlink:to="ptgef_NotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_NotePayable_doc" xml:lang="en-US">Notes payable balance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RepaymentOfNotesPayable" xlink:to="ptgef_RepaymentOfNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_RepaymentOfNotesPayable_doc" xml:lang="en-US">Repayment of notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnExtinguishmentOfDebt" xlink:to="ptgef_LossOnExtinguishmentOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_LossOnExtinguishmentOfDebt_doc" xml:lang="en-US">Represent Loss on extinguishment of debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AggregatePrincipalAmountOfUnsecuredNotes" xlink:to="ptgef_AggregatePrincipalAmountOfUnsecuredNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_AggregatePrincipalAmountOfUnsecuredNotes_doc" xml:lang="en-US">Aggregate principal amount of Unsecured Notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnsecuredNotesInterest" xlink:to="ptgef_UnsecuredNotesInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_UnsecuredNotesInterest_doc" xml:lang="en-US">Unsecured Notes interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IssuanceOfUnsecuredNotesDescription" xlink:to="ptgef_IssuanceOfUnsecuredNotesDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgef_IssuanceOfUnsecuredNotesDescription_doc" xml:lang="en-US">Issuance of unsecured notes, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_3_lbl" xml:lang="en-US">Current liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_2_lbl" xml:lang="en-US">Non-current liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_4_lbl" xml:lang="en-US">Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_2_lbl" xml:lang="en-US">Equity and liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_2_lbl" xml:lang="en-US">Profit (loss) from operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpense_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_2_lbl" xml:lang="en-US">Profit (loss) before tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xml:lang="en-US">Tax expense (income)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_2_lbl" xml:lang="en-US">Comprehensive income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2_lbl" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLossIncome" xlink:to="ptgef_NetLossIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetLossIncome_2_lbl" xml:lang="en-US">NetLossIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2_lbl" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TotalComprehensiveLossIncomeForYear" xlink:to="ptgef_TotalComprehensiveLossIncomeForYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TotalComprehensiveLossIncomeForYear_2_lbl" xml:lang="en-US">TotalComprehensiveLossIncomeForYear</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" xlink:to="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">WeightedAveragesSharesoutstandingBasicAndDiluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_2_lbl" xml:lang="en-US">Payments for share issue costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedLossOnInvestmentInInvestments" xlink:to="ptgef_UnrealizedLossOnInvestmentInInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnrealizedLossOnInvestmentInInvestments_2_lbl" xml:lang="en-US">UnrealizedLossOnInvestmentInInvestments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_2_lbl" xml:lang="en-US">Adjustments for decrease (increase) in other assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2_lbl" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentProperty" xlink:to="ifrs-full_PurchaseOfInvestmentProperty_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInvestmentProperty_2_lbl" xml:lang="en-US">Purchase of investment property</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareIssuanceCosts" xlink:to="ptgef_ShareIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareIssuanceCosts_2_lbl" xml:lang="en-US">ShareIssuanceCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentAssetAvailableForSale" xlink:to="ptgef_InvestmentAssetAvailableForSale_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InvestmentAssetAvailableForSale_3_lbl" xml:lang="en-US">Investment in marketable equity securities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NotePayable" xlink:to="ptgef_NotePayable_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NotePayable_4_lbl" xml:lang="en-US">NotePayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AmortizationOfDebtDiscount" xlink:to="ptgef_AmortizationOfDebtDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AmortizationOfDebtDiscount_2_lbl" xml:lang="en-US">AmortizationOfDebtDiscount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingExercisePrice" xlink:to="ptgef_WarrantsOutstandingExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsOutstandingExercisePrice_3_lbl" xml:lang="en-US">WarrantsOutstandingExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingShares" xlink:to="ptgef_WarrantsOutstandingShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsOutstandingShares_3_lbl" xml:lang="en-US">WarrantsOutstandingShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingAmount" xlink:to="ptgef_WarrantsOutstandingAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsOutstandingAmount_3_lbl" xml:lang="en-US">WarrantsOutstandingAmount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockShares" xlink:to="ptgef_CommonStockShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommonStockShares_3_lbl" xml:lang="en-US">CommonStockShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockValues" xlink:to="ptgef_CommonStockValues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommonStockValues_3_lbl" xml:lang="en-US">CommonStockValues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionReserve_4_lbl" xml:lang="en-US">StockOptionReserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilities" xlink:to="ptgef_AccountsPayableAndAccruedLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities_3_lbl" xml:lang="en-US">AccountsPayableAndAccruedLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPayables" xlink:to="ifrs-full_NoncurrentPayables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentPayables_2_lbl" xml:lang="en-US">Trade and other non-current payables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantLiability" xlink:to="ptgef_WarrantLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantLiability_2_lbl" xml:lang="en-US">WarrantLiability</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ptgef-20210630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://portagebiotech.com/role/Cover" xlink:href="ptgef-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:href="ptgef-20210630.xsd#InterimStatementsOfFinancialPosition" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss" xlink:href="ptgef-20210630.xsd#InterimStatementsOfOperationsAndOtherComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:href="ptgef-20210630.xsd#InterimStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:href="ptgef-20210630.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperations" xlink:href="ptgef-20210630.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Liquidity" xlink:href="ptgef-20210630.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentation" xlink:href="ptgef-20210630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:href="ptgef-20210630.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecurities" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociate" xlink:href="ptgef-20210630.xsd#InvestmentInAssociate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/DispositionOfPpl" xlink:href="ptgef-20210630.xsd#DispositionOfPpl" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentsInPrivateCompanies" xlink:href="ptgef-20210630.xsd#InvestmentsInPrivateCompanies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Goodwill" xlink:href="ptgef-20210630.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:href="ptgef-20210630.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiability" xlink:href="ptgef-20210630.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStock" xlink:href="ptgef-20210630.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserve" xlink:href="ptgef-20210630.xsd#StockOptionReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShare" xlink:href="ptgef-20210630.xsd#LossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:href="ptgef-20210630.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:href="ptgef-20210630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosures" xlink:href="ptgef-20210630.xsd#CapitalDisclosures" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterest" xlink:href="ptgef-20210630.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventsAfterBalanceSheetDate" xlink:href="ptgef-20210630.xsd#EventsAfterBalanceSheetDate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:href="ptgef-20210630.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillTables" xlink:href="ptgef-20210630.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:href="ptgef-20210630.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:href="ptgef-20210630.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockTables" xlink:href="ptgef-20210630.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveTables" xlink:href="ptgef-20210630.xsd#StockOptionReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareTables" xlink:href="ptgef-20210630.xsd#LossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:href="ptgef-20210630.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:href="ptgef-20210630.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:href="ptgef-20210630.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ptgef-20210630.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:href="ptgef-20210630.xsd#PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetails" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative" xlink:href="ptgef-20210630.xsd#InvestmentInMarketableEquitySecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:href="ptgef-20210630.xsd#InvestmentInAssociateDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/DispositionOfPplDetailsNarrative" xlink:href="ptgef-20210630.xsd#DispositionOfPplDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative" xlink:href="ptgef-20210630.xsd#InvestmentsInPrivateCompaniesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetails" xlink:href="ptgef-20210630.xsd#GoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:href="ptgef-20210630.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:href="ptgef-20210630.xsd#InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:href="ptgef-20210630.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:href="ptgef-20210630.xsd#UnsecuredNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:href="ptgef-20210630.xsd#WarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetails" xlink:href="ptgef-20210630.xsd#CapitalStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:href="ptgef-20210630.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:href="ptgef-20210630.xsd#StockOptionReserveDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails" xlink:href="ptgef-20210630.xsd#LossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails1" xlink:href="ptgef-20210630.xsd#LossPerShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="ptgef-20210630.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ptgef-20210630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:href="ptgef-20210630.xsd#FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:href="ptgef-20210630.xsd#CapitalDisclosuresDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:href="ptgef-20210630.xsd#Non-controllingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" xlink:href="ptgef-20210630.xsd#EventsAfterBalanceSheetDateDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:title="00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-fullStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-fullAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-fullCurrentAssetsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-fullNoncurrentAssetsAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-fullOtherReceivables" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentProperty" xlink:label="loc_ifrs-fullInvestmentProperty" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullInvestmentProperty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-fullGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InprocessResearchAndDevelopment" xlink:label="loc_ptgefInprocessResearchAndDevelopment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ptgefInprocessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-fullOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-fullEquityAndLiabilitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullCurrentLiabilitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantLiabilityCurrent" xlink:label="loc_ptgefWarrantLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ptgefWarrantLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnsecuredNotesPayable" xlink:label="loc_ptgefUnsecuredNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ptgefUnsecuredNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullNoncurrentLiabilitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-fullDeferredTaxLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullDeferredTaxLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-fullNoncurrentLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-fullEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-fullIssuedCapital" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullIssuedCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-fullOtherReserves" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullOtherReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-fullAccumulatedOtherComprehensiveIncome" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullAccumulatedOtherComprehensiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-fullEquityAndLiabilities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullEquityAndLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommitmentAndContingencies" xlink:label="loc_ptgefCommitmentAndContingencies" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ptgefCommitmentAndContingencies" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss" xlink:title="00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive (Loss) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-fullProfitLossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-fullGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-fullProfitLossFromOperatingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:label="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-fullInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsOnDisposalsOfInvestmentProperties" xlink:label="loc_ifrs-fullGainsOnDisposalsOfInvestmentProperties" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullOtherComprehensiveIncomeAbstract" xlink:to="loc_ifrs-fullGainsOnDisposalsOfInvestmentProperties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullOtherComprehensiveIncomeAbstract" xlink:to="loc_ifrs-fullComprehensiveIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-fullProfitLossAttributableToAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NetLossIncome" xlink:label="loc_ptgefNetLossIncome" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ptgefNetLossIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToOwnersOfParent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToNoncontrollingInterests" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_TotalComprehensiveLossIncomeForYear" xlink:label="loc_ptgefTotalComprehensiveLossIncomeForYear" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:to="loc_ptgefTotalComprehensiveLossIncomeForYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-fullEarningsPerShareAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BasicAndDilutedLossPerShare" xlink:label="loc_ptgefBasicAndDilutedLossPerShare" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEarningsPerShareAbstract" xlink:to="loc_ptgefBasicAndDilutedLossPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="loc_ifrs-fullWeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullWeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" xlink:label="loc_ptgefWeightedAveragesSharesoutstandingBasicAndDiluted" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullWeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="loc_ptgefWeightedAveragesSharesoutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-fullStatementOfChangesInEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullIssuedCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ptgefStockOptionReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-fullAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuedUnderPrivatePlacement" xlink:label="loc_ptgefIssuedUnderPrivatePlacement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuedUnderPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuedUnderPrivatePlacementShares" xlink:label="loc_ptgefIssuedUnderPrivatePlacementShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuedUnderPrivatePlacementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-fullPaymentsForShareIssueCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPaymentsForShareIssueCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="loc_ptgefSharesIssuedOrAccruedForServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="loc_ptgefSharesIssuedOrAccruedForServicesShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServicesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderAtm" xlink:label="loc_ptgefSharesIssuedUnderAtm" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderAtmShares" xlink:label="loc_ptgefSharesIssuedUnderAtmShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtmShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderOffering" xlink:label="loc_ptgefSharesIssuedUnderOffering" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedUnderOfferingShares" xlink:label="loc_ptgefSharesIssuedUnderOfferingShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderOfferingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedLossOnInvestmentInInvestments" xlink:label="loc_ptgefUnrealizedLossOnInvestmentInInvestments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnrealizedLossOnInvestmentInInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-fullStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_LossIncomeOnFairValueOfWarrantLiability" xlink:label="loc_ptgefLossIncomeOnFairValueOfWarrantLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ptgefLossIncomeOnFairValueOfWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ValueOfSharesIssuedForServices" xlink:label="loc_ptgefValueOfSharesIssuedForServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ptgefValueOfSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="loc_ifrs-fullAdjustmentsForAmortisationExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForAmortisationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainLossOnHedgeIneffectiveness" xlink:label="loc_ifrs-fullGainLossOnHedgeIneffectiveness" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullGainLossOnHedgeIneffectiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NetChangeInWorkingCapitalComponentsAbstract" xlink:label="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IncreasingDecreasingAccountsReceivable" xlink:label="loc_ptgefIncreasingDecreasingAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ptgefIncreasingDecreasingAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_OtherAsset" xlink:label="loc_ptgefOtherAsset" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ptgefOtherAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfInvestmentProperty" xlink:label="loc_ifrs-fullPurchaseOfInvestmentProperty" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullPurchaseOfInvestmentProperty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderRegisteredOffering" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderRegisteredOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ShareIssuanceCosts" xlink:label="loc_ptgefShareIssuanceCosts" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefShareIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SupplementalDisclosureOfCashFlowInformation" xlink:label="loc_ptgefSupplementalDisclosureOfCashFlowInformation" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefSupplementalDisclosureOfCashFlowInformation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CashPaidForInterest" xlink:label="loc_ptgefCashPaidForInterest" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSupplementalDisclosureOfCashFlowInformation" xlink:to="loc_ptgefCashPaidForInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IncreaseInAccountsPayableForStockIssuanceCosts" xlink:label="loc_ptgefIncreaseInAccountsPayableForStockIssuanceCosts" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSupplementalDisclosureOfCashFlowInformation" xlink:to="loc_ptgefIncreaseInAccountsPayableForStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:label="loc_ptgefSupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefSupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueOfWarrantLiabilityForPortageWarrantsIssued" xlink:label="loc_ptgefFairValueOfWarrantLiabilityForPortageWarrantsIssued" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:to="loc_ptgefFairValueOfWarrantLiabilityForPortageWarrantsIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedLossOnInvestmentInInvestment" xlink:label="loc_ptgefUnrealizedLossOnInvestmentInInvestment" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:to="loc_ptgefUnrealizedLossOnInvestmentInInvestment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="00000006 - Disclosure - NATURE OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NatureOfOperationsAbstract" xlink:label="loc_ptgefNatureOfOperationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NatureOfOperationsTextBlock" xlink:label="loc_ptgefNatureOfOperationsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNatureOfOperationsAbstract" xlink:to="loc_ptgefNatureOfOperationsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Liquidity" xlink:title="00000007 - Disclosure - LIQUIDITY">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureLiquidityAbstract" xlink:label="loc_ptgefDisclosureLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_LiquidityTextBlock" xlink:label="loc_ptgefLiquidityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLiquidityAbstract" xlink:to="loc_ptgefLiquidityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BasisOfPresentationAbstract" xlink:label="loc_ptgefBasisOfPresentationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="loc_ifrs-fullDisclosureOfBasisOfConsolidationExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefBasisOfPresentationAbstract" xlink:to="loc_ifrs-fullDisclosureOfBasisOfConsolidationExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SignificantAccountingPoliciesAbstract" xlink:label="loc_ptgefSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PrepaidExpensesAndOtherReceivableAbstract" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfOtherAssetsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" xlink:to="loc_ifrs-fullDisclosureOfOtherAssetsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecurities" xlink:title="00000011 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentInBiohavenAbstract" xlink:label="loc_ptgefInvestmentInBiohavenAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAvailableforsaleAssetsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfAvailableforsaleAssetsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInBiohavenAbstract" xlink:to="loc_ifrs-fullDisclosureOfAvailableforsaleAssetsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociate" xlink:title="00000012 - Disclosure - INVESTMENT IN ASSOCIATE">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInvestmentInAssociateAbstract" xlink:label="loc_ptgefDisclosureInvestmentInAssociateAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentInAssociateDisclosureTextBlock" xlink:label="loc_ptgefInvestmentInAssociateDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentInAssociateAbstract" xlink:to="loc_ptgefInvestmentInAssociateDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DispositionOfPpl" xlink:title="00000013 - Disclosure - DISPOSITION OF PPL">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureDispositionOfPplAbstract" xlink:label="loc_ptgefDisclosureDispositionOfPplAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DispositionOfPplTextBlock" xlink:label="loc_ptgefDispositionOfPplTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDispositionOfPplAbstract" xlink:to="loc_ptgefDispositionOfPplTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentsInPrivateCompanies" xlink:title="00000014 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract" xlink:label="loc_ptgefDisclosureInvestmentsInPrivateCompaniesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock" xlink:label="loc_ptgefDisclosureOfPrivateCompaniesExplanatoryTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentsInPrivateCompaniesAbstract" xlink:to="loc_ptgefDisclosureOfPrivateCompaniesExplanatoryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Goodwill" xlink:title="00000015 - Disclosure - GOODWILL">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_GoodwilAbstract" xlink:label="loc_ptgefGoodwilAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-fullDisclosureOfResearchAndDevelopmentExpenseExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwilAbstract" xlink:to="loc_ifrs-fullDisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:title="00000016 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:label="loc_ptgefDisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability" xlink:label="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:title="00000017 - Disclosure - UNSECURED NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureUnsecuredNotesPayableAbstract" xlink:label="loc_ptgefDisclosureUnsecuredNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnsecuredNotesPayableAndWarrantsTextBlock" xlink:label="loc_ptgefUnsecuredNotesPayableAndWarrantsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureUnsecuredNotesPayableAbstract" xlink:to="loc_ptgefUnsecuredNotesPayableAndWarrantsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="00000018 - Disclosure - WARRANT LIABILITY">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantLiabilitytextblock" xlink:label="loc_ptgefWarrantLiabilitytextblock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ptgefWarrantLiabilitytextblock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStock" xlink:title="00000019 - Disclosure - CAPITAL STOCK">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureCapitalStockAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CapitalStockTextBlock" xlink:label="loc_ptgefCapitalStockTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAbstract" xlink:to="loc_ptgefCapitalStockTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="00000020 - Disclosure - STOCK OPTION RESERVE">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ShareBasedPaymentAbstract" xlink:label="loc_ptgefShareBasedPaymentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfSharebasedPaymentArrangementsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefShareBasedPaymentAbstract" xlink:to="loc_ifrs-fullDisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="00000021 - Disclosure - (LOSS) PER SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="loc_ifrs-fullEarningsPerShareExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullEarningsPerShareExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommitmentsAndContingenciesAbstract" xlink:label="loc_ptgefCommitmentsAndContingenciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCommitmentsAndContingenciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="00000023 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="loc_ifrs-fullRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-fullDisclosureOfRelatedPartyExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRelatedPartyTransactionsAbstract" xlink:to="loc_ifrs-fullDisclosureOfRelatedPartyExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFinancialInstrumentsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosures" xlink:title="00000025 - Disclosure - CAPITAL DISCLOSURES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureCapitalDisclosuresAbstract" xlink:label="loc_ptgefDisclosureCapitalDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:label="loc_ptgefDisclosureOfCapitalManagementExplanatoryTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalDisclosuresAbstract" xlink:to="loc_ptgefDisclosureOfCapitalManagementExplanatoryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="00000026 - Disclosure - NON-CONTROLLING INTEREST">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NonControllingInterestAbstract" xlink:label="loc_ptgefNonControllingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfInterestsInOtherEntitiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNonControllingInterestAbstract" xlink:to="loc_ifrs-fullDisclosureOfInterestsInOtherEntitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventsAfterBalanceSheetDate" xlink:title="00000027 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureEventsAfterBalanceSheetDateAbstract" xlink:label="loc_ptgefDisclosureEventsAfterBalanceSheetDateAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock" xlink:label="loc_ptgefDisclosureOfEventAfterBalanceSheetDateTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureEventsAfterBalanceSheetDateAbstract" xlink:to="loc_ptgefDisclosureOfEventAfterBalanceSheetDateTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SignificantAccountingPoliciesAbstract" xlink:label="loc_ptgefSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PrepaidExpensesAndOtherReceivableAbstract" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:label="loc_ptgefDisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" xlink:to="loc_ptgefDisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables" xlink:title="00000030 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentInBiohavenAbstract" xlink:label="loc_ptgefInvestmentInBiohavenAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:label="loc_ifrs-fullDisclosureOfInvestmentPropertyExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInBiohavenAbstract" xlink:to="loc_ifrs-fullDisclosureOfInvestmentPropertyExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:title="00000031 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInvestmentInAssociateAbstract" xlink:label="loc_ptgefDisclosureInvestmentInAssociateAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfInvestmentAssociatetableTextBlock" xlink:label="loc_ptgefDisclosureOfInvestmentAssociatetableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentInAssociateAbstract" xlink:to="loc_ptgefDisclosureOfInvestmentAssociatetableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock" xlink:label="loc_ptgefScheduleOfInvestmentInStimunitySaTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentInAssociateAbstract" xlink:to="loc_ptgefScheduleOfInvestmentInStimunitySaTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillTables" xlink:title="00000032 - Disclosure - GOODWILL (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_GoodwilAbstract" xlink:label="loc_ptgefGoodwilAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ptgefDisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwilAbstract" xlink:to="loc_ptgefDisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:title="00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:label="loc_ptgefDisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" xlink:label="loc_ptgefScheduleOfInProcessResearchAndDevelopmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ptgefScheduleOfInProcessResearchAndDevelopmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:title="00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureUnsecuredNotesPayableAbstract" xlink:label="loc_ptgefDisclosureUnsecuredNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfNotesPayableTableTextBlock" xlink:label="loc_ptgefScheduleOfNotesPayableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureUnsecuredNotesPayableAbstract" xlink:to="loc_ptgefScheduleOfNotesPayableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="00000035 - Disclosure - WARRANT LIABILITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:label="loc_ptgefScheduleOfWarrantLiabilityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ptgefScheduleOfWarrantLiabilityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockTables" xlink:title="00000036 - Disclosure - CAPITAL STOCK (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureCapitalStockAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" xlink:label="loc_ptgefCommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAbstract" xlink:to="loc_ptgefCommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="00000037 - Disclosure - STOCK OPTION RESERVE (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ShareBasedPaymentAbstract" xlink:label="loc_ptgefShareBasedPaymentAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfTermsStockOptionReserveExplanatory" xlink:label="loc_ptgefDisclosureOfTermsStockOptionReserveExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefShareBasedPaymentAbstract" xlink:to="loc_ptgefDisclosureOfTermsStockOptionReserveExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" xlink:label="loc_ptgefDisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefShareBasedPaymentAbstract" xlink:to="loc_ptgefDisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefShareBasedPaymentAbstract" xlink:to="loc_ifrs-fullDisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="00000038 - Disclosure - (LOSS) PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_EarningsPerShareTableTextBlock" xlink:label="loc_ptgefEarningsPerShareTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefEarningsPerShareTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock" xlink:label="loc_ptgefScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="00000039 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:label="loc_ptgefDisclosureOfFinancialAssetsAndFinancialLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ptgefDisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="00000040 - Disclosure - NON-CONTROLLING INTEREST (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NonControllingInterestAbstract" xlink:label="loc_ptgefNonControllingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:label="loc_ptgefScheduleOfNoncontrollingInterestTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNonControllingInterestAbstract" xlink:to="loc_ptgefScheduleOfNoncontrollingInterestTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:title="00000041 - Disclosure - NATURE OF OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NatureOfOperationsAbstract" xlink:label="loc_ptgefNatureOfOperationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNatureOfOperationsAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxGroupPlcMember" xlink:label="loc_ptgefSalvaRxGroupPlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxGroupPlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuanceAndSales" xlink:label="loc_ptgefIssuanceAndSales" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuanceAndSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_MaximumAggregateOfferingPrice" xlink:label="loc_ptgefMaximumAggregateOfferingPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefMaximumAggregateOfferingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CashFundDescription" xlink:label="loc_ptgefCashFundDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCashFundDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:title="00000042 - Disclosure - LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureLiquidityAbstract" xlink:label="loc_ptgefDisclosureLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-fullCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLiquidityAbstract" xlink:to="loc_ifrs-fullCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLiquidityAbstract" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLiquidityAbstract" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLiquidityAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOnHand" xlink:label="loc_ifrs-fullCashOnHand" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLiquidityAbstract" xlink:to="loc_ifrs-fullCashOnHand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_OfferingAndThroughThatProcessDescription" xlink:label="loc_ptgefOfferingAndThroughThatProcessDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureLiquidityAbstract" xlink:to="loc_ptgefOfferingAndThroughThatProcessDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000043 - Disclosure - BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BasisOfPresentationAbstract" xlink:label="loc_ptgefBasisOfPresentationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefBasisOfPresentationAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SubsidiariesOneMember" xlink:label="loc_ptgefSubsidiariesOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSubsidiariesOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SubsidiariesTwoMember" xlink:label="loc_ptgefSubsidiariesTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSubsidiariesTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PortageGlasgowLtdMember" xlink:label="loc_ptgefPortageGlasgowLtdMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefPortageGlasgowLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SubsidiariesThreeMember" xlink:label="loc_ptgefSubsidiariesThreeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSubsidiariesThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SubsidiariesMember" xlink:label="loc_ifrs-fullSubsidiariesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ifrs-fullSubsidiariesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="00000044 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PrepaidExpensesAndOtherReceivableAbstract" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="loc_ifrs-fullCurrentAdvancesToSuppliers" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" xlink:to="loc_ifrs-fullCurrentAdvancesToSuppliers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ResearchAndDevelopmentCredit" xlink:label="loc_ptgefResearchAndDevelopmentCredit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" xlink:to="loc_ptgefResearchAndDevelopmentCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-fullCurrentPrepaidExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" xlink:to="loc_ifrs-fullCurrentPrepaidExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" xlink:to="loc_ifrs-fullOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepayments" xlink:label="loc_ifrs-fullCurrentPrepayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" xlink:to="loc_ifrs-fullCurrentPrepayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:title="00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PrepaidExpensesAndOtherReceivableAbstract" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivableAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PPLSettlementMember" xlink:label="loc_ptgefPPLSettlementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefPPLSettlementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Accruals" xlink:label="loc_ifrs-fullAccruals" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LoansPayableInDefault" xlink:label="loc_ifrs-fullLoansPayableInDefault" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullLoansPayableInDefault" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-fullTradeAndOtherReceivables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="loc_ifrs-fullCurrentPortionOfLongtermBorrowings" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentPortionOfLongtermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PrepaidExpensesAndOtherReceivables" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetails" xlink:title="00000046 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentInBiohavenAbstract" xlink:label="loc_ptgefInvestmentInBiohavenAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentAssetAvailableForSale" xlink:label="loc_ptgefInvestmentAssetAvailableForSale" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInBiohavenAbstract" xlink:to="loc_ptgefInvestmentAssetAvailableForSale" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedLossGainOnInvestment" xlink:label="loc_ptgefUnrealizedLossGainOnInvestment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInBiohavenAbstract" xlink:to="loc_ptgefUnrealizedLossGainOnInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentAssetAvailableForSale" xlink:label="loc_ptgefInvestmentAssetAvailableForSale_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInBiohavenAbstract" xlink:to="loc_ptgefInvestmentAssetAvailableForSale_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative" xlink:title="00000047 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentInBiohavenAbstract" xlink:label="loc_ptgefInvestmentInBiohavenAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" xlink:label="loc_ifrs-fullDisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInBiohavenAbstract" xlink:to="loc_ifrs-fullDisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypeOfMeasurementOfExpectedCreditLossesAxis" xlink:label="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable" xlink:to="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypeOfMeasurementOfExpectedCreditLossesMember" xlink:label="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesAxis" xlink:to="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BiohavenMember" xlink:label="loc_ptgefBiohavenMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypeOfMeasurementOfExpectedCreditLossesMember" xlink:to="loc_ptgefBiohavenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentInMarketableEquitySecurities" xlink:label="loc_ptgefInvestmentInMarketableEquitySecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInvestmentInMarketableEquitySecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-fullProceedsFromIssuingShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromIssuingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedGains" xlink:label="loc_ptgefUnrealizedGains" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnrealizedGains" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:title="00000048 - Disclosure - INVESTMENT IN ASSOCIATE  (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInvestmentInAssociateAbstract" xlink:label="loc_ptgefDisclosureInvestmentInAssociateAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentInAssociateAbstract" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StimunitySAMember" xlink:label="loc_ptgefStimunitySAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:to="loc_ptgefStimunitySAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NameOfAssociate" xlink:label="loc_ifrs-fullNameOfAssociate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNameOfAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:label="loc_ifrs-fullPrincipalPlaceOfBusinessOfAssociate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPrincipalPlaceOfBusinessOfAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:label="loc_ifrs-fullCountryOfIncorporationOrResidenceOfAssociate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCountryOfIncorporationOrResidenceOfAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:title="00000049 - Disclosure - INVESTMENT IN ASSOCIATE  (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInvestmentInAssociateAbstract" xlink:label="loc_ptgefDisclosureInvestmentInAssociateAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentInAssociateAbstract" xlink:to="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AdditionalInvestments" xlink:label="loc_ptgefAdditionalInvestments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentInAssociateAbstract" xlink:to="loc_ptgefAdditionalInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrecognisedShareOfGainLossesOfAssociates" xlink:label="loc_ptgefUnrecognisedShareOfGainLossesOfAssociates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentInAssociateAbstract" xlink:to="loc_ptgefUnrecognisedShareOfGainLossesOfAssociates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentInAssociateAbstract" xlink:to="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:title="00000050 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInvestmentInAssociateAbstract" xlink:label="loc_ptgefDisclosureInvestmentInAssociateAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentInAssociateAbstract" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StimunitySAMember" xlink:label="loc_ptgefStimunitySAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:to="loc_ptgefStimunitySAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AdditionalInvestments" xlink:label="loc_ptgefAdditionalInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_EquityInLossIncome" xlink:label="loc_ptgefEquityInLossIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefEquityInLossIncome" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/DispositionOfPplDetailsNarrative" xlink:title="00000051 - Disclosure - DISPOSITION OF PPL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureDispositionOfPplAbstract" xlink:label="loc_ptgefDisclosureDispositionOfPplAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable" xlink:label="loc_deiEntitiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureDispositionOfPplAbstract" xlink:to="loc_deiEntitiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntitiesTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntitiesTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PortageGlasgowLtdMember" xlink:label="loc_ptgefPortageGlasgowLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ptgefPortageGlasgowLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DispositionPercentage" xlink:label="loc_ptgefDispositionPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ptgefDispositionPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DispositionValue" xlink:label="loc_ptgefDispositionValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ptgefDispositionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IntercompanyReceivable" xlink:label="loc_ptgefIntercompanyReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ptgefIntercompanyReceivable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative" xlink:title="00000052 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract" xlink:label="loc_ptgefDisclosureInvestmentsInPrivateCompaniesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentsInPrivateCompaniesAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember" xlink:label="loc_ptgefSeriesAPreferredStockInSentienBiotechnologiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefSeriesAPreferredStockInSentienBiotechnologiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IntensityMember" xlink:label="loc_ptgefIntensityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIntensityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-fullBusinessCombinationsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullBusinessCombinationsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullBusinessCombinationsAxis" xlink:to="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AcquisitionOfSalvaRxMember" xlink:label="loc_ptgefAcquisitionOfSalvaRxMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" xlink:to="loc_ptgefAcquisitionOfSalvaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AcquisitionOfIntensityHoldingLimitedMember" xlink:label="loc_ptgefAcquisitionOfIntensityHoldingLimitedMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" xlink:to="loc_ptgefAcquisitionOfIntensityHoldingLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentOwnedShares" xlink:label="loc_ptgefInvestmentOwnedShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInvestmentOwnedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InvestmentOwnershipPercentage" xlink:label="loc_ptgefInvestmentOwnershipPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnrealizedGainLossOnInvestment" xlink:label="loc_ptgefUnrealizedGainLossOnInvestment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnrealizedGainLossOnInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-fullEquityInterestsOfAcquirer" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquityInterestsOfAcquirer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" xlink:label="loc_ptgefNumberOfPrivateCompanyShareConsistsInSoleAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfPrivateCompanyShareConsistsInSoleAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetails" xlink:title="00000053 - Disclosure - GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_GoodwilAbstract" xlink:label="loc_ptgefGoodwilAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-fullGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwilAbstract" xlink:to="loc_ifrs-fullGoodwill" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:title="00000054 - Disclosure - GOODWILL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_GoodwilAbstract" xlink:label="loc_ptgefGoodwilAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="loc_ifrs-fullDescriptionOfDiscountRatesAppliedToCashFlowProjections" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwilAbstract" xlink:to="loc_ifrs-fullDescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:title="00000055 - Disclosure - IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:label="loc_ptgefDisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IMM60IOXMelanomaLungCancersMember" xlink:label="loc_ptgefIMM60IOXMelanomaLungCancersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIMM60IOXMelanomaLungCancersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IMM65IOXOvarianProstateCancersMember" xlink:label="loc_ptgefIMM65IOXOvarianProstateCancersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIMM65IOXOvarianProstateCancersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_OncomerSaugatuckDNAAptamersMember" xlink:label="loc_ptgefOncomerSaugatuckDNAAptamersMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefOncomerSaugatuckDNAAptamersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_InprocessResearchAndDevelopment" xlink:label="loc_ptgefInprocessResearchAndDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInprocessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-fullDeferredTaxLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeferredTaxLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:title="00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:label="loc_ptgefDisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncome" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ifrs-fullDeferredTaxExpenseIncome" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:title="00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureUnsecuredNotesPayableAbstract" xlink:label="loc_ptgefDisclosureUnsecuredNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureUnsecuredNotesPayableAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PplMember" xlink:label="loc_ptgefPplMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefPplMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IoxMember" xlink:label="loc_ptgefIoxMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIoxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NotePayable" xlink:label="loc_ptgefNotePayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNotePayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RepaymentOfNotesPayable" xlink:label="loc_ptgefRepaymentOfNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRepaymentOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AmortizationOfDebtDiscount" xlink:label="loc_ptgefAmortizationOfDebtDiscount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAmortizationOfDebtDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ValueOfNotesExchangedInWarrantExercise" xlink:label="loc_ptgefValueOfNotesExchangedInWarrantExercise" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefValueOfNotesExchangedInWarrantExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SettlementInConnectionWithDispositionOfPpl" xlink:label="loc_ptgefSettlementInConnectionWithDispositionOfPpl" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSettlementInConnectionWithDispositionOfPpl" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_LossOnExtinguishmentOfDebt" xlink:label="loc_ptgefLossOnExtinguishmentOfDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ProceedsFromLoanPayable" xlink:label="loc_ptgefProceedsFromLoanPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefProceedsFromLoanPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NotePayable" xlink:label="loc_ptgefNotePayable_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNotePayable_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:title="00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureUnsecuredNotesPayableAbstract" xlink:label="loc_ptgefDisclosureUnsecuredNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureUnsecuredNotesPayableAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IoxMember" xlink:label="loc_ptgefIoxMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIoxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PortageMember" xlink:label="loc_ptgefPortageMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefPortageMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AggregatePrincipalAmountOfUnsecuredNotes" xlink:label="loc_ptgefAggregatePrincipalAmountOfUnsecuredNotes" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregatePrincipalAmountOfUnsecuredNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_UnsecuredNotesInterest" xlink:label="loc_ptgefUnsecuredNotesInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnsecuredNotesInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IssuanceOfUnsecuredNotesDescription" xlink:label="loc_ptgefIssuanceOfUnsecuredNotesDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuanceOfUnsecuredNotesDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-fullFinancialLiabilitiesAtFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullFinancialLiabilitiesAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PaymentForSettlement" xlink:label="loc_ptgefPaymentForSettlement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPaymentForSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsExercised" xlink:label="loc_ptgefWarrantsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ExercisePrice" xlink:label="loc_ptgefExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ContractualValueOfWarrantsExercisedDescription" xlink:label="loc_ptgefContractualValueOfWarrantsExercisedDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefContractualValueOfWarrantsExercisedDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesReceived" xlink:label="loc_ptgefSharesReceived" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfExerciseOfWarrantsIssued" xlink:label="loc_ptgefNumberOfExerciseOfWarrantsIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfExerciseOfWarrantsIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfExerciseOfWarrantsOutstanding" xlink:label="loc_ptgefNumberOfExerciseOfWarrantsOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfExerciseOfWarrantsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_LossOnExtinguishmentOfDebt" xlink:label="loc_ptgefLossOnExtinguishmentOfDebt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DescriptionOfBusinessCombination" xlink:label="loc_ptgefDescriptionOfBusinessCombination" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDescriptionOfBusinessCombination" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="loc_ifrs-fullIssueOfConvertibleInstruments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIssueOfConvertibleInstruments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="00000059 - Disclosure - WARRANT LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxGroupPlcMember" xlink:label="loc_ptgefSalvaRxGroupPlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxGroupPlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingExercisePrice" xlink:label="loc_ptgefWarrantsOutstandingExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsOutstandingExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingShares" xlink:label="loc_ptgefWarrantsOutstandingShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsOutstandingShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingAmount" xlink:label="loc_ptgefWarrantsOutstandingAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsOutstandingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueAdjustmentExercisePriceAtEnd" xlink:label="loc_ptgefFairValueAdjustmentExercisePriceAtEnd" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueAdjustmentExercisePriceAtEnd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueAdjustmentShares" xlink:label="loc_ptgefFairValueAdjustmentShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueAdjustmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueAdjustment" xlink:label="loc_ptgefFairValueAdjustment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingExercisePrice" xlink:label="loc_ptgefWarrantsOutstandingExercisePrice_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsOutstandingExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingShares" xlink:label="loc_ptgefWarrantsOutstandingShares_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsOutstandingShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsOutstandingAmount" xlink:label="loc_ptgefWarrantsOutstandingAmount_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsOutstandingAmount_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetails" xlink:title="00000060 - Disclosure - CAPITAL STOCK (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureCapitalStockAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommonStockShares" xlink:label="loc_ptgefCommonStockShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAbstract" xlink:to="loc_ptgefCommonStockShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommonStockValues" xlink:label="loc_ptgefCommonStockValues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAbstract" xlink:to="loc_ptgefCommonStockValues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostsShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAbstract" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAbstract" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedForServicesShares" xlink:label="loc_ptgefSharesIssuedForServicesShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAbstract" xlink:to="loc_ptgefSharesIssuedForServicesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedForService" xlink:label="loc_ptgefSharesIssuedForService" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAbstract" xlink:to="loc_ptgefSharesIssuedForService" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommonStockShares" xlink:label="loc_ptgefCommonStockShares_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAbstract" xlink:to="loc_ptgefCommonStockShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommonStockValues" xlink:label="loc_ptgefCommonStockValues_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAbstract" xlink:to="loc_ptgefCommonStockValues_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:title="00000061 - Disclosure - CAPITAL STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureCapitalStockAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AccreditedInvestorsMember" xlink:label="loc_ptgefAccreditedInvestorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DirectorsMember" xlink:label="loc_ptgefDirectorsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostsShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PricePerShare" xlink:label="loc_ptgefPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_OfferingExpenses" xlink:label="loc_ptgefOfferingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PublicofferingDescription" xlink:label="loc_ptgefPublicofferingDescription" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPublicofferingDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="00000062 - Disclosure - STOCK OPTION RESERVE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ShareBasedPaymentAbstract" xlink:label="loc_ptgefShareBasedPaymentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefShareBasedPaymentAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ptgefStockOptionReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionReserve" xlink:label="loc_ptgefStockOptionReserve" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockOptionReserve" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionReserve" xlink:label="loc_ptgefStockOptionReserve_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockOptionReserve_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="00000063 - Disclosure - STOCK OPTION RESERVE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ShareBasedPaymentAbstract" xlink:label="loc_ptgefShareBasedPaymentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefShareBasedPaymentAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PBI2013OptionPlanMember" xlink:label="loc_ptgefPBI2013OptionPlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2013OptionPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IOxOptionPlanMember" xlink:label="loc_ptgefIOxOptionPlanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefIOxOptionPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption_3" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption_3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="00000064 - Disclosure - STOCK OPTION RESERVE (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ShareBasedPaymentAbstract" xlink:label="loc_ptgefShareBasedPaymentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefShareBasedPaymentAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PBI2013OptionPlanMember" xlink:label="loc_ptgefPBI2013OptionPlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2013OptionPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IOxOptionPlanMember" xlink:label="loc_ptgefIOxOptionPlanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefIOxOptionPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="00000065 - Disclosure - STOCK OPTION RESERVE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ShareBasedPaymentAbstract" xlink:label="loc_ptgefShareBasedPaymentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefShareBasedPaymentAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_N2021EquityIncentivePlanMember" xlink:label="loc_ptgefN2021EquityIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefN2021EquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_Equity2021IncentivePlanMember" xlink:label="loc_ptgefEquity2021IncentivePlanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefEquity2021IncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BoardOfDirectorsMember" xlink:label="loc_ptgefBoardOfDirectorsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefBoardOfDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_ConsultantsMember" xlink:label="loc_ptgefConsultantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionsIssued" xlink:label="loc_ptgefStockOptionsIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockOptionsIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockGranted" xlink:label="loc_ptgefStockGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValuePerShare" xlink:label="loc_ptgefFairValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CommunicationExpense" xlink:label="loc_ifrs-fullCommunicationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCommunicationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="00000066 - Disclosure - (LOSS) PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NumeratorAbstract" xlink:label="loc_ptgefNumeratorAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefNumeratorAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNumeratorAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DenominatorAbstract" xlink:label="loc_ptgefDenominatorAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefDenominatorAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-fullWeightedAverageShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDenominatorAbstract" xlink:to="loc_ifrs-fullWeightedAverageShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_BasicAndDilutedLossPerShare" xlink:label="loc_ptgefBasicAndDilutedLossPerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDenominatorAbstract" xlink:to="loc_ptgefBasicAndDilutedLossPerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="00000067 - Disclosure - (LOSS) PER SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockOptionsMember" xlink:label="loc_ptgefStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantsMember" xlink:label="loc_ptgefWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AntidilutiveEffectOnLossPerShar" xlink:label="loc_ptgefAntidilutiveEffectOnLossPerShar" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAntidilutiveEffectOnLossPerShar" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000068 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommitmentsAndContingenciesAbstract" xlink:label="loc_ptgefCommitmentsAndContingenciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCommitmentsAndContingenciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StimunitySAMember" xlink:label="loc_ptgefStimunitySAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefStimunitySAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_CommitmentToInvestment" xlink:label="loc_ptgefCommitmentToInvestment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCommitmentToInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DiscretionaryInvestment" xlink:label="loc_ptgefDiscretionaryInvestment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDiscretionaryInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AdditionalDiscretionaryInvestment" xlink:label="loc_ptgefAdditionalDiscretionaryInvestment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalDiscretionaryInvestment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="loc_ifrs-fullRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestCostsIncurred" xlink:label="loc_ifrs-fullInterestCostsIncurred" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRelatedPartyTransactionsAbstract" xlink:to="loc_ifrs-fullInterestCostsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany" xlink:label="loc_ptgefRepaymentsOfAdvanceToBoardMemberOfCompany" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRelatedPartyTransactionsAbstract" xlink:to="loc_ptgefRepaymentsOfAdvanceToBoardMemberOfCompany" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="00000070 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AmortizedCostMember" xlink:label="loc_ptgefAmortizedCostMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefAmortizedCostMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="loc_ptgefFairValueToOtherComprehensiveIncomeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefFairValueToOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PrepaidExpensesAndOtherReceivables" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentInvestments" xlink:label="loc_ifrs-fullCurrentInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentPayables" xlink:label="loc_ifrs-fullNoncurrentPayables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncurrentPayables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_WarrantLiability" xlink:label="loc_ptgefWarrantLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:title="00000071 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_FairValueMarketPricePerShare" xlink:label="loc_ptgefFairValueMarketPricePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ptgefFairValueMarketPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:title="00000072 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureCapitalDisclosuresAbstract" xlink:label="loc_ptgefDisclosureCapitalDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PayablesAndAccruedExpense" xlink:label="loc_ptgefPayablesAndAccruedExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalDisclosuresAbstract" xlink:to="loc_ptgefPayablesAndAccruedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalDisclosuresAbstract" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalDisclosuresAbstract" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="00000073 - Disclosure - NON-CONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NonControllingInterestAbstract" xlink:label="loc_ptgefNonControllingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNonControllingInterestAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_PglMember" xlink:label="loc_ptgefPglMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefPglMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IoxMember" xlink:label="loc_ptgefIoxMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIoxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSaugatuckMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_StockBasedCompensationExpense" xlink:label="loc_ptgefStockBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="loc_ptgefNetLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" xlink:title="00000074 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_DisclosureEventsAfterBalanceSheetDateAbstract" xlink:label="loc_ptgefDisclosureEventsAfterBalanceSheetDateAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureEventsAfterBalanceSheetDateAbstract" xlink:to="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-fullNonadjustingEventsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_EventsAfterTheBalanceSheetDateMember" xlink:label="loc_ptgefEventsAfterTheBalanceSheetDateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNonadjustingEventsMember" xlink:to="loc_ptgefEventsAfterTheBalanceSheetDateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ptgefSalvaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20210630.xsd#ptgef_RepaymentOfInstallmentNoteReceivable" xlink:label="loc_ptgefRepaymentOfInstallmentNoteReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRepaymentOfInstallmentNoteReceivable" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>pipe.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pipe.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &O R$# 2(  A$! Q$!_\0
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M&G6(6Y,DUA#=,ZM%"SGY2 6"$GC<O/%=%#X*O/#>M>&-0\!?"[Q1X8U>RU&
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M\-%?#K_H:+7_ +]R?_$T\?M!_#UH6E'B:V,:L%9MDG!.2!]WV/Y5\!U?A_Y
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M"^B601E-VUB595<;3U!7/I0%C[2_X:*^'7_0T6O_ '[D_P#B:/\ AHKX=?\
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MJ:+##:Z-H^F:5IUOL\FRC$CHN)"[Y+,2V_)!R>F,8KZ1_P"&3?A]_P ^M_\
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M%O;0WDD"R)Y%P6".KHR,#M(/1CT-?8/_  R;\/O^?6__ / QJ/\ ADWX??\
M/K?_ /@8U 7/FK2_C9>:&\,&FZ#I>FZ1'',ATVT:5 S2J%:3S=_F!\* &#<#
M(K3D_:+U6:^CNI=!TQY8B?*823JT0,(A<*V_()55^;.01D&OH+_ADWX??\^M
M_P#^!C4?\,F_#[_GUO\ _P #&H$?(WCWQM<?$#5+>^NK2&R:"TCLUC@=W!1,
M[26<EB?FY)/-;MK\9]5M?$6H:PMA9-/>2V<SQG?M4VV-@'.<''/Z5].?\,F_
M#[_GUO\ _P #&H_X9-^'W_/K?_\ @8U [GRUH?Q7U+09M'EALK21M+CO(XA)
MNPXN7+N6P>Q/&/QJU'\9M57Q)I^L"TMH;BS6ZC0Q;N!<2,[L,G[RECM[<#.:
M^F_^&3?A]_SZW_\ X&-1_P ,F_#[_GUO_P#P,:@+GSW\4_B!X:U[PN--T*%3
M<W>J-JEW.EHUOEO+*_.&=@7)8D[,*.W6O**^V_\ ADWX??\ /K?_ /@8U'_#
M)OP^_P"?6_\ _ QJ!7/B2BOMO_ADWX??\^M__P"!C4?\,F_#[_GUO_\ P,:@
M=SXDHK[;_P"&3?A]_P ^M_\ ^!C4?\,F_#[_ )];_P#\#&H"Y!^R'_R2,_\
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MG_0S^'?_ "8_^-T?\, ^-/\ H9_#O_DQ_P#&Z^O_ +8P'_/U?B?GW^K^:?\
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ME:@Z<<#RR[KE77RMTT/ENBOIS_A@'QI_T,_AW_R8_P#C='_# /C3_H9_#O\
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M,:$R#8",Y/)YZ@\TO@?X9:M\,? Y\.>$[K0=*)3!OY+2>:5Y",&5QO&YN_4
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M_?\ T-'VZ#^_^AH L457^W0?W_T-'VZ#^_\ H: +%,F_U,G^Z?Y5%]N@_O\
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M6J6X@XN>!^\0_P +YSGU%><J6.BZ;3?2^JWOKIUT^[=79SJGBER:OI?7SU_
MBD^*&J)\']-\5BVM?[0N7B5XMK>4-TVPX&<]/?K5>3QUXXU#5_$_]C6&BW6G
MZ)=M 8+AI4N)@%#?*02N<'O45K\&]<6ULO#]SXBAF\'V=TMPEJMKBY95?>L;
M/G&W/?&:LS?#/Q9#K'B)M,\2V>FZ9K5TT\P%D9+A 5"D*Q; .!Z4G]>DHN2D
MK))V<;W2=WO:S=O\A?[2^6Z?1.UKWL[OTO8=XD^,%Q_PA.A:IX;T_P"VZKK
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M=XPNX9_&OF^O7_@[\8-%\!>&WT36;.ZOK"_U5I-3MX4!6:Q>T:%T&6&7W%6
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MQ%$'4LP!ZL<?@2 >;T'0O#O[)O@V^\<>.;TZ]X_U<L\]PS!I[B8CBW@ST49
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M[?Y6)J***\D]X**** "BBB@ HHHH *9-_J7_ -T_RI],F_U,G^Z?Y4 -MO\
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M>P^E?2FK?LV_##7-0FO;WP3I,MS,V]W6$H&/KA2!G\*IG]E?X3'KX%TL_P#
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MXZ?H?6_ES_\ /9?^^/\ Z]'ES_\ /9?^^/\ Z]?/7AOPOI]K\*?&FMQ"8:E
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M_P"^/_KU-17FGL$/ES_\]E_[X_\ KT>7/_SV7_OC_P"O4U% $/ES_P#/9?\
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M?/\ 4?RJ:@ HHHH @OO^/27Z5/5;4-WV&?9C?M.-W3/O5/=KG]W3_P#OI_\
M"@#5HK*W:W_=T_\ [Z?_  HW:W_=T_\ [Z?_  H U:*RMVM_W=/_ .^G_P *
M-VM_W=/_ .^G_P * -6BLK=K?]W3_P#OI_\ "C=K?]W3_P#OI_\ "@"_=?ZL
M?[Z_^A"IJQ;@ZUY8W+I^-R_Q2>H]J;]OU,3>49=*\W=L\OS6W;L9QC'7'./2
M@#<HK$6^U1IO)$NEF;)'EB5MV0 2,8]"#^(JE)XH>)F5]4T%&4X96N\$=N:
M.HHK(636I%#*-.96&0P=R"/RIV[6_P"[I_\ WT_^% &K165NUO\ NZ?_ -]/
M_A4?VC5S,80=-\T*',?F/N"DX!QCID'\J -FBLG?K>XC;I^1VW/_ (4N[6_[
MNG_]]/\ X4 :M0-_Q^1?[C?S6J.[6_[NG_\ ?3_X5$QUK[5'\NG[MC8^9_5?
M:@#R0? _Q';Z:'L]0L;36;>&)+2Z#.0A\^Y,N?EZ&&XP/]H>V:M7'P+U".2Z
M6QGL[:*'[5)IK%F+0RG[,ULQ^7LUN=V.QXSFO5MVM_W=/_[Z?_"C=K?]W3_^
M^G_PH \?D^!.IP:Q8ZO)!I6MSVR0M-97SLL5W,R3"X=CL.#OE#+D'..<<58L
M?@WXCTW1;C0TNK"XL-6AM$O[B220/:^4Y++$NT[UV;47)!&,GTKUC=K?]W3_
M /OI_P#"C=K?]W3_ /OI_P#"@#$\<?##1_'MUIMS?HWG6<Z2%E9OWD:[LQ\,
M,9+=>O%5_&7A'4)M4\/:GHMM8WCZ3%/;BPU&1DC9)$5=P<*V&7:!R#D,PKH]
MVM_W=/\ ^^G_ ,*-VM_W=/\ ^^G_ ,* /')?@/K4MU<1R36+6]U+#=LUM<2P
M0V\D<(0(EN%P0"HVDL, G(/0];X;^&>HZ9X4\3:5=3VOFZI806D3QEF562QC
MMV+9 XWH2/;'TKMMVM_W=/\ ^^G_ ,*-VM_W=/\ ^^G_ ,* /-(?A+J]YI>I
M_:X]-MM0O+G2I5:&1G\I;41!\.4!S\C%>/XN<<UA6?P U86,=G=26DR6D<=M
M')->2RK<1BZBE?,90+&"L9^7YLL>H'->T;M;_NZ?_P!]/_A1NUO^[I__ 'T_
M^% 'D?C;X8>([K7-1U.(VITR&XDO8HK>4QDQ_9&BV"%8\-+DGYRQR, 8K#OO
M!VMVO@G2=:N+.STS6+#2;.ST6WTV*262:\5EDC,B[!L'!0J<@;Y,FO>-VM_W
M=/\ ^^G_ ,*-VM_W=/\ ^^G_ ,* (?!?AU?"?A?3M+#;Y((OWLG_ #TE8EI'
M_%RQ_&MNLK=K?]W3_P#OI_\ "C=K?]W3_P#OI_\ "@#5HK*W:W_=T_\ [Z?_
M  HW:W_=T_\ [Z?_  H U:*RMVM_W=/_ .^G_P *-VM_W=/_ .^G_P * ,/X
MO>$YO'GPW\0>'+:017.IV<MO$[' #E"5S[$@#\:_)K7-'O\ PSJEUI>KVDNF
MZE;.8YK:Y7:R,/8]1[]#7Z^3'6O,@RMA]_CYG_NGVKD?%UQX?N+Y8_$=OX5O
M+N,8 OH?/=/;E3BOI<GS.>!YJ:IN:>NFY\9Q#DM+,^2M*JJ;CI=[-?>CXRT7
M]HWPEX;T> VZZWJL$4%NMOX1U58I["QN8V0F>"Y=FD7!4LJ@#!;'08I^G_M#
M^#/#L.J6EE+X@U:#5+ZZU66XU*.,26\LK1XA0"0Y7",6?(R0ORU]6;/AY_T"
M?!'_ (+U_P#C=&SX>?\ 0)\$?^"]?_C=>E];IN]\-/7^NW_!?6YXJR^LK)8R
MGI_7\WX;+HD?*%Q^T)X-U/4Y]9N)M>L[ZWL=7TRUTZWCC:UN([N29XY9#Y@V
ML/-&Y0&R5!!XKR7X<>/+#P;HOBVVNEDFGU2PM[>V\K&T/'<QS'>2> 50C(SR
M17Z$[?AW_P! GP/_ ."]?_C=&WX=]/[)\#Y_[!Z__&ZWIYC&G%Q6&G9V_!W[
M=SFJY/.K*,Y8RG=7_%6?7L?*M]^T'X%T^+Q5-HLFO/?>(;^_U20W$$48MI;B
MTDA6-"LA)"O)RW'';CFOX)_:>T?PSK"75ZNJWL \,Z;HFQ9%W)+"NV:5"6X(
MW,R-U)QG&:^LMOP[Z?V3X'S_ -@]?_C=&WX=_P#0)\#_ /@O7_XW6'UNDXN+
MPTW?^NQU?V?74E..-IJW]?S'QCKWQL\/67PEO/ WA^]UN[Q;1PP:M?A(99LW
M?GRHP5V*1A< #)R2V<9J#XU?&;PU\1O">GVMDE]/K:WBW,]Y>11P%4$(C*.8
MWVSOD<2E$.T 8K[5\OX>?] CP1_X+U_^-T;/AXO/]D^" ?\ L'K_ /&ZUAF$
M(24UAIW3;^;M?IY&%3*9U(.G+&4[-*/HE>UO>\]_U/E_]A?X;ZOJWQ)/C'[/
M)!H>E6TT8N74A)YI$*!$/\6 23CI@>M?H#;?\>\7^X/Y5P%O\1-*L[5;:VU/
M0X($7:D47F*JCT "\5)%\3K%(D7^V-'X4#[\O_Q->!F-3$YA7]LZ371*SV^X
M^LRBE@LIPJP\:\9.]V[K=_/R/0**X'_A:5A_T&=%_P"^Y?\ XFE_X6A8_P#0
M8T;_ +[E_P#B:\SZKB/^?;^YGL_7L)_S]C_X$O\ ,[VBN"_X6A8_]!C1O^^Y
M?_B:/^%H6/\ T&-&_P"^Y?\ XFCZKB/^?;^YC^O87_G['_P)?YG>T5P2_$^Q
M9@!K&C9/^W+_ /$T7'Q2TJSD$<_B?PO!(3@+)J 4D], $\U+P]9;P?W,I8S#
M2VJ1^]'>T5P<WQ0TRWC+S>)/#4,8X+R7VU?S-+'\3M-EC$D?B/PW)&1D.M[E
M2/7(XQ4^QJ;\K^XOZQ1O;G7WH[NH(?\ CXN/JO\ *N(@^*FDW2DP>)O#%P%.
M"8;\.!]<5'%\4M(^V30KXG\,&XXS$+_YQ@?W>M'L:O\ *_N%]9H;\Z^]'H5%
M<#-\5-)MV19O$_A>%G^ZLE^%+?0$\TZ;XH:9;QEYO$GAJ&,<%Y+[:OYFCV-7
M^5_<'UFAK[ZT\T=Y17"1_$[398Q(GB/PV\9&0ZWN5(]<],4R#XJ:3=*3!XF\
M,7"J<$PWX<#\J/8U?Y7]P_K-#^=?>COJ*X%?BII+3F >)_"[3CK"+\%Q]5SF
MB;XJ:3;LBS>)_"\+/]U9+\*6^@)YH]C5VY7]POK-"U^=?>COJ*X.;XH:9;QF
M2;Q)X:AC'!>2^VK^9I8_B=ILT8DC\1^&Y(R,AUO<J1ZYZ8H]C4WY7]P_K%&]
MN=?>CNZAN/OP?[_]#7'Z3\1++7KA8--\0>&]0F9MH2VOO,);L.._M6Y,=:W1
M973_ +_'S2>A]JB4)0=I*QI"I"HKP::\C:HK*W:W_=T__OI_\*-VM_W=/_[Z
M?_"H-#5HK*W:W_=T_P#[Z?\ PHW:W_=T_P#[Z?\ PH U:*RMVM_W=/\ ^^G_
M ,*-VM_W=/\ ^^G_ ,* -6BLK=K?]W3_ /OI_P#"C=K?]W3_ /OI_P#"@#5I
MDW^ID_W3_*LW=K?]W3_^^G_PIDAUORWRNGXP?XG_ ,* -.V_X]XO]P?RJ6L:
M ZUY$>%T_&T8^9_3Z5)NUO\ NZ?_ -]/_A0!JT5E;M;_ +NG_P#?3_X4;M;_
M +NG_P#?3_X4 :M%96[6_P"[I_\ WT_^%&[6_P"[I_\ WT_^% &K165NUO\
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M "[Z_@6\MK[K":^L?\^VGX[GG7C30;?0[ZV%F&^R7, EC9I1*&Y(.&P#CCN
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MHHTO2]%_9U\-7?BGQ5=_VQXPU(GS)V;?--(?^646>0O3)^F> M:7P]^#NN^
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M<;<L::MRQBMMMY=WLMEU9HT4FX>M&X>M>"?5BT4FX>M&X>M "T4FX>M&X>M
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MD>Q-PZ$Y)SCTKTZBE+,L3)27-;FWLDOT*CDV"C*,N1OEVNVTODW8ANO]6/\
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MN*TO&/B#5-67PEJNG7>H:+IK:W:VUQI]S9M;S7&Z4*0Y;D)C/ 'S>N*['0_
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M+"L[V.EK''OD4>;( Y8G&<#K@#-;3>.-*\RW1HIY(8TV,\=O'#D&=),! 2O
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MTA_@0X&?J0!^8K%TG2]%_9U\+W/B?Q1<G6/&&I$M+,3NFGD(XBBST49&3_0
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M_P"^11]FB_YY)_WR*EHKPCZHB^S1?\\D_P"^11]FB_YY)_WR*EHH B^S1?\
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M24C+*,YV=1DU:^'WP[U+P3>7DMQXA_MA;QFEN6EL4CFFE)X=Y0Q)P/E"] ,
M8Q7=44 <EX6\*ZCX3DTS3[>_6?1+:WN!*LD8$DDSS!T8$=  7'7G(J70_ -C
MHDNMSJ(YKO4[N:Z-RT*B2/S !L#=2!C]:ZBB@#S#5/@C'J&EZ-:)K4T)TS3(
M=-!: ,DZQR(_[Q<C<K>7@IG!S6?8_L\PV;60_MQBEO=F[S'8Q121DS>:5A=<
M&)3]T@9!7C ZUZ_10!YYX'^#ECX'UI+VWN(I8;=)8[6-;**.15=L_O)0-TA
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M;]4_Z!2?^!0_PK5HH Q;B^U,QC.EJ/F7_EZ'J/:I?M^J?] I/_ H?X5?NO\
M5C_?7_T(5-0!E?;]4_Z!2?\ @4/\*/M^J?\ 0*3_ ,"A_A6K10!E?;]4_P"@
M4G_@4/\ "C[?JG_0*3_P*'^%:M% &5]OU3_H%)_X%#_"C[?JG_0*3_P*'^%:
MM% &5]OU3_H%)_X%#_"C[?JG_0*3_P "A_A6K10!E?;]4_Z!2?\ @4/\*B:^
MU/[5&?[+7.QN/M0]5]JVJ@;_ (_(O]QOYK0!1^WZI_T"D_\  H?X4?;]4_Z!
M2?\ @4/\*\9\*_%SQ#!K6GW6LW$=SX;:S1+Z7RU5K662ZGCBF.!]S]VJ-Z9!
M]:MZ7JOBK7;/X?7)\6WEH?$,;"Y2&UMR$*0,^Y,H>I4>O6@#UO[?JG_0*3_P
M*'^%'V_5/^@4G_@4/\*\XDU7QBGBY]%LO$EK?WABG:\W62_9=+0C_1F+##-*
MW&4)YR3@ "LO0?&GBC7O$ \*'6;K3;K[;/F\O+&%;Y((X$=0T>#'AW?(8#E5
M[&@#UO[?JG_0*3_P*'^%'V_5/^@4G_@4/\*\IN?CBUQ\/=,^RW<;^+[N2WM)
M8+6'S)(V>7RVD2,\$G!(!.,D9XKN_ACKEYK.BWJ:C=3W-]97LEK*+NW2">+
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M;-0W'WX/]_\ H:_H24Y3=Y.Y\;"G"FK0BDO(H?;]4_Z!2?\ @4/\*/M^J?\
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M5]OU3_H%)_X%#_"C[?JG_0*3_P "A_A6K10!E?;]4_Z!2?\ @4/\*/M^J?\
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MB3[I]/3ZT 26W_'O%_N#^52U%;?\>\7^X/Y5+0 4444 %%%% !1110 4444
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MK_\ T"+K_OBOP'^R\U_Z!ZG_ (!+_(^U^L8;^>/WHR?M$W_/:3_OLT?:)O\
MGM)_WV:UO^$)U_\ Z!%U_P!\4?\ "$Z__P! BZ_[XH_LO-?^@>I_X!+_ "#Z
MQAOYX_>C)^T3?\]I/^^S1]HF_P">TG_?9K6_X0G7_P#H$77_ 'Q1_P (3K__
M $"+K_OBC^R\U_Z!ZG_@$O\ (/K&&_GC]Z,G[1-_SVD_[[-'VB;_ )[2?]]F
MM;_A"=?_ .@1=?\ ?%'_  A.O_\ 0(NO^^*/[+S7_H'J?^ 2_P @^L8;^>/W
MHR?M$W_/:3_OLUU6CZ-%K'A4;)95U=[B06Y\QL2A%4F/KUP21]*R_P#A"M?'
M/]D77_?%6X= \40VUM%%IMTD<$QN(BL8!5R!SG\!7KY;@\9AJDY8K!U)Q<;6
MY)=6M5IHTKV?1VTM<Y<15I5(I4ZL4T[[K^K=S3U;PDBZJ\$6H26DUP9#9VN&
M8$(.=S9^7)!QUK,USP]_95G=20ZK+<S6LD<<\91D"[UR,'<<^]:,@\;2^=OT
M^9GD+GS#;)O3<,-L/5<^U4KK1?%=XMVLNF7+"Z9'EQ$!DH,+]*]_'8?#5HU'
MA\OK*4F[/DFK>Z[:*35^>W2W)HE=:\-&=2+C[2O&RMU6NJ\K[?._4V/^$9MK
M@:!<(TJ6XB5]1_>-TV;P>O\ $,BI[C2-.6XFL[>W62=GF!@FN9(K@X)V& D[
M6  _'FL7[!XQ%O+ -/NA%)%'"ZB(<K&<H/\ /6K)/C9MQ;3IG?<S)*ULA>,M
MUV-U7KVKUJ=;#Q37]GU$W:[]C?:R:C?1744[V?O2E=6LSFE"=_X\=/[UO/7Y
MNWHD5FT>*?QA8Z?OFBMGMXI9$61MQ/E;V R>I(/YU9\.S6'B*\53I+6WE>8=
MZ3R& J(V*K(2<@Y Y'O6?+H7BN;4(KTZ==K=1!%21$ (V@!?T%7I$\9R=-,D
MA7YBR0VJ(K%E*EF ZG!/)KR\+S4J\JDL'4Y?:.5O8J7-%\O+&[^'EL]M[V.B
MI:4%%58WY4K\]K/6[TWOY]BY?Z58V5H;^6%7FAL_M#VMK<R-!)ND"HP;.<=2
M0#Z5RFL7J726MS;6L^GB1"'42,8G8'&4).?K[UL6.G^,-/AMX8=.N/*@#JB/
M"K J_P!Y3GJI(S@U!JF@^*=8DC:YTJXVQKLCCCA5$1?15' KFS.-;%T+8;!U
M(-I77L?M:7ESI76EU9))_%9<S2TP[A2G>I5BUKKS=.UMO/\ #H<Y]HF_Y[2?
M]]FD^T3?\]I/^^S6O_PA.O\ _0(NO^^*3_A"]>)(&D761U^2OD/[+S7_ *!Z
MG_@$O\CU/K&&_GC]Z,K[1-_SVD_[[-'VB;_GM)_WV:UO^$)U_P#Z!%U_WQ1_
MPA.O_P#0(NO^^*/[+S7_ *!ZG_@$O\A_6,-_/'[T9/VB;_GM)_WV:/M$W_/:
M3_OLUK?\(3K_ /T"+K_OBC_A"=?_ .@1=?\ ?%']EYK_ - ]3_P"7^0?6,-_
M/'[T9/VB;_GM)_WV:/M$W_/:3_OLUK?\(3K_ /T"+K_OBC_A"=?_ .@1=?\
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M--.32;44W%I-^C\DW9'/7R; TX<T:?;K+3SW.VU#XE3Z<C?:]&OK<;S$?,N
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M?[4C9;_NZ>EK-KYW]W^9J7PVN[^HX._+]7=_\4OZ]>VFY9_X7'#_ - ^Y_\
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M/_DD/_D0_L/ ?\^_Q?\ F>F?\+BB_P"@==?^!(_^)H_X7%%_T#KK_P "1_\
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M9YF=LDKG!!&!SSUKVJB@#RWX3^&7A\3>)-9(F&E+<26NC1W$#0F.%W\Z?"L
M=IF8@''1!VQ4%OX/\?Q:MK6LR/X>GUVZBE@L;^6XG9;*(G]W&D7EX Z%CG+$
M<\8 ]9HH XWX8^%]2\)Z5=6VIP6(N99?/DN[:YDGENI"/GDE9T7YB0, < <#
M  %=E110 4444 %%%% !1110!#%_KY_J/Y5-4,7^OG^H_E4U !1110!!??\
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MW6G6>CO/;6%K%*8VNU_Y:&0.&;:25;[H'R[J/:2_D?X?YC^HT7+E6)A_Y/\
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M_P!!2]_\"'_QK\D_UMX5_P"A/'_R7_(^F_LS,O\ H*?XGJO_  JOP[_<OO\
MOMO\*/\ A5?AW^Y??]]M_A7E7_"1:M_T%+W_ ,"'_P :/^$BU;_H*7O_ ($/
M_C1_K;PK_P!">/\ Y+_D']F9E_T%/\3U7_A5?AW^Y??]]M_A1_PJOP[_ '+[
M_OMO\*\J_P"$BU;_ *"E[_X$/_C1_P )%JW_ $%+W_P(?_&C_6WA7_H3Q_\
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M6HK;_CWB_P!P?RJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6K:[J=K/!)HDZB6-HMRPR?*"X;N.VT"MW_A:L/\ S]:C_P" T'^-'_"U8?\
MGZU'_P !H/\ &JEA\EE2=%Y[[K5K>S25NRLM%V2T72PE/%J7/]3U]6<!_8&J
M?] V\_\  =_\*/[!U,DC^SKS(Z_N'_PKO_\ A:L/_/UJ/_@-!_C3%^*4*R.W
MVK4,-C_EVA]/K7@_ZM<)_P#0W_\ )3M_M#,O^@7\3@_[ U3_ *!MY_X#O_A1
M_8&J?] V\_\  =_\*[__ (6K#_S]:C_X#0?XT?\ "U8?^?K4?_ :#_&C_5KA
M/_H;_P#DH?VAF7_0+^)P']@:I_T#;S_P'?\ PH_L#5/^@;>?^ [_ .%=_P#\
M+5A_Y^M1_P# :#_&C_A:L/\ S]:C_P" T'^-'^K7"?\ T-__ "4/[0S+_H%_
M$X#^P-4_Z!MY_P" [_X4?V!JG_0-O/\ P'?_  KO_P#A:L/_ #]:C_X#0?XT
M?\+5A_Y^M1_\!H/\:/\ 5KA/_H;_ /DH?VAF7_0+^)P']@:I_P! V\_\!W_P
MKI/!?@'4=2U:WGN[62TLH7$CM,I4O@Y"@'GK6W_PM6'_ )^M1_\  :#_ !K;
M\-^+8_$T_P!GM]:G@N<9$,]M&"P]B.#7MY+PMPI4Q])1S+VKNFH6Y>9K9:[^
MBU9R8O,<RC1E>ARKOO8[BH;C[\'^_P#T-4/[-U'_ *"[_P#@/'_A4<VG:@&A
MSJ[GY_\ GWC]#[5_3!\ ;-%97]FZC_T%W_\  >/_  H_LW4?^@N__@/'_A0!
MJT5E?V;J/_07?_P'C_PH_LW4?^@N_P#X#Q_X4 :M%97]FZC_ -!=_P#P'C_P
MH_LW4?\ H+O_ . \?^% &K165_9NH_\ 07?_ ,!X_P#"C^S=1_Z"[_\ @/'_
M (4 :M,F_P!3)_NG^59O]FZC_P!!=_\ P'C_ ,*;+INH^6^=7?&#_P N\?\
MA0!I6W_'O%_N#^52UCV^G:B8(R-7<#:/^7>/T^E/_LW4?^@N_P#X#Q_X4 :M
M%97]FZC_ -!=_P#P'C_PH_LW4?\ H+O_ . \?^% &K165_9NH_\ 07?_ ,!X
M_P#"C^S=1_Z"[_\ @/'_ (4 :M%97]FZC_T%W_\  >/_  H_LW4?^@N__@/'
M_A0!JT5E?V;J/_07?_P'C_PH_LW4?^@N_P#X#Q_X4 :M%97]FZC_ -!=_P#P
M'C_PH_LW4?\ H+O_ . \?^% &K165_9NH_\ 07?_ ,!X_P#"C^S=1_Z"[_\
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M HHHH **** "BBF2RI!$\DCK'&@+,[' 4#DDGTH ?7AWQ<_:8/@#XEZ/\/\
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M\JFJ&+_7S_4?RJ:@ HHHH @OO^/27Z5/4%]_QZ2_2IZ "BBB@ HHHH ****
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MM*U]+DOAC5;;6M#M;NUMYK2)UQ]GGMV@>-AP5,9Y4@Y_^O6K38XQ%&J#)"@
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M )Y2?]\&CR9?^>4G_?!H_M;-?^@FI_X'+_,/JV&_Y]Q^Y&Q_PG'B#_H+W/\
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M[G_OH?X5C^3+_P \I/\ O@T>3+_SRD_[X->/_:V:_P#034_\#E_F=?U;#?\
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MO]QOYK4]0-_Q^1?[C?S6@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/^->-44?\10S_M3_ / 7_P#)!_J[@O[WW_\  /9_^%M:+_SVF_\  8_XT?\
M"VM%_P">LW_@,?\ &O+/"R-)XBT\+;QW;>:"()&"A\<XR>,_UKMKG1QKT,5Q
M=+//;VYE)6]A^SSK@+P2@)=!G^$9R:^HRSC/B/-,-*M2=-23M;D=M.6[;YNG
M->R4FK:I)IGG8C*L!AZBA)2MZKSZ6\NK1N_\+:T7_GK-_P" Q_QH_P"%M:+_
M ,]9O_ 8_P"-<Y=>#=&L]0ALY(;C?=W7DQOYQ'EKY:OC!')R2!GUK/7P]9-I
M\NHG0K]2FU%T\S'+Y<J7!QNP,8Z8R:ZZG$O%E&<H3E1O&][1F[<J3=[)[)I^
M=TE=W2RCE^6R2:4];6U77;]?U.S_ .%M:+_SUF_\!C_C1_PMK1?^>LW_ (#'
M_&N8N/"FB:=/]FDM[BY8Q7,_FK/MP(CD)C&,]B?:IK/P-IEY##,+>:..\A$L
M69F8QGR@^!A><$]6(]JVCQ!Q?*?LHRH.2LFK3TNE:[VZI:-J[7G:7@LL2YFI
MV^7]=&=#_P +:T7_ )ZS?^ Q_P :/^%M:+_SUF_\!C_C7B]+7PW_ !%#/^U/
M_P !?_R1['^KN"_O??\ \ ]G_P"%M:+_ ,]9O_ 8_P"-1Q_%?1EEE8RS88C'
M^C'T^M>.44?\10S_ +4__ 7_ /)!_J[@O[WW_P# /9_^%M:+_P ]9O\ P&/^
M-'_"VM%_YZS?^ Q_QKQBBC_B*&?]J?\ X"__ )(/]7<%_>^__@'L_P#PMK1?
M^>LW_@,?\:/^%M:+_P ]9O\ P&/^->,44?\ $4,_[4__  %__)!_J[@O[WW_
M / /9_\ A;6B_P#/6;_P&/\ C1_PMK1?^>LW_@,?\:\8HH_XBAG_ &I_^ O_
M .2#_5W!?WOO_P" >S_\+:T7_GK-_P" Q_QK9T'QAI_B1FCLKQ&F49,,D91\
M>N">?PKY_K0\.SSV^O:=);9\\3H%V]\D C\LUZ66^*&;RQ=.&*IPE!M)I)IZ
MOIJ]?EJ<]?AW#*E)TY--=WI^1]%[9O[Z?]\G_&H9UFWP_,GW_P"Z?0^]6ZAN
M/OP?[_\ 0U_4A^=B[9O[Z?\ ?)_QHVS?WT_[Y/\ C4M% $6V;^^G_?)_QHVS
M?WT_[Y/^-2T4 1;9O[Z?]\G_ !HVS?WT_P"^3_C4M% $6V;^^G_?)_QHVS?W
MT_[Y/^-2T4 1;9O[Z?\ ?)_QIDRS>2_S)]T_PGT^M6*9-_J9/]T_RH \S^*M
M]?PQZ99Z9HE[/<7UM)!<:W96'VF2RMR%WH@_OOP!G@8R<X KCYOAKJ5QX:\>
M#2Y=>TFTDMDCT_2D6-1=(ME&@#*R%BQ(*'!'2O>K;_CWB_W!_*I: /+_ (C7
MVIZ;I.@VNF:%>3ZC<6[6\FKVMA]JDTV(HOF;5Z[VP !TR,G@8/':7X7N--T^
M/P_:>&M5^QG6[;5H+B>WR!9QQ1ED=B>)<1M'L/)+CL:^@:* /&_ FDIXUOM2
MN?$?AF^T\R6"V=MI%UIYAL[2T20,D(;I(Y(5F[<  8'-BQT/QS9_"/3['0Y+
M73+N'2&B-K<0,+I9\-M".'"H>F,@\UZY10!\W6^A^)K?2Y(A8:S<:1<74 D@
MFM[E!$PB?>YB$YED#-L!^=4W8;I3;/P+XCUSPK?W6M6.LW&J6UAID-K;W$LF
M"ZS'SCLW89@H7).>,<]Z^DZ* /*/AC!JMUXRUBUO+F6;3/#+2Z=:2&<N+DRN
M)@SG/+1Q&./GH=WK7/27DFI:I?7U_P"!-7>QTF*ZCTCP_'I>V&8L<O+(Y^4M
M(1PN,*"2<DU[;I>D6.B6OV;3[2&RM]S/Y5O&$7<QR3@=R>]6Z //OA)%<3KK
M6JZG;7\.NZC/'+>M>6;6T8PFU(X5)R411C<>2<D]<#T&BB@ HHHH **** "B
MBB@"&+_7S_4?RJ:H8O\ 7S_4?RJ:@ HHHH @OO\ CTE^E3U!??\ 'I+]*GH
M**** "BBB@ HHHH ANO]6/\ ?7_T(5-4-U_JQ_OK_P"A"IJ "BBB@ HHHH *
M*** "BBB@ JI=7,-K=0F:6.(%& ,C!<\KZU;JI=6L-U=0B:*.8!&($BAL<KZ
MT ']K67_ #^6_P#W]7_&C^UK+_G\M_\ OZO^-</X;^)?A+Q-X@M-&@L_L]]=
MV;WL"W%LBB15E>-E!!/S QDX].?6J(^*6DS+HSVO@W5+R+6(]]E)#;6^)?D+
MD<R#!"@YSZ4 >C?VM9?\_EO_ -_5_P :/[6LO^?RW_[^K_C7 R?%#PU;RL+C
M0;^VA/G+!.^G K<R1 ^9'& 2Q888#@ [3@D<T[_A9.@E3"OAR_;5UN3:G1UL
MXC=!A$)2V-VW;L(.=W<#KQ0!WG]K67_/Y;_]_5_QH_M:R_Y_+?\ [^K_ (US
M<_BGPW#X/MO$B6JW%A<K&8(X;8&:5I"%2-4_OECC!Z'.<8J]X:O--\3:>UTF
MC26#QRM#);WUJJ2(R]>F01R"&4D'/6@#6_M:R_Y_+?\ [^K_ (T?VM9?\_EO
M_P!_5_QH_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  H /[6LO^?RW_[^K_C1
M_:UE_P _EO\ ]_5_QH_LFQ_Y\K?_ +]+_A1_9-C_ ,^5O_WZ7_"@ _M:R_Y_
M+?\ [^K_ (T?VM9?\_EO_P!_5_QH_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_
M  H /[6LO^?RW_[^K_C1_:UE_P _EO\ ]_5_QH_LFQ_Y\K?_ +]+_A1_9-C_
M ,^5O_WZ7_"@ _M:R_Y_+?\ [^K_ (T?VM9?\_EO_P!_5_QH_LFQ_P"?*W_[
M]+_A1_9-C_SY6_\ WZ7_  H /[6LO^?RW_[^K_C1_:UE_P _EO\ ]_5_QH_L
MFQ_Y\K?_ +]+_A1_9-C_ ,^5O_WZ7_"@".6_M+B2!%N8),N<J)%/&UNU<5JG
MPETJ\NGEM-0:Q1CDQ !U'TY&!787\-AI,0O&MX84AW.[K& 0H1B:\FU3XJZQ
M=W3M9^58V^?DC$2NV/<D=?I7YGQKC^'<+2I4\]I>T;NXI+WO-WO&RVZZ^=CZ
M#*:..J2E+!RY>[>WY/\ (W/^%-VO_0</_?E?_BJ/^%-VO_0</_?E?_BJY?\
MX65XB_Y_D_\  >/_ .)H_P"%E>(O^?Y/_ >/_P")K\C_ +6\/_\ H7U?O?\
M\M/IOJV=_P#/Z/\ 7_;IU'_"F[7_ *#A_P"_*_\ Q5'_  INU_Z#A_[\K_\
M%5R__"RO$7_/\G_@/'_\31_PLKQ%_P _R?\ @/'_ /$T?VMX?_\ 0OJ_>_\
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M\1_$*LS"]3+=?]'C_P#B:YO[6\/_ /H7U/O?_P M-/JV=_\ /Z/]?]NG5?\
M"F[7_H.'_ORO_P 51_PINU_Z#A_[\K_\57+_ /"RO$7_ #_)_P" \?\ \31_
MPLKQ%_S_ "?^ \?_ ,31_:WA_P#]"^K][_\ EH?5L[_Y_1_K_MTZC_A3=K_T
M'#_WY7_XJC_A3=K_ -!P_P#?E?\ XJN7_P"%E>(O^?Y/_ >/_P")H_X65XB_
MY_D_\!X__B:/[6\/_P#H7U?O?_RT/JV=_P#/Z/\ 7_;IU'_"F[7_ *#A_P"_
M*_\ Q5'_  INU_Z#A_[\K_\ %5R__"RO$7_/\G_@/'_\31_PLKQ%_P _R?\
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M 6VG 8X&?>JGF:S_ ,^]C_W_ '_^(H U**R_,UG_ )]['_O^_P#\11YFL_\
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MX=_Z"7AK_P "C_\ $5^4_P#$-\-_T-:?W+_Y,^I_M?$_] D_Q_\ D3R3>O\
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M?_6:'_/K\?\ @'S]O7^\/SHWK_>'YU]#?8K[_H&Z5_WVW_QNC[%??] W2O\
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M^_\ \11YFL_\^]C_ -_W_P#B* -2BLOS-9_Y]['_ +_O_P#$4>9K/_/O8_\
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MZW)RM%7;26K^2/OL1PW@\+6]A*4V[+5**C=NRNWHOFSV7_A9WA+_ *&/3?\
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MA)9=JKGU[_A7T_;?\>\7^X/Y5^P\(YEB\URN.(QGQ7:O:W,EU[=UIV/S3B3
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MA@>QJY:^/M:\G1/$=[XEMK"RU6]*QZ/+ISO"MOYOEA3.BEEEY4Y8A=QQC'-
M'J/]IZC_ - :3_P(C_QH_M/4?^@-)_X$1_XUK44 9/\ :>H_] :3_P "(_\
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MGJ/_ $!I/_ B/_&N'A^-T:W6B"]T"\L+#6RCV%Y)+&RO S*HE< Y3F2+@]I
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M#K_AZZO+#3X8Y;V:+R?.$.Z9&4Y8G>Q ;CFA</94]L/#_P  B']LY@MZTO\
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M3;?\>\7^X/Y5URH+#VIQ5DMK',JKK7G)W;,[^T]1_P"@-)_X$1_XT?VGJ/\
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M4?\ H#2?^!$?^-1S:EJ.Z'.CR??_ .?B/T/O6U4-Q]^#_?\ Z&@#/_M/4?\
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M9VVB6]MO>_ECG:.YD8GF.,*I8$'"]ST% 'J_]IZC_P! :3_P(C_QH_M/4?\
MH#2?^!$?^-<9X>\0>(_^%C'1[K4K75XA#--J%O9V^V+3,L/LZ"7JSLN<JW/!
M/ QGTF@#)_M/4?\ H#2?^!$?^-']IZC_ - :3_P(C_QK6HH R?[3U'_H#2?^
M!$?^-']IZC_T!I/_  (C_P :UJ* ,G^T]1_Z TG_ ($1_P"-']IZC_T!I/\
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M)4]AQTKE-<^!?[07B+XC#QQ>^!Y&\0"[AO0\;6RP^9%MV?N_-QCY%XK]+_\
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MW:?\];S_ ,#)?_BJ -6BLK_A&[3_ )ZWG_@9+_\ %4?\(W:?\];S_P #)?\
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(- !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>org.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 org.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '" R # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\N9%AL+>7S[E5"S7.,#(')]N:DOH9A,(+6(++,H\Z[" %@..2._^-5E_=_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "J]]?0:;:O<7#[(D&2<$GZ
M#J:L44UOJ)WMH>/>+/'VK:T7M["WN+&RZ9"D2./<]A["N)^PW/\ S[R_]\&O
MI>BO4IXZ-)<L(6^9\_6RF>(ESU*MWZ?\$\2\*_#6_P!>VSW.ZQLNNYU^=_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N>\<>-K+P#HT>I:A%/-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5\M?\)YXC_Z#=]_W_;_&C_A.O$FT'^VK_!XSY[?XT?V#5_G7XA_K5A_^?;_
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MJ6BOEK_A//$?_0;OO^_[?XT?\)YXC_Z#=]_W_;_&J_L&M_.OQ%_K5A_^?;_
M^I:*^6O^$\\1_P#0;OO^_P"W^-'_  GGB/\ Z#=]_P!_V_QH_L&M_.OQ#_6K
M#_\ /M_@?4M%?+7_  GGB/\ Z#=]_P!_V_QH_P"$\\1_]!N^_P"_[?XT?V#6
M_G7XA_K5A_\ GV_P/J6BOFW0_BUXDT>Z1Y+YM1MP?FM[H AA[/C<#^)'L:]_
M\.>(+7Q1HUMJ5H3Y,P^ZWWD8'#*?<$$5Y>,R^M@K.>J?5'MY=F^'S)N-.ZDN
MC_,TZ***\L]P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB#^R<?\ \^9?<>>T5Z%_PHCQ3_SVT?\ \"I?_C-'_"B/%/\ SVT?_P "I?\
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M$('[O:6E3;QD[L-D\50_X41XI_Y[:/\ ^!4O_P 9H_X41XI_Y[:/_P"!4O\
M\9J74P[5OK/X_P!>7I8N-+%J5W@]->GW=.FOJGY&@UO87]K9M%#9ZCJ4.D6J
MVUM>3!$(WOYA/S %@,<9[U/;^']'VWTFFZ?I]_$NJI!NNI\(D1B!D",6&[!W
M8Z\<\UD?\*(\4_\ /;1__ J7_P",U:_X4WXR_LLZ=]KT?[&9OM'E_:)/O[=N
M<^3GIVSBHE.A]G$+[_\ @_Y;LTC3Q3UGA']R_5>>N^RT)[>P\-0?9H([.SO+
M>4Z@?.ED;?MC),0!##&>.>I%&GZ3H%Y,MP+>T6]FTZVG6U7#1[V9A(0K2IR
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M7_"B/%/_ #VT?_P*E_\ C-'_  HCQ3_SVT?_ ,"I?_C-7_:&%_Y^(G^R<?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *YOQU_P >&F?]A6R_]'I725S?CK_CPTS_ +"ME_Z/2KA\2)EL
M=)1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)7']K:OXMU.
MRMM:FTRUM+>W=8X8(GW,YDR274G^ 5UM<WI/_(^>(?\ KTLOYSU<>K)ET#_A
M&]:_Z&R]_P# 2V_^-T?\(WK7_0V7O_@);?\ QNNDHHYG_2#E1S?_  C>M?\
M0V7O_@);?_&Z/^$;UK_H;+W_ ,!+;_XW7244<S_I!RHYO_A&]:_Z&R]_\!+;
M_P"-T?\ "-ZU_P!#9>_^ EM_\;KI**.9_P!(.5'-_P#"-ZU_T-E[_P" EM_\
M;H_X1O6O^ALO?_ 2V_\ C==)11S/^D'*CF_^$;UK_H;+W_P$MO\ XW1_PC>M
M?]#9>_\ @);?_&ZZ2BCF?](.5'-_\(WK7_0V7O\ X"6W_P ;H_X1O6O^ALO?
M_ 2V_P#C==)11S/^D'*CF_\ A&]:_P"ALO?_  $MO_C='_"-ZU_T-E[_ . E
MM_\ &ZZ2BCF?](.5'-_\(WK7_0V7O_@);?\ QNC_ (1O6O\ H;+W_P !+;_X
MW7244<S_ *0<J.;_ .$;UK_H;+W_ ,!+;_XW6-J6G^(H?$6E:=%XMNTCNH;B
M5W-G;$@Q^7@#]W_MG\J[VN;U;_D?/#W_ %Z7O\X*J,G?_@(F4="M_P (KXB_
MZ':^_P# "U_^-T?\(KXB_P"AVOO_   M?_C==;14\[_I(KE1R7_"*^(O^AVO
MO_ "U_\ C='_  BOB+_H=K[_ , +7_XW76T4<[_I(.5')?\ "*^(O^AVOO\
MP M?_C='_"*^(O\ H=K[_P  +7_XW76T4<[_ *2#E1R7_"*^(O\ H=K[_P
M+7_XW1_PBOB+_H=K[_P M?\ XW76T4<[_I(.5')?\(KXB_Z':^_\ +7_ .-T
M?\(KXB_Z':^_\ +7_P"-UUM%'._Z2#E1R7_"*^(O^AVOO_ "U_\ C='_  BO
MB+_H=K[_ , +7_XW76T4<[_I(.5')?\ "*^(O^AVOO\ P M?_C='_"*^(O\
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M ( 6O_QNC_A%?$7_ $.U]_X 6O\ \;KK:*.=_P!)!RHY+_A%?$7_ $.U]_X
M6O\ \;H_X17Q%_T.U]_X 6O_ ,;KK:*.=_TD'*CDO^$5\1?]#M??^ %K_P#&
MZ/\ A%?$7_0[7W_@!:__ !NNMHHYW_20<J.2_P"$5\1?]#M??^ %K_\ &Z/^
M$5\1?]#M??\ @!:__&ZZVBCG?])!RHY+_A%?$7_0[7W_ ( 6O_QNC_A%?$7_
M $.U]_X 6O\ \;KK:*.=_P!)!RHY+_A%?$7_ $.U]_X 6O\ \;JAX@T7Q+H^
M@ZE?Q^,[R22UMI)U5K&UP2J%@#^[]J[RL3QO_P B7K__ &#[C_T6U5&3NO\
M)"<58H6>@ZW<6D$K>*[T-(BL0+2V[C/_ #SJ;_A&]:_Z&R]_\!+;_P"-UM:7
M_P @VT_ZXI_Z"*M5/,_Z0<J.;_X1O6O^ALO?_ 2V_P#C='_"-ZU_T-E[_P"
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MBO%#I%@>ME;G_MDO^%)_8]A_SXVW_?E?\*OV*[D^T?8]LHKQ/^Q[#_GQMO\
MORO^%']CV'_/C;?]^5_PH]BNX>T?8]LKF])_Y'SQ#_UZ67\YZ\W_ +'L/^?&
MV_[\K_A1_8]A_P ^-M_WY7_"FJ25]1<[['ME%>)_V/8?\^-M_P!^5_PH_L>P
M_P"?&V_[\K_A2]BNX_:/L>V45XG_ &/8?\^-M_WY7_"C^Q[#_GQMO^_*_P"%
M'L5W#VC['ME%>*+I5DARMG;J?41*/Z5IV.J7^EL#:7LR*/\ EE*QDCQZ;6/
M_P!W'UI.EV8_:=T>L45SOAWQA%JTBVUR@MKTCY5!RDN.NT^O?:>?3.":Z*L&
MG%V9HG?8****0PHK'U[Q-:Z"H1PT]TPREO']['J3_"/<^AQGI7%WWBS5]08_
MZ2+&(_\ +*U49QZ%V!)/N-M:1IN1#DD>F45Y T]TQR=1U'\+Z8?^S4GF7/\
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MH;QE\*O >@V'AO0/"E[I/A_X9Z)XENY-7MIFN)?,<0/$A1P,D!2&(X(;.[(
MD\1?&+Q_\._&/[0OB*VCT'6X-'O/#]KI>D7UM,8H1=F(1JN)0$_=S/O('S28
M;A1MJ>1=RN9]C]3ZQ/&__(EZ_P#]@^X_]%M7Y_>/OV@?&7PU\>>'- U'3_ ^
MLNEUI=CX@M]'TV_=X)+R8H&$S#R;<!2A1)&=Y,,<**Y7X0_%CQSX:U.6WUUM
M!UY-=^+=WX8D>6TF+VT*QR&00[I2$0&.,1J0=HW9W$@AJ*3W%S-K8_3S2_\
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M%_*MJ<;NYG-V1E^(_$&G>#_#FIZYJL_V/2=+M);R[G",_E0QH7=MJ@L<*I.
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MKI&H+J^DV5\B&-+J!)PC')4,H;'ZUK:+?'3==T^X!P&E6W<>JR$+C_OHJW_
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M!\QP<#BKX^(WA,VM[<CQ/HQM[&__ +*NIO[0BV6]X65?LTAW867<RKY9PV6
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MU+2;Z#6M>U"YTW5QK437DEL TPL/L(5EB@0;/)QPH'S '.,BN9L?V;;?P_\
M%#X7I!"L?A'P1:W_ )%_J5\CW6I7%QETB:)45=L69I,GVP.IKZ1KR#XT:+J.
MJ^,/#GEZ/'X@TV31M;LUTVXD,<$]]+##Y"2.,[%:)+M-^. [#^+!EI6'=F9X
MB_9C^&?CJSM4\-2+X,MVM+JUE'@=K6SCOK2YV+/%*JQLK(YA4;@ P*<,*K^)
M/V-?!OB"]O9H]8\0:3!<3QW"V=E<0-# RV/V%O+$L+GYX JDDEE*!D*').=\
M'_A_K7@WQ?X&@N=)&E:A'I^M76N?9V0VVZXN+9T5!'\B*9 YC09*K&V2223]
M%T))[H+M'R=K7[*.K_\ "XO#LFG1M)X*M)M,GO9[K5@1="TL9;3,EJL(/GLA
MC7>CA-N3M!%>R_"#X!:!\%M-U&QT:_U2]@O(XK<?VC+$WV>&)2L<48CC08 8
M_,P9VZLS5Z91344M0NSP>/\ 8U\#PZ%::3'?ZY%;PZ#!X?=X[F)7N([>=9[:
M>0B+!GBD7*L !AB"K XJ!/V-/#,*ZI/%XJ\5Q:OJ>KVFNW6KK<6GGO?6[2-'
M.%-MY0)\S! CVG:O .2??Z*.5!=G)?#/X:Z9\+/#LFDZ;<WVH-<7<U_>:AJ4
MHEN;NYE<O)+(P55W$G^%0    *ZVBBJ$=)\.<_VMJ_IY%O\ ^A35WE<C\.[,
MK9WEZP_X^)?+0^J)Q_Z$7_2NNKCJ:R9O#X0HHHK,L**** "BBB@ HHHH *YS
MQAX=;5H4NK9<WL ("]/-3NOU[C/?(XR371T4TW%W0FKJQX\K;O48."",$$<$
M$=C[4M>@Z]X0MM9D:XC?['>GK,BY5^WSKQGZY!X'..*Y&\\*ZS9,?]"%VG_/
M2UD4C'N&*G/L :ZXS4C!Q:,RBIOL%[_T#[W_ ,!9/_B:/L%[_P! ^]_\!9/_
M (FKN20T5#K%VGA_3Y;_ %02:;8Q#,ES=Q-%&GU9@ *\]D_:+^',,C(WBBW)
M']V*5A^83%;TZ-6JKTXM^BN<M;%4,.[5JBCZM+\STBBO-?\ AH_X<?\ 0T0?
M]^)O_B*/^&C_ (<?]#1!_P!^)O\ XBM?JF)_Y]R^YF']I8+_ )_Q_P# E_F>
ME45YK_PT?\./^AH@_P"_$W_Q%=CX3\8:/XZ@DF\/7R:TD?\ K/L2M(8_3< ,
MK^-9SP]:FN:<&EYIFM/&8:M+DI5(R?9-,V:*F^P7O_0/O?\ P%D_^)H^P7O_
M $#[W_P%D_\ B:Y[G80T5.NG7S'"Z=>LQZ VSK^I  _$UHV/@W5[YAYL4>G1
M]VG8._X*A(/XL*.9+=A9LR8HI+B:."",RSR'"1KU)_H/?M7I7AW0UT'3A#D/
M.Y\R:0#[SD8X]@  /8>M)H?AVTT&,^2&EG<8>XEP7;V] /88'XUJURSGS:(V
MC&VK"L3Q5H)US3QY6!>0'?"3P#ZH3Z$?D0#VK;HK-.SNBWKH>/<AF5E9'4[6
M1A@J1U!'K2UZ%XA\)P:T?/C?[+>@8\X+E7'HZ]_KP1ZXXKB;[0=4TUB)["61
M>TEHIF4_0*-P_%179&:D8.+13HJ)KJ)20TBQL.JN=K#Z@\BD^V0?\]X_^^Q5
MD$U%0_;(/^>\?_?8K,U;QIX?T&14U/7=,TYV&Y5N[R.(D>HW,*J,92=HJY$I
MQ@N:3LC9HKE?^%K>"?\ H<= _P#!G!_\51_PM;P3_P!#CH'_ (,X/_BJU]A5
M_D?W,P^MX?\ Y^1^]'545RO_  M;P3_T..@?^#.#_P"*H_X6MX)_Z''0/_!G
M!_\ %4>PJ_R/[F'UO#_\_(_>CJJ*Q=)\:>'M>D:/3->TS474;F6TO(Y2!ZD*
MQK4^V0?\]X_^^Q64HRB[25C>,XS7-%W1-14/VR ])HR?0,":O6>DZCJ3 6VG
MW!S_ !S1F%![Y?&1_N@GVJ=MRRLS!5))P!7=>"_#[Z="][=)LNYQM6-NL4?4
M#ZD\GZ =J/#_ (+CTZ1+J]=;F[7E%4?NXCZC/WC_ +1_ "NGKFJ5+Z(VC'JP
MJEK&EQ:SILUG*=JR#AAU5@<JP]P0#^%7:*P-3R*YM9["YDMKE-EQ']X#H1V8
M>H/;\NH(IE>FZYX?M=>@59@T<J9\N>/ATSU^H]CQ^0KA=1\+:KIC'-O]MA'_
M "VM1DX]T^\#[#=]:[(U%+<YY1:,RBHWG6%MLVZW?^Y.AC;\F --^V0?\]X_
M^^Q6A ZXMXKRWE@GB2>"52DD4BAE=2,%2#P01VK,C\(Z%%X8/AM-%TY/#OV<
MV?\ 9"VD8M/((VF+R<;-A!(VXQ@]*T?MD'_/>/\ [[%5=2\0:9HUE)>7^HVM
ME:QC+S3S*B+]2332;=DA.2BKMZ&'J'PD\#:M?6][?>#/#U[>V\,5O#<7&E02
M2111L&B16*9"HRJ5 X! (QBI_P#A67@_^U)M2_X1/0_[1FO8]2EO/[-A\Y[J
M,,([AGVY,JAW"N3N 9L'DURMQ^TO\-;69HW\3(67J8[2X=?S6,@U'_PT_P##
M/_H9?_)"Z_\ C5=?U'%?\^I?^ O_ "/,_M;+UH\1#_P*/^9VUIX#\,V'B.]\
M06WAW2;?7KU/+NM4AL8ENITX^5Y0NYAP.">U,M?A[X5L;?1[>V\,Z/;P:,)!
MID45A$JV.]2K^0 N(]RLP.W&02#UKC/^&G_AG_T,O_DA=?\ QJC_ (:?^&?_
M $,O_DA=?_&J?U'%?\^I?^ O_(7]K9?_ -!$/_ X_P"9VNA^ O#/AFXMKC1_
M#FDZ5/:V?]GP2V-C%"T5KOW^0A505CW_ #;!\N><9K>KC/"_QC\%^,[@6^D>
M(;2XN6^[!(6AD;OPKA2?P%=;]L@_Y[Q_]]BN:=.=)\LXM/S5COI5Z6(CSTIJ
M2[IW7X$U%0_;(/\ GO'_ -]BK5K:7=^P%K8W5QGHRQ%4/_ VPOZUF;$==-X)
MT%KFY359UQ!&#]F4_P ;$8,GTP2!ZY)]#4VB^ V9EFU9D91R+2,Y4_[[=_\
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M]]BC[9!_SWC_ .^Q0!-14/VR#_GO'_WV*/MD'_/>/_OL4 345#]L@_Y[Q_\
M?8I\4GVAML"273?W;>-I2/J%!Q0 ^K&G:9/K5XMI;Y5CS)+CB)/[Q]_0=S[
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M;YGZ'P+]8O6W]EIZ<WE\M_D='1117P)^N!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45C0^-/#]Q'OBUW3)4SC<EY&1^C4#-FBLG_A+-#_ .@SI_\ X%1_XU9TO7-.
MUR%Y=-O[74(D;8SVLRRJK8S@E2<'% >9<90ZE6 92,$$<&L9O!/AYF).@Z82
M>239Q_\ Q-;5%4I2CLS.4(R^)7,3_A"?#O\ T -+_P# ./\ ^)H_X0GP[_T
M-+_\ X__ (FMNBJ]I/NR/8T_Y5]QB?\ "$^'?^@!I?\ X!Q__$UIV5A;:;;B
M"TMH;6!>1'"@11^ JQ14N4I:-E1IPB[Q204445)H%%%% !1110 4444 %%%%
M !1110 5@^(? ?AGQ=(DFN^'=)UJ2,81M0L8IRH] 74XK>K\G_VQF@C_ &K_
M (@RS^';C7%M]0T:[D:&V$BB&+3 \T+,0=H= 7/!&(&)& 2/2P&'EB:CC&7*
MTK_BEW7<\S,,1##TDYPYDW:S]&^S['Z5?\*0^'/_ $('A?\ \$UM_P#$4?\
M"D/AS_T('A?_ ,$UM_\ $5^.&FS)IMC"H\!W&JFW=G+W6FA1-&/LRY<JI(P8
M9P0#UG/.0<W-8N+1;K4I6^'5]IUKM1$:73UW6[B*6!G;]VJ_ZZ6!MG W1A>K
M9KW?[,K?\_W_ %_V\?/_ %_#6_W>/]?]NG[!_P#"D/AS_P!"!X7_ /!-;?\
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MDECGCE#V[;)$O;J[#;6A*G+7MPA# @HPXW -7KEM MK;Q0J<K&@0$@#@#'8
M?E4M% !1110 4444 %%%% !1110 5\'_ +1W[*?Q/^(/Q>^(NK>']'TB_P!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1M*NKNSLM^=+;47O&,H)?"EQ"8V1&'1IBH&TX\ZOKJ\O=1\(*UE8:[IK>/\
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M6M35O^G;7Y]CZ3AC\F&./<S;%"[F.2<#J3ZT^H;.U6QLX+9&=TAC6-6D<NQ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<FV^ ^IZ-X2?0M&\50V4=YH<.B:C-/I?G-*(HGC6:(><OEL5<@AMXX7 !R2
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MX$C\[1\X/4[5(+$ YK0N/C-H,%QJ4/D:I+]@N_[/DECL7,<EUYBH((VZ.Y+
M\< <DC!KC;?]F.QM7M]MUH]V&M+*WO)]2\/PW=R6MX8X=]O)(Q$(=(ERK+(
M<D8)-=AJ'PN:Z\+ZYI"7]I(-3U234BM_IJ75L0\@<PRPNWSKQC(9#T((H ZW
MP_KD'B+2X[ZWAN;=&9D:&\@:&5&5BK*R, 1@@\]#U!((-85Q\4_#]KJ-I8S7
M$L5U<ZJ^C)&T1R+A5W?-Z*04PW0^8GK6=X%\$ZSX#DTO3(=1AN]&"WDUW'';
M>5%'(\D;0QP*TCM'&H,@"98=<L. <OQE\#5\4>(==UBWUR33+F_M8A:A;<2"
MSO$DA;[4/F&XD6ML-O'$9Y^;@ A_X: TVW\0:L)K:\E\/6NFV^H+>6MA+(8X
MS-=1RS2D9 B @5EXR06/(Z='-\3]-TZZU*&::74+B/4QIUK96%D[3N_V:.<H
M/F._".7,GR* 0",C+9UQ\&K?^P_$FE6FH&UM=6\-6_AR(&#>;98DN$$I^8;\
MBX^[Q]SKSPV3X1W-KJ4VJZ;KD=KK"ZI_:-M-/9>;"@-G%:O%)&)%+AA%NR&0
M@D>AR 5;OXY6MGXB$1T_49M*_LEK]TATV8W<#I.\<OF)_"J[.F,D]-PKH/'W
MC]?"_@RQ\0V&R\M;B]T^,,(GEWP3W$4;,B)\S-LD)4#/..#TJM:_#6]^V7U[
MJ/B!]2O;W29--EE:U" %Y9)-RJ&X1?,VJAR<*,L3DU<NOA]]I\#^'_#OV_;_
M &3+ITOVGR<^;]DEBDQMW?+O\K'4XW=\<@$5O\6=(NK&66*RU9[V*\^P2:6+
M!_M:3>6)<,G0#RV5]Q.W!'.3BH8_C/X=N/L7V5-2O?M$"W,BVUA*[6L9E:+=
M*H&5_>(ZD8)&QLC S65XF^#-SK>KZKJ%OK<$8O\ 4TU%[&^L6N+1PMG';>7+
M&LT9DQY>\$D $\J<9K ;]FU_^$;TO1TUS3_+L8IHH[IM#07-KOGDE\RTE216
MMY ) O5T^12$'((![?12*-J@=:6@ HHHH **** "BBB@ HHHH **** "BBB@
M HK.U7Q%INAS6L5_=QVSW7F>5OSC"(7=B>BJJJ26. .!G) //Z?\7/"NI6]U
M/'J$T,5M%'<2->6-Q;Y@=@JSJ)(UWQ9/,BY0#DD#F@#A->\4>)?#'BCXH:SI
MMSICZ9H<%M?36-^DCR3JMKO:.-UD40Y"G#%7RQZ#',FE_&3Q)K'B</;:*&\.
M_P!MOHS1O:%)5"RF%IC<&;;G>-WE>5G;T8FM7QQ<?#73?&DAUW1Y;WQ 8(;V
M=[71;N]_=!F6)I6AB==H,3X#]"I..]=1I/A3P?KM]:^,-/TZPO+B\5;R#4HD
M!$A9,+,.V\H<;\;L<9Q0!YAH/QT\5:MI<6MMHL*Z1J.G7E[:![1HOLQCA>6(
M-*9S]H!";6"I&5)],FNS\">-/$=]XFMM*\0?V7-]OT5-9@;38)(?L^756A<O
M(_F??7#@)T/RU#)%\-=!\3:K9G2X8-2D9+.[DCTZ=H4:\=$$7FJAC1I6EC+*
M&!(8,PP,UWMOX?TZTOH+V&TCCNH+7[%'*!RL.0=@]LJ/RH \RU[XMZMI7CN&
MRMVLKS1_[9M]'EA@TZY=XVE"@LUV66$.&?\ U2HYP!E@3@97_"WO%\>B>'?$
M#KH3:7X@L;R^M[);>87%H([26XB1W\W$I^10Y"I@Y !R"._\1>"?!.FW5QXI
MU?2[&&:VE2^DOI4/[N5"NV4 ='^51N R1QR.*YS1?@+:6GBH:MJ5QI]]!$+H
M10VVF"VD?[0&63SG$A5LJS9$:1!B=Q!(% &5=_$WQQ;2Z#I8@TZYUC4]/?6'
M>QTJ:XC@A_=*L(0W*%VW2-F7< !M_=\U0O/CIXLOHW?2O#\4<UAH]MJ5]:R0
MFY5Y95=C$)UF184 C.)2L@.2=HVG/K>N> ?#WB2ULK;4])M[N*R4I;!UYB4J
M%*JPY"D  C." ,YJ#5/AGX4UI[-KWP_I\_V.%;:%3  BPJ<K$5'!0$<(05'I
M0!YAX\\:^)?$7AW7;RSDT_2]%T_6;'3GM)HY/MKDS6S,_G+)L7F4 )L;<HSN
M&[ V?BMXKUGP?\0M&U*WNT?1K'PYK&I7.E^2Y:Y,'V9L!A(%#88!6*';\_7?
M\O3^,_!_@B.27Q'XATFS9XY(#)=/"S$N'58F(7JP8J V,@=P*Z'5?#.EZY?6
M%Y?6,5S=6)<VTKCYH]X <#U! &0>#@>E '*^%_%/B*/Q98Z'XAETF];4=*DU
M2"?28)(5@\N2)'C</(^\'SU*R#;G:WRBL#7OBUJVE^/(+&W:QO-'.M6^C2Q0
MZ=<LT;2A06:\++"'#/S$J.< 98$X':Z=X7\*?#/3]1U2ST^ST2UAMS)=7*)@
M1P1@MC/\,:C<0HX'.!5;_A _!^M^(I=6;0H9=4AGAN_M<ELZ#S@%9)48@*S@
M*H++D\;2>HH \\M_C5XHTC0=,\0ZU:Z5>Z=J6GZC=QV&G02Q3Q-:Q/*,R-(P
M<.L9& B[2PY;%;GAN]\2R?&#1H]?U#2[M9O#5U<HFDQ20HI-Q:\,KR/OQ_#)
MD9RWRKCGOX/!^BVT>FQQZ; L>G"06B[<B(.I5P![@D'ZUSO]A> _A-<QZJMC
M9Z%-)#-;K=)&WRPI&9Y$R,[8U2 MCA1MP.3@@',:WX^\0Z;J7B.#0]/M3)%X
MA^QRSI9R7LBQ#3[>7S/LRS(TAW.%/ED;5 .T\FNHN?B"R_"FW\4176G"XGMX
M2LKI<-;^<[K'@1A/.8[VP(]H<MA>"<C6U'P%X:\102O=Z5;W*W5R+]I""KF;
MREC$@8$%6\M57((X&*LZAX9T!?"<FCW>GV:>'X8 IM&C"PQQIAA@#[NW:"".
MA (Y% 'DL'QXUC1X]2FURVMI+/2[^:QN;A;":QD<FP%W PADD=DW,&CP22Q:
M,C;DBI-/^-GB"]TMTN$TC3M4L(H[34M]M<W"KJ#WDD'EPQ1$R286"5Q&.6WQ
M_.HR:[C0O!7@>^TF:QT[0[>33+[[+JKYM9!#<MG=#+O88=P8P3R6'R[OO#.Q
M=_#_ ,.7UOJ<$^CVLD>I7*WMW\F#+.H4+*2.0P"+@C!&* /(Q\4->\16LL#1
MVEIK%K_;-H+]K*: JT-O%(DBP&;<A(D *LS'*Y!'2F:%\0/$FA^'[1$_LV_U
MIM*\,QB]N(IE60WEU+"3(/-8G8N#D')8L3P0J^N:/\.?#/A_;_9VB6EH%>60
M"-.-TB*DC$=RRHNXGKC)Y)K)U3P[X(^'F@K<7.F):V$<EG#'';P37$C/'.7M
MD2- SL5ED)55!Y/I0!S-O\2/%DNOR>$3)HP\0)K#:?\ VM]BE%H8A8QW>X6_
MG;MY$@3;YN/E+9XVT[4_&'B36O@3X[U&2YL;#7]-CU:U6ZL(Y#$/L[2IO0&3
M<K%4X.[Y6(.#C!Z7QC\.;3QAIK2:>+.PN;J\CU&=[_3VG69UA$2ETWQR(P0*
M 4=&&T Y!93:\&_#73?"O@63PQ*D5[97)N#=HL(BBD\]W:15C!.U/G*A<D@
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MQ#9^ _#<>I#5K6QC6/3KZ^NXI(6ES:2RK)=LR '*M(%)&"21P* '_##QE?\
MBBSU2+5I(?[2L+@1R1II\]A(BLBLN^&5GP>3AE=U8#((.0/.9?V@M9TUIKF6
M&PU:PN=)N]1L7M;"ZM80T4D*H!<3'_2(R)@3*D:  9&0:]F\-^$]'\)6LL&C
MV$5E',_F2E,EI&P "S$DL0  ,G@ "L!O@[X5MK>].EZ/9Z7?7%K-:)=QVZ2&
M*.0890C@J4SSY9&WVH XWQ%\1O'7A75K_1IY/#NI7X326M;B*TG@CS=WQMG$
MB&9R H&00W/IVJ#7/BWXRT?6]8L;?3K351X>-O%J#0:>\:7DDD:2N4D:YQ;*
M$D &X2Y(.2!71^!_@CI_AF\O[W4?[/O[FZ%H EC8M:P1_9I&EB;:TLK%P[ Y
M+X 1   .>KU;X?\ AO7M9BU;4-%L[O4(]@$\L8);8=R;AT;:>5W9VGD8H \[
ML?C!XDU+Q<XMM'1_#R:Z^B,IM2KKLE,+3?:#-MSO&[RO*R5Z,35?P_\ $+XA
M^(I/#*QS^&;4>(;>[FB+:?<2?8_(91EA]H'F[PPX&S9GJ^.?3/\ A7_AO_A(
MCKW]BV?]KE_-^U>6-WF;=OF8Z;]OR[\;L<9Q5NQ\*Z1IO]G&UL(8?[/22.TV
M@_N5?&\+]<#\J /%1\?/%.LZ=%=:-HENSVNA6FK7L)MGF2229'?RQ+YT8@0!
M#^\99.I^7Y3G>OOBAXIAOM8U%(M)BT#2]=T_2'LI;>1KN5+E;/+>:)=B,C7?
M38P8+CY>I[>[^%7A"^CL([CP]8S1V,"VL"/%D"%3E8R/XD!YVMD9YQ6I<>$M
M'NH[V.73X72\NXKZX4@XDGC\ORY#[KY,6/\ <% '(_!"ZUN\\/ZW)K>I1:G,
MNOZI#&\<#QE%CO)4V_-(_P HV_*!C:N%YQD\%X^U+Q2OC+Q=%;ZM;O;0ZGX;
MCLK5XI5$327J=6$I&T_-O 4%LCD8Y]2A\!^'E\80ZA:6+6FHV4\FHO)' ZQR
MR3H\;'>1L)(#%E4YSM+8R-VG?^!]"U36#JMUID,VH$0J9SD$^5*)8LX."5=0
MP)Z8H \OU+XO>*=)U"?PT]O8W_B*/6CIJWUCI\C0-$+&.[WBV,X8OB0)M\['
M!;/&VNKTWQMK^H?"?7-;ETU;?Q#8P7RQVZ+\LLL.\1L$W,5W%5RA)*DE<G&3
MK>*O#/A%;"]N==L;06]Y>V\TTTP.6NCLMX7!'*O_ *M 5P><=ZW]&T6P\.Z;
M!I^F6<-A8P@B.WMT"(N22>!W)))/<DF@#S+PSX8\.:7HO@_Q*?$>HQZE>M;,
M=2.H22G59)4_U3HQ9&5R20H4;-HV[0*SU^+WB:W\-Z+XDN(M(ET[Q#:74]C8
MPP2B>R9+26YC\YS(1*-L)5]JQ[68 9KT/2?ACX4T/6!JMAH%C:7ZL[I-'$!Y
M;/G>R#HA;)R5 SDYHM_AGX5L[R]NH=!LHY[Q)8YG6/JLO,H _AWGEMN-QY.:
M /,M0^)7Q#TZSU*>23PRWV/PXOB4JMC<<IB0M:_Z_K^[XFZ#_GD>VEJ/Q1\4
M6TGB[5XO[%&@>';^WMGL7@E-W<QR06\KXE$H5''GG:/+;=@#Y>M>E7'A#1KJ
M.XCETZ%TN+'^S)5(/SVWS?NC_L_,WYUSFF_!WP_;^)M7UR^LK74;R\U".^@:
M2#!M_+@AB1#R0^TPEU)'RES@ \D XB\^.&MV>L2B/^SK_3KB/4_LK0:;=1QQ
MO:Q22)_I,C*MP#Y1#"-% )(#'&3;D^)WC32;>X-[;Z/J%P="C\110V-K-&4A
M65/M%O\ -*WF/Y;'8XV#<!E#TKLG^&7@NUUJ.7_A'+<7UU]H*S1VSLJAU99A
MN VQAQ(V1E=Q)."1QK:IX65K=IM&^QZ;K"6?V"VO;BV-PD,.X$H8PZ;AQTW#
MG'7H0#CI-<N/'&EZMXELQ#-8^'[Z:?1-DY@2^:&V>-_-D+;?+,SR+G& (\_3
M1^%GC;5/%$FJV6N&&/5+(0RM;KIL]A*D<@;!:.1Y%9=R. Z2,#M(PI%=#X7\
M%Z9X5\%V'A>WMXYM+M;069BEC4K*FW#;UQ@[LDD8P<FG^&?!6A^#4G71M,@L
M//V^:T8)9PHPH+')PH)P.@R<=: //(?B5XKNK33M7@71CIFL:E<:596+02_:
M()%,RQ222>9AQNAR\812H8X8[><.T_:&U75KE(K*PLD^W6=K!I_FJ[$:F[6P
MGB?#<I&+R,X&#^ZER>./6K7X?^'+'Q ^N0:-:1:L[O(;I8QN#N,.X'168<%@
M 3DY)HM_ 'ARSFM98=&M(Y+6]FU&!EC&8[F4,))1_M-O;/UH \YM/BQXFLWT
M[5M4CTJ70;[6M2TA;.SMI5ND%M]K*2^892K%A:8*;!RV0W\-8UO\=/&,?A.]
MURYT6U\B;P]=:U9%K5H(XGCC61(RQG8W"$/S(JQXP/E^88]AL/#^AW$<"P:;
MY::=J$UU"LL#Q[+ES)YDJ;@-V[SI?F&5.\X-4K3X5>$;&'4(K?P]8PQW\#VM
MPJ1X#0N<O$/[J$\E5P,\XH X?Q9\0_&O@FZ@&IMH[6,%JMY?:A;:7<RP1AI&
M!1]DS20*J+GSV1U8[CM0*:I^'_%OB3P_JU[<F?3[K0+OQC-I1M9(I&N@))-J
MR+-YFU0K8'E^6<@$[AG%>G^(/A_X=\57D%WJ^CVM_<0IY:R3)DE,[MC?WESS
MM;(SVJRWA+1VC"'3X=GVW^T=N#_Q\[MWF_[V>: /*O"/CKQ7XA.C:9HC>'])
M1]$;5)&O;:><;A</'L4"=2%( )8EMI['.!T=Q\67M_A_X.\9S00V>C:D;>34
M_-)8VT4T1V,C9 .)FB7)'*L:LWWP3\-ZEX@@O;JPMI]/M].&GPZ>T1Q&/-9V
M8/NSAMV"N,'OGI74Z]H.BZEX9N=+U6RM9="\G;-:RH!"(DP0".@ VCZ8H \@
MT?X[:_J&C-]MM=*TK5["UDDU6.>*X=+>:6XCCLD5(]SLSH[-L )9E"C;NR'0
M_&#QA=6VH6=O96\^H6.K"SFNUT6</Y!M4G606#7 E)RX4XD) PVWG ].C\)^
M%O$UA?7RZ99WMMX@B@FN9C'_ ,?:HH\EFSSE1M*G@C Z&L?4OAYX T.UM+&Z
MT6SMH]1U!1#LC??)=F-@&WK\P<HK@N2,C()YH R?'7CB^O/@,WB#398Y;R\A
MM4:2QEDMU'FSQQ2['=0\1 =^64,A'(R*XM;>YTG6E\&7BOI]O<ZSI_VV/3]1
MGEM7MI8+EE12^'B+R6RJZYPP(/\ &17NR>'-*CT'^Q%TVU&C^1]F^P>2OD>5
MC&S9C&W'&*R[;X:>%K30[K2(M#M!I]U(LL\13<9'7&URQ^8LNU=ISE=HQC H
M YCP7KT?@_0/'C3FZN=&\.ZG<+:HI:XE\D013-$F26;$DDB*N>,!>@KS#1/%
MNI^*8_B*L&N2W&N7EMIMXUI!.UNMO%YI$UK;R/M"-Y9$8?*[G;=D9X]_T_P+
MH&EG2S::5;VYTMI7LS&N#$TH(E8>K-DY)R3DFK%YX7TC4?[3^UZ=;W(U.)8+
MQ9D#+/&H(56!X( 9OSH \-TO3M5US7O$&D:3I&H6_AO3[G3[YM!U*^,3S+)#
M<I+&&WMY:[Q;R^62,[2<#?6A\+?'E[9W5BFMQW6I,(-/TH:D)PT:[U81R -A
MW\YU+F3'W'AR,AL>N:3X+T30]'NM+L--AM;*[W&XC3.9BR[6+MG<QV@#).<
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M,>.*V;SQWIK>!=1\36=VB6-K;S2M->6\R>28MP<21;1(I4J05V[N#Q0!Y/\
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MKY56)&QN/E.':E\1O#^C^)?[ NKV1-4%NMV\2VLSI%"V_$LDBH4C3]V_S,P
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M@6#1[V0W.PXD$.V$^:4/W@FXK@[L8-=3)XRT6/PJGB5M1A&AO;K=)>Y.QHV
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MV4$.L>$KK7[--.OYTEC\J.%FC=U"LI87"D,C K@C)X:@#TSXD^#YO&FAV]I
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M !+H'Q&\76V+74+4R:78Z79R2/&L<UP7 9V .%QN9L D[5 KNO!?BC4-8O\
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MTNX8*LL# @'*Y7KSC1^*WQ,UVW\)W4.C>18WLWA^/5A=%FW1EIHT*KCV<X-
M'K6CKJ:V\HU62UDG\^4QFS1D40[SY8(8D[PFW<1P3G  XJ_7CLGQJUB/Q)<V
M$.@3:C;Z??PZ9=FSL+V1I)&$?FRQR+"855#(3M=\D(3D9 .SX-^)VI:YXVN=
M#U738=';%P8+:=;B*X(BD"AE+QB.=64[MT3G;P#GJ #TFBO+_&GQ"OO"_B;7
M(-.T^.]O(H]$AB2YO)4B=KN\F@Y7E4VXR65<MQG.U0.C\!^*M1UZX\0Z;K%M
M:V^IZ+?+9RO8NS0RAX(IU9=P!'RS $'/*GGF@#K:*** "BBB@ HHHH ****
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MB3 P6"Y(SDG)J&W^#OA&WU2&_72W>6%IC#!->3R6T/G(Z2K' SF)%=78%54
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M(?.$\IEF239(/,1G).QLKSP *[.B@#C&^#_A)FLS_9DBI:P06PA6\G6*:.$
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M/9N[YS74T4 <C)\)_"LNG_8FTLBW%LEHH6YF5DC2;SDVL'W*RR?.'!# @8/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*YC^T-?U35M7M]/DTVUM]/N%A#7,,DK39ABDQ\KJ$YD(W?-_N\<]/7(VVAZN
MVN>(9[;4I--AN;Q&56MTD#*+:!=Z9Z'<K#G(^7IZ@#[;Q3?Z\UO::=!!9WI2
M1[M[H-+';%)&B*@*5,A+HX!RO"Y[@5#J7B[4]%L;V&>T@N]6M9K-%6 E(KB.
MXG$2N 22ASO&"3C;G)!J^W@];..S;2[R2PO+9'3[0RB7S@[;G\U3]XEOFR"#
MDG!P2"J^#UDMYC=7LUU>SW-O<2W3*H)\F59$C51PJ J>.OS,<DG- &;?-XE_
MX2C28(]0T^)I+&[DDC^S2M%D20 <>:,D!L!N.K<#.!?_ +2UG5;Z\M].>RMH
M[%UAEFNH'D\Z78KL$4.NU0& W$MSGCC)O:UHDNH75K>6EZUA?6RR1I+Y8D4H
M^W<K*>O*(>"#E1VR#7N?#MVE]/=:;JC6#W15KF-H%E1V"A=Z@_=;:JCJ1\HX
MZY ,VQ\4ZKK-KIUM:PV=MJERDTLLDFZ6&!(Y-G !5G))&!E>C'C&"R]\:7V@
M6VIIJ,-O<W5J\$4+6JNJS-*<*2GS,@'< L< XR>*GF\+C0](M);2\O#>V D"
M7$<(F>59'#,CQ@ ,"=IXP1MX(YS7T/PO>:I::K/K4UPD]]-%)"V$CE@$0!1@
M%RJD."0"6XP&SDB@";P_XDU>]U:*VN+5KNSD1BUXFGS60@8<A2LS$N#S\PQ@
MXXP<CKJSM)L]0M!)]OU%;\G 3;;B+:!GK@G)/X#CH*T: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>f6k_082621p_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ptgef="http://portagebiotech.com/20210630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ptgef-20210630.xsd" xlink:type="simple"/>
    <context id="From2021-04-01to2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2018-08-13_custom_SalvaRxGroupPlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxGroupPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-13</instant>
        </period>
    </context>
    <context id="From2015-02-012015-02-10_custom_SubsidiariesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-01</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SubsidiariesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2018-01-032018-01-31_custom_PortageGlasgowLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PortageGlasgowLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-03</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SubsidiariesThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_ifrs-full_SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2016-10-31_custom_PPLSettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PPLSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_PPLSettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PPLSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2020-08-012020-08-30_custom_BiohavenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypeOfMeasurementOfExpectedCreditLossesAxis">ptgef:BiohavenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-05-302020-06-01_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-30</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-03-012021-03-03_custom_PortageGlasgowLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:PortageGlasgowLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-03</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-03_custom_PortageGlasgowLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:PortageGlasgowLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-03</instant>
        </period>
    </context>
    <context id="AsOf2015-08-31_custom_SeriesAPreferredStockInSentienBiotechnologiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:SeriesAPreferredStockInSentienBiotechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SeriesAPreferredStockInSentienBiotechnologiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:SeriesAPreferredStockInSentienBiotechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_IntensityMember_custom_AcquisitionOfSalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfSalvaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IntensityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_IntensityMember_custom_AcquisitionOfSalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfSalvaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IntensityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-07-11_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfIntensityHoldingLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IntensityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-11</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_IntensityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IntensityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfIntensityHoldingLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IntensityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_IMM60IOXMelanomaLungCancersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM60IOXMelanomaLungCancersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_IMM60IOXMelanomaLungCancersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM60IOXMelanomaLungCancersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_IMM65IOXOvarianProstateCancersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM65IOXOvarianProstateCancersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_IMM65IOXOvarianProstateCancersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM65IOXOvarianProstateCancersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_OncomerSaugatuckDNAAptamersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:OncomerSaugatuckDNAAptamersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_OncomerSaugatuckDNAAptamersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:OncomerSaugatuckDNAAptamersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_PplMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PplMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_IoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_PplMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PplMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_IoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_PplMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PplMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_IoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_PplMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PplMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_IoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_PplMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PplMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_IoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-01-31_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="From2020-09-012020-09-30_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-10-31_custom_PortageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:PortageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="From2019-01-032019-01-31_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-03</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="From2019-01-032019-01-31_custom_IoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-03</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SalvaRxGroupPlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxGroupPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SalvaRxGroupPlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxGroupPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SalvaRxGroupPlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxGroupPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2020-06-022020-06-16_custom_AccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:AccreditedInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-02</startDate>
            <endDate>2020-06-16</endDate>
        </period>
    </context>
    <context id="From2020-06-022020-06-16_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-02</startDate>
            <endDate>2020-06-16</endDate>
        </period>
    </context>
    <context id="From2021-06-012021-06-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:N2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="AsOf2021-01-13_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="AsOf2021-01-13_custom_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_PBI2013OptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_PBI2013OptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_IOxOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_IOxOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_PBI2013OptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_IOxOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_IOxOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_PBI2013OptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_PBI2013OptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_PBI2013OptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2013OptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_IOxOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_IOxOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_Equity2021IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:Equity2021IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember444649546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2020-07-012020-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_AmortizedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_AmortizedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_PglMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_PglMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_PglMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_PglMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_PglMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_IoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_PglMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:PglMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_IoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-07-31_custom_EventsAfterTheBalanceSheetDateMember_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ptgef:EventsAfterTheBalanceSheetDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-04-01to2021-06-30">0001095435</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-04-01to2021-06-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2021-04-01to2021-06-30">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-04-01to2021-06-30">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-04-01to2021-06-30">--03-31</dei:CurrentFiscalYearEndDate>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0135"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0147"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:GainsOnDisposalsOfInvestmentProperties
      contextRef="From2021-04-01to2021-06-30"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IssuedUnderPrivatePlacement
      contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0208"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IssuedUnderPrivatePlacement
      contextRef="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0209"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IssuedUnderPrivatePlacement
      contextRef="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IssuedUnderPrivatePlacement
      contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0228"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UnrealizedLossOnInvestmentInInvestments
      contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UnrealizedLossOnInvestmentInInvestments
      contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UnrealizedLossOnInvestmentInInvestments
      contextRef="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UnrealizedLossOnInvestmentInInvestments
      contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossIncomeOnFairValueOfWarrantLiability
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ValueOfSharesIssuedForServices
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="From2021-04-01to2021-06-30"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IncreasingDecreasingAccountsReceivable
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:OtherAsset
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfInvestmentProperty
      contextRef="From2021-04-01to2021-06-30"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2021-04-01to2021-06-30"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CashPaidForInterest
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IncreaseInAccountsPayableForStockIssuanceCosts
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FairValueOfWarrantLiabilityForPortageWarrantsIssued
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UnrealizedLossOnInvestmentInInvestment
      contextRef="From2021-04-01to2021-06-30"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:InvestmentAssetAvailableForSale
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UnrealizedLossGainOnInvestment
      contextRef="From2021-04-01to2021-06-30"
      id="xdx2ixbrl0540"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:InvestmentAssetAvailableForSale
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalInvestments
      contextRef="From2021-04-01to2021-06-30"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RepaymentOfNotesPayable
      contextRef="From2020-04-012021-03-31_custom_PplMember"
      id="xdx2ixbrl0704"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RepaymentOfNotesPayable
      contextRef="From2020-04-012021-03-31_custom_IoxMember"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AmortizationOfDebtDiscount
      contextRef="From2020-04-012021-03-31_custom_PplMember"
      id="xdx2ixbrl0712"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AmortizationOfDebtDiscount
      contextRef="From2020-04-012021-03-31_custom_IoxMember"
      id="xdx2ixbrl0714"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ValueOfNotesExchangedInWarrantExercise
      contextRef="From2020-04-012021-03-31_custom_PplMember"
      id="xdx2ixbrl0720"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ValueOfNotesExchangedInWarrantExercise
      contextRef="From2020-04-012021-03-31_custom_IoxMember"
      id="xdx2ixbrl0722"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SettlementInConnectionWithDispositionOfPpl
      contextRef="From2020-04-012021-03-31_custom_IoxMember"
      id="xdx2ixbrl0730"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SettlementInConnectionWithDispositionOfPpl
      contextRef="From2020-04-012021-03-31_custom_SalvaRxMember"
      id="xdx2ixbrl0732"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnExtinguishmentOfDebt
      contextRef="From2020-04-012021-03-31_custom_PplMember"
      id="xdx2ixbrl0736"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossOnExtinguishmentOfDebt
      contextRef="From2020-04-012021-03-31_custom_IoxMember"
      id="xdx2ixbrl0738"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromLoanPayable
      contextRef="From2020-04-012021-03-31_custom_PplMember"
      id="xdx2ixbrl0744"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromLoanPayable
      contextRef="From2020-04-012021-03-31_custom_SalvaRxMember"
      id="xdx2ixbrl0748"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NotePayable
      contextRef="AsOf2021-03-31_custom_PplMember"
      id="xdx2ixbrl0752"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NotePayable
      contextRef="AsOf2021-03-31_custom_SalvaRxMember"
      id="xdx2ixbrl0756"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromLoanPayable
      contextRef="From2021-04-012021-06-30_custom_PplMember"
      id="xdx2ixbrl0760"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromLoanPayable
      contextRef="From2021-04-012021-06-30_custom_IoxMember"
      id="xdx2ixbrl0762"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromLoanPayable
      contextRef="From2021-04-012021-06-30_custom_SalvaRxMember"
      id="xdx2ixbrl0764"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromLoanPayable
      contextRef="From2021-04-01to2021-06-30"
      id="xdx2ixbrl0766"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NotePayable
      contextRef="AsOf2021-06-30_custom_PplMember"
      id="xdx2ixbrl0768"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NotePayable
      contextRef="AsOf2021-06-30_custom_SalvaRxMember"
      id="xdx2ixbrl0772"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FairValueAdjustmentExercisePriceAtEnd
      contextRef="From2021-04-012021-06-30_custom_SalvaRxGroupPlcMember"
      id="xdx2ixbrl0816"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ptgef:FairValueAdjustmentShares
      contextRef="From2021-04-012021-06-30_custom_SalvaRxGroupPlcMember"
      id="xdx2ixbrl0818"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForServicesShares
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0860"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForService
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0862"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2020-04-012020-06-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0912"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2020-03-31_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl0945"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2021-03-31_custom_PBI2013OptionPlanMember"
      id="xdx2ixbrl0947"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl0955"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2020-04-012020-06-30_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl0957"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl0959"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2020-04-012020-06-30_custom_PBI2013OptionPlanMember"
      id="xdx2ixbrl0961"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2021-04-012021-06-30_custom_IOxOptionPlanMember"
      id="xdx2ixbrl0963"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2020-04-012020-06-30_custom_IOxOptionPlanMember"
      id="xdx2ixbrl0965"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl0967"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2020-04-012020-06-30_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl0969"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2021-04-012021-06-30_custom_PBI2013OptionPlanMember"
      id="xdx2ixbrl0971"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2020-04-012020-06-30_custom_PBI2013OptionPlanMember"
      id="xdx2ixbrl0973"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2021-04-012021-06-30_custom_IOxOptionPlanMember"
      id="xdx2ixbrl0975"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2020-04-012020-06-30_custom_IOxOptionPlanMember"
      id="xdx2ixbrl0977"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2020-06-30_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl0981"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2021-06-30_custom_PBI2013OptionPlanMember"
      id="xdx2ixbrl0983"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="AsOf2020-06-30_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl0993"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="AsOf2021-06-30_custom_PBI2013OptionPlanMember"
      id="xdx2ixbrl0995"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2020-04-012020-06-30_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl1007"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2021-04-012021-06-30_custom_PBI2013OptionPlanMember"
      id="xdx2ixbrl1009"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ptgef:AntidilutiveEffectOnLossPerShar
      contextRef="From2020-04-012020-06-30_custom_RestrictedStockUnitsMember"
      id="xdx2ixbrl1058"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:AntidilutiveEffectOnLossPerShar
      contextRef="From2020-04-012020-06-30_custom_WarrantsMember"
      id="xdx2ixbrl1062"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1094"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1098"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivables
      contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1102"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivables
      contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1106"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentInvestments
      contextRef="AsOf2021-06-30_custom_AmortizedCostMember"
      id="xdx2ixbrl1108"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentInvestments
      contextRef="AsOf2021-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1112"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1118"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1122"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1126"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1130"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:WarrantLiability
      contextRef="AsOf2021-06-30_custom_AmortizedCostMember"
      id="xdx2ixbrl1132"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:WarrantLiability
      contextRef="AsOf2021-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1134"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-03-31_custom_PglMember"
      id="xdx2ixbrl1174"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-03-31_custom_SalvaRxMember"
      id="xdx2ixbrl1176"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2021-04-012021-06-30_custom_PglMember"
      id="xdx2ixbrl1184"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2021-04-012021-06-30_custom_SalvaRxMember"
      id="xdx2ixbrl1186"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2021-04-012021-06-30_custom_SaugatuckMember"
      id="xdx2ixbrl1190"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2021-04-012021-06-30_custom_PglMember"
      id="xdx2ixbrl1194"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2021-04-012021-06-30_custom_SalvaRxMember"
      id="xdx2ixbrl1196"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-06-30_custom_PglMember"
      id="xdx2ixbrl1204"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-06-30_custom_SalvaRxMember"
      id="xdx2ixbrl1206"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2020-04-012020-06-30_custom_PglMember"
      id="xdx2ixbrl1219"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2020-04-012020-06-30_custom_SalvaRxMember"
      id="xdx2ixbrl1221"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2020-04-012020-06-30_custom_SaugatuckMember"
      id="xdx2ixbrl1225"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2020-04-012020-06-30_custom_PglMember"
      id="xdx2ixbrl1229"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2020-04-012020-06-30_custom_SalvaRxMember"
      id="xdx2ixbrl1231"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-04-01to2021-06-30">6-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-04-01to2021-06-30">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber contextRef="From2021-04-01to2021-06-30">0-30314</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-04-01to2021-06-30">Portage                                             Biotech Inc.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="From2021-04-01to2021-06-30">Craigmuir Chambers</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-04-01to2021-06-30">Road Town</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2021-04-01to2021-06-30">Tortola</dei:EntityAddressAddressLine3>
    <dei:EntityAddressPostalZipCode contextRef="From2021-04-01to2021-06-30">VG1110</dei:EntityAddressPostalZipCode>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">28617000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">2770000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">1995000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">2176000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CurrentAssets contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">30612000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">4946000</ifrs-full:CurrentAssets>
    <ifrs-full:OtherReceivables contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">22000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">22000</ifrs-full:OtherReceivables>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">1691000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1735000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentProperty contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">7409000</ifrs-full:InvestmentProperty>
    <ifrs-full:InvestmentProperty contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">7409000</ifrs-full:InvestmentProperty>
    <ifrs-full:Goodwill contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">43324000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">43324000</ifrs-full:Goodwill>
    <ptgef:InprocessResearchAndDevelopment contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">117388000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">117388000</ptgef:InprocessResearchAndDevelopment>
    <ifrs-full:OtherAssets contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">36000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">36000</ifrs-full:OtherAssets>
    <ifrs-full:Assets contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">200482000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">174860000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">1605000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1938000</ifrs-full:TradeAndOtherCurrentPayables>
    <ptgef:WarrantLiabilityCurrent contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">751000</ptgef:WarrantLiabilityCurrent>
    <ptgef:WarrantLiabilityCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1120000</ptgef:WarrantLiabilityCurrent>
    <ptgef:UnsecuredNotesPayable contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">150000</ptgef:UnsecuredNotesPayable>
    <ptgef:UnsecuredNotesPayable contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">150000</ptgef:UnsecuredNotesPayable>
    <ifrs-full:CurrentLiabilities contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">2506000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">3208000</ifrs-full:CurrentLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">24171000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">24050000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">24171000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">24050000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">26677000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">27258000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">157895000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">130649000</ifrs-full:IssuedCapital>
    <ifrs-full:OtherReserves contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">10059000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">7977000</ifrs-full:OtherReserves>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">958000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">958000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:RetainedEarnings contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">-41201000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">-38135000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">127711000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">101449000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">46094000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">46153000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">173805000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">147602000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">200482000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">174860000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">1546000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">452000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">2047000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">521000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3593000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-973000</ifrs-full:ProfitLossFromOperatingActivities>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">369000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-44000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">440000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:InterestExpense
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">34000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">122000</ifrs-full:InterestExpense>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3302000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-655000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-79000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3223000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-655000</ifrs-full:ProfitLoss>
    <ifrs-full:GainsOnDisposalsOfInvestmentProperties
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">78000</ifrs-full:GainsOnDisposalsOfInvestmentProperties>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3223000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-577000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3066000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-696000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-157000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">41000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ptgef:NetLossIncome
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3223000</ptgef:NetLossIncome>
    <ptgef:NetLossIncome
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-655000</ptgef:NetLossIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3066000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-618000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-157000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">41000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ptgef:TotalComprehensiveLossIncomeForYear
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3223000</ptgef:TotalComprehensiveLossIncomeForYear>
    <ptgef:TotalComprehensiveLossIncomeForYear
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-577000</ptgef:TotalComprehensiveLossIncomeForYear>
    <ptgef:BasicAndDilutedLossPerShare
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.25</ptgef:BasicAndDilutedLossPerShare>
    <ptgef:BasicAndDilutedLossPerShare
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.06</ptgef:BasicAndDilutedLossPerShare>
    <ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="Shares">12213000</ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted>
    <ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="Shares">11104000</ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">10988000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">117817000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">58000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">958000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-22302000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">96531000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">49110000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2020-03-31" decimals="-3" unitRef="USD">145641000</ifrs-full:Equity>
    <ptgef:IssuedUnderPrivatePlacementShares
      contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">698000</ptgef:IssuedUnderPrivatePlacementShares>
    <ptgef:IssuedUnderPrivatePlacement
      contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">6980000</ptgef:IssuedUnderPrivatePlacement>
    <ptgef:IssuedUnderPrivatePlacement
      contextRef="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">6980000</ptgef:IssuedUnderPrivatePlacement>
    <ptgef:IssuedUnderPrivatePlacement
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">6980000</ptgef:IssuedUnderPrivatePlacement>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2020-04-012020-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">248000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">248000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">248000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">295000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">295000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ptgef:UnrealizedLossOnInvestmentInInvestments
      contextRef="From2020-04-012020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">79000</ptgef:UnrealizedLossOnInvestmentInInvestments>
    <ptgef:UnrealizedLossOnInvestmentInInvestments
      contextRef="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">79000</ptgef:UnrealizedLossOnInvestmentInInvestments>
    <ptgef:UnrealizedLossOnInvestmentInInvestments
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">79000</ptgef:UnrealizedLossOnInvestmentInInvestments>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012020-06-30_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-696000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">-696000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">41000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-655000</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2020-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">11686000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2020-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">124549000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-06-30_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">58000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">1037000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-06-30_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-22998000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">102646000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">49446000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2020-06-30" decimals="-3" unitRef="USD">152092000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">12084000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">130649000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">7977000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">958000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-38135000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">101449000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">46153000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">147602000</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">2082000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">2082000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">98000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">2180000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ptgef:SharesIssuedUnderAtmShares
      contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">91000</ptgef:SharesIssuedUnderAtmShares>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">2643000</ptgef:SharesIssuedUnderAtm>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">2643000</ptgef:SharesIssuedUnderAtm>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">2643000</ptgef:SharesIssuedUnderAtm>
    <ptgef:SharesIssuedUnderOfferingShares
      contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">1150000</ptgef:SharesIssuedUnderOfferingShares>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">26450000</ptgef:SharesIssuedUnderOffering>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">26450000</ptgef:SharesIssuedUnderOffering>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">26450000</ptgef:SharesIssuedUnderOffering>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">1877000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">1877000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">1877000</ifrs-full:PaymentsForShareIssueCosts>
    <ptgef:SharesIssuedOrAccruedForServicesShares
      contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">1000</ptgef:SharesIssuedOrAccruedForServicesShares>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">30000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">30000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">30000</ptgef:SharesIssuedOrAccruedForServices>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-06-30_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-3066000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">-3066000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">-157000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3223000</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2021-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">13326000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2021-06-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">157895000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-06-30_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">10059000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-06-30_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">958000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-06-30_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-41201000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">127711000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">46094000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">173805000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3223000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-655000</ifrs-full:ProfitLoss>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">121000</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
    <ptgef:LossIncomeOnFairValueOfWarrantLiability
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-369000</ptgef:LossIncomeOnFairValueOfWarrantLiability>
    <ptgef:ValueOfSharesIssuedForServices
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">30000</ptgef:ValueOfSharesIssuedForServices>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">56000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:GainLossOnHedgeIneffectiveness
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">44000</ifrs-full:GainLossOnHedgeIneffectiveness>
    <ifrs-full:GainLossOnHedgeIneffectiveness
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-440000</ifrs-full:GainLossOnHedgeIneffectiveness>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">2180000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">296000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ptgef:IncreasingDecreasingAccountsReceivable
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-215000</ptgef:IncreasingDecreasingAccountsReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">394000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">2000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-544000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">53000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ptgef:OtherAsset
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">2000</ptgef:OtherAsset>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-1580000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-688000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfInvestmentProperty
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">1000000</ifrs-full:PurchaseOfInvestmentProperty>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-1000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ptgef:ProceedsFromSharesIssuedUnderRegisteredOffering
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">29093000</ptgef:ProceedsFromSharesIssuedUnderRegisteredOffering>
    <ptgef:ProceedsFromSharesIssuedUnderRegisteredOffering
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">6980000</ptgef:ProceedsFromSharesIssuedUnderRegisteredOffering>
    <ptgef:ShareIssuanceCosts
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">1666000</ptgef:ShareIssuanceCosts>
    <ptgef:ShareIssuanceCosts
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">248000</ptgef:ShareIssuanceCosts>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">27427000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">6732000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">25847000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">5044000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">2770000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2020-03-31" decimals="-3" unitRef="USD">3152000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">28617000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2020-06-30" decimals="-3" unitRef="USD">8196000</ifrs-full:CashAndCashEquivalents>
    <ptgef:CashPaidForInterest
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">11000</ptgef:CashPaidForInterest>
    <ptgef:IncreaseInAccountsPayableForStockIssuanceCosts
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">210000</ptgef:IncreaseInAccountsPayableForStockIssuanceCosts>
    <ptgef:FairValueOfWarrantLiabilityForPortageWarrantsIssued
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">751000</ptgef:FairValueOfWarrantLiabilityForPortageWarrantsIssued>
    <ptgef:UnrealizedLossOnInvestmentInInvestment
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">78000</ptgef:UnrealizedLossOnInvestmentInInvestment>
    <ptgef:NatureOfOperationsTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_801_ecustom--NatureOfOperationsTextBlock_zGbLtoA3Nq6k" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
1. &lt;span id="xdx_82F_z2lcUwxfNAW6"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Portage
Biotech Inc. (the "Company" or &#x201c;Portage&#x201d;) is incorporated in the British Virgin Islands ("BVI") with its
registered office located at FH Chambers, P.O. Box 4649, Road Town, Tortola, BVI. Its Toronto agent, Portage Services Ltd., is located
at 6 Adelaide Street East, Suite 300, Toronto, Ontario, M5C 1H6, Canada.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is a reporting issuer with the securities commissions of the provinces of Ontario and British Columbia. Its ordinary shares were
listed on the Canadian Stock Exchange (&#x201c;CSE&#x201d;) under the symbol &#x201c;PBT.U&#x201d;. On February 25, 2021, the ordinary shares
of the Company began trading on the NASDAQ Capital Market (&#x201c;NASDAQ&#x201d;) under the symbol &#x201c;PRTG&#x201d;. The Company voluntarily
delisted its common shares from the CSE at the market close on April 23, 2021, since the Company&#x2019;s shares began trading on NASDAQ.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Portage
is a clinical stage immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets
at various development stages. We source, nurture and develop the creation of early- to mid-stage, first- and best-in-class therapies
for a variety of cancers, by funding, implementing viable, cost effective product development strategies, clinical counsel/trial design,
shared services, financial and project management to enable efficient, turnkey execution of commercially informed development plans.
Our drug development pipeline portfolio encompasses products or technologies based on biology addressing known resistance pathways/mechanisms
of current check point inhibitors with established scientific rationales, including intratumoral delivery, nanoparticles, liposomes,
aptamers, and virus-like particles.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 13, 2018, the Company reached a definitive agreement to acquire &lt;span id="xdx_902_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pdp0_dp_c20180813__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zcxKJl7CVWq8"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of SalvaRx Limited (&#x201c;SalvaRx&#x201d;) in exchange for &lt;span id="xdx_906_eifrs-full--NumberOfInstrumentsOrInterestsIssuedOrIssuable_iI_pid_uShares_c20180813__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zYRBfyjXUu2j"&gt;8,050,701
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ordinary shares of the Company (the "SalvaRx
Acquisition"). The SalvaRx Acquisition was completed on January 8, 2019 (the &#x201c;Acquisition Date&#x201d;) upon receiving shareholder
and regulatory approval. In connection with the SalvaRx Acquisition, the Company acquired interests in SalvaRx&#x2019;s five research
and development invested entities and subsidiaries: iOx Therapeutics Ltd. (&#x201c;iOx&#x201d;), Nekonal Oncology Limited (&#x201c;Nekonal&#x201d;),
Intensity Therapeutics, Inc. (&#x201c;Intensity&#x201d;), Saugatuck Therapeutics Ltd. (&#x201c;Saugatuck&#x201d;) and Rift Biotherapeutics
Inc. (&#x201c;Rift&#x201d;).&#160; In connection with the SalvaRx Acquisition, the Company also acquired an option in Nekonal SARL, a Luxembourg-based
company holding intellectual property rights for therapeutics and diagnostics in the field of autoimmune disorders and oncology, to participate
in the funding of its autoimmune programs. During fiscal 2021, the Company abandoned its interests in Nekonal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;On
June 5, 2020, the Company effected a 100:1 reverse stock split. All share and per share information included in the consolidated financial
statements have been retroactively adjusted to reflect the impact of the reverse stock split. The shares of ordinary shares authorized
remained at an unlimited number of ordinary shares without par value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Portage
filed a registration statement and prospectus with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) pursuant to Rule 424(b)(2)
under which it may sell shares, debt securities, warrants and units that Portage may sell in one or more offerings from time to time,
which became effective on March 8, 2021 (&#x201c;Registration Statement&#x201d; or &#x201c;Prospectus&#x201d;). The Registration Statement
includes:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a
                                            base prospectus, which covers the offering, issuance and sales by us of up to $&lt;span id="xdx_90A_ecustom--IssuanceAndSales_pn3p0_c20210401__20210630_zTGX4glTyxdd" title="Issuance and sales"&gt;200,000,000
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;in
                                            the aggregate of the securities identified above from time to time in one or more offerings;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a
                                            sales agreement supplemental prospectus covering the offer, issuance and sale by us of up
                                            to a maximum aggregate offering price of up to $&lt;span id="xdx_901_ecustom--MaximumAggregateOfferingPrice_pn3p0_c20210401__20210630_zukpUnWZB5u2" title="Maximum aggregate offering price"&gt;50,000,000
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;of
                                            our ordinary shares that may be issued and sold from time to time at-the-market, under sales
                                            agreement, or sales agreement, with Cantor Fitzgerald &amp;amp; Co., or Cantor Fitzgerald, the
                                            sales agent; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a
                                            prospectus supplement dated June 24, 2021, for the offer, issuance and sale by us of 1,150,000
                                            ordinary shares for gross proceeds of approximately $26.5 million in a firm commitment underwriting
                                            with Cantor Fitzgerald.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span id="xdx_90F_ecustom--CashFundDescription_c20210401__20210630" style="font: 10pt Times New Roman, Times, Serif"&gt;The
specific terms of any securities to be offered through the sales agreement with Cantor Fitzgerald, in the at the market offering, are
specified in the sales agreement prospectus. The $50,000,000 of ordinary shares that may be offered, issued and sold under the sales
agreement prospectus is included in the $200,000,000 of securities that may be offered, issued and sold by us under the base prospectus.
The sales under the prospectus will be deemed to be made pursuant to an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4)
promulgated under the Securities Act of 1933 (the Securities Act). Upon termination of the sales agreement, any portion of the $50,000,000
included in the sales agreement prospectus that is not sold pursuant to the sales agreement will be available for sale in other offerings
pursuant to the base prospectus, and if no shares are sold under the sales agreement, the full $50,000,000 of securities may be sold
in other offerings pursuant to the base prospectus. See Note 2, &#x201c;Liquidity&#x201d; and Note 14, &#x201c;Capital Stock&#x201d; for
a further discussion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ptgef:NatureOfOperationsTextBlock>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="AsOf2018-08-13_custom_SalvaRxGroupPlcMember"
      decimals="INF"
      unitRef="Pure">1</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="AsOf2018-08-13_custom_SalvaRxGroupPlcMember"
      decimals="INF"
      unitRef="Shares">8050701</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <ptgef:IssuanceAndSales
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">200000000</ptgef:IssuanceAndSales>
    <ptgef:MaximumAggregateOfferingPrice
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">50000000</ptgef:MaximumAggregateOfferingPrice>
    <ptgef:CashFundDescription contextRef="From2021-04-01to2021-06-30">The
specific terms of any securities to be offered through the sales agreement with Cantor Fitzgerald, in the at the market offering, are
specified in the sales agreement prospectus. The $50,000,000 of ordinary shares that may be offered, issued and sold under the sales
agreement prospectus is included in the $200,000,000 of securities that may be offered, issued and sold by us under the base prospectus.
The sales under the prospectus will be deemed to be made pursuant to an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4)
promulgated under the Securities Act of 1933 (the Securities Act). Upon termination of the sales agreement, any portion of the $50,000,000
included in the sales agreement prospectus that is not sold pursuant to the sales agreement will be available for sale in other offerings
pursuant to the base prospectus, and if no shares are sold under the sales agreement, the full $50,000,000 of securities may be sold
in other offerings pursuant to the base prospectus. See Note 2, &#x201c;Liquidity&#x201d; and Note 14, &#x201c;Capital Stock&#x201d; for
a further discussion.</ptgef:CashFundDescription>
    <ptgef:LiquidityTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_800_ecustom--LiquidityTextBlock_z6ArZJZLYESf" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
2. &lt;span id="xdx_823_zLyl4Ou6YAE9"&gt;LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021, the Company had cash and cash equivalents of $&lt;span id="xdx_904_eifrs-full--Cash_iI_pn3n3_dm_c20210630_zI0LcaPotXu2"&gt;28.6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million and total current liabilities of $2.5
million &lt;span id="xdx_900_eifrs-full--CurrentLiabilities_iI_pn3n3_c20210630_zOdx01OTFGhf" style="display: none"&gt;2,506 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(inclusive
of $0.7 million warrant liability settleable on a non-cash basis). For the three months ended June 30, 2021, the Company is reporting
a net loss of ($3.2) million &lt;span id="xdx_904_eifrs-full--ProfitLoss_iN_pn3n3_di_c20210401__20210630_zokCQreGsQQh" style="display: none"&gt;3,223 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and
cash used in operating activities of $1.6 million&lt;span id="xdx_903_eifrs-full--CashFlowsFromUsedInOperatingActivities_pn3n3_c20210401__20210630_zfekiL6TnMF1" style="display: none"&gt;(1,580)&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.
As of July 31, 2021, we had approximately $&lt;span id="xdx_903_eifrs-full--CashOnHand_iI_pn3n3_dm_c20210630_zupEaMVPfY2d"&gt;28.0 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million
of cash on hand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span id="xdx_900_ecustom--OfferingAndThroughThatProcessDescription_c20210401__20210630_zzJfa1HSREWe" style="font: 10pt Times New Roman, Times, Serif" title="Offering and through that process description"&gt;During the quarter ended June 30, 2021, the Company commenced an &#x201c;at the market&#x201d; offering, under which
it sold 90,888 shares generating gross proceeds of approximately $2.6 million ($2.5 million, net of commissions). Further,
the Company initiated an offering pursuant to the Prospectus. On June 24, 2021, the Company completed a firm commitment underwritten
public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $26.5
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $1.8
million, including approximately $1.6 million of management, underwriting and selling expenses. The Company will use the net proceeds
raised to fund its research and development activities and support operations. The amount raised is sufficient to fund operations through
September 2022. Funds may be used to accelerate development activities to advance the Company&#x2019;s product portfolio, working capital
and general corporate purposes&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the
foreseeable future and may never become profitable. The losses result primarily from its conduct of research and development activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company historically has funded its operations principally from proceeds from issuances of equity and debt securities and would expect
to enter the capital markets if additional funding is required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;COVID-19 Effect&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;B&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;eginning
in early March 2020, the COVID-19 pandemic and the measures imposed to contain this pandemic have disrupted and are expected to continue
to impact the Company's business operations. The magnitude of the impact of the COVID-19 pandemic on the Company's productivity, results
of operations and financial position, and its disruption to the Company's business and clinical programs and timelines, will depend,
in part, on the length and severity of these restrictions and on the Company's ability to conduct business in the ordinary course.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ptgef:LiquidityTextBlock>
    <ifrs-full:Cash contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">28600000</ifrs-full:Cash>
    <ifrs-full:CurrentLiabilities contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">2506000</ifrs-full:CurrentLiabilities>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3223000</ifrs-full:ProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-1580000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashOnHand contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">28000000.0</ifrs-full:CashOnHand>
    <ptgef:OfferingAndThroughThatProcessDescription contextRef="From2021-04-01to2021-06-30">During the quarter ended June 30, 2021, the Company commenced an &#x201c;at the market&#x201d; offering, under which
it sold 90,888 shares generating gross proceeds of approximately $2.6 million ($2.5 million, net of commissions). Further,
the Company initiated an offering pursuant to the Prospectus. On June 24, 2021, the Company completed a firm commitment underwritten
public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $26.5
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $1.8
million, including approximately $1.6 million of management, underwriting and selling expenses. The Company will use the net proceeds
raised to fund its research and development activities and support operations. The amount raised is sufficient to fund operations through
September 2022. Funds may be used to accelerate development activities to advance the Company&#x2019;s product portfolio, working capital
and general corporate purposes</ptgef:OfferingAndThroughThatProcessDescription>
    <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_80B_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_zFnmQM81bXg4" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
3. &lt;span id="xdx_822_zZne0Bfe82Vg"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Statement
of Compliance and Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
condensed consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards
(&#x201c;IFRS&#x201d;) issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;), IAS 34 &lt;i&gt;Interim Financial Reporting
&lt;/i&gt;and interpretations of the International Financial Reporting Interpretations Committee. These condensed consolidated interim financial
statements do not include all of the information required for full annual financial statements and should be read in conjunction with
the audited consolidated financial statements of the Company for the year ended March 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
condensed consolidated interim financial statements have been prepared on an historical cost basis except for items disclosed herein
at fair value (see Note ----19, Financial Instruments and Risk Management&#x201d;). In addition, these condensed consolidated interim
financial statements have been prepared using the accrual basis of accounting, except for cash flow information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has only one reportable operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
condensed consolidated interim financial statements were approved and authorized for issuance by the Audit Committee and Board of Directors
on August &lt;span style="background-color: white"&gt;26&lt;/span&gt;, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
condensed consolidated interim financial statements include the accounts of the Company and,&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(a)
SalvaRx Limited (&#x201c;SalvaRx&#x201d;), a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(b)
iOx Therapeutics Ltd. (&#x201c;iOx&#x201d;), a United Kingdom based immune-oncology company, a &lt;span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20150201__20150210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesOneMember_ztp9stDcFj0f"&gt;60.49&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
subsidiary, incorporated in the United Kingdom on February 10, 2015.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(c)
Saugatuck Therapeutics, Ltd. (&#x201c;Saugatuck&#x201d;), a &lt;span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_zyDYIPfh9ZY7"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
owned subsidiary incorporated in the British Virgin Islands.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(d)
Portage Developmental Services, a 100% owned subsidiary incorporated in Delaware, which provides human resources, and other services
to each operating subsidiary via a shared services agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;























&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following companies were disposed of on March 3, 2021 (see Note 8, &#x201c;Disposition of PPL&#x201d;):&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 12.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Portage
                                            Pharmaceuticals Ltd. (&#x201c;PPL&#x201d;), a wholly-owned subsidiary acquired in a merger
                                            on July 23, 2013, incorporated in the British Virgin Islands.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 12.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;EyGen
                                            Limited, (&#x201c;EyGen&#x201d;), a wholly-owned subsidiary of PPL, incorporated on September
                                            20, 2016, in the British Virgin Islands.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 12.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Portage
                                            Glasgow Ltd. (&#x201c;PGL&#x201d;), a &lt;span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pdp0_dp_c20180103__20180131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PortageGlasgowLtdMember_zPapxxO7Q17d"&gt;65&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
                                            subsidiary of PPL, incorporated in Glasgow, Scotland.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;All
inter-company balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Non-controlling
interest in the equity of a subsidiary is accounted for and reported as a component of stockholders&#x2019; equity. Non-controlling interests
represent the &lt;span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesThreeMember_zZM5gvi1rFQk"&gt;39.51&lt;/span&gt;&lt;/span&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;%
shareholder ownership interest in iOx and the &lt;span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_zM3ZcHUgUOPj"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;%
shareholder ownership interest in Saugatuck, which are consolidated by the Company. In years prior to March 31, 2021, non-controlling
interest also included &lt;span id="xdx_908_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--SubsidiariesMember_zclBkFNGkO7g"&gt;35&lt;/span&gt;&lt;/span&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;%
in PGL.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Functional
and Presentation Currency&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s functional and presentation currency is the U.S. Dollar.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates
and Judgments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of the condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments,
estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income
and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which
the estimates are revised and in any future periods affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Significant
areas where estimates are made include valuation of financial instruments, research and development costs, fair value used for acquisition
and measurement of share-based compensation. Significant areas where critical judgments are applied include assessment of impairment
of investments and goodwill and the determination of the accounting acquirer and acquiree in the business combination accounting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Certain
prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on
the reported results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;















</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2015-02-012015-02-10_custom_SubsidiariesOneMember"
      decimals="INF"
      unitRef="Pure">0.6049</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2021-04-012021-06-30_custom_SubsidiariesTwoMember"
      decimals="INF"
      unitRef="Pure">0.70</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2018-01-032018-01-31_custom_PortageGlasgowLtdMember"
      decimals="INF"
      unitRef="Pure">0.65</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2021-04-012021-06-30_custom_SubsidiariesThreeMember"
      decimals="INF"
      unitRef="Pure">0.3951</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
      contextRef="From2021-04-012021-06-30_custom_SubsidiariesTwoMember"
      decimals="INF"
      unitRef="Pure">0.30</ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests>
    <ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
      contextRef="From2021-04-012021-06-30_ifrs-full_SubsidiariesMember"
      decimals="INF"
      unitRef="Pure">0.35</ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_80C_eifrs-full--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_z4WsQ66SBqCh" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
4. &lt;span id="xdx_823_zGRLTd8XwCPj"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
accounting policies are set out in Note 4 to the fiscal 2021 audited consolidated financial statements. These policies have been applied
consistently to all periods presented in these condensed consolidated interim financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_z4mLy5fbVNWa" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span id="xdx_868_zhHGqONeO9Ik" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Recent
Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Impact of Adoption
of Significant New IFRS Standards in 2020&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;IAS
                                            1: Presentation of Financial Statements, and IAS 8: Accounting Policies, Changes in Accounting
                                            Estimates and Errors (Amendment)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
amendments to IAS 1 and IAS 8 clarify the definition of material and seek to align the definition used in the Conceptual Framework with
that in the standards themselves, as well as ensuring the definition of material is consistent across all IFRS. The Company adopted these
amendments effective January 1, 2020. The adoption of these amendments did not have a significant impact on the Company&#x2019;s annual
consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Conceptual
                                            Framework for Financial Reporting&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;Together
with the revised Conceptual Framework published in March 2018, the IASB also issued Amendments to References to the Conceptual Framework
in IFRS Standards. The Company adopted the Revised Conceptual Framework effective January 1, 2020. The adoption of these amendments did
not have a significant impact on the Company&#x2019;s annual consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;IFRS Pronouncements
Issued But Not Yet Effective&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;New Accounting
Standards, Interpretations and Amendments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Standards
issued but not yet effective up to the date of issuance of the Company's condensed consolidated interim financial statements are listed
below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date.
The Company intends to adopt those standards when they become effective.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Annual
                                            Improvements to IFRS Standards 2018-2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.35in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
annual improvements process addresses issues in the 2018-2020 reporting cycles including changes to IFRS 9, &#x201c;Financial Instruments,&#x201d;
IFRS 1, &#x201c;First Time Adoption of IFRS,&#x201d; IFRS 16, &#x201c;Leases,&#x201d; and IAS 41, &#x201c;Biological Assets&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;i)
The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition of financial liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ii)
The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent to also measure cumulative translation differences
using the amounts reported by the parent based on the parent&#x2019;s date of transition to IFRS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iii)
The amendment to IFRS 16&#x2019;s illustrative example 13 removes the illustration of payments from the lessor related to leasehold improvements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
amendments will be effective for annual periods beginning on or after January 1, 2022. The Company is currently evaluating the new guidance
and impacts on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



















&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(d)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;IAS
                                            37: Onerous Contracts - Cost of Fulfilling a Contract&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
amendment to IAS 37 clarifies the meaning of costs to fulfil a contract and that before a separate provision for an onerous contract
is established, an entity recognizes any impairment loss that has occurred on assets used in fulfilling the contract, rather than on
assets dedicated to the contract. This amendment will be effective for annual periods beginning on or after January 1, 2022. The Company
is currently evaluating the new guidance and impacts on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(e)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;IAS
                                            16: Proceeds Before Intended Use&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
amendment to IAS 16 prohibits an entity from deducting from the cost of an item of Property, plant and equipment any proceeds received
from selling items produced while the entity is preparing the assets for its intended use (for example, the proceeds from selling samples
produced when testing a machine to see if it is functioning properly). It also clarifies that an entity is testing whether the asset
is functioning properly when it assesses the technical and physical performance of the asset. The amendment also requires certain related
disclosures. This amendment will be effective for annual periods beginning on or after January 1, 2022. The Company is currently evaluating
the new guidance and impacts on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(f)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;IAS
                                            1: Presentation of Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
amendment to IAS 1 clarifies how to classify debt and other liabilities as either current or non-current. The amendment will be effective
for annual periods beginning on or after January 1, 2023. The Company is currently evaluating the new guidance and impacts on its consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(g)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amendments
                                            to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate
                                            or Joint Venture&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
amendment addresses the conflict between IFRS 10 and IAS 28 in dealing with the loss of control of a subsidiary that is sold or contributed
to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that
constitute a business, as defined in IFRS 3, between an investor and its associate or joint venture, is recognized in full. Any gain
or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognized only to the extent
of unrelated investors' interests in the associate or joint venture. The IASB has deferred the effective date of these amendments indefinitely,
but an entity that early adopts the amendments must apply them prospectively. The Company is evaluating whether the adoption of the above
amendment will have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;















</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_844_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_z4mLy5fbVNWa" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span id="xdx_868_zhHGqONeO9Ik" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Recent
Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Impact of Adoption
of Significant New IFRS Standards in 2020&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;IAS
                                            1: Presentation of Financial Statements, and IAS 8: Accounting Policies, Changes in Accounting
                                            Estimates and Errors (Amendment)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
amendments to IAS 1 and IAS 8 clarify the definition of material and seek to align the definition used in the Conceptual Framework with
that in the standards themselves, as well as ensuring the definition of material is consistent across all IFRS. The Company adopted these
amendments effective January 1, 2020. The adoption of these amendments did not have a significant impact on the Company&#x2019;s annual
consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Conceptual
                                            Framework for Financial Reporting&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;Together
with the revised Conceptual Framework published in March 2018, the IASB also issued Amendments to References to the Conceptual Framework
in IFRS Standards. The Company adopted the Revised Conceptual Framework effective January 1, 2020. The adoption of these amendments did
not have a significant impact on the Company&#x2019;s annual consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;IFRS Pronouncements
Issued But Not Yet Effective&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;New Accounting
Standards, Interpretations and Amendments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Standards
issued but not yet effective up to the date of issuance of the Company's condensed consolidated interim financial statements are listed
below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date.
The Company intends to adopt those standards when they become effective.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Annual
                                            Improvements to IFRS Standards 2018-2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.35in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
annual improvements process addresses issues in the 2018-2020 reporting cycles including changes to IFRS 9, &#x201c;Financial Instruments,&#x201d;
IFRS 1, &#x201c;First Time Adoption of IFRS,&#x201d; IFRS 16, &#x201c;Leases,&#x201d; and IAS 41, &#x201c;Biological Assets&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;i)
The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition of financial liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ii)
The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent to also measure cumulative translation differences
using the amounts reported by the parent based on the parent&#x2019;s date of transition to IFRS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iii)
The amendment to IFRS 16&#x2019;s illustrative example 13 removes the illustration of payments from the lessor related to leasehold improvements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
amendments will be effective for annual periods beginning on or after January 1, 2022. The Company is currently evaluating the new guidance
and impacts on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



















&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(d)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;IAS
                                            37: Onerous Contracts - Cost of Fulfilling a Contract&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
amendment to IAS 37 clarifies the meaning of costs to fulfil a contract and that before a separate provision for an onerous contract
is established, an entity recognizes any impairment loss that has occurred on assets used in fulfilling the contract, rather than on
assets dedicated to the contract. This amendment will be effective for annual periods beginning on or after January 1, 2022. The Company
is currently evaluating the new guidance and impacts on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(e)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;IAS
                                            16: Proceeds Before Intended Use&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
amendment to IAS 16 prohibits an entity from deducting from the cost of an item of Property, plant and equipment any proceeds received
from selling items produced while the entity is preparing the assets for its intended use (for example, the proceeds from selling samples
produced when testing a machine to see if it is functioning properly). It also clarifies that an entity is testing whether the asset
is functioning properly when it assesses the technical and physical performance of the asset. The amendment also requires certain related
disclosures. This amendment will be effective for annual periods beginning on or after January 1, 2022. The Company is currently evaluating
the new guidance and impacts on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(f)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;IAS
                                            1: Presentation of Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
amendment to IAS 1 clarifies how to classify debt and other liabilities as either current or non-current. The amendment will be effective
for annual periods beginning on or after January 1, 2023. The Company is currently evaluating the new guidance and impacts on its consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(g)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amendments
                                            to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate
                                            or Joint Venture&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
amendment addresses the conflict between IFRS 10 and IAS 28 in dealing with the loss of control of a subsidiary that is sold or contributed
to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that
constitute a business, as defined in IFRS 3, between an investor and its associate or joint venture, is recognized in full. Any gain
or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognized only to the extent
of unrelated investors' interests in the associate or joint venture. The IASB has deferred the effective date of these amendments indefinitely,
but an entity that early adopts the amendments must apply them prospectively. The Company is evaluating whether the adoption of the above
amendment will have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;















</ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_809_eifrs-full--DisclosureOfOtherAssetsExplanatory_zT8NhJfCrF9a" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
5. &lt;span id="xdx_822_zL3MH4R5mVM9"&gt;PREPAID EXPENSES AND OTHER RECEIVABLES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_zzPU8Y1MX4l" style="width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zATsIatsLBW3" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20210630_zLITEimfRkmb" style="white-space: nowrap; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_492_20210331_zc7OQMsU7nra" style="white-space: nowrap; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;b&gt;As
    of&lt;br/&gt; June 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;b&gt;As
    of&lt;br/&gt; March 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid
    insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,032&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,445&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
    &amp;amp; development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;849&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;649&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
    prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
    receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--CurrentPrepayments_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,995&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,176&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
October 2016, the Company's wholly-owned subsidiary, PPL, agreed to a settlement, from a claim made against a supplier, to receive $&lt;span id="xdx_90A_eifrs-full--Accruals_c20161031__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0"&gt;120,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;in annual instalments of $&lt;span id="xdx_907_eifrs-full--LoansPayableInDefault_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0"&gt;11,250&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.&#160;
Through June 30, 2021, the Company has collected $&lt;span id="xdx_909_eifrs-full--TradeAndOtherReceivables_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0"&gt;86,250&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.
The balance of $&lt;span id="xdx_900_eifrs-full--CurrentPortionOfLongtermBorrowings_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0"&gt;33,750
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;was classified $11,250 as a current asset in
prepaid expenses and other receivables and $&lt;span id="xdx_903_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0"&gt;22,500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;as a long-term receivable as of each of June
30, 2021 and March 31, 2021. The installment receivable was assigned to Portage by PPL prior to the disposition of PPL (see Note 8, &#x201c;Disposition
of PPL&#x201d;). The installment note was repaid in full in July 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_zzPU8Y1MX4l" style="width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zATsIatsLBW3" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20210630_zLITEimfRkmb" style="white-space: nowrap; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_492_20210331_zc7OQMsU7nra" style="white-space: nowrap; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;b&gt;As
    of&lt;br/&gt; June 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;b&gt;As
    of&lt;br/&gt; March 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid
    insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,032&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,445&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
    &amp;amp; development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;849&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;649&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
    prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
    receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--CurrentPrepayments_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,995&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,176&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock>
    <ifrs-full:CurrentAdvancesToSuppliers contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">1032000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1445000</ifrs-full:CurrentAdvancesToSuppliers>
    <ptgef:ResearchAndDevelopmentCredit contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">849000</ptgef:ResearchAndDevelopmentCredit>
    <ptgef:ResearchAndDevelopmentCredit contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">649000</ptgef:ResearchAndDevelopmentCredit>
    <ifrs-full:CurrentPrepaidExpenses contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">80000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">48000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentReceivables contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">34000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">34000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">1995000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">2176000</ifrs-full:CurrentPrepayments>
    <ifrs-full:Accruals
      contextRef="AsOf2016-10-31_custom_PPLSettlementMember"
      decimals="0"
      unitRef="USD">120000</ifrs-full:Accruals>
    <ifrs-full:LoansPayableInDefault
      contextRef="AsOf2021-06-30_custom_PPLSettlementMember"
      decimals="0"
      unitRef="USD">11250</ifrs-full:LoansPayableInDefault>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="AsOf2021-06-30_custom_PPLSettlementMember"
      decimals="0"
      unitRef="USD">86250</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="AsOf2021-06-30_custom_PPLSettlementMember"
      decimals="0"
      unitRef="USD">33750</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ptgef:PrepaidExpensesAndOtherReceivables
      contextRef="AsOf2021-06-30_custom_PPLSettlementMember"
      decimals="0"
      unitRef="USD">22500</ptgef:PrepaidExpensesAndOtherReceivables>
    <ifrs-full:DisclosureOfAvailableforsaleAssetsExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_80D_eifrs-full--DisclosureOfAvailableforsaleAssetsExplanatory_zQ4StmvrigO7" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
6. &lt;span id="xdx_825_ztpAoZiaBXYk"&gt;INVESTMENT IN MARKETABLE EQUITY SECURITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of March 31, 2020, the Company&#x2019;s investment in marketable equity securities was comprised of &lt;span id="xdx_906_ecustom--InvestmentInMarketableEquitySecurities_pp0p0_c20200401__20200630_zXT1LewwsJi7" title="Investment in marketable equity securities"&gt;2,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares in Biohaven Pharmaceutical Holding Company
Limited (&#x201c;Biohaven&#x201d;), a public company listed on the New York Stock Exchange. The Company accounted for its investment in
Biohaven as a financial asset classified as fair value through the statement of other comprehensive income (&#x201c;FVTOCI&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2020, the Company sold the shares of Biohaven for proceeds of $&lt;span id="xdx_90D_eifrs-full--ProceedsFromIssuingShares_c20200801__20200830__ifrs-full--TypeOfMeasurementOfExpectedCreditLossesAxis__custom--BiohavenMember_pp0p0"&gt;140,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;resulting in a gain of $&lt;span id="xdx_903_ecustom--UnrealizedGains_c20200801__20200830__ifrs-full--TypeOfMeasurementOfExpectedCreditLossesAxis__custom--BiohavenMember_pp0p0"&gt;72,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table is a roll-forward of the investment in Biohaven as of June 30, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eifrs-full--DisclosureOfInvestmentPropertyExplanatory_pn3n3_zEAii1U9Fq69" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_8B8_zSrRpKxvKXVh" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of investment in marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--InvestmentAssetAvailableForSale_iS_pn3n3_c20210401__20210630_zCA5Qnlbfw9e" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of year"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0536"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InvestmentAssetAvailableForSale_iS_pn3n3_c20200401__20200630_zlwkqBfF1wz1" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, beginning of year"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;68&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Unrealized
    gain on investment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--UnrealizedLossGainOnInvestment_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Unrealized (loss) gain on investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0540"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--UnrealizedLossGainOnInvestment_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Unrealized (loss) gain on investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;78&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--InvestmentAssetAvailableForSale_iE_pn3n3_c20210401__20210630_zP6Npos3TaPe" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of year"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0544"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--InvestmentAssetAvailableForSale_iE_pn3n3_c20200401__20200630_zsb26HMHNDYf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of year"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;146&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfAvailableforsaleAssetsExplanatory>
    <ptgef:InvestmentInMarketableEquitySecurities
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">2000</ptgef:InvestmentInMarketableEquitySecurities>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="From2020-08-012020-08-30_custom_BiohavenMember"
      decimals="0"
      unitRef="USD">140000</ifrs-full:ProceedsFromIssuingShares>
    <ptgef:UnrealizedGains
      contextRef="From2020-08-012020-08-30_custom_BiohavenMember"
      decimals="0"
      unitRef="USD">72000</ptgef:UnrealizedGains>
    <ifrs-full:DisclosureOfInvestmentPropertyExplanatory contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eifrs-full--DisclosureOfInvestmentPropertyExplanatory_pn3n3_zEAii1U9Fq69" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_8B8_zSrRpKxvKXVh" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of investment in marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--InvestmentAssetAvailableForSale_iS_pn3n3_c20210401__20210630_zCA5Qnlbfw9e" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of year"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0536"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InvestmentAssetAvailableForSale_iS_pn3n3_c20200401__20200630_zlwkqBfF1wz1" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, beginning of year"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;68&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Unrealized
    gain on investment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--UnrealizedLossGainOnInvestment_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Unrealized (loss) gain on investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0540"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--UnrealizedLossGainOnInvestment_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Unrealized (loss) gain on investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;78&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--InvestmentAssetAvailableForSale_iE_pn3n3_c20210401__20210630_zP6Npos3TaPe" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of year"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0544"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--InvestmentAssetAvailableForSale_iE_pn3n3_c20200401__20200630_zsb26HMHNDYf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of year"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;146&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInvestmentPropertyExplanatory>
    <ptgef:InvestmentAssetAvailableForSale contextRef="AsOf2020-03-31" decimals="-3" unitRef="USD">68000</ptgef:InvestmentAssetAvailableForSale>
    <ptgef:UnrealizedLossGainOnInvestment
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">78000</ptgef:UnrealizedLossGainOnInvestment>
    <ptgef:InvestmentAssetAvailableForSale contextRef="AsOf2020-06-30" decimals="-3" unitRef="USD">146000</ptgef:InvestmentAssetAvailableForSale>
    <ptgef:InvestmentInAssociateDisclosureTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_807_ecustom--InvestmentInAssociateDisclosureTextBlock_zNgueblrnsHf" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
7. &lt;span id="xdx_828_zIAPcWTwcxFf"&gt;INVESTMENT IN ASSOCIATE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Details
of the Company&#x2019;s associate as of June 30, 2021 and March 31, 2021 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_z67DQh5jFEVl" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE  (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_8BA_zMrtrCHDZEqc" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of investment associate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Principal
    Activity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Place
    of Incorporation and &lt;br/&gt;Principal Place of Business&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Voting
    Rights Held as &lt;br/&gt;of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Voting
    Rights Held as &lt;br/&gt;of March&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; font-size: 10pt; text-align: justify"&gt;&lt;span id="xdx_906_eifrs-full--NameOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif"&gt;Associate:
    Stimunity S.A.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90E_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif"&gt;Paris,
    France&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z8kB5OGIJDr9" style="font: 10pt Times New Roman, Times, Serif"&gt;44&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.0%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210101__20210331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zrKCG6wMVcLi" style="font: 10pt Times New Roman, Times, Serif"&gt;44.0&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A2_zMp0Lez7Lbig" style="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
abovementioned associate is accounted for using the equity method in these condensed consolidated interim financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table is a roll-forward of the Company&#x2019;s investment in Stimunity S.A. as of June 30, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_z2mnB0ETQFp1" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE  (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zZOiRpE3Z168" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of investment in Stimunity S.A.&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20210401__20210630_z9Y2sFe9cxhc" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,735&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20200401__20200630_ztP8YlyKyPad" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,225&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Additional
    investment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--AdditionalInvestments_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Additional investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0571"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AdditionalInvestments_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Additional investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Share
    of (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--UnrecognisedShareOfGainLossesOfAssociates_pn3n3_c20210401__20210630_zyj2KG9btyu5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share of (loss) income"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(44&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--UnrecognisedShareOfGainLossesOfAssociates_pn3n3_c20200401__20200630_zlhnYiClQRm8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share of (loss) income"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;440&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20210401__20210630_z8ORzsOCDjP5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,691&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20200401__20200630_zZNFddVsYCwi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,665&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zgBSoYA7TdLb" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 1, 2020, the Company made an additional $&lt;span id="xdx_90D_ecustom--AdditionalInvestments_pn3n3_dm_c20200530__20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zMcJ4aw24Umf"&gt;1.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million investment in Stimunity upon Stimunity's
achievement of certain agreed milestones, increasing its equity share in Stimunity to &lt;span id="xdx_902_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zkmJHsDGjHP7"&gt;44&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
(see Note 17, &#x201c;Commitments and Contingent Liabilities&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for its investment in Stimunity under the equity method and accordingly, records its share of Stimunity&#x2019;s earnings
or loss based on its ownership percentage. The Company recorded equity in (loss) income in Stimunity of ($&lt;span id="xdx_900_ecustom--EquityInLossIncome_pn3p0_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z1hYvKNiFmk6" title="Equity in loss income"&gt;44,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)
and $&lt;span id="xdx_90B_ecustom--EquityInLossIncome_pn3p0_c20200401__20200630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zJJo5SMvZXE9"&gt;440,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the three months ended June 30, 2021 and
2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the shareholders agreement, Portage has (i) a preferential subscription right to maintain its equity interest in Stimunity in the event
of a capital increase from the issuance of new securities by Stimunity, except for issuances of new securities for stock options under
a merger plan or for an acquisition, or (ii) the right to vote against any (a) issuances of additional securities that would call for
the Company to waive its preferential subscription right, or (b) any dilutive issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





































</ptgef:InvestmentInAssociateDisclosureTextBlock>
    <ptgef:DisclosureOfInvestmentAssociatetableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_z67DQh5jFEVl" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE  (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_8BA_zMrtrCHDZEqc" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of investment associate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Principal
    Activity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Place
    of Incorporation and &lt;br/&gt;Principal Place of Business&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Voting
    Rights Held as &lt;br/&gt;of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Voting
    Rights Held as &lt;br/&gt;of March&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; font-size: 10pt; text-align: justify"&gt;&lt;span id="xdx_906_eifrs-full--NameOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif"&gt;Associate:
    Stimunity S.A.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90E_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif"&gt;Paris,
    France&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z8kB5OGIJDr9" style="font: 10pt Times New Roman, Times, Serif"&gt;44&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.0%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210101__20210331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zrKCG6wMVcLi" style="font: 10pt Times New Roman, Times, Serif"&gt;44.0&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ptgef:DisclosureOfInvestmentAssociatetableTextBlock>
    <ifrs-full:NameOfAssociate contextRef="From2021-04-012021-06-30_custom_StimunitySAMember">Associate:
    Stimunity S.A.</ifrs-full:NameOfAssociate>
    <ifrs-full:PrincipalPlaceOfBusinessOfAssociate contextRef="From2021-04-012021-06-30_custom_StimunitySAMember">Biotechnology</ifrs-full:PrincipalPlaceOfBusinessOfAssociate>
    <ifrs-full:CountryOfIncorporationOrResidenceOfAssociate contextRef="From2021-04-012021-06-30_custom_StimunitySAMember">Paris,
    France</ifrs-full:CountryOfIncorporationOrResidenceOfAssociate>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="From2021-04-012021-06-30_custom_StimunitySAMember"
      decimals="INF"
      unitRef="Pure">0.44</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="From2021-01-012021-03-31_custom_StimunitySAMember"
      decimals="INF"
      unitRef="Pure">0.440</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <ptgef:ScheduleOfInvestmentInStimunitySaTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_z2mnB0ETQFp1" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE  (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zZOiRpE3Z168" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of investment in Stimunity S.A.&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20210401__20210630_z9Y2sFe9cxhc" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,735&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20200401__20200630_ztP8YlyKyPad" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,225&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Additional
    investment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--AdditionalInvestments_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Additional investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0571"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AdditionalInvestments_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Additional investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Share
    of (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--UnrecognisedShareOfGainLossesOfAssociates_pn3n3_c20210401__20210630_zyj2KG9btyu5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share of (loss) income"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(44&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--UnrecognisedShareOfGainLossesOfAssociates_pn3n3_c20200401__20200630_zlhnYiClQRm8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share of (loss) income"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;440&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20210401__20210630_z8ORzsOCDjP5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,691&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20200401__20200630_zZNFddVsYCwi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,665&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfInvestmentInStimunitySaTableTextBlock>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1735000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2020-03-31" decimals="-3" unitRef="USD">1225000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ptgef:AdditionalInvestments
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">1000000</ptgef:AdditionalInvestments>
    <ptgef:UnrecognisedShareOfGainLossesOfAssociates
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-44000</ptgef:UnrecognisedShareOfGainLossesOfAssociates>
    <ptgef:UnrecognisedShareOfGainLossesOfAssociates
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">440000</ptgef:UnrecognisedShareOfGainLossesOfAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">1691000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2020-06-30" decimals="-3" unitRef="USD">2665000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ptgef:AdditionalInvestments
      contextRef="From2020-05-302020-06-01_custom_StimunitySAMember"
      decimals="-3"
      unitRef="USD">1000000.0</ptgef:AdditionalInvestments>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="From2021-04-012021-06-30_custom_StimunitySAMember"
      decimals="INF"
      unitRef="Pure">0.44</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <ptgef:EquityInLossIncome
      contextRef="From2021-04-012021-06-30_custom_StimunitySAMember"
      decimals="-3"
      unitRef="USD">44000</ptgef:EquityInLossIncome>
    <ptgef:EquityInLossIncome
      contextRef="From2020-04-012020-06-30_custom_StimunitySAMember"
      decimals="-3"
      unitRef="USD">440000</ptgef:EquityInLossIncome>
    <ptgef:DispositionOfPplTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_807_ecustom--DispositionOfPplTextBlock_zFwwE7s7p7La" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
8. &lt;span id="xdx_829_zDtrM7TLPvs1"&gt;DISPOSITION OF PPL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
March 3, 2021, the Company disposed of &lt;span id="xdx_908_ecustom--DispositionPercentage_dp_c20210301__20210303__dei--LegalEntityAxis__custom--PortageGlasgowLtdMember_zojUfQwrx9Ui" title="Disposition Percentage"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of its interest in PPL, which includes PPL&#x2019;s interest in PGL and EyGen for $&lt;span id="xdx_90A_ecustom--DispositionValue_pp0p0_c20210301__20210303__dei--LegalEntityAxis__custom--PortageGlasgowLtdMember_z6e1bqDWqmNd" title="Disposition value"&gt;10
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;to an entity controlled by one of the Company&#x2019;s
current directors and one of the Company&#x2019;s former directors (the &#x201c;Purchaser&#x2019;s Executives&#x201d;). Under the terms of
the arrangement, all outstanding payable obligations were assumed by the purchaser. Simultaneously, the Company and the Purchaser&#x2019;s
Executives entered into a Revenue Share Deed with PPL under which they will be entitled to certain revenue shares based on the achievement
of milestones defined in the Revenue Share Deed. The Company may also be entitled to recover an intercompany receivable from the purchaser
in the amount of $&lt;span id="xdx_908_ecustom--IntercompanyReceivable_iI_pp0p0_c20210303__dei--LegalEntityAxis__custom--PortageGlasgowLtdMember_zYWRAmXayFtg" title="Intercompany receivable"&gt;229,848
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;on the fourth anniversary of the Revenue Share
Deed. The Company valued its interest in the Revenue Share Deed and the recovery of the $229,848 at zero for financials statement purposes.
All other intercompany balances were cancelled. The Company no longer has any interest or obligations associated with PPL, PGL and EyGen,
other than the interests provided for in the Revenue Share Deed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ptgef:DispositionOfPplTextBlock>
    <ptgef:DispositionPercentage
      contextRef="From2021-03-012021-03-03_custom_PortageGlasgowLtdMember"
      decimals="INF"
      unitRef="Pure">1</ptgef:DispositionPercentage>
    <ptgef:DispositionValue
      contextRef="From2021-03-012021-03-03_custom_PortageGlasgowLtdMember"
      decimals="0"
      unitRef="USD">10</ptgef:DispositionValue>
    <ptgef:IntercompanyReceivable
      contextRef="AsOf2021-03-03_custom_PortageGlasgowLtdMember"
      decimals="0"
      unitRef="USD">229848</ptgef:IntercompanyReceivable>
    <ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_80B_ecustom--DisclosureOfPrivateCompaniesExplanatoryTextBlock_zIxMHPCnZrwe" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
9. &lt;span id="xdx_823_z5UEKgMCo2p3"&gt;INVESTMENTS IN PRIVATE COMPANIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following is a discussion of our investments in private companies as of June 30, 2021 and March 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Sentien&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2015, the Company acquired &lt;span id="xdx_90E_ecustom--InvestmentOwnedShares_iI_c20150831__ifrs-full--CounterpartiesAxis__custom--SeriesAPreferredStockInSentienBiotechnologiesMember_zQjWjYloYLBj"&gt;210,210
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of Series A preferred stock in Sentien
(&#x201c;Preferred Stock&#x201d;), a Medford, MA based private company for $700,000 of cash. The Preferred Stock is fully convertible into
an equal number of common shares. The Company&#x2019;s holdings represent &lt;span id="xdx_906_ecustom--InvestmentOwnershipPercentage_iI_dp_c20210331__ifrs-full--CounterpartiesAxis__custom--SeriesAPreferredStockInSentienBiotechnologiesMember_zCPDoNwOxsbj"&gt;5.06&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the equity of Sentien on a fully diluted basis as of June 30, 2021 and March 31, 2021, respectively. The investment in Sentien has
been irrevocably designated as a financial asset recorded at fair value with changes in fair value recorded through other comprehensive
income. As of March 31, 2020, the Company recorded an unrealized loss of $&lt;span id="xdx_909_ecustom--UnrealizedGainLossOnInvestment_pn3n3_dm_c20210401__20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_z2ZHsIjzFTFk"&gt;0.7
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million after determining that cost no longer
was the best estimate of fair value due to a significant change in the strategy of Sentien and determined that the investment in Sentien
no longer had any fair value as Sentien was no longer pursing the proposed indication from the time of the Company's initial investment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Intensity&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the SalvaRx Acquisition in fiscal 2019, the Company acquired a $4.5 million interest in Intensity, a clinical stage biotechnology
company, of &lt;span id="xdx_90B_ecustom--InvestmentOwnedShares_iI_pp0n3_dm_c20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_zbmw6dwLk7j5"&gt;1.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million shares, which represented a &lt;span id="xdx_90A_ecustom--InvestmentOwnershipPercentage_iI_dp_c20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_zbksqj4IWeg3"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
equity interest in Intensity. The investment was recorded at fair value (which approximates cost) at the acquisition date. The investment
in Intensity has been irrevocably designated as a financial asset recorded at fair value with gains and losses recorded through other
comprehensive income. The fair value of the asset is determined by considering other comparable equity funding transactions by Intensity
with unrelated investors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
July 11, 2019, the Company entered into an agreement with Fast Forward Innovations Limited ("Fast Forward") to purchase Intensity
Holdings Limited ("IHL"), a wholly-owned subsidiary of Fast Forward. The Company paid $&lt;span id="xdx_909_eifrs-full--EquityInterestsOfAcquirer_iI_pn3n3_dm_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zmpUmR68PASd"&gt;1.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million for IHL through the issuance of &lt;span id="xdx_90D_eifrs-full--NumberOfInstrumentsOrInterestsIssuedOrIssuable_iI_uShares_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_znzpDI4xcVl6"&gt;129,806
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ordinary shares. The sole asset of IHL consists
of &lt;span id="xdx_902_ecustom--NumberOfPrivateCompanyShareConsistsInSoleAsset_iI_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zIUbGEVr0V4h"&gt;288,458
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of the private company, Intensity. This
transaction increased the Company's ownership to &lt;span id="xdx_909_eifrs-full--NumberOfSharesOutstanding_iI_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zspeD25odiX8"&gt;1,288,458
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of Intensity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended March 31, 2020, the Company recorded an unrealized gain of $&lt;span id="xdx_907_ecustom--UnrealizedGainLossOnInvestment_pn3n3_dm_c20200401__20200630__ifrs-full--CounterpartiesAxis__custom--IntensityMember_ziHX5cqInkz5"&gt;1.6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million with respect to its investment in Intensity
based upon Intensity&#x2019;s then most recent valuation. There were no unrealized gains or losses recognized in the three-month periods
ended June 30, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of each of June 30, 2021 and March 31, 2021, the Company owned approximately &lt;span id="xdx_908_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_dp_c20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zb1vK55IFOQb"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the outstanding shares of Intensity, on a fully diluted basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;















</ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock>
    <ptgef:InvestmentOwnedShares
      contextRef="AsOf2015-08-31_custom_SeriesAPreferredStockInSentienBiotechnologiesMember"
      decimals="INF"
      unitRef="Shares">210210</ptgef:InvestmentOwnedShares>
    <ptgef:InvestmentOwnershipPercentage
      contextRef="AsOf2021-03-31_custom_SeriesAPreferredStockInSentienBiotechnologiesMember"
      decimals="INF"
      unitRef="Pure">0.0506</ptgef:InvestmentOwnershipPercentage>
    <ptgef:UnrealizedGainLossOnInvestment
      contextRef="From2021-04-012021-06-30_custom_IntensityMember_custom_AcquisitionOfSalvaRxMember"
      decimals="-3"
      unitRef="USD">700000</ptgef:UnrealizedGainLossOnInvestment>
    <ptgef:InvestmentOwnedShares
      contextRef="AsOf2021-06-30_custom_IntensityMember_custom_AcquisitionOfSalvaRxMember"
      decimals="0"
      unitRef="Shares">1000000.0</ptgef:InvestmentOwnedShares>
    <ptgef:InvestmentOwnershipPercentage
      contextRef="AsOf2021-06-30_custom_IntensityMember_custom_AcquisitionOfSalvaRxMember"
      decimals="INF"
      unitRef="Pure">0.075</ptgef:InvestmentOwnershipPercentage>
    <ifrs-full:EquityInterestsOfAcquirer
      contextRef="AsOf2019-07-11_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember"
      decimals="-3"
      unitRef="USD">1300000</ifrs-full:EquityInterestsOfAcquirer>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="AsOf2019-07-11_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember"
      decimals="INF"
      unitRef="Shares">129806</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <ptgef:NumberOfPrivateCompanyShareConsistsInSoleAsset
      contextRef="AsOf2019-07-11_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember"
      decimals="INF"
      unitRef="Shares">288458</ptgef:NumberOfPrivateCompanyShareConsistsInSoleAsset>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2019-07-11_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember"
      decimals="INF"
      unitRef="Shares">1288458</ifrs-full:NumberOfSharesOutstanding>
    <ptgef:UnrealizedGainLossOnInvestment
      contextRef="From2020-04-012020-06-30_custom_IntensityMember"
      decimals="-3"
      unitRef="USD">1600000</ptgef:UnrealizedGainLossOnInvestment>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="AsOf2021-06-30_custom_IntensityMember_custom_AcquisitionOfIntensityHoldingLimitedMember"
      decimals="INF"
      unitRef="Pure">0.08</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_80D_eifrs-full--DisclosureOfResearchAndDevelopmentExpenseExplanatory_zoQbroQX59w7" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
10. &lt;span id="xdx_822_zdx7OPza6mSl"&gt;GOODWILL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_zmHSAVyZd0R6" style="width: 100%" summary="xdx: Disclosure - GOODWILL (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zwqsJO77v4r5" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of IPR&amp;amp;D projects&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;b&gt;As
    of&lt;br/&gt; June 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;b&gt;As
    of&lt;br/&gt; March 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--Goodwill_iI_pn3n3_c20210331_znUtYuntDBEk" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Goodwill"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;43,324&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--Goodwill_iI_pn3n3_c20200331_zSHCIr1yeFxf" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right" title="Goodwill"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;43,324&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--Goodwill_iI_pn3n3_c20210630_zeVA6ToRAL12" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Goodwill"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;43,324&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;43,324&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s goodwill arose from the acquisition of SalvaRx and its portfolio of several projects and investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021, the Company determined that it has only one cash-generating unit (&#x201c;CGU&#x201d;), the consolidated Portage Biotech,
Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Impairment
Review&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;On
an annual basis, pursuant to IAS 36, &#x201c;Impairment of Assets,&#x201d; the Company assesses its long-lived assets with definite lives,
which are not yet available for use, for potential indicators of impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
any such indication exists, the Company estimates the recoverable amount of the asset or CGU and compares it to the carrying value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company performed its annual impairment test in each of fiscal 2021 and fiscal 2020 and estimated the recoverable amount of the above-noted
CGU based on its value in use, which was determined using a capitalized cash flow methodology and categorized within level 3 of the fair
market value hierarchy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



























&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
recoverable amount of the CGU has been determined based on its value in use. The recoverable amount considered assumptions based on probabilities
of technical, regulatory and clinical acceptances and financial support. Further, Management uses risk-adjusted cash flow projections
based on financial budgets. Management believes that any reasonably possible change in the key assumptions on which the recoverable amount
is based would not cause the carrying amount to exceed its recoverable amount. The discount rate has been determined based on the Company&#x2019;s
best estimate of a risk adjusted discount rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
key assumptions used in the calculation of the recoverable amount include forecasts of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 35pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;revenues;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 35pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;normalized
                                            operating expenses;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 35pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;income
                                            taxes; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 35pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;capital
                                            expenditures.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Discounted
cash flows are determined with reference to undiscounted risk adjusted cash flows, and the discount rate approximated &lt;span id="xdx_90D_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_dp_c20210630_zvsSfxI3eRV4"&gt;20.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;%
and &lt;span id="xdx_90F_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_dp_c20210331_z7BKk5fH5mih"&gt;20.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;%
as of March 31, 2021 and 2020, respectively, based on the individual characteristics of the Company&#x2019;s CGU, the risk-free rate of
return and other economic and operating factors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 28.1pt; text-align: left"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Additionally,
at the end of each reporting period, the Company is required to assess whether there is any indication that an asset may be impaired.
Pursuant to IAS 36, the Company reviewed its assets for any indicators of impairment and considered underlying fundamentals, execution,
de-risking/advancement of assets and the value creation activities during the three months ended June 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021, management assessed whether any indications of impairment existed for the Company&#x2019;s CGU and concluded no indicators
were present. Therefore, a test for impairment was not required and no impairment was recorded for the three months ended June 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
    <ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_zmHSAVyZd0R6" style="width: 100%" summary="xdx: Disclosure - GOODWILL (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zwqsJO77v4r5" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of IPR&amp;amp;D projects&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;b&gt;As
    of&lt;br/&gt; June 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;b&gt;As
    of&lt;br/&gt; March 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--Goodwill_iI_pn3n3_c20210331_znUtYuntDBEk" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Goodwill"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;43,324&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--Goodwill_iI_pn3n3_c20200331_zSHCIr1yeFxf" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right" title="Goodwill"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;43,324&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--Goodwill_iI_pn3n3_c20210630_zeVA6ToRAL12" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Goodwill"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;43,324&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;43,324&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:Goodwill contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">43324000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="AsOf2020-03-31" decimals="-3" unitRef="USD">43324000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">43324000</ifrs-full:Goodwill>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections contextRef="AsOf2021-06-30" decimals="INF" unitRef="Pure">0.200</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections contextRef="AsOf2021-03-31" decimals="INF" unitRef="Pure">0.205</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_80A_ecustom--InProcessResearchAndDevelopmentAndDeferredTaxLiability_zFU0nASzyqN4" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
11. &lt;span id="xdx_827_zLFz3OUZaRC5"&gt;IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In-process
research and development (&#x201c;IPR&amp;amp;D&#x201d;) consists of the following projects (in 000&#x2019;$):&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_zy1DxOYFfoY3" style="width: 100%" summary="xdx: Disclosure - IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BF_zTlal8IvyLKh" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of In process research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Project
    #&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Value
    as of &lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Value
    as of &lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iOx:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 25%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;IMM 60&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Melanoma
    &amp;amp; Lung Cancers&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_z3i3mZ6d6ZE5" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;84,213&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_zPtYiObznPV" style="width: 22%; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;84,213&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;IMM 65&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Ovarian/Prostate
    Cancers&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_zG31u7vWUGz3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;32,997&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_zax1oFtyREpb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;32,997&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;117,210&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;117,210&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Oncomer/Saugatuck&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;DNA
    Aptamers&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zU6geDRVgr47" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;178&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zhv7HNT8Gt7g" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;178&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--InprocessResearchAndDevelopment_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;117,388&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--InprocessResearchAndDevelopment_c20210331_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;117,388&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
    tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--DeferredTaxLiabilities_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Deferred tax liability"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;24,171&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--DeferredTaxLiabilities_c20210331_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax liability"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;24,050&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

























&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021, management assessed whether any indications of impairment existed for the Company&#x2019;s IPR&amp;amp;D and concluded no
indicators were present. Therefore, a test for impairment was not required and no impairment was recorded for the three months ended
June 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
tax liability (DTL) represents iOx&#x2019;s estimated tax on the difference between book and tax basis of the IPR&amp;amp;D which is taxable
in the United Kingdom. As of June 30, 2021, the Company recorded deferred tax expense of $&lt;span id="xdx_900_eifrs-full--DeferredTaxExpenseIncome_pn3n3_dm_c20210401__20210630_zcvnznLgvfCb"&gt;0.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million to reflect the effect of the change in
currency translation rate during the three months ended June 30, 2021 for this obligation settleable in Great British Pounds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability>
    <ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_zy1DxOYFfoY3" style="width: 100%" summary="xdx: Disclosure - IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BF_zTlal8IvyLKh" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of In process research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Project
    #&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Value
    as of &lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Value
    as of &lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iOx:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 25%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;IMM 60&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Melanoma
    &amp;amp; Lung Cancers&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_z3i3mZ6d6ZE5" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;84,213&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_zPtYiObznPV" style="width: 22%; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;84,213&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;IMM 65&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Ovarian/Prostate
    Cancers&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_zG31u7vWUGz3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;32,997&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_zax1oFtyREpb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;32,997&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;117,210&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;117,210&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Oncomer/Saugatuck&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;DNA
    Aptamers&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zU6geDRVgr47" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;178&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zhv7HNT8Gt7g" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;178&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--InprocessResearchAndDevelopment_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;117,388&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--InprocessResearchAndDevelopment_c20210331_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;117,388&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
    tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--DeferredTaxLiabilities_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Deferred tax liability"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;24,171&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--DeferredTaxLiabilities_c20210331_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax liability"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;24,050&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2021-06-30_custom_IMM60IOXMelanomaLungCancersMember"
      decimals="-3"
      unitRef="USD">84213000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2021-03-31_custom_IMM60IOXMelanomaLungCancersMember"
      decimals="-3"
      unitRef="USD">84213000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2021-06-30_custom_IMM65IOXOvarianProstateCancersMember"
      decimals="-3"
      unitRef="USD">32997000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2021-03-31_custom_IMM65IOXOvarianProstateCancersMember"
      decimals="-3"
      unitRef="USD">32997000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2021-06-30_custom_OncomerSaugatuckDNAAptamersMember"
      decimals="-3"
      unitRef="USD">178000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2021-03-31_custom_OncomerSaugatuckDNAAptamersMember"
      decimals="-3"
      unitRef="USD">178000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">117388000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">117388000</ptgef:InprocessResearchAndDevelopment>
    <ifrs-full:DeferredTaxLiabilities contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">24171000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">24050000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">100000</ifrs-full:DeferredTaxExpenseIncome>
    <ptgef:UnsecuredNotesPayableAndWarrantsTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_807_ecustom--UnsecuredNotesPayableAndWarrantsTextBlock_zK8Oxtgar8F3" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
12. &lt;span id="xdx_829_zWk638dEkwXe"&gt;UNSECURED NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Following
is a roll-forward of notes payable:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfNotesPayableTableTextBlock_pn3n3_ztEgvgtOF8Zd" style="width: 100%" summary="xdx: Disclosure - UNSECURED NOTES PAYABLE (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zi5BnKUOfUDh" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;CURRENT&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;CURRENT&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;NON-CURRENT&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PPL&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iOx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SalvaRx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, April
    1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zlYDbqWAGgE3" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zExGdy5tgmS" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zBTF3CFoBMc5" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,361&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NotePayable_iS_pn3n3_c20200401__20210331_zt0fJP5fmmij" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,661&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Repayment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0704"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1,020&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--RepaymentOfNotesPayable_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1,020&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization
    of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0712"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0714"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;76&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AmortizationOfDebtDiscount_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;76&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Value of notes exchanged in
    warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0720"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0722"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2,640&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2,640&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Settlement
    in connection with disposition of PPL&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(200&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0732"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(200&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Loss on extinguishment
    of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0736"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0738"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;223&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;223&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Proceeds
    from loan payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0744"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0748"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ProceedsFromLoanPayable_c20200401__20210331_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zzSP6nG3oOTj" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0752"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zlP79saAfey7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zn77sbxo7mMg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0756"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NotePayable_iS_pn3n3_c20210401__20210630_zJl31BJTq3ol" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Proceeds
    from loan payable&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0762"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ProceedsFromLoanPayable_c20210401__20210630_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zItD8ZbzNFMc" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zFT0XLbrU3Qi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zezgC9M9RB79" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NotePayable_iE_pn3n3_c20210401__20210630_zQD9myfIu3o7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;PPL
and EyGen Unsecured Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended March 31, 2017, the Company's subsidiaries, PPL and EyGen, completed a private placement of unsecured notes (the "PPL
Unsecured Notes"). The balance outstanding as of March 31, 2020 was $&lt;span id="xdx_908_ecustom--AggregatePrincipalAmountOfUnsecuredNotes_iI_pn3n3_dm_c20200630_zmJbTMSfezDj"&gt;0.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
PPL Unsecured Notes were settled as part of the disposition of PPL in March 2021 (see Note 8, &#x201c;Disposition of PPL&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;SalvaRx Unsecured
Notes Payable and Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the SalvaRx Acquisition in January 2019, the Company assumed $&lt;span id="xdx_903_ecustom--AggregatePrincipalAmountOfUnsecuredNotes_iI_pn3n3_dm_c20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zx9XK5gC54T4"&gt;3.96
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million of principal in unsecured notes due on
March 2, 2021 (or earlier upon a qualifying event), that bear interest at &lt;span id="xdx_900_ecustom--UnsecuredNotesInterest_iI_dp_c20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_z81XE7Yw0t66"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
per annum (the "SalvaRx Notes"). The fair value of the SalvaRx Notes was determined to be $3.4 million at January 2019. As the
SalvaRx Acquisition was a qualifying event, the SalvaRx Notes became due upon the acquisition. In December 2019, the maturity date of
the SalvaRx Notes was extended to June 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--IssuanceOfUnsecuredNotesDescription_c20210401__20210630"&gt;The
holders of the SalvaRx Notes received $7,500 of warrants in respect of each $10 thousand of principal issued. The warrants vest in the
event of a qualifying transaction and are exercisable at a 30% discount to the implied valuation of SalvaRx. &lt;/span&gt;On the Acquisition Date,
the fair value of the warrants, which are included in non-controlling interest, was determined to be $&lt;/span&gt;&lt;span id="xdx_903_eifrs-full--FinancialLiabilitiesAtFairValue_iI_pn3n3_dm_c20210630_zAB7i6dt8Icj" style="font: 10pt Times New Roman, Times, Serif"&gt;2.5
&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million
using the Black Scholes Model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
September 2020, the Company settled the SalvaRx Notes obligations originally due in June 2021 in an aggregate principal amount of approximately
$3.7 million, plus accrued interest of $0.75 million in exchange for cash payments totaling $&lt;span id="xdx_902_ecustom--PaymentForSettlement_pn3n3_dm_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zM4CrL3LFm0e" title="Payment for settlement"&gt;1.77
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million and &lt;span id="xdx_90D_ecustom--WarrantsExercised_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zEMVYcvnYzz" title="Warrants exercised"&gt;397,604
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;of the associated SalvaRx warrants with an exercise
price of $&lt;span id="xdx_90F_ecustom--ExercisePrice_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zdoM3WGX9Cm" title="Exercise Price"&gt;6.64
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The noteholders who
accepted the offer exchanged their SalvaRx warrants for an equal number of Portage shares at the same price per share. &lt;span id="xdx_905_ecustom--ContractualValueOfWarrantsExercisedDescription_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zU6auhgVe2ai" title="Contractual value of warrants exercised description"&gt;The
Company accounted for the contractual value of the exercised and outstanding warrants of $2.64 million (397,604 shares at $6.64 per share)
as accrued equity issuable at September 30, 2020. The Company also recorded a loss of $1.26 million during the year ended March 31, 2021,
to recognize the discount between the fair value of the underlying shares on October 13, 2020, the settlement date, ($9.80 per share)
and the warrant exercise (contract) price of $6.64 per share.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Four
of the Company's directors, Gregory Bailey, James Mellon (former director), Steven Mintz (in trust) and Kam Shah, received, in total,
&lt;span id="xdx_908_ecustom--SharesReceived_c20210401__20210630_zO9EQYOTMV2g" title="Shares received"&gt;363,718 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;of
the warrants pursuant to this transaction. Subsequent to the exercise of the warrants in October 2020, Portage had &lt;span id="xdx_907_ecustom--NumberOfExerciseOfWarrantsIssued_iI_c20201031__ifrs-full--CounterpartiesAxis__custom--PortageMember_z2S2GcYLfb39" title="Number of exercise of warrants issued"&gt;12,083,395
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and &lt;span id="xdx_90B_ecustom--NumberOfExerciseOfWarrantsOutstanding_iI_c20201031__ifrs-full--CounterpartiesAxis__custom--PortageMember_zrNHnvXtt3o" title="Number of exercise of warrants outstanding"&gt;49,701
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;issued and outstanding shares and warrants, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company also recorded a loss on early extinguishment of debt of $&lt;span id="xdx_904_ecustom--LossOnExtinguishmentOfDebt_pn3n3_dm_c20210401__20210630_zxld0Tc5zLC9"&gt;0.22
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million in the year ended March 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;iOx Unsecured
Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the SalvaRx Acquisition in January 2019, the &lt;span id="xdx_90B_ecustom--DescriptionOfBusinessCombination_c20190103__20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember"&gt;Company
assumed $2.0 million of 7% convertible notes issued by iOx, a wholly owned subsidiary of SalvaRx (the &#x201c;Convertible Notes&#x201d;),
of which the Company holds $1.9 million. &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As a
result of the SalvaRx Acquisition, iOx became a subsidiary of the Company during the year ended March 31, 2019. In accordance with IFRS
3, the fair value, including interest receivable, of the Convertible Notes were effectively settled against the note receivable upon
the business combination. $0.15 million Convertible Notes were outstanding at each of June 30, 2021 and March 31, 2021. The holder of
the Convertible Notes can convert the notes and accrued interest into ordinary shares of iOx at any time before maturity at &#xa3;120
per share. There is an automatic conversion in the event iOx raises $&lt;span id="xdx_90C_eifrs-full--IssueOfConvertibleInstruments_pn3n3_dm_c20190103__20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zUK8feurVK12"&gt;2.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million, and the conversion price will be determined
based on the timing of the capital raised and the price at which the money was raised. iOx has the right to repay the Convertible Notes
together with accrued interest at any time. &lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ptgef:UnsecuredNotesPayableAndWarrantsTextBlock>
    <ptgef:ScheduleOfNotesPayableTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfNotesPayableTableTextBlock_pn3n3_ztEgvgtOF8Zd" style="width: 100%" summary="xdx: Disclosure - UNSECURED NOTES PAYABLE (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zi5BnKUOfUDh" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;CURRENT&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;CURRENT&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;NON-CURRENT&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PPL&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iOx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SalvaRx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, April
    1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zlYDbqWAGgE3" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zExGdy5tgmS" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zBTF3CFoBMc5" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,361&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NotePayable_iS_pn3n3_c20200401__20210331_zt0fJP5fmmij" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,661&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Repayment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0704"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1,020&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--RepaymentOfNotesPayable_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1,020&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization
    of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0712"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0714"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;76&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AmortizationOfDebtDiscount_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;76&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Value of notes exchanged in
    warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0720"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0722"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2,640&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2,640&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Settlement
    in connection with disposition of PPL&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(200&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0732"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(200&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Loss on extinguishment
    of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0736"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0738"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;223&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;223&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Proceeds
    from loan payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0744"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0748"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ProceedsFromLoanPayable_c20200401__20210331_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zzSP6nG3oOTj" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0752"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zlP79saAfey7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zn77sbxo7mMg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0756"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NotePayable_iS_pn3n3_c20210401__20210630_zJl31BJTq3ol" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Proceeds
    from loan payable&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0762"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ProceedsFromLoanPayable_c20210401__20210630_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zItD8ZbzNFMc" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zFT0XLbrU3Qi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zezgC9M9RB79" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NotePayable_iE_pn3n3_c20210401__20210630_zQD9myfIu3o7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:ScheduleOfNotesPayableTableTextBlock>
    <ptgef:NotePayable
      contextRef="AsOf2020-03-31_custom_PplMember"
      decimals="-3"
      unitRef="USD">200000</ptgef:NotePayable>
    <ptgef:NotePayable
      contextRef="AsOf2020-03-31_custom_IoxMember"
      decimals="-3"
      unitRef="USD">100000</ptgef:NotePayable>
    <ptgef:NotePayable
      contextRef="AsOf2020-03-31_custom_SalvaRxMember"
      decimals="-3"
      unitRef="USD">3361000</ptgef:NotePayable>
    <ptgef:NotePayable contextRef="AsOf2020-03-31" decimals="-3" unitRef="USD">3661000</ptgef:NotePayable>
    <ptgef:RepaymentOfNotesPayable
      contextRef="From2020-04-012021-03-31_custom_SalvaRxMember"
      decimals="-3"
      unitRef="USD">-1020000</ptgef:RepaymentOfNotesPayable>
    <ptgef:RepaymentOfNotesPayable
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-1020000</ptgef:RepaymentOfNotesPayable>
    <ptgef:AmortizationOfDebtDiscount
      contextRef="From2020-04-012021-03-31_custom_SalvaRxMember"
      decimals="-3"
      unitRef="USD">76000</ptgef:AmortizationOfDebtDiscount>
    <ptgef:AmortizationOfDebtDiscount
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">76000</ptgef:AmortizationOfDebtDiscount>
    <ptgef:ValueOfNotesExchangedInWarrantExercise
      contextRef="From2020-04-012021-03-31_custom_SalvaRxMember"
      decimals="-3"
      unitRef="USD">-2640000</ptgef:ValueOfNotesExchangedInWarrantExercise>
    <ptgef:ValueOfNotesExchangedInWarrantExercise
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-2640000</ptgef:ValueOfNotesExchangedInWarrantExercise>
    <ptgef:SettlementInConnectionWithDispositionOfPpl
      contextRef="From2020-04-012021-03-31_custom_PplMember"
      decimals="-3"
      unitRef="USD">-200000</ptgef:SettlementInConnectionWithDispositionOfPpl>
    <ptgef:SettlementInConnectionWithDispositionOfPpl
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-200000</ptgef:SettlementInConnectionWithDispositionOfPpl>
    <ptgef:LossOnExtinguishmentOfDebt
      contextRef="From2020-04-012021-03-31_custom_SalvaRxMember"
      decimals="-3"
      unitRef="USD">223000</ptgef:LossOnExtinguishmentOfDebt>
    <ptgef:LossOnExtinguishmentOfDebt
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">223000</ptgef:LossOnExtinguishmentOfDebt>
    <ptgef:ProceedsFromLoanPayable
      contextRef="From2020-04-012021-03-31_custom_IoxMember"
      decimals="-3"
      unitRef="USD">50000</ptgef:ProceedsFromLoanPayable>
    <ptgef:ProceedsFromLoanPayable
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">50000</ptgef:ProceedsFromLoanPayable>
    <ptgef:NotePayable
      contextRef="AsOf2021-03-31_custom_IoxMember"
      decimals="-3"
      unitRef="USD">150000</ptgef:NotePayable>
    <ptgef:NotePayable contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">150000</ptgef:NotePayable>
    <ptgef:NotePayable
      contextRef="AsOf2021-06-30_custom_IoxMember"
      decimals="-3"
      unitRef="USD">150000</ptgef:NotePayable>
    <ptgef:NotePayable contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">150000</ptgef:NotePayable>
    <ptgef:AggregatePrincipalAmountOfUnsecuredNotes contextRef="AsOf2020-06-30" decimals="-3" unitRef="USD">200000</ptgef:AggregatePrincipalAmountOfUnsecuredNotes>
    <ptgef:AggregatePrincipalAmountOfUnsecuredNotes
      contextRef="AsOf2019-01-31_custom_SalvaRxMember"
      decimals="-3"
      unitRef="USD">3960000</ptgef:AggregatePrincipalAmountOfUnsecuredNotes>
    <ptgef:UnsecuredNotesInterest
      contextRef="AsOf2019-01-31_custom_SalvaRxMember"
      decimals="INF"
      unitRef="Pure">0.07</ptgef:UnsecuredNotesInterest>
    <ptgef:IssuanceOfUnsecuredNotesDescription contextRef="From2021-04-01to2021-06-30">The
holders of the SalvaRx Notes received $7,500 of warrants in respect of each $10 thousand of principal issued. The warrants vest in the
event of a qualifying transaction and are exercisable at a 30% discount to the implied valuation of SalvaRx.</ptgef:IssuanceOfUnsecuredNotesDescription>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">2500000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ptgef:PaymentForSettlement
      contextRef="From2020-09-012020-09-30_custom_SalvaRxMember"
      decimals="-3"
      unitRef="USD">1770000</ptgef:PaymentForSettlement>
    <ptgef:WarrantsExercised
      contextRef="From2020-09-012020-09-30_custom_SalvaRxMember"
      decimals="INF"
      unitRef="Shares">397604</ptgef:WarrantsExercised>
    <ptgef:ExercisePrice
      contextRef="From2020-09-012020-09-30_custom_SalvaRxMember"
      decimals="INF"
      unitRef="USDPShares">6.64</ptgef:ExercisePrice>
    <ptgef:ContractualValueOfWarrantsExercisedDescription contextRef="From2020-09-012020-09-30_custom_SalvaRxMember">The
Company accounted for the contractual value of the exercised and outstanding warrants of $2.64 million (397,604 shares at $6.64 per share)
as accrued equity issuable at September 30, 2020. The Company also recorded a loss of $1.26 million during the year ended March 31, 2021,
to recognize the discount between the fair value of the underlying shares on October 13, 2020, the settlement date, ($9.80 per share)
and the warrant exercise (contract) price of $6.64 per share.</ptgef:ContractualValueOfWarrantsExercisedDescription>
    <ptgef:SharesReceived
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">363718</ptgef:SharesReceived>
    <ptgef:NumberOfExerciseOfWarrantsIssued
      contextRef="AsOf2020-10-31_custom_PortageMember"
      decimals="INF"
      unitRef="Shares">12083395</ptgef:NumberOfExerciseOfWarrantsIssued>
    <ptgef:NumberOfExerciseOfWarrantsOutstanding
      contextRef="AsOf2020-10-31_custom_PortageMember"
      decimals="INF"
      unitRef="Shares">49701</ptgef:NumberOfExerciseOfWarrantsOutstanding>
    <ptgef:LossOnExtinguishmentOfDebt
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">220000</ptgef:LossOnExtinguishmentOfDebt>
    <ptgef:DescriptionOfBusinessCombination contextRef="From2019-01-032019-01-31_custom_SalvaRxMember">Company
assumed $2.0 million of 7% convertible notes issued by iOx, a wholly owned subsidiary of SalvaRx (the &#x201c;Convertible Notes&#x201d;),
of which the Company holds $1.9 million.</ptgef:DescriptionOfBusinessCombination>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="From2019-01-032019-01-31_custom_IoxMember"
      decimals="-3"
      unitRef="USD">2000000.0</ifrs-full:IssueOfConvertibleInstruments>
    <ptgef:WarrantLiabilitytextblock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_801_ecustom--WarrantLiabilitytextblock_zVtRf63FGr3k" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
13. &lt;span id="xdx_822_zCgSE3x6Mvug"&gt;WARRANT LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Below
is the roll-forward of warrants issued by entity (see Note 12, &#x201c;Unsecured Notes Payable&#x201d;):&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_pn3n3_zLpnmYFaPf87" style="width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_8BD_zuItXHtnvEu8" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PBI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants
    outstanding, April 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsOutstandingExercisePrice_iS_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zTPyaeEkSLpb" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.64&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsOutstandingShares_iS_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zsqnFSGA76og" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;49,701&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsOutstandingAmount_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zxFVDjkYPCCc" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,120&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
    value adjustment as of June 30, 2021 (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueAdjustmentExercisePriceAtEnd_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zIQqk64MIAA" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment , exercise price at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FairValueAdjustmentShares_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_ziKIvKEhzQC2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, shares at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0818"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--FairValueAdjustment_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, amount at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(369&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants
    outstanding, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--WarrantsOutstandingExercisePrice_iE_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zCvelJGfAYTe" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, exercise price, at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.64&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsOutstandingShares_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zMH5rwvsDHRa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;49,701&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--WarrantsOutstandingAmount_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zX3jMALENqka" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount, at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;751&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td id="xdx_F01_z1ewmPsvx5Ze" style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F1C_zAFv9abyuCT9"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Portage
                                            warrant liability valued at contract price, adjusted for fair value using the Black Scholes
                                            model.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The Black
Scholes assumptions used in the fair value calculation of the warrants as of June 30, 2021 were:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk free
rate: 0.11%&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
Dividend: $0&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
Life: 1.28 years&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility:
92.6%&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td id="xdx_F08_zsJ7wNBixOVh" style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F18_zgzS229mfuje"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
                                            Company recognized a gain of $0.4 million in the three months ended June 30, 2021 to reflect
                                            the change in fair value of the underlying warrants. The warrants were not outstanding during
                                            the three months ended June 30, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A4_zazPGgavwiS4" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;















</ptgef:WarrantLiabilitytextblock>
    <ptgef:ScheduleOfWarrantLiabilityTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_pn3n3_zLpnmYFaPf87" style="width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_8BD_zuItXHtnvEu8" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PBI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants
    outstanding, April 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsOutstandingExercisePrice_iS_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zTPyaeEkSLpb" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.64&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsOutstandingShares_iS_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zsqnFSGA76og" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;49,701&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsOutstandingAmount_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zxFVDjkYPCCc" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,120&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
    value adjustment as of June 30, 2021 (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueAdjustmentExercisePriceAtEnd_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zIQqk64MIAA" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment , exercise price at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FairValueAdjustmentShares_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_ziKIvKEhzQC2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, shares at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0818"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--FairValueAdjustment_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, amount at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(369&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants
    outstanding, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--WarrantsOutstandingExercisePrice_iE_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zCvelJGfAYTe" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, exercise price, at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.64&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsOutstandingShares_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zMH5rwvsDHRa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;49,701&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--WarrantsOutstandingAmount_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zX3jMALENqka" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount, at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;751&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td id="xdx_F01_z1ewmPsvx5Ze" style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F1C_zAFv9abyuCT9"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Portage
                                            warrant liability valued at contract price, adjusted for fair value using the Black Scholes
                                            model.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The Black
Scholes assumptions used in the fair value calculation of the warrants as of June 30, 2021 were:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk free
rate: 0.11%&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
Dividend: $0&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
Life: 1.28 years&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility:
92.6%&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td id="xdx_F08_zsJ7wNBixOVh" style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F18_zgzS229mfuje"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
                                            Company recognized a gain of $0.4 million in the three months ended June 30, 2021 to reflect
                                            the change in fair value of the underlying warrants. The warrants were not outstanding during
                                            the three months ended June 30, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</ptgef:ScheduleOfWarrantLiabilityTableTextBlock>
    <ptgef:WarrantsOutstandingExercisePrice
      contextRef="AsOf2021-03-31_custom_SalvaRxGroupPlcMember"
      decimals="INF"
      unitRef="USDPShares">6.64</ptgef:WarrantsOutstandingExercisePrice>
    <ptgef:WarrantsOutstandingShares
      contextRef="AsOf2021-03-31_custom_SalvaRxGroupPlcMember"
      decimals="-3"
      unitRef="Shares">49701000</ptgef:WarrantsOutstandingShares>
    <ptgef:WarrantsOutstandingAmount
      contextRef="AsOf2021-03-31_custom_SalvaRxGroupPlcMember"
      decimals="-3"
      unitRef="USD">1120000</ptgef:WarrantsOutstandingAmount>
    <ptgef:FairValueAdjustment
      contextRef="From2021-04-012021-06-30_custom_SalvaRxGroupPlcMember"
      decimals="-3"
      unitRef="USD">-369000</ptgef:FairValueAdjustment>
    <ptgef:WarrantsOutstandingExercisePrice
      contextRef="AsOf2021-06-30_custom_SalvaRxGroupPlcMember"
      decimals="INF"
      unitRef="USDPShares">6.64</ptgef:WarrantsOutstandingExercisePrice>
    <ptgef:WarrantsOutstandingShares
      contextRef="AsOf2021-06-30_custom_SalvaRxGroupPlcMember"
      decimals="-3"
      unitRef="Shares">49701000</ptgef:WarrantsOutstandingShares>
    <ptgef:WarrantsOutstandingAmount
      contextRef="AsOf2021-06-30_custom_SalvaRxGroupPlcMember"
      decimals="-3"
      unitRef="USD">751000</ptgef:WarrantsOutstandingAmount>
    <ptgef:CapitalStockTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_800_ecustom--CapitalStockTextBlock_zwRvIEEfyWnh" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
14. &lt;span id="xdx_82A_zNUlRCPdb2W"&gt;CAPITAL STOCK&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Authorized
                                            ordinary shares&lt;b&gt;: &lt;/b&gt;Unlimited number of common shares without par value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Following
                                            is a roll-forward of ordinary shares as of June 30, 2021, and 2020:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_zRkyUBL1D6gg" style="width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zhn5R5cV7JL9" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Common
    shares: Unlimited number of common shares without par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Ordinary&lt;br/&gt;
    Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Ordinary
    &lt;br/&gt; Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--CommonStockShares_iS_c20210401__20210630_zlzUa9RsTd1e" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,084&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--CommonStockValues_iS_pn3n3_c20210401__20210630_z11lCw4pUSD5" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;130,649&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--CommonStockShares_iS_c20200401__20200630_zOu78bXbLPEc" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, Shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,988&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--CommonStockValues_iS_pn3n3_c20200401__20200630_zXtX2fGTQpz2" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;117,817&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Shares
    issued in a private placement, net of share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20210401__20210630_zPkcaW29phk2" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in a private placement, net of issue costs, shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,241&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in a private placement, net of issue costs"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;27,216&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200401__20200630_zzCcZWr2avR1" style="font-size: 10pt; text-align: right" title="Shares issued in a private placement, net of issue costs, shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;698&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Shares issued in a private placement, net of issue costs"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,732&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Shares
    issued for services&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharesIssuedForServicesShares_c20210401__20210630_z0VSIXjjYzka" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued for services, shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharesIssuedForService_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued for services"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SharesIssuedForServicesShares_c20200401__20200630_zi6tOKZv1YL7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued for services, shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharesIssuedForService_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued for services"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0862"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--CommonStockShares_iE_c20210401__20210630_zT7P8a1BZyj3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;13,326&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CommonStockValues_iE_pn3n3_c20210401__20210630_zHt1zAznjl7a" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;157,895&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--CommonStockShares_iE_c20200401__20200630_zn1ldTTL3RJe" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, Shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,686&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CommonStockValues_iE_pn3n3_c20200401__20200630_z6urXE1KhlGh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;124,549&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number
                                            of ordinary shares have been retroactively adjusted to reflect the impact of 100:1 reverse
                                            stock split on June 5, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A1_zfUuQoNrH3ba" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 16, 2020, the Company completed a private placement of &lt;span id="xdx_903_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zjx3yytMieNb" title="Shares issued in a private placement, net of issue costs, shares"&gt;698,145
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;restricted ordinary shares at a price of $&lt;span id="xdx_908_ecustom--PricePerShare_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zQ6NIvQm8x04" title="Shares price"&gt;10.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share for gross proceeds of $&lt;span id="xdx_90E_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zxIHEVwg11v9" title="Shares issued in a private placement, net of issue costs"&gt;6.98
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million to accredited investors. Directors of
the Company subscribed for &lt;span id="xdx_900_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_pdd"&gt;215,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares, or approximately 30.8% of the private
placement, for proceeds of $&lt;span id="xdx_905_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_zX6L3YwwCq5a"&gt;2.15
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million. The Company incurred costs of approximately
$0.25 million in connection with the offering, which was treated as contra-equity on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the quarter ended June 30, 2021, the Company commenced an &#x201c;at the market&#x201d; offering, under which it sold &lt;span id="xdx_909_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostShares_c20210401__20210630_z5ins8HYbrdl" title="Shares issued in private placement net of issue cost, shares"&gt;90,888
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares generating gross proceeds of approximately
$&lt;span id="xdx_907_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCost_pn3n3_dm_c20210401__20210630_zDuczjqXzZD6" title="Shares issued in private placement net of issue cost"&gt;2.6 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million
($&lt;span id="xdx_909_ecustom--OfferingExpenses_pn3n3_dm_c20210401__20210630_zfALxTQkixQk" title="Offering expenses"&gt;2.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million,
net of commissions). Further, the Company initiated an offering pursuant to the Prospectus. On June 24, 2021, the &lt;span id="xdx_90B_ecustom--PublicofferingDescription_c20210601__20210624_zR1ipCS3eRT9" title="Public offering description"&gt;Company
completed a firm commitment underwritten public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share
for gross proceeds of approximately $26.5 million and was settled June 28, 2021. The Company incurred aggregate offering expenses for
the public offering of approximately $1.8 million, including approximately $1.6 million of management, underwriting and selling expenses.
The Company will use the net proceeds raised to fund its research and development activities and support operations. The amount raised
is sufficient to fund operations through at least September 2022. Funds may be used to accelerate development activities to advance the
Company&#x2019;s product portfolio, working capital and general corporate purposes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;















</ptgef:CapitalStockTextBlock>
    <ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_zRkyUBL1D6gg" style="width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zhn5R5cV7JL9" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Common
    shares: Unlimited number of common shares without par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Ordinary&lt;br/&gt;
    Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Ordinary
    &lt;br/&gt; Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    000&#x2019;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--CommonStockShares_iS_c20210401__20210630_zlzUa9RsTd1e" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,084&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--CommonStockValues_iS_pn3n3_c20210401__20210630_z11lCw4pUSD5" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;130,649&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--CommonStockShares_iS_c20200401__20200630_zOu78bXbLPEc" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, Shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,988&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--CommonStockValues_iS_pn3n3_c20200401__20200630_zXtX2fGTQpz2" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;117,817&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Shares
    issued in a private placement, net of share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20210401__20210630_zPkcaW29phk2" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in a private placement, net of issue costs, shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,241&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in a private placement, net of issue costs"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;27,216&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200401__20200630_zzCcZWr2avR1" style="font-size: 10pt; text-align: right" title="Shares issued in a private placement, net of issue costs, shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;698&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Shares issued in a private placement, net of issue costs"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,732&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Shares
    issued for services&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharesIssuedForServicesShares_c20210401__20210630_z0VSIXjjYzka" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued for services, shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharesIssuedForService_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued for services"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SharesIssuedForServicesShares_c20200401__20200630_zi6tOKZv1YL7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued for services, shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharesIssuedForService_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued for services"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0862"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--CommonStockShares_iE_c20210401__20210630_zT7P8a1BZyj3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;13,326&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CommonStockValues_iE_pn3n3_c20210401__20210630_zHt1zAznjl7a" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;157,895&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--CommonStockShares_iE_c20200401__20200630_zn1ldTTL3RJe" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, Shares"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,686&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CommonStockValues_iE_pn3n3_c20200401__20200630_z6urXE1KhlGh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;124,549&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number
                                            of ordinary shares have been retroactively adjusted to reflect the impact of 100:1 reverse
                                            stock split on June 5, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock>
    <ptgef:CommonStockShares contextRef="AsOf2021-03-31" decimals="-3" unitRef="Shares">12084000</ptgef:CommonStockShares>
    <ptgef:CommonStockValues contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">130649000</ptgef:CommonStockValues>
    <ptgef:CommonStockShares contextRef="AsOf2020-03-31" decimals="-3" unitRef="Shares">10988000</ptgef:CommonStockShares>
    <ptgef:CommonStockValues contextRef="AsOf2020-03-31" decimals="-3" unitRef="USD">117817000</ptgef:CommonStockValues>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="Shares">1241000</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">27216000</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="Shares">698000</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">6732000</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts>
    <ptgef:SharesIssuedForServicesShares
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="Shares">1000</ptgef:SharesIssuedForServicesShares>
    <ptgef:SharesIssuedForService
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">30000</ptgef:SharesIssuedForService>
    <ptgef:CommonStockShares contextRef="AsOf2021-06-30" decimals="-3" unitRef="Shares">13326000</ptgef:CommonStockShares>
    <ptgef:CommonStockValues contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">157895000</ptgef:CommonStockValues>
    <ptgef:CommonStockShares contextRef="AsOf2020-06-30" decimals="-3" unitRef="Shares">11686000</ptgef:CommonStockShares>
    <ptgef:CommonStockValues contextRef="AsOf2020-06-30" decimals="-3" unitRef="USD">124549000</ptgef:CommonStockValues>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares
      contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember"
      decimals="INF"
      unitRef="Shares">698145</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares>
    <ptgef:PricePerShare
      contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember"
      decimals="INF"
      unitRef="USDPShares">10.00</ptgef:PricePerShare>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts
      contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember"
      decimals="-3"
      unitRef="USD">6980000</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares
      contextRef="From2020-06-022020-06-16_custom_DirectorsMember"
      decimals="INF"
      unitRef="Shares">215000</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts
      contextRef="From2020-06-022020-06-16_custom_DirectorsMember"
      decimals="-3"
      unitRef="USD">2150000</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostShares
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">90888</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostShares>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCost
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">2600000</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCost>
    <ptgef:OfferingExpenses
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">2500000</ptgef:OfferingExpenses>
    <ptgef:PublicofferingDescription contextRef="From2021-06-012021-06-24">Company
completed a firm commitment underwritten public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share
for gross proceeds of approximately $26.5 million and was settled June 28, 2021. The Company incurred aggregate offering expenses for
the public offering of approximately $1.8 million, including approximately $1.6 million of management, underwriting and selling expenses.
The Company will use the net proceeds raised to fund its research and development activities and support operations. The amount raised
is sufficient to fund operations through at least September 2022. Funds may be used to accelerate development activities to advance the
Company&#x2019;s product portfolio, working capital and general corporate purposes.</ptgef:PublicofferingDescription>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_80D_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zkWVFaiUwAz9" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
15. &lt;span id="xdx_82E_zID4ZEqor7dj"&gt;STOCK OPTION RESERVE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
                                            following table provides the activity for the Company&#x2019;s stock option reserve for the
                                            three months ended June 30, 2021 and 2020:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_z7NxeJz9tr0d" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B8_zpTnk8nOdM8j" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Disclosure
    Of Terms Stock Option Reserve Explanatory&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Controlling
    Interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock
    Option Reserve&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Controlling
    Interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock
    Option Reserve&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zVgCUGYXjmfe" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,468&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z7fDbdd6HIWa" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7,977&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zw1XEjSd9zNl" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,618&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionReserve_iS_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zWo1XYbIESG8" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;58&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Share-based
    compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,082&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--AdjustmentsForSharebasedPayments_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;295&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--AdjustmentsForSharebasedPayments_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_znP2zHBj2vll" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,566&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zOQ78WEhryZa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,059&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--StockOptionReserve_iE_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zp7t4u5MtwMi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,913&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--StockOptionReserve_iE_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zqdYdRcFI4kf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;58&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_z2YZMzXmfhl3" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Board of Directors of the Company (the "Board") established a stock option plan (the "2013 Option Plan") under which
options to acquire ordinary shares of the Company are granted to directors, employees and consultants of the Company. The maximum number
of ordinary shares issuable under the 2013 Option Plan shall not exceed 10% of the total number of issued and outstanding ordinary shares,
inclusive of all shares presently reserved for issuance pursuant to previously granted stock options. If a stock option was surrendered,
terminated or expired without being exercised, the ordinary shares reserved for issuance pursuant to such stock option were available
for new stock options granted under the 2013 Option Plan. The options vest on a schedule determined by the Board of Directors, generally
over two to four years, and expire after five years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of March 31, 2019, the Board decided to discontinue the 2013 Option Plan and during the year ended March 31, 2021, &lt;span id="xdx_90A_ecustom--StockOptionsIssued_iI_c20210331_zU93VLwXJ2x"&gt;2,980
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;outstanding options issued under the plan expired
unexercised and no options remained outstanding under the 2013 Option Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 25, 2020, at the annual meeting of shareholders, the Company&#x2019;s new incentive stock option plan (the &#x201c;2020 Stock Option
Plan&#x201d;) was approved, which authorized the directors to fix the option exercise price and to issue stock options under the plan
as they see fit. The Company's 2020 Stock Option Plan is a 10% rolling stock option plan under which the directors are authorized to
grant up to a maximum of 10% of the issued and outstanding ordinary shares on the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;Effective
January 13, 2021, the Company amended and restated its 2020 Stock Option Plan to permit the grant of additional types of equity compensation
securities, including restricted stock units and dividend equivalent rights (the "2021 Equity Incentive Plan"). The aggregate
number of equity securities, which may be issued under the 2021 Equity Incentive Plan has not been changed.&#160; Pursuant to the 2021
Equity Incentive Plan, on January 13, 2021, the Company granted an aggregate of &lt;span id="xdx_903_eifrs-full--NumberOfSharesIssued_iI_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_zgLVKAilDJo7"&gt;868,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;stock options exercisable
at a price of US$&lt;span id="xdx_909_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_zlTdZAQ2czc4"&gt;17.75
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;per share, representing
the closing price of the shares on the day immediately preceding the grant date, which expire on January 13, 2031 to various directors,
officers and consultants of the Company. &lt;span id="xdx_900_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember_pdd"&gt;350,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;options granted to members
of the board of directors vest 1/3 on grant date, 1/3 on the first anniversary of the grant and 1/3 on the second anniversary of the
grant. &lt;span id="xdx_907_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--ConsultantsMember_pdd"&gt;518,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;options granted to consultants
(one of whom is also a director) vest 1/3 on each of the first three anniversaries of the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;Additionally,
the Company granted &lt;span id="xdx_90C_ecustom--StockGranted_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zyqhCmCPkRQ5" title="Stock granted"&gt;243,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;restricted stock units
on January 13, 2021, with a fair value of $&lt;span id="xdx_903_ecustom--FairValuePerShare_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zwTvxiYV6oF2" title="Fair value per share"&gt;17.75
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;per share, which was
the closing price on the day immediately preceding the grant date. The restricted stock units vested on the date of grant but underlying
shares cannot be sold until one of four conditions are met.&#160; In accordance with IFRS 2, &#x201c;Share-based Payment,&#x201d; the Company
recognized compensation expense of $&lt;span id="xdx_908_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zLFHweFdJzJ7"&gt;4.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;million in the year
ended March 31, 2021, in connection with the RSU grants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
                                            movements in the number of options issued were:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_pn3n3_zMAggIIvjj86" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_8BF_zE2XtvBR4Cmd" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PBI 2021 Equity Incentive&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Plan&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PBI
    2013 Option Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;iOx Option Plan &lt;br/&gt;
(Subsidiary Plan)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5cUWyWsYI36" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;868,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zjBndRClykJ9" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0945"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zL1SKWkjEdyj" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0947"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_z7Pne5dtHer9" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,980&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z66b0QW0sXDi" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,924&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z8qkZVzpDI4b" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,599&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zVyjffxYdIp7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0955"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zrvrPFAScIZj" style="font-size: 10pt; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0957"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zi4WmCdd6TQ1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0959"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zfYnHSB62ff9" style="font-size: 10pt; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zE1QXRt1TJv3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z7LPACdAytPa" style="font-size: 10pt; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired
    or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5GJnboORkdk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0967"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zKFXqOmCz04f" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0969"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zmQ49OvXqBzc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0971"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zREWgvErtZfl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zttlqUIjGvyl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z4N4xeM7afHa" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--NumberOfOutstandingShareOption_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zE2zzv1YlAvi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;868,000&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zOhWqISGDhFk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zpA8nuZSaTVg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zgterYG3Uxki" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,980&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NumberOfOutstandingShareOption_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zNexzDUBma89" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,924&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NumberOfOutstandingShareOption_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zDRGHHyGAnH9" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,599&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_ztIOzBJSZGNi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;116,666&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_ziMDLPhqXPX3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0993"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zdRUTPdfivP" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_ztnNGqmKAxI9" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,980&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zieZS7Gy9Mxg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,764&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z1dX11pVDoRc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,723&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z2XevsW82nH" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Board discontinued the 2013 Option Plan in fiscal 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Following
                                            are the weighted average exercise price and the remaining contractual life for outstanding
                                            options by plan:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zering4CO0M8" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_8BC_z6PsFLfELT93" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of weighted average exercise price and the remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PBI 2021 Equity Incentive&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Plan&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PBI 2013 Option Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;iOx Option Plan
(Subsidiary Plan)&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
    of June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
    of June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
    of June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zE1mY1GDkDd3" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;17.75&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z1POhsB5IPEg" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zss2jKWoqvy5" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zohgv9HVRNWk" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;15.00&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z4KSKT6wkWLe" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;165.20&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z13AHMaYUHoe" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;152.74&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zBrxBbA4j4Ui" style="font: 10pt Times New Roman, Times, Serif"&gt;9.54&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zw4zAr4h3jFf" style="font: 10pt Times New Roman, Times, Serif"&gt;1.47&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zC1ewvJmO1w" style="font: 10pt Times New Roman, Times, Serif"&gt;0.70&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zVtzm8V1AT3f" style="font: 10pt Times New Roman, Times, Serif"&gt;1.24&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zZo41SzkVBZf" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
vested options can be exercised at any time in accordance with the applicable option agreement. The exercise price was greater than the
market price on the date of the grants for all options outstanding as of June 30, 2021 and March 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recorded approximately $&lt;span id="xdx_904_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--Equity2021IncentivePlanMember_zuIUFRNx9Gr3"&gt;2.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million of stock-based compensation expense with
respect to the 2021 Equity Incentive Plan in the three months ended June 30, 2021. There were no stock options outstanding in the prior
year period under this plan. The Company expects to record additional stock-based compensation expense of $8.9 million through January
2024 with respect to the 2021 Equity Incentive Plan. Additionally, the intrinsic value of the stock options granted under the 2021 Equity
Incentive Plan was approximately $2.8 million at June 30, 2021, of which $0.4 million is associated with vested&lt;/span&gt; exercisable options.&lt;/p&gt;
&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recorded $&lt;span id="xdx_908_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20210630_zArnk8aTBm6"&gt;0.1&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million
and $&lt;span id="xdx_904_eifrs-full--CommunicationExpense_pn3n3_dm_c20200401__20200630_zYIJKquvZGIb"&gt;0.3&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million
of stock-based compensation expense related to the iOx stock option plan for the three months ended June 30, 2021 and 2020, respectively.
The Company expects to record $0.1 million of aggregate stock-based compensation expense through the remaining vesting period of outstanding
iOx options. Additionally, the intrinsic value of the iOx stock options was approximately $0.1 million at June 30, 2021, substantially
all of which is associated with vested exercisable options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ptgef:DisclosureOfTermsStockOptionReserveExplanatory contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_z7NxeJz9tr0d" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B8_zpTnk8nOdM8j" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Disclosure
    Of Terms Stock Option Reserve Explanatory&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Controlling
    Interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock
    Option Reserve&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Controlling
    Interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock
    Option Reserve&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zVgCUGYXjmfe" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,468&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z7fDbdd6HIWa" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7,977&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zw1XEjSd9zNl" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,618&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionReserve_iS_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zWo1XYbIESG8" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;58&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Share-based
    compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,082&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--AdjustmentsForSharebasedPayments_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;295&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--AdjustmentsForSharebasedPayments_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_znP2zHBj2vll" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,566&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zOQ78WEhryZa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,059&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--StockOptionReserve_iE_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zp7t4u5MtwMi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,913&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--StockOptionReserve_iE_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zqdYdRcFI4kf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;58&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ptgef:DisclosureOfTermsStockOptionReserveExplanatory>
    <ptgef:StockOptionReserve
      contextRef="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">11468000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2021-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">7977000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2020-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">10618000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2020-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">58000</ptgef:StockOptionReserve>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2021-04-012021-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">98000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2021-04-012021-06-30_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">2082000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2020-04-012020-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">295000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ptgef:StockOptionReserve
      contextRef="AsOf2021-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">11566000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2021-06-30_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">10059000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2020-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">10913000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2020-06-30_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">58000</ptgef:StockOptionReserve>
    <ptgef:StockOptionsIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">2980</ptgef:StockOptionsIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">868000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">17.75</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2021-01-13_custom_BoardOfDirectorsMember"
      decimals="INF"
      unitRef="Shares">350000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2021-01-13_custom_ConsultantsMember"
      decimals="INF"
      unitRef="Shares">518000</ifrs-full:NumberOfSharesIssued>
    <ptgef:StockGranted
      contextRef="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember"
      decimals="INF"
      unitRef="Shares">243000</ptgef:StockGranted>
    <ptgef:FairValuePerShare
      contextRef="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember"
      decimals="INF"
      unitRef="USDPShares">17.75</ptgef:FairValuePerShare>
    <ifrs-full:CommunicationExpense
      contextRef="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember"
      decimals="-3"
      unitRef="USD">4300000</ifrs-full:CommunicationExpense>
    <ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_pn3n3_zMAggIIvjj86" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_8BF_zE2XtvBR4Cmd" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PBI 2021 Equity Incentive&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Plan&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PBI
    2013 Option Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;iOx Option Plan &lt;br/&gt;
(Subsidiary Plan)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5cUWyWsYI36" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;868,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zjBndRClykJ9" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0945"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zL1SKWkjEdyj" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0947"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_z7Pne5dtHer9" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,980&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z66b0QW0sXDi" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,924&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z8qkZVzpDI4b" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,599&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zVyjffxYdIp7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0955"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zrvrPFAScIZj" style="font-size: 10pt; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0957"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zi4WmCdd6TQ1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0959"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zfYnHSB62ff9" style="font-size: 10pt; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zE1QXRt1TJv3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z7LPACdAytPa" style="font-size: 10pt; text-align: right" title="Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired
    or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5GJnboORkdk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0967"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zKFXqOmCz04f" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0969"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zmQ49OvXqBzc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0971"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zREWgvErtZfl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zttlqUIjGvyl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z4N4xeM7afHa" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--NumberOfOutstandingShareOption_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zE2zzv1YlAvi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;868,000&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zOhWqISGDhFk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zpA8nuZSaTVg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zgterYG3Uxki" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,980&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NumberOfOutstandingShareOption_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zNexzDUBma89" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,924&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NumberOfOutstandingShareOption_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zDRGHHyGAnH9" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,599&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,
    end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_ztIOzBJSZGNi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;116,666&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_ziMDLPhqXPX3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0993"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zdRUTPdfivP" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_ztnNGqmKAxI9" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,980&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zieZS7Gy9Mxg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,764&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z1dX11pVDoRc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,723&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2021-03-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="-3"
      unitRef="Shares">868000000</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2020-03-31_custom_PBI2013OptionPlanMember"
      decimals="-3"
      unitRef="Shares">2980000</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2021-03-31_custom_IOxOptionPlanMember"
      decimals="-3"
      unitRef="Shares">1924000</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2020-03-31_custom_IOxOptionPlanMember"
      decimals="-3"
      unitRef="Shares">2599000</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2021-06-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="-3"
      unitRef="Shares">868000000</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2020-06-30_custom_PBI2013OptionPlanMember"
      decimals="-3"
      unitRef="Shares">2980000</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2021-06-30_custom_IOxOptionPlanMember"
      decimals="-3"
      unitRef="Shares">1924000</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2020-06-30_custom_IOxOptionPlanMember"
      decimals="-3"
      unitRef="Shares">2599000</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="AsOf2021-06-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="-3"
      unitRef="Shares">116666000</ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="AsOf2020-06-30_custom_PBI2013OptionPlanMember"
      decimals="-3"
      unitRef="Shares">2980000</ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="AsOf2021-06-30_custom_IOxOptionPlanMember"
      decimals="-3"
      unitRef="Shares">1764000</ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="AsOf2020-06-30_custom_IOxOptionPlanMember"
      decimals="-3"
      unitRef="Shares">1723000</ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zering4CO0M8" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_8BC_z6PsFLfELT93" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of weighted average exercise price and the remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PBI 2021 Equity Incentive&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Plan&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PBI 2013 Option Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;iOx Option Plan
(Subsidiary Plan)&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
    of June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
    of June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
    of June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zE1mY1GDkDd3" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;17.75&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z1POhsB5IPEg" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zss2jKWoqvy5" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zohgv9HVRNWk" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;15.00&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z4KSKT6wkWLe" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;165.20&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z13AHMaYUHoe" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;152.74&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zBrxBbA4j4Ui" style="font: 10pt Times New Roman, Times, Serif"&gt;9.54&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zw4zAr4h3jFf" style="font: 10pt Times New Roman, Times, Serif"&gt;1.47&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zC1ewvJmO1w" style="font: 10pt Times New Roman, Times, Serif"&gt;0.70&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zVtzm8V1AT3f" style="font: 10pt Times New Roman, Times, Serif"&gt;1.24&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">17.75</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2020-04-012020-06-30_custom_PBI2013OptionPlanMember"
      decimals="INF"
      unitRef="USDPShares">15.00</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2021-04-012021-06-30_custom_IOxOptionPlanMember"
      decimals="INF"
      unitRef="USDPShares">165.20</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2020-04-012020-06-30_custom_IOxOptionPlanMember"
      decimals="INF"
      unitRef="USDPShares">152.74</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember">P9Y6M14D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2020-04-012020-06-30_custom_PBI2013OptionPlanMember">P1Y5M19D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2021-04-012021-06-30_custom_IOxOptionPlanMember">P0Y8M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2020-04-012020-06-30_custom_IOxOptionPlanMember">P1Y2M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:CommunicationExpense
      contextRef="From2021-04-012021-06-30_custom_Equity2021IncentivePlanMember"
      decimals="-3"
      unitRef="USD">2100000</ifrs-full:CommunicationExpense>
    <ifrs-full:CommunicationExpense
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">100000</ifrs-full:CommunicationExpense>
    <ifrs-full:CommunicationExpense
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">300000</ifrs-full:CommunicationExpense>
    <ifrs-full:EarningsPerShareExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_807_eifrs-full--EarningsPerShareExplanatory_zaKLvMEzsKw" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
16. &lt;span id="xdx_82A_zAI8S5FIHX84"&gt;(LOSS) PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
earnings per share ("EPS") is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company
by the weighted average number of ordinary shares outstanding during the year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Diluted
EPS is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number
of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion
of all the dilutive potential ordinary shares into ordinary shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table reflects the loss and share data used in the basic and diluted EPS calculations (dollars in thousands, except per share
amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--EarningsPerShareTableTextBlock_pn3n3_zJY953plXK6i" style="width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zVjRZhdMMRh1" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of basic and diluted EPS calculations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20210401__20210630_zmfwE9kNqg6l" style="text-align: right; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20200401__20200630_zPOOnXkZb191" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Numerator
    (in 000&#x2019;$)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Net
    loss attributable to owners of the Company&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(3,066&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(696&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Denominator
    (in 000&#x2019;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--WeightedAverageShares_i01_pdd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    average number of shares &#x2013; Basic and Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,213&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,104&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BasicAndDilutedLossPerShare_i01_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
    and diluted (loss) per share (Actual)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(0.06&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zliuc5yfZvT5" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
inclusion of the Company's stock options, restricted stock units and share purchase warrants in the computation of diluted loss per share
would have an anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference
between basic loss per share and diluted loss per share for the three months ended June 30, 2021, and 2020. The following table reflects
the outstanding securities by year that would have an anti-dilutive effect on loss per share, and accordingly, were excluded from the
calculation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock_zQ4g5JGfAVhi" style="width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B8_ztjYhz3FiGl7" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of Anti-Dilutive effect on Loss Per Share&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As
    of June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock
    options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;868,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,980&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted
    stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;243,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1058"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;49,701&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zvs5VAoxOgpc" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Inclusion
of outstanding options or other common stock equivalents in the computation of diluted loss per share would have an anti-dilutive effect
on the loss per share and are therefore excluded from the computation. Consequently, there is no difference between loss per share and
diluted loss per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:EarningsPerShareExplanatory>
    <ptgef:EarningsPerShareTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--EarningsPerShareTableTextBlock_pn3n3_zJY953plXK6i" style="width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zVjRZhdMMRh1" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of basic and diluted EPS calculations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20210401__20210630_zmfwE9kNqg6l" style="text-align: right; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20200401__20200630_zPOOnXkZb191" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Numerator
    (in 000&#x2019;$)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Net
    loss attributable to owners of the Company&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(3,066&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(696&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Denominator
    (in 000&#x2019;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--WeightedAverageShares_i01_pdd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    average number of shares &#x2013; Basic and Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,213&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,104&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BasicAndDilutedLossPerShare_i01_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
    and diluted (loss) per share (Actual)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(0.06&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:EarningsPerShareTableTextBlock>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-3066000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-696000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">12213</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">11104</ifrs-full:WeightedAverageShares>
    <ptgef:BasicAndDilutedLossPerShare
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.25</ptgef:BasicAndDilutedLossPerShare>
    <ptgef:BasicAndDilutedLossPerShare
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.06</ptgef:BasicAndDilutedLossPerShare>
    <ptgef:ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock_zQ4g5JGfAVhi" style="width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B8_ztjYhz3FiGl7" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of Anti-Dilutive effect on Loss Per Share&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As
    of June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock
    options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;868,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,980&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted
    stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;243,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1058"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;49,701&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock>
    <ptgef:AntidilutiveEffectOnLossPerShar
      contextRef="From2021-04-012021-06-30_custom_StockOptionsMember"
      decimals="INF"
      unitRef="Shares">868000</ptgef:AntidilutiveEffectOnLossPerShar>
    <ptgef:AntidilutiveEffectOnLossPerShar
      contextRef="From2020-04-012020-06-30_custom_StockOptionsMember"
      decimals="INF"
      unitRef="Shares">2980</ptgef:AntidilutiveEffectOnLossPerShar>
    <ptgef:AntidilutiveEffectOnLossPerShar
      contextRef="From2021-04-012021-06-30_custom_RestrictedStockUnitsMember444649546"
      decimals="INF"
      unitRef="Shares">243000</ptgef:AntidilutiveEffectOnLossPerShar>
    <ptgef:AntidilutiveEffectOnLossPerShar
      contextRef="From2021-04-012021-06-30_custom_WarrantsMember"
      decimals="INF"
      unitRef="Shares">49701</ptgef:AntidilutiveEffectOnLossPerShar>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_805_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_z494Ywm4Tcpd" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
17. &lt;span id="xdx_821_zKtvJZzd3z1h"&gt;COMMITMENTS AND CONTINGENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is committed to invest approximately &#x20ac;1.5 million ($&lt;span id="xdx_906_ecustom--CommitmentToInvestment_iI_pn3n3_dm_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StimunitySAMember_ziXI1jq90ycj"&gt;1.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million) in Stimunity upon Stimunity&#x2019;s
achievement of certain agreed milestones. During the year ended March 31, 2019, the Company made a discretionary investment of &#x20ac;600,129
($&lt;span id="xdx_90A_ecustom--DiscretionaryInvestment_iI_pp0p0_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StimunitySAMember_zjNOfGa8xkPj" title="Discretionary Investment"&gt;688,359&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)
and on June 1, 2020, the Company made an additional discretionary investment of &#x20ac;800,000 ($&lt;span id="xdx_906_ecustom--AdditionalDiscretionaryInvestment_iI_pp0n3_dm_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StimunitySAMember_zmMm1gKONWpb"&gt;1.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million) investment towards the commitment. The
remaining commitment was &#x20ac;100,000 as of March 31, 2021 (see Note 7, &#x201c;Investment in Associate&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;















</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ptgef:CommitmentToInvestment
      contextRef="AsOf2021-06-30_custom_StimunitySAMember"
      decimals="-3"
      unitRef="USD">1900000</ptgef:CommitmentToInvestment>
    <ptgef:DiscretionaryInvestment
      contextRef="AsOf2021-06-30_custom_StimunitySAMember"
      decimals="0"
      unitRef="USD">688359</ptgef:DiscretionaryInvestment>
    <ptgef:AdditionalDiscretionaryInvestment
      contextRef="AsOf2021-06-30_custom_StimunitySAMember"
      decimals="0"
      unitRef="USD">1000000.0</ptgef:AdditionalDiscretionaryInvestment>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_80A_eifrs-full--DisclosureOfRelatedPartyExplanatory_zrFzE5tclF64" style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
18. &lt;span id="xdx_82D_zePOtrKEiKy"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Investments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has entered into related party transactions and certain services agreements with its investees.&#160; Key management of the Company
has also entered into related party transactions with investees. Key management personnel are those persons having the authority and
responsibility for planning, directing and controlling the activities of the Company. The Board of Directors, Chairman, Chief Executive
Officer and Chief Financial Officer are key management personnel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following subsidiaries and associates are considered related parties:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stimunity&lt;/b&gt;.
                                            One of the three directors on the Board of Directors of Stimunity is controlled by Portage
                                            (see Note 7, &#x201c;Investment in Associate&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;iOx&lt;/b&gt;.
                                            Two of the five directorships on the Board of Directors of iOx is controlled by Portage.
                                            Additionally, Portage has an observer on the Board of iOx. The CEO of the Company is also
                                            the CEO of iOx, and the management team of the Company comprise the management team of iOx.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Saugatuck&lt;/b&gt;.
                                            One of the three directorships on the Board of Directors of Saugatuck is controlled by Portage.
                                            Additionally, the CEO of the Company is also the CEO of Saugatuck and the management team
                                            of the Company comprise the management team of Saugatuck.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intensity&lt;/b&gt;.
                                            One of the four directorships on the Board of Directors of Intensity is represented by Portage.
                                            Additionally, the CEO of the Company is an officer and employee of Intensity (see Note 9,
                                            &#x201c;Investments in Private Companies&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(e)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;PGL&lt;/b&gt;.
                                            PPL holds 65% equity in PGL, committed to provide financing and also handles financial and
                                            administrative matters of PGL. The Company disposed of 100% of its interests in PPL and PGL
                                            on March 3, 2021 (see Note 8, &#x201c;Disposition of PPL&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(f)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Portage
                                            Development Services&lt;/b&gt;. A 100% owned subsidiary incorporated in Delaware, which provides
                                            human resources, and other services to each operating subsidiary via a shared services agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following are significant related party balances and transactions other than those disclosed elsewhere in the condensed consolidated
interim financial statements:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Interest
expense includes $&lt;span id="xdx_907_eifrs-full--InterestCostsIncurred_pn3n3_dm_c20200401__20200630_zl3jDwBfmcoc"&gt;0.06&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million
interest incurred on notes issued to directors during the three months ended June 30, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
January 2020, a board member of the Company advanced the Company $&lt;span id="xdx_900_ecustom--RepaymentsOfAdvanceToBoardMemberOfCompany_pn3n3_dm_c20200701__20200731_zXSivIGa33lj"&gt;1.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million, which was repaid in July 2020. There
was no interest or fees associated with this advance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Transactions
between the parent company and its subsidiaries, which are related parties, have been eliminated in consolidation and are not disclosed
in this note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:InterestCostsIncurred
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">60000.00</ifrs-full:InterestCostsIncurred>
    <ptgef:RepaymentsOfAdvanceToBoardMemberOfCompany
      contextRef="From2020-07-012020-07-31"
      decimals="-3"
      unitRef="USD">1000000.0</ptgef:RepaymentsOfAdvanceToBoardMemberOfCompany>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_801_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zoIeLwv6Z8G5" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
19. &lt;span id="xdx_82B_zpkgRBNRAka7"&gt;FINANCIAL INSTRUMENTS AND RISK MANAGEMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s financial instruments recognized in the Company&#x2019;s condensed consolidated interim statements of financial position
consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
value estimates are made at a specific point in time, based on relevant market information and information about financial instruments.
These estimates are subject to and involve uncertainties and matters of significant judgment, therefore cannot be determined with precision.
Changes in assumptions could significantly affect the estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the Company&#x2019;s financial instruments as of June 30, 2021 and March 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilities_pn3n3_z0Nqakhay848" style="width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zZRv6Wy5BGWi" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As
    of June 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As
    of March 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amortized
    Cost&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
    Value through Other Comprehensive &lt;br/&gt;Income (FVTOCI)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amortized
    Cost&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;FVTOCI&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Financial
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--CashAndCashEquivalents_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Cash and cash equivalents"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,617&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--CashAndCashEquivalents_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Cash and cash equivalents"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1094"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--CashAndCashEquivalents_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Cash and cash equivalents"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,770&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--CashAndCashEquivalents_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Cash and cash equivalents"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1098"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid
    expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Prepaid expenses and Other Receivables"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,995&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Prepaid expenses and Other Receivables"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--PrepaidExpensesAndOtherReceivables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Prepaid expenses and Other Receivables"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,176&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--PrepaidExpensesAndOtherReceivables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Prepaid expenses and Other Receivables"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1106"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--CurrentInvestments_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1108"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--CurrentInvestments_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9,100&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--CurrentInvestments_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--CurrentInvestments_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9,144&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortized
    Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
    Value through Profit or Loss (FVTPL)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortized
    Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Financial
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts
    payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AccountsPayableAndAccruedLiabilities_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Accounts payable and accrued liabilities"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,605&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--AccountsPayableAndAccruedLiabilities_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Accounts payable and accrued liabilities"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AccountsPayableAndAccruedLiabilities_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Accounts payable and accrued liabilities"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,938&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AccountsPayableAndAccruedLiabilities_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Accounts payable and accrued liabilities"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Unsecured
    notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NoncurrentPayables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Unsecured notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NoncurrentPayables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Unsecured notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncurrentPayables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Unsecured notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NoncurrentPayables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Unsecured notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1130"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant
    liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--WarrantLiability_iI_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_z64vCpi2M7Dh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrant liability"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1132"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--WarrantLiability_iI_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z9mvXqtUPtGl" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;751&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantLiability_iI_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zyOG7DWITl7f" style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1134"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantLiability_iI_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zMoBBnRcpHni" style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,120&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zdkAELRgL3K4" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s risk exposures as it relates to financial instruments are reflected below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Fair value
of financial instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s financial assets and liabilities are comprised of cash, receivables and investments in equities and private entities,
accounts payable, warrant liability and unsecured notes payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company classifies the fair value of these transactions according to the following fair value hierarchy based on the amount of observable
inputs used to value the instrument:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 41.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
                                            1 &#x2013; Values are based on unadjusted quoted prices available in active markets for identical
                                            assets or liabilities as of the reporting date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 41.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
                                            2 &#x2013; Values are based on inputs, including quoted forward prices for commodities, time
                                            value and volatility factors, which can be substantially observed or corroborated in the
                                            marketplace. Prices in Level 2 are either directly or indirectly observable as of the reporting
                                            date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 41.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
                                            3 &#x2013; Values are based on prices or valuation techniques that are not based on observable
                                            market data. Investments are classified as Level 3 financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Assessment
of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair
value hierarchy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Management
has assessed that the fair values of cash and cash equivalents, other receivables and accounts payable approximate their carrying amounts
largely due to the short-term maturities of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following methods and assumptions were used to estimate their fair values:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Investment
in Biohaven&lt;/b&gt;: Fair value was based on a quoted market price of $&lt;span id="xdx_903_ecustom--FairValueMarketPricePerShare_c20210401__20210630_pdd"&gt;34.03
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share as of March 31, 2020 (Level 1). The
investment was sold in August 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Investment
in Sentien&lt;/b&gt;: Fair value of the asset is determined by considering strategy changes by Sentien (Level 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Investment
in Intensity&lt;/b&gt;: Fair value of the asset is determined by considering other comparable equity funding transactions by Intensity with
unrelated investors (Level 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Accrued
equity issuable: &lt;/b&gt;The fair value is estimated based on the average of the quoted market prices for the period in which the shares
were earned (Level 1).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Unsecured
notes payable&lt;/b&gt;: The fair value is estimated using a Black Scholes model (Level 3) (see Note 12, Unsecured Notes Payable&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Warrant
Liability&lt;/b&gt;: The fair value is estimated using a Black Scholes model (Level 3) (see Note 13, &#x201c;Warrant Liability&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;There
have been no transfers between levels of the fair value hierarchy for the three months ended June 30, 2021 and the year ended March 31,
2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s financial instruments are exposed to certain financial risks: credit risk and liquidity risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Credit
risk is the risk of loss associated with a counterparty&#x2019;s inability to fulfil its payment obligations. The credit risk is attributable
to various financial instruments, as noted below. The credit risk is limited to the carrying value as reflected in the Company&#x2019;s
condensed consolidated interim statements of financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;.
&lt;/b&gt;Cash is held with major international financial institutions and therefore the risk of loss is minimal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Other
receivables.&lt;/i&gt;&lt;/b&gt; The Company was exposed to credit risk attributable to its debtor since a significant portion of this amount represents
the amount agreed on a settlement of a claim by PPL (see Note 5, &#x201c;Prepaid Expenses and Other Receivables&#x201d;), originally payable
over the next four years. The installment note was repaid in full in July 2021 (see Note 22, &#x201c;Events After the Balance Sheet Date
&#x2013; Installment Note Receivable&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Liquidity Risk&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Liquidity
risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities
when due, under both normal and stressed conditions without incurring unacceptable losses or risking harm to the Company&#x2019;s reputation.
The Company holds sufficient cash to satisfy obligations under accounts payable and accruals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company monitors its liquidity position regularly to assess whether it has the funds necessary to meet its operating needs and needs
for investing in new projects. The Company believes that it has sufficient funding to finance the committed drug development work, apart
from meeting its operational needs for the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;However,
as a biotech company at an early stage of development and without significant internally generated cash flows, there are inherent liquidity
risks, including the possibility that additional financing may not be available to the Company, or that actual drug development expenditures
may exceed those planned. The current uncertainty in global markets could have an impact on the Company&#x2019;s future ability to access
capital on terms that are acceptable to the Company. There can be no assurance that required financing will be available to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilities contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilities_pn3n3_z0Nqakhay848" style="width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zZRv6Wy5BGWi" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As
    of June 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As
    of March 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amortized
    Cost&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
    Value through Other Comprehensive &lt;br/&gt;Income (FVTOCI)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amortized
    Cost&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;FVTOCI&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Financial
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--CashAndCashEquivalents_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Cash and cash equivalents"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,617&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--CashAndCashEquivalents_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Cash and cash equivalents"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1094"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--CashAndCashEquivalents_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Cash and cash equivalents"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,770&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--CashAndCashEquivalents_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Cash and cash equivalents"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1098"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid
    expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Prepaid expenses and Other Receivables"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,995&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Prepaid expenses and Other Receivables"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--PrepaidExpensesAndOtherReceivables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Prepaid expenses and Other Receivables"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,176&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--PrepaidExpensesAndOtherReceivables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Prepaid expenses and Other Receivables"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1106"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--CurrentInvestments_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1108"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--CurrentInvestments_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9,100&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--CurrentInvestments_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--CurrentInvestments_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Investment"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9,144&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortized
    Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
    Value through Profit or Loss (FVTPL)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortized
    Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Financial
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts
    payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AccountsPayableAndAccruedLiabilities_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Accounts payable and accrued liabilities"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,605&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--AccountsPayableAndAccruedLiabilities_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Accounts payable and accrued liabilities"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AccountsPayableAndAccruedLiabilities_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Accounts payable and accrued liabilities"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,938&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AccountsPayableAndAccruedLiabilities_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Accounts payable and accrued liabilities"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Unsecured
    notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NoncurrentPayables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Unsecured notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NoncurrentPayables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Unsecured notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncurrentPayables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Unsecured notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NoncurrentPayables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Unsecured notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1130"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant
    liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--WarrantLiability_iI_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_z64vCpi2M7Dh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrant liability"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1132"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--WarrantLiability_iI_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z9mvXqtUPtGl" style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;751&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantLiability_iI_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zyOG7DWITl7f" style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1134"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantLiability_iI_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zMoBBnRcpHni" style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,120&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilities>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2021-06-30_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">28617000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2021-03-31_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">2770000</ifrs-full:CashAndCashEquivalents>
    <ptgef:PrepaidExpensesAndOtherReceivables
      contextRef="AsOf2021-06-30_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">1995000</ptgef:PrepaidExpensesAndOtherReceivables>
    <ptgef:PrepaidExpensesAndOtherReceivables
      contextRef="AsOf2021-03-31_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">2176000</ptgef:PrepaidExpensesAndOtherReceivables>
    <ifrs-full:CurrentInvestments
      contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">9100000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">9144000</ifrs-full:CurrentInvestments>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2021-06-30_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">1605000</ptgef:AccountsPayableAndAccruedLiabilities>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2021-03-31_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">1938000</ptgef:AccountsPayableAndAccruedLiabilities>
    <ifrs-full:NoncurrentPayables
      contextRef="AsOf2021-06-30_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">150000</ifrs-full:NoncurrentPayables>
    <ifrs-full:NoncurrentPayables
      contextRef="AsOf2021-03-31_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">150000</ifrs-full:NoncurrentPayables>
    <ptgef:WarrantLiability
      contextRef="AsOf2021-06-30_custom_FairValueToOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">751000</ptgef:WarrantLiability>
    <ptgef:WarrantLiability
      contextRef="AsOf2021-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">1120000</ptgef:WarrantLiability>
    <ptgef:FairValueMarketPricePerShare
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">34.03</ptgef:FairValueMarketPricePerShare>
    <ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_808_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zeJpidIDOKSh" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
20. &lt;span id="xdx_82D_z8e7foYhSSBb"&gt;CAPITAL DISCLOSURES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company considers the items included in shareholders&#x2019; equity as capital. The Company had accounts payable and accrued expenses
of approximately $&lt;span id="xdx_90D_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20210630_zNpSjU4YOAk"&gt;1.6&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million
as of June 30, 2021 (approximately $&lt;span id="xdx_901_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20210331_zLupsvr6eSf1"&gt;1.9 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million
as of March 31, 2021) and current assets of approximately $30.6 million &lt;span id="xdx_90B_eifrs-full--CurrentAssets_iI_pn3n3_c20210630_z3Gzo6gsTzsl" style="display: none"&gt;30,612
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;as of June 30, 2021 (approximately $4.9 million
as &lt;span id="xdx_903_eifrs-full--CurrentAssets_iI_pn3n3_c20210331_zb8I0J07bUrh" style="display: none"&gt;4,946 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;of
March 31, 2021). The Company&#x2019;s objectives when managing capital are to safeguard the Company&#x2019;s ability to continue as a going
concern in order to pursue new business opportunities and to maintain a flexible capital structure, which optimizes the costs of capital
at an acceptable risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics
of the underlying assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021, shareholders&#x2019; equity attributable to the owners of the company was approximately $127.7 million &lt;span id="xdx_905_eifrs-full--EquityAttributableToOwnersOfParent_iI_pn3n3_c20210630_zs033cEJaeq9" style="display: none"&gt;127,711
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(approximately $101.4 million &lt;span id="xdx_90B_eifrs-full--EquityAttributableToOwnersOfParent_iI_pn3n3_c20210331_zzAFv2fQ4ja2" style="display: none"&gt;101,449
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;as of March 31, 2021).&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is not subject to any externally imposed capital requirements and does not presently utilize any quantitative measures to monitor
its capital. There have been no changes to the Company&#x2019;s approach to capital management during the three months ended June 30,
2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;















</ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock>
    <ptgef:PayablesAndAccruedExpense contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">1600000</ptgef:PayablesAndAccruedExpense>
    <ptgef:PayablesAndAccruedExpense contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1900000</ptgef:PayablesAndAccruedExpense>
    <ifrs-full:CurrentAssets contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">30612000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">4946000</ifrs-full:CurrentAssets>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">127711000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">101449000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_809_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zeuic0PQH5yl" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
21. &lt;span id="xdx_823_zmmLhXdLHzd2"&gt;NON-CONTROLLING INTEREST&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zjsCpKSB6cw9" style="width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zq0dsri5ZC34" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PGL&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SalvaRx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iOx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Saugatuck&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 45%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-controlling
    interest as of April 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zYWBmeuA7dhh" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1174"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zuA7TgGQ6LP5" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_z3OImeKTvcQi" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;46,173&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zhjVPEJPPNVf" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(20&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630_zyc8qumhnDX2" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;46,153&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based
    compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1184"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1190"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--StockBasedCompensationExpense_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Net
    (loss) attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1194"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(140&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(17&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(157&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-controlling
    interest as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zXxATiNflqT7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zXby7ThrGE84" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1206"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zfCUJoiK2Yld" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;46,131&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zAFFANIZmoij" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(37&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630_zSDG3aEFH5Gi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;46,094&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PGL&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SalvaRx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iOx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Saugatuck&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 45%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-controlling
    interest as of April 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zolCUCYq2U0f" style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(81&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zxvOxzbumpn2" style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,451&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zFGjxaOJuHcb" style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;46,712&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zIEImgneAMri" style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630_zRmGV96fe2F3" style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;49,110&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based
    compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1221"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;295&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1225"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--StockBasedCompensationExpense_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;295&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Net
    income attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1231"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-controlling
    interest as of June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zmQnHefF1W72" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(81&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zyqyFfq0D8Wf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,451&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_z7wy3kYV4Evd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;47,048&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zVDevKtSFpxf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630_zCCxi9NwywZf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;49,446&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zIVT69K3drjc" style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory>
    <ptgef:ScheduleOfNoncontrollingInterestTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zjsCpKSB6cw9" style="width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zq0dsri5ZC34" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Schedule
    of non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PGL&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SalvaRx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iOx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Saugatuck&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 45%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-controlling
    interest as of April 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zYWBmeuA7dhh" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1174"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zuA7TgGQ6LP5" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_z3OImeKTvcQi" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;46,173&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zhjVPEJPPNVf" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(20&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630_zyc8qumhnDX2" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;46,153&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based
    compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1184"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1190"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--StockBasedCompensationExpense_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Net
    (loss) attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1194"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(140&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(17&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(157&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-controlling
    interest as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zXxATiNflqT7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zXby7ThrGE84" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1206"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zfCUJoiK2Yld" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;46,131&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zAFFANIZmoij" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(37&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630_zSDG3aEFH5Gi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;46,094&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(In
    thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PGL&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SalvaRx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iOx&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Saugatuck&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 45%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-controlling
    interest as of April 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zolCUCYq2U0f" style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(81&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zxvOxzbumpn2" style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,451&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zFGjxaOJuHcb" style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;46,712&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zIEImgneAMri" style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630_zRmGV96fe2F3" style="width: 8%; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;49,110&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based
    compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1221"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;295&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1225"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--StockBasedCompensationExpense_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;295&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Net
    income attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1231"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-controlling
    interest as of June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zmQnHefF1W72" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(81&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zyqyFfq0D8Wf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,451&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_z7wy3kYV4Evd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;47,048&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zVDevKtSFpxf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630_zCCxi9NwywZf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;49,446&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfNoncontrollingInterestTableTextBlock>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-03-31_custom_IoxMember"
      decimals="-3"
      unitRef="USD">46173000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-03-31_custom_SaugatuckMember"
      decimals="-3"
      unitRef="USD">-20000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">46153000</ifrs-full:NoncontrollingInterests>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2021-04-012021-06-30_custom_IoxMember"
      decimals="-3"
      unitRef="USD">98000</ptgef:StockBasedCompensationExpense>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">98000</ptgef:StockBasedCompensationExpense>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2021-04-012021-06-30_custom_IoxMember"
      decimals="-3"
      unitRef="USD">-140000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2021-04-012021-06-30_custom_SaugatuckMember"
      decimals="-3"
      unitRef="USD">-17000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2021-04-01to2021-06-30"
      decimals="-3"
      unitRef="USD">-157000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-06-30_custom_IoxMember"
      decimals="-3"
      unitRef="USD">46131000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-06-30_custom_SaugatuckMember"
      decimals="-3"
      unitRef="USD">-37000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">46094000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2020-03-31_custom_PglMember"
      decimals="-3"
      unitRef="USD">-81000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2020-03-31_custom_SalvaRxMember"
      decimals="-3"
      unitRef="USD">2451000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2020-03-31_custom_IoxMember"
      decimals="-3"
      unitRef="USD">46712000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2020-03-31_custom_SaugatuckMember"
      decimals="-3"
      unitRef="USD">28000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2020-03-31" decimals="-3" unitRef="USD">49110000</ifrs-full:NoncontrollingInterests>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2020-04-012020-06-30_custom_IoxMember"
      decimals="-3"
      unitRef="USD">295000</ptgef:StockBasedCompensationExpense>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">295000</ptgef:StockBasedCompensationExpense>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2020-04-012020-06-30_custom_IoxMember"
      decimals="-3"
      unitRef="USD">41000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">41000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2020-06-30_custom_PglMember"
      decimals="-3"
      unitRef="USD">-81000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2020-06-30_custom_SalvaRxMember"
      decimals="-3"
      unitRef="USD">2451000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2020-06-30_custom_IoxMember"
      decimals="-3"
      unitRef="USD">47048000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2020-06-30_custom_SaugatuckMember"
      decimals="-3"
      unitRef="USD">28000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2020-06-30" decimals="-3" unitRef="USD">49446000</ifrs-full:NoncontrollingInterests>
    <ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_800_ecustom--DisclosureOfEventAfterBalanceSheetDateTextBlock_zRbn0bX8A67b" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
22. &lt;span id="xdx_828_zyvsqUR0YKBe"&gt;EVENTS AFTER THE BALANCE SHEET DATE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Installment
Note Receivable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
installment note receivable of approximately $&lt;span id="xdx_90D_ecustom--RepaymentOfInstallmentNoteReceivable_pn3n3_dm_c20210701__20210731__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--EventsAfterTheBalanceSheetDateMember__dei--LegalEntityAxis__custom--SalvaRxMember_zmV99IQkh0b6"&gt;0.034
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million described in Note 5, &#x201c;Prepaid Expenses
and Other Receivables,&#x201d; was repaid in full in July 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock>
    <ptgef:RepaymentOfInstallmentNoteReceivable
      contextRef="From2021-07-012021-07-31_custom_EventsAfterTheBalanceSheetDateMember_custom_SalvaRxMember"
      decimals="-3"
      unitRef="USD">34000.000</ptgef:RepaymentOfInstallmentNoteReceivable>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807724904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-30314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Portage
                                            Biotech Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Craigmuir Chambers<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Road Town<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Tortola<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">VG1110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806756088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Financial Position (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,617<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">2,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current asset</a></td>
<td class="nump">30,612<span></span>
</td>
<td class="nump">4,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Long-term assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Long-term portion of other receivables</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Investment in associate</a></td>
<td class="nump">1,691<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentProperty', window );">Investments in private companies</a></td>
<td class="nump">7,409<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">43,324<span></span>
</td>
<td class="nump">43,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">117,388<span></span>
</td>
<td class="nump">117,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Other assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">200,482<span></span>
</td>
<td class="nump">174,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,605<span></span>
</td>
<td class="nump">1,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">751<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_UnsecuredNotesPayable', window );">Unsecured notes payable</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">2,506<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">24,171<span></span>
</td>
<td class="nump">24,050<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">24,171<span></span>
</td>
<td class="nump">24,050<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">26,677<span></span>
</td>
<td class="nump">27,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Capital stock</a></td>
<td class="nump">157,895<span></span>
</td>
<td class="nump">130,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Stock option reserve</a></td>
<td class="nump">10,059<span></span>
</td>
<td class="nump">7,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(41,201)<span></span>
</td>
<td class="num">(38,135)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Total equity attributable to owners of the Company</a></td>
<td class="nump">127,711<span></span>
</td>
<td class="nump">101,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="nump">46,094<span></span>
</td>
<td class="nump">46,153<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">173,805<span></span>
</td>
<td class="nump">147,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 200,482<span></span>
</td>
<td class="nump">$ 174,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property (land or a building - or part of a building - or both) held (by the owner or by the lessee as a right-of-use asset) to earn rentals or for capital appreciation or both, rather than for: (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2020-01-01<br> -Paragraph 76<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_76&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2020-01-01<br> -Paragraph 22<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InprocessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InprocessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnsecuredNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnsecuredNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806719960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Operations and Other Comprehensive (Loss) (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,546<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,047<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss from operations</a></td>
<td class="num">(3,593)<span></span>
</td>
<td class="num">(973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_GainsLossesOnChangeInFairValueOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">369<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of (loss) income in associates accounted for using equity method</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest (expense)</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before provision for income taxes</a></td>
<td class="num">(3,302)<span></span>
</td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit</a></td>
<td class="nump">79<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net (loss)</a></td>
<td class="num">(3,223)<span></span>
</td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsOnDisposalsOfInvestmentProperties', window );">Unrealized gain on investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive (loss) for period</a></td>
<td class="num">(3,223)<span></span>
</td>
<td class="num">(577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Net (loss) income attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="num">(3,066)<span></span>
</td>
<td class="num">(696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="num">(157)<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NetLossIncome', window );">Net (loss) income</a></td>
<td class="num">(3,223)<span></span>
</td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Comprehensive (loss) income attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="num">(3,066)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="num">(157)<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_TotalComprehensiveLossIncomeForYear', window );">Total comprehensive (loss) income for year</a></td>
<td class="num">$ (3,223)<span></span>
</td>
<td class="num">$ (577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>(Loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_BasicAndDilutedLossPerShare', window );">Basic and diluted</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">12,213<span></span>
</td>
<td class="nump">11,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnDisposalsOfInvestmentProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain on disposals of investment properties. [Refer: Investment property]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnDisposalsOfInvestmentProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2020-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BasicAndDilutedLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BasicAndDilutedLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainsLossesOnChangeInFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainsLossesOnChangeInFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetLossIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetLossIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TotalComprehensiveLossIncomeForYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TotalComprehensiveLossIncomeForYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475809572296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Issued capital [member]</div></th>
<th class="th"><div>Stock Option Reserve [Member]</div></th>
<th class="th"><div>Accumulated other comprehensive income [member]</div></th>
<th class="th"><div>Retained earnings [member]</div></th>
<th class="th"><div>Equity attributable to owners of parent [member]</div></th>
<th class="th"><div>Non-controlling interests [member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 117,817<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
<td class="num">$ (22,302)<span></span>
</td>
<td class="nump">$ 96,531<span></span>
</td>
<td class="nump">$ 49,110<span></span>
</td>
<td class="nump">$ 145,641<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="nump">10,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IssuedUnderPrivatePlacement', window );">Issued under private placement</a></td>
<td class="nump">$ 6,980<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,980<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IssuedUnderPrivatePlacementShares', window );">Issued under private placement, shares</a></td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Share issuance costs</a></td>
<td class="num">$ (248)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(248)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_UnrealizedLossOnInvestmentInInvestments', window );">Unrealized gain on investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(696)<span></span>
</td>
<td class="num">(696)<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 124,549<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
<td class="num">(22,998)<span></span>
</td>
<td class="nump">102,646<span></span>
</td>
<td class="nump">49,446<span></span>
</td>
<td class="nump">152,092<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance, shares at Jun. 30, 2020</a></td>
<td class="nump">11,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 130,649<span></span>
</td>
<td class="nump">7,977<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="num">(38,135)<span></span>
</td>
<td class="nump">101,449<span></span>
</td>
<td class="nump">46,153<span></span>
</td>
<td class="nump">147,602<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance, shares at Mar. 31, 2021</a></td>
<td class="nump">12,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Share issuance costs</a></td>
<td class="num">$ (1,877)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,877)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedOrAccruedForServices', window );">Shares issued or accrued for services</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedOrAccruedForServicesShares', window );">Shares issued or accrued for services, shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,082<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,082<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedUnderAtm', window );">Shares issued under ATM</a></td>
<td class="nump">$ 2,643<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,643<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedUnderAtmShares', window );">Shares issued under ATM, shares</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedUnderOffering', window );">Shares issued under offering</a></td>
<td class="nump">$ 26,450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedUnderOfferingShares', window );">Shares issued under offering, shares</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,066)<span></span>
</td>
<td class="num">(3,066)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="num">(3,223)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 157,895<span></span>
</td>
<td class="nump">$ 10,059<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
<td class="num">$ (41,201)<span></span>
</td>
<td class="nump">$ 127,711<span></span>
</td>
<td class="nump">$ 46,094<span></span>
</td>
<td class="nump">$ 173,805<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance, shares at Jun. 30, 2021</a></td>
<td class="nump">13,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IssuedUnderPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IssuedUnderPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IssuedUnderPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IssuedUnderPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedOrAccruedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedOrAccruedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedOrAccruedForServicesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedOrAccruedForServicesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderAtm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderAtm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderAtmShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderAtmShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnrealizedLossOnInvestmentInInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnrealizedLossOnInvestmentInInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475809557416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">$ (3,223)<span></span>
</td>
<td class="num">$ (655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset', window );">Increase in deferred tax liability</a></td>
<td class="nump">121<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_LossIncomeOnFairValueOfWarrantLiability', window );">Income on fair value of warrant liability</a></td>
<td class="num">(369)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ValueOfSharesIssuedForServices', window );">Value of shares issued for services</a></td>
<td class="nump">30<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmortisationExpense', window );">Amortization of debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectiveness', window );">Share of loss (gain) in associates</a></td>
<td class="nump">44<span></span>
</td>
<td class="num">(440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Stock-based compensation expense</a></td>
<td class="nump">2,180<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IncreasingDecreasingAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(215)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(544)<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_OtherAsset', window );">Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,580)<span></span>
</td>
<td class="num">(688)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentProperty', window );">Investment in associates</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering', window );">Proceeds from shares issued under registered offering</a></td>
<td class="nump">29,093<span></span>
</td>
<td class="nump">6,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(1,666)<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">27,427<span></span>
</td>
<td class="nump">6,732<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Increase in cash and cash equivalents during period</a></td>
<td class="nump">25,847<span></span>
</td>
<td class="nump">5,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">3,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">28,617<span></span>
</td>
<td class="nump">8,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_CashPaidForInterest', window );">Cash paid for interest</a></td>
<td class="nump">11<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IncreaseInAccountsPayableForStockIssuanceCosts', window );">Increase in accounts payable for stock issuance costs</a></td>
<td class="nump">210<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_FairValueOfWarrantLiabilityForPortageWarrantsIssued', window );">Fair value of warrant liability for Portage warrants issued</a></td>
<td class="nump">751<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_UnrealizedLossOnInvestmentInInvestment', window );">Unrealized (loss) on investment in investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnHedgeIneffectiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) on hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 24C<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24C_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnHedgeIneffectiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investment property. [Refer: Investment property]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashPaidForInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashPaidForInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfWarrantLiabilityForPortageWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfWarrantLiabilityForPortageWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncreaseInAccountsPayableForStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncreaseInAccountsPayableForStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncreasingDecreasingAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncreasingDecreasingAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossIncomeOnFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossIncomeOnFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OtherAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OtherAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnrealizedLossOnInvestmentInInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnrealizedLossOnInvestmentInInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ValueOfSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ValueOfSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475808701064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NatureOfOperationsAbstract', window );"><strong>Nature Of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NatureOfOperationsTextBlock', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p id="xdx_801_ecustom--NatureOfOperationsTextBlock_zGbLtoA3Nq6k" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
1. <span id="xdx_82F_z2lcUwxfNAW6">NATURE OF OPERATIONS</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Portage
Biotech Inc. (the "Company" or &#8220;Portage&#8221;) is incorporated in the British Virgin Islands ("BVI") with its
registered office located at FH Chambers, P.O. Box 4649, Road Town, Tortola, BVI. Its Toronto agent, Portage Services Ltd., is located
at 6 Adelaide Street East, Suite 300, Toronto, Ontario, M5C 1H6, Canada.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is a reporting issuer with the securities commissions of the provinces of Ontario and British Columbia. Its ordinary shares were
listed on the Canadian Stock Exchange (&#8220;CSE&#8221;) under the symbol &#8220;PBT.U&#8221;. On February 25, 2021, the ordinary shares
of the Company began trading on the NASDAQ Capital Market (&#8220;NASDAQ&#8221;) under the symbol &#8220;PRTG&#8221;. The Company voluntarily
delisted its common shares from the CSE at the market close on April 23, 2021, since the Company&#8217;s shares began trading on NASDAQ.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Portage
is a clinical stage immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets
at various development stages. We source, nurture and develop the creation of early- to mid-stage, first- and best-in-class therapies
for a variety of cancers, by funding, implementing viable, cost effective product development strategies, clinical counsel/trial design,
shared services, financial and project management to enable efficient, turnkey execution of commercially informed development plans.
Our drug development pipeline portfolio encompasses products or technologies based on biology addressing known resistance pathways/mechanisms
of current check point inhibitors with established scientific rationales, including intratumoral delivery, nanoparticles, liposomes,
aptamers, and virus-like particles.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
August 13, 2018, the Company reached a definitive agreement to acquire <span id="xdx_902_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pdp0_dp_c20180813__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zcxKJl7CVWq8">100</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of SalvaRx Limited (&#8220;SalvaRx&#8221;) in exchange for <span id="xdx_906_eifrs-full--NumberOfInstrumentsOrInterestsIssuedOrIssuable_iI_pid_uShares_c20180813__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zYRBfyjXUu2j">8,050,701
</span></span><span style="font: 10pt Times New Roman, Times, Serif">ordinary shares of the Company (the "SalvaRx
Acquisition"). The SalvaRx Acquisition was completed on January 8, 2019 (the &#8220;Acquisition Date&#8221;) upon receiving shareholder
and regulatory approval. In connection with the SalvaRx Acquisition, the Company acquired interests in SalvaRx&#8217;s five research
and development invested entities and subsidiaries: iOx Therapeutics Ltd. (&#8220;iOx&#8221;), Nekonal Oncology Limited (&#8220;Nekonal&#8221;),
Intensity Therapeutics, Inc. (&#8220;Intensity&#8221;), Saugatuck Therapeutics Ltd. (&#8220;Saugatuck&#8221;) and Rift Biotherapeutics
Inc. (&#8220;Rift&#8221;).&#160; In connection with the SalvaRx Acquisition, the Company also acquired an option in Nekonal SARL, a Luxembourg-based
company holding intellectual property rights for therapeutics and diagnostics in the field of autoimmune disorders and oncology, to participate
in the funding of its autoimmune programs. During fiscal 2021, the Company abandoned its interests in Nekonal.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">On
June 5, 2020, the Company effected a 100:1 reverse stock split. All share and per share information included in the consolidated financial
statements have been retroactively adjusted to reflect the impact of the reverse stock split. The shares of ordinary shares authorized
remained at an unlimited number of ordinary shares without par value.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Portage
filed a registration statement and prospectus with the Securities and Exchange Commission (&#8220;SEC&#8221;) pursuant to Rule 424(b)(2)
under which it may sell shares, debt securities, warrants and units that Portage may sell in one or more offerings from time to time,
which became effective on March 8, 2021 (&#8220;Registration Statement&#8221; or &#8220;Prospectus&#8221;). The Registration Statement
includes:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">a
                                            base prospectus, which covers the offering, issuance and sales by us of up to $<span id="xdx_90A_ecustom--IssuanceAndSales_pn3p0_c20210401__20210630_zTGX4glTyxdd" title="Issuance and sales">200,000,000
                                            </span></span><span style="font: 10pt Times New Roman, Times, Serif">in
                                            the aggregate of the securities identified above from time to time in one or more offerings;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">a
                                            sales agreement supplemental prospectus covering the offer, issuance and sale by us of up
                                            to a maximum aggregate offering price of up to $<span id="xdx_901_ecustom--MaximumAggregateOfferingPrice_pn3p0_c20210401__20210630_zukpUnWZB5u2" title="Maximum aggregate offering price">50,000,000
                                            </span></span><span style="font: 10pt Times New Roman, Times, Serif">of
                                            our ordinary shares that may be issued and sold from time to time at-the-market, under sales
                                            agreement, or sales agreement, with Cantor Fitzgerald &amp; Co., or Cantor Fitzgerald, the
                                            sales agent; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">a
                                            prospectus supplement dated June 24, 2021, for the offer, issuance and sale by us of 1,150,000
                                            ordinary shares for gross proceeds of approximately $26.5 million in a firm commitment underwriting
                                            with Cantor Fitzgerald.</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span id="xdx_90F_ecustom--CashFundDescription_c20210401__20210630" style="font: 10pt Times New Roman, Times, Serif">The
specific terms of any securities to be offered through the sales agreement with Cantor Fitzgerald, in the at the market offering, are
specified in the sales agreement prospectus. The $50,000,000 of ordinary shares that may be offered, issued and sold under the sales
agreement prospectus is included in the $200,000,000 of securities that may be offered, issued and sold by us under the base prospectus.
The sales under the prospectus will be deemed to be made pursuant to an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4)
promulgated under the Securities Act of 1933 (the Securities Act). Upon termination of the sales agreement, any portion of the $50,000,000
included in the sales agreement prospectus that is not sold pursuant to the sales agreement will be available for sale in other offerings
pursuant to the base prospectus, and if no shares are sold under the sales agreement, the full $50,000,000 of securities may be sold
in other offerings pursuant to the base prospectus. See Note 2, &#8220;Liquidity&#8221; and Note 14, &#8220;Capital Stock&#8221; for
a further discussion.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NatureOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NatureOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NatureOfOperationsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NatureOfOperationsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475808565912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureLiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_LiquidityTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p id="xdx_800_ecustom--LiquidityTextBlock_z6ArZJZLYESf" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
2. <span id="xdx_823_zLyl4Ou6YAE9">LIQUIDITY</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, the Company had cash and cash equivalents of $<span id="xdx_904_eifrs-full--Cash_iI_pn3n3_dm_c20210630_zI0LcaPotXu2">28.6
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million and total current liabilities of $2.5
million <span id="xdx_900_eifrs-full--CurrentLiabilities_iI_pn3n3_c20210630_zOdx01OTFGhf" style="display: none">2,506 </span></span><span style="font: 10pt Times New Roman, Times, Serif">(inclusive
of $0.7 million warrant liability settleable on a non-cash basis). For the three months ended June 30, 2021, the Company is reporting
a net loss of ($3.2) million <span id="xdx_904_eifrs-full--ProfitLoss_iN_pn3n3_di_c20210401__20210630_zokCQreGsQQh" style="display: none">3,223 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and
cash used in operating activities of $1.6 million<span id="xdx_903_eifrs-full--CashFlowsFromUsedInOperatingActivities_pn3n3_c20210401__20210630_zfekiL6TnMF1" style="display: none">(1,580)</span></span><span style="font: 10pt Times New Roman, Times, Serif">.
As of July 31, 2021, we had approximately $<span id="xdx_903_eifrs-full--CashOnHand_iI_pn3n3_dm_c20210630_zupEaMVPfY2d">28.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
of cash on hand.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span id="xdx_900_ecustom--OfferingAndThroughThatProcessDescription_c20210401__20210630_zzJfa1HSREWe" style="font: 10pt Times New Roman, Times, Serif" title="Offering and through that process description">During the quarter ended June 30, 2021, the Company commenced an &#8220;at the market&#8221; offering, under which
it sold 90,888 shares generating gross proceeds of approximately $2.6 million ($2.5 million, net of commissions). Further,
the Company initiated an offering pursuant to the Prospectus. On June 24, 2021, the Company completed a firm commitment underwritten
public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $26.5
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $1.8
million, including approximately $1.6 million of management, underwriting and selling expenses. The Company will use the net proceeds
raised to fund its research and development activities and support operations. The amount raised is sufficient to fund operations through
September 2022. Funds may be used to accelerate development activities to advance the Company&#8217;s product portfolio, working capital
and general corporate purposes</span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the
foreseeable future and may never become profitable. The losses result primarily from its conduct of research and development activities.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company historically has funded its operations principally from proceeds from issuances of equity and debt securities and would expect
to enter the capital markets if additional funding is required.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt"><b><i>COVID-19 Effect</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">B<span style="font: 10pt Times New Roman, Times, Serif">eginning
in early March 2020, the COVID-19 pandemic and the measures imposed to contain this pandemic have disrupted and are expected to continue
to impact the Company's business operations. The magnitude of the impact of the COVID-19 pandemic on the Company's productivity, results
of operations and financial position, and its disruption to the Company's business and clinical programs and timelines, will depend,
in part, on the length and severity of these restrictions and on the Company's ability to conduct business in the ordinary course.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475809358584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_BasisOfPresentationAbstract', window );"><strong>Basis Of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_80B_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_zFnmQM81bXg4" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
3. <span id="xdx_822_zZne0Bfe82Vg">BASIS OF PRESENTATION</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Statement
of Compliance and Basis of Presentation</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">These
condensed consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards
(&#8220;IFRS&#8221;) issued by the International Accounting Standards Board (&#8220;IASB&#8221;), IAS 34 <i>Interim Financial Reporting
</i>and interpretations of the International Financial Reporting Interpretations Committee. These condensed consolidated interim financial
statements do not include all of the information required for full annual financial statements and should be read in conjunction with
the audited consolidated financial statements of the Company for the year ended March 31, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">These
condensed consolidated interim financial statements have been prepared on an historical cost basis except for items disclosed herein
at fair value (see Note ----19, Financial Instruments and Risk Management&#8221;). In addition, these condensed consolidated interim
financial statements have been prepared using the accrual basis of accounting, except for cash flow information.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has only one reportable operating segment.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">These
condensed consolidated interim financial statements were approved and authorized for issuance by the Audit Committee and Board of Directors
on August <span style="background-color: white">26</span>, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Consolidation</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
condensed consolidated interim financial statements include the accounts of the Company and,</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">(a)
SalvaRx Limited (&#8220;SalvaRx&#8221;), a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">(b)
iOx Therapeutics Ltd. (&#8220;iOx&#8221;), a United Kingdom based immune-oncology company, a <span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20150201__20150210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesOneMember_ztp9stDcFj0f">60.49</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
subsidiary, incorporated in the United Kingdom on February 10, 2015.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">(c)
Saugatuck Therapeutics, Ltd. (&#8220;Saugatuck&#8221;), a <span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_zyDYIPfh9ZY7">70</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
owned subsidiary incorporated in the British Virgin Islands.</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">(d)
Portage Developmental Services, a 100% owned subsidiary incorporated in Delaware, which provides human resources, and other services
to each operating subsidiary via a shared services agreement.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>























<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following companies were disposed of on March 3, 2021 (see Note 8, &#8220;Disposition of PPL&#8221;):</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 12.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Portage
                                            Pharmaceuticals Ltd. (&#8220;PPL&#8221;), a wholly-owned subsidiary acquired in a merger
                                            on July 23, 2013, incorporated in the British Virgin Islands.</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 12.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">EyGen
                                            Limited, (&#8220;EyGen&#8221;), a wholly-owned subsidiary of PPL, incorporated on September
                                            20, 2016, in the British Virgin Islands.</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 12.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Portage
                                            Glasgow Ltd. (&#8220;PGL&#8221;), a <span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pdp0_dp_c20180103__20180131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PortageGlasgowLtdMember_zPapxxO7Q17d">65</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
                                            subsidiary of PPL, incorporated in Glasgow, Scotland.</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">All
inter-company balances and transactions have been eliminated in consolidation.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">Non-controlling
interest in the equity of a subsidiary is accounted for and reported as a component of stockholders&#8217; equity. Non-controlling interests
represent the <span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesThreeMember_zZM5gvi1rFQk">39.51</span></span><span style="font: normal 10pt Times New Roman, Times, Serif">%
shareholder ownership interest in iOx and the <span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_zM3ZcHUgUOPj">30</span></span><span style="font: normal 10pt Times New Roman, Times, Serif">%
shareholder ownership interest in Saugatuck, which are consolidated by the Company. In years prior to March 31, 2021, non-controlling
interest also included <span id="xdx_908_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_dp_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--SubsidiariesMember_zclBkFNGkO7g">35</span></span><span style="font: normal 10pt Times New Roman, Times, Serif">%
in PGL.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Functional
and Presentation Currency</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s functional and presentation currency is the U.S. Dollar.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Use of Estimates
and Judgments</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of the condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments,
estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income
and expenses. Actual results may differ from these estimates.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which
the estimates are revised and in any future periods affected.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Significant
areas where estimates are made include valuation of financial instruments, research and development costs, fair value used for acquisition
and measurement of share-based compensation. Significant areas where critical judgments are applied include assessment of impairment
of investments and goodwill and the determination of the accounting acquirer and acquiree in the business combination accounting.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Reclassifications</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Certain
prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on
the reported results of operations.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475830673720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80C_eifrs-full--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_z4WsQ66SBqCh" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
4. <span id="xdx_823_zGRLTd8XwCPj">SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
accounting policies are set out in Note 4 to the fiscal 2021 audited consolidated financial statements. These policies have been applied
consistently to all periods presented in these condensed consolidated interim financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_844_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_z4mLy5fbVNWa" style="margin: 0pt 0; font-size: 10pt"><span id="xdx_868_zhHGqONeO9Ik" style="font: 10pt Times New Roman, Times, Serif"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Impact of Adoption
of Significant New IFRS Standards in 2020</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(a)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            1: Presentation of Financial Statements, and IAS 8: Accounting Policies, Changes in Accounting
                                            Estimates and Errors (Amendment)</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendments to IAS 1 and IAS 8 clarify the definition of material and seek to align the definition used in the Conceptual Framework with
that in the standards themselves, as well as ensuring the definition of material is consistent across all IFRS. The Company adopted these
amendments effective January 1, 2020. The adoption of these amendments did not have a significant impact on the Company&#8217;s annual
consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(b)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Conceptual
                                            Framework for Financial Reporting</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b>Together
with the revised Conceptual Framework published in March 2018, the IASB also issued Amendments to References to the Conceptual Framework
in IFRS Standards. The Company adopted the Revised Conceptual Framework effective January 1, 2020. The adoption of these amendments did
not have a significant impact on the Company&#8217;s annual consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>IFRS Pronouncements
Issued But Not Yet Effective</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>New Accounting
Standards, Interpretations and Amendments</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Standards
issued but not yet effective up to the date of issuance of the Company's condensed consolidated interim financial statements are listed
below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date.
The Company intends to adopt those standards when they become effective.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(c)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Annual
                                            Improvements to IFRS Standards 2018-2020</b></span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.35in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
annual improvements process addresses issues in the 2018-2020 reporting cycles including changes to IFRS 9, &#8220;Financial Instruments,&#8221;
IFRS 1, &#8220;First Time Adoption of IFRS,&#8221; IFRS 16, &#8220;Leases,&#8221; and IAS 41, &#8220;Biological Assets&#8221;.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">i)
The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition of financial liabilities.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">ii)
The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent to also measure cumulative translation differences
using the amounts reported by the parent based on the parent&#8217;s date of transition to IFRS.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">iii)
The amendment to IFRS 16&#8217;s illustrative example 13 removes the illustration of payments from the lessor related to leasehold improvements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">These
amendments will be effective for annual periods beginning on or after January 1, 2022. The Company is currently evaluating the new guidance
and impacts on its consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



















<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(d)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            37: Onerous Contracts - Cost of Fulfilling a Contract</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment to IAS 37 clarifies the meaning of costs to fulfil a contract and that before a separate provision for an onerous contract
is established, an entity recognizes any impairment loss that has occurred on assets used in fulfilling the contract, rather than on
assets dedicated to the contract. This amendment will be effective for annual periods beginning on or after January 1, 2022. The Company
is currently evaluating the new guidance and impacts on its consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(e)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            16: Proceeds Before Intended Use</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment to IAS 16 prohibits an entity from deducting from the cost of an item of Property, plant and equipment any proceeds received
from selling items produced while the entity is preparing the assets for its intended use (for example, the proceeds from selling samples
produced when testing a machine to see if it is functioning properly). It also clarifies that an entity is testing whether the asset
is functioning properly when it assesses the technical and physical performance of the asset. The amendment also requires certain related
disclosures. This amendment will be effective for annual periods beginning on or after January 1, 2022. The Company is currently evaluating
the new guidance and impacts on its consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(f)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            1: Presentation of Financial Statements</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment to IAS 1 clarifies how to classify debt and other liabilities as either current or non-current. The amendment will be effective
for annual periods beginning on or after January 1, 2023. The Company is currently evaluating the new guidance and impacts on its consolidated
financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(g)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Amendments
                                            to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate
                                            or Joint Venture</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment addresses the conflict between IFRS 10 and IAS 28 in dealing with the loss of control of a subsidiary that is sold or contributed
to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that
constitute a business, as defined in IFRS 3, between an investor and its associate or joint venture, is recognized in full. Any gain
or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognized only to the extent
of unrelated investors' interests in the associate or joint venture. The IASB has deferred the effective date of these amendments indefinitely,
but an entity that early adopts the amendments must apply them prospectively. The Company is evaluating whether the adoption of the above
amendment will have a material impact on its financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475809359832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivableAbstract', window );"><strong>Prepaid Expenses And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">PREPAID EXPENSES AND OTHER RECEIVABLES</a></td>
<td class="text"><p id="xdx_809_eifrs-full--DisclosureOfOtherAssetsExplanatory_zT8NhJfCrF9a" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
5. <span id="xdx_822_zL3MH4R5mVM9">PREPAID EXPENSES AND OTHER RECEIVABLES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_zzPU8Y1MX4l" style="width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span id="xdx_8B1_zATsIatsLBW3" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of prepaid expenses and other receivables</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_496_20210630_zLITEimfRkmb" style="white-space: nowrap; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_492_20210331_zc7OQMsU7nra" style="white-space: nowrap; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br/> June 30, 2021</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br/> March 31, 2021</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
    insurance</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,032</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,445</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Research
    &amp; development tax credits</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">849</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">649</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Other
    prepaid expenses</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">80</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
    receivables</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--CurrentPrepayments_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    prepaid expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,995</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,176</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2016, the Company's wholly-owned subsidiary, PPL, agreed to a settlement, from a claim made against a supplier, to receive $<span id="xdx_90A_eifrs-full--Accruals_c20161031__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0">120,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in annual instalments of $<span id="xdx_907_eifrs-full--LoansPayableInDefault_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0">11,250</span></span><span style="font: 10pt Times New Roman, Times, Serif">.&#160;
Through June 30, 2021, the Company has collected $<span id="xdx_909_eifrs-full--TradeAndOtherReceivables_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0">86,250</span></span><span style="font: 10pt Times New Roman, Times, Serif">.
The balance of $<span id="xdx_900_eifrs-full--CurrentPortionOfLongtermBorrowings_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0">33,750
</span></span><span style="font: 10pt Times New Roman, Times, Serif">was classified $11,250 as a current asset in
prepaid expenses and other receivables and $<span id="xdx_903_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PPLSettlementMember_pp0p0">22,500
</span></span><span style="font: 10pt Times New Roman, Times, Serif">as a long-term receivable as of each of June
30, 2021 and March 31, 2021. The installment receivable was assigned to Portage by PPL prior to the disposition of PPL (see Note 8, &#8220;Disposition
of PPL&#8221;). The installment note was repaid in full in July 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807774120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN MARKETABLE EQUITY SECURITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InvestmentInBiohavenAbstract', window );"><strong>Investment In Marketable Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAvailableforsaleAssetsExplanatory', window );">INVESTMENT IN MARKETABLE EQUITY SECURITIES</a></td>
<td class="text"><p id="xdx_80D_eifrs-full--DisclosureOfAvailableforsaleAssetsExplanatory_zQ4StmvrigO7" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
6. <span id="xdx_825_ztpAoZiaBXYk">INVESTMENT IN MARKETABLE EQUITY SECURITIES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, the Company&#8217;s investment in marketable equity securities was comprised of <span id="xdx_906_ecustom--InvestmentInMarketableEquitySecurities_pp0p0_c20200401__20200630_zXT1LewwsJi7" title="Investment in marketable equity securities">2,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares in Biohaven Pharmaceutical Holding Company
Limited (&#8220;Biohaven&#8221;), a public company listed on the New York Stock Exchange. The Company accounted for its investment in
Biohaven as a financial asset classified as fair value through the statement of other comprehensive income (&#8220;FVTOCI&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2020, the Company sold the shares of Biohaven for proceeds of $<span id="xdx_90D_eifrs-full--ProceedsFromIssuingShares_c20200801__20200830__ifrs-full--TypeOfMeasurementOfExpectedCreditLossesAxis__custom--BiohavenMember_pp0p0">140,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">resulting in a gain of $<span id="xdx_903_ecustom--UnrealizedGains_c20200801__20200830__ifrs-full--TypeOfMeasurementOfExpectedCreditLossesAxis__custom--BiohavenMember_pp0p0">72,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table is a roll-forward of the investment in Biohaven as of June 30, 2021 and 2020:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_eifrs-full--DisclosureOfInvestmentPropertyExplanatory_pn3n3_zEAii1U9Fq69" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8B8_zSrRpKxvKXVh" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of investment in marketable equity securities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--InvestmentAssetAvailableForSale_iS_pn3n3_c20210401__20210630_zCA5Qnlbfw9e" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of year"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--InvestmentAssetAvailableForSale_iS_pn3n3_c20200401__20200630_zlwkqBfF1wz1" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, beginning of year"><span style="font: 10pt Times New Roman, Times, Serif">68</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Unrealized
    gain on investment</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--UnrealizedLossGainOnInvestment_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Unrealized (loss) gain on investment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--UnrealizedLossGainOnInvestment_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Unrealized (loss) gain on investment"><span style="font: 10pt Times New Roman, Times, Serif">78</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--InvestmentAssetAvailableForSale_iE_pn3n3_c20210401__20210630_zP6Npos3TaPe" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of year"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--InvestmentAssetAvailableForSale_iE_pn3n3_c20200401__20200630_zsb26HMHNDYf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of year"><span style="font: 10pt Times New Roman, Times, Serif">146</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAvailableforsaleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets classified as available for sale. [Refer: Financial assets available-for-sale]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2021-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_10_e&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAvailableforsaleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentInBiohavenAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentInBiohavenAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475809043464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN ASSOCIATE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureInvestmentInAssociateAbstract', window );"><strong>Investment In Associate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InvestmentInAssociateDisclosureTextBlock', window );">INVESTMENT IN ASSOCIATE</a></td>
<td class="text"><p id="xdx_807_ecustom--InvestmentInAssociateDisclosureTextBlock_zNgueblrnsHf" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
7. <span id="xdx_828_zIAPcWTwcxFf">INVESTMENT IN ASSOCIATE</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Details
of the Company&#8217;s associate as of June 30, 2021 and March 31, 2021 are as follows:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_z67DQh5jFEVl" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE  (Details)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_8BA_zMrtrCHDZEqc" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of investment associate</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Principal
    Activity</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Place
    of Incorporation and <br/>Principal Place of Business</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Voting
    Rights Held as <br/>of June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Voting
    Rights Held as <br/>of March&#160;31, 2021</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-size: 10pt; text-align: justify"><span id="xdx_906_eifrs-full--NameOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif">Associate:
    Stimunity S.A.</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_907_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif">Biotechnology</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90E_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif">Paris,
    France</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90D_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z8kB5OGIJDr9" style="font: 10pt Times New Roman, Times, Serif">44</span><span style="font: 10pt Times New Roman, Times, Serif">.0%</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90B_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210101__20210331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zrKCG6wMVcLi" style="font: 10pt Times New Roman, Times, Serif">44.0</span><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8A2_zMp0Lez7Lbig" style="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
abovementioned associate is accounted for using the equity method in these condensed consolidated interim financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table is a roll-forward of the Company&#8217;s investment in Stimunity S.A. as of June 30, 2021 and 2020:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_z2mnB0ETQFp1" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE  (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B3_zZOiRpE3Z168" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of investment in Stimunity S.A.</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20210401__20210630_z9Y2sFe9cxhc" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">1,735</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20200401__20200630_ztP8YlyKyPad" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">1,225</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Additional
    investment</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--AdditionalInvestments_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Additional investment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--AdditionalInvestments_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Additional investment"><span style="font: 10pt Times New Roman, Times, Serif">1,000</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Share
    of (loss) income</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--UnrecognisedShareOfGainLossesOfAssociates_pn3n3_c20210401__20210630_zyj2KG9btyu5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share of (loss) income"><span style="font: 10pt Times New Roman, Times, Serif">(44</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--UnrecognisedShareOfGainLossesOfAssociates_pn3n3_c20200401__20200630_zlhnYiClQRm8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share of (loss) income"><span style="font: 10pt Times New Roman, Times, Serif">440</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20210401__20210630_z8ORzsOCDjP5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">1,691</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20200401__20200630_zZNFddVsYCwi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">2,665</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A0_zgBSoYA7TdLb" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
June 1, 2020, the Company made an additional $<span id="xdx_90D_ecustom--AdditionalInvestments_pn3n3_dm_c20200530__20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zMcJ4aw24Umf">1.0
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million investment in Stimunity upon Stimunity's
achievement of certain agreed milestones, increasing its equity share in Stimunity to <span id="xdx_902_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zkmJHsDGjHP7">44</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
(see Note 17, &#8220;Commitments and Contingent Liabilities&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for its investment in Stimunity under the equity method and accordingly, records its share of Stimunity&#8217;s earnings
or loss based on its ownership percentage. The Company recorded equity in (loss) income in Stimunity of ($<span id="xdx_900_ecustom--EquityInLossIncome_pn3p0_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z1hYvKNiFmk6" title="Equity in loss income">44,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">)
and $<span id="xdx_90B_ecustom--EquityInLossIncome_pn3p0_c20200401__20200630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zJJo5SMvZXE9">440,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the three months ended June 30, 2021 and
2020, respectively.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Under
the shareholders agreement, Portage has (i) a preferential subscription right to maintain its equity interest in Stimunity in the event
of a capital increase from the issuance of new securities by Stimunity, except for issuances of new securities for stock options under
a merger plan or for an acquisition, or (ii) the right to vote against any (a) issuances of additional securities that would call for
the Company to waive its preferential subscription right, or (b) any dilutive issuance.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>





































<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureInvestmentInAssociateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureInvestmentInAssociateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentInAssociateDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentInAssociateDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807806280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSITION OF PPL<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureDispositionOfPplAbstract', window );"><strong>Disposition Of Ppl</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DispositionOfPplTextBlock', window );">DISPOSITION OF PPL</a></td>
<td class="text"><p id="xdx_807_ecustom--DispositionOfPplTextBlock_zFwwE7s7p7La" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
8. <span id="xdx_829_zDtrM7TLPvs1">DISPOSITION OF PPL</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
March 3, 2021, the Company disposed of <span id="xdx_908_ecustom--DispositionPercentage_dp_c20210301__20210303__dei--LegalEntityAxis__custom--PortageGlasgowLtdMember_zojUfQwrx9Ui" title="Disposition Percentage">100</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of its interest in PPL, which includes PPL&#8217;s interest in PGL and EyGen for $<span id="xdx_90A_ecustom--DispositionValue_pp0p0_c20210301__20210303__dei--LegalEntityAxis__custom--PortageGlasgowLtdMember_z6e1bqDWqmNd" title="Disposition value">10
</span></span><span style="font: 10pt Times New Roman, Times, Serif">to an entity controlled by one of the Company&#8217;s
current directors and one of the Company&#8217;s former directors (the &#8220;Purchaser&#8217;s Executives&#8221;). Under the terms of
the arrangement, all outstanding payable obligations were assumed by the purchaser. Simultaneously, the Company and the Purchaser&#8217;s
Executives entered into a Revenue Share Deed with PPL under which they will be entitled to certain revenue shares based on the achievement
of milestones defined in the Revenue Share Deed. The Company may also be entitled to recover an intercompany receivable from the purchaser
in the amount of $<span id="xdx_908_ecustom--IntercompanyReceivable_iI_pp0p0_c20210303__dei--LegalEntityAxis__custom--PortageGlasgowLtdMember_zYWRAmXayFtg" title="Intercompany receivable">229,848
</span></span><span style="font: 10pt Times New Roman, Times, Serif">on the fourth anniversary of the Revenue Share
Deed. The Company valued its interest in the Revenue Share Deed and the recovery of the $229,848 at zero for financials statement purposes.
All other intercompany balances were cancelled. The Company no longer has any interest or obligations associated with PPL, PGL and EyGen,
other than the interests provided for in the Revenue Share Deed.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureDispositionOfPplAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureDispositionOfPplAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DispositionOfPplTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DispositionOfPplTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475809179928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS IN PRIVATE COMPANIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract', window );"><strong>Investments In Private Companies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock', window );">INVESTMENTS IN PRIVATE COMPANIES</a></td>
<td class="text"><p id="xdx_80B_ecustom--DisclosureOfPrivateCompaniesExplanatoryTextBlock_zIxMHPCnZrwe" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
9. <span id="xdx_823_z5UEKgMCo2p3">INVESTMENTS IN PRIVATE COMPANIES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following is a discussion of our investments in private companies as of June 30, 2021 and March 31, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Sentien</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2015, the Company acquired <span id="xdx_90E_ecustom--InvestmentOwnedShares_iI_c20150831__ifrs-full--CounterpartiesAxis__custom--SeriesAPreferredStockInSentienBiotechnologiesMember_zQjWjYloYLBj">210,210
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Series A preferred stock in Sentien
(&#8220;Preferred Stock&#8221;), a Medford, MA based private company for $700,000 of cash. The Preferred Stock is fully convertible into
an equal number of common shares. The Company&#8217;s holdings represent <span id="xdx_906_ecustom--InvestmentOwnershipPercentage_iI_dp_c20210331__ifrs-full--CounterpartiesAxis__custom--SeriesAPreferredStockInSentienBiotechnologiesMember_zCPDoNwOxsbj">5.06</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity of Sentien on a fully diluted basis as of June 30, 2021 and March 31, 2021, respectively. The investment in Sentien has
been irrevocably designated as a financial asset recorded at fair value with changes in fair value recorded through other comprehensive
income. As of March 31, 2020, the Company recorded an unrealized loss of $<span id="xdx_909_ecustom--UnrealizedGainLossOnInvestment_pn3n3_dm_c20210401__20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_z2ZHsIjzFTFk">0.7
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million after determining that cost no longer
was the best estimate of fair value due to a significant change in the strategy of Sentien and determined that the investment in Sentien
no longer had any fair value as Sentien was no longer pursing the proposed indication from the time of the Company's initial investment.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Intensity</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the SalvaRx Acquisition in fiscal 2019, the Company acquired a $4.5 million interest in Intensity, a clinical stage biotechnology
company, of <span id="xdx_90B_ecustom--InvestmentOwnedShares_iI_pp0n3_dm_c20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_zbmw6dwLk7j5">1.0
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million shares, which represented a <span id="xdx_90A_ecustom--InvestmentOwnershipPercentage_iI_dp_c20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_zbksqj4IWeg3">7.5</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
equity interest in Intensity. The investment was recorded at fair value (which approximates cost) at the acquisition date. The investment
in Intensity has been irrevocably designated as a financial asset recorded at fair value with gains and losses recorded through other
comprehensive income. The fair value of the asset is determined by considering other comparable equity funding transactions by Intensity
with unrelated investors.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
July 11, 2019, the Company entered into an agreement with Fast Forward Innovations Limited ("Fast Forward") to purchase Intensity
Holdings Limited ("IHL"), a wholly-owned subsidiary of Fast Forward. The Company paid $<span id="xdx_909_eifrs-full--EquityInterestsOfAcquirer_iI_pn3n3_dm_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zmpUmR68PASd">1.3
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million for IHL through the issuance of <span id="xdx_90D_eifrs-full--NumberOfInstrumentsOrInterestsIssuedOrIssuable_iI_uShares_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_znzpDI4xcVl6">129,806
</span></span><span style="font: 10pt Times New Roman, Times, Serif">ordinary shares. The sole asset of IHL consists
of <span id="xdx_902_ecustom--NumberOfPrivateCompanyShareConsistsInSoleAsset_iI_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zIUbGEVr0V4h">288,458
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the private company, Intensity. This
transaction increased the Company's ownership to <span id="xdx_909_eifrs-full--NumberOfSharesOutstanding_iI_c20190711__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zspeD25odiX8">1,288,458
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Intensity.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended March 31, 2020, the Company recorded an unrealized gain of $<span id="xdx_907_ecustom--UnrealizedGainLossOnInvestment_pn3n3_dm_c20200401__20200630__ifrs-full--CounterpartiesAxis__custom--IntensityMember_ziHX5cqInkz5">1.6
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million with respect to its investment in Intensity
based upon Intensity&#8217;s then most recent valuation. There were no unrealized gains or losses recognized in the three-month periods
ended June 30, 2021 and 2020.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of each of June 30, 2021 and March 31, 2021, the Company owned approximately <span id="xdx_908_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_dp_c20210630__ifrs-full--CounterpartiesAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zb1vK55IFOQb">8</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the outstanding shares of Intensity, on a fully diluted basis.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475809082872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_GoodwilAbstract', window );"><strong>Goodwil Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">GOODWILL</a></td>
<td class="text"><p id="xdx_80D_eifrs-full--DisclosureOfResearchAndDevelopmentExpenseExplanatory_zoQbroQX59w7" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
10. <span id="xdx_822_zdx7OPza6mSl">GOODWILL</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_zmHSAVyZd0R6" style="width: 100%" summary="xdx: Disclosure - GOODWILL (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span id="xdx_8B3_zwqsJO77v4r5" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of IPR&amp;D projects</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br/> June 30, 2021</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br/> March 31, 2021</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eifrs-full--Goodwill_iI_pn3n3_c20210331_znUtYuntDBEk" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Goodwill"><span style="font: 10pt Times New Roman, Times, Serif">43,324</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--Goodwill_iI_pn3n3_c20200331_zSHCIr1yeFxf" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right" title="Goodwill"><span style="font: 10pt Times New Roman, Times, Serif">43,324</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--Goodwill_iI_pn3n3_c20210630_zeVA6ToRAL12" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Goodwill"><span style="font: 10pt Times New Roman, Times, Serif">43,324</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">43,324</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s goodwill arose from the acquisition of SalvaRx and its portfolio of several projects and investments.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, the Company determined that it has only one cash-generating unit (&#8220;CGU&#8221;), the consolidated Portage Biotech,
Inc.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Impairment
Review</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">On
an annual basis, pursuant to IAS 36, &#8220;Impairment of Assets,&#8221; the Company assesses its long-lived assets with definite lives,
which are not yet available for use, for potential indicators of impairment.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">If
any such indication exists, the Company estimates the recoverable amount of the asset or CGU and compares it to the carrying value.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company performed its annual impairment test in each of fiscal 2021 and fiscal 2020 and estimated the recoverable amount of the above-noted
CGU based on its value in use, which was determined using a capitalized cash flow methodology and categorized within level 3 of the fair
market value hierarchy.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>



























<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
recoverable amount of the CGU has been determined based on its value in use. The recoverable amount considered assumptions based on probabilities
of technical, regulatory and clinical acceptances and financial support. Further, Management uses risk-adjusted cash flow projections
based on financial budgets. Management believes that any reasonably possible change in the key assumptions on which the recoverable amount
is based would not cause the carrying amount to exceed its recoverable amount. The discount rate has been determined based on the Company&#8217;s
best estimate of a risk adjusted discount rate.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
key assumptions used in the calculation of the recoverable amount include forecasts of the following:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">revenues;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">normalized
                                            operating expenses;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(c)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">income
                                            taxes; and</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(d)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">capital
                                            expenditures.</span></td>
</tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">Discounted
cash flows are determined with reference to undiscounted risk adjusted cash flows, and the discount rate approximated <span id="xdx_90D_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_dp_c20210630_zvsSfxI3eRV4">20.0</span></span><span style="font: normal 10pt Times New Roman, Times, Serif">%
and <span id="xdx_90F_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_dp_c20210331_z7BKk5fH5mih">20.5</span></span><span style="font: normal 10pt Times New Roman, Times, Serif">%
as of March 31, 2021 and 2020, respectively, based on the individual characteristics of the Company&#8217;s CGU, the risk-free rate of
return and other economic and operating factors.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 28.1pt; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">Additionally,
at the end of each reporting period, the Company is required to assess whether there is any indication that an asset may be impaired.
Pursuant to IAS 36, the Company reviewed its assets for any indicators of impairment and considered underlying fundamentals, execution,
de-risking/advancement of assets and the value creation activities during the three months ended June 30, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">As
of June 30, 2021, management assessed whether any indications of impairment existed for the Company&#8217;s CGU and concluded no indicators
were present. Therefore, a test for impairment was not required and no impairment was recorded for the three months ended June 30, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GoodwilAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GoodwilAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807293576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract', window );"><strong>In-process Research And Development And Deferred Tax Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability', window );">IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</a></td>
<td class="text"><p id="xdx_80A_ecustom--InProcessResearchAndDevelopmentAndDeferredTaxLiability_zFU0nASzyqN4" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
11. <span id="xdx_827_zLFz3OUZaRC5">IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In-process
research and development (&#8220;IPR&amp;D&#8221;) consists of the following projects (in 000&#8217;$):</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_zy1DxOYFfoY3" style="width: 100%" summary="xdx: Disclosure - IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold"><span id="xdx_8BF_zTlal8IvyLKh" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of In process research and development</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Project
    #</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Description</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value
    as of <br/>June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value
    as of <br/>March 31, 2021</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">iOx:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 25%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">IMM 60</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Melanoma
    &amp; Lung Cancers</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_z3i3mZ6d6ZE5" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">84,213</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_zPtYiObznPV" style="width: 22%; font-size: 10pt; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">84,213</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">IMM 65</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Ovarian/Prostate
    Cancers</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_zG31u7vWUGz3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">32,997</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_zax1oFtyREpb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">32,997</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">117,210</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">117,210</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Oncomer/Saugatuck</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">DNA
    Aptamers</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zU6geDRVgr47" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">178</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zhv7HNT8Gt7g" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">178</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--InprocessResearchAndDevelopment_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">117,388</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--InprocessResearchAndDevelopment_c20210331_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">117,388</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
    tax liability</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eifrs-full--DeferredTaxLiabilities_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Deferred tax liability"><span style="font: 10pt Times New Roman, Times, Serif">24,171</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--DeferredTaxLiabilities_c20210331_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax liability"><span style="font: 10pt Times New Roman, Times, Serif">24,050</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

























<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, management assessed whether any indications of impairment existed for the Company&#8217;s IPR&amp;D and concluded no
indicators were present. Therefore, a test for impairment was not required and no impairment was recorded for the three months ended
June 30, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
tax liability (DTL) represents iOx&#8217;s estimated tax on the difference between book and tax basis of the IPR&amp;D which is taxable
in the United Kingdom. As of June 30, 2021, the Company recorded deferred tax expense of $<span id="xdx_900_eifrs-full--DeferredTaxExpenseIncome_pn3n3_dm_c20210401__20210630_zcvnznLgvfCb">0.1
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million to reflect the effect of the change in
currency translation rate during the three months ended June 30, 2021 for this obligation settleable in Great British Pounds.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475809089624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNSECURED NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureUnsecuredNotesPayableAbstract', window );"><strong>Unsecured Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_UnsecuredNotesPayableAndWarrantsTextBlock', window );">UNSECURED NOTES PAYABLE</a></td>
<td class="text"><p id="xdx_807_ecustom--UnsecuredNotesPayableAndWarrantsTextBlock_zK8Oxtgar8F3" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
12. <span id="xdx_829_zWk638dEkwXe">UNSECURED NOTES PAYABLE</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Following
is a roll-forward of notes payable:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfNotesPayableTableTextBlock_pn3n3_ztEgvgtOF8Zd" style="width: 100%" summary="xdx: Disclosure - UNSECURED NOTES PAYABLE (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BD_zi5BnKUOfUDh" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of notes payable</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CURRENT</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CURRENT</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">NON-CURRENT</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PPL</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">iOx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">SalvaRx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance, April
    1, 2020</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zlYDbqWAGgE3" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">200</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zExGdy5tgmS" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">100</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zBTF3CFoBMc5" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">3,361</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--NotePayable_iS_pn3n3_c20200401__20210331_zt0fJP5fmmij" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">3,661</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Repayment</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0704">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"><span style="font: 10pt Times New Roman, Times, Serif">(1,020</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--RepaymentOfNotesPayable_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"><span style="font: 10pt Times New Roman, Times, Serif">(1,020</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
    of debt discount</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0714">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"><span style="font: 10pt Times New Roman, Times, Serif">76</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--AmortizationOfDebtDiscount_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"><span style="font: 10pt Times New Roman, Times, Serif">76</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Value of notes exchanged in
    warrant exercise</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0720">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0722">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"><span style="font: 10pt Times New Roman, Times, Serif">(2,640</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"><span style="font: 10pt Times New Roman, Times, Serif">(2,640</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Settlement
    in connection with disposition of PPL</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"><span style="font: 10pt Times New Roman, Times, Serif">(200</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0730">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0732">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"><span style="font: 10pt Times New Roman, Times, Serif">(200</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Loss on extinguishment
    of debt</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0736">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0738">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"><span style="font: 10pt Times New Roman, Times, Serif">223</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"><span style="font: 10pt Times New Roman, Times, Serif">223</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from loan payable</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0744">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif">50</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ProceedsFromLoanPayable_c20200401__20210331_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif">50</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    March 31, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zzSP6nG3oOTj" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0752">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zlP79saAfey7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zn77sbxo7mMg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0756">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--NotePayable_iS_pn3n3_c20210401__20210630_zJl31BJTq3ol" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from loan payable</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0760">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0762">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0764">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ProceedsFromLoanPayable_c20210401__20210630_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zItD8ZbzNFMc" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zFT0XLbrU3Qi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zezgC9M9RB79" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--NotePayable_iE_pn3n3_c20210401__20210630_zQD9myfIu3o7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>PPL
and EyGen Unsecured Notes Payable</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended March 31, 2017, the Company's subsidiaries, PPL and EyGen, completed a private placement of unsecured notes (the "PPL
Unsecured Notes"). The balance outstanding as of March 31, 2020 was $<span id="xdx_908_ecustom--AggregatePrincipalAmountOfUnsecuredNotes_iI_pn3n3_dm_c20200630_zmJbTMSfezDj">0.2
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
PPL Unsecured Notes were settled as part of the disposition of PPL in March 2021 (see Note 8, &#8220;Disposition of PPL&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>SalvaRx Unsecured
Notes Payable and Warrants</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the SalvaRx Acquisition in January 2019, the Company assumed $<span id="xdx_903_ecustom--AggregatePrincipalAmountOfUnsecuredNotes_iI_pn3n3_dm_c20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zx9XK5gC54T4">3.96
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million of principal in unsecured notes due on
March 2, 2021 (or earlier upon a qualifying event), that bear interest at <span id="xdx_900_ecustom--UnsecuredNotesInterest_iI_dp_c20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_z81XE7Yw0t66">7</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
per annum (the "SalvaRx Notes"). The fair value of the SalvaRx Notes was determined to be $3.4 million at January 2019. As the
SalvaRx Acquisition was a qualifying event, the SalvaRx Notes became due upon the acquisition. In December 2019, the maturity date of
the SalvaRx Notes was extended to June 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--IssuanceOfUnsecuredNotesDescription_c20210401__20210630">The
holders of the SalvaRx Notes received $7,500 of warrants in respect of each $10 thousand of principal issued. The warrants vest in the
event of a qualifying transaction and are exercisable at a 30% discount to the implied valuation of SalvaRx. </span>On the Acquisition Date,
the fair value of the warrants, which are included in non-controlling interest, was determined to be $</span><span id="xdx_903_eifrs-full--FinancialLiabilitiesAtFairValue_iI_pn3n3_dm_c20210630_zAB7i6dt8Icj" style="font: 10pt Times New Roman, Times, Serif">2.5
</span><span style="font: 10pt Times New Roman, Times, Serif">million
using the Black Scholes Model.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">During
September 2020, the Company settled the SalvaRx Notes obligations originally due in June 2021 in an aggregate principal amount of approximately
$3.7 million, plus accrued interest of $0.75 million in exchange for cash payments totaling $<span id="xdx_902_ecustom--PaymentForSettlement_pn3n3_dm_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zM4CrL3LFm0e" title="Payment for settlement">1.77
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million and <span id="xdx_90D_ecustom--WarrantsExercised_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zEMVYcvnYzz" title="Warrants exercised">397,604
</span></span><span style="font: 10pt Times New Roman, Times, Serif">of the associated SalvaRx warrants with an exercise
price of $<span id="xdx_90F_ecustom--ExercisePrice_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zdoM3WGX9Cm" title="Exercise Price">6.64
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">The noteholders who
accepted the offer exchanged their SalvaRx warrants for an equal number of Portage shares at the same price per share. <span id="xdx_905_ecustom--ContractualValueOfWarrantsExercisedDescription_c20200901__20200930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zU6auhgVe2ai" title="Contractual value of warrants exercised description">The
Company accounted for the contractual value of the exercised and outstanding warrants of $2.64 million (397,604 shares at $6.64 per share)
as accrued equity issuable at September 30, 2020. The Company also recorded a loss of $1.26 million during the year ended March 31, 2021,
to recognize the discount between the fair value of the underlying shares on October 13, 2020, the settlement date, ($9.80 per share)
and the warrant exercise (contract) price of $6.64 per share.</span></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Four
of the Company's directors, Gregory Bailey, James Mellon (former director), Steven Mintz (in trust) and Kam Shah, received, in total,
<span id="xdx_908_ecustom--SharesReceived_c20210401__20210630_zO9EQYOTMV2g" title="Shares received">363,718 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of
the warrants pursuant to this transaction. Subsequent to the exercise of the warrants in October 2020, Portage had <span id="xdx_907_ecustom--NumberOfExerciseOfWarrantsIssued_iI_c20201031__ifrs-full--CounterpartiesAxis__custom--PortageMember_z2S2GcYLfb39" title="Number of exercise of warrants issued">12,083,395
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_90B_ecustom--NumberOfExerciseOfWarrantsOutstanding_iI_c20201031__ifrs-full--CounterpartiesAxis__custom--PortageMember_zrNHnvXtt3o" title="Number of exercise of warrants outstanding">49,701
</span></span><span style="font: 10pt Times New Roman, Times, Serif">issued and outstanding shares and warrants, respectively.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company also recorded a loss on early extinguishment of debt of $<span id="xdx_904_ecustom--LossOnExtinguishmentOfDebt_pn3n3_dm_c20210401__20210630_zxld0Tc5zLC9">0.22
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million in the year ended March 31, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>iOx Unsecured
Notes Payable</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the SalvaRx Acquisition in January 2019, the <span id="xdx_90B_ecustom--DescriptionOfBusinessCombination_c20190103__20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember">Company
assumed $2.0 million of 7% convertible notes issued by iOx, a wholly owned subsidiary of SalvaRx (the &#8220;Convertible Notes&#8221;),
of which the Company holds $1.9 million. </span></span><span style="font: 10pt Times New Roman, Times, Serif">As a
result of the SalvaRx Acquisition, iOx became a subsidiary of the Company during the year ended March 31, 2019. In accordance with IFRS
3, the fair value, including interest receivable, of the Convertible Notes were effectively settled against the note receivable upon
the business combination. $0.15 million Convertible Notes were outstanding at each of June 30, 2021 and March 31, 2021. The holder of
the Convertible Notes can convert the notes and accrued interest into ordinary shares of iOx at any time before maturity at &#163;120
per share. There is an automatic conversion in the event iOx raises $<span id="xdx_90C_eifrs-full--IssueOfConvertibleInstruments_pn3n3_dm_c20190103__20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zUK8feurVK12">2.0
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, and the conversion price will be determined
based on the timing of the capital raised and the price at which the money was raised. iOx has the right to repay the Convertible Notes
together with accrued interest at any time. </span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureUnsecuredNotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureUnsecuredNotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnsecuredNotesPayableAndWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnsecuredNotesPayableAndWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475808861096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WarrantLiabilitytextblock', window );">WARRANT LIABILITY</a></td>
<td class="text"><p id="xdx_801_ecustom--WarrantLiabilitytextblock_zVtRf63FGr3k" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
13. <span id="xdx_822_zCgSE3x6Mvug">WARRANT LIABILITY</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Below
is the roll-forward of warrants issued by entity (see Note 12, &#8220;Unsecured Notes Payable&#8221;):</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_pn3n3_zLpnmYFaPf87" style="width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8BD_zuItXHtnvEu8" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of warrant liability</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PBI</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Warrants</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amount</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;$</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Warrants
    outstanding, April 1, 2021</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--WarrantsOutstandingExercisePrice_iS_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zTPyaeEkSLpb" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at beginning"><span style="font: 10pt Times New Roman, Times, Serif">6.64</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--WarrantsOutstandingShares_iS_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zsqnFSGA76og" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at beginning"><span style="font: 10pt Times New Roman, Times, Serif">49,701</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--WarrantsOutstandingAmount_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zxFVDjkYPCCc" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at beginning"><span style="font: 10pt Times New Roman, Times, Serif">1,120</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Fair
    value adjustment as of June 30, 2021 (1) (2)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--FairValueAdjustmentExercisePriceAtEnd_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zIQqk64MIAA" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment , exercise price at end"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--FairValueAdjustmentShares_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_ziKIvKEhzQC2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, shares at end"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0818">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--FairValueAdjustment_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, amount at end"><span style="font: 10pt Times New Roman, Times, Serif">(369</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Warrants
    outstanding, June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--WarrantsOutstandingExercisePrice_iE_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zCvelJGfAYTe" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, exercise price, at end"><span style="font: 10pt Times New Roman, Times, Serif">6.64</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--WarrantsOutstandingShares_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zMH5rwvsDHRa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at ending"><span style="font: 10pt Times New Roman, Times, Serif">49,701</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--WarrantsOutstandingAmount_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zX3jMALENqka" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount, at end"><span style="font: 10pt Times New Roman, Times, Serif">751</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td id="xdx_F01_z1ewmPsvx5Ze" style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="width: 0.25in"/><td id="xdx_F1C_zAFv9abyuCT9"><span style="font: 10pt Times New Roman, Times, Serif">Portage
                                            warrant liability valued at contract price, adjusted for fair value using the Black Scholes
                                            model.</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">The Black
Scholes assumptions used in the fair value calculation of the warrants as of June 30, 2021 were:</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Risk free
rate: 0.11%</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expected
Dividend: $0</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expected
Life: 1.28 years</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Volatility:
92.6%</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td id="xdx_F08_zsJ7wNBixOVh" style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="width: 0.25in"/><td id="xdx_F18_zgzS229mfuje"><span style="font: 10pt Times New Roman, Times, Serif">The
                                            Company recognized a gain of $0.4 million in the three months ended June 30, 2021 to reflect
                                            the change in fair value of the underlying warrants. The warrants were not outstanding during
                                            the three months ended June 30, 2020.</span></td></tr></table>

<p id="xdx_8A4_zazPGgavwiS4" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiabilitytextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiabilitytextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807876680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureCapitalStockAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_CapitalStockTextBlock', window );">CAPITAL STOCK</a></td>
<td class="text"><p id="xdx_800_ecustom--CapitalStockTextBlock_zwRvIEEfyWnh" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
14. <span id="xdx_82A_zNUlRCPdb2W">CAPITAL STOCK</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Authorized
                                            ordinary shares<b>: </b>Unlimited number of common shares without par value.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Following
                                            is a roll-forward of ordinary shares as of June 30, 2021, and 2020:</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_zRkyUBL1D6gg" style="width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BE_zhn5R5cV7JL9" style="font: 10pt Times New Roman, Times, Serif; display: none">Common
    shares: Unlimited number of common shares without par value</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Ordinary<br/>
    Shares</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amount</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Ordinary
    <br/> Shares</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amount</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;$</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;$</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--CommonStockShares_iS_c20210401__20210630_zlzUa9RsTd1e" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"><span style="font: 10pt Times New Roman, Times, Serif">12,084</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--CommonStockValues_iS_pn3n3_c20210401__20210630_z11lCw4pUSD5" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">130,649</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--CommonStockShares_iS_c20200401__20200630_zOu78bXbLPEc" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, Shares"><span style="font: 10pt Times New Roman, Times, Serif">10,988</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--CommonStockValues_iS_pn3n3_c20200401__20200630_zXtX2fGTQpz2" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">117,817</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued in a private placement, net of share issue costs</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20210401__20210630_zPkcaW29phk2" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in a private placement, net of issue costs, shares"><span style="font: 10pt Times New Roman, Times, Serif">1,241</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in a private placement, net of issue costs"><span style="font: 10pt Times New Roman, Times, Serif">27,216</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200401__20200630_zzCcZWr2avR1" style="font-size: 10pt; text-align: right" title="Shares issued in a private placement, net of issue costs, shares"><span style="font: 10pt Times New Roman, Times, Serif">698</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Shares issued in a private placement, net of issue costs"><span style="font: 10pt Times New Roman, Times, Serif">6,732</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued for services</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--SharesIssuedForServicesShares_c20210401__20210630_z0VSIXjjYzka" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued for services, shares"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--SharesIssuedForService_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued for services"><span style="font: 10pt Times New Roman, Times, Serif">30</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--SharesIssuedForServicesShares_c20200401__20200630_zi6tOKZv1YL7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued for services, shares"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0860">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--SharesIssuedForService_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued for services"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0862">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--CommonStockShares_iE_c20210401__20210630_zT7P8a1BZyj3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"><span style="font: 10pt Times New Roman, Times, Serif">13,326</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--CommonStockValues_iE_pn3n3_c20210401__20210630_zHt1zAznjl7a" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">157,895</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--CommonStockShares_iE_c20200401__20200630_zn1ldTTL3RJe" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, Shares"><span style="font: 10pt Times New Roman, Times, Serif">11,686</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--CommonStockValues_iE_pn3n3_c20200401__20200630_z6urXE1KhlGh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">124,549</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Number
                                            of ordinary shares have been retroactively adjusted to reflect the impact of 100:1 reverse
                                            stock split on June 5, 2020.</span></td></tr></table>

<p id="xdx_8A1_zfUuQoNrH3ba" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
June 16, 2020, the Company completed a private placement of <span id="xdx_903_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zjx3yytMieNb" title="Shares issued in a private placement, net of issue costs, shares">698,145
</span></span><span style="font: 10pt Times New Roman, Times, Serif">restricted ordinary shares at a price of $<span id="xdx_908_ecustom--PricePerShare_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zQ6NIvQm8x04" title="Shares price">10.00
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share for gross proceeds of $<span id="xdx_90E_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zxIHEVwg11v9" title="Shares issued in a private placement, net of issue costs">6.98
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million to accredited investors. Directors of
the Company subscribed for <span id="xdx_900_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_pdd">215,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares, or approximately 30.8% of the private
placement, for proceeds of $<span id="xdx_905_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_zX6L3YwwCq5a">2.15
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million. The Company incurred costs of approximately
$0.25 million in connection with the offering, which was treated as contra-equity on the Company&#8217;s balance sheet.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the quarter ended June 30, 2021, the Company commenced an &#8220;at the market&#8221; offering, under which it sold <span id="xdx_909_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostShares_c20210401__20210630_z5ins8HYbrdl" title="Shares issued in private placement net of issue cost, shares">90,888
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares generating gross proceeds of approximately
$<span id="xdx_907_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCost_pn3n3_dm_c20210401__20210630_zDuczjqXzZD6" title="Shares issued in private placement net of issue cost">2.6 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
($<span id="xdx_909_ecustom--OfferingExpenses_pn3n3_dm_c20210401__20210630_zfALxTQkixQk" title="Offering expenses">2.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million,
net of commissions). Further, the Company initiated an offering pursuant to the Prospectus. On June 24, 2021, the <span id="xdx_90B_ecustom--PublicofferingDescription_c20210601__20210624_zR1ipCS3eRT9" title="Public offering description">Company
completed a firm commitment underwritten public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share
for gross proceeds of approximately $26.5 million and was settled June 28, 2021. The Company incurred aggregate offering expenses for
the public offering of approximately $1.8 million, including approximately $1.6 million of management, underwriting and selling expenses.
The Company will use the net proceeds raised to fund its research and development activities and support operations. The amount raised
is sufficient to fund operations through at least September 2022. Funds may be used to accelerate development activities to advance the
Company&#8217;s product portfolio, working capital and general corporate purposes.</span></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475830739832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ShareBasedPaymentAbstract', window );"><strong>Stock Option Reserve</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">STOCK OPTION RESERVE</a></td>
<td class="text"><p id="xdx_80D_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zkWVFaiUwAz9" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
15. <span id="xdx_82E_zID4ZEqor7dj">STOCK OPTION RESERVE</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">The
                                            following table provides the activity for the Company&#8217;s stock option reserve for the
                                            three months ended June 30, 2021 and 2020:</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_z7NxeJz9tr0d" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span id="xdx_8B8_zpTnk8nOdM8j" style="font: 10pt Times New Roman, Times, Serif; display: none">Disclosure
    Of Terms Stock Option Reserve Explanatory</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Non-Controlling
    Interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    Option Reserve</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Non-Controlling
    Interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    Option Reserve</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zVgCUGYXjmfe" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">11,468</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z7fDbdd6HIWa" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">7,977</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zw1XEjSd9zNl" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">10,618</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--StockOptionReserve_iS_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zWo1XYbIESG8" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">58</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Share-based
    compensation expense</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">98</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">2,082</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eifrs-full--AdjustmentsForSharebasedPayments_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">295</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eifrs-full--AdjustmentsForSharebasedPayments_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0912">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_znP2zHBj2vll" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">11,566</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zOQ78WEhryZa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">10,059</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--StockOptionReserve_iE_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zp7t4u5MtwMi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">10,913</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--StockOptionReserve_iE_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zqdYdRcFI4kf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">58</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p id="xdx_8A0_z2YZMzXmfhl3" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock Options</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Board of Directors of the Company (the "Board") established a stock option plan (the "2013 Option Plan") under which
options to acquire ordinary shares of the Company are granted to directors, employees and consultants of the Company. The maximum number
of ordinary shares issuable under the 2013 Option Plan shall not exceed 10% of the total number of issued and outstanding ordinary shares,
inclusive of all shares presently reserved for issuance pursuant to previously granted stock options. If a stock option was surrendered,
terminated or expired without being exercised, the ordinary shares reserved for issuance pursuant to such stock option were available
for new stock options granted under the 2013 Option Plan. The options vest on a schedule determined by the Board of Directors, generally
over two to four years, and expire after five years.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2019, the Board decided to discontinue the 2013 Option Plan and during the year ended March 31, 2021, <span id="xdx_90A_ecustom--StockOptionsIssued_iI_c20210331_zU93VLwXJ2x">2,980
</span></span><span style="font: 10pt Times New Roman, Times, Serif">outstanding options issued under the plan expired
unexercised and no options remained outstanding under the 2013 Option Plan.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
June 25, 2020, at the annual meeting of shareholders, the Company&#8217;s new incentive stock option plan (the &#8220;2020 Stock Option
Plan&#8221;) was approved, which authorized the directors to fix the option exercise price and to issue stock options under the plan
as they see fit. The Company's 2020 Stock Option Plan is a 10% rolling stock option plan under which the directors are authorized to
grant up to a maximum of 10% of the issued and outstanding ordinary shares on the date of grant.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Effective
January 13, 2021, the Company amended and restated its 2020 Stock Option Plan to permit the grant of additional types of equity compensation
securities, including restricted stock units and dividend equivalent rights (the "2021 Equity Incentive Plan"). The aggregate
number of equity securities, which may be issued under the 2021 Equity Incentive Plan has not been changed.&#160; Pursuant to the 2021
Equity Incentive Plan, on January 13, 2021, the Company granted an aggregate of <span id="xdx_903_eifrs-full--NumberOfSharesIssued_iI_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_zgLVKAilDJo7">868,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">stock options exercisable
at a price of US$<span id="xdx_909_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_zlTdZAQ2czc4">17.75
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">per share, representing
the closing price of the shares on the day immediately preceding the grant date, which expire on January 13, 2031 to various directors,
officers and consultants of the Company. <span id="xdx_900_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember_pdd">350,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">options granted to members
of the board of directors vest 1/3 on grant date, 1/3 on the first anniversary of the grant and 1/3 on the second anniversary of the
grant. <span id="xdx_907_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--ConsultantsMember_pdd">518,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">options granted to consultants
(one of whom is also a director) vest 1/3 on each of the first three anniversaries of the date of grant.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Additionally,
the Company granted <span id="xdx_90C_ecustom--StockGranted_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zyqhCmCPkRQ5" title="Stock granted">243,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">restricted stock units
on January 13, 2021, with a fair value of $<span id="xdx_903_ecustom--FairValuePerShare_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zwTvxiYV6oF2" title="Fair value per share">17.75
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">per share, which was
the closing price on the day immediately preceding the grant date. The restricted stock units vested on the date of grant but underlying
shares cannot be sold until one of four conditions are met.&#160; In accordance with IFRS 2, &#8220;Share-based Payment,&#8221; the Company
recognized compensation expense of $<span id="xdx_908_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zLFHweFdJzJ7">4.3
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">million in the year
ended March 31, 2021, in connection with the RSU grants.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">The
                                            movements in the number of options issued were:</span></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_pn3n3_zMAggIIvjj86" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8BF_zE2XtvBR4Cmd" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of outstanding stock options</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">PBI 2021 Equity Incentive</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Plan&#160;</span></p></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PBI
    2013 Option Plan</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; text-align: center">iOx Option Plan <br/>
(Subsidiary Plan)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5cUWyWsYI36" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">868,000</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zjBndRClykJ9" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0945">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zL1SKWkjEdyj" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0947">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_z7Pne5dtHer9" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">2,980</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z66b0QW0sXDi" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">1,924</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z8qkZVzpDI4b" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">2,599</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zVyjffxYdIp7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0955">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zrvrPFAScIZj" style="font-size: 10pt; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0957">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zi4WmCdd6TQ1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0959">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zfYnHSB62ff9" style="font-size: 10pt; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0961">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zE1QXRt1TJv3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0963">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z7LPACdAytPa" style="font-size: 10pt; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0965">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired
    or forfeited</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5GJnboORkdk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0967">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zKFXqOmCz04f" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0969">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zmQ49OvXqBzc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0971">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zREWgvErtZfl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zttlqUIjGvyl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z4N4xeM7afHa" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--NumberOfOutstandingShareOption_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zE2zzv1YlAvi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">868,000</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zOhWqISGDhFk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zpA8nuZSaTVg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0983">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zgterYG3Uxki" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">2,980</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--NumberOfOutstandingShareOption_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zNexzDUBma89" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">1,924</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--NumberOfOutstandingShareOption_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zDRGHHyGAnH9" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">2,599</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_ztIOzBJSZGNi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif">116,666</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_ziMDLPhqXPX3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0993">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zdRUTPdfivP" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0995">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_ztnNGqmKAxI9" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif">2,980</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zieZS7Gy9Mxg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif">1,764</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z1dX11pVDoRc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif">1,723</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A9_z2XevsW82nH" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Board discontinued the 2013 Option Plan in fiscal 2019.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Following
                                            are the weighted average exercise price and the remaining contractual life for outstanding
                                            options by plan:</span></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zering4CO0M8" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8BC_z6PsFLfELT93" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of weighted average exercise price and the remaining contractual life</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">PBI 2021 Equity Incentive</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Plan&#160;</span></p></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PBI 2013 Option Plan</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="padding-bottom: 1pt; font-size: 10pt; text-align: center">iOx Option Plan
(Subsidiary Plan)<span style="font: 10pt Times New Roman, Times, Serif"/></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
    of June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
    of June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
    of June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zE1mY1GDkDd3" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">17.75</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z1POhsB5IPEg" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1007">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zss2jKWoqvy5" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1009">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zohgv9HVRNWk" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">15.00</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z4KSKT6wkWLe" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">165.20</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z13AHMaYUHoe" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">152.74</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average remaining contractual life (in years)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zBrxBbA4j4Ui" style="font: 10pt Times New Roman, Times, Serif">9.54</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zw4zAr4h3jFf" style="font: 10pt Times New Roman, Times, Serif">1.47</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zC1ewvJmO1w" style="font: 10pt Times New Roman, Times, Serif">0.70</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zVtzm8V1AT3f" style="font: 10pt Times New Roman, Times, Serif">1.24</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zZo41SzkVBZf" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
vested options can be exercised at any time in accordance with the applicable option agreement. The exercise price was greater than the
market price on the date of the grants for all options outstanding as of June 30, 2021 and March 31, 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded approximately $<span id="xdx_904_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--Equity2021IncentivePlanMember_zuIUFRNx9Gr3">2.1
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million of stock-based compensation expense with
respect to the 2021 Equity Incentive Plan in the three months ended June 30, 2021. There were no stock options outstanding in the prior
year period under this plan. The Company expects to record additional stock-based compensation expense of $8.9 million through January
2024 with respect to the 2021 Equity Incentive Plan. Additionally, the intrinsic value of the stock options granted under the 2021 Equity
Incentive Plan was approximately $2.8 million at June 30, 2021, of which $0.4 million is associated with vested</span> exercisable options.</p>
<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded $<span id="xdx_908_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20210630_zArnk8aTBm6">0.1</span></span> <span style="font: 10pt Times New Roman, Times, Serif">million
and $<span id="xdx_904_eifrs-full--CommunicationExpense_pn3n3_dm_c20200401__20200630_zYIJKquvZGIb">0.3</span></span> <span style="font: 10pt Times New Roman, Times, Serif">million
of stock-based compensation expense related to the iOx stock option plan for the three months ended June 30, 2021 and 2020, respectively.
The Company expects to record $0.1 million of aggregate stock-based compensation expense through the remaining vesting period of outstanding
iOx options. Additionally, the intrinsic value of the iOx stock options was approximately $0.1 million at June 30, 2021, substantially
all of which is associated with vested exercisable options.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareBasedPaymentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareBasedPaymentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475809358584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">(LOSS) PER SHARE</a></td>
<td class="text"><p id="xdx_807_eifrs-full--EarningsPerShareExplanatory_zaKLvMEzsKw" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
16. <span id="xdx_82A_zAI8S5FIHX84">(LOSS) PER SHARE</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Basic
earnings per share ("EPS") is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company
by the weighted average number of ordinary shares outstanding during the year.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Diluted
EPS is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number
of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion
of all the dilutive potential ordinary shares into ordinary shares.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table reflects the loss and share data used in the basic and diluted EPS calculations (dollars in thousands, except per share
amounts):</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--EarningsPerShareTableTextBlock_pn3n3_zJY953plXK6i" style="width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B2_zVjRZhdMMRh1" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of basic and diluted EPS calculations</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_496_20210401__20210630_zmfwE9kNqg6l" style="text-align: right; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_499_20200401__20200630_zPOOnXkZb191" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Numerator
    (in 000&#8217;$)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss attributable to owners of the Company</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(3,066</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(696</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Denominator
    (in 000&#8217;)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eifrs-full--WeightedAverageShares_i01_pdd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average number of shares &#8211; Basic and Diluted</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">12,213</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">11,104</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--BasicAndDilutedLossPerShare_i01_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Basic
    and diluted (loss) per share (Actual)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(0.25</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(0.06</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p id="xdx_8A3_zliuc5yfZvT5" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
inclusion of the Company's stock options, restricted stock units and share purchase warrants in the computation of diluted loss per share
would have an anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference
between basic loss per share and diluted loss per share for the three months ended June 30, 2021, and 2020. The following table reflects
the outstanding securities by year that would have an anti-dilutive effect on loss per share, and accordingly, were excluded from the
calculation.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock_zQ4g5JGfAVhi" style="width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B8_ztjYhz3FiGl7" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of Anti-Dilutive effect on Loss Per Share</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>As
    of June 30,</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    options</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif">868,000</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif">2,980</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Restricted
    stock units</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif">243,000</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Warrants</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif">49,701</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1062">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zvs5VAoxOgpc" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Inclusion
of outstanding options or other common stock equivalents in the computation of diluted loss per share would have an anti-dilutive effect
on the loss per share and are therefore excluded from the computation. Consequently, there is no difference between loss per share and
diluted loss per share.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807853976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments And Contingent Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><p id="xdx_805_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_z494Ywm4Tcpd" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
17. <span id="xdx_821_zKtvJZzd3z1h">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is committed to invest approximately &#8364;1.5 million ($<span id="xdx_906_ecustom--CommitmentToInvestment_iI_pn3n3_dm_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StimunitySAMember_ziXI1jq90ycj">1.9
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million) in Stimunity upon Stimunity&#8217;s
achievement of certain agreed milestones. During the year ended March 31, 2019, the Company made a discretionary investment of &#8364;600,129
($<span id="xdx_90A_ecustom--DiscretionaryInvestment_iI_pp0p0_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StimunitySAMember_zjNOfGa8xkPj" title="Discretionary Investment">688,359</span></span><span style="font: 10pt Times New Roman, Times, Serif">)
and on June 1, 2020, the Company made an additional discretionary investment of &#8364;800,000 ($<span id="xdx_906_ecustom--AdditionalDiscretionaryInvestment_iI_pp0n3_dm_c20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StimunitySAMember_zmMm1gKONWpb">1.0
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million) investment towards the commitment. The
remaining commitment was &#8364;100,000 as of March 31, 2021 (see Note 7, &#8220;Investment in Associate&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807746968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_80A_eifrs-full--DisclosureOfRelatedPartyExplanatory_zrFzE5tclF64" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
18. <span id="xdx_82D_zePOtrKEiKy">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Investments</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has entered into related party transactions and certain services agreements with its investees.&#160; Key management of the Company
has also entered into related party transactions with investees. Key management personnel are those persons having the authority and
responsibility for planning, directing and controlling the activities of the Company. The Board of Directors, Chairman, Chief Executive
Officer and Chief Financial Officer are key management personnel.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following subsidiaries and associates are considered related parties:</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Stimunity</b>.
                                            One of the three directors on the Board of Directors of Stimunity is controlled by Portage
                                            (see Note 7, &#8220;Investment in Associate&#8221;).</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>iOx</b>.
                                            Two of the five directorships on the Board of Directors of iOx is controlled by Portage.
                                            Additionally, Portage has an observer on the Board of iOx. The CEO of the Company is also
                                            the CEO of iOx, and the management team of the Company comprise the management team of iOx.</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Saugatuck</b>.
                                            One of the three directorships on the Board of Directors of Saugatuck is controlled by Portage.
                                            Additionally, the CEO of the Company is also the CEO of Saugatuck and the management team
                                            of the Company comprise the management team of Saugatuck.</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(d)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Intensity</b>.
                                            One of the four directorships on the Board of Directors of Intensity is represented by Portage.
                                            Additionally, the CEO of the Company is an officer and employee of Intensity (see Note 9,
                                            &#8220;Investments in Private Companies&#8221;).</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(e)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>PGL</b>.
                                            PPL holds 65% equity in PGL, committed to provide financing and also handles financial and
                                            administrative matters of PGL. The Company disposed of 100% of its interests in PPL and PGL
                                            on March 3, 2021 (see Note 8, &#8220;Disposition of PPL&#8221;).</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(f)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Portage
                                            Development Services</b>. A 100% owned subsidiary incorporated in Delaware, which provides
                                            human resources, and other services to each operating subsidiary via a shared services agreement.</span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following are significant related party balances and transactions other than those disclosed elsewhere in the condensed consolidated
interim financial statements:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Interest
expense includes $<span id="xdx_907_eifrs-full--InterestCostsIncurred_pn3n3_dm_c20200401__20200630_zl3jDwBfmcoc">0.06</span></span> <span style="font: 10pt Times New Roman, Times, Serif">million
interest incurred on notes issued to directors during the three months ended June 30, 2020.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2020, a board member of the Company advanced the Company $<span id="xdx_900_ecustom--RepaymentsOfAdvanceToBoardMemberOfCompany_pn3n3_dm_c20200701__20200731_zXSivIGa33lj">1.0
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, which was repaid in July 2020. There
was no interest or fees associated with this advance.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Transactions
between the parent company and its subsidiaries, which are related parties, have been eliminated in consolidation and are not disclosed
in this note.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806627208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Financial Instruments And Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</a></td>
<td class="text"><p id="xdx_801_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zoIeLwv6Z8G5" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
19. <span id="xdx_82B_zpkgRBNRAka7">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s financial instruments recognized in the Company&#8217;s condensed consolidated interim statements of financial position
consist of the following:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Fair
value estimates are made at a specific point in time, based on relevant market information and information about financial instruments.
These estimates are subject to and involve uncertainties and matters of significant judgment, therefore cannot be determined with precision.
Changes in assumptions could significantly affect the estimates.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the Company&#8217;s financial instruments as of June 30, 2021 and March 31, 2021:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilities_pn3n3_z0Nqakhay848" style="width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BF_zZRv6Wy5BGWi" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of financial instruments</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>As
    of June 30, 2021</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>As
    of March 31, 2021</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amortized
    Cost</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fair
    Value through Other Comprehensive <br/>Income (FVTOCI)</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amortized
    Cost</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>FVTOCI</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Financial
    assets</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--CashAndCashEquivalents_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Cash and cash equivalents"><span style="font: 10pt Times New Roman, Times, Serif">28,617</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eifrs-full--CashAndCashEquivalents_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Cash and cash equivalents"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1094">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--CashAndCashEquivalents_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Cash and cash equivalents"><span style="font: 10pt Times New Roman, Times, Serif">2,770</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eifrs-full--CashAndCashEquivalents_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Cash and cash equivalents"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1098">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
    expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Prepaid expenses and Other Receivables"><span style="font: 10pt Times New Roman, Times, Serif">1,995</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Prepaid expenses and Other Receivables"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--PrepaidExpensesAndOtherReceivables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Prepaid expenses and Other Receivables"><span style="font: 10pt Times New Roman, Times, Serif">2,176</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--PrepaidExpensesAndOtherReceivables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Prepaid expenses and Other Receivables"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1106">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Investments</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eifrs-full--CurrentInvestments_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Investment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1108">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--CurrentInvestments_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Investment"><span style="font: 10pt Times New Roman, Times, Serif">9,100</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eifrs-full--CurrentInvestments_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Investment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--CurrentInvestments_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Investment"><span style="font: 10pt Times New Roman, Times, Serif">9,144</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Fair
    Value through Profit or Loss (FVTPL)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">FVTPL</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Financial
    liabilities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--AccountsPayableAndAccruedLiabilities_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Accounts payable and accrued liabilities"><span style="font: 10pt Times New Roman, Times, Serif">1,605</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--AccountsPayableAndAccruedLiabilities_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Accounts payable and accrued liabilities"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--AccountsPayableAndAccruedLiabilities_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Accounts payable and accrued liabilities"><span style="font: 10pt Times New Roman, Times, Serif">1,938</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--AccountsPayableAndAccruedLiabilities_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Accounts payable and accrued liabilities"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Unsecured
    notes payable</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eifrs-full--NoncurrentPayables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Unsecured notes payable"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--NoncurrentPayables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Unsecured notes payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1126">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncurrentPayables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Unsecured notes payable"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eifrs-full--NoncurrentPayables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Unsecured notes payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1130">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Warrant
    liability</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--WarrantLiability_iI_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_z64vCpi2M7Dh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrant liability"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1132">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--WarrantLiability_iI_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z9mvXqtUPtGl" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">751</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--WarrantLiability_iI_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zyOG7DWITl7f" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--WarrantLiability_iI_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zMoBBnRcpHni" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,120</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A0_zdkAELRgL3K4" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s risk exposures as it relates to financial instruments are reflected below.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Fair value
of financial instruments</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s financial assets and liabilities are comprised of cash, receivables and investments in equities and private entities,
accounts payable, warrant liability and unsecured notes payable.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company classifies the fair value of these transactions according to the following fair value hierarchy based on the amount of observable
inputs used to value the instrument:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 41.05pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Level
                                            1 &#8211; Values are based on unadjusted quoted prices available in active markets for identical
                                            assets or liabilities as of the reporting date.</span></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 41.05pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Level
                                            2 &#8211; Values are based on inputs, including quoted forward prices for commodities, time
                                            value and volatility factors, which can be substantially observed or corroborated in the
                                            marketplace. Prices in Level 2 are either directly or indirectly observable as of the reporting
                                            date.</span></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 41.05pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Level
                                            3 &#8211; Values are based on prices or valuation techniques that are not based on observable
                                            market data. Investments are classified as Level 3 financial instrument.</span></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Assessment
of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair
value hierarchy.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Management
has assessed that the fair values of cash and cash equivalents, other receivables and accounts payable approximate their carrying amounts
largely due to the short-term maturities of these instruments.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following methods and assumptions were used to estimate their fair values:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Biohaven</b>: Fair value was based on a quoted market price of $<span id="xdx_903_ecustom--FairValueMarketPricePerShare_c20210401__20210630_pdd">34.03
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share as of March 31, 2020 (Level 1). The
investment was sold in August 2020.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Sentien</b>: Fair value of the asset is determined by considering strategy changes by Sentien (Level 3).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Intensity</b>: Fair value of the asset is determined by considering other comparable equity funding transactions by Intensity with
unrelated investors (Level 3).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Accrued
equity issuable: </b>The fair value is estimated based on the average of the quoted market prices for the period in which the shares
were earned (Level 1).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Unsecured
notes payable</b>: The fair value is estimated using a Black Scholes model (Level 3) (see Note 12, Unsecured Notes Payable&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrant
Liability</b>: The fair value is estimated using a Black Scholes model (Level 3) (see Note 13, &#8220;Warrant Liability&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">There
have been no transfers between levels of the fair value hierarchy for the three months ended June 30, 2021 and the year ended March 31,
2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s financial instruments are exposed to certain financial risks: credit risk and liquidity risk.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Credit Risk</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Credit
risk is the risk of loss associated with a counterparty&#8217;s inability to fulfil its payment obligations. The credit risk is attributable
to various financial instruments, as noted below. The credit risk is limited to the carrying value as reflected in the Company&#8217;s
condensed consolidated interim statements of financial position.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Cash</i>.
</b>Cash is held with major international financial institutions and therefore the risk of loss is minimal.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Other
receivables.</i></b> The Company was exposed to credit risk attributable to its debtor since a significant portion of this amount represents
the amount agreed on a settlement of a claim by PPL (see Note 5, &#8220;Prepaid Expenses and Other Receivables&#8221;), originally payable
over the next four years. The installment note was repaid in full in July 2021 (see Note 22, &#8220;Events After the Balance Sheet Date
&#8211; Installment Note Receivable&#8221;).</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>





















<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Liquidity Risk</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Liquidity
risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities
when due, under both normal and stressed conditions without incurring unacceptable losses or risking harm to the Company&#8217;s reputation.
The Company holds sufficient cash to satisfy obligations under accounts payable and accruals.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company monitors its liquidity position regularly to assess whether it has the funds necessary to meet its operating needs and needs
for investing in new projects. The Company believes that it has sufficient funding to finance the committed drug development work, apart
from meeting its operational needs for the foreseeable future.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">However,
as a biotech company at an early stage of development and without significant internally generated cash flows, there are inherent liquidity
risks, including the possibility that additional financing may not be available to the Company, or that actual drug development expenditures
may exceed those planned. The current uncertainty in global markets could have an impact on the Company&#8217;s future ability to access
capital on terms that are acceptable to the Company. There can be no assurance that required financing will be available to the Company.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475808719736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL DISCLOSURES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureCapitalDisclosuresAbstract', window );"><strong>Capital Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock', window );">CAPITAL DISCLOSURES</a></td>
<td class="text"><p id="xdx_808_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zeJpidIDOKSh" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
20. <span id="xdx_82D_z8e7foYhSSBb">CAPITAL DISCLOSURES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers the items included in shareholders&#8217; equity as capital. The Company had accounts payable and accrued expenses
of approximately $<span id="xdx_90D_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20210630_zNpSjU4YOAk">1.6</span></span> <span style="font: 10pt Times New Roman, Times, Serif">million
as of June 30, 2021 (approximately $<span id="xdx_901_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20210331_zLupsvr6eSf1">1.9 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
as of March 31, 2021) and current assets of approximately $30.6 million <span id="xdx_90B_eifrs-full--CurrentAssets_iI_pn3n3_c20210630_z3Gzo6gsTzsl" style="display: none">30,612
</span></span><span style="font: 10pt Times New Roman, Times, Serif">as of June 30, 2021 (approximately $4.9 million
as <span id="xdx_903_eifrs-full--CurrentAssets_iI_pn3n3_c20210331_zb8I0J07bUrh" style="display: none">4,946 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of
March 31, 2021). The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as a going
concern in order to pursue new business opportunities and to maintain a flexible capital structure, which optimizes the costs of capital
at an acceptable risk.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics
of the underlying assets.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, shareholders&#8217; equity attributable to the owners of the company was approximately $127.7 million <span id="xdx_905_eifrs-full--EquityAttributableToOwnersOfParent_iI_pn3n3_c20210630_zs033cEJaeq9" style="display: none">127,711
</span></span><span style="font: 10pt Times New Roman, Times, Serif">(approximately $101.4 million <span id="xdx_90B_eifrs-full--EquityAttributableToOwnersOfParent_iI_pn3n3_c20210331_zzAFv2fQ4ja2" style="display: none">101,449
</span></span><span style="font: 10pt Times New Roman, Times, Serif">as of March 31, 2021).</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is not subject to any externally imposed capital requirements and does not presently utilize any quantitative measures to monitor
its capital. There have been no changes to the Company&#8217;s approach to capital management during the three months ended June 30,
2021 and 2020.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475830638264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NonControllingInterestAbstract', window );"><strong>Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory', window );">NON-CONTROLLING INTEREST</a></td>
<td class="text"><p id="xdx_809_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zeuic0PQH5yl" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
21. <span id="xdx_823_zmmLhXdLHzd2">NON-CONTROLLING INTEREST</span></b></span></p>

<p style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zjsCpKSB6cw9" style="width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span id="xdx_8B6_zq0dsri5ZC34" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of non-controlling interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PGL</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">SalvaRx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">iOx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Saugatuck</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of April 1, 2021</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zYWBmeuA7dhh" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1174">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zuA7TgGQ6LP5" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_z3OImeKTvcQi" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">46,173</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zhjVPEJPPNVf" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">(20</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630_zyc8qumhnDX2" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">46,153</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
    compensation expense</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1184">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">98</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1190">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--StockBasedCompensationExpense_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">98</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    (loss) attributable to non-controlling interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">(140</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">(17</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">(157</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zXxATiNflqT7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zXby7ThrGE84" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1206">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zfCUJoiK2Yld" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">46,131</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zAFFANIZmoij" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">(37</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630_zSDG3aEFH5Gi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">46,094</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PGL</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">SalvaRx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">iOx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Saugatuck</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of April 1, 2020</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zolCUCYq2U0f" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(81</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zxvOxzbumpn2" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,451</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zFGjxaOJuHcb" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">46,712</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zIEImgneAMri" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">28</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630_zRmGV96fe2F3" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">49,110</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
    compensation expense</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1219">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1221">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">295</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1225">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--StockBasedCompensationExpense_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">295</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    income attributable to non-controlling interest</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1229">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1231">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">41</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">41</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of June 30, 2020</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zmQnHefF1W72" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(81</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zyqyFfq0D8Wf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,451</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_z7wy3kYV4Evd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">47,048</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zVDevKtSFpxf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">28</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630_zCCxi9NwywZf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">49,446</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zIVT69K3drjc" style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interests in other entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 1<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_1&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NonControllingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NonControllingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807808936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EVENTS AFTER THE BALANCE SHEET DATE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureEventsAfterBalanceSheetDateAbstract', window );"><strong>Events After Balance Sheet Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock', window );">EVENTS AFTER THE BALANCE SHEET DATE</a></td>
<td class="text"><p id="xdx_800_ecustom--DisclosureOfEventAfterBalanceSheetDateTextBlock_zRbn0bX8A67b" style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
22. <span id="xdx_828_zyvsqUR0YKBe">EVENTS AFTER THE BALANCE SHEET DATE</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Installment
Note Receivable</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
installment note receivable of approximately $<span id="xdx_90D_ecustom--RepaymentOfInstallmentNoteReceivable_pn3n3_dm_c20210701__20210731__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--EventsAfterTheBalanceSheetDateMember__dei--LegalEntityAxis__custom--SalvaRxMember_zmV99IQkh0b6">0.034
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million described in Note 5, &#8220;Prepaid Expenses
and Other Receivables,&#8221; was repaid in full in July 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureEventsAfterBalanceSheetDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureEventsAfterBalanceSheetDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807897768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_844_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_z4mLy5fbVNWa" style="margin: 0pt 0; font-size: 10pt"><span id="xdx_868_zhHGqONeO9Ik" style="font: 10pt Times New Roman, Times, Serif"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Impact of Adoption
of Significant New IFRS Standards in 2020</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(a)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            1: Presentation of Financial Statements, and IAS 8: Accounting Policies, Changes in Accounting
                                            Estimates and Errors (Amendment)</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendments to IAS 1 and IAS 8 clarify the definition of material and seek to align the definition used in the Conceptual Framework with
that in the standards themselves, as well as ensuring the definition of material is consistent across all IFRS. The Company adopted these
amendments effective January 1, 2020. The adoption of these amendments did not have a significant impact on the Company&#8217;s annual
consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(b)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Conceptual
                                            Framework for Financial Reporting</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b>Together
with the revised Conceptual Framework published in March 2018, the IASB also issued Amendments to References to the Conceptual Framework
in IFRS Standards. The Company adopted the Revised Conceptual Framework effective January 1, 2020. The adoption of these amendments did
not have a significant impact on the Company&#8217;s annual consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>IFRS Pronouncements
Issued But Not Yet Effective</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>New Accounting
Standards, Interpretations and Amendments</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">Standards
issued but not yet effective up to the date of issuance of the Company's condensed consolidated interim financial statements are listed
below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date.
The Company intends to adopt those standards when they become effective.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(c)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Annual
                                            Improvements to IFRS Standards 2018-2020</b></span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.35in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
annual improvements process addresses issues in the 2018-2020 reporting cycles including changes to IFRS 9, &#8220;Financial Instruments,&#8221;
IFRS 1, &#8220;First Time Adoption of IFRS,&#8221; IFRS 16, &#8220;Leases,&#8221; and IAS 41, &#8220;Biological Assets&#8221;.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">i)
The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition of financial liabilities.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">ii)
The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent to also measure cumulative translation differences
using the amounts reported by the parent based on the parent&#8217;s date of transition to IFRS.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">iii)
The amendment to IFRS 16&#8217;s illustrative example 13 removes the illustration of payments from the lessor related to leasehold improvements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">These
amendments will be effective for annual periods beginning on or after January 1, 2022. The Company is currently evaluating the new guidance
and impacts on its consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



















<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(d)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            37: Onerous Contracts - Cost of Fulfilling a Contract</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment to IAS 37 clarifies the meaning of costs to fulfil a contract and that before a separate provision for an onerous contract
is established, an entity recognizes any impairment loss that has occurred on assets used in fulfilling the contract, rather than on
assets dedicated to the contract. This amendment will be effective for annual periods beginning on or after January 1, 2022. The Company
is currently evaluating the new guidance and impacts on its consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(e)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            16: Proceeds Before Intended Use</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment to IAS 16 prohibits an entity from deducting from the cost of an item of Property, plant and equipment any proceeds received
from selling items produced while the entity is preparing the assets for its intended use (for example, the proceeds from selling samples
produced when testing a machine to see if it is functioning properly). It also clarifies that an entity is testing whether the asset
is functioning properly when it assesses the technical and physical performance of the asset. The amendment also requires certain related
disclosures. This amendment will be effective for annual periods beginning on or after January 1, 2022. The Company is currently evaluating
the new guidance and impacts on its consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(f)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>IAS
                                            1: Presentation of Financial Statements</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment to IAS 1 clarifies how to classify debt and other liabilities as either current or non-current. The amendment will be effective
for annual periods beginning on or after January 1, 2023. The Company is currently evaluating the new guidance and impacts on its consolidated
financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(g)</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>Amendments
                                            to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate
                                            or Joint Venture</b></span></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">The
amendment addresses the conflict between IFRS 10 and IAS 28 in dealing with the loss of control of a subsidiary that is sold or contributed
to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that
constitute a business, as defined in IFRS 3, between an investor and its associate or joint venture, is recognized in full. Any gain
or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognized only to the extent
of unrelated investors' interests in the associate or joint venture. The IASB has deferred the effective date of these amendments indefinitely,
but an entity that early adopts the amendments must apply them prospectively. The Company is evaluating whether the adoption of the above
amendment will have a material impact on its financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475830738472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivableAbstract', window );"><strong>Prepaid Expenses And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock', window );">Schedule of prepaid expenses and other receivables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_zzPU8Y1MX4l" style="width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span id="xdx_8B1_zATsIatsLBW3" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of prepaid expenses and other receivables</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_496_20210630_zLITEimfRkmb" style="white-space: nowrap; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_492_20210331_zc7OQMsU7nra" style="white-space: nowrap; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br/> June 30, 2021</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br/> March 31, 2021</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
    insurance</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,032</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,445</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Research
    &amp; development tax credits</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">849</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">649</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Other
    prepaid expenses</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">80</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
    receivables</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--CurrentPrepayments_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    prepaid expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,995</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,176</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807513672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN MARKETABLE EQUITY SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InvestmentInBiohavenAbstract', window );"><strong>Investment In Marketable Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentPropertyExplanatory', window );">Schedule of investment in marketable equity securities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_eifrs-full--DisclosureOfInvestmentPropertyExplanatory_pn3n3_zEAii1U9Fq69" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8B8_zSrRpKxvKXVh" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of investment in marketable equity securities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--InvestmentAssetAvailableForSale_iS_pn3n3_c20210401__20210630_zCA5Qnlbfw9e" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of year"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--InvestmentAssetAvailableForSale_iS_pn3n3_c20200401__20200630_zlwkqBfF1wz1" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, beginning of year"><span style="font: 10pt Times New Roman, Times, Serif">68</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Unrealized
    gain on investment</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--UnrealizedLossGainOnInvestment_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Unrealized (loss) gain on investment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--UnrealizedLossGainOnInvestment_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Unrealized (loss) gain on investment"><span style="font: 10pt Times New Roman, Times, Serif">78</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--InvestmentAssetAvailableForSale_iE_pn3n3_c20210401__20210630_zP6Npos3TaPe" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of year"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--InvestmentAssetAvailableForSale_iE_pn3n3_c20200401__20200630_zsb26HMHNDYf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of year"><span style="font: 10pt Times New Roman, Times, Serif">146</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentPropertyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS40_g74-79_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentPropertyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentInBiohavenAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentInBiohavenAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475808687416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN ASSOCIATE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureInvestmentInAssociateAbstract', window );"><strong>Investment In Associate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureOfInvestmentAssociatetableTextBlock', window );">Schedule of investment associate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_z67DQh5jFEVl" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE  (Details)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_8BA_zMrtrCHDZEqc" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of investment associate</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Principal
    Activity</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Place
    of Incorporation and <br/>Principal Place of Business</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Voting
    Rights Held as <br/>of June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Voting
    Rights Held as <br/>of March&#160;31, 2021</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-size: 10pt; text-align: justify"><span id="xdx_906_eifrs-full--NameOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif">Associate:
    Stimunity S.A.</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_907_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif">Biotechnology</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90E_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" style="font: 10pt Times New Roman, Times, Serif">Paris,
    France</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90D_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210401__20210630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z8kB5OGIJDr9" style="font: 10pt Times New Roman, Times, Serif">44</span><span style="font: 10pt Times New Roman, Times, Serif">.0%</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90B_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pdp0_dp_c20210101__20210331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zrKCG6wMVcLi" style="font: 10pt Times New Roman, Times, Serif">44.0</span><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock', window );">Schedule of investment in Stimunity S.A.</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_z2mnB0ETQFp1" style="width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE  (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B3_zZOiRpE3Z168" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of investment in Stimunity S.A.</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20210401__20210630_z9Y2sFe9cxhc" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">1,735</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20200401__20200630_ztP8YlyKyPad" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">1,225</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Additional
    investment</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--AdditionalInvestments_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Additional investment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--AdditionalInvestments_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Additional investment"><span style="font: 10pt Times New Roman, Times, Serif">1,000</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Share
    of (loss) income</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--UnrecognisedShareOfGainLossesOfAssociates_pn3n3_c20210401__20210630_zyj2KG9btyu5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share of (loss) income"><span style="font: 10pt Times New Roman, Times, Serif">(44</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--UnrecognisedShareOfGainLossesOfAssociates_pn3n3_c20200401__20200630_zlhnYiClQRm8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share of (loss) income"><span style="font: 10pt Times New Roman, Times, Serif">440</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20210401__20210630_z8ORzsOCDjP5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">1,691</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20200401__20200630_zZNFddVsYCwi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">2,665</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureInvestmentInAssociateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureInvestmentInAssociateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfInvestmentAssociatetableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfInvestmentAssociatetableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807832440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_GoodwilAbstract', window );"><strong>Goodwil Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory', window );">Schedule of IPR&amp;D projects</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_zmHSAVyZd0R6" style="width: 100%" summary="xdx: Disclosure - GOODWILL (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span id="xdx_8B3_zwqsJO77v4r5" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of IPR&amp;D projects</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br/> June 30, 2021</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>As
    of<br/> March 31, 2021</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eifrs-full--Goodwill_iI_pn3n3_c20210331_znUtYuntDBEk" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Goodwill"><span style="font: 10pt Times New Roman, Times, Serif">43,324</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--Goodwill_iI_pn3n3_c20200331_zSHCIr1yeFxf" style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right" title="Goodwill"><span style="font: 10pt Times New Roman, Times, Serif">43,324</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--Goodwill_iI_pn3n3_c20210630_zeVA6ToRAL12" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Goodwill"><span style="font: 10pt Times New Roman, Times, Serif">43,324</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">43,324</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GoodwilAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GoodwilAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475809382696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract', window );"><strong>In-process Research And Development And Deferred Tax Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock', window );">Schedule of In process research and development</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_zy1DxOYFfoY3" style="width: 100%" summary="xdx: Disclosure - IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold"><span id="xdx_8BF_zTlal8IvyLKh" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of In process research and development</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Project
    #</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Description</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value
    as of <br/>June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value
    as of <br/>March 31, 2021</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">iOx:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 25%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">IMM 60</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Melanoma
    &amp; Lung Cancers</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_z3i3mZ6d6ZE5" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">84,213</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_zPtYiObznPV" style="width: 22%; font-size: 10pt; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">84,213</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">IMM 65</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Ovarian/Prostate
    Cancers</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_zG31u7vWUGz3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">32,997</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_zax1oFtyREpb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">32,997</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">117,210</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">117,210</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Oncomer/Saugatuck</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">DNA
    Aptamers</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210630__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zU6geDRVgr47" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">178</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20210331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zhv7HNT8Gt7g" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">178</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--InprocessResearchAndDevelopment_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">117,388</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--InprocessResearchAndDevelopment_c20210331_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="In-process research and development"><span style="font: 10pt Times New Roman, Times, Serif">117,388</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
    tax liability</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eifrs-full--DeferredTaxLiabilities_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Deferred tax liability"><span style="font: 10pt Times New Roman, Times, Serif">24,171</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--DeferredTaxLiabilities_c20210331_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax liability"><span style="font: 10pt Times New Roman, Times, Serif">24,050</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807812920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNSECURED NOTES PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureUnsecuredNotesPayableAbstract', window );"><strong>Unsecured Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ScheduleOfNotesPayableTableTextBlock', window );">Schedule of notes payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfNotesPayableTableTextBlock_pn3n3_ztEgvgtOF8Zd" style="width: 100%" summary="xdx: Disclosure - UNSECURED NOTES PAYABLE (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BD_zi5BnKUOfUDh" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of notes payable</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CURRENT</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CURRENT</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">NON-CURRENT</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PPL</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">iOx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">SalvaRx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance, April
    1, 2020</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zlYDbqWAGgE3" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">200</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zExGdy5tgmS" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">100</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--NotePayable_iS_pn3n3_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zBTF3CFoBMc5" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">3,361</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--NotePayable_iS_pn3n3_c20200401__20210331_zt0fJP5fmmij" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">3,661</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Repayment</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0704">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--RepaymentOfNotesPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"><span style="font: 10pt Times New Roman, Times, Serif">(1,020</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--RepaymentOfNotesPayable_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Repayment"><span style="font: 10pt Times New Roman, Times, Serif">(1,020</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
    of debt discount</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0714">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--AmortizationOfDebtDiscount_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"><span style="font: 10pt Times New Roman, Times, Serif">76</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--AmortizationOfDebtDiscount_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Amortization of debt discount"><span style="font: 10pt Times New Roman, Times, Serif">76</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Value of notes exchanged in
    warrant exercise</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0720">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0722">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"><span style="font: 10pt Times New Roman, Times, Serif">(2,640</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ValueOfNotesExchangedInWarrantExercise_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Value of notes exchanged in warrant exercise"><span style="font: 10pt Times New Roman, Times, Serif">(2,640</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Settlement
    in connection with disposition of PPL</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"><span style="font: 10pt Times New Roman, Times, Serif">(200</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0730">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0732">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--SettlementInConnectionWithDispositionOfPpl_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Settlement in connection with disposition of PPL"><span style="font: 10pt Times New Roman, Times, Serif">(200</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Loss on extinguishment
    of debt</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0736">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0738">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"><span style="font: 10pt Times New Roman, Times, Serif">223</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--LossOnExtinguishmentOfDebt_c20200401__20210331_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on extinguishment of debt"><span style="font: 10pt Times New Roman, Times, Serif">223</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from loan payable</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0744">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif">50</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ProceedsFromLoanPayable_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ProceedsFromLoanPayable_c20200401__20210331_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif">50</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    March 31, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zzSP6nG3oOTj" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0752">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zlP79saAfey7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--NotePayable_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zn77sbxo7mMg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0756">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--NotePayable_iS_pn3n3_c20210401__20210630_zJl31BJTq3ol" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from loan payable</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0760">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0762">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ProceedsFromLoanPayable_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0764">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ProceedsFromLoanPayable_c20210401__20210630_pn3n3" style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Proceeds from loan payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PplMember_zItD8ZbzNFMc" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zFT0XLbrU3Qi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--NotePayable_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zezgC9M9RB79" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--NotePayable_iE_pn3n3_c20210401__20210630_zQD9myfIu3o7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureUnsecuredNotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureUnsecuredNotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfNotesPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfNotesPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475808701064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ScheduleOfWarrantLiabilityTableTextBlock', window );">Schedule of warrant liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_pn3n3_zLpnmYFaPf87" style="width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8BD_zuItXHtnvEu8" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of warrant liability</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PBI</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Warrants</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amount</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;$</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Warrants
    outstanding, April 1, 2021</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--WarrantsOutstandingExercisePrice_iS_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zTPyaeEkSLpb" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at beginning"><span style="font: 10pt Times New Roman, Times, Serif">6.64</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--WarrantsOutstandingShares_iS_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zsqnFSGA76og" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at beginning"><span style="font: 10pt Times New Roman, Times, Serif">49,701</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--WarrantsOutstandingAmount_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zxFVDjkYPCCc" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at beginning"><span style="font: 10pt Times New Roman, Times, Serif">1,120</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Fair
    value adjustment as of June 30, 2021 (1) (2)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--FairValueAdjustmentExercisePriceAtEnd_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zIQqk64MIAA" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment , exercise price at end"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--FairValueAdjustmentShares_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_ziKIvKEhzQC2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, shares at end"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0818">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--FairValueAdjustment_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, amount at end"><span style="font: 10pt Times New Roman, Times, Serif">(369</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Warrants
    outstanding, June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--WarrantsOutstandingExercisePrice_iE_pdp0_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zCvelJGfAYTe" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, exercise price, at end"><span style="font: 10pt Times New Roman, Times, Serif">6.64</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--WarrantsOutstandingShares_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zMH5rwvsDHRa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at ending"><span style="font: 10pt Times New Roman, Times, Serif">49,701</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--WarrantsOutstandingAmount_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zX3jMALENqka" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount, at end"><span style="font: 10pt Times New Roman, Times, Serif">751</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td id="xdx_F01_z1ewmPsvx5Ze" style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="width: 0.25in"/><td id="xdx_F1C_zAFv9abyuCT9"><span style="font: 10pt Times New Roman, Times, Serif">Portage
                                            warrant liability valued at contract price, adjusted for fair value using the Black Scholes
                                            model.</span></td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">The Black
Scholes assumptions used in the fair value calculation of the warrants as of June 30, 2021 were:</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Risk free
rate: 0.11%</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expected
Dividend: $0</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expected
Life: 1.28 years</span></p>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Volatility:
92.6%</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td id="xdx_F08_zsJ7wNBixOVh" style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="width: 0.25in"/><td id="xdx_F18_zgzS229mfuje"><span style="font: 10pt Times New Roman, Times, Serif">The
                                            Company recognized a gain of $0.4 million in the three months ended June 30, 2021 to reflect
                                            the change in fair value of the underlying warrants. The warrants were not outstanding during
                                            the three months ended June 30, 2020.</span></td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807513672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureCapitalStockAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock', window );">Common shares: Unlimited number of common shares without par value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_zRkyUBL1D6gg" style="width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BE_zhn5R5cV7JL9" style="font: 10pt Times New Roman, Times, Serif; display: none">Common
    shares: Unlimited number of common shares without par value</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Ordinary<br/>
    Shares</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amount</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Ordinary
    <br/> Shares</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amount</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;$</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">In
    000&#8217;$</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--CommonStockShares_iS_c20210401__20210630_zlzUa9RsTd1e" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"><span style="font: 10pt Times New Roman, Times, Serif">12,084</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--CommonStockValues_iS_pn3n3_c20210401__20210630_z11lCw4pUSD5" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">130,649</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--CommonStockShares_iS_c20200401__20200630_zOu78bXbLPEc" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, Shares"><span style="font: 10pt Times New Roman, Times, Serif">10,988</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--CommonStockValues_iS_pn3n3_c20200401__20200630_zXtX2fGTQpz2" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">117,817</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued in a private placement, net of share issue costs</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20210401__20210630_zPkcaW29phk2" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in a private placement, net of issue costs, shares"><span style="font: 10pt Times New Roman, Times, Serif">1,241</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in a private placement, net of issue costs"><span style="font: 10pt Times New Roman, Times, Serif">27,216</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200401__20200630_zzCcZWr2avR1" style="font-size: 10pt; text-align: right" title="Shares issued in a private placement, net of issue costs, shares"><span style="font: 10pt Times New Roman, Times, Serif">698</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Shares issued in a private placement, net of issue costs"><span style="font: 10pt Times New Roman, Times, Serif">6,732</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued for services</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--SharesIssuedForServicesShares_c20210401__20210630_z0VSIXjjYzka" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued for services, shares"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--SharesIssuedForService_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued for services"><span style="font: 10pt Times New Roman, Times, Serif">30</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--SharesIssuedForServicesShares_c20200401__20200630_zi6tOKZv1YL7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued for services, shares"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0860">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--SharesIssuedForService_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued for services"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0862">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--CommonStockShares_iE_c20210401__20210630_zT7P8a1BZyj3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"><span style="font: 10pt Times New Roman, Times, Serif">13,326</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--CommonStockValues_iE_pn3n3_c20210401__20210630_zHt1zAznjl7a" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">157,895</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--CommonStockShares_iE_c20200401__20200630_zn1ldTTL3RJe" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, Shares"><span style="font: 10pt Times New Roman, Times, Serif">11,686</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--CommonStockValues_iE_pn3n3_c20200401__20200630_z6urXE1KhlGh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">124,549</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Number
                                            of ordinary shares have been retroactively adjusted to reflect the impact of 100:1 reverse
                                            stock split on June 5, 2020.</span></td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807828056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ShareBasedPaymentAbstract', window );"><strong>Stock Option Reserve</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureOfTermsStockOptionReserveExplanatory', window );">Disclosure Of Terms Stock Option Reserve Explanatory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_z7NxeJz9tr0d" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span id="xdx_8B8_zpTnk8nOdM8j" style="font: 10pt Times New Roman, Times, Serif; display: none">Disclosure
    Of Terms Stock Option Reserve Explanatory</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Non-Controlling
    Interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    Option Reserve</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Non-Controlling
    Interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    Option Reserve</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zVgCUGYXjmfe" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">11,468</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z7fDbdd6HIWa" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">7,977</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--StockOptionReserve_iS_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zw1XEjSd9zNl" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">10,618</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--StockOptionReserve_iS_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zWo1XYbIESG8" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">58</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Share-based
    compensation expense</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">98</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">2,082</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eifrs-full--AdjustmentsForSharebasedPayments_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">295</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eifrs-full--AdjustmentsForSharebasedPayments_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0912">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_znP2zHBj2vll" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">11,566</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20210630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zOQ78WEhryZa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">10,059</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--StockOptionReserve_iE_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zp7t4u5MtwMi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">10,913</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--StockOptionReserve_iE_pn3n3_c20200401__20200630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zqdYdRcFI4kf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">58</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory', window );">Schedule of outstanding stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_pn3n3_zMAggIIvjj86" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8BF_zE2XtvBR4Cmd" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of outstanding stock options</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">PBI 2021 Equity Incentive</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Plan&#160;</span></p></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PBI
    2013 Option Plan</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; text-align: center">iOx Option Plan <br/>
(Subsidiary Plan)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    beginning of period</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5cUWyWsYI36" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">868,000</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zjBndRClykJ9" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0945">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zL1SKWkjEdyj" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0947">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_z7Pne5dtHer9" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">2,980</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iS_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z66b0QW0sXDi" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">1,924</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--NumberOfOutstandingShareOption_iS_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z8qkZVzpDI4b" style="width: 8%; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">2,599</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zVyjffxYdIp7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0955">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zrvrPFAScIZj" style="font-size: 10pt; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0957">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zi4WmCdd6TQ1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0959">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zfYnHSB62ff9" style="font-size: 10pt; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0961">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zE1QXRt1TJv3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0963">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z7LPACdAytPa" style="font-size: 10pt; text-align: right" title="Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0965">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired
    or forfeited</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5GJnboORkdk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0967">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zKFXqOmCz04f" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0969">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zmQ49OvXqBzc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0971">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zREWgvErtZfl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zttlqUIjGvyl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z4N4xeM7afHa" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--NumberOfOutstandingShareOption_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zE2zzv1YlAvi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">868,000</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zOhWqISGDhFk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zpA8nuZSaTVg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0983">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zgterYG3Uxki" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">2,980</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--NumberOfOutstandingShareOption_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zNexzDUBma89" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">1,924</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--NumberOfOutstandingShareOption_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zDRGHHyGAnH9" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">2,599</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
    end of period</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_c20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_ztIOzBJSZGNi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif">116,666</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_c20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_ziMDLPhqXPX3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0993">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zdRUTPdfivP" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0995">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_ztnNGqmKAxI9" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif">2,980</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zieZS7Gy9Mxg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif">1,764</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iE_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z1dX11pVDoRc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"><span style="font: 10pt Times New Roman, Times, Serif">1,723</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of weighted average exercise price and the remaining contractual life</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zering4CO0M8" style="width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_8BC_z6PsFLfELT93" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of weighted average exercise price and the remaining contractual life</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">PBI 2021 Equity Incentive</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Plan&#160;</span></p></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PBI 2013 Option Plan</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="padding-bottom: 1pt; font-size: 10pt; text-align: center">iOx Option Plan
(Subsidiary Plan)<span style="font: 10pt Times New Roman, Times, Serif"/></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
    of June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
    of June 30,</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
    of June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zE1mY1GDkDd3" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">17.75</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z1POhsB5IPEg" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1007">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zss2jKWoqvy5" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1009">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zohgv9HVRNWk" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">15.00</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z4KSKT6wkWLe" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">165.20</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pdp0_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_z13AHMaYUHoe" style="border-bottom: Black 2.5pt double; width: 8%; font-size: 10pt; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">152.74</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average remaining contractual life (in years)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zBrxBbA4j4Ui" style="font: 10pt Times New Roman, Times, Serif">9.54</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2013OptionPlanMember_zw4zAr4h3jFf" style="font: 10pt Times New Roman, Times, Serif">1.47</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20210630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zC1ewvJmO1w" style="font: 10pt Times New Roman, Times, Serif">0.70</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20200630__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zVtzm8V1AT3f" style="font: 10pt Times New Roman, Times, Serif">1.24</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfTermsStockOptionReserveExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfTermsStockOptionReserveExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareBasedPaymentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareBasedPaymentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807780104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_EarningsPerShareTableTextBlock', window );">Schedule of basic and diluted EPS calculations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--EarningsPerShareTableTextBlock_pn3n3_zJY953plXK6i" style="width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B2_zVjRZhdMMRh1" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of basic and diluted EPS calculations</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_496_20210401__20210630_zmfwE9kNqg6l" style="text-align: right; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_499_20200401__20200630_zPOOnXkZb191" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Numerator
    (in 000&#8217;$)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss attributable to owners of the Company</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(3,066</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(696</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Denominator
    (in 000&#8217;)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eifrs-full--WeightedAverageShares_i01_pdd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average number of shares &#8211; Basic and Diluted</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">12,213</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">11,104</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--BasicAndDilutedLossPerShare_i01_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Basic
    and diluted (loss) per share (Actual)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(0.25</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(0.06</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock', window );">Schedule of Anti-Dilutive effect on Loss Per Share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock_zQ4g5JGfAVhi" style="width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B8_ztjYhz3FiGl7" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of Anti-Dilutive effect on Loss Per Share</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>As
    of June 30,</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    options</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif">868,000</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="width: 12%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif">2,980</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Restricted
    stock units</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif">243,000</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Warrants</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShar_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif">49,701</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--AntidilutiveEffectOnLossPerShar_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per shar"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1062">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_EarningsPerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_EarningsPerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475830799736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Financial Instruments And Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilities', window );">Schedule of financial instruments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilities_pn3n3_z0Nqakhay848" style="width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BF_zZRv6Wy5BGWi" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of financial instruments</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>As
    of June 30, 2021</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>As
    of March 31, 2021</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amortized
    Cost</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fair
    Value through Other Comprehensive <br/>Income (FVTOCI)</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amortized
    Cost</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>FVTOCI</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Financial
    assets</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--CashAndCashEquivalents_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Cash and cash equivalents"><span style="font: 10pt Times New Roman, Times, Serif">28,617</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eifrs-full--CashAndCashEquivalents_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Cash and cash equivalents"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1094">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--CashAndCashEquivalents_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Cash and cash equivalents"><span style="font: 10pt Times New Roman, Times, Serif">2,770</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eifrs-full--CashAndCashEquivalents_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Cash and cash equivalents"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1098">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
    expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Prepaid expenses and Other Receivables"><span style="font: 10pt Times New Roman, Times, Serif">1,995</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--PrepaidExpensesAndOtherReceivables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Prepaid expenses and Other Receivables"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--PrepaidExpensesAndOtherReceivables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Prepaid expenses and Other Receivables"><span style="font: 10pt Times New Roman, Times, Serif">2,176</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--PrepaidExpensesAndOtherReceivables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Prepaid expenses and Other Receivables"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1106">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Investments</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eifrs-full--CurrentInvestments_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Investment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1108">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--CurrentInvestments_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Investment"><span style="font: 10pt Times New Roman, Times, Serif">9,100</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eifrs-full--CurrentInvestments_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Investment"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--CurrentInvestments_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Investment"><span style="font: 10pt Times New Roman, Times, Serif">9,144</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Fair
    Value through Profit or Loss (FVTPL)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">FVTPL</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Financial
    liabilities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--AccountsPayableAndAccruedLiabilities_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Accounts payable and accrued liabilities"><span style="font: 10pt Times New Roman, Times, Serif">1,605</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--AccountsPayableAndAccruedLiabilities_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Accounts payable and accrued liabilities"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--AccountsPayableAndAccruedLiabilities_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Accounts payable and accrued liabilities"><span style="font: 10pt Times New Roman, Times, Serif">1,938</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--AccountsPayableAndAccruedLiabilities_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Accounts payable and accrued liabilities"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Unsecured
    notes payable</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eifrs-full--NoncurrentPayables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Unsecured notes payable"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--NoncurrentPayables_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Unsecured notes payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1126">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncurrentPayables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_pn3n3" style="font-size: 10pt; text-align: right" title="Unsecured notes payable"><span style="font: 10pt Times New Roman, Times, Serif">150</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eifrs-full--NoncurrentPayables_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Unsecured notes payable"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1130">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Warrant
    liability</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--WarrantLiability_iI_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_z64vCpi2M7Dh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrant liability"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1132">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--WarrantLiability_iI_c20210630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z9mvXqtUPtGl" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">751</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--WarrantLiability_iI_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zyOG7DWITl7f" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--WarrantLiability_iI_c20210331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zMoBBnRcpHni" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,120</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475809082872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NonControllingInterestAbstract', window );"><strong>Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ScheduleOfNoncontrollingInterestTableTextBlock', window );">Schedule of non-controlling interest</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zjsCpKSB6cw9" style="width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span id="xdx_8B6_zq0dsri5ZC34" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
    of non-controlling interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PGL</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">SalvaRx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">iOx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Saugatuck</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of April 1, 2021</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zYWBmeuA7dhh" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1174">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zuA7TgGQ6LP5" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8211;</span></span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_z3OImeKTvcQi" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">46,173</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zhjVPEJPPNVf" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">(20</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20210630_zyc8qumhnDX2" style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font: 10pt Times New Roman, Times, Serif">46,153</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
    compensation expense</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1184">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">98</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--StockBasedCompensationExpense_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1190">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--StockBasedCompensationExpense_c20210401__20210630_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">98</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    (loss) attributable to non-controlling interest</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">(140</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">(17</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_c20210401__20210630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">(157</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of June 30, 2021</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zXxATiNflqT7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zXby7ThrGE84" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1206">&#8211;</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zfCUJoiK2Yld" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">46,131</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zAFFANIZmoij" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">(37</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20210630_zSDG3aEFH5Gi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">46,094</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0pt 0 0pt 21.3pt; font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(In
    thousands)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">PGL</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">SalvaRx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">iOx</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Saugatuck</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of April 1, 2020</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zolCUCYq2U0f" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(81</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zxvOxzbumpn2" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,451</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_zFGjxaOJuHcb" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">46,712</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zIEImgneAMri" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">28</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20200401__20200630_zRmGV96fe2F3" style="width: 8%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">49,110</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
    compensation expense</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1219">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1221">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">295</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--StockBasedCompensationExpense_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1225">&#8211;</span></span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--StockBasedCompensationExpense_c20200401__20200630_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="font: 10pt Times New Roman, Times, Serif">295</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    income attributable to non-controlling interest</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1229">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1231">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">41</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--NetLossAttributableToNoncontrollingInterest_c20200401__20200630_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"><span style="font: 10pt Times New Roman, Times, Serif">41</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
    interest as of June 30, 2020</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--PglMember_zmQnHefF1W72" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(81</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zyqyFfq0D8Wf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,451</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IoxMember_z7wy3kYV4Evd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">47,048</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zVDevKtSFpxf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">28</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20200401__20200630_zCCxi9NwywZf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">49,446</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NonControllingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NonControllingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475808670072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 13, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IssuanceAndSales', window );">Issuance and sales</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_CashFundDescription', window );">Cash fund, description</a></td>
<td class="text">The
specific terms of any securities to be offered through the sales agreement with Cantor Fitzgerald, in the at the market offering, are
specified in the sales agreement prospectus. The $50,000,000 of ordinary shares that may be offered, issued and sold under the sales
agreement prospectus is included in the $200,000,000 of securities that may be offered, issued and sold by us under the base prospectus.
The sales under the prospectus will be deemed to be made pursuant to an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4)
promulgated under the Securities Act of 1933 (the Securities Act). Upon termination of the sales agreement, any portion of the $50,000,000
included in the sales agreement prospectus that is not sold pursuant to the sales agreement will be available for sale in other offerings
pursuant to the base prospectus, and if no shares are sold under the sales agreement, the full $50,000,000 of securities may be sold
in other offerings pursuant to the base prospectus. See Note 2, &#8220;Liquidity&#8221; and Note 14, &#8220;Capital Stock&#8221; for
a further discussion.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxGroupPlcMember', window );">SalvaRx Group plc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Number of instruments or interests issued or issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashFundDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash fund, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashFundDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IssuanceAndSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IssuanceAndSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxGroupPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxGroupPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806488376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureLiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">2,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit (loss)</a></td>
<td class="nump">3,223<span></span>
</td>
<td class="nump">$ 655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flows from (used in) operating activities</a></td>
<td class="nump">1,580<span></span>
</td>
<td class="nump">$ 688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOnHand', window );">Cash on hand</a></td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_OfferingAndThroughThatProcessDescription', window );">Offering and through that process description</a></td>
<td class="text">During the quarter ended June 30, 2021, the Company commenced an &#8220;at the market&#8221; offering, under which
it sold 90,888 shares generating gross proceeds of approximately $2.6 million ($2.5 million, net of commissions). Further,
the Company initiated an offering pursuant to the Prospectus. On June 24, 2021, the Company completed a firm commitment underwritten
public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $26.5
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $1.8
million, including approximately $1.6 million of management, underwriting and selling expenses. The Company will use the net proceeds
raised to fund its research and development activities and support operations. The amount raised is sufficient to fund operations through
September 2022. Funds may be used to accelerate development activities to advance the Company&#8217;s product portfolio, working capital
and general corporate purposes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOnHand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash held by the entity. This does not include demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOnHand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OfferingAndThroughThatProcessDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OfferingAndThroughThatProcessDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806249720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2015</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesOneMember', window );">United Kingdom based immune-oncology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">60.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesTwoMember', window );">Saugatuck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests', window );">Proportion of ownership interests held by non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_PortageGlasgowLtdMember', window );">Portage Glasgow Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesThreeMember', window );">IOX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.51%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests', window );">Proportion of ownership interests held by non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_PortageGlasgowLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_PortageGlasgowLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475808712600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivableAbstract', window );"><strong>Prepaid Expenses And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Prepaid insurance</a></td>
<td class="nump">$ 1,032<span></span>
</td>
<td class="nump">$ 1,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ResearchAndDevelopmentCredit', window );">Research &amp; development tax credits</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Other prepaid expenses</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Total prepaid expenses and other receivables</a></td>
<td class="nump">$ 1,995<span></span>
</td>
<td class="nump">$ 2,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ResearchAndDevelopmentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ResearchAndDevelopmentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475808938776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative) - PPL Settlement [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Accruals', window );">Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LoansPayableInDefault', window );">Loans payable in default</a></td>
<td class="nump">$ 11,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">86,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPortionOfLongtermBorrowings', window );">Current portion of non-current borrowings</a></td>
<td class="nump">33,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivables', window );">Prepaid expenses and Other Receivables</a></td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Accruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Accruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPortionOfLongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPortionOfLongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansPayableInDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loans payable in default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansPayableInDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid expenses and other receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_PPLSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_PPLSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807892696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InvestmentInBiohavenAbstract', window );"><strong>Investment In Marketable Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InvestmentAssetAvailableForSale', window );">Balance, beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_UnrealizedLossGainOnInvestment', window );">Unrealized (loss) gain on investment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InvestmentAssetAvailableForSale', window );">Balance, end of year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentAssetAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentAssetAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentInBiohavenAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentInBiohavenAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnrealizedLossGainOnInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnrealizedLossGainOnInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806686184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InvestmentInMarketableEquitySecurities', window );">Investment in marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypeOfMeasurementOfExpectedCreditLossesAxis=ptgef_BiohavenMember', window );">Biohaven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_UnrealizedGains', window );">Unrealized gains</a></td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentInMarketableEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentInMarketableEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypeOfMeasurementOfExpectedCreditLossesAxis=ptgef_BiohavenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypeOfMeasurementOfExpectedCreditLossesAxis=ptgef_BiohavenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475830821800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN ASSOCIATE  (Details) - Stimunity S.A. [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NameOfAssociate', window );">Name of associate</a></td>
<td class="text">Associate:
    Stimunity S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfAssociate', window );">Principal place of business of associate</a></td>
<td class="text">Biotechnology<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfAssociate', window );">Country of incorporation of associate</a></td>
<td class="text">Paris,
    France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate', window );">Proportion of voting rights held in associate</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporationOrResidenceOfAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The country in which an associate of the entity is incorporated. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_21_a_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporationOrResidenceOfAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NameOfAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The name of an associate. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_21_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NameOfAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PrincipalPlaceOfBusinessOfAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The principal place of business of an associate. [Refer: Principal place of business; Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_21_a_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PrincipalPlaceOfBusinessOfAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_StimunitySAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_StimunitySAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806740008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN ASSOCIATE  (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureInvestmentInAssociateAbstract', window );"><strong>Investment In Associate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Balance</a></td>
<td class="nump">$ 1,735<span></span>
</td>
<td class="nump">$ 1,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AdditionalInvestments', window );">Additional investment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_UnrecognisedShareOfGainLossesOfAssociates', window );">Share of (loss) income</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Balance</a></td>
<td class="nump">$ 1,691<span></span>
</td>
<td class="nump">$ 2,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AdditionalInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AdditionalInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureInvestmentInAssociateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureInvestmentInAssociateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnrecognisedShareOfGainLossesOfAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnrecognisedShareOfGainLossesOfAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806957928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN ASSOCIATE (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AdditionalInvestments', window );">Additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_StimunitySAMember', window );">Stimunity S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AdditionalInvestments', window );">Additional investment</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate', window );">Proportion of voting rights held in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_EquityInLossIncome', window );">Equity in loss income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AdditionalInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AdditionalInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_EquityInLossIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_EquityInLossIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_StimunitySAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_StimunitySAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807834904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DISPOSITION OF PPL (Details Narrative) - Portage Glasgow Ltd. [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DispositionPercentage', window );">Disposition Percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DispositionValue', window );">Disposition value</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IntercompanyReceivable', window );">Intercompany receivable</a></td>
<td class="nump">$ 229,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DispositionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DispositionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DispositionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DispositionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IntercompanyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IntercompanyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ptgef_PortageGlasgowLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ptgef_PortageGlasgowLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475780600200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS IN PRIVATE COMPANIES (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th">
<div>Jul. 11, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember', window );">Series A preferred stock in Sentien Biotechnologies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InvestmentOwnedShares', window );">Number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InvestmentOwnershipPercentage', window );">InvestmentOwnershipPercentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_IntensityMember', window );">Intensity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_UnrealizedGainLossOnInvestment', window );">Unrealized Gain (Loss) On Investment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_IntensityMember', window );">Intensity [Member] | Acquisition Of SalvaRx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InvestmentOwnedShares', window );">Number of shares purchased</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InvestmentOwnershipPercentage', window );">InvestmentOwnershipPercentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_UnrealizedGainLossOnInvestment', window );">Unrealized Gain (Loss) On Investment | $</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_IntensityMember', window );">Intensity [Member] | Acquisition Of Intensity Holding Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Equity interests of acquirer | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Number of instruments or interests issued or issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset', window );">Number Of Private Company Share Consists In Sole Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,288,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityInterestsOfAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityInterestsOfAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentOwnedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentOwnedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of equity ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the number of private company share consists in sole asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnrealizedGainLossOnInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnrealizedGainLossOnInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_IntensityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_IntensityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ptgef_AcquisitionOfSalvaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ptgef_AcquisitionOfSalvaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ptgef_AcquisitionOfIntensityHoldingLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ptgef_AcquisitionOfIntensityHoldingLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475808721176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_GoodwilAbstract', window );"><strong>Goodwil Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 43,324<span></span>
</td>
<td class="nump">$ 43,324<span></span>
</td>
<td class="nump">$ 43,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GoodwilAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GoodwilAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807405432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL (Details Narrative)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_GoodwilAbstract', window );"><strong>Goodwil Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate applied to cash flow projections</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph d<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_d_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph e<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_e_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GoodwilAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GoodwilAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806635624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">$ 117,388<span></span>
</td>
<td class="nump">$ 117,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">24,171<span></span>
</td>
<td class="nump">24,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_IMM60IOXMelanomaLungCancersMember', window );">IMM 60 IOX Melanoma &amp;amp;amp;amp; Lung Cancers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">84,213<span></span>
</td>
<td class="nump">84,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_IMM65IOXOvarianProstateCancersMember', window );">IMM 65 IOX Ovarian/Prostate Cancers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">32,997<span></span>
</td>
<td class="nump">32,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_OncomerSaugatuckDNAAptamersMember', window );">Oncomer Saugatuck DNA Aptamers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InprocessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InprocessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_IMM60IOXMelanomaLungCancersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_IMM60IOXMelanomaLungCancersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_IMM65IOXOvarianProstateCancersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_IMM65IOXOvarianProstateCancersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_OncomerSaugatuckDNAAptamersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_OncomerSaugatuckDNAAptamersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807405432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract', window );"><strong>In-process Research And Development And Deferred Tax Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475780356136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNSECURED NOTES PAYABLE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 3,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_RepaymentOfNotesPayable', window );">Repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,020)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ValueOfNotesExchangedInWarrantExercise', window );">Value of notes exchanged in warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SettlementInConnectionWithDispositionOfPpl', window );">Settlement in connection with disposition of PPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_LossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ProceedsFromLoanPayable', window );">Proceeds from loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_PplMember', window );">Ppl [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_RepaymentOfNotesPayable', window );">Repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ValueOfNotesExchangedInWarrantExercise', window );">Value of notes exchanged in warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SettlementInConnectionWithDispositionOfPpl', window );">Settlement in connection with disposition of PPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_LossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ProceedsFromLoanPayable', window );">Proceeds from loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IoxMember', window );">Iox [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_RepaymentOfNotesPayable', window );">Repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ValueOfNotesExchangedInWarrantExercise', window );">Value of notes exchanged in warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SettlementInConnectionWithDispositionOfPpl', window );">Settlement in connection with disposition of PPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_LossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ProceedsFromLoanPayable', window );">Proceeds from loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember', window );">SalvaRx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_RepaymentOfNotesPayable', window );">Repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,020)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ValueOfNotesExchangedInWarrantExercise', window );">Value of notes exchanged in warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SettlementInConnectionWithDispositionOfPpl', window );">Settlement in connection with disposition of PPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_LossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ProceedsFromLoanPayable', window );">Proceeds from loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent Loss on extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes payable balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromLoanPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromLoanPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RepaymentOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RepaymentOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SettlementInConnectionWithDispositionOfPpl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SettlementInConnectionWithDispositionOfPpl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ValueOfNotesExchangedInWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ValueOfNotesExchangedInWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_PplMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_PplMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475780634072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNSECURED NOTES PAYABLE (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AggregatePrincipalAmountOfUnsecuredNotes', window );">Aggregate principal amount of Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IssuanceOfUnsecuredNotesDescription', window );">Issuance of unsecured notes, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
holders of the SalvaRx Notes received $7,500 of warrants in respect of each $10 thousand of principal issued. The warrants vest in the
event of a qualifying transaction and are exercisable at a 30% discount to the implied valuation of SalvaRx.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesReceived', window );">Shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_LossOnExtinguishmentOfDebt', window );">Loss On Extinguishment Of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_PortageMember', window );">Portage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfExerciseOfWarrantsIssued', window );">Number of exercise of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,083,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfExerciseOfWarrantsOutstanding', window );">Number of exercise of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember', window );">SalvaRx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AggregatePrincipalAmountOfUnsecuredNotes', window );">Aggregate principal amount of Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_UnsecuredNotesInterest', window );">Unsecured Notes interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_PaymentForSettlement', window );">Payment for settlement</a></td>
<td class="nump">$ 1,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">397,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 6.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_ContractualValueOfWarrantsExercisedDescription', window );">Contractual value of warrants exercised description</a></td>
<td class="text">The
Company accounted for the contractual value of the exercised and outstanding warrants of $2.64 million (397,604 shares at $6.64 per share)
as accrued equity issuable at September 30, 2020. The Company also recorded a loss of $1.26 million during the year ended March 31, 2021,
to recognize the discount between the fair value of the underlying shares on October 13, 2020, the settlement date, ($9.80 per share)
and the warrant exercise (contract) price of $6.64 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_LossOnExtinguishmentOfDebt', window );">Loss On Extinguishment Of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DescriptionOfBusinessCombination', window );">Acquistion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Company
assumed $2.0 million of 7% convertible notes issued by iOx, a wholly owned subsidiary of SalvaRx (the &#8220;Convertible Notes&#8221;),
of which the Company holds $1.9 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IoxMember', window );">Iox [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_LossOnExtinguishmentOfDebt', window );">Loss On Extinguishment Of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity resulting from the issuing of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AggregatePrincipalAmountOfUnsecuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate principal amount of Unsecured Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AggregatePrincipalAmountOfUnsecuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ContractualValueOfWarrantsExercisedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ContractualValueOfWarrantsExercisedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IssuanceOfUnsecuredNotesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of unsecured notes, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IssuanceOfUnsecuredNotesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent Loss on extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfExerciseOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfExerciseOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfExerciseOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfExerciseOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PaymentForSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PaymentForSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnsecuredNotesInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsecured Notes interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnsecuredNotesInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_PortageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_PortageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807797464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details) - SalvaRx Group plc. [Member]<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WarrantsOutstandingExercisePrice', window );">Warrants outstanding exercise price at beginning | $ / shares</a></td>
<td class="nump">$ 6.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WarrantsOutstandingShares', window );">Warrants outstanding, shares at beginning | shares</a></td>
<td class="nump">49,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WarrantsOutstandingAmount', window );">Warrants outstanding, amount at beginning | $</a></td>
<td class="nump">$ 1,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_FairValueAdjustmentExercisePriceAtEnd', window );">Fair value adjustment , exercise price at end | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_FairValueAdjustmentShares', window );">Fair value adjustment, shares at end | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_FairValueAdjustment', window );">Fair value adjustment, amount at end | $</a></td>
<td class="num">$ (369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WarrantsOutstandingExercisePrice', window );">Warrants outstanding, exercise price, at end | $ / shares</a></td>
<td class="nump">$ 6.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WarrantsOutstandingShares', window );">Warrants outstanding, amount at ending | shares</a></td>
<td class="nump">49,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WarrantsOutstandingAmount', window );">Warrants outstanding, amount, at end | $</a></td>
<td class="nump">$ 751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueAdjustmentExercisePriceAtEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueAdjustmentExercisePriceAtEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueAdjustmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueAdjustmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsOutstandingExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsOutstandingExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxGroupPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxGroupPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806933128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK (Details) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureCapitalStockAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_CommonStockShares', window );">Balance, Shares</a></td>
<td class="nump">12,084<span></span>
</td>
<td class="nump">10,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_CommonStockValues', window );">Balance</a></td>
<td class="nump">$ 130,649<span></span>
</td>
<td class="nump">$ 117,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares', window );">Shares issued in a private placement, net of issue costs, shares</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts', window );">Shares issued in a private placement, net of issue costs</a></td>
<td class="nump">$ 27,216<span></span>
</td>
<td class="nump">$ 6,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedForServicesShares', window );">Shares issued for services, shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedForService', window );">Shares issued for services</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_CommonStockShares', window );">Balance, Shares</a></td>
<td class="nump">13,326<span></span>
</td>
<td class="nump">11,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_CommonStockValues', window );">Balance</a></td>
<td class="nump">$ 157,895<span></span>
</td>
<td class="nump">$ 124,549<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommonStockValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommonStockValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedForService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedForService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedForServicesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedForServicesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475780324920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 24, 2021</div></th>
<th class="th"><div>Jun. 16, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares', window );">Shares issued in a private placement, net of issue costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,241,000<span></span>
</td>
<td class="nump">698,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts', window );">Shares issued in a private placement, net of issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,216<span></span>
</td>
<td class="nump">$ 6,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares', window );">Shares issued in private placement net of issue cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost', window );">Shares issued in private placement net of issue cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_OfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_PublicofferingDescription', window );">Public offering description</a></td>
<td class="text">Company
completed a firm commitment underwritten public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share
for gross proceeds of approximately $26.5 million and was settled June 28, 2021. The Company incurred aggregate offering expenses for
the public offering of approximately $1.8 million, including approximately $1.6 million of management, underwriting and selling expenses.
The Company will use the net proceeds raised to fund its research and development activities and support operations. The amount raised
is sufficient to fund operations through at least September 2022. Funds may be used to accelerate development activities to advance the
Company&#8217;s product portfolio, working capital and general corporate purposes.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_AccreditedInvestorsMember', window );">Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares', window );">Shares issued in a private placement, net of issue costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_PricePerShare', window );">Shares price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts', window );">Shares issued in a private placement, net of issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_DirectorsMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares', window );">Shares issued in a private placement, net of issue costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts', window );">Shares issued in a private placement, net of issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PublicofferingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PublicofferingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_AccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_AccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807468584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Stock based compensation expense</a></td>
<td class="nump">$ 2,180<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember', window );">Non-controlling interests [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Balance</a></td>
<td class="nump">11,468<span></span>
</td>
<td class="nump">10,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Stock based compensation expense</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Balance</a></td>
<td class="nump">11,566<span></span>
</td>
<td class="nump">10,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ptgef_StockOptionReserveMember', window );">Stock Option Reserve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Balance</a></td>
<td class="nump">7,977<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Stock based compensation expense</a></td>
<td class="nump">2,082<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Balance</a></td>
<td class="nump">$ 10,059<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockOptionReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option reserve for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockOptionReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ptgef_StockOptionReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ptgef_StockOptionReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806526008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 1) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember', window );">P B I 2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="nump">868,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement', window );">Expired or forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="nump">868,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="nump">868,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements', window );">Exercisable as at end</a></td>
<td class="nump">116,666<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements', window );">Exercisable as at end</a></td>
<td class="nump">116,666<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2013OptionPlanMember', window );">P B I 2013 Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement', window );">Expired or forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements', window );">Exercisable as at end</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements', window );">Exercisable as at end</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember', window );">I Ox Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="nump">1,924<span></span>
</td>
<td class="nump">2,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement', window );">Expired or forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="nump">1,924<span></span>
</td>
<td class="nump">2,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="nump">1,924<span></span>
</td>
<td class="nump">2,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements', window );">Exercisable as at end</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements', window );">Exercisable as at end</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2013OptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2013OptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806656920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember', window );">P B I 2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price</a></td>
<td class="nump">$ 17.75<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">9 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2013OptionPlanMember', window );">P B I 2013 Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 5 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember', window );">I Ox Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price</a></td>
<td class="nump">$ 165.20<span></span>
</td>
<td class="nump">$ 152.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">1 year 2 months 26 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2013OptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2013OptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806532664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_StockOptionsIssued', window );">Stock options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CommunicationExpense', window );">Communication expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_BoardOfDirectorsMember', window );">Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_N2021EquityIncentivePlanMember', window );">N 2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">868,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_StockGranted', window );">Stock granted</a></td>
<td class="nump">243,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_FairValuePerShare', window );">Fair value per share</a></td>
<td class="nump">$ 17.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CommunicationExpense', window );">Communication expense</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_Equity2021IncentivePlanMember', window );">Equity 2021 Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CommunicationExpense', window );">Communication expense</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommunicationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from communication.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommunicationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockOptionsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockOptionsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_N2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_N2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_Equity2021IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_Equity2021IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807852104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(LOSS) PER SHARE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NumeratorAbstract', window );"><strong>Numerator (in 000&#8217;$)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Net loss attributable to owners of the Company</a></td>
<td class="num">$ (3,066)<span></span>
</td>
<td class="num">$ (696)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DenominatorAbstract', window );"><strong>Denominator (in 000&#8217;)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares &#8211; Basic and Diluted</a></td>
<td class="nump">12,213<span></span>
</td>
<td class="nump">11,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_BasicAndDilutedLossPerShare', window );">Basic and diluted (loss) per share (Actual)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BasicAndDilutedLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BasicAndDilutedLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807273912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(LOSS) PER SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember', window );">PBI 2013 Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShar', window );">Anti-dilutive effect on loss per shar</a></td>
<td class="nump">868,000<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShar', window );">Anti-dilutive effect on loss per shar</a></td>
<td class="nump">243,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShar', window );">Anti-dilutive effect on loss per shar</a></td>
<td class="nump">49,701<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AntidilutiveEffectOnLossPerShar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AntidilutiveEffectOnLossPerShar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806001864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) - Stimunity S.A. [Member]<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_CommitmentToInvestment', window );">Commitment To Investment</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DiscretionaryInvestment', window );">Discretionary Investment</a></td>
<td class="nump">688,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AdditionalDiscretionaryInvestment', window );">Additional Discretionary Investment</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AdditionalDiscretionaryInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of additional discretionary investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AdditionalDiscretionaryInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommitmentToInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to commitment to investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommitmentToInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DiscretionaryInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DiscretionaryInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StimunitySAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StimunitySAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475830727416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestCostsIncurred', window );">Interest costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany', window );">Repayments Of Advance To Board Member Of Company</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest costs that an entity incurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of Repayments Of Advance To Board member of company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475780588888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,617<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
<td class="nump">$ 8,196<span></span>
</td>
<td class="nump">$ 3,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember', window );">Amortized cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">28,617<span></span>
</td>
<td class="nump">2,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivables', window );">Prepaid expenses and Other Receivables</a></td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">2,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,605<span></span>
</td>
<td class="nump">1,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentPayables', window );">Unsecured notes payable</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WarrantLiability', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember', window );">Fair Value to Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivables', window );">Prepaid expenses and Other Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Investment</a></td>
<td class="nump">9,100<span></span>
</td>
<td class="nump">9,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentPayables', window );">Unsecured notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">$ 751<span></span>
</td>
<td class="nump">$ 1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current trade payables and non-current other payables. [Refer: Other non-current payables; Non-current trade payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid expenses and other receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806115832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Financial Instruments And Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_FairValueMarketPricePerShare', window );">Fair value market price per share</a></td>
<td class="nump">$ 34.03<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueMarketPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value market price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueMarketPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475806773928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CAPITAL DISCLOSURES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_DisclosureCapitalDisclosuresAbstract', window );"><strong>Capital Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_PayablesAndAccruedExpense', window );">Payables and accrued expenses</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">30,612<span></span>
</td>
<td class="nump">4,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to owners of parent</a></td>
<td class="nump">$ 127,711<span></span>
</td>
<td class="nump">$ 101,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PayablesAndAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PayablesAndAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475780285496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Balance</a></td>
<td class="nump">$ 46,153<span></span>
</td>
<td class="nump">$ 49,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_StockBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NetLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to non-controlling interest</a></td>
<td class="num">(157)<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="nump">46,094<span></span>
</td>
<td class="nump">49,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_PglMember', window );">Pgl [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_StockBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NetLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember', window );">SalvaRx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_StockBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NetLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IoxMember', window );">Iox [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Balance</a></td>
<td class="nump">46,173<span></span>
</td>
<td class="nump">46,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_StockBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NetLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to non-controlling interest</a></td>
<td class="num">(140)<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="nump">46,131<span></span>
</td>
<td class="nump">47,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember', window );">SaugatuckMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Balance</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_StockBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_NetLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to non-controlling interest</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="num">$ (37)<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2020-01-01<br> -Paragraph 22<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net loss attributable to non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_PglMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_PglMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140475807853976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EVENTS AFTER THE BALANCE SHEET DATE (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ptgef_EventsAfterTheBalanceSheetDateMember', window );">Events After The Balance Sheet Date [Member] | SalvaRx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgef_RepaymentOfInstallmentNoteReceivable', window );">Working capital</a></td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RepaymentOfInstallmentNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RepaymentOfInstallmentNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ptgef_EventsAfterTheBalanceSheetDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ptgef_EventsAfterTheBalanceSheetDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ptgef_SalvaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ptgef_SalvaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&* E746[E-^QIP5M%N16>#%+R_HO>FIDK0&*=R5G6:,,'F1)OO\?_6@"<:1
MG!X%TB@00<'NLV W"K:@X 0]"DZCX(@N^3T*;J/@BA;"'@6O4?#$-;@]"GZC
MX L*V.Y1"!J%H,[N/AUU+B<1CT;7!7M"124-:-5%71"U-J0PR:O:O><%?)N
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M+;041:M]*N%894KOFBDXW\$'L8(F&%"XG(Q=RA;,VB<!Q[!D-NWS8*. V*^
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MT_$H3.[MC=.U_R%@H9W3E;]<"92'H05XO]3P+]Z0@NZ7H;/_ 5!+ P04
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M.N\+)%W'\TPUW$#%4&P<P?$>"X\>E;Q"6RMGNS;.9ORAGC&KG2-W">>(>"C
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M1C]K:NDX#!PCI($M<7[>))UHP]3O6AT+E]("4P"ZJFD"5@/.RHC35^@-] !
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MP>6OUMI9J<Y)-")A/I)0<OO)HJZ._%P.8H(L+]W3B0J>1/D07]T'!.F@-?7
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M)ZC2*D/,_<8OT.W'_C#(DLJ82S:=!X,M5?/&X,(?%O@4!1LEJ(@[J^:LN<N
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M0/[(88L;W8D"X=Y*G<I2J&C!?2;]$]PKBH2MECHUMC16U'U(+K\8+_4V"B/
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MVUUZ+'"=)L\"^#YS.&JT+VR@NZ!?_ =02P,$%     @ EXH>4W)EN:-N!
M@ D  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULO5;?<^(V$'[W7['C
MR]Q<9CAL3!*XA#!# M>C#0D#7-H^"GO!:FS))\DA^>^[DHU#VDM>.M,'L&3O
M?OOM+ZT&.ZD>=(IHX"G/A+[T4V.*\R#0<8HYTVU9H* O&ZER9FBKMH$N%++$
M*>59$(7A69 S+OSAP+V;J^% EB;C N<*=)GG3#U?829WEW['W[]8\&UJ[(M@
M."C8%I=HOA=S1;N@04EXCD)S*4#AYM(?=<ZO3JR\$[CGN-,':[">K*5\L)MI
M<NF'EA!F&!N+P.CQB->891:(:/RH,?W&I%4\7._1OSK?R9<UTW@ML]]Y8M)+
MO^]#@AM69F8A=]^P]N?4XL4RT^X?=I7L6=>'N-1&YK4R,<BYJ)[LJ8[#@4(_
M?$,AJA4BQ[LRY%B.F6'#@9([4%::T.S"N>JTB1P7-BE+H^@K)STSG-Y^GB_N
MKB?+)2PFR\EH<?T-1K=C&$_N)S=W\]GD=E7OOTX6B\D85J,_X&8ZNIK>3%=_
M#@)#'"Q2$-?VKBI[T1OVNC"3PJ0:)B+!Y+5^0-P;!Z*] U?1NX"_EJ(-W; %
M41AUWL'K-@'I.KSN6P$1GPLE8]0:%JB1J3B%D4A@C(]4P075HZGW&U0*$UBQ
M)[CA;,TS;I[?(7#2$#AQ!$[^MXR\:\]V_;DN6(R7/K6U1O6(_O#V;C7Q.ITV
M_#<V\!)-3^VCR2AZR4$T/WW\T(^B\&(Z7WQD>7$Q=OO.Q3'$DII?&PUR R9%
MV,B,#A$NMD"@?U%?:_C$!81A:%4ZO8NCXW-O2>=64F;HD=)4P#Z9;YGWYA64
M]X%2JF/%"W=:W+.L1(\YTP=KC]\]G7O3V0S.0IAAQH3,F>=HPTU)Q*Z9B%%I
M.(+^22OJ=)M%I70*=X],<28",JL-,^CM-;I1Z\N77OV@V/=(*X3ZZ=V)6.:H
M@B4KM\R4\0.,;T?>J# LM\J=7M_^O".GT.WWH5EY^TKU#%5JMJ]4$HA.6IU>
MIUJ$IR&,M(T9-10V#=6BLT;0X>P2Q;2F2%+)[U*D="@*Y3-PD?"8V9BY6/&\
M8%PY<7RBW)$T30Z7O6M)W\1SG2H-3;Y=2BC7<5;2F0!">C6H),]VJ!!<80K3
MAA6910+$%C PJ(U#/S"ZHS0):2C=/TINV]-B"_E/$86Q5,D!.9,J1,BKLPGM
MV>2]"D0;W@CCI_'JYICP:HH:J$(:%XD@I\E!=JP2E94UE? -(2%E'=9H=H@"
M[-1R3*T8#1G>E/Q+D'8II^JE+R3#UE3?O(+[+K@U\!NU12+S-F41_IW%@_B_
M^)[LCS!K%9]HSFNTND<0MCM>SK/,=H*1=OC:*>I0D,C3LJ87ITQLD8K BTME
M?7H&HYC0F:L(4.0[)*6R+?OS*+\F6J?#NK_.^+8"T6A,AM9EL@._T-7#P)7B
MANL4YK(4B6[#S\[=X& J4I-LW>S75&BE,-6 ;-XVUXM1-55?Q*N[R8RI+:<"
MSW!#JF&[=^J#JN9]M3&R<#-V+0U-;+=,Z8J$R@K0]XV49K^Q!II+U_!O4$L#
M!!0    ( )>*'E/&5XMX 0D  "$6   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;*U8:V_;.!;]KE]!>-+=!- XEIS829L$2-ITMK-M&B3M#/8C+=$6
M45E422J.^^OG7%*492?I++ +)-:+O,]SS[W2V4KI;Z80PK+'95F9\T%A;?WZ
M\-!DA5AR,U2UJ/!DKO226USJQ:&IM>"YV[0L#]/1:'*XY+(:7)RY>[?ZXDPU
MMI25N-7,-,LEU^LK4:K5^2 9A!MW<E%8NG%X<5;SA;@7]FM]JW%UV$G)Y5)4
M1JJ*:3$_'UPFKZ^.:+U;\(<4*],[9^3)3*EO=/$A/Q^,R"!1BLR2!([#@W@K
MRI($P8SOK<Q!IY(V]L^#]/?.=_@RXT:\5>6?,K?%^>!DP'(QYTUI[]3J7Z+U
MYYCD9:HT[I>M_-KT:,"RQEBU;#?#@J6L_)$_MG'H;3@9O; A;3>DSFZOR%GY
MCEM^<:;5BFE:#6ETXEQUNV&<K"@I]U;CJ<0^>_'UYO[Z[=>[ZW?LYO.7ZWMV
M>_F?RZN/UV>'%L)IR6'6"KKR@M(7!(W9)U79PK#K*A?Y]OY#&-59E@;+KM*?
M"OR]J89L/(I9.DJ3G\@;=YZ.G;SQ2YY61F2-%CF[4588=LO7?%:*GT@^ZB0?
M.<E'_WL,?RJ("O"UJ7DFS@>H,"/T@QA<D,PH28?L!37LO2I16K):1-(PSC0N
M?T6UKKC.F9JSRGE;>V]?1_<HZ[PI1;3[*(+LN^N;+RP<;S[?_-J>1_L?JL@6
MJC&\RLT!N[W]R.3G1W;/RP=^]\B^*,O+Z(J7O,I$S"YK+<LH<:D;L3T<Z#=Q
MO^-X/$G<<3))HCL![:AQR_[QRTF:)&^ZXWX2T^:#[B2Z7"IMY0].U4S6YV)F
M62Y-IIIG]D\G^(O^X&4C-E$0CUG!JP4P(*L( =(<.\6CT)DTXJD):3PY<B:T
M)Q$XRI:"[(UDQ3)552VYK*0MR)9:&>EN0"4%:9]</WA&,MV./BIC&!:+1XOT
M-=(43G3P;7=7FH[I/[K5*A,B-]%<JR4K%:]"#KNEQZ/>:9>8Z!/76<'&/C.4
MA; (V3D>[5[_-XI>.&Y4HHQ%5\9_IY%B%@%B['K]FZC8"R7+WC6:X&X+P=:"
M:R:(<EC?N60:,WK\5BUK7JW_:=!U9D;FDFLI3.QRT^F)D<EE70H+(9P!NP_<
M"E:7*$0'3>2CZ2SQ0-HGX0.R=L?&P<&0?<&SF?>?H0\:"TVPEW%#HK9R,&(K
MW-UCHV$:+659 CIN?T0&[KJ_$EHPXR"8D["::V<<V?(,]H!0K\M%?M\(X>2P
MD]@%/1V]>?=DDWN0O($3H;0[(Z+M'%#T_O059!C88;<8R*@@XS+[#G![/;#J
M=UXU&  H3:=;:8)3& [@'.AA>#H)$2';D)4JDS4O2<!N-G*J\:I%=]I";5\!
M&%R74FC6U#0 L.\-+^5\3;D0#\CL 6GGELT(1+*RB*^Q##>F[%548Q^OJF;9
M)CLXLY7F.9>:/022Z?O<I@QIR@$LC=8-<ZV"+K8W'AZQX!NT]>,Q9)>&Y$3/
MQ8ZD/?4B?D;O3&1\*5Q@G.^T@F\D#9$Q]DX WS-XN<D#IAR4EEVSG"I S:/G
M/0)?^9*#/ZZ^*> >MX4J<Z'-\]'0T(@9#/F=QL=@0"Q:!0A)FO%,#0C1;<&1
MR;UDQ$+3V<$ <")RGX).P@,E3SI?(Q<8VK,5+HN%AK?C(&1RU%/+_A[32#ZX
MZM6FJ\!!<D."'B3LIDSS4"ZM;T.6#H\#5*/&.$78<P7^^,;0;E4)US^I7)3#
MP%SWHK8A]NEHNP9"@3\-GYJ5<N'4XUS+A:QX6:Y=DJFJ0B+H DS-%PLM%H[)
MNKCQI?.*XE+76CU*)%R4ZPB(G 9$QF"^!CC+,MVX1MF6!3;MC8;3XPZYLNKZ
M*<.\P3)N"M:V<V"81@**!8A].)UVM4QQ'Y].X\GH*&I!@JI7F>1$O\'A+JF.
M2WC5->D(SF2NV/;89#@Y<F5J"F32HX$((6!P5:@(;E"L?3C5?([5FR$ ]U"^
M3W22,Z22D,-  )0GHD>,'WA/\=H,@85D&JHS;]2V*5%':IG#$O218-H#K@04
M,TORM\@C>)F[,/5[1V<<>9["\2X-^VTT>W;M460VYAQ$?)-/>$4%3A44,+]!
M8]NG1SZ6G0.E452[2N>N0Y9N;($=R3"==';D#MKL)TTY3>+(>DF+2OX0H7'Y
M4IL)NQ+"4]536FT@39>NBEL_H?)S9A69G8SC7B&9;DAS-!:S_;W3X<EH*QZ5
M!\23$7 _I.: ;8"V'<TA!NY&!^QN!HQ<PC&K-*:+WU!X"H1^Q64IUC$(?DD4
M@%=/RA>]24-86(\F=&^)K]@GU-H/MD\4IO'F=^! \&^^9/<%+^*./6-'<E1>
M<32>C.-I<A*HND-)W6CD-Q 8W@MZU(?>CED(.! ;@NL"T+K5I^4091_A4 4%
MSUF2QJ,3#/2GQRZB1Z?Q=)1$GIR?(#C $[>#]#A0/MPJUSM5\RSH*M?2USL3
M,PL3LZ,%S%+=,-7V@Y<1.73O,2\-.?^GN2;JYIIT.&*]J6;ZBKC@0>"]AM3Y
M:::-WVQ-IL5P'3Q&/*]6-$)T<^RZUX/\B-).=6][$IT[8:B+";2K0F;%5L,A
MNC14S*>L&T$QA/ (R6E*N]O*>T['+GCMK,%W3.NK^'MNH,GG0^6X4N=N<G;1
M_O#^[CX:QSND0!60E8V#5=>??'E0VN*-^IU(^!%:H VTF-N,TPLN*^,IG=+0
M$^<F*%=>,^KN CC$^\(,W==7$[IBLNF*+^C<>@^P?KZ!E=MO1U0;N_ D(O8-
M+13Y4PT9KP*..@=\I3WIXCA1&!Y@!Z4I4.G<)9+&'R3+2F1S)D!3O8&0T^MH
M,AF_2=+13L_%,OKP@.0U5F&#S%IC3*\ _4!&6C0'S] [#VHAZF:.P,B]G9Z
M5UA!0_-FBH[H*US.VJD6UE),VXQGO)8@1J\D[Z1Z4?!A@_ZEJL3:3;-^K2>"
M@KOIFVGZF,=<L\)$\SR8T,L6 D]T.Z3LAKH7SB%[[C/38>^S'3K"PGV<)'"A
M'?HO>-W=[OOGI?_LMUGN/YX"-1@'#2O%'%MI3!MX'\*%5;7["#A3%DERIX7@
M0!4MP/.Y@DOM!2GHO@I?_ 502P,$%     @ EXH>4TA!:1_* P  !0@  !D
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M* <2+"U_I5;=2%N 6<!3)>EXETC&GN0(I"[X*3X6EZ:JC!:M\#%\(_R5\EB
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M+$#O%\;X[8(=]-]+9_\!4$L#!!0    ( )>*'E-/U2!2+ H  !@=   9
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M6O^$)8L=G.-,DI:0UE1Z!T'*;$TB7I= ER]D(0UD8<WT$VIZUFCU7)>&KZ7
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M&VI=A!*!]=\?8/HX[9V.&231 Z@+T0\=#<<JU(KS'Z:EWH8/=]&VYBK/9:K
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M2@&%@@O@][G6KKI!!?6?H1?_!U!+ P04    " "7BAY3[B(6O^H$  "9#
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M)][0@PQWK"[,%WGX"]M\+BU?*@OM?N'0^"8C#]):&UFV8(J@Y*+Y9Z]M'<X
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M>!P$SL0;+-FC'E5,Q%6W'[P%W>WC7>BHJ=4A6YWGR*.P!^@R:4J,2N50"@>
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M?A=1#88WO]V@K<,[N[!(KW98EO29!(X%Z'YI+>XV;*#_\)K_"U!+ P04
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M'.BR'/FEHL7*CMF9T#BTK;C$6Q*D,<#SN1!ZIY@ U;W;_0E02P,$%     @
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ME#; ^'-A^F\-FZ#;LM/?4$L#!!0    ( )>*'E-I'?3>$PD  .P7   9
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M2J>XOW]&O_:^DR\K9O!2B1\\M\4X/ \AQS6KA?VFMC>X\\<;F"EA_!>VC>R
M&+/:6%7NE.E<<MFL['$7ASV%\_B 0K)32+S=#9&W\C.S;#+2:@O:21.:VWA7
MO389QZ5+2FHUO7+2LY/YW?U5NKR]NEO"_ ZF:?KU<CY=7L')DJT$FM-19(G%
MR4;9#G'6("8'$/MPJZ0M#%S)'/.7^A%9UYJ8/)LX2XX"?JEE%_IQ!Y(XZ1W!
MZ[<N]SU>_Y#+\@&-I<*R,)<P-49EG%D\@CQHD0<>>7  .:66R6N!H-; _["P
MURD:WX\BNI:\,!7+<!Q2SQG4#QBV-,$!FN".E0@+S67&*R:"J:M\;I]@(0C)
M:<UEIG2E-&LZ0^9PKRR7F\ WI8$;%#GAO7X;M"&["%++RUHZ[+0[[<*,*XM9
M(950&Z)CFIM.<*V9S! & ^C&[VCIQO .CD1[V$9[^#_1YA)>6O5:U(\B_U/4
M_Z(+EH5&#/:; *B$T95P<#*7@2U4;2CFYM17M/O$P8P)%Z5.L,(-EY*B[MRJ
M4'.5PUOH=3[TAWY-DF$PS7/N,D>YW;/D_9OSI-?[1#)Q' =IP;2W]40H0U14
M#(JJXH32<$I)V&-$2O]+KK.//5J3SMG9\-5$17OSID2]\5/50*9J:9O1T]ZV
M@WO:S*L_XLW4OV6:_#4@<$VJ<?<#948WD[0Y6%7YZ;52EF:AWQ;T\T'M!.A]
MK:CD=@='T/[.)K\!4$L#!!0    ( )>*'E/N($_'/@(  .<$   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;'U446_:,!!^YU=8UC2U$B(AH6O%2"1H
MMY6I51%LZ[-)#N+5\66VTW3_?K8#*9. E_C.ON^[[YP[3QI4+[H ,.2M%%(G
MM#"F&@>!S@HHF1Y@!=*>;%"5S%A7;0-=*6"Y!Y4BB,+P4U R+FDZ\7L+E4ZP
M-H)+6"BBZ[)DZN\,!#8)'=+]QI)O"^,V@G12L2VLP/RL%LIZ0<>2\Q*DYBB)
M@DU"I\/Q;.3B?< O#HT^L(FK9(WXXIQYGM#0"0(!F7$,S"ZO< M"."(KX\^.
MDW8I'?#0WK-_];7;6M9,PRV*9YZ;(J$WE.2P8;4P2VSN85?/E>/+4&C_)4T;
M&UU3DM7:8+D#6P4EE^W*WG;W< "X"4\ HAT@\KK;1%[E'3,LG2ALB'+1ELT9
MOE2/MN*X=#]E990]Y19GTF]/3W?/\X<'<O&#K07HRTE@+*T[#+(=Q:REB$Y0
MQ.01I2DT^2)SR/_'!U9.IRG::YI%9PF_UW) XK!/HC :GN&+NQICSQ>?JA$Q
M;[@@T[4VRK;!&<I11SGRE*,3E"L[''DM@."&S!?+CZRL/M^12N%OVVWZV!V>
MY7.C-]85RR"A=K8TJ%>@79+>T22]B[GLF0)KS62N+\E4NSC_[<V88#*#?F\-
M6RXEEULGM +%,2<?R"CNQ]&H,][#0>;G LFQFPL.FJ\$M?4CIDF&M31M'W:[
MW11/V^9]#V^?@$>FK%Q-!&PL-!Q<7U&BVK%J'8.5;^4U&CL8WBSL2P3*!=CS
M#:+9.RY!][:E_P!02P,$%     @ EXH>4T--BM'K @  ! 8  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&ULC51M;]HP$/Z>7W'*IFF3NN8%.E@'2 $R
MC0D* M9M'TUR@%?'SFRG=/]^=M[*I+;:!_"=?<]SS]FY&YR$O%-'1 T/&>-J
MZ!ZUSJ\]3R5'S(BZ%#ER<[(7,B/:N/+@J5PB24M0QKS0]S]X&:'<'0W*O94<
M#42A&>6XDJ"*+"/RSQB9. W=P&TVUO1PU';#&PUR<L -ZF_Y2AK/:UE2FB%7
M5'"0N!^Z47 ][MKX,N"6XDF=V6 KV0EQ9YU9.G1]*P@9)MHR$+/<XP09LT1&
MQN^:TVU36N"YW;!_+FLWM>R(PHE@WVFJCT.W[T**>U(PO1:G+UC7<V7Y$L%4
M^0^G*K87NI 42HNL!AL%&>752A[J>S@#]/UG &$-"$O=5:)2Y91H,AI(<0)I
MHPV;-<I22[011[E]E(V6YI0:G![-;MZOULM)O-G .M[$T7KR!:*;*4SCVWB^
M7"WBFVWM?X[7ZW@*V^@'S&?1>#:?;7_"VRW9,53O!IXV8BREE]2)QU7B\)G$
M'5@(KH\*8IYB^B_>,T6TE81-)>/P1<*O!;^$CG\!H1\&+_!UVIOIE'R=YVZ&
MO\^E2% I6*-"(I,C1#R%*=Z;3SDW'Z:N_3U*B2ELR0/,*=E11O6?%P1T6P'=
M4D#W&0$;TX!IP1#$'F8<&C&R$4-,\O11S%-/\&("V^_7*B<)#MW<LLI[=-NL
MSO]E=592_#(=YKPR%Z$22?.RV6X)*] ARFH_LQVZ?+AV9HL%?/!A@8QPD1'G
M#<GR3S O^ $FA"<H%;R&?O<B##JM48&N8'E/)"7<,VF5)AJ=!M$)+SY^[-6+
M$P0]@_*A7ITE3T2&TMN0XD!TD=S!]"9RHER3S(*#7M_^G-<EH-/O0VLYS?LZ
MVKPO:][7!(3=BZ 75(9_Y<-33^Z==:;)="CGCX)$%%Q73=KNMB,NJCK[,;R:
MCPLB#Y0K8+@W4/^R=^6"K&9.Y6B1EWV^$]I,C=(\FC&-T@:8\[T0NG%L@G;P
MC_X"4$L#!!0    ( )>*'E,YM5PK'@,   0'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;(U5;6_:,!#^GE]QRJ:I2*QYHZSJ  DZIG5J*8)VTSZ:
MY"#6'#NSG4+WZV<[(6-=Z2:U\=FYY[GG?-QEL!7RN\H1->P*QM70S[4N+X)
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MM#29,!M;\0%N7,(%%^#:\%GD>J-@DB>8_%N_1:Y5_@5'_\9!+>"?1=Z$MM>
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MS-(-*LL^K9QHL;6]T5)HZK2LN*'6%J790/]70NCCQ!BHFN71/U!+ P04
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M[V<[D-&N,&W2I"B^L^^>N^>2._<V7*QE!J#0-J=,]MU,J>+*\V2208[E!2^
MZ9,E%SE66A4K3Q8"<&J=<NJ%OG_IY9@P=]"S>Q,QZ/%24<)@(I L\QR+'S=
M^:;O!NY^8TI6F3(;WJ!7X!7,0'TI)D)K7HV2DAR8))PA <N^>QU<W<3&WAI\
M);"1!S(R3!:<KXTR3/NN;Q(""HDR"%@O3W +E!H@G<;W':9;AS2.A_(>_:/E
MKKDLL(1;3K^15&5]M^.B%):XI&K*-Y]@QZ=E\!).I7VC364;M5V4E%+Q?.>L
M,\@)JU:\W=7AP*'C'W$(=PZAS;L*9+/\@!4>] 3?(&&L-9H1+%7KK9,CS'R4
MF1+ZE&@_-1B-1^>WX]%\.GYX&([NT7 TOYO>S>:H,<<+"O*LYRD=QAA[R0[R
MIH(,CT!&Z)$SE4ETQU)(G_M[.KTZQW"?XTUX$O!SR2Y0Y#=1Z(?!";RHYAQ9
MO.@89\[.$YVBX%0?K="0*1 @U0GHN(:.+71\!'JFFR8M*2"^1.Q%&/)JF*H
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MQS&8G&DTL$;99'^MJ6;K\# UA *LI-43I]L.Q3.<A<,970E"N/OSG%91LQJ
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M9EWZ2L^K\[B:2%:41]J"275 EL-$76'(M8'ZOF1,ODWT*=E<BJ-_4$L#!!0
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M-^#Z4DJS']AV5/]]>G\ 4$L#!!0    ( )>*'E,-%L0,L0(  .@&   9
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ME(VK:U.1+'VUG&BQ=M:T$-H8G1MFYBI":0/,]Z40>C^Q":K++?H#4$L#!!0
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MPB3H\RWGZK0P N5G;O ;4$L#!!0    ( )>*'E.&!?5PMP(  $L'   9
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M*62"L QQV(RLL7LU&^CU9L$]@;TXB)'.9,W8HQ[,XY'EZ T!A4AJ!JP>.Y@
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MY^PCRXU%^DOLF^1N01QCG#78TRVH*=CG+$;2XA'C8L<[J'C3([RWW#98TOK
MTB1M/DZ&[.S=^9\H,3FI[:2UG33 MH[ ?M4H<,O&PJ'0"\>>QI3 1@C*/9^
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MF D1=,C2OY)8SOO>A0=B.B7+5#ZQ]1^T**BKXT4L%>87K#=]NY<>B)9"LJP
M*P99DF_^R4LQ$%L %:<:@ H ^AD0'@#@ H!-H1MFIJQ;(LF@Q]D:<-U;1=,-
M,S8&K:I)<CV-8\G5TT3AY.#Y\_AN^/QT=PL^__GE;@Q&UW]?WSS<@?>W5)(D
M%1_ 1_ \O@7OWWT [T"2@R]SMA0DCT7/ERJ_CN)'1:Z;32YT(!<&CRR7<P'N
M\IC&%?BA&P^1(X"O"B^K1Z_5WR!GQ$_+_ S@X#>  @2K"+GACX0K.*R"[]#!
MY61@$P\?B'<_Y6(LB:1JG\@']?!>-07XIIO M/]Q9.F463HF2^= EAN2DCRB
M5?.W 78-4 O :@"[0<]?;0_)?A\<AK#LM$.I6U+J.BD]T07YH8NNFH,---Q*
M^!$&**C.&)890V?&ZXQQF?Q'C):PJ=KY$PGB1$1L6<TBW&-Q'E93."\IG#LI
M?"7IDNK<.9-4 /H2S4D^H['>96O".<FENDEYE(BJR1J>[X\+"CL'QN6B)'7A
M)*5T6Z9F_6D:$<OS0F_7B9SK 5HPD;P.VFCT4$7LHH)8<(#79<GKTLGK@0D!
M5%;Z(I-\MDS$W' L9JYJ+5_NL4#HY[5<U0=7$X6!5=3 277$641I+,"4LPRD
MC.1 K6XR22NWG#N8=O$KL2 1[7O*I@7E*^H-0*5V!GO%= \,.MQR!]A4*PID
MZ!2+7W3:984L*^0>X44*OCW2;$*Y2Q"AU5UX2N&%5GEA8^EU(^NL@\[^HCZT
M^Z 5:/@&A79CC^*^2\NJ.&Q9QMWQ&E"U:@]/*_?N\ V86TN I_<$6,<4H'4%
MV+(M#-T!ZP\CLKZ VO0%=[ :>M!"H-V"K7F@QN;A1M:I[NV!=JNS)H3<)G3/
M7HXQ(61-")W2A) U(=38A-"^=^Q[>E6G0SL968-!;S 8-[;!+%N#02T;C#M>
M ZK68-!I#<8=O@%S:S#H] ;C3M& O?4@U+8'N0/6YXJM!^$V/<@=K(9*X^/?
M3;"U%]S87O Q[R:_Z+3+RMH"=MO"F*0K\G24->"M[T*GM 9LK0$WM@8WLLY:
MV+</C ]]0,+6/_ ;_ /7^H:$K3O@EMT!'_\9"5OAQZ<5?ESK2Q*VLHY/+^ON
M% VDTLHZ;EO6<8W/21TKV9TV)=L=K,8V;2'0;L%6USN-==V-K%-=6Z\-_M;1
M2T;YS)Q("6 $8',*4]XM3[VNS5F/;[MOCLP>"9\EN0 IG2IH<':N1(MO3J$V
M%Y(MS$'.A$G),M.<4Q)3KCNHYU.F]G]QH1.49X&#_P%02P,$%     @ EXH>
M4[+ML#Z*!@  -A8  !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULM5AM
M;]LV$/Z>7T%XZ9  GBU1?FT3 XGC=AG:)(B;%4.Q#[1TMHGJK21EQ_OU.U*R
MY"0RG:WH%UNB>'</[X[/'7FV3L0WN010Y#$*8WG>6"J5OFVWI;^$B,E6DD*,
M7^:)B)C"5[%HRU0 "XQ0%+:IX_3:$>-Q8W1FQN[$Z"S)5,ACN!-$9E'$Q.82
MPF1]WG ;VX%[OE@J/= >G:5L 5-0#^F=P+=VJ27@$<22)S$1,#]O7+AO/]">
M%C S_N2PECO/1"]EEB3?],MU<-YP-"((P5=:!<._%8PA#+4FQ/&]4-HH;6K!
MW>>M]O=F\;B8&9,P3L(O/%#+\\:@00*8LRQ4]\GZ=R@6U-7Z_"24YI>LB[E.
M@_B95$E4""."B,?Y/WLL'/$: 5H(T-<*>(6 ]UJ!3B'0>2;@]O8(= N![G.!
MSAZ!7B'0>ZU OQ#HFV#EWC6AN6**C<Y$LB9"ST9M^L'$UTAC1'BL4W&J!'[E
M**=&#S?3R?CA?G)%;FX_3Z;D[N*OB\N/$W)R!8KQ4)(;)@33Z7)*?B,/TRMR
M<GQ*CDF;R"43( F/R4/,E6SB(#Y_7B:99'$@S]H*X6DC;;^ <IE#H7N@N.13
M$JNE)),X@*!&_LHN[QV2GQRP3RT*VNC7TKETZ]Q+:M4XA;1%/*=)J$.=&D!C
MN_@?+$9Q5XN[PSI_'!#/XM*Z6^<.N_@G)K;6:\7?V\5O?56*UZW]P^O!.Y90
M>&6>>T:?MT??]5S(J6(*D$;51_QXC8^2?-6/Q#S_;;'2*:UTC)7.'BL7BX6
M!5HAJ>"QSU,6$A8E6:Q(,L=](L'/! 3D)E%0MT,^Y.J[1KVN(JL1UI2S]JH&
M4[?$U+5BNI8R8[$/&D%6(H@U@B:2MO0%3W55J$LPN^;/2SA:)F$ 0FKE:@ED
MRL(5NW_,%XBER@=DCH <]YM=Q]&3UII.8F5X ^DCQ8JDAX'Y2W+L.J@DYP\]
M6/F0XQH@:"&[0*5A!5)I-6CW"%:0^YB1[QD+^7S#XP51.%&RHN:A3B0L H\@
M?"[9+ 3"%,[WG#<DX-(W45*)60:/TI C[A4+,V;$476QMI8E3WIE3'I6S[WG
M,8:$X\I"SF8\Y(KK:"">.>/"F(6Z>/1>ID=W7W[T2RQ]*Y9ISN/;6-69S17T
M=LQZ/:_O#NH-#TK# ZOACXF4Y#8FDT>%P<JX7.J]26[GY IFJ@['X.7R:;7Z
MG-3JYGCU0(<ET*$5Z%TB%+9EY.LGB&8@;$3A.E7==7XB(;D[]=VU@K_)-&:S
MQ_+,AZ?;T.RL.GHO].Y&W:7.P/.&W7IWNK3"1'\$$W;,4N%^Q:RH!49? .L,
M^XZ[!U55(5S/OA$*[GI-F*N"X'9^9I@KDG?M7/RCE6=<Z-_=.-ZPMX=;W(KH
M7#O3/;.,?*T Z:9N>X\/J.JW'.>-S5D5X[EVRKMC&T,U>)(C$I0*371J.];^
M"Z^X_?X^KU3,Y]JI[\LVU;?Y7[<#+PLE3WAWV.\YG3WF*SYS[80VV>ZZ.\']
MND)S62CH[YCNM7I[#-.*]*AC-3S&_EI@0<82G1>Y)_N^=,:!MN3R@!7=EXR3
M*&7Q!H^ZIK"C3AUL7=O].@SZ0V7>]!\5">TPTYP<4_0#GL3"4+<%)QB0)D9D
M>QK""GZL'452Y#<S=GK$I$8AD&8)?,^XVAC2W38@>$90AF_*;C=O<\H%A#+1
MQ3D1@49&0ETU-0ZW17LECB 3IN%!P0TP04"?8 BV\-A6;7OXYI'*-2UB_@^8
MN67?,P.U!C"]U$X+LO5,AMI$:%JJ8IUH$AO\1,-VO1QVTTRMMA,)D(V:>%P<
MM@;.$W^@=U75R%4UX&0;FE--8GG'^LR;MN:+5C61VFOB?^X\)O1E,=S;5M"J
M#E)[';SP,1^DSO)#G?CX@*8B6S#79!;IAINVG#(YT(W]-SKO5R 4UWD7YUQL
M:C^984+>/F+W2=;8S8<;DJQC');93/* ,['9:7[)B8[<K[\,L/%Z-][1:-C=
MC+OO3IM'>ELO.2:?VDEE?5:0.G&'6VC6<%:%F]H+]W7RJJ)-JZ)-?V;1IE71
MIO:B_3_RT*I0WUN^E2GSX;R1XC8%L8+&B-BP5H6<VJNO/D::';F;1SR62F0:
M=&U/06O.*\Z+\TI[Y_8J K$P%Y.2&&+*[UK*T?+R\\)<^3T;OW3?CO,KS$I-
M?J.*1+A K"2$.:IT6GV$)/)+ROQ%):FY(YLE2B61>5P"0];3$_#[/,'\+EZT
M@?*J>/0O4$L#!!0    ( )>*'E.'F]IN*P,  .P)   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4Y+GAM;*6666_:0!#'O\K(RD,B47QPA0B0(&E:JJ2*(&E4
M17E8[ %O8^^ZNVN@4C]\=VW'. F0HR^PAV?^O]F9/7HK+AYDB*A@'4=,]JU0
MJ>3$MJ4?8DQDG2?(],R<BY@HW14+6R8"29 9Q9'M.4[;C@EEUJ"7C5V)08^G
M*J(,KP3(-(Z)^#/"B*_ZEFL]#DSH(E1FP![T$K+ *:J;Y$KHGEUZ"6B,3%+.
M0."\;PW=DY'K&8/LBQ\45[+2!A/*C/,'TQD'?<LQ1!BAKXP+HO^6>(I19#QI
MCM^%4ZO4-(;5]J/W\RQX'<R,2#SET2T-5-BWCBT(<$[22$WXZBL6 ;6,/Y]'
M,ON%5?&M8X&?2L7CPE@3Q)3E_V1=+$3%H-'98> 5!ME"V+E01GE&%!GT!%^!
M,%]K;Z:1A9I9:SC*3%:F2NA9JNW4X'8XF0R_7\/%>#@:7XRO?\+A&2I"(WD$
MGV!*HB69K.&+X&D"2>37X>X2XQF*>S@ &V1(!$J@#&X85;)6&;@.>2H)"_3@
MP9-^SU::VZC;?L$XRAF]'8P-N.1,A1(^LP"#I_:VCK<,VGL,>N3M=?@M975H
M.#7P',^]F9[!X<'1)IS\=X],HUS;1B;3V"$SG@LY542AKF)UH2?'NBGASC0A
M:]_O46F6*LU,I;DK@T0(PI0$O>>DTBM,V0)PC<*G$B$1U$<@"F:XH(R9N;^5
MU&U+1B[7R>3,IEX.VO5VLV<OMT"V2LC6NR'+:GE&MYLLUVA7R)K=CN-N1VN7
M:.T/H)&8ITR]6+AM5+G[5H7*=3UG.U2GA.KLA3HG5,"21*G.7?!+'P.FA*"V
M):_(@E<SNE?+G/LG,B$^]BU]L$L42[0&L*<RC\L@CM\?1#7K.?MN[KWNW\_=
M+;F['^'>E$2QYMN0NR^*X5.CW=U>#*ZS.:2=#]3HTV*HO;4:"JVW;7"W<I&X
M_[6/,#^9]N6[4'CC!G>]#9KW8;3:*PDM7%<SVFD])[(K%W",8I$],R3X1B"_
MB\O1\BDSS"_PS>?Y.^B2"'W>2(APKDV=>D<KB_QID7<43[+K?,:5?AQDS5 _
MQU"8#_3\G'/UV#$"Y0-O\ ]02P,$%     @ EXH>4\70\-,: P  ! H  !D
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MVUQW3=S(KV<:54RC]^H7U>CG!\$6IQHK)\)>/2OLK"\_YPT*#N=&M1$(X$M
M#U?_K4Z\<;WB3ZQ/[*[CN.]5N/3<%*\=M=M;"M=8^7OJ$Z_O1.Q]>(66D*_J
MSPG=;;J-@77S<RKF)(:NI;H;<ZY6#S4IO;Z!<?,5W*3T[BV*'<>/MKGOFNU(
M;6_\TG/@4]/I""7B@LKB'UFM5MW4F>DAMM;[NLLRK<(:IFC1K@B?IE2@#"8*
MTCEI*T*\Z'J*B61STS@\,JG:$#.<J4X1N#90^Q/&Y,M$!ZAZS]X_4$L#!!0
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MUB).FQM&ETPF'<SUE1#Z<) ,4.P$#_X#4$L#!!0    ( )>*'E-><+YL1@,
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M7XS2'C#["R'T;F()ZDY[\!M02P,$%     @ EXH>4]N ,=C@ P  E0X  !D
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M<V7O+-1N@9U?*$5OCCM'S2V8_@902P,$%     @ EXH>4RU@EU)X @  O04
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M(0 E>AY!K6:OH@;[?NM <C7(Q5Z[7G*GD-PQ2AXG:Q!2-Z].EA&K_?M:K$@
M/4L9M "^!JN/ZD;8Y3REXORB.-_\V@<!2]5;@E;D16]]U@\2!#Q5WX2(DCF-
MJ*3U'?&K'6D[AQVI"?(;G?J.8&=G1XY1]J-Z=X*4*XT)DU"HK[46IZJ@=3!V
MAK\)*JO<,TUL5/F5<$X26>SC2ZT^(\<9;] K$)7KW#D2=HUUWA+*T1<2I8 D
MR[_-0Q:K-*'^K;A68RX)6 RG3%6\<RC<>,.YBG?&@,W.<-9D-7.=T\W+B<KU
M[NP*M]YH1)N)SRG^<J)R\3L7Q68;-0][7+5$'SN585(7U6P>F28[Y\1FZ[QD
M5)NIS^G,Y43E\G<NC,TV?,[(?RU3?@6B<K4[6\9F7S[-.OS*#V&OA0_?QFH0
MQNZAM]E[9T-]]%>GEB>:"!3!4L&<*T_A^?8TO;V0;)4=%^=,JL-GM@R!+(#K
M /5\R527\@M] BW^I]'_'U!+ P04    " "7BAY3R H"WS4"  "&!   &0
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MC\#3X_ ?1&BX/P9W=>^# <%@0&#YPD,&D)HJPF!.9<:X; 3*(ZSAP!I:UN@
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M0M H&VX(]@E+#>3S%:7B]2*=H&Q4C_X'4$L#!!0    ( )>*'E,]<-.L6 (
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M;FS:D&%L9,.\; (K;%E=9UVQ2>V9-F0;&]DV@UO#K\ J)F0;&]DV<(JF%4W
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M4];?SFV_.7YZEKUMA]=\-OVA]>894$L! A0#%     @ EXH>4P=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " "7BAY3-&&$MNX    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " "7BAY3F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( )>*
M'E/%",/++@,  (L+   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " "7BAY3NJ B38<%  #A%0  &
M        @(%Q"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ EXH>4X:QJ[9-!0  QA,  !@              ("!+A$  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( )>*'E,I%)XK[08  (<F   8
M              " @;$6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " "7BAY3D6R05^L%  !X&   &               @('4'0  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ EXH>4SKEO"WI"@
M)1H  !@              ("!]2,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( )>*'E,&(V]:408  %0.   8              " @10O
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "7BAY3#M<M
MLA0(  #Y$P  &               @(&;-0  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ EXH>4YOPS^Q9"0  ^1@  !@
M ("!Y3T  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( )>*
M'E,@XVXJVP,  #L(   9              " @71'  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ EXH>4Y>T@!_$ P  + @  !D
M         ("!ADL  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " "7BAY3OZ\RXD\%  #="P  &0              @(&!3P  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( )>*'E,)6V(@^P,  .L(
M   9              " @0=5  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ EXH>4Y15T*1+!@  ! \  !D              ("!.5D
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "7BAY3_R=0
M9<T&  "L#P  &0              @(&[7P  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( )>*'E-R9;FC;@0  ( )   9
M  " @;]F  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
MEXH>4\97BW@!"0  (18  !D              ("!9&L  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " "7BAY32$%I'\H#   %"   &0
M            @(&<=   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( )>*'E,.F.'%^ 4  #L-   9              " @9UX  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ EXH>4T_5(%(L"@
M&!T  !D              ("!S'X  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " "7BAY3[B(6O^H$  "9#   &0              @($O
MB0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( )>*'E.U
MCTFE)@,  -,&   9              " @5".  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ EXH>4^EHVI1I!   F@D  !D
M     ("!K9$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )>*'E-I'?3>$PD  .P7   9              "
M@>NJ  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ EXH>
M4]KDYPB< @  K@4  !D              ("!-;0  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " "7BAY3@&GNU)4"  "1!0  &0
M        @($(MP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( )>*'E.D-34!^ (  -H&   9              " @=2Y  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ EXH>4^X@3\<^ @  YP0
M !D              ("! [T  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " "7BAY30TV*T>L"   $!@  &0              @(%XOP
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( )>*'E,YM5PK
M'@,   0'   9              " @9K"  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ EXH>4W^_0UIX P  ? <  !D
M ("![\4  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "7
MBAY30U>1)R,#  "I!@  &0              @(&>R0  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( )>*'E->]&S$]P,  #@+   9
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M970T,2YX;6Q02P$"% ,4    " "7BAY3O3C>S^($  !P#   &0
M    @($CX   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M )>*'E/;51!&!0,  ,0+   9              " @3SE  !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ EXH>4Y9.L1BJ @  ( <  !D
M             ("!>.@  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " "7BAY3+]&SJ*X"  ")!@  &0              @(%9ZP  >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( )>*'E,-%L0,L0(
M .@&   9              " @3[N  !X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ EXH>4]ARNPFN @  \@8  !D              ("!
M)O$  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " "7BAY3
MA@7U<+<"  !+!P  &0              @($+]   >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( )>*'E/3;U_EI (  /8&   9
M      " @?GV  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ EXH>4R$Q\ #) @  . @  !D              ("!U/D  'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "7BAY35$SNACD"  #S!
M&0              @('4_   >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( )>*'E.EM7AT7P0  &0/   9              " @43_  !X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ EXH>4\LU_3SX
M 0  V 0  !D              ("!V@,! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " "7BAY35<.IBO8!  !]!   &0
M@($)!@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( )>*
M'E.--=#C'P,  /4)   9              " @38( 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ EXH>4W=[[_E7 @  M@0  !D
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M=#8P+GAM;%!+ 0(4 Q0    ( )>*'E.D<?I6'P4  #T1   9
M  " @8 @ 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @
MEXH>4YZU#"HL P  APH  !D              ("!UB4! 'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6Q02P$"% ,4    " "7BAY373P1T1\$   5%@  &0
M            @($Y*0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4
M Q0    ( )>*'E-><+YL1@,  '4+   9              " @8\M 0!X;"]W
M;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ EXH>4]N ,=C@ P
ME0X  !D              ("!##$! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX
M;6Q02P$"% ,4    " "7BAY33-3MGMH"   4!P  &0              @($C
M-0$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( )>*'E,X
MZ 44R@(  *8(   9              " @30X 0!X;"]W;W)K<VAE971S+W-H
M965T-C<N>&UL4$L! A0#%     @ EXH>4\\IHLQ+ @  $04  !D
M     ("!-3L! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )>*'E-+A8SN;P0  +06   9              "
M@9M) 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ EXH>
M4SUPTZQ8 @  \P0  !D              ("!04X! 'AL+W=O<FMS:&5E=',O
M<VAE970W-"YX;6Q02P$"% ,4    " "7BAY3%J'#TP$#  ")#P  #0
M        @ '04 $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )>*'E.7BKL<
MP    !,"   +              "  ?Q3 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( )>*'E.(@AB>K04  +4P   /              "  >54 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "7BAY3Q]=S3T<"  #5*P  &@
M    @ &_6@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "7BAY3'YV%;PD"  #8*@  $P              @ $^70$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     4@!2 '46  !X7P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>149</ContextCount>
  <ElementCount>320</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InterimStatementsOfFinancialPosition</Role>
      <ShortName>Condensed Consolidated Interim Statements of Financial Position (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Interim Statements of Operations and Other Comprehensive (Loss) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InterimStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/NatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Liquidity</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInMarketableEquitySecurities</Role>
      <ShortName>INVESTMENT IN MARKETABLE EQUITY SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INVESTMENT IN ASSOCIATE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInAssociate</Role>
      <ShortName>INVESTMENT IN ASSOCIATE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - DISPOSITION OF PPL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/DispositionOfPpl</Role>
      <ShortName>DISPOSITION OF PPL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentsInPrivateCompanies</Role>
      <ShortName>INVESTMENTS IN PRIVATE COMPANIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Goodwill</Role>
      <ShortName>GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability</Role>
      <ShortName>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - UNSECURED NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://portagebiotech.com/role/UnsecuredNotesPayable</Role>
      <ShortName>UNSECURED NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - WARRANT LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiability</Role>
      <ShortName>WARRANT LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - CAPITAL STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStock</Role>
      <ShortName>CAPITAL STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - STOCK OPTION RESERVE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserve</Role>
      <ShortName>STOCK OPTION RESERVE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShare</Role>
      <ShortName>(LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - CAPITAL DISCLOSURES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalDisclosures</Role>
      <ShortName>CAPITAL DISCLOSURES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - NON-CONTROLLING INTEREST</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterest</Role>
      <ShortName>NON-CONTROLLING INTEREST</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/EventsAfterBalanceSheetDate</Role>
      <ShortName>EVENTS AFTER THE BALANCE SHEET DATE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables</Role>
      <ShortName>INVESTMENT IN MARKETABLE EQUITY SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInMarketableEquitySecurities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInAssociateTables</Role>
      <ShortName>INVESTMENT IN ASSOCIATE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInAssociate</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/GoodwillTables</Role>
      <ShortName>GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Goodwill</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables</Role>
      <ShortName>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://portagebiotech.com/role/UnsecuredNotesPayableTables</Role>
      <ShortName>UNSECURED NOTES PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/UnsecuredNotesPayable</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - WARRANT LIABILITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityTables</Role>
      <ShortName>WARRANT LIABILITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiability</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - CAPITAL STOCK (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockTables</Role>
      <ShortName>CAPITAL STOCK (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStock</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - STOCK OPTION RESERVE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveTables</Role>
      <ShortName>STOCK OPTION RESERVE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserve</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareTables</Role>
      <ShortName>(LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - NON-CONTROLLING INTEREST (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterestTables</Role>
      <ShortName>NON-CONTROLLING INTEREST (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Non-controllingInterest</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - NATURE OF OPERATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative</Role>
      <ShortName>NATURE OF OPERATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/NatureOfOperations</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - LIQUIDITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>LIQUIDITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Liquidity</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/BasisOfPresentation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetails</Role>
      <ShortName>INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative</Role>
      <ShortName>INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - INVESTMENT IN ASSOCIATE  (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInAssociateDetails</Role>
      <ShortName>INVESTMENT IN ASSOCIATE  (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInAssociateTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - INVESTMENT IN ASSOCIATE  (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInAssociateDetails1</Role>
      <ShortName>INVESTMENT IN ASSOCIATE  (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInAssociateTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative</Role>
      <ShortName>INVESTMENT IN ASSOCIATE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInAssociateTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - DISPOSITION OF PPL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/DispositionOfPplDetailsNarrative</Role>
      <ShortName>DISPOSITION OF PPL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/DispositionOfPpl</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative</Role>
      <ShortName>INVESTMENTS IN PRIVATE COMPANIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentsInPrivateCompanies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/GoodwillDetails</Role>
      <ShortName>GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/GoodwillTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - GOODWILL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/GoodwillDetailsNarrative</Role>
      <ShortName>GOODWILL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/GoodwillTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails</Role>
      <ShortName>IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative</Role>
      <ShortName>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://portagebiotech.com/role/UnsecuredNotesPayableDetails</Role>
      <ShortName>UNSECURED NOTES PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/UnsecuredNotesPayableTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative</Role>
      <ShortName>UNSECURED NOTES PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/UnsecuredNotesPayableTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - WARRANT LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetails</Role>
      <ShortName>WARRANT LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - CAPITAL STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockDetails</Role>
      <ShortName>CAPITAL STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStockTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - CAPITAL STOCK (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockDetailsNarrative</Role>
      <ShortName>CAPITAL STOCK (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStockTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - STOCK OPTION RESERVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails</Role>
      <ShortName>STOCK OPTION RESERVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - STOCK OPTION RESERVE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails1</Role>
      <ShortName>STOCK OPTION RESERVE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - STOCK OPTION RESERVE (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails2</Role>
      <ShortName>STOCK OPTION RESERVE (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - STOCK OPTION RESERVE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetailsNarrative</Role>
      <ShortName>STOCK OPTION RESERVE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareDetails</Role>
      <ShortName>(LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShareTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - (LOSS) PER SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareDetails1</Role>
      <ShortName>(LOSS) PER SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/RelatedPartyTransactions</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative</Role>
      <ShortName>CAPITAL DISCLOSURES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalDisclosures</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - NON-CONTROLLING INTEREST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterestDetails</Role>
      <ShortName>NON-CONTROLLING INTEREST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Non-controllingInterestTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="f6k_082621p.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>00000074 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative</Role>
      <ShortName>EVENTS AFTER THE BALANCE SHEET DATE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/EventsAfterBalanceSheetDate</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" original="f6k_082621p.htm">f6k_082621p.htm</File>
    <File>exh_992.htm</File>
    <File>ptgef-20210630.xsd</File>
    <File>ptgef-20210630_cal.xml</File>
    <File>ptgef-20210630_def.xml</File>
    <File>ptgef-20210630_lab.xml</File>
    <File>ptgef-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f6k_082621p.htm": {
   "axisCustom": 0,
   "axisStandard": 10,
   "contextCount": 149,
   "dts": {
    "calculationLink": {
     "local": [
      "ptgef-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptgef-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f6k_082621p.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptgef-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/labels/doc_full_ifrs-en_2020-03-16.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptgef-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_40/ref_ias_40_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_3/ref_ifrs_3_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_2/ref_ias_2_2020-03-16.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_17/ref_ifrs_17_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/sic_29/ref_sic_29_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_23/ref_ias_23_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_29/ref_ias_29_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifric_2/ref_ifric_2_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_27/ref_ias_27_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_6/ref_ifrs_6_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_12/ref_ifrs_12_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_24/ref_ias_24_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_20/ref_ias_20_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_15/ref_ifrs_15_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifric_5/ref_ifric_5_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_16/ref_ias_16_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_7/ref_ias_7_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_10/ref_ias_10_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_21/ref_ias_21_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_14/ref_ifrs_14_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_12/ref_ias_12_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_16/ref_ifrs_16_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_1/ref_ifrs_1_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_5/ref_ifrs_5_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_33/ref_ias_33_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_38/ref_ias_38_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_36/ref_ias_36_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_26/ref_ias_26_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_41/ref_ias_41_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_13/ref_ifrs_13_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_7/ref_ifrs_7_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_8/ref_ifrs_8_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_34/ref_ias_34_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_37/ref_ias_37_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_4/ref_ifrs_4_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_8/ref_ias_8_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_2/ref_ifrs_2_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_1/ref_ias_1_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_19/ref_ias_19_2020-03-16.xml"
     ]
    },
    "schema": {
     "local": [
      "ptgef-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 405,
   "entityCount": 1,
   "hidden": {
    "http://portagebiotech.com/20210630": 93,
    "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full": 41,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 139
   },
   "keyCustom": 128,
   "keyStandard": 192,
   "memberCustom": 37,
   "memberStandard": 6,
   "nsprefix": "ptgef",
   "nsuri": "http://portagebiotech.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://portagebiotech.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES",
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAvailableforsaleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES",
     "role": "http://portagebiotech.com/role/InvestmentInMarketableEquitySecurities",
     "shortName": "INVESTMENT IN MARKETABLE EQUITY SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAvailableforsaleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:InvestmentInAssociateDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - INVESTMENT IN ASSOCIATE",
     "role": "http://portagebiotech.com/role/InvestmentInAssociate",
     "shortName": "INVESTMENT IN ASSOCIATE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:InvestmentInAssociateDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DispositionOfPplTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - DISPOSITION OF PPL",
     "role": "http://portagebiotech.com/role/DispositionOfPpl",
     "shortName": "DISPOSITION OF PPL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DispositionOfPplTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES",
     "role": "http://portagebiotech.com/role/InvestmentsInPrivateCompanies",
     "shortName": "INVESTMENTS IN PRIVATE COMPANIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - GOODWILL",
     "role": "http://portagebiotech.com/role/Goodwill",
     "shortName": "GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY",
     "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability",
     "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - UNSECURED NOTES PAYABLE",
     "role": "http://portagebiotech.com/role/UnsecuredNotesPayable",
     "shortName": "UNSECURED NOTES PAYABLE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:WarrantLiabilitytextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - WARRANT LIABILITY",
     "role": "http://portagebiotech.com/role/WarrantLiability",
     "shortName": "WARRANT LIABILITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:WarrantLiabilitytextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:CapitalStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - CAPITAL STOCK",
     "role": "http://portagebiotech.com/role/CapitalStock",
     "shortName": "CAPITAL STOCK",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:CapitalStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)",
     "role": "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition",
     "shortName": "Condensed Consolidated Interim Statements of Financial Position (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - STOCK OPTION RESERVE",
     "role": "http://portagebiotech.com/role/StockOptionReserve",
     "shortName": "STOCK OPTION RESERVE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - (LOSS) PER SHARE",
     "role": "http://portagebiotech.com/role/LossPerShare",
     "shortName": "(LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES",
     "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://portagebiotech.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT",
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - CAPITAL DISCLOSURES",
     "role": "http://portagebiotech.com/role/CapitalDisclosures",
     "shortName": "CAPITAL DISCLOSURES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - NON-CONTROLLING INTEREST",
     "role": "http://portagebiotech.com/role/Non-controllingInterest",
     "shortName": "NON-CONTROLLING INTEREST",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE",
     "role": "http://portagebiotech.com/role/EventsAfterBalanceSheetDate",
     "shortName": "EVENTS AFTER THE BALANCE SHEET DATE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)",
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive (Loss) (Unaudited)",
     "role": "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss",
     "shortName": "Condensed Consolidated Interim Statements of Operations and Other Comprehensive (Loss) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfAvailableforsaleAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Tables)",
     "role": "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables",
     "shortName": "INVESTMENT IN MARKETABLE EQUITY SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfAvailableforsaleAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfInvestmentAssociatetableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)",
     "role": "http://portagebiotech.com/role/InvestmentInAssociateTables",
     "shortName": "INVESTMENT IN ASSOCIATE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfInvestmentAssociatetableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - GOODWILL (Tables)",
     "role": "http://portagebiotech.com/role/GoodwillTables",
     "shortName": "GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)",
     "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables",
     "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:ScheduleOfNotesPayableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)",
     "role": "http://portagebiotech.com/role/UnsecuredNotesPayableTables",
     "shortName": "UNSECURED NOTES PAYABLE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:ScheduleOfNotesPayableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ptgef:WarrantLiabilitytextblock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - WARRANT LIABILITY (Tables)",
     "role": "http://portagebiotech.com/role/WarrantLiabilityTables",
     "shortName": "WARRANT LIABILITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ptgef:WarrantLiabilitytextblock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - CAPITAL STOCK (Tables)",
     "role": "http://portagebiotech.com/role/CapitalStockTables",
     "shortName": "CAPITAL STOCK (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfTermsStockOptionReserveExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - STOCK OPTION RESERVE (Tables)",
     "role": "http://portagebiotech.com/role/StockOptionReserveTables",
     "shortName": "STOCK OPTION RESERVE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfTermsStockOptionReserveExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:EarningsPerShareTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - (LOSS) PER SHARE (Tables)",
     "role": "http://portagebiotech.com/role/LossPerShareTables",
     "shortName": "(LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:EarningsPerShareTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)",
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2020-03-31_ifrs-full_IssuedCapitalMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)",
     "role": "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
     "shortName": "Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2020-03-31_ifrs-full_IssuedCapitalMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - NON-CONTROLLING INTEREST (Tables)",
     "role": "http://portagebiotech.com/role/Non-controllingInterestTables",
     "shortName": "NON-CONTROLLING INTEREST (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ptgef:NatureOfOperationsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:IssuanceAndSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - NATURE OF OPERATIONS (Details Narrative)",
     "role": "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative",
     "shortName": "NATURE OF OPERATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ptgef:NatureOfOperationsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:IssuanceAndSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:LiquidityTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - LIQUIDITY (Details Narrative)",
     "role": "http://portagebiotech.com/role/LiquidityDetailsNarrative",
     "shortName": "LIQUIDITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:LiquidityTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2015-02-012015-02-10_custom_SubsidiariesOneMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - BASIS OF PRESENTATION (Details Narrative)",
     "role": "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
     "shortName": "BASIS OF PRESENTATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2015-02-012015-02-10_custom_SubsidiariesOneMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentAdvancesToSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentAdvancesToSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2016-10-31_custom_PPLSettlementMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Accruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)",
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2016-10-31_custom_PPLSettlementMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Accruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
       "ifrs-full:DisclosureOfAvailableforsaleAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:InvestmentAssetAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)",
     "role": "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetails",
     "shortName": "INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
       "ifrs-full:DisclosureOfAvailableforsaleAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:InvestmentAssetAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfAvailableforsaleAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ptgef:InvestmentInMarketableEquitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details Narrative)",
     "role": "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative",
     "shortName": "INVESTMENT IN MARKETABLE EQUITY SECURITIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfAvailableforsaleAssetsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ptgef:InvestmentInMarketableEquitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfInvestmentAssociatetableTextBlock",
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-012021-06-30_custom_StimunitySAMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NameOfAssociate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - INVESTMENT IN ASSOCIATE  (Details)",
     "role": "http://portagebiotech.com/role/InvestmentInAssociateDetails",
     "shortName": "INVESTMENT IN ASSOCIATE  (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfInvestmentAssociatetableTextBlock",
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-012021-06-30_custom_StimunitySAMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NameOfAssociate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - INVESTMENT IN ASSOCIATE  (Details 1)",
     "role": "http://portagebiotech.com/role/InvestmentInAssociateDetails1",
     "shortName": "INVESTMENT IN ASSOCIATE  (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfInvestmentInStimunitySaTableTextBlock",
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)",
     "role": "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Interim Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfInvestmentInStimunitySaTableTextBlock",
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:AdditionalInvestments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)",
     "role": "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative",
     "shortName": "INVESTMENT IN ASSOCIATE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2020-05-302020-06-01_custom_StimunitySAMember",
      "decimals": "-3",
      "lang": null,
      "name": "ptgef:AdditionalInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:DispositionOfPplTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-03-012021-03-03_custom_PortageGlasgowLtdMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:DispositionPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - DISPOSITION OF PPL (Details Narrative)",
     "role": "http://portagebiotech.com/role/DispositionOfPplDetailsNarrative",
     "shortName": "DISPOSITION OF PPL (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:DispositionOfPplTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-03-012021-03-03_custom_PortageGlasgowLtdMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:DispositionPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2015-08-31_custom_SeriesAPreferredStockInSentienBiotechnologiesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:InvestmentOwnedShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - INVESTMENTS IN PRIVATE COMPANIES (Details Narrative)",
     "role": "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative",
     "shortName": "INVESTMENTS IN PRIVATE COMPANIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2015-08-31_custom_SeriesAPreferredStockInSentienBiotechnologiesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:InvestmentOwnedShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Goodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - GOODWILL (Details)",
     "role": "http://portagebiotech.com/role/GoodwillDetails",
     "shortName": "GOODWILL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory",
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - GOODWILL (Details Narrative)",
     "role": "http://portagebiotech.com/role/GoodwillDetailsNarrative",
     "shortName": "GOODWILL (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:InprocessResearchAndDevelopment",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)",
     "role": "http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
     "shortName": "IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock",
       "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30_custom_IMM60IOXMelanomaLungCancersMember",
      "decimals": "-3",
      "lang": null,
      "name": "ptgef:InprocessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DeferredTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)",
     "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative",
     "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DeferredTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfNotesPayableTableTextBlock",
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:NotePayable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)",
     "role": "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
     "shortName": "UNSECURED NOTES PAYABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfNotesPayableTableTextBlock",
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "ptgef:NotePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:AggregatePrincipalAmountOfUnsecuredNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)",
     "role": "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative",
     "shortName": "UNSECURED NOTES PAYABLE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:AggregatePrincipalAmountOfUnsecuredNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
       "ptgef:WarrantLiabilitytextblock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31_custom_SalvaRxGroupPlcMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:WarrantsOutstandingExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - WARRANT LIABILITY (Details)",
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetails",
     "shortName": "WARRANT LIABILITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
       "ptgef:WarrantLiabilitytextblock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31_custom_SalvaRxGroupPlcMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:WarrantsOutstandingExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:NatureOfOperationsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000006 - Disclosure - NATURE OF OPERATIONS",
     "role": "http://portagebiotech.com/role/NatureOfOperations",
     "shortName": "NATURE OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:NatureOfOperationsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock",
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:CommonStockShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - CAPITAL STOCK (Details)",
     "role": "http://portagebiotech.com/role/CapitalStockDetails",
     "shortName": "CAPITAL STOCK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock",
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:CommonStockShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock",
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - CAPITAL STOCK (Details Narrative)",
     "role": "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
     "shortName": "CAPITAL STOCK (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "INF",
      "lang": null,
      "name": "ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdjustmentsForSharebasedPayments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - STOCK OPTION RESERVE (Details)",
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails",
     "shortName": "STOCK OPTION RESERVE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfTermsStockOptionReserveExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember",
      "decimals": "-3",
      "lang": null,
      "name": "ptgef:StockOptionReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31_custom_PBI2021EquityIncentivePlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:NumberOfOutstandingShareOption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - STOCK OPTION RESERVE (Details 1)",
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails1",
     "shortName": "STOCK OPTION RESERVE (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31_custom_PBI2021EquityIncentivePlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:NumberOfOutstandingShareOption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - STOCK OPTION RESERVE (Details 2)",
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails2",
     "shortName": "STOCK OPTION RESERVE (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-012021-06-30_custom_PBI2021EquityIncentivePlanMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:StockOptionsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - STOCK OPTION RESERVE (Details Narrative)",
     "role": "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative",
     "shortName": "STOCK OPTION RESERVE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:StockOptionsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - (LOSS) PER SHARE (Details)",
     "role": "http://portagebiotech.com/role/LossPerShareDetails",
     "shortName": "(LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:EarningsPerShareTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "INF",
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-012021-06-30_custom_StockOptionsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:AntidilutiveEffectOnLossPerShar",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure - (LOSS) PER SHARE (Details 1)",
     "role": "http://portagebiotech.com/role/LossPerShareDetails1",
     "shortName": "(LOSS) PER SHARE (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-012021-06-30_custom_StockOptionsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:AntidilutiveEffectOnLossPerShar",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30_custom_StimunitySAMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:CommitmentToInvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000068 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30_custom_StimunitySAMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:CommitmentToInvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestCostsIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestCostsIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:LiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - LIQUIDITY",
     "role": "http://portagebiotech.com/role/Liquidity",
     "shortName": "LIQUIDITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgef:LiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000070 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)",
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilities",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30_custom_AmortizedCostMember",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:FairValueMarketPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000071 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)",
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgef:FairValueMarketPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:PayablesAndAccruedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000072 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)",
     "role": "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative",
     "shortName": "CAPITAL DISCLOSURES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:PayablesAndAccruedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncontrollingInterests",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000073 - Disclosure - NON-CONTROLLING INTEREST (Details)",
     "role": "http://portagebiotech.com/role/Non-controllingInterestDetails",
     "shortName": "NON-CONTROLLING INTEREST (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock",
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:NoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-07-012021-07-31_custom_EventsAfterTheBalanceSheetDateMember_custom_SalvaRxMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:RepaymentOfInstallmentNoteReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000074 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE (Details Narrative)",
     "role": "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative",
     "shortName": "EVENTS AFTER THE BALANCE SHEET DATE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock",
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-07-012021-07-31_custom_EventsAfterTheBalanceSheetDateMember_custom_SalvaRxMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgef:RepaymentOfInstallmentNoteReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://portagebiotech.com/role/BasisOfPresentation",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://portagebiotech.com/role/SignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "f6k_082621p.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 47,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r145",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/DispositionOfPplDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/DispositionOfPplDetailsNarrative",
      "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Listings [Line Items]"
       }
      }
     },
     "localname": "EntityListingsLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/DispositionOfPplDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/DispositionOfPplDetailsNarrative",
      "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "ifrs-full_Accruals": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees."
       }
      },
      "en-us": {
       "role": {
        "label": "Accruals"
       }
      }
     },
     "localname": "Accruals",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income [member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AdjustmentsForAmortisationExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortization of debt discount"
       }
      }
     },
     "localname": "AdjustmentsForAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other assets",
        "verboseLabel": "Prepaid expenses and other receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade accounts payable",
        "verboseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for non-cash items:"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "verboseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "auth_ref": [
      "r44",
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r19",
      "r102",
      "r103",
      "r104",
      "r126",
      "r128"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      }
     },
     "localname": "BusinessCombinationsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Cash": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r14",
      "r77",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r69",
      "r78"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by (used in) financing activities:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r69",
      "r78"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by (used in) investing activities:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r69",
      "r78"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "negatedLabel": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by (used in) operating activities:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashOnHand": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash held by the entity. This does not include demand deposits."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash on hand"
       }
      }
     },
     "localname": "CashOnHand",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CommunicationExpense": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from communication."
       }
      },
      "en-us": {
       "role": {
        "label": "Communication expense"
       }
      }
     },
     "localname": "CommunicationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r3",
      "r28",
      "r80",
      "r82",
      "r92",
      "r96"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive (loss) for period"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive (loss) income attributable to:"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r3",
      "r31"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ptgef_TotalComprehensiveLossIncomeForYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to non-controlling interests",
        "verboseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "auth_ref": [
      "r3",
      "r32"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ptgef_TotalComprehensiveLossIncomeForYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to owners of parent",
        "verboseLabel": "Owners of the Company"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CounterpartiesAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      }
     },
     "localname": "CounterpartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CounterpartiesMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "localname": "CounterpartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CountryOfIncorporationOrResidenceOfAssociate": {
     "auth_ref": [
      "r51",
      "r55",
      "r90"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The country in which an associate of the entity is incorporated. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Country of incorporation of associate"
       }
      }
     },
     "localname": "CountryOfIncorporationOrResidenceOfAssociate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      },
      "en-us": {
       "role": {
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "CurrentAdvancesToSuppliers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r21",
      "r92",
      "r93"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Total current asset",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative",
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentInvestments": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current investments."
       }
      },
      "en-us": {
       "role": {
        "label": "Investment"
       }
      }
     },
     "localname": "CurrentInvestments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r22",
      "r92",
      "r94"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities [Default Label]",
        "totalLabel": "Total current liabilities",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPortionOfLongtermBorrowings": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current portion of non-current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current portion of non-current borrowings"
       }
      }
     },
     "localname": "CurrentPortionOfLongtermBorrowings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      },
      "en-us": {
       "role": {
        "label": "Other prepaid expenses"
       }
      }
     },
     "localname": "CurrentPrepaidExpenses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentPrepayments": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Total prepaid expenses and other receivables"
       }
      }
     },
     "localname": "CurrentPrepayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income)"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "auth_ref": [
      "r16",
      "r20",
      "r40"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit plans [axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DefinedBenefitPlansMember": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      }
     },
     "localname": "DefinedBenefitPlansMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections": {
     "auth_ref": [
      "r62",
      "r63"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Discount rate applied to cash flow projections"
       }
      }
     },
     "localname": "DescriptionOfDiscountRatesAppliedToCashFlowProjections",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/GoodwillDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DisclosureOfAvailableforsaleAssetsExplanatory": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets classified as available for sale. [Refer: Financial assets available-for-sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "INVESTMENT IN MARKETABLE EQUITY SECURITIES"
       }
      }
     },
     "localname": "DisclosureOfAvailableforsaleAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for consolidation."
       }
      },
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "DisclosureOfBasisOfConsolidationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansTable": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to defined benefit plans."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [table]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for interests in other entities."
       }
      },
      "en-us": {
       "role": {
        "label": "NON-CONTROLLING INTEREST"
       }
      }
     },
     "localname": "DisclosureOfInterestsInOtherEntitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterest"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInvestmentPropertyExplanatory": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for investment property."
       }
      },
      "en-us": {
       "role": {
        "label": "Schedule of investment in marketable equity securities"
       }
      }
     },
     "localname": "DisclosureOfInvestmentPropertyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Schedule of weighted average exercise price and the remaining contractual life"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the offsetting of financial assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of offsetting of financial assets [table]"
       }
      }
     },
     "localname": "DisclosureOfOffsettingOfFinancialAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER RECEIVABLES"
       }
      }
     },
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in the loss allowance and explanation of changes in the gross carrying amount for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "GOODWILL"
       }
      }
     },
     "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "STOCK OPTION RESERVE"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserve"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": {
     "auth_ref": [
      "r53",
      "r57",
      "r101"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to associates."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of associates [table]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "(LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EntitysTotalForAssociatesMember": {
     "auth_ref": [
      "r53",
      "r57",
      "r101",
      "r133",
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      }
     },
     "localname": "EntitysTotalForAssociatesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "auth_ref": [
      "r111",
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r19",
      "r24",
      "r79",
      "r81",
      "r102",
      "r103",
      "r104"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent",
        "totalLabel": "Total equity attributable to owners of the Company"
       }
      }
     },
     "localname": "EquityAttributableToOwnersOfParent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative",
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent [member]"
       }
      }
     },
     "localname": "EquityAttributableToOwnersOfParentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EquityInterestsOfAcquirer": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity interests of acquirer"
       }
      }
     },
     "localname": "EquityInterestsOfAcquirer",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options"
       }
      }
     },
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValue": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, at fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainLossOnHedgeIneffectiveness": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gain (loss) on hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item."
       }
      },
      "en-us": {
       "role": {
        "label": "Share of loss (gain) in associates"
       }
      }
     },
     "localname": "GainLossOnHedgeIneffectiveness",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsOnDisposalsOfInvestmentProperties": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gain on disposals of investment properties. [Refer: Investment property]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unrealized gain on investments"
       }
      }
     },
     "localname": "GainsOnDisposalsOfInvestmentProperties",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Goodwill": {
     "auth_ref": [
      "r12",
      "r61",
      "r64",
      "r112"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/GoodwillDetails",
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r33",
      "r37",
      "r38",
      "r39",
      "r48",
      "r99",
      "r125"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents",
        "totalLabel": "Increase in cash and cash equivalents during period"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase in deferred tax liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestCostsIncurred": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest costs that an entity incurs."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest costs incurred"
       }
      }
     },
     "localname": "InterestCostsIncurred",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpense": {
     "auth_ref": [
      "r98",
      "r124",
      "r130"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense",
        "negatedLabel": "Interest (expense)"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentProperty": {
     "auth_ref": [
      "r11",
      "r66",
      "r67"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of property (land or a building - or part of a building - or both) held (by the owner or by the lessee as a right-of-use asset) to earn rentals or for capital appreciation or both, rather than for: (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business."
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in private companies"
       }
      }
     },
     "localname": "InvestmentProperty",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investment in associate",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "InvestmentsInSubsidiariesJointVenturesAndAssociates",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/InvestmentInAssociateDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfConvertibleInstruments": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The change in equity resulting from the issuing of convertible instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of convertible instruments"
       }
      }
     },
     "localname": "IssueOfConvertibleInstruments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Capital stock"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "auth_ref": [
      "r44",
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      }
     },
     "localname": "LevelsOfFairValueHierarchyAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r19",
      "r102",
      "r103",
      "r104",
      "r126",
      "r129"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LoansPayableInDefault": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of loans payable in default."
       }
      },
      "en-us": {
       "role": {
        "label": "Loans payable in default"
       }
      }
     },
     "localname": "LoansPayableInDefault",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NameOfAssociate": {
     "auth_ref": [
      "r50",
      "r54",
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The name of an associate. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Name of associate"
       }
      }
     },
     "localname": "NameOfAssociate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncontrollingInterests": {
     "auth_ref": [
      "r17",
      "r83",
      "r87"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interest",
        "periodEndLabel": "Non-controlling interest",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "NoncontrollingInterests",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interests [member]"
       }
      }
     },
     "localname": "NoncontrollingInterestsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r22",
      "r92",
      "r95"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities [Default Label]",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentPayables": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current trade payables and non-current other payables. [Refer: Other non-current payables; Non-current trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other non-current payables",
        "verboseLabel": "Unsecured notes payable"
       }
      }
     },
     "localname": "NoncurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of instruments or interests issued or issuable"
       }
      }
     },
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative",
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OtherAssets": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 7.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherCurrentReceivables": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other receivables"
       }
      }
     },
     "localname": "OtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReceivables": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Long-term portion of other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Stock option reserve"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments for share issue costs",
        "negatedLabel": "Share issuance costs"
       }
      }
     },
     "localname": "PaymentsForShareIssueCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of voting equity interests acquired"
       }
      }
     },
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative",
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PrincipalPlaceOfBusinessOfAssociate": {
     "auth_ref": [
      "r51",
      "r55",
      "r90"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The principal place of business of an associate. [Refer: Principal place of business; Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Principal place of business of associate"
       }
      }
     },
     "localname": "PrincipalPlaceOfBusinessOfAssociate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r4",
      "r27",
      "r73",
      "r80",
      "r82",
      "r92",
      "r126",
      "r127",
      "r131",
      "r132"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net loss for period",
        "negatedLabel": "Profit (loss)",
        "totalLabel": "Net (loss)",
        "verboseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses"
       }
      }
     },
     "localname": "ProfitLossAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net (loss) income attributable to:"
       }
      }
     },
     "localname": "ProfitLossAttributableToAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r29",
      "r86"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ptgef_NetLossIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to non-controlling interests",
        "verboseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ptgef_NetLossIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Owners of the Company",
        "verboseLabel": "Net loss attributable to owners of the Company"
       }
      }
     },
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss",
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r114",
      "r126",
      "r127"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r34",
      "r58"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "auth_ref": [
      "r52",
      "r56",
      "r88"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interests held by non-controlling interests"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfVotingPowerHeldInAssociate": {
     "auth_ref": [
      "r52",
      "r56",
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of voting rights held in associate"
       }
      }
     },
     "localname": "ProportionOfVotingPowerHeldInAssociate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PurchaseOfInvestmentProperty": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of investment property. [Refer: Investment property]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of investment property",
        "negatedLabel": "Investment in associates"
       }
      }
     },
     "localname": "PurchaseOfInvestmentProperty",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transactions [abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r24",
      "r35"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r7",
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share of (loss) income in associates accounted for using equity method"
       }
      }
     },
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "auth_ref": [
      "r53",
      "r57",
      "r101",
      "r133",
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Associates [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SubsidiariesMember": {
     "auth_ref": [
      "r45",
      "r53",
      "r57",
      "r100"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for entities that are controlled by another entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [member]"
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "auth_ref": [
      "r13",
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other receivables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherReceivables": {
     "auth_ref": [
      "r13",
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other receivables"
       }
      }
     },
     "localname": "TradeAndOtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypeOfMeasurementOfExpectedCreditLossesAxis": {
     "auth_ref": [
      "r119",
      "r121"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Type of measurement of expected credit losses [axis]"
       }
      }
     },
     "localname": "TypeOfMeasurementOfExpectedCreditLossesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypeOfMeasurementOfExpectedCreditLossesMember": {
     "auth_ref": [
      "r119",
      "r121"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement of expected credit losses. Expected credit losses are the weighted average of credit losses with the respective risks of a default occurring as the weights. This member also represents the standard value for the 'Type of measurement of expected credit losses' axis if no other member is used."
       }
      }
     },
     "localname": "TypeOfMeasurementOfExpectedCreditLossesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of shares \u2013 Basic and Diluted"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_AccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accounts payable and accrued liabilities.",
        "label": "AccountsPayableAndAccruedLiabilities",
        "verboseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilities",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_AccreditedInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accredited Investors [Member]"
       }
      }
     },
     "localname": "AccreditedInvestorsMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_AcquisitionOfIntensityHoldingLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the acquisition of Intensity Holding Limited.",
        "label": "Acquisition Of Intensity Holding Limited [Member]"
       }
      }
     },
     "localname": "AcquisitionOfIntensityHoldingLimitedMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_AcquisitionOfSalvaRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the acquisition of SalvaRx.",
        "label": "Acquisition Of SalvaRx [Member]"
       }
      }
     },
     "localname": "AcquisitionOfSalvaRxMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_AdditionalDiscretionaryInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of additional discretionary investment.",
        "label": "Additional Discretionary Investment"
       }
      }
     },
     "localname": "AdditionalDiscretionaryInvestment",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_AdditionalInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional investments.",
        "label": "Additional investment"
       }
      }
     },
     "localname": "AdditionalInvestments",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails1",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_AggregatePrincipalAmountOfUnsecuredNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate principal amount of Unsecured Notes.",
        "label": "Aggregate principal amount of Unsecured Notes"
       }
      }
     },
     "localname": "AggregatePrincipalAmountOfUnsecuredNotes",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_AmortizationOfDebtDiscount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AmortizationOfDebtDiscount",
        "verboseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscount",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_AmortizedCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized cost [Member]"
       }
      }
     },
     "localname": "AmortizedCostMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_AntidilutiveEffectOnLossPerShar": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive effect on loss per shar"
       }
      }
     },
     "localname": "AntidilutiveEffectOnLossPerShar",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_BasicAndDilutedLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted",
        "verboseLabel": "Basic and diluted (loss) per share (Actual)"
       }
      }
     },
     "localname": "BasicAndDilutedLossPerShare",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss",
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ptgef_BasisOfPresentationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_BiohavenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biohaven [Member]"
       }
      }
     },
     "localname": "BiohavenMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_BoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_CapitalStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITAL STOCK"
       }
      }
     },
     "localname": "CapitalStockTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_CashFundDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash fund, description.",
        "label": "Cash fund, description"
       }
      }
     },
     "localname": "CashFundDescription",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_CashPaidForInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "CashPaidForInterest",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_CommitmentAndContingencies": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingent Liabilities (Note 17)"
       }
      }
     },
     "localname": "CommitmentAndContingencies",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_CommitmentToInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount related to commitment to investment.",
        "label": "Commitment To Investment"
       }
      }
     },
     "localname": "CommitmentToInvestment",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_CommitmentsAndContingenciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingent Liabilities"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares: Unlimited number of common shares without par value"
       }
      }
     },
     "localname": "CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_CommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockShares",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "CommonStockShares",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_CommonStockValues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockValues",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "CommonStockValues",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_ConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]"
       }
      }
     },
     "localname": "ConsultantsMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_ContractualValueOfWarrantsExercisedDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual value of warrants exercised description"
       }
      }
     },
     "localname": "ContractualValueOfWarrantsExercisedDescription",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator (in 000\u2019)"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_DescriptionOfBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquistion, description"
       }
      }
     },
     "localname": "DescriptionOfBusinessCombination",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_DirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors [Member]"
       }
      }
     },
     "localname": "DirectorsMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_DisclosureCapitalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Disclosures"
       }
      }
     },
     "localname": "DisclosureCapitalDisclosuresAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_DisclosureCapitalStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock"
       }
      }
     },
     "localname": "DisclosureCapitalStockAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_DisclosureDispositionOfPplAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposition Of Ppl"
       }
      }
     },
     "localname": "DisclosureDispositionOfPplAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_DisclosureEventsAfterBalanceSheetDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After Balance Sheet Date"
       }
      }
     },
     "localname": "DisclosureEventsAfterBalanceSheetDateAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "In-process Research And Development And Deferred Tax Liability"
       }
      }
     },
     "localname": "DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_DisclosureInvestmentInAssociateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment In Associate"
       }
      }
     },
     "localname": "DisclosureInvestmentInAssociateAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_DisclosureInvestmentsInPrivateCompaniesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments In Private Companies"
       }
      }
     },
     "localname": "DisclosureInvestmentsInPrivateCompaniesAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_DisclosureLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "localname": "DisclosureLiquidityAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITAL DISCLOSURES"
       }
      }
     },
     "localname": "DisclosureOfCapitalManagementExplanatoryTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses and other receivables"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EVENTS AFTER THE BALANCE SHEET DATE"
       }
      }
     },
     "localname": "DisclosureOfEventAfterBalanceSheetDateTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/EventsAfterBalanceSheetDate"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of financial instruments"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAndFinancialLiabilities",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of IPR&amp;D projects"
       }
      }
     },
     "localname": "DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_DisclosureOfInvestmentAssociatetableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of investment associate"
       }
      }
     },
     "localname": "DisclosureOfInvestmentAssociatetableTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVESTMENTS IN PRIVATE COMPANIES"
       }
      }
     },
     "localname": "DisclosureOfPrivateCompaniesExplanatoryTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompanies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of outstanding stock options"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_DisclosureOfTermsStockOptionReserveExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Terms Stock Option Reserve Explanatory"
       }
      }
     },
     "localname": "DisclosureOfTermsStockOptionReserveExplanatory",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_DisclosureUnsecuredNotesPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Notes Payable"
       }
      }
     },
     "localname": "DisclosureUnsecuredNotesPayableAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_DisclosureWarrantLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability"
       }
      }
     },
     "localname": "DisclosureWarrantLiabilityAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_DiscretionaryInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discretionary Investment"
       }
      }
     },
     "localname": "DiscretionaryInvestment",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_DispositionOfPplTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DISPOSITION OF PPL"
       }
      }
     },
     "localname": "DispositionOfPplTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/DispositionOfPpl"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_DispositionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposition Percentage"
       }
      }
     },
     "localname": "DispositionPercentage",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/DispositionOfPplDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgef_DispositionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposition value"
       }
      }
     },
     "localname": "DispositionValue",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/DispositionOfPplDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_EarningsPerShareTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of basic and diluted EPS calculations"
       }
      }
     },
     "localname": "EarningsPerShareTableTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_Equity2021IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity 2021 Incentive Plan [Member]"
       }
      }
     },
     "localname": "Equity2021IncentivePlanMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_EquityInLossIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity in loss income"
       }
      }
     },
     "localname": "EquityInLossIncome",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_EventsAfterTheBalanceSheetDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After The Balance Sheet Date [Member]"
       }
      }
     },
     "localname": "EventsAfterTheBalanceSheetDateMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "ptgef_FairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment, amount at end"
       }
      }
     },
     "localname": "FairValueAdjustment",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_FairValueAdjustmentExercisePriceAtEnd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment , exercise price at end"
       }
      }
     },
     "localname": "FairValueAdjustmentExercisePriceAtEnd",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ptgef_FairValueAdjustmentShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment, shares at end"
       }
      }
     },
     "localname": "FairValueAdjustmentShares",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_FairValueMarketPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value market price per share.",
        "label": "Fair value market price per share"
       }
      }
     },
     "localname": "FairValueMarketPricePerShare",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "ptgef_FairValueOfWarrantLiabilityForPortageWarrantsIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant liability for Portage warrants issued"
       }
      }
     },
     "localname": "FairValueOfWarrantLiabilityForPortageWarrantsIssued",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_FairValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value per share"
       }
      }
     },
     "localname": "FairValuePerShare",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "ptgef_FairValueToOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value to Other Comprehensive Income [Member]"
       }
      }
     },
     "localname": "FairValueToOtherComprehensiveIncomeMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_FinancialInstrumentsAndRiskManagementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments And Risk Management"
       }
      }
     },
     "localname": "FinancialInstrumentsAndRiskManagementAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_GainsLossesOnChangeInFairValueOfWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "GainsLossesOnChangeInFairValueOfWarrants",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_GoodwilAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwilAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_IMM60IOXMelanomaLungCancersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for IMM 60 IOX Melanoma &amp;amp;amp;amp; Lung Cancers.",
        "label": "IMM 60 IOX Melanoma &amp;amp;amp;amp; Lung Cancers [Member]"
       }
      }
     },
     "localname": "IMM60IOXMelanomaLungCancersMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_IMM65IOXOvarianProstateCancersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for IMM 65 IOX Ovarian/Prostate Cancers.",
        "label": "IMM 65 IOX Ovarian/Prostate Cancers [Member]"
       }
      }
     },
     "localname": "IMM65IOXOvarianProstateCancersMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_IOxOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "I Ox Option Plan [Member]"
       }
      }
     },
     "localname": "IOxOptionPlanMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_IfrsStatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IfrsStatementLineItems [Line Items]"
       }
      }
     },
     "localname": "IfrsStatementLineItems",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative",
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/InvestmentInAssociateDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative",
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative",
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative",
      "http://portagebiotech.com/role/StockOptionReserveDetails",
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentAndDeferredTaxLiability",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_IncreaseInAccountsPayableForStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in accounts payable for stock issuance costs"
       }
      }
     },
     "localname": "IncreaseInAccountsPayableForStockIssuanceCosts",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_IncreasingDecreasingAccountsReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "IncreasingDecreasingAccountsReceivable",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_InprocessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 6.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "In-process research and development"
       }
      }
     },
     "localname": "InprocessResearchAndDevelopment",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_IntensityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intensity [Member]"
       }
      }
     },
     "localname": "IntensityMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_IntercompanyReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intercompany receivable"
       }
      }
     },
     "localname": "IntercompanyReceivable",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/DispositionOfPplDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_InvestmentAssetAvailableForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in marketable equity securities [Default Label]",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year"
       }
      }
     },
     "localname": "InvestmentAssetAvailableForSale",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_InvestmentInAssociateDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVESTMENT IN ASSOCIATE"
       }
      }
     },
     "localname": "InvestmentInAssociateDisclosureTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociate"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_InvestmentInBiohavenAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment In Marketable Equity Securities"
       }
      }
     },
     "localname": "InvestmentInBiohavenAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_InvestmentInMarketableEquitySecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in marketable equity securities"
       }
      }
     },
     "localname": "InvestmentInMarketableEquitySecurities",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_InvestmentOwnedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased.",
        "label": "Number of shares purchased"
       }
      }
     },
     "localname": "InvestmentOwnedShares",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_InvestmentOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of equity ownership percentage.",
        "label": "InvestmentOwnershipPercentage"
       }
      }
     },
     "localname": "InvestmentOwnershipPercentage",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgef_IoxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Iox [Member]"
       }
      }
     },
     "localname": "IoxMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_IssuanceAndSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and sales"
       }
      }
     },
     "localname": "IssuanceAndSales",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_IssuanceOfUnsecuredNotesDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of unsecured notes, description.",
        "label": "Issuance of unsecured notes, description"
       }
      }
     },
     "localname": "IssuanceOfUnsecuredNotesDescription",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_IssuedUnderPrivatePlacement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued under private placement"
       }
      }
     },
     "localname": "IssuedUnderPrivatePlacement",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_IssuedUnderPrivatePlacementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued under private placement, shares"
       }
      }
     },
     "localname": "IssuedUnderPrivatePlacementShares",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_LiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY"
       }
      }
     },
     "localname": "LiquidityTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/Liquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_LossIncomeOnFairValueOfWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income on fair value of warrant liability"
       }
      }
     },
     "localname": "LossIncomeOnFairValueOfWarrantLiability",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_LossOnExtinguishmentOfDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent Loss on extinguishment of debt.",
        "label": "Loss on extinguishment of debt",
        "verboseLabel": "Loss On Extinguishment Of Debt"
       }
      }
     },
     "localname": "LossOnExtinguishmentOfDebt",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_N2021EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "N 2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "N2021EquityIncentivePlanMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_NatureOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Operations"
       }
      }
     },
     "localname": "NatureOfOperationsAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_NatureOfOperationsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperationsTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/NatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_NetChangeInWorkingCapitalComponentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating working capital:"
       }
      }
     },
     "localname": "NetChangeInWorkingCapitalComponentsAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_NetLossAttributableToNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss attributable to non-controlling interest.",
        "label": "Net income (loss) attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetLossAttributableToNoncontrollingInterest",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_NetLossIncome": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NetLossIncome",
        "totalLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetLossIncome",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_NonControllingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling Interest"
       }
      }
     },
     "localname": "NonControllingInterestAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_NotePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes payable balance.",
        "label": "NotePayable",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "NotePayable",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_NumberOfExerciseOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of exercise of warrants issued"
       }
      }
     },
     "localname": "NumberOfExerciseOfWarrantsIssued",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_NumberOfExerciseOfWarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of exercise of warrants outstanding"
       }
      }
     },
     "localname": "NumberOfExerciseOfWarrantsOutstanding",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_NumberOfOutstandingShareOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement.",
        "label": "Balance",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOption",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the number of private company share consists in sole asset.",
        "label": "Number Of Private Company Share Consists In Sole Asset"
       }
      }
     },
     "localname": "NumberOfPrivateCompanyShareConsistsInSoleAsset",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement.",
        "label": "Exercisable as at end",
        "periodEndLabel": "Exercisable as at end"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired or forfeited"
       }
      }
     },
     "localname": "NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement.",
        "label": "Granted"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator (in 000\u2019$)"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_OfferingAndThroughThatProcessDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering and through that process description"
       }
      }
     },
     "localname": "OfferingAndThroughThatProcessDescription",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_OfferingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering expenses"
       }
      }
     },
     "localname": "OfferingExpenses",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_OncomerSaugatuckDNAAptamersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Oncomer Saugatuck DNA Aptamers.",
        "label": "Oncomer Saugatuck DNA Aptamers [Member]"
       }
      }
     },
     "localname": "OncomerSaugatuckDNAAptamersMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InProcessResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_OtherAsset": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other"
       }
      }
     },
     "localname": "OtherAsset",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_PBI2013OptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "P B I 2013 Option Plan [Member]"
       }
      }
     },
     "localname": "PBI2013OptionPlanMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_PBI2021EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "P B I 2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "PBI2021EquityIncentivePlanMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_PPLSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PPL Settlement [Member]"
       }
      }
     },
     "localname": "PPLSettlementMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_PayablesAndAccruedExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and accrued expenses"
       }
      }
     },
     "localname": "PayablesAndAccruedExpense",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_PaymentForSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for settlement"
       }
      }
     },
     "localname": "PaymentForSettlement",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_PglMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pgl [Member]"
       }
      }
     },
     "localname": "PglMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_PortageGlasgowLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portage Glasgow Ltd. [Member]"
       }
      }
     },
     "localname": "PortageGlasgowLtdMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/DispositionOfPplDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_PortageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portage [Member]"
       }
      }
     },
     "localname": "PortageMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_PplMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ppl [Member]"
       }
      }
     },
     "localname": "PplMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_PrepaidExpensesAndOtherReceivableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Receivables"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherReceivableAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_PrepaidExpensesAndOtherReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepaid expenses and other receivables.",
        "label": "Prepaid expenses and Other Receivables"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherReceivables",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_PricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares price"
       }
      }
     },
     "localname": "PricePerShare",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "ptgef_ProceedsFromLoanPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from loan payable"
       }
      }
     },
     "localname": "ProceedsFromLoanPayable",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from shares issued under registered offering"
       }
      }
     },
     "localname": "ProceedsFromSharesIssuedUnderRegisteredOffering",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_PublicofferingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering description"
       }
      }
     },
     "localname": "PublicofferingDescription",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_RepaymentOfInstallmentNoteReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital"
       }
      }
     },
     "localname": "RepaymentOfInstallmentNoteReceivable",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_RepaymentOfNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of notes payable.",
        "label": "Repayment"
       }
      }
     },
     "localname": "RepaymentOfNotesPayable",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_RepaymentsOfAdvanceToBoardMemberOfCompany": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of Repayments Of Advance To Board member of company.",
        "label": "Repayments Of Advance To Board Member Of Company"
       }
      }
     },
     "localname": "RepaymentsOfAdvanceToBoardMemberOfCompany",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_ResearchAndDevelopmentCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities.",
        "label": "Research &amp; development tax credits"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCredit",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_RestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_SalvaRxGroupPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SalvaRx Group plc. [Member]"
       }
      }
     },
     "localname": "SalvaRxGroupPlcMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_SalvaRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SalvaRx [Member]"
       }
      }
     },
     "localname": "SalvaRxMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_SaugatuckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SaugatuckMember"
       }
      }
     },
     "localname": "SaugatuckMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-Dilutive effect on Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntiDilutiveEffectOnLossPerShareTableTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of In process research and development"
       }
      }
     },
     "localname": "ScheduleOfInProcessResearchAndDevelopmentTableTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of investment in Stimunity S.A."
       }
      }
     },
     "localname": "ScheduleOfInvestmentInStimunitySaTableTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_ScheduleOfNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of non-controlling interest"
       }
      }
     },
     "localname": "ScheduleOfNoncontrollingInterestTableTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_ScheduleOfNotesPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of notes payable"
       }
      }
     },
     "localname": "ScheduleOfNotesPayableTableTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_ScheduleOfWarrantLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrant liability"
       }
      }
     },
     "localname": "ScheduleOfWarrantLiabilityTableTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_SeriesAPreferredStockInSentienBiotechnologiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A preferred stock in Sentien Biotechnologies [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockInSentienBiotechnologiesMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_SettlementInConnectionWithDispositionOfPpl": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement in connection with disposition of PPL"
       }
      }
     },
     "localname": "SettlementInConnectionWithDispositionOfPpl",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_ShareBasedPaymentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Reserve"
       }
      }
     },
     "localname": "ShareBasedPaymentAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_ShareIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareIssuanceCosts",
        "negatedLabel": "Share issuance costs"
       }
      }
     },
     "localname": "ShareIssuanceCosts",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_SharesIssuedForService": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for services"
       }
      }
     },
     "localname": "SharesIssuedForService",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_SharesIssuedForServicesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for services, shares"
       }
      }
     },
     "localname": "SharesIssuedForServicesShares",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_SharesIssuedInPrivatePlacementNetOfIssueCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in private placement net of issue cost"
       }
      }
     },
     "localname": "SharesIssuedInPrivatePlacementNetOfIssueCost",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in private placement net of issue cost, shares"
       }
      }
     },
     "localname": "SharesIssuedInPrivatePlacementNetOfIssueCostShares",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in a private placement, net of issue costs"
       }
      }
     },
     "localname": "SharesIssuedInPrivatePlacementNetOfIssueCosts",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails",
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in a private placement, net of issue costs, shares"
       }
      }
     },
     "localname": "SharesIssuedInPrivatePlacementNetOfIssueCostsShares",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails",
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_SharesIssuedOrAccruedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued or accrued for services"
       }
      }
     },
     "localname": "SharesIssuedOrAccruedForServices",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_SharesIssuedOrAccruedForServicesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued or accrued for services, shares"
       }
      }
     },
     "localname": "SharesIssuedOrAccruedForServicesShares",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_SharesIssuedUnderAtm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under ATM"
       }
      }
     },
     "localname": "SharesIssuedUnderAtm",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_SharesIssuedUnderAtmShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under ATM, shares"
       }
      }
     },
     "localname": "SharesIssuedUnderAtmShares",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_SharesIssuedUnderOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under offering"
       }
      }
     },
     "localname": "SharesIssuedUnderOffering",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_SharesIssuedUnderOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under offering, shares"
       }
      }
     },
     "localname": "SharesIssuedUnderOfferingShares",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_SharesReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares received"
       }
      }
     },
     "localname": "SharesReceived",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_SignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ptgef_StimunitySAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stimunity S.A. [Member]"
       }
      }
     },
     "localname": "StimunitySAMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/InvestmentInAssociateDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_StockBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation expense.",
        "label": "Stock based compensation expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpense",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_StockGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock granted"
       }
      }
     },
     "localname": "StockGranted",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_StockOptionReserve": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option reserve for option under share-based payment arrangement.",
        "label": "StockOptionReserve",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockOptionReserve",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_StockOptionReserveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Reserve [Member]"
       }
      }
     },
     "localname": "StockOptionReserveMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_StockOptionsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options issued",
        "label": "Stock options issued"
       }
      }
     },
     "localname": "StockOptionsIssued",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PBI 2013 Option Plan [Member]"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_SubsidiariesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom based immune-oncology [Member]"
       }
      }
     },
     "localname": "SubsidiariesOneMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_SubsidiariesThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IOX [Member]"
       }
      }
     },
     "localname": "SubsidiariesThreeMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_SubsidiariesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Saugatuck [Member]"
       }
      }
     },
     "localname": "SubsidiariesTwoMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_SupplementalDisclosureOfCashFlowInformation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalDisclosureOfCashFlowInformation",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesAbstract",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgef_TotalComprehensiveLossIncomeForYear": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalComprehensiveLossIncomeForYear",
        "totalLabel": "Total comprehensive (loss) income for year"
       }
      }
     },
     "localname": "TotalComprehensiveLossIncomeForYear",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_UnrealizedGainLossOnInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) On Investment"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestment",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentsInPrivateCompaniesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_UnrealizedGains": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized gains.",
        "label": "Unrealized gains"
       }
      }
     },
     "localname": "UnrealizedGains",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_UnrealizedLossGainOnInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized (loss) gain on investment"
       }
      }
     },
     "localname": "UnrealizedLossGainOnInvestment",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInMarketableEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_UnrealizedLossOnInvestmentInInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized (loss) on investment in investments"
       }
      }
     },
     "localname": "UnrealizedLossOnInvestmentInInvestment",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_UnrealizedLossOnInvestmentInInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "UnrealizedLossOnInvestmentInInvestments",
        "verboseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "UnrealizedLossOnInvestmentInInvestments",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_UnrecognisedShareOfGainLossesOfAssociates": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share of (loss) income"
       }
      }
     },
     "localname": "UnrecognisedShareOfGainLossesOfAssociates",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_UnsecuredNotesInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured Notes interest.",
        "label": "Unsecured Notes interest"
       }
      }
     },
     "localname": "UnsecuredNotesInterest",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgef_UnsecuredNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured notes payable"
       }
      }
     },
     "localname": "UnsecuredNotesPayable",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_UnsecuredNotesPayableAndWarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNSECURED NOTES PAYABLE"
       }
      }
     },
     "localname": "UnsecuredNotesPayableAndWarrantsTextBlock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_ValueOfNotesExchangedInWarrantExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of notes exchanged in warrant exercise"
       }
      }
     },
     "localname": "ValueOfNotesExchangedInWarrantExercise",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_ValueOfSharesIssuedForServices": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of shares issued for services"
       }
      }
     },
     "localname": "ValueOfSharesIssuedForServices",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_WarrantLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantLiability",
        "verboseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantLiability",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_WarrantLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability"
       }
      }
     },
     "localname": "WarrantLiabilityCurrent",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_WarrantLiabilitytextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANT LIABILITY"
       }
      }
     },
     "localname": "WarrantLiabilitytextblock",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgef_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgef_WarrantsOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsOutstandingAmount",
        "periodEndLabel": "Warrants outstanding, amount, at end",
        "periodStartLabel": "Warrants outstanding, amount at beginning"
       }
      }
     },
     "localname": "WarrantsOutstandingAmount",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgef_WarrantsOutstandingExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsOutstandingExercisePrice",
        "periodEndLabel": "Warrants outstanding, exercise price, at end",
        "periodStartLabel": "Warrants outstanding exercise price at beginning"
       }
      }
     },
     "localname": "WarrantsOutstandingExercisePrice",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ptgef_WarrantsOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsOutstandingShares",
        "periodEndLabel": "Warrants outstanding, amount at ending",
        "periodStartLabel": "Warrants outstanding, shares at beginning"
       }
      }
     },
     "localname": "WarrantsOutstandingShares",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAveragesSharesoutstandingBasicAndDiluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAveragesSharesoutstandingBasicAndDiluted",
     "nsuri": "http://portagebiotech.com/20210630",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r1": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r10": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r100": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r101": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r102": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r103": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r104": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r105": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r106": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r107": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r108": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r109": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r11": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r110": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r111": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r112": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r113": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r114": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2020-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r115": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "13C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_13C&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r116": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r117": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_24C_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r118": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r119": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r12": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r120": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r121": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r122": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B52",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r123": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2020-01-01"
  },
  "r124": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r125": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r126": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r127": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r128": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r129": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r13": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r130": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r131": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r132": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r133": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39M&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r134": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Note": "Expiry date 2021-01-01",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_10_e&doctype=Standard&forcepdf=true",
   "URIDate": "2020-01-01"
  },
  "r135": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "4",
   "Paragraph": "39J",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39J&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r136": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r137": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r138": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r139": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r14": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r140": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r141": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r142": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r143": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r144": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r145": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r146": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r147": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r148": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r149": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r15": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r150": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r151": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r152": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r153": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r154": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r16": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r17": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r18": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r19": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r2": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r20": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "56",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r21": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r22": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r23": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r24": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r25": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r26": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r27": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r28": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r29": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r3": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r30": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r31": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r32": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r33": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r34": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r35": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2020-01-01"
  },
  "r36": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2020-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r37": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r38": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r39": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r4": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r40": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r41": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r42": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r43": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2020-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r44": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2020-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r45": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_19_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r46": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r47": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2020-01-01"
  },
  "r48": {
   "Clause": "viii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2020-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r49": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r5": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r50": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_16_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r51": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_16_b_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r52": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r53": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r54": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_17_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r55": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_17_b_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r56": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r57": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r58": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2020-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2020-01-01"
  },
  "r59": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2020-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r6": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r60": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2020-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r61": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2020-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r62": {
   "Clause": "v",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2020-en-r&anchor=para_134_d_v&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r63": {
   "Clause": "v",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2020-en-r&anchor=para_134_e_v&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r64": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2020-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r65": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r66": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2020-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r67": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2020-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r68": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "40",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS40_g74-79_TI",
   "URIDate": "2020-01-01"
  },
  "r69": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r7": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r70": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r71": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r72": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r73": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r74": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r75": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r76": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r77": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r78": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r79": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r8": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r80": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r81": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r82": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r83": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "10",
   "Paragraph": "22",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2020-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r84": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "1",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_1&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r85": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_12_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r86": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r87": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r88": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r89": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_21_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r9": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r90": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_21_a_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r91": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r92": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r93": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r94": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r95": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r96": {
   "Clause": "ix",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r97": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r98": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r99": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001171843-21-006231-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-21-006231-xbrl.zip
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M,WB,(SF_K,IOL<'TM:L%<92P"N BA3#%%#"%4E?:B[YJ0U*&F;+V+HS4KEV
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M]D428XWQT^;&V3DT8Y(+K<D&A+SJ7V6D6Q5^13@_POORVC5Z/682E:1;VN4
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M=HX.JN%1F"F D7\RBT<FMI:8E!Y'/?Z],SF:,-2A_1)F?)F//CDR^ALMV;9
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M@8B..: '^1LZQ;",15B80:1F2CF+E2"6 ;%?1WZB!Q')!. AW<!6L^% %?/
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M(GHQT3-QN"+8V:XDF1%V@"#?&PM&?U9TR$:F+#N_S.G=#A+I-,K/2-#D'(2
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MA$&ZJ20#H W].#IQT,](%$/4!73%[XD^EQ!F+8U#/T(5(M2;Z5U),+W;_&3
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MR=S<-GX YQE@X]WE+7-S=]N^JS4[3*?%W-Y=73)<GL]R):9URW!%D7RZ:U[
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MK\%*87ZOHK\041C,ZB%*U"%O_-1#2&9$ @CN34Q^KH-NKDP9,D2&R &\*4Q
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M0,Y\TSRV9U7S@598&[2'R1>F(0_TID<^QHX]YI&CDE6F/!2DB6@004,2FK=
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M<.HI_,95!8*@3I"X8V6*:<]E):B(**[<)#315PZR896=)6BWQ9MS,;$IM.K
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M0A6DM>3S(2\/4$.N\UBEI1*MOGDGN68XRI;9FY25G#8][]PK_00YRJ2LC"!
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M8IZ;D5S29 1P/=,'CVW)9;),*$+.CQ7MA#%$G+%9]\G-2A_XR_2Z!->4<IB
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M4FJ'2.V0.K/N.;5W9P)WT^XXM8IO27*BCHY#NZHME94X9457;&D)Q6APH5T
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MY#5;_\AI+AW,%-E.M/UA$JG >$9+!?(_QJDDPD6B#^0 -P@%65*P/*'[:71
MZ@:2'#^Q>RNCF>I,#]*#0A@Q5W\R/[!/Y%(FYS=(_;LRHJE$B$7(8X8:F./
MRQ.):!SH->DD891F&4TD9"J)H-L^5"Z5$P\YP>#ZJ*3N0C*$AM@9\T"6P]H
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MQZZ'+>W"Z:TIHH4M;0QSNE'J5%Y8IT9P635XL(7[%1=SJ3,V3H8^TI]@'Q;
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MHB8= &J20^J%-4E]+G<GCU]_%[H5;CSE0B/UW2!B?+!OW\(4-CQ0C,TZD:,
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MUQ_O<HUX4%R:/0G\7J);TQOI*^GY)<(+3;6F2C&9JMS\>.DD$\$7NA%Z6RH
M>ENA-?T]T >E5.^I<"LL3Z4<T=M61F]+K(+>!FS72'9NA>YKX>ERF^AM0(VY
M2^599S-Z^]Z5/SL(]+9X:YK.<86^)-<S6G;;/!\Z>ALH 5ULMI5?X[O73E ;
M]9.@MV5!"@Y+X\+DZ=[(!C5[(XO>EFA-KWYE[WN/\88T#:K._TST-K#.W^K)
M9$]-WO747?!L0/2V;8]0+4GZ4*71B5JW/I0#S$Q=^!4PQ\?C<D;/##/7_,X
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M/<.2@CQ2/\_K?6H!S3P6)2(2"G$52:Z+C \ -P<K);%XBY<9.$\X8_(<=3"
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M*ZY^%_,$.8]/:_D=3M&DTX Z5>Z-YY%BE KE5QMLQOI"<*5A'D%\C3/8[MQ
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M>^J7.+L2]CR>DI3UXQG<HL34[/-GQ5:%*[:F^<I;CF]/1L4[$X"HJZH&P7/
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M!%'%R+]V,;4?AZ4I[)KE>[2 7Y]6O(1G*/QA^ IJ+-.)9BI!ZL>QV/@/%$\
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MPW'_FE7RR7T?!I/.3+)10TU/;\#Y<OE*]/F)\+UA&R-G2(#[=#)0]L:2B4;
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MGW57NGORN7O*?\(I[^:!Z\V!"XK<$;2,K*JTS8-:D?-3B5?4?*? *( W?PC
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M$AQ9M3$3"X@PRN?YAWCS+B=C_=R:_.9;J0HK9*O(2?3 (>H+E-R<KW>Z8U^
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MQ*PA-SG1$O%TB>'Z0+\#?XUU&?X 7(:%5TT8041G!]@0Q.\)#^$]@+P-J'=
MEX%LB&6.7(W%'<$#UIBCNA#["C^"UAX@& ZPNK<M+6M-P]K \T\QX]+I>RZV
M.Q+;R4^QW62FK^ G*^J(3UM(#S :",XE\D,$!\)Z*'.FH,4TL*[C%F(R:BA[
M)S)04DU1W &$)"O@><!D87M !9" 3HJI>EO5@,P&VH,XMY@_7"]<@Z+(;5C
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MRM:/1EV$1';._GS='N2XJ/7<*  =C11Y)@QAF 3< 9[.,HHRAYX>T[T.9"]
MD"XOSC%.YQ<HHO: JO$+"-XA0 !-5TROY-+';PN+G7K,W^) 46QD%=(8\EI/
MYJR34%5].#*C(%,>F,.+@ 6PD>W'83MQ1X<M[K,6P(=7;@48^\& ZMMC)KP$
M&?/?V"IPBTT!02T=&LS"CVEY*)!7!.+O?\R%+'-A<%O3A64^1Q;=A+R#!5XI
M]QB%MY)B/#CQ\;%,EAQQW.=9)9\]<3W#)*;(0S/#Q/,+)S1YE6AX8/)(,A=;
MSQDIH+>H0'?RO.'45NH(S,=8R\<Z[8!&@ FI\$66-S0+>3]&$4A/P[&?IMN'
M^.L-0[2RBN:B\P):/G+C6KH@O,45&P<001F&FG;0@*4*H)@2)J@ /2 +%R28
MZC&'^*8*0 &'K KP;\"#NN##'B-UP=O!]]93%X=&_>6>Q0%G >U3 %=8A''R
M:9C"'&9#, H2VRC-88YU@"6$@N?VF#JX=_E.I(4]/^F2F?BS2)>0%=4]Q<]/
MT>K9\?QD@5H \AJ"_F\,GF-E74T&A[<0V]Q&CL($J+O=Y5GOD#IF\ SISN#E
M,N)W9K3+5+0@DWY^0BH"SR@0.59,TQG0<MC)V3I4;'2G@/3WV<GI*M)[+2=R
MF>W)4&\>RAR ]I)<L)^JZ;3@,8)\Q58%>,A3A5GU@-#4)8E_W"/:>43+*K7,
MJD+MXH=#O:) &(G_LZBM6K[-/9W/3!:%A^;GA,?:/)#VDFR*EPX/A$:;UZ;P
M0Q$E>R^XVLY4K057TWH*.)(A6$ /'"=8)8>E=(G'*-STU2%K"%XX!^S-NF"I
M)3X_P4O<8SHVIW(SI1?E 9OV)<LK&@-DS.IBF"FL_HVQ@(G!%&&8-VPF8P+)
MQT'9!S_Z#F=P9A9PV 10"4##6<F^YO(6H''2RDR0/3\AI!+,I%#T.^ <(IS$
M I1?&2 A9/!0507\'3FH> 4Z)U>8#7#52LZ%F>NZV!$ CIMN+&0LRFU1Z*)D
M!A59DFO(#-[+:)HBM'7-3&% ::% U]+WD,PK-%8E>94!O^N1HC"$L8R%1VSI
M-K/RF%1;&KWE!MT@U^<G=AG18NT1+<&*:*G+.!:VEG0.2%F 6W4(2>[SA=^=
M(,*,VH/D\ 9]&6WT)SRX'B]:R#9D^BAY"X!;0L@#@+N.$(*F6XG*II!24,AY
M&XW!8X'A!ETM#CD4)\DJ\S10"13@!"N/]-N"5R'R6J200[^/75S9I9*-BN%W
MD -P?!N8LQA0#EE =;8H!S"O8,X=S%Z"6@ID F:^N,*/@$G%(]>V+8V<Z0(]
MQ7(. H-<$\TP!HJ4L"(#Z!$8UH5"QJ9B>I<:YF)J>O33J>D+M?,5DQ4!P!^E
M+UK6R?.3#$Q%A%D2 #XX$EU!*I'%T" V@NO1FB!K0G"RW@JEN2Y"C 6J%7@D
M4JM6RR3)Y3JC$\1.Z(YFO2O$B"@@5.[QP""- (:S"LXF;:]$#UIMY5P%^D99
M5^$/0Q ;8S'?]Q*Y0ZO&[AC-)3^,F5B=50H97[QW:-K!N<E7_@.2K_P?1JA3
M%(.=Y(0+!=WDJPLG7WF/2;[R?AC12*Z@"Z'*(!>\8O(5.'2AT\YE&XPZJ[,/
MEGP%2)^JR42[7*S-.L&'2[X"ATQ%*\J\TZ-3A3\K]PILO=YJ-O*C427JX1X]
M]PJP]&JT0HR9:+Y:.2*?]GNG6>$?AJCX<6HZ(7/>JPOF,]*A 0\,-.*E$=^;
M-^NW.+[[YU?!4ONI)^UA>W1<.315_=KFR\F)56=:+9FE$^P";I]O8<TM(;+#
MJ[/,4UH:<P(P2X N8_IT,$[H=&#&&8RG@5<#FUOM(*?)RNJV>7*@$P4\;(ZU
M>=@K ^8?N=;U89Y@E-;%P!BB#%0QB>E"(*\<N@+J  $$NJ[PR-G5813X UC=
MJH"JXM%)"IIY@"@8H.KP[ 0>E<HO'@0?#PU':(G;ZE.?GZ8]7H(']FH.D85M
M$WO ;E6&L.!?@OJT8J:V01^88*5!"5I/UC58;*@K*.ZM2PS+\B/3/H".%K-R
M">(:_+K'*,.%_VVK_04_TC6$1T"*V_T+/5GD5/MN4.X<>(J%CFL8:"Y^.VMN
M,3:!$4].</M#4!)&?@24<&#BR )S%DY,<%!=F((J(F0R,QZ!NL$CWPE P!YC
MM1( 1Z%B$L^"[V'7$SOFR2,>CBP&&"'QO)5?AWZ#R7>*E?, OP9,1P*+!K31
MYUG-\JPL%MKF18&?+&K@K%?;\&29;+'HG6+Z 6'9JZ!!58I3]"[&P<B8/#)3
MF&1E ,@+NK+!2A1YB):,%K):-?(ZFNM>A,R@9:7R/$*UCJX!(G61;&LM"7D*
M0*W GA[@Q+&V976QUFG",D8)9DP Q%(U*P7#?C@0218<Q^XUM-S!T#77Y27>
M+"5&/*(CRE-8V@S=P"BJ)DCP5SM#-&7B6L$TRNQ ?-4*8* *2\YD>BN',TP/
M9>9FV25O:R:PSMZ@Y]!Z JL![K.-<SST0(*'ZRAM!#X2:$T\RB&6592?+4D\
M9T4TS!;&@,M904%3+G=%N0T>O6A> 'B?R)DR &9&@G6PVB*]92L"B; 5LP5K
M( -78:R#&0D:E.^PW%09VBI-;2Q^?;-HD;!0U*SZEA![T!6+\IAE1CIG@R&2
M5Y\ T-&$M-D :^W/@]-!>17 &JQ&4W3^QUJZ:41061'U@\IWPN9YK%+.HS.(
M&PQ@U?,*>$U(E-G!C[4F7'A@E0M[]*,^##XU$KAD))\NW\Z.(O$W;#VC-T!&
M@$G'^SMRLU<NA]H_?H?I0K("K*Q(LAS.Y,O54K2\/!@'!;2<%F-;[_MC)2N:
MLEK0^*%JL4 S_(G2V*#F!2ZQF,4BAQ%P;XLWK(OC'K.K7,$VKXJW8BVHPL56
MQP 8]U86=V2%N8N&[:NY7%;0!K8V1,W5/[BAK>.MD1N5^U5/,T\//D_FWOO@
MS]K$'M_ZS[?5^N_-M[_Q'_J!G7C$0\!,P=.0A 4P7D_;^?D%R(G30 [;2AH9
M?:1.%!]?[A 7ACGLSW@1F >W8(Y=)&%^ ^9K^?+$7V:QCR6V%ZV!MK"?PM]\
MF/4@;/-<0FN##,+FLVCTJ-5QV-"?BANRKZM6#'75DID35,#AY[!YI,3O.Z'5
M>(VUEUR6&K8:80+\]!'DM<H9#B$$SUL0LY_BCHJ20P\ $4,[D,13N+]=57I7
M/8#32&/K #RO0<\V0[H,<<B=YZ<-BE@3&DL]5&Y# T^ UASR1"Q]( LU%"J>
MR.;O /,3-C+:I<W:U%@(,D$R$WL8K"NC7C[@0Z XPRY)& J$P@M'NJ+J/#(S
MVS!E%9JS\@BF(D P+3H3(K<,T+=A(AX## M^)J 0J+4ZF(G$:L@Y8Z:"RR--
M& ))KEHFIZI9]7_H>H!FR-JQ:=+?)67OJIX)I+!:(-V$O%7<.H 'AAJ^F8E8
M*.L$'K@(PZKH#*P"&=A\$B"$/#15]853:Y'=BORCX%I($& MJB:PZK(V%[F9
M1+/J$M&H0X[.@6HG;4)MC06_?JI?;B0-07C+4PGJJA;T65OFT08O)TC_FW^O
M*/6N<?(H>A]M>UU%SJ,7Y3L%!O+?G?)5!5R>C:88?AP\E;U__>8K"UT IE<_
ML3U\X$)2=U/"$CCQYCE0P3G^5)#0->C8A.P4/7V&O/VI7$@2 S"]>CS;BNI%
M=:%-<>P,+N%8F2.@Q&+8P;"/6B;(&/P4O&[A<Q2&9NKC0B!9/BXKE1\($T[F
MS6=868S@'AUV2S1X]*BQ#ALCPLC'9-F^ 8DMRP___ 1]SW:+&\BZM6J/A4#;
M$UBQAY86BQPN73\8IRL+K^<GE1]F70?:SSE%O3=*(Z0^C$'![X^0N812.*)Y
MVUEI>8$#TO*"'X84&FLB)8WB..NFY5TX+<]W3%H>0!*!C<IBA^FF6YXKIN7%
M/HS.W#_(I@HY+BD\6%H>4'B2TR#;4.-:Q=]]N+2\\(<Q%GE)KG5+?,3W9^7E
M!3Z,1D;*T;GBG"D=.8+#>7EYX"1Y8C0<\R,U*QR1:OV]\_)( !4U'_!YNZ%Y
MP^^ O+SKA<16BKH]EH4HAU<U-2FA\HVH-3K"%M+:"(H%U\R-(Y\%P*T++%XH
M)KQS\791,6([*@;$UW"8Z36X3,+@R!_@RMRO<#Y7*>4SF60NCB5SE6@I6JX<
M'1I#_X,W4CN:[UZ6.^Q5ZBX:1"VS/9[317"^< @P>)P"6!%0AA:G74&6GBV"
M>I@:M3R)H'<5.#GN7985:_35\"A=#OG8*?0HF%."T,/_QE;HB?W"]ATQ]C/"
M:XP@JG_MTNY^'#8A=\<@7&O[*^T#(L ALZ@6&+&$4<@'Y##.J8K@;86IE2PZ
M%%?^P39L^06@S34#LQ9\_,L&<#,K!$#\Y"FB_V [MG\I5%^;' =$ _P8.006
MQW>):8\+9?H^4UA=^+GP<^'GPN\[P>_@<?/7$*;'>^&3DKD*F#.I,A('K:]'
MQ(:=[C%BY1YS K84XAD7N-<";ID1)TQIY@+X6@ 6\BYPKXB]>I?1=';@@OA:
M(*[(&B.>)JK_P;:]=$JW_9/$/:\D%7@EO=Z_=HCSQ6 J[ZXY6%N;/7ECN76S
MUES&PK:U6O32(T40,2N@NP?'%OZ ZZ[V@/GH1RWD-M/3U[-"=CMNU ^AO)9T
ML-XXVCY7/0S[\,J*P*OY3LGLXEJ C?MY=7VN>J$K+N:F-^NA(:_3?J[7^X%I
M@@:W9C5ZV?3H!$X W)E3UNVW_5)Y]I<P^]43.(X'CP80)(596Q$)PN^!"(#\
MY!OI"H=,,[\77GQJ);E4LY]J?/>A&DL57% .()I*-U[T90K>!Z8<GTLY?Q#E
M4/>AG*2\I!HJGQSRZ<J$+0H.I)HOTO3V .RSW#P+!A]+$%PB;=[W2OBWQS"X
ME/N-*3=R+YEG&9 +^NWU:X5HJE#(U3K.H]^?5R3@#4B<1,:P=AQ\MDG/)/Z0
MM+S/I>N2\5555V/.!L;ZL"=%&J3S2/ *%'@AB>G]-A+S+ =3W4P#VR*6FVZJ
MK,GLX!>:?F(N!-;5\!)LJP-PQJK6/MEG>4V><N^SW^0F2T$-(1J"  W;0+FH
MG;Z\XPCQIR7[06^WIMGL.LH?IX+O-E9PX"S_D0-0PB6-3=+ ;TT:Z]ZA[T4>
M9SF)'( 6+GELDD?HUN2Q<@$]!FE\TDCD4X!]-HISE31\#:]0,'"6?NL ]'3)
M=)-,@[>78NO^GL<@U@/E6!!WY=@W(Y#P.03R&,A]#4ETPE#H;RQZKIVP<\K^
M+IMWE>,U<U4_86?DO[8:G3QP"<N!J6+WQK%]8AV<3 8<R7KKC]U.TJM[<7(\
M:J@-^Z<?B2<'9^PY5#$XU/]SDX3$>RH.+MT>J&W<@VX_<S']N;1[J'/*I=T_
MFG:]]Z7=??ZO;T>W>W(P3(/E",C?TI&V)R^#\!R<F.%\YO((!7B/R%<"]]8)
M/G/8N=SE(MSEBKE?A-]E,2Z+.3B6?2Z+<=G#V>SA;-_I/D[@_;:LX&X):YM<
MA7P[ISOK(161:\VF+\@/SUOYJ1P1O17C9!W0BG.2: ^L8HE>KVJR,:,K0JXC
MCBO^%3,]B56>!^&;N%A(_"SWZ/H.[\^:+NYE<4ESS1JZ!VENE&8VVG-_I:?$
MHP'/GT">9WE 7?+\@\C3?Q_RM-5_=L+5E"RDR:;(/3)I7K;*Y5HI@;#LA=H>
MM>&R!Y<].$FQWBHRI6,Q.I=L#66A_\!,XM+5J#?R2%+GN2&<QC NZ91T><5%
M>851CL0I)AI+>./" ]/Y%<C\,K(?#WJ^%2E_EKIIS4)Q<'/Y4T?DW+&)^O$B
MS^W[ZO9]_1; =?N^7AG ;M]7M^_K(X/8[?MJ]7W%]^#8_H8I]^KY<PNS*'9\
M@Q]\:1;AEXA-RF*X&FZ.R2K>.:@=D$,='OAZ^ZWE!B_IZ@@<[!L]NB70';ML
M?6?R.C"^>&GRVH@OSB;YF='6AR.)O#&)79'"UO9X 0<$^>KQ/@!]G=B1\CL3
MV0E=8B]!9+8H82S>GS'YE)Y@V]^'P"X<V?,3I$M=#TA=]+U$V$:0+1E-#KL2
M3V<5X?O0V"7B8AMB[+S>!BZ5W8?*3FBTNDEE1FD8KP5]'9Z,48]/(9<0.L%7
M@KA>KV+'MOCX;BU3;]H=Z&95,IYC6@%=UN=RJ49"M\\=)8(7;8EUES2O[XG.
ML5NC\W4:F-X>I4G"16EGHO11W0POZU%P(#I?M*\;OBQ=QJ^73DP&O9?M\^;2
MUL5HZZB&OM?P)SB0P@X5&%Y78#@3J:/G(+4#$?*Z+/]/X_!_4-M.JTG#I=MV
M.KWIQLT8C?_T#AO7]"3<HS_''>3OH3Z(RZ2%W:D4S:6U;:%^#UIS6A/-V],;
M=:B#Q*6W[T!O=Y9M3FI\>1M5_MP^4S?QY7C.*PMWN<!#<('[$\I9ZW)1R[FH
MM1(PY.4$C"LB3A01KD1P1KK'?1L.[BO%^9)W.;*QP2W2Q"+'=S&X<+G.L"@E
M^$Z,J/O)LUH<.+>,QZ["WKF,YV)M#F[?GL0EV56D\QXDNU$"-!_/8YTQ'@G4
M.PXAVRM2[5U+@YQ'L^?9"7\LX0;O0[BVLB+_=$X-FC5/=,)]?Z*]J+?(_XI[
M#BZ$<"GVFU L>2]1NU&J5(OPD[16CHUF?X2PO5\)DTNYWX1R+R!KC7!X)@1S
MT_FT]8VI[C)E41Z/[UN1V,ZV>M8&<_H0W,?^_G>TQ+< 37P8R5K%%TQ3G-)G
ME^CBJ 9\SFP+N G5M3\/'D/# ^0<@=5HBL[_6',U1P25%6555_A\)SKA)8WN
M +((,2(CL7RYQ_-:! CB"GA)2)39P8^U<\5MHX>.?-"'46I+>+L1H'W^]FZ$
MN%Q!ZK_MW[E\)?K\1))OF/F,Y1[( +#6)^JX6L*;Z1#_XW>T%LU5RA@=JT1+
M6"41Q4)TALZ%HU@Y$8U6L A=B2X/J?W[,"S:ASJ"Q/%P$R3UAE]0%)EK.68]
MYX#V7^%W4E(U1A2'8#//3SE9X[$2S_+"!'('@,).A]2=UE+I\<]/P@IT@)D#
MR"E+R$'_/3,:*?(,B!F-%^?8?]:1-XA'5@18XD?,'#XFW[$=!SR,U5E8\IP;
M6@UW_<N&NWZ*6%/&@:QD.,32I"XB9Q71,WB)K,#/"F +,K>NF-NN UO;)'U+
M6__@>.'7KPS?9<2HI G:_%,_VK 6#":+@Q[>]GT>,CMD]_O&=OF74_W\MEX!
M!^WF,AXPWZ;.@+_AU'9S7B@.UA*R3D.[H0#T'P ^#D@%16CS0#&4,$2TWE<,
M9GZ1^#\%!<!3X# KPUQ]?F(D#LMK/5ZQD;;ZBBXG@$["J)AU"W@81"'X,Z4#
MG(60?3N1X%;TND<<VH0107\8!8FN-&;C;&SH/UBF;+SAU)6Y]]WEOMU-&V._
M2/_R2?_SZQ<6$WB1^QLKZ2+_J\!T>>S7K]__<L)D\R5 S<,879-7K0A0BV7[
MI9:&KLFCA7KNV9TP8-\4N/^W];]M.>]KZSE_V_<$^JY0^=0,E0,=H9R,Y^A*
MM10MFZK L>_;^^Q3-[#W@05=474&"&--Q@"[ UQMK L*#Z4)"JC#S\I Z"H"
M]$P!!LGV& D<(,UJ\&LB2'E>GY_,.[N"JBGP63W 'CG(#%E&AR5&6D] _!+(
M4OB>-H]BE^ +P)8%\)XVWV/$#M:>H]>!1?**><$K_$#A=0G<A1X(D+4G*V!C
MW-OUH+KJ3:[:>I%O]BI?5/ZL"&?7*TWJ :\3F9$*/E[\]F4?<T!P^[N>[GS;
M#L5L[5LHQ[F_S;V:_]-Z%PCTW0,:MXU>)Z(OH+5"OE2AX\!N20*;)YS DKGP
MVW6I[BC\V'K+VA%>"3^HX[$C-/_;.O_%;D_)NUN\?T=7WJ\6\*Z^8S38O(25
M>\STD'9*/O*_/^RK/231:1ULG^[UR/5_L7;G+#3<$_@.D,D2T/ %1L3RG8[
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M"1Z.[["C!KVM1X3M9<);I]:PY7^UXLTDDN5*B1K''9 -'0?U>#Z][!YYH%S
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M?7R2B 3')/"O5O7[%!&SP"T/;T?"X6C6 5^GLZZ$83?/BWIM-X"C[D;/T(6
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M535A*Q!%P+62T/FI!Q:4T0/!>7;:"4(_7)+,E=V9\7?5V9T@<1Z%+Q=*J$L
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MLNS-TDXVSL_Q5%77B;VBFH1*V-UM);,]V&3 @HXMQ,&M2?X8_JZ,2';S15[
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MF+_^ /!-O"41@'8W8J?+4F;J _$12 "9B3_]^_,V!H\HRZ,T^?-7[[YY^Q5
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M2M]B>J1)@1\9_KG-+"D0?MB%:O!4:-DEKU83^HR5JGA$4QV<0VYBG8N.$I[
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M1](-91BH?,(T8A[298A-118B[Y J5_LLZV$7ST%B46L'O0JPS9FO0,X+NBC
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M"C[&*13ORO1D+-<#9.$-2@&V A[Q@$4E*@!(!0&5=,B"2YA\R?:[(GA99&F
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ME6,H7C#MB[S [PP>B,>[4*>/-R\!=WYY\*YSQP-S(Q:OX#FP@9V[>0PM^+*
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MB"%U\(7&Z'],RYTZVIZK5!H])U&Q'"BG!#^(B1/*^Y?PJ,3*+S,083$R^X&
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M-9N.MP"M:FI4U07S21+2U/.VKHQT0#;0MID$8-BD;OB_IJIS-AZ&5U11I38
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M\IDP]HHLM[,74OD)R^W2K-P]R.Y0'H4H";1&03,CEH^Q#VC@X$#;P()'K#X
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M.1$XDRU8.DO.U]B7QJ]5$=&;ZYL;PH1;@@HMN]NO6DT8U&*4J3AGH!E.WK$
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MY@N]>Q3F7_F3C"D->7.RM6VH,B7SLI=V.**\LGTV.HG?B9, )83NF[F(%7S
MO&KAUWK$FR6YP:/LPG_ X9;OLR1>\&BTID?,6>@^N<@G3DE3AZPBH"NY";TY
MFZBE(4"J7IH@*Q,;LW2]1JF?X.5^:0N'O <C@51^9Y3*#-R,$'LC36,TQW35
M=$';NC#Q2<$! 9+_O<FS0XBM43XX4;3RPC&BMY^8_(<C@53_V2356;@9)?9_
MKX@-@Y+P!4+ORF @R3^8)#D'0Z-4SVU&7#A$Y&2OC@;2_1>CR@D'1Z.$)XI\
M&!:1.]".9XT'$O]7D\3GXVD-^7,K:S^E7LZ!/1 @$_YJ"Q,JV!KEPP@E. [(
MM9\ .% 9#*3]1Y.TYV!H =5[40"E^78HV&HR3_(2>D8)?H-3WPN+==V0WZ5B
MHC.&0PEOQ%Z5HFD!\?] 7@(F_=Y@*.&-F+ 2%(V0O;M*DH,E"<\9_F@HX8T8
MKS(DC5"^%V4X>Z%MNH:KQ?W.,7M(\>HH**6-&*P\I Q2>..QB#+:A$Q$Y?)(
M**6-V*DBY Q2NTNP2F@$+4#/OZ,7$;DK0Z'T-F*?"M$S2/!1@A=>\C+!OOP8
MJ8Z%DMR(52I&T"#-I]YS/R"XY773E%1RTG-!H!PP8I*"T#7(B'[DQ\DRWG-'
M=VD%>_+2C0/A42\!A#+%B*VJ@+I!UCA!0(B6KO\SP!&Z%#&$.1P<CS+'!@&:
M5A'_G1KQW\&);\2&E:)I%?'?JQ'_/9SX1NQ8*9KFB=\E_W23:?S$B7]S!T,)
M;\2.E:!HGNSY/>0FHR1^Q$4/9!GM*Q!0!A@T;\7(FN?"6A& [/S-2"C5#9JZ
M;.3,4WL4IYD7_C^\E.F<[/%0RALT>D6(FG%:%GN .C]X"4ZE(5 J&[%SF>B8
M(2SE=H(\_E8^' $EJQ'CE86,$:H.8AIG>8@CH:>W.@I*72-6* \I,P<R38=.
MN8?!WI_!.79&CMLR&D:(^37!&5D'+;Y916N/#R<.QQD*);(1TU&(GA&"3_(N
MB[2VZ=:CSPMX(9O:K'%04ALQ%/F(&:'S**'=%Q:(*.MYIAFMH$C<V8QW(HO&
M0^ENQ$Z4(VH#_?MIND*)*A<84%!>&#$9H4B;.7F*9D$OE^_NI[0>B'/N5$9!
M*6[$7.0A983"PWB:>/2)K\G+XCX.^04OS(%0.ALQ#@6H&2'UP6K81"X-@9+7
MB%7(1,?H*=%[]O.GFOAY%.R14#(;L1)%R!D^D^>@,WFN>"8;L19Y2!FE<)'A
M3F3,O0_Q_. A*#:QF0#@^B&3=!>@:J92,2]HHF]#)HM\-3?D'VSB<X9"R6ZF
M)%2$GAF"KP*<H:!8V+;1P>X=.P[MI5!0-IBI&04B;3"(\!6%X>]1_!1-D)?&
M$0H* T$41^""0'EA,'8I0=<@([[$X8K0*LF35Q../'"&0@EO,&;)0<]DIFB1
ME+V]F8K'@45TYT% R6\P>"E&UF@&78;HRO$CNO8R;[U.$1=X$% N& QDBI$U
M7 60=,FU-(_%<?O20"C-#:;O,E$S2.K)P@O#JU6*(Y0*3YO20"BI#>;I,E$S
M2.K> B5S<MA]2N*G[&%=T2HB.0< 2GJ#V;A"5$VRX'E73U]4^@GISQ@-[M5@
MD/A<),TV)-D^IT9N^RCP$@[M1>.AU#=:2,I'U C]U^]6[#2M?$E]8O.)TB_D
M4%!>&#%UH4B;O'GW^AH(+]Z#<5"J&S1J68B9K A;W8?8OPEC3ZC''PR#4MF@
M!<M RR"1K[SH6[):9OY+WLL?T5!-NI4_@!D%G #*&(.VK1(I3#H<XL6"EDK%
M_K>\&W+JKK*4'I1DE4*W@Q .RB"31:L Q(UJ2NFNF T%5R]C^@8$39B8HN?L
M*MQ[:IRM. ' H5PRVGT)3 8&L_[VIH+7@/Q"<T?9W*&"%SN/NCO;NME'Z[=[
MMHL^:#C[KG/1V8+E'6?)QZ,4!?1?:1SB@!*AL_[ ;FC:B6>=[3<ZFX]T?KR+
MO,+;_Y?:?6LWVQ?/DC1G<^8]QU&\>'E3[-WW%Y>_O)FMPO!/.F+WKPO"M3]W
M0_+MG?\^'[%=.H,V@IZWVPE@\+6%5@_23IJB+(6@5QYIJG^N(KT/A9B+37.'
MJQX^K6]G.+LX ,;Z\\HH7V:0$&&+^>2E]*TD^A_ZS-^C%W*"MCM$.1#&>OP"
M65!AF!!S>SE&T[?0YA7-;?AG^YBFB'524&.-@FOR$$@+>YEY@"[X>#386[BN
ML+'PM)<MPSCR52\P/HRQKL2J=Y@,;7L95GY26,2HZEAC[8OAE"^SBH>PO2PZ
M>+-TLKI/<8"]!*/TOV(<95_([^EC,N0PWSXF*^1BK>F,M4JNS^@CR-:&O3!*
MXB5*,I;?GD&"W6AC_9:;X&09:7L9M7D;5\2>W1ACC9CK,Z6,X+&L8#S?E/^*
M;'GA"[4, N=P4C!SK9B5B0Y#R':1R&]>N<)^,,Q<V^8C-8RV*.QR?JBR0J.?
M L@ +NW)DHNWK <%GMQUY8O*XLP+\Y'6<8WZ7;(7<@#LO;L),;7$<.8Z1C?C
MZH50Q5Y)7%OZBAP509GK2ZW&$H[/HY5<9#G6U@^Y*WL8=W#F^EZK, 7B9"S3
M0IO:6'Z:GI\ DH_G#C?7 KL&Z<6H:*;X7932VD84#&-B2Z\9S:,W9["Y[M=U
MJ2W$VMYSJHJEVBUCLDWV,6<2'^_7J"?N;!=%M4(":*X;]W&:!8@>]@KM]7I;
M3KUGH.#R(,SU\5;D19F#8A+8RSHFMLH2:+('^)&,$Q+@-9Z]0#[7XJY&'TL]
M[GXG/%U?.G!/B^J-J:&+^7$W)AMC>\_9O'M!T/66.&,V;=P%E0X'FFMR+B-U
M)1K&PM!>AJSC[2E*'D'9!9N!YOJ?JS*$B:&]#'%\?[58A329NW#,Q M"VP?:
MYO81T7QW9BNQG7,= FZNA;HJ\Q2H82]+QRCS<(2"GI=$M-1'Q+_J6'.=V%69
MQ</37LZL$<NR!-^O,NH:FL;N4X22U)V-/(Y#LDP6(;2YAN^JW(/3XC6JCE2O
MCJ.,+)-\;IY7T:!4''GE@IAK0Z_*<PG6M@NN7#A-]J^O)X"O6<A8)HYJ/-QD
ML_Q&;#4F]N:XS8T7T2)8G*?UT6J2.&]7@2*?S;(<1 1AKNU^+:9)\>$>D-;4
ME;I+5+QUF6YCO/O*\R#>:WET4&GZ_IA*T]U7.UX4=/+O=@X^W/F1?OHO%A>@
M%G;%%B^(/XD+8MD)/$KB&<XH R!8L48;+S>5<*=R[/)1ME>]8>>0]IZ75 [%
MYJ,0T'S5J8 ;57,20 1[>?@)$=O)"VD%0[# 4?[J/&VD"."B%-1\3:H"'X&$
ML)>3.UQO""'6-UPT=VA?3*D."P V7YVJP$TP,2Q4:3]Y.$KITE'J1MW\]8)^
M=./AY(L7KI"[2<WB*KAP>/-UK'*6*J)DNY3FG7K<V0YO=[8K'5MWW$/!39S<
MI62_%L; +<H>F!T>M],>,ZOY^E@%N3Z>?/9NC8UC"W#U5H::KZ%58"('4?6C
M^&-Q%$=H3FT].[U).[I<H5F<H*GW#+N(]X:;+YRM=?56$'Z-WL+"T"-(KG=S
MX8%9T3=9MDX&N4TN@S=?<*LDWW"2O':AA\FZ#<6[M43\-4LV+Y0/\4G)82VH
M'%;U44$)8J^*E=L1;G2-TV6<>B'1'BMM 22&,G0&"VJ.P>RJN$*4J&0OMQ63
MDHY)0M)9L%R;C[ TI%=S7N]=8 ?I(8HQ! ZL!77-1\04A 2Q5X)Y&,"SGZ S
M6%#F#&87E,_2O*B6<+M&UI/R5!841S?.?WC>E-H=\(B2^SA%6IS?0Y0CPKVM
M\U&E01945ZORCH7&Z[V96<J+\A6M,(D%!>"J=[4RB>P]QJ6HP&]OY:ELJ"=7
MYJ3R7F@XX;F!\]S@;JJA'=2?TX*:]1/LKS8J#E-Z_55R!POL;N+D#^2Q7@C+
M84&@%A2[U^8\',O7JX-LRGU&*,F#R*#Z6RZ,!17TJAJ&C #:6OI<>2GV:7H<
M#E<T8D-VW68-/(D4@EA0WRZE90Q%QG9E[BO"\P>R:H><W=X<%0]-Y4ER_URE
MY/?LOP-DZ\B)+2B%5Q7 1DBIK]79X=?3XO/Q[DFQTC;FB:[Z/!94S3?#FO@H
M,FC1K:RI\RB2]F@3=4J(AS@D/$U+M60']1T_'U/?L?Y:!T>=_>_]'V\9I__1
M*3YK<6G'7@/3+=W@74,@T);=,OPE3SG]_P#83F'= "MRI^F,@3.UFO4HPW$_
M6:#AQNED#=O/D],!T;>'N:G'O-'V\^!@GQVV3.?@M&_P629.U,J+H^+@76^Q
M9RSUB+ @6LHX*5Y[)426\6Z3L\QYTGQG@AR,LX5/XIW'*3;>(+&7QFH94P[:
M)<EYPQQNOJI-D3D"I+59(?EKQNZ2TF3=#(E+[1R /]Y\\1F,W!(T;/</ %H?
MR>5%81+S56B*4J1,('MY7>Z<)&<L#\)\X9DB%\6HV\LR>;LDJ*8!F<-\*5DM
M_0-.'GL9S0G9R;DK 31?6*;(4A A[.5CXRVCFM<GA5:Q4-".=G(N48+C@'PW
MR>R,,@Y7=)NYL\+=Z^[<O4(1Y ,9TV+K,%F*O&F^\[U<N:ES%Q%BCA+\2# >
MA9Z/A$\#BD",::D*;)-CH=G6$WR[V$$U2+\!-*9@-LB 0R+8>V6-O)<\\'(3
M%T'M'*5N+,O0%D 9TR/KG'IR]$W6N/(]+?GN*K:?FQ K-5GEC1,F*'G$/E_X
MY'#&5$95V8.20)^W2[( \3$(A3;6/:!I?K3E0.Q'?H*\%%VCXK_3AR1>S1_R
MY=^3GX/UD3%-O"CU?$B+@!KS&6L94.<0/89D)Q'/_(9VL@5$&'=CC57U'R-Z
M951/2E_XD5>&,%=0WP2QFSW;X"1W9T0?8=NG[+7N ,R5N!]-\#+6IZ>WXCXO
M@YDK2V^,]B?:\7<1N5!"_*\B\=:-=JT,^GO_YG("#&ZN/ER5(XH4>9UE1=HZ
M]&BH$*]EE8I:]%C&"ZC/^\]W)NNTZ[N]Z;H;<8#V(DO[737K]E;ALU$O @P5
M3:RW)[7;2Q]NPOB)TZC_PU&)W&3N3CYY2]*U-[103=2NPEDFXML5TH;*=X1]
M_8C15AE4R*\XD_%>_A#^5C-/:]'+WDM:G\*D,76@'@\TMCNT6B<NJITVP8PQ
M\N/(QR%2>XU#81(+4C2;V2#*A+-7S,N.V'[$>"S]Q4E3)'MI!CZ-^9Q.=0;*
M'-@ NFES>>SJ^EU&D_SM8G@N#S"X^2S.VGQ30U0SO];?W?>4 0*Q,BCSR9C'
M<0=&%7M/TD/LG04QJ'":4Q_0X!\ ;#XS\_A3$TPC>]E,F^46?M3/**#/DJ#9
M#%'5 45(K"O+(,UW_3^>P3#JV,O=0PI4PM%"_LIAS7?U;UJ$^132=GL.4;9Y
M$>AKG'PCFONZ9&V7."ZP6S:-&.%3F._4?YS5HHZQ9@:N56>RAK7RG*.1/^63
MDAV)\".G!T#AJ05"&TX/J$/PN ::[3I0=];2YK]YC5QN)BF<K9)I#"<J','Z
M>OA^/SZJJM4]3;P K06#7$&R[B&UIC.<?-'\?E(BHY7='W?[GW=/[(\PG*MQ
M[%U01=;>\QZFJQP?+K*B@W]#[F0UFKW&9IT,"A2924T$&X4S6? .0%/A1@#%
M[#TW1JO$?R!7$>/M(6&FD!C.@I<":C*J$I,$T.=UOJT'(^#Q9X(5SP@TM%O4
M:/:=W"@W./(BOXD;13B3!4\2-'6C "BFS4M$#C<?H2!?326G?(SF.*6='@)9
M/8/R-#9T_*_'B?@8M#5S<ULI2[#@U@KOZ@=*(VWHQ7\\3_@T^&XN;@;)CC]Z
MK>C.?]S^4,;X]5[<5=\4I8D3!?0_-+_^T0MED3CX'!:\+5#KLE:ETFO<*>K[
MXMA=H#$CK;;*IH'GUG==:HKS"H4G.E\C:)#WMI0>\17!U7(9YLAZX35._3!.
M5PG:(=Z/9G&RR*G/U1!5IH"RUQ+_GCJ"FA5W^LV1AX,\:E3TUN/QA3D42G]-
M=5UU2!G+<#I-?@2YTS<!_W5$CN;;T,;!(#M*=18HHS2UC3F64?6(IL_>9:*3
MNC/:KI*@M//&18&:7TI K1K30[ENB;.J6>0U[P%!BCG9E*.BX'+]E[5[AL?O
M6E-!>:NI&TW3;(J/I8=F=L/:+/ X#(4&U\ZTCZEJ!&3PT4R%]-#+\IMJ';+?
M;U1U4!?]2^>BLR,9^6'H3._&O8Y[TW%'O;$S[;O#2:U*9WZJ;&5ITLQ8 43#
M:;R5+TT)^:_()-_@B]L#,54U+"4;8Z<#<+=F>P\PL2X#[K-MOY9W]:#_WW?]
MZ_[TCV:W\NX;VP7)]K(0I.$*O,T'I'N8-=+HU@40]K"(CHNJ-5N6/K5(&_KO
M3<S>O'\M;]XK9]*?T!-Y-.Y->L-I?B@WNY$9BY-M9"&(9:ZY?=MMO>Y=VX^B
MSBOT(KHB85J/TC1&Y0? SXKOK@:1K!&N"9Y'>(9]HEFO+6VBX8W(TOW]P-2!
MF'TLB]FD_VG8O^EWG>&TXW2[[MUPVA]^ZHS<0;_;[S6L! D7+#6T8< 6"^%D
MM5AXR8LK1J6&6-:8V*B@*NT#H<C6)JDU0DQ.JZ6'@W71+7WY.,\QWQ46L27Y
M\FU9DLD].7+ZUYW>/T:]X:0WZ3C#ZXX[_=P;=\:];J__Q;D:-"W0TL7+A%IA
M HL%>Z\$J(;T\J"-BJ@R9X5B*B:0-;*X[^:X]9)O*'^7JN@D.$'^*CE,^3B0
MQ\NR//:'7WJ3Z2U17<D_.[?.^/?>E(I@IT>LLND?G4FO>S?N3QN_9/>1N,+Q
M@_>(I&JM&,9BR7,>/1Q2)LWB)/7(KJPKA(")C,HCA*M"$013RDII)*N-?>QE
MB"U\[\3"YTPF;K?O3'NZ'"',I<*=(A+PIF.:C(_MUB)UF\#A+7&F@)A3BF"J
MD<@:D2%K7,8IIA,2.W@9LJ7E?5E:KON3D3OI4P]+[G$9#70)2GF!<!GA0S8K
M'N7O2.5! &") ,B(?K#WI?A;L]GW&J;WH_4+7K2,UXNX2MK/_'MB0B^*T9B8
M2=->I^O>CIQAXZH9ZTQBK+W.Q2&<IG$)V6H5Y6_NZ1,0P5&<QQ)Y4F)>6;AJ
MD<X:F?L4Q\$3#CD7RX>R>'URW>NO_4'#U\EZ$3(QJ0RSV(X9$T81]M(TTFOT
MB,)X2;?7VOJN8<[ YS,J4QQ."@T955)9(SO]Z&)):\'2E(U"_E.U<2E;U"HI
M#/WAQ6CL=GN328<&S)QQ]W/N ;SN?>D-W%%N"A4_W_3&X]YU9^K\HS/H.U?]
M@<8(<3^J@[+*!7C<_$V;5J,C&%PUM.K-9LTMV03K2W;9,?2UYB"X(P>53R@4
M#,D?TG*/GP,QK^1TW USOR&1WZ$[[4TZ(^</ZE34);_,I<+%4P+>=-8?ZV-1
ML$D^E"JD"A-8(F,@]I0R^Q2)9(W4<'M#'PA,)8_DJS,>T^"V]JNNO#ZXE/ A
MFQ60\G<RPH=[D4 ( "P1 !G1#_:^%']K]OJZ*5E>+<'>YY5$CJXSZD^=06<R
M=;N_Z]KC^^N"[V\V5-/%4;MO2 ]ZSF!+]K2(R*6** '.UNSE?'GNDDY(U;;D
MD:WJO*LD-.0[N>..<K<TM6G&7QK6<_(V$%=[+9.E.4A\ (N="Y7.T X]!^?%
M4U]UTHW \YG-,I)Q5YQ9I$@T:^2-5FR,4-$.G"UIE52%'P?N9/*7SJ@W[DP^
M.^-Z4J:U#T6\0-OB-$BG*"Z(96+:\Y((1_,MPX#2* 0S_FB;A%_5ISKE1+!&
MNKKQ8H$+WS\M^8_S/$.T4RIYH:=WE12%KGM[VU^'GJACKNOFJ;>]/5NE\0 4
M9_60]%L0J&72=5"]+&=<C:M0=5:C%Z("]X578SU26B/"8Q323ETC+\E>IN1.
M3PG>W%K!=Y5DB7%OX$Q[UYV1,Y[^T9F.G>'$Z=:O&-2W^WEX0NY/.:S%HKZ_
M^%JQ,PZX\8L5RE%)_$Q('6O$=%VS[!%U@F"WVAPW8YQ^NR5K+C1QMLQ6TCQN
M^D-GV.T[@TY_.)F.[W:W[K@_^;USZPR=3SWZRV:O6Q *LHM7<1*+Y9*%20WY
ME$YC])*MQ7.AP +)9HW@KMU2>ST)V%):R1;9N#"O^Y,NL4COQOKRKZIK5'9G
M,F'U95JMO[K;0W53K8 3V>4,%3"*FV"E1#%KI&<81^1$C3+R P&:5UI='8A0
MM9&%.[R@AN38'0QH'6=_..T1,6KX7B-K[%:7*&UH(8&R^.;:+#9=/_?4(R9/
M38L1-)79#AH@[@JO+ 5Z62-XO<?\JIZ1E5]Y(>U/-GE *+OF%9V\J^1F]+X4
M:N4-D;G.]'.O<^4,B-K9ZTP^]WK3SK7& A3!XN$7&V@2?3=<_GGFUY7N-] T
MEMQN"FSC7G,*9+-&UH35VL(.!N\J"1Z2#@:='S?S_>4[:6; %S:4^@E>%J4=
MI<_29FU.$*__.$1/D\R+ B\))'=<L1V/G[A]_0B:PMPRT93W(YCRNQ*\JZ2E
MP+H2='XL)FU81*UO3P"Z%Z]1YN&0OC^P[;OJW,>K3+JXG*9*=V=CGVIG[P)]
M]+!,R&&-#@2"_KZ2K0-O=Z!)V+^KO@?5E^=JF:+"2=K=[P!$(2L%<EMQ+I(_
M2;N1;<<#3<+6SM8'[/VQ_6RF?%\")K'$TE1O@E"+6/JZN/L/*%B%!VOI1Y,,
M+U81O;0\F+*C/ WT#3K[^%>38M8<B9M28]$I6$FJVA0<:SKV3EIY##K&-E22
ME,:!*HDK8G_$Y#:7%3>)IV5"4[/&6"1CE02HXRJ-3Z"0?$\EQ_NGO'#SJM^/
M2M-9H^8T7G1\)(6M.1J8E9\BP:]D47%JC[5+=)N*D'>[I4)F!>$3P5HB:>JE
MQRJDL49JRC6C(H&I)#15:H^UBXK]1<B[7< DK8*0R. M$12E$F55ZE@C)P>U
MJ (9J60L'=0M:Y</BPN8X\4BCHH'XN^B$"]P1L[6U>(>)47%Q>:/7W'V0$,0
M7O'L%DQJFIK=$IF"ET@W2E5KI*U:4RV2N4JB$JNR6I/H&2^Q!GE1IBA9I%6B
M*KI+(+.THR*Z%FJ:/<"5XNP<$=H^$45I3K^]]:7KA^XD8;$*GC4G-NLEKL_6
MH^AX+*=/$RDM#GO:X0CA^0,Y_9U'E) S=8P6'J9EQWFN*R'6R@L'>$8?*UAE
M*<W4(7_+Z;.F1(T JYYO0Q\3M;&K@DYN6',[[W=@$-W+E53&<A^&X^[D5]R0
M@7M)E%L)P+1C&93QPD]@1P40,B<+U#I1AJ]QN"(7".K-9LC/W*@B&@KVONI\
MQB[E6FP[EF[6G'Z@ DC1L5C)(057[VJR85I3Q@O2G;<+*5Z V;T.36_<2A,3
MD;(,G:F]];BU4;9,)CE%A0(I_+F2X,DK+=0D=!;5&(*"/1&/ODIA'\@L+2H.
MK(6?;;)3>2&\R I/A]1#3R]IM@!5,C19C\QW?EQ/UMG.UK0<F7]X_C2&_GY#
ME"N4/2$4[;4ZV:2S0TUWZ&PR8:QL9ATR"7[R_BA4M_KRV\;[YI-E;;5D(K6H
M3_[)54%XHPVSXBC:,HY-'II;]TY=-N@3QRY9[3Q."%H';89H$=TS9O%S"RJ#
M?#V\!:.\9YY:QN:\FO\EG<:9%][$R>'B;Q'U\(EX#0*WA>&P+5UM:0G!<:>H
M-:R6>N&C-W[^E,2KY2CTN1PIM#/V8//.$X5==JANBK"W-V8Q0HE/"3PG)\N7
MF!81%^5XVU8:CD]^3G;**TNT%"8Q6]TEO/ KTJ1,&WO9O,D]V/-&N,FN74J:
MKE! ?D'^*]-656<R&Z-4Y'@],FES:N<?BGSZ4 HY7OC>L>HXL\$Z&-4Y2]=,
MTUOO&2]6"V<^3]"<+-&=S5!">R<DV&=M_!Q* @2D]GOCU 8AKXWT72]]N%G1
MY/5M]PINXAAK*)#,/QLGLP!1:_Q+ TSNKH#<9C"W4J7D;=#_[[O^=9Y<K-N7
MM/ON=M'P)$H&B&5W,]TM8B.5_MV2%$@N!QB&Y@XM>Q6C[BI)$+.//I,5C-&V
ME.HJ<(:+\QZ?"!I%Q=*@H -WL?E*'U%R'Z<H'VL=CT=)/,,9C64+C9B]46;5
MISH\K>*HSLN/!2^C7#4([.1E?K6&\5-Z0VAVE](>.6O_<S1?)PW*9!@X@UFE
MKNZ)"Z?-Z]T?;O39BX0.B_U19K7*NGP^Q%&;RKXQ$(AY-GU(XM7\8?K@9>MZ
M5( >#X<'LN&#<38HXF69VG_EI3AU::^R[<0P Z!2CW_E3/H3&E8>T5*.X32/
M+.LW!A@(R(P!(8AEY]<YM"SEV#FVW,+XXSFV?(XMGV/+5C"\E;'EU7U*M#(O
M7W6$)+%E]N 6QY9%V.LKJ=C[ZO0IAM-\;[ Q1TJC-*]@KXWFHT)M_Q1ZZ3Q^
M&F2!F.K<X<:<%T?374*!T^QV,E;AC#D8;LR=T.R.KU+ 7A_^_L+E=S5KM#'G
MPS%,$V)D.\]H=V0BZ?D;!>Y3A)+T 2\WF1;]:(N2L.A989)6Y1VITJ:E;$X_
MHS"X>F&79\AB-?6G;55&4@,$M,;W*'_C8^T\9'L@*XT!H8]\K&?]WE[YT!XT
M=X)'FKI%+JW):KD,,=F<@. Y$ZJ=#W> 4-.LM[*;@G83%&#NSA/#F#T?CWM%
M!4(->V_+]38JD0 @4Q4(LPD,C0D4AQ+V<C#'<[WXO7M-Q$(NB-D$A.-Y**&%
MO4S<WWQYKR&P"&Y&F\TI:%;\#BG0/F52$M>N=,]5U"JU!;J_8_WR' 1O1HS/
M(7&;PZ;GD/@Y)'X.B5O!\#:&Q$>CP01E1)6A)X<D3,@:VMYPN !S>XT*Q_>3
ME1<*S\?=F#:%*\J8V<N#04S.\O4#(/WH&LV\52AL'\H!:%4$08BTO;PB]VZ
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M .'\**/_N"@.K,N+]Y<Y)N17A38EZ!Y*QI2&V&6;RJB_$8DJ'D>;FO7I_3+
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MN'FE?C+Q5G,O6_G?KH>.L\R\A90= $#S21=@7H#)H#'H+U0T^6%_"5A[4BU
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M6<'P%B=K?4KBU7(4^J"DK?+@]A;!"['7'@38,^%!#FPY7%N"]5 *6%NCS$!
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M[=[Y^+*OD< LVH]EBW;<&SC3WG5GY(RG?W2F8V<X<;JTFT=S5JP^Q81'"TB
M5PYKF1:V>;^W&Z=9VH_\%4TX$(>PF0#&$P*A7*LH64(*:/1O+]=-EEUR7#QZ
MD8^F<5Y#5J@=+KTIEU[TPG=W@R<PKXVI,D<50\M.TQL<D=5BC^PM@M]JXUP9
MX_3;K1=Y1>\O4;[SKV_+)^I-?^@,NWUGT.D/)]/QW<Y;..Y/?N_<.D/G4X_^
M\LA$:'YI P0GF9M0<1++SLI]LWU;!'&+//H;NG"R3=,496J^0L!$-K@):[%?
MZ# $('[V%:K[D\ ;L^UNP@%Z1&&ZA_!GC!)"N(<7F9M0!ODJV K&UEX/H2-:
MO-Q#" *WA=>PW5Q]PQZ"HRX/H;,@^@_^%PJHZBSV$3*'FM=+%7;8H8'/QUQ_
M;>DT=K,'E%#E-T$/*$J)#5VDJ8IYH#"!^4J3NIQ1II*]M2A=+WV@(5GR']HH
MZ=$+$?LIH[TP QNB!<YA*0Z:I6N4$&L3!^M"6:K:YMMGC'Q$UD#N5ZYR"(%L
MC=L83@:+Y89Z<*)LYVT5RPQC=!L<S4($=#OY?9\V[DE'W@O=$V27D-\D*Q3L
MY4)Q-0$0;&O:2ZB0PF11JL9V/''A,XVR-0V$XL8:W8;.%T($S+-7EL2[V8U<
M=W)U7!NZ77"6KH4?]KN2Q5&Z7R^/]REK2SUMC7=9;I[=>LDWE.5-G<!=@)@P
M1K7VH_R] .0LB]ATO27.O#V/&RSR_>N[2BZW,^I/B41=]R?=@3NY&Y\B<7NW
M@BH>TDX3(-B&C:WUS;G3EO@]F0JSA ]@5$I4"']H9\DH8+UY5;B> 9;59J!9
M&[@.IWB8F%?W-&;EYBVYZS8=@D";-:Z/V@=PXEASL1%SA3 \RL@/!&B^2781
M)A^\+U]J0W=X08N2QNY@T!]^(NKBM$<N-FVY!F31W>J:I6W*)%"62=JY_ C"
M-(XDGBN/;*Y.:6M*P;GRZ%QY=*X\,EYY-)J'DA>>=P/,YQ H[*9#$[",I;[N
MWE[XZ(V?)55<AX/,9P#4I2L36VVT[<<2NNX-:&\7D@J6&O?J:NYE*_^;;+>6
MAIE_RZ3^?F5B;*\#B$; JBJ[-.K'!&E39HH$[]K^H"5*<!R0A229EA!@WC@H
M?Q*7)D,AHO.)N^#O6C[Q@5J3T )"7MMI-D2,CM7L?<3U:JA,T8;$%76LOI\#
M\<]W[4A]@>#1R*G8BP(KPO"]QSP .B/X77DA+46;/""471-"P0*%/Y=]JKTO
M1;3]9MH;=Z:?>YTK9^ ,N[W.Y'.O-^U<.],3/'F_6Y$ 07@$$32)9<*[[Q$A
MN]D+_KE*:0ND/5S&B&X+\KM1OB>5?+%*4]K@D*VU)83^6242G)VTZHZ\&MNV
M[9Y:&,HRKZW*+*^,\;5H8*]+MXJ%W(_+A[&%U^J[',!>W=[;O85.'U#YYI"\
M;PZ"->_SE6VWPU?.%0C2A)&3;D0L1?Y/\_CQ38!P+EST'Q>%"%U>O+_,>49^
M]>< S;VU^XIS8I)1E4&V"$E#!R(+Q29>,5?F1K& ZWCAX8C-BL,1AOG HEN%
MLH<KUM:Q3E^<H_FSI$(5XZ&,;;\5=T:3?KTPI#\,B26\*__B414&VP)OKP(V
M7';P713KO]#_N_=21'[S_P%02P$"% ,4    " "7BAY3# 3%.T!@   8L (
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K=&=E9BTR,#(Q,#8S,%]P<F4N>&UL4$L%!@     '  < Q@$  *=G @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
